<SEC-DOCUMENT>0001144204-15-029365.txt : 20150511
<SEC-HEADER>0001144204-15-029365.hdr.sgml : 20150511
<ACCEPTANCE-DATETIME>20150511170126
ACCESSION NUMBER:		0001144204-15-029365
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150511
DATE AS OF CHANGE:		20150511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		15851617

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v409108_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Mark One)</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 10%"><font style="font-family: Wingdings">x</font></td>
    <td style="width: 90%"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><b>For the quarterly period ended March 31, 2015 &nbsp;</b></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 10%">&nbsp;<font style="font-family: Wingdings">&uml;</font></td>
    <td style="width: 90%"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934</b></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><b>For the transition period from &nbsp;<u>____________</u> to&nbsp;<u>____________</u> &nbsp;</b></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 1-12584</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Name of small business issuer in its
charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nevada</B></FONT></TD>
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13-3808303</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of&nbsp;incorporation&nbsp;or&nbsp;organization)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(IRS&nbsp;Employer&nbsp;Identification&nbsp;Number)</I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>155 Gibbs Street, Suite 412</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Rockville, MD</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>20850</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Address&nbsp;of&nbsp;principal&nbsp;executive&nbsp;offices)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Zip&nbsp;Code)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>617 Detroit Street, Suite 100</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Ann Arbor, MI</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>48104</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Mailing Address)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Zip&nbsp;Code)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734) 332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock, $0.001 par value per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(g) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>None.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Title of Class)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the issuer: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"> x</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">
&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">
x</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"> &uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated file, a non-accelerated file, or a smaller reporting company.&nbsp;&nbsp;See the definitions
of &ldquo;large accelerated filer,&nbsp;&ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.&nbsp;&nbsp;(Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 27%">Large&nbsp;accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 27%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 23%">Accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 23%"><FONT STYLE="font-family: Wingdings">x</FONT></TD></tr>
<tr style="vertical-align: top">
    <TD>Non-Accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></tr>
<tr style="vertical-align: top">
    <TD COLSPAN="4">(Do&nbsp;not&nbsp;check&nbsp;if&nbsp;a&nbsp;smaller&nbsp;reporting&nbsp;company)</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">
&uml;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"> x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 8, 2015 the registrant had 73,179,307 shares of
common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 10%">&nbsp;</td>
    <td style="width: 78%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 9%; border-bottom: black 1pt solid; text-align: center">Page</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_001"><font style="font-size: 10pt; color: blue"><u>PART I. FINANCIAL INFORMATION</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">1</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">Item 1.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_002"><font style="font-size: 10pt; color: blue"><u>Financial Statements (Unaudited)</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">1</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_003"><font style="font-size: 10pt; color: blue"><u>Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">1</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_004"><font style="font-size: 10pt; color: blue"><u>Consolidated Statements of Operations for the three months ended March 31, 2015 and 2014</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">2</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_005"><font style="font-size: 10pt; color: blue"><u>Consolidated Statements of Cash Flows for the three months ended March 31, 2015 and 2014</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">3</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_006"><font style="font-size: 10pt; color: blue"><u>Notes to Consolidated Financial Statements</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">4</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 2.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_007"><font style="font-size: 10pt; color: blue"><u>Management&rsquo;s Discussion and Analysis of Financial&nbsp;Information and Results of Operations</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">10</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">Item 3.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_008"><font style="font-size: 10pt; color: blue"><u>Quantitative and Qualitative Disclosures About Market Risks</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">21</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 4.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_009"><font style="font-size: 10pt; color: blue"><u>Controls and Procedures</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">21</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom"></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_010"><font style="font-size: 10pt; color: blue"><u>PART II. OTHER INFORMATION</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">22</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">Item 1.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_011"><font style="font-size: 10pt; color: blue"><u>Legal Proceedings</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">22</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 1A.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_012"><font style="font-size: 10pt; color: blue"><u>Risk Factors</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">22</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">Item 2.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_013"><font style="font-size: 10pt; color: blue"><u>Unregistered Sales of Equity Securities and Use of Proceeds</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">23</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 3.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_014"><font style="font-size: 10pt; color: blue"><u>Defaults Upon Senior Securities</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">23</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">Item 4.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_015"><font style="font-size: 10pt; color: blue"><u>Mine Safety Disclosures</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">23</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Item 5.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_016"><font style="font-size: 10pt; color: blue"><u>Other Information</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">23</td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top">Item 6.</td>
    <td style="vertical-align: top; text-decoration: underline"><A HREF="#a_017"><font style="font-size: 10pt; color: blue"><u>Exhibits</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">24</td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-decoration: underline"><A HREF="#a_018"><font style="font-size: 10pt; color: blue"><u>SIGNATURES</u></font></A></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">25</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>PART I.-FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_002"></A><B>ITEM 1. FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><B>&nbsp;</B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands except share and per share
amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March 31, 2015</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December 31, 2014</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Audited)</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Current Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 70%; padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12,049</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17,525</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,574</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,548</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Current Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13,623</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19,073</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Property and equipment, net</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">75</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Deposits and other assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13,716</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>19,144</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Liabilities and Stockholders' Equity (Deficit)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Current Liabilities:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounts payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,559</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">996</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accrued expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,646</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,298</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrant liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,908</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,756</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accrued employee benefits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">228</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">538</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Current Liabilities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15,341</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,588</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Liabilities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15,341</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,588</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Commitments and Contingencies</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stockholders' Equity (Deficit):</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Preferred stock, $0.001 par value; 10,000,000 shares
    authorized,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">none issued and outstanding</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common stock,&nbsp;&nbsp;$0.001 par value; 100,000,000 shares authorized,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">72,725,987 issued and 72,807,469 outstanding and</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">72,594,626 issued and 72,513,144 outstanding</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">73</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">72</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">111,702</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">110,526</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accumulated deficit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(113,400</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(101,042</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Synthetic Biologics, Inc. and Subsidiaries
    Equity (Deficit)</B></FONT> </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1,625</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,556</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-controlling interest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Stockholders'&nbsp;&nbsp;Equity (Deficit)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1,625</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,556</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Liabilities and Stockholders' Equity</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13,716</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>19,144</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to unaudited consolidated
financial statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.4pt; text-align: center"><B><A NAME="a_004"></A>Synthetic Biologics, Inc. and
Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.4pt; text-align: center"><B>Consolidated Statements of
Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.4pt; text-align: center"><B>(In thousands except share
and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.4pt; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.4pt; text-align: center; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="7" NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the three months ended March 31,</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2015</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Operating Costs and Expenses:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 74%; padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">General and administrative</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,713</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,122</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research and development</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,494</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,717</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Operating Costs and Expenses</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8,207</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,839</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Loss from Operations</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(8,207</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3,839</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other Income (Expense):</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Change in fair value of warrant liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4,152</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interest income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total Other&nbsp;&nbsp;Income (Expense)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4,151</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net Loss</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(12,358</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3,838</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net Loss Attributable to Non-controlling Interest</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net Loss Attributable to Synthetic Biologics, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>and Subsidiaries</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(12,358</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(3,838</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net Loss Per Share - Basic and Dilutive</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(0.17</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(0.07</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(0.17</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(0.07</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Weighted average number of shares outstanding</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>during the period - Basic and Dilutive</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">72,673,959</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">58,324,260</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to unaudited consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Operating Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left">Net Loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(12,358</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(3,838</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">827</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">362</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Stock issued for milestone payments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">350</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Change in fair value of warrant liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,152</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Depreciation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(26</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">259</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Deposits and other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(12</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">563</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">631</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,348</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued employee benefits</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(310</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(885</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Operating Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5,458</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,470</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Investing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Purchases of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(18</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Investing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(18</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Financing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from issuance of common stock for stock option exercises</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By Financing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net decrease in cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,476</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,470</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Cash at beginning of period</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,525</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,625</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash at end of period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">12,049</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">11,155</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: left">Supplemental disclosures of cash flow information:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes to unaudited consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(Unaudited)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.4pt; text-indent: -37.4pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>1.</B> <B>Organization and Nature of Operations and Basis of Presentation</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.4pt; text-indent: -37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Description of Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Synthetic Biologics&rdquo;) is a microbiome-focused,&nbsp;clinical-stage company developing therapeutics to protect the
microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome
(gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of<I> C. difficile</I> infection and an
oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C).
In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon
Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive
dysfunction in MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 26%; border-bottom: black 1pt solid; text-align: center"><b>Therapeutic&nbsp;Area</b></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 26%; border-bottom: black 1pt solid; text-align: center"><b>Product&nbsp;Candidate</b></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 46%; border-bottom: black 1pt solid; text-align: center"><b>Status</b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 11pt; text-indent: -11pt"><i>C. difficile</i> infection prevention</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SYN-004</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(oral enzyme)</P></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">Initiated Phase 2a SYN-004 clinical trial during <FONT STYLE="font-size: 10pt">1<SUP>st</SUP></FONT>
    quarter 2015; Phase 2b proof-of- concept SYN-004 clinical trial is expected to initiate during 2<FONT STYLE="font-size: 10pt"><SUP>nd</SUP></FONT>&nbsp;&nbsp;half
    2015</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 11pt; text-indent: -11pt">Irritable bowel syndrome with constipation (IBS-C)</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SYN-010</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(oral compound)</P></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">Intend to initiate Phase 2 clinical trials during 2<font style="font-size: 10pt"><sup>nd</sup></font>&nbsp;&nbsp;quarter of 2015; Collaboration with Cedars-Sinai Medical Center</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 11pt; text-indent: -11pt">Pertussis</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SYN-005</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(monoclonal antibodies)</P></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">Positive preclinical research findings reported at ECCMID in April 2015; Seeking non-dilutive funding to support clinical development of SYN-005; Collaborations with Intrexon and The University of Texas at Austin</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 11pt; text-indent: -11pt">Relapsing-remitting MS</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Trimesta</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(oral estriol)</P></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">The lead principal investigator presented additional Phase 2 clinical outcome data,
    including     more detailed results on improvements in cognitive and disability measures at the ACTRIMS-ECTRIMS Joint
    Meeting     in September     2014; Partnership discussions ongoing pending data from University of California, Los Angeles (UCLA);
    MRI     data     review underway     by UCLA</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top; padding-left: 11pt; text-indent: -11pt">Cognitive dysfunction in MS</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Trimesta</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(oral estriol)</P></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="vertical-align: top">Patient enrollment underway in Phase 2 clinical trial</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial
statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (&ldquo;SEC&rdquo;) for
interim financial information. Accordingly, they do not include all of the information and notes required by U.S. Generally Accepted
Accounting Principles (&ldquo;GAAP&rdquo;) for complete financial statements. The accompanying consolidated financial statements
include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state our results
of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative
of results that may be expected for any other interim period or for the full year. These consolidated financial statements should
be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K
for the year ended December&nbsp;31, 2014 (&ldquo;2014 Form 10-K&rdquo;) as filed with the SEC. The interim results for the three
months ended March 31, 2015, are not necessarily indicative of results for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements are
prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of
assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that
the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties
in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future
periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>2.</B> <B>Management&rsquo;s Plan</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has incurred an accumulated
deficit of $113.4 million through March 31, 2015. With the exception of the quarter ended June 30, 2010, the Company has incurred
negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial
amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials,
and research and discovery efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The actual amount of funds
the Company will need to operate is subject to many factors, some of which are beyond the Company&rsquo;s control. These factors
include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: white">
    <td style="width: 6%">&nbsp;</td>
    <td style="width: 4%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%; text-align: justify">the progress of research activities;</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-family: Symbol">&middot;</font></td>
    <td style="text-align: justify">the number and scope of research programs;</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-family: Symbol">&middot;</font></td>
    <td style="text-align: justify">the progress of preclinical and clinical development activities;</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-family: Symbol">&middot;</font></td>
    <td style="text-align: justify">the progress of the development efforts of parties with whom the Company has entered into research and development agreements;</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-family: Symbol">&middot;</font></td>
    <td style="text-align: justify">the costs associated with additional clinical trials of product candidates;</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-family: Symbol">&middot;</font></td>
    <td style="text-align: justify">the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-family: Symbol">&middot;</font></td>
    <td style="text-align: justify">the ability to achieve milestones under licensing arrangements;</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-family: Symbol">&middot;</font></td>
    <td style="text-align: justify">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td><font style="font-family: Symbol">&middot;</font></td>
    <td style="text-align: justify">the costs and timing of regulatory approvals.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has based its estimate on assumptions
that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates.
Potential sources of financing include strategic relationships, public or private sales of the Company&rsquo;s shares or debt and
other sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may seek to access the public
or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed
sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will
be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible
into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing
when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations
and its business, financial condition and results of operations would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>3.</B> <B>Fair Value of Financial Instruments</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value accounting standards define
fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an
asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.8pt; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</td>
    <TD STYLE="width: 4%"><font style="font-family: Symbol">&middot;</font></td>
    <TD STYLE="width: 90%">Level 1 inputs: Quoted prices (unadjusted)&nbsp;for identical assets or liabilities in active markets;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.8pt; text-indent: -13.2pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</td>
    <TD STYLE="width: 4%"><font style="font-family: Symbol">&middot;</font></td>
    <TD STYLE="width: 90%">Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.8pt; text-indent: -13.2pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</td>
    <TD STYLE="width: 4%"><font style="font-family: Symbol">&middot;</font></td>
    <TD STYLE="width: 90%">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the inputs used to measure fair value
fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant
to the fair value measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include money
market accounts&nbsp;of $8.5 million and $13.6 million as of March 31, 2015 and December 31, 2014, respectively, that are measured
using Level 1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>4.</B> <B>Selected Balance Sheet Information</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Prepaid expenses and other current assets
(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,&nbsp;2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Intrexon prepaid research and development expenses</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,060</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,067</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid insurance</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">140</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">228</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">374</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">253</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,574</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,548</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The anticipated Intrexon research and development
expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and
receive a cash refund of the remaining balance minus any amounts owed to Intrexon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Property and equipment (in thousands):</I>&nbsp;
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,&nbsp;2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Computer and office equipment</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">111</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">93</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Software</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">122</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">104</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(47</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(39</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">75</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">65</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Accrued expenses (in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,&nbsp;2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,&nbsp;2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Accrued manufacturing costs</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">74</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">247</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued vendor payments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">225</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">176</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued milestone payments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">350</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued clinical consulting services</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,347</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">525</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,646</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,298</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>5.</B> <B>Stock-Based Compensation</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.4pt; text-indent: -37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2001, the Company&rsquo;s Board
of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &ldquo;2001 Stock Plan&rdquo;). The total number of shares
of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or
a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock
Plan shall terminate upon the termination of the grantee&rsquo;s employment for any reason. Awards include options, restricted
shares, stock appreciation rights, performance shares and cash-based awards (the &ldquo;Awards&rdquo;). The 2001 Stock Plan contains
certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan.
The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration
date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of March
31, 2015, there were 682,449 options issued and outstanding under the 2001 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2007, the Company&rsquo;s
Board of Directors approved the 2007 Stock Incentive Plan (the &ldquo;2007 Stock Plan&rdquo;) for the issuance of up to 2,500,000
shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend
equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors
and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price
of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal
to or greater than the fair market value of the Company&rsquo;s common stock on the date the option is granted. The total number
of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the
Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 250,000. Options become exercisable over
various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are 428,657
options issued and outstanding under the 2007 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2010, the Board of Directors
and stockholders adopted the 2010 Stock Incentive Plan (&ldquo;2010 Stock Plan&rdquo;) for the issuance of up to 3,000,000 shares
of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend
equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors
and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to
the Company&rsquo;s 2010 Incentive Stock Plan to increase the number of shares of the Company&rsquo;s common stock reserved for
issuance under the Plan from 3,000,000 to 6,000,000. The exercise price of stock options under the 2010 Stock Plan is determined
by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&rsquo;s
common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally
expire ten years after the grant date. As of March 31, 2015, there are 5,420,000 options issued and outstanding under the 2010
Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of an employee&rsquo;s termination,
the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial
grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has applied fair value accounting
for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of
grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the three months ended March 31, 2015
and 2014 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font-size: 10pt; text-align: left">Expected dividends</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; font-size: 10pt; text-align: right">0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; font-size: 10pt; text-align: right">0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">131</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">126</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Risk free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.03</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.57</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected life of option</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10&nbsp;years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5&nbsp;years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected forfeitures</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based compensation
based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</td>
    <TD STYLE="width: 4%"><font style="font-family: Symbol">&middot;</font></td>
    <TD STYLE="width: 90%">immediate vesting,</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol">&middot;</font></td>
    <TD>half vesting immediately and the remainder over three years,</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol">&middot;</font></td>
    <TD>quarterly over three years,</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol">&middot;</font></td>
    <TD>annually over three years,</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol">&middot;</font></td>
    <TD>one-third immediate vesting and remaining annually over two years,</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol">&middot;</font></td>
    <TD>one half immediate vesting with remaining vesting over nine months,</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol">&middot;</font></td>
    <TD>one quarter immediate vesting with the remaining over three years,</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol">&middot;</font></td>
    <TD>one quarter immediate vesting with the remaining over 33 months; and</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><font style="font-family: Symbol">&middot;</font></td>
    <TD>monthly over three years.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 80.3pt; text-indent: -17.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31,
2015, the Company granted 550,000 options to employees having an approximate fair value of $817,000 based upon the Black-Scholes
option pricing model.&nbsp;During the same period in 2014, the Company granted 587,500 options to employees and consultants having
an approximate fair value of $1.4 million based upon the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of stock option activities as
of March 31, 2015, and for the year ended December 31, 2014, is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Remaining</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Aggregate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Average&nbsp;Exercise</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Contractual</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Intrinsic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Life</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-size: 10pt; padding-bottom: 2.5pt">Balance - December 31, 2013</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 2.5pt; font-size: 10pt; text-align: right">3,909,580</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; padding-bottom: 2.5pt; font-size: 10pt; text-align: right">1.78</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: right; padding-bottom: 2.5pt">5.59&nbsp;years</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">785,000</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,382,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.36</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6,583</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.58</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Forfeited</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(304,391</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1.93</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Balance - December 31, 2014</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">5,981,106</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">2.01</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 2.5pt">5.80 years</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">685,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">550,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.54</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Forfeited</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Balance - March 31, 2015 - outstanding</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,531,106</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.97</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 2.5pt">5.79&nbsp;years</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,628,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Balance - March 31, 2015 - exercisable</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,168,043</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.89</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 2.5pt">4.98&nbsp;years</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,939,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Grant date fair value of options granted - March 31, 2015</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">817,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Weighted average grant date fair value - March 31, 2015</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.49</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Grant date fair value of options granted - December 31, 2014</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,974,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Weighted average grant date fair value - December 31, 2014</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2.09</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation expense included
in general and administrative expenses and research and development expenses relating to stock options issued to employees and
consultants for the three months ended March 31, 2015 and 2014 were $826,000 and $362,000, respectively</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2015, total unrecognized
stock-based compensation expense related to stock options was $4.0 million, which is expected to be expensed through February 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>6.</B> <B>Stock Purchase Warrants</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">On October 10, 2014, the Company
raised net proceeds of $19.1 million through the sale of 14,059,616 units at a price of $1.47 per unit to certain institutional
investors in a registered direct offering. Each unit consisted of one share of the Company&rsquo;s common stock and a warrant to
purchase 0.5 shares of common stock. The warrants, exercisable for an aggregate of 7,029,808 shares of common stock, have an exercise
price of $1.75 per share and a life of five years. The warrants vested immediately and expire October 10, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">The warrants issued in conjunction
with the registered direct offering in October 2014 include a provision, that if the Company were to enter into a certain transaction,
as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the
warrants as a liability at their estimated fair value on the issuance date and changes in estimated fair value will be recorded
as non-cash income or expense in the Company&rsquo;s statement of operations at each subsequent period. At March 31, 2015, the
fair value of the warrant liability was $10.9 million, which represented non-cash expense of $4.2 million for the three months
ended March 31, 2015. In accordance with authoritative accounting guidance, the warrant was valued on the date of grant and in
subsequent periods using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following
table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March 31, </B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2015</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December 31,</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuance</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Date</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font: 10pt Times New Roman, Times, Serif; text-indent: -11pt; padding-left: 11pt">Closing stock price</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.19</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.46</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1.75</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">Expected dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">Expected volatility</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">95</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">Risk free interest rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.26</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.59</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.39</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11pt; padding-left: 11pt">Expected life of warrant</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.55 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.79&nbsp;&nbsp;years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">5&nbsp;&nbsp;years</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify; text-indent: -6.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify; text-indent: -6.6pt">The
following table summarizes the estimated fair value of the warrant liability<I> (in thousands)</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify; text-indent: -6.6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font-size: 10pt">Balance at December 31, 2014</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">6,756</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,152</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Balance at March 31, 2015</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">10,908</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify; text-indent: -6.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify; text-indent: -6.6pt">As of
March 31, 2015, all of the warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify; text-indent: -6.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 25, 2012, the Company entered
into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants
to purchase 635,855 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price
of $1.60 and a life of five years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted
as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect
to equity. Warrants outstanding as of March 31, 2015 were 316,522.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of warrant activity for the Company
for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Weighted&nbsp;Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Warrants</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt">Balance at December 31, 2013</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,632,501</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.99</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,029,808</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(232,619</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.47</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Forfeited</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(454,896</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1.88</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Balance at December 31, 2014</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,974,794</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.80</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Forfeited</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Balance at March 31, 2015</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,974,794</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.80</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of all outstanding and exercisable warrants as of
March 31, 2015 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Weighted&nbsp;Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Exercise</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Remaining</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Aggregate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Intrinsic&nbsp;Value</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 17%; font-size: 10pt; text-align: right">1.60</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font-size: 10pt; text-align: right">316,522</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">316,522</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 18%; font-size: 10pt; text-align: center">2.57&nbsp;years</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">187,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,029.808</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,029,808</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">4.53 years</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,903,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.22</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">517,257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">517,257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">1.66&nbsp;years</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.30</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">61,207</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">61,207</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0.16&nbsp;years</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3.75</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">0.88&nbsp;years</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.80</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,974,794</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,974,794</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 2.5pt">4.21&nbsp;years</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,280,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>7.</B> <B>Stockholders&rsquo;
Equity (Deficit)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.4pt; text-indent: -37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended
March 31, 2015, the Company issued 212,843 shares of common stock to Prev ABR LLC, with a fair value of $350,000,  that was <FONT STYLE="font: 10pt Times New Roman, Times, Serif">recorded
as research and development expense,</FONT> in consideration for achieving the first two milestones as set forth in the Asset
Purchase Agreement dated November 28, 2012. In lieu of receiving any cash payment for achieving the first two milestones,
Prev ABR LLC exercised its option to receive the milestone payments in shares of the Company&rsquo;s common stock. The number
of shares of common stock issued upon achievement of each milestone was based upon the average of the opening and closing
prices of the Company&rsquo;s stock on the date each milestone was achieved as specified in the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>8.</B> <B>Net Loss per Share</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss per share is computed by dividing
net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by
the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent
shares were anti-dilutive at March 31, 2014 and 2015, as such there is no separate computation for diluted loss per share. The
number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common
share for the three months ended March 31, 2015 were 6,531,106 and 7,974,794, respectively, and for the three months ended March
31, 2014 were 4,490,497 and 963,168, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_007"></A><B>ITEM 2. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL
INFORMATION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion should be read
in conjunction with the attached unaudited consolidated financial statements and notes thereto, and with our audited consolidated
financial statements and notes thereto for the fiscal year ended December 31, 2014, found in our Annual Report on Form 10-K. In
addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties
and assumptions. Where possible, we have tried to identify these forward looking statements by using words such as &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;intends,&rdquo; or similar expressions. Our actual results could differ materially from those anticipated
by the forward-looking statements due to important factors and risks including, but not limited to, those set forth under &ldquo;Risk
Factors&rdquo; in this 10-Q and as applicable in Part I, Item 1A of our Annual Report on Form 10-K.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a microbiome-focused,&nbsp;clinical-stage
company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. We are developing an oral
biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention
of<I> C. difficile</I> infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable
bowel syndrome with constipation (IBS-C). In addition, we are developing a monoclonal antibody combination for the treatment of
Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting
multiple sclerosis (MS) and cognitive dysfunction in MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.1pt"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.1pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.4pt; text-indent: 29.7pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.4pt"><I>Summary of Pathogen-Specific Therapy Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37.4pt; text-indent: 29.7pt"><I>&nbsp;</I></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 98%; text-align: justify"><b><i>C. difficile</i> infections (CDI):</b> &nbsp; We are in clinical
    development of a novel second-generation oral enzyme candidate, SYN-004, for co-administration with commonly used IV
    beta-lactam antibiotics, intended to protect the microbiome and prevent the development of and severe effects from CDI. CDIs
    are a leading type of hospital acquired infection (HAI) and are frequently associated with IV antibiotic treatment. Designed
    to be given orally and co-administered with certain IV beta-lactam antibiotics (e.g., penicillins and cephalosporins),
    SYN-004 is intended to protect the gut while the IV antibiotics fight the primary infection. SYN-004 is believed to not only
    have a similar profile to its first-generation predecessor, which demonstrated protection of the microbiome (gut flora)
    during treatment with certain penicillins, but also has the potential to  protect the gut from a broader spectrum of IV
    beta-lactam antibiotics. Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly
    used penicillin and cephalosporin classes of antibiotics. SYN-004&rsquo;s target market is significant and represented by
    annual U.S. hospitals purchases of approximately 118 million doses of IV beta-lactam antibiotics which are administered to
    approximately 14 million patients.* Currently there are no approved treatments designed to protect the gut microbiome from
    the damaging effects of IV antibiotics. This worldwide market could represent a multi-billion dollar opportunity for us. In
    November 2014, the U.S. Patent and Trademark Office (USPTO) issued Patent No. 8,894,994 that has claims to compositions of
    matter and pharmaceutical compositions of beta-lactamases, including SYN-004, and carries a patent term to at least 2031. We
    also have an extensive patent estate on other aspects of this program which includes patent applications that could carry a
    term to at least 2035. In the fourth quarter of 2014, we initiated our randomized, double-blind placebo-controlled Phase 1a
    clinical trial, reported positive topline safety and tolerability results from the Phase 1a clinical trial, and initiated the
    Phase 1b clinical trial evaluating multiple ascending doses of SYN-004. In February 2015, we reported positive topline
    results from the Phase 1b clinical trial of escalating doses of oral SYN-004, with no safety or tolerability issues reported
    at dose levels and dose regimens both meeting and exceeding those expected to be studied in upcoming clinical trials. In
    March 2015, we reported positive pharmacokinetics data from both Phase 1 clinical trials, with supportive evidence that
    SYN-004 should have no effect on the IV antibiotic in the bloodstream, allowing the antibiotic to fight the primary
    infection. We also initiated a Phase 2a clinical trial to evaluate the GI antibiotic-degrading effects and the safety of
    SYN-004 in March 2015. The initiation of a Phase 2b proof-of-concept clinical trial is expected in the second half of 2015,
    with Phase 2b topline data anticipated during the second half of 2015.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%">&nbsp;</td>
    <td style="width: 1%"><b>*</b></td>
    <td style="width: 95%; text-align: justify">This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 98%; text-align: justify"><b>IBS-C:</b> &nbsp;&nbsp;In December 2013, through our majority-owned
    subsidiary, Synthetic Biomics, Inc., we entered into a worldwide exclusive license agreement with Cedars-Sinai Medical Center
    (CSMC) for the right to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including
    the development of SYN-010 to target IBS-C. An investigational team led by Mark Pimentel, M.D., at CSMC discovered that
    SYN-010 may reduce the production of methane gas by certain gastrointestinal (GI) microorganisms. Methane produced by these
    organisms is perceived as an underlying cause of pain, bloating, and constipation associated with IBS-C, and may contribute
    to the pathology of other diseases. SYN-010 is a modified release formulation of a statin being designed to reduce the impact
    of methane producing organisms on IBS-C. A 505(b)(2) regulatory pathway is anticipated for the development of SYN-010. We
    licensed an extensive intellectual property portfolio from CSMC including granted use patents and pending patent applications
    for SYN-010. Additional worldwide patent filings having composition of matter claims, which were recently filed by CSMC and
    licensed to us, could extend patent protection of SYN-010 to 2035. Based on guidance from the members on our IBS clinical
    advisory board, we plan to file an Investigational New Drug (IND) application with the U.S.  Food and Drug Administration
    (FDA) to support the initiation of Phase 2 clinical trials in the second quarter of 2015, with Phase 2 topline data
    anticipated during the second half of 2015.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 98%; text-align: justify"><b>Pertussis:</b> &nbsp;&nbsp;In December 2012, in collaboration with Intrexon Corporation (NYSE: XON) (Intrexon), we initiated development of a monoclonal antibody (mAb) therapy for the treatment of Pertussis infections, more commonly known as whooping cough. Combining two mAbs, SYN-005 is designed to target and neutralize pertussis toxin as a prophylaxis for high-risk newborns and in order to reduce the mortality rate in infected infants. To further the development of this potential therapy for Pertussis, we entered into an agreement with The University of Texas at Austin (UT) to license the rights to certain research and pending patents related to pertussis antibodies. We have patents pending on compositions and uses of SYN-005 and we have an issued U.S. patent on other pertussis mAbs from UT. According to the World Health Organization, each year,<i> B. pertussis</i> infection is estimated to cause up to 300,000 deaths worldwide, primarily among unvaccinated infants. Positive preclinical research findings for SYN-005 were reported in April 2014, and again in September 2014, for our proprietary mAb combination therapy for treating Pertussis, in non-human primate studies. In September 2014 we received a U.S. Orphan Drug designation for SYN-005 for the treatment of Pertussis. We intend to seek non-dilutive funding to support preclinical and clinical development of SYN-005 for prophylaxis and treatment of Pertussis, including the anticipated filing of an IND application and the anticipated initiation of a Phase 1 clinical trial.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify; text-indent: -29.7pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 98%; text-align: justify"><b><i>Acinetobacter infections:</i></b> &nbsp;&nbsp;In September 2012, in collaboration with Intrexon, we initiated efforts to develop a mAb therapy for the treatment of<i> Acinetobacter</i> infections. Many strains of<i> Acinetobacter</i> are multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected by natural disasters. A treatment for<i> Acinetobacter</i> infections represents a billion dollar market opportunity. This program is in the discovery stage and the generation of a panel of antibodies to treat this infection is ongoing.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify; text-indent: -29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt"><I>Summary of Multiple
Sclerosis Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 98%; text-align: justify"><b>Relapsing-Remitting MS:</b> &nbsp;&nbsp;Patient follow-up is complete in the
    University of California, Los Angeles (UCLA) led Phase 2, investigator-initiated, randomized (n = 158), double-blinded,
    placebo-controlled     trial     which     evaluated     our drug candidate, Trimesta, in women with relapsing-remitting MS
    at 16 sites across the     U.S. In     April 2014,     the lead principal     investigator presented positive Phase 2
    topline     efficacy and safety results. In     September     2014, the lead     principal     investigator presented
    additional Phase 2     clinical outcome data, including     more detailed     results on     improvements in cognitive
    and disability measures,     at the 2014 Joint Americas and     European Committees for     Treatment and     Research in
    Multiple Sclerosis     Meeting     (ACTRIMS-ECTRIMS) in Boston. The     data as reported by the lead     principal
    investigator for the UCLA-led Phase 2     study     supported the potential of Trimesta to have     a novel dual
    mechanism of action for     both the     anti-inflammatory effects that     improve relapse rate, and a     neuroprotective
    effect that     improves     standard measures of     disability and cognition.     Further analyses of the magnetic
    resonance imaging (MRI) data are     ongoing, with topline data     expected from the     lead principal investigator during
    the     first     half of 2015. This     investigator-initiated Phase 2 clinical trial     was     supported by grants
    exceeding $8     million,     awarded primarily by     the     National Multiple Sclerosis Society (NMSS) in     partnership
    with the     NMSS&rsquo;s Southern     California chapter,     and the     National Institutes of Health. Annual
    worldwide sales         of MS therapies are forecasted to     be     approximately $17.8 billion in     2019. We have
    licensed issued     method of     treatment patents     in the U.S. for MS     therapy with estriol and estriol combination
    therapies (including         estriol with Copaxone<SUP>&reg;</SUP>) from UCLA,     and     numerous     new provisional patent
    applications have been     filed based     on     the Phase 2 clinical results. We are     engaging with     the
    neurology community and potential strategic     partners, as     we determine next steps for     Trimesta.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify; text-indent: -29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify; text-indent: -29.7pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt; text-align: justify; text-indent: -29.7pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 98%; text-align: justify"><b>Cognitive Dysfunction in MS:</b> &nbsp;&nbsp;Trimesta is also being developed
    for the treatment of cognitive dysfunction in female MS patients. This 12-month, UCLA-led, randomized, double-blind,
    placebo-controlled investigator-initiated Phase 2 clinical trial is being conducted at four sites in the United States. The
    primary endpoint is the effect on cognitive function as assessed by Paced Auditory Serial Addition Test (PASAT). Patient
    enrollment is ongoing. The majority of the costs of this trial are being funded by grants from foundations and charitable
    organizations through direct funding to the lead principal investigator and we have pledged approximately $500,000 to UCLA to
    partially fund this trial, payable over three years. An estimated 50&nbsp;-&nbsp;65% of MS patients are expected to develop
    disabilities due to cognitive dysfunction and there is currently no approved treatment for this indication.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in January 2001, our
efforts and resources have been focused primarily on acquiring and developing our product candidates, our clinical trials, raising
capital, manufacturing and recruiting personnel. To date, we have financed our operations primarily through public and private
sales of our common stock, and we expect to continue to seek to obtain the required capital in a similar manner. We have incurred
an accumulated deficit of $113.4 million through March 31, 2015. We cannot provide any assurance that we will be able to achieve
profitability on a sustained basis, if at all, obtain the required funding, obtain the required regulatory approvals, or complete
additional corporate partnering or acquisition transactions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pipeline Programs and Therapeutic Areas</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Pathogen-Specific Therapy Programs</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">We are developing pathogen-specific
therapies for serious infections and diseases, with a focus on protecting the microbiome. Infectious disease outbreaks are increasing
while intervention options are declining due to widespread multidrug-resistant bacteria, increasing numbers of immuno-compromised
patients (e.g., the elderly and cancer patients), and the isolation of new pathogens. We are developing an oral biologic to protect
the GI microflora from the effects of certain IV beta-lactam antibiotics for the prevention of CDI, an oral treatment to reduce
the impact of methane producing organisms on IBS-C and a monoclonal antibody combination for the treatment of Pertussis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"><B>Microbiome-Focused Therapies:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Our<I> C. difficile</I> and IBS-C
programs are focused on protecting the microbiome, or our gut flora, which is home to billions of bacteria and composed of a natural
balance of both &ldquo;good&rdquo; beneficial bacteria and &ldquo;bad&rdquo; pathogenic bacteria. When that natural balance of
all of these bacteria is disrupted, a person&rsquo;s health can be compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>C. difficile</I>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">According to the Agency for
Healthcare Research and Quality, aggregate costs associated with CDI related stays in the hospital were $8.2 billion in the
U.S. during 2009. CDI is a rising global HAI problem in which the toxins produced by<I> C. difficile</I> bacteria result in
 antibiotic-associated diarrhea (AAD), and in the most serious cases, pseudomembranous colitis (erosion of the lower
GI tract) that can lead to death. The Centers for Disease Control and Prevention (CDC) identified<I> C. difficile </I> as an
&ldquo;urgent public health threat,&rdquo; particularly given its resistance to many drugs used to treat other infections.
CDI is a major, unintended risk associated with the prophylactic or therapeutic use of IV antibiotics, which may alter the
natural balance of microflora that normally protect the GI tract, leading to<I> C. difficile</I> overgrowth and infection.
Other risk factors for CDI include hospitalization, prolonged length of stay, underlying illness, immune-compromising
conditions including the administration of chemotherapy, and advanced age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CDI is a widespread and often drug resistant
infectious disease. It is estimated that 1.1 million patients are infected with<I> C. difficile</I> annually in the U.S.*, and
it has been reported that 30,000 patients die with a<I> C. difficile</I> infection each year. CDI has surpassed methicillin-resistant
staphylococcus aureus (MRSA) as the most frequent hospital acquired infection. Controlling the spread of CDI has proven challenging,
as the <I>C. difficile</I> spores are easily transferred to patients via normal contact with healthcare personnel and with inanimate
objects. There is currently no vaccine or approved product for the prevention of CDI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">*</td>
    <td style="width: 99%; text-align: justify">This information is an estimated derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>C. difficile: Acquisition of Clinical-Stage
Program</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In November 2012, we acquired
a series of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention of CDI, the leading HAI
that generally occurs secondary to treatment with IV antibiotics. The acquired assets include a pre-IND package for P3A (now known
 as SYN-004), Phase 1 and Phase 2 clinical data for P1A, manufacturing processes and data, and a portfolio of issued and pending
U.S. and international patents intended to support an IND and Biologics License Application (BLA) with the FDA. Utilizing this
portfolio of assets, we developed a proprietary, second generation oral beta-lactamase enzyme product candidate, SYN-004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">When co-administered with certain
IV beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the GI tract, thus preserving
the natural balance of the patient&rsquo;s microflora, and preventing opportunistic infections including CDI. Beta-lactam antibiotics
are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics.
SYN-004&rsquo;s target market is significant and represented by annual U.S. hospitals purchases of approximately 118 million doses
of IV beta-lactam antibiotics which are administered to approximately 14 million patients.* Currently there are no approved treatments
designed to protect the microbiome from the damaging effects of IV antibiotics. The worldwide market for SYN-004 could represent
a multi-billion dollar opportunity for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">*</td>
    <td style="width: 99%; text-align: justify">This information is an estimated derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>C. difficile: Oral Enzyme Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Beta-lactamase enzymes have the
ability to degrade beta-lactam antibiotics that may be excreted into the GI tract. P1A (the first generation candidate) showed
acceptable safety and tolerability in a Phase 1 study. In addition, two Phase 2 clinical studies demonstrated that P1A had the
ability to preserve GI microflora in hospitalized patients treated with IV ampicillin or the combination of piperacillin and tazobactam.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>C. difficile: Preclinical and Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Compared to the first generation
oral enzyme candidate, P1A, we believe that the second generation candidate, SYN-004, will have activity against a broader spectrum
of beta-lactam antibiotics, including both penicillins and certain cephalosporins. Due to the structural similarities between P1A
and SYN-004, and based on previous discussions with the FDA, certain preclinical data collected on P1A was used in support of an
IND for our new product candidate, SYN-004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In June 2014, we formed a Clinical
Advisory Board (CAB) to support development of SYN-004. The CAB is comprised of industry leaders Mark Wilcox, M.D., (Chairman),
Curtis Donskey, M.D., Ciar&aacute;n Kelly, M.D. and Tom Louie, M.D., all of whom are providing expertise and guidance on each aspect
of the<I> C. difficile</I> clinical program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In August 2014, we
announced an agreement with Evonik Corporation for Good Manufacturing Practices (GMP) manufacturing of our proprietary oral
beta-lactamase enzyme, SYN-004. Evonik formulated and encapsulated enterically coated SYN-004 for oral delivery for use in
our Phase 1a, 1b and planned Phase 2a clinical trials, using material generated by our API manufacturer FUJIFILM Diosynth
Biotechnologies UK Limited. In January 2015, we entered into an agreement with Halo Pharmaceutical (Whippany, NJ) to
formulate and encapsulate enterically coated SYN-004 for oral delivery for use in our planned Phase 2b and other future
clinical trials, using material generated by our Active Pharmaceutical Ingredient (API) manufacturer FUJIFILM Diosynth
Biotechnologies UK Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In December 2014, we initiated
Phase 1a and 1b clinical trials of SYN-004, and also reported positive topline safety and tolerability results from the Phase 1a
study. In February 2015, we reported positive topline results from the Phase 1b clinical trial of escalating doses of oral SYN-004,
with no safety or tolerability issues reported at dose levels and dose regimens both meeting and exceeding those expected to be
studied in upcoming clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In March 2015, we reported positive
pharmacokinetic data from both Phase 1 clinical trials, with supportive evidence that SYN-004 should have no effect on the IV
antibiotic in the bloodstream, allowing the antibiotic to fight the primary infection. We also initiated a Phase 2a clinical trial
to evaluate the GI antibiotic-degrading effects and the safety of SYN-004. The initiation of a Phase 2b proof-of-concept clinical
trial is expected in the second half of 2015, with Phase 2b topline data anticipated during the second half of 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In March 2015, we also announced
that late-breaking preclinical results supporting the development of SYN-004 were accepted for poster presentation at Digestive
Disease Week<SUP>&reg;</SUP> (DDW) 2015 in Washington DC in May 2015. The late-breaking abstract title is &ldquo;<I>SYN-004, a Clinical Stage
Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-Mediated Damage in Humanized Pigs.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2015, we announced that
clinical data supporting the development of SYN-004 were selected for poster presentation at the 115<SUP>th</SUP> General
Meeting of the American Society of Microbiology (ASM2015) in New Orleans, LA in May-June 2015. The abstract title is
&ldquo;<I>Clinical Evaluation of SYN-004, an Oral Beta-Lactamase Therapy for the Prevention of Antibiotic-Induced Disruption
of Intestinal Microflora</I>.&rdquo; A second poster featured data that support expanding the development of therapeutics
designed to protect the microbiome from all beta-lactam antibiotics for the prevention of <I>C. difficile</I> infection,
beyond penicillins and cephalosporins was also selected. The abstract title is &ldquo;<I>Development of Therapeutic Agents
that Protect the Colonic Microflora from All Beta-Lactam Antibiotics for the Prevention of Clostridium
difficile Infection</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"><I>C. difficile</I>: <I>Intellectual
Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In November 2014, the USPTO
issued U.S. Patent 8,894,994 that has claims to compositions of matter and pharmaceutical compositions of
beta-lactamases, including SYN-004, and carries a patent term to at least 2031.  In addition to this newly granted patent, we have numerous related granted and pending U.S. and international
patent applications that are central to our intellectual property estate. Further, we continue to grow our intellectual
property estate with new filings, many of which would expire in at least 2035, if granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"><B>IBS-C:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Irritable Bowel Syndrome (IBS)
is a functional GI disorder characterized by gas, abdominal pain, bloating and diarrhea or constipation, or alternating episodes
of both. According to reports published by The International Foundation for Functional Gastrointestinal Disorders (IFFGD), IBS
affects an estimated 10 to 15 percent of the population, or as many as 40 million Americans. The illness affects both men and women;
two-thirds of diagnosed sufferers are women. The onset of IBS can begin anytime from adolescence to adulthood. Four bowel patterns
may be seen with IBS, including: IBS-C (constipation predominant), IBS-D (diarrhea predominant), IBS-M (mixed diarrhea and constipation)
and IBS-A (alternating diarrhea and constipation). The development of SYN-010 is an oral treatment intended to reduce the impact
of methane producing organisms on IBS-C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">It has been reported that up
to one-third of all IBS patients have IBS-C. Current FDA-approved therapies for the treatment of IBS-C include AMITIZA<SUP><SUP>&reg;</SUP>
</SUP>(lubiprostone) and LINZESS<SUP>&reg;</SUP> (linaclotide). Prescription and over-the-counter laxatives are also used by IBS-C patients
for symptomatic relief. According to GlobalData, sales of approved drugs to treat IBS-C in seven major markets are projected to
reach $1.3 billion by 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>IBS-C: Acquisition of Clinical-Stage
Program</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In December 2013, we entered
into a worldwide exclusive license agreement with CSMC for the right to develop products for therapeutic and prophylactic treatments
for acute and chronic diseases. We licensed from CSMC a portfolio of intellectual property comprised of several U.S. and international
patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team
led by Mark Pimentel, M.D. at CSMC has discovered that these products may reduce the production of methane gas by certain GI microorganisms.
Methane produced by these microorganisms is perceived as the underlying cause of pain, bloating, and constipation associated with
IBS-C, and may contribute to the pathology of other diseases. Initially we will focus on the development of SYN-010, an oral treatment
being designed to reduce the impact of methane producing organisms on IBS-C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>IBS: Gas Producing Organisms Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In the 1990&rsquo;s, research
showed that IBS patients (over a given time) produced five times more gas than did people without IBS. Since the only source of
those gases was bacterial, the initial presumption was that IBS patients had excessive bacteria in the colon. Subsequent studies
showed that IBS patients had excessive quantities of gas in the small bowel; these data were the catalyst for studying small bowel
bacteria in IBS. Normally the small intestine contains a very small quantity of bacteria. In published studies, indirect measures
of small bowel bacteria suggest that 84% of IBS sufferers have excessive quantities of bacteria typically found in the colon. The
CSMC investigational team led by Dr. Pimentel is researching a recent theory that defines IBS as a bacterial disease. Gut microflora
that should normally be confined to the large intestine inappropriately colonize the small intestine. This process is referred
to as small intestine bacterial overgrowth (SIBO), which results in gas, bloating, abdominal pain and altered stool habits characterized
by IBS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>IBS-C: Methane Producing Organisms Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Further research by the CSMC
investigational team led by Dr. Pimentel is focused on the IBS-C patient population. Extensive studies conducted by Dr. Pimentel
and collaborators have shown that overproduction of methane gas is directly associated with bloating, pain and constipation in
IBS-C patients. CSMC investigators have discovered that inhibiting intestinal methane production may reverse constipation associated
with IBS-C, and can be beneficial in other major diseases such as obesity and type 2 diabetes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>IBS-C: Preclinical and Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Efforts led by Dr. Pimentel included formulating
and testing non-antibiotic FDA-approved oral drug candidates for ultimate product registration via potential expedited pathways.
Such candidates are intended for the reduction or elimination of methane gas production within the intestines, with the goal of
having little or no unintended impact on a patient&rsquo;s normal GI microflora.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In April 2014, we formed a CAB
to support development of SYN-010, and also announced that gastroenterologist and lead investigator for the IBS-C program, Dr.
Mark Pimentel, is the Chair of the CAB. In October 2014, we announced the expansion of the IBS-C CAB to include William Chey, M.D.,
Gail M. Comer, M.D., Anthony J. Lembo, M.D., and, Philip Schoenfeld, M.D., MSEd, MSc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In September 2014, we announced
that our candidate, SYN-010, is a modified release formulation of a statin being designed to reduce the impact of methane producing
organisms on IBS-C. A 505(b)(2) regulatory pathway is anticipated for the development of SYN-010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Based on guidance from the members
on our IBS CAB, we plan to file an IND application with the U.S. FDA to support the initiation of Phase 2 clinical trials in the
second quarter of 2015, with Phase 2 topline data anticipated during the second half of 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In February 2015, we announced
that preclinical results supporting the development of SYN-010 (based on research performed at Cedars-Sinai Medical Center under
the direction of Dr. Mark Pimentel), our candidate therapy to reduce the impact of methane producing organisms on IBS-C, were accepted
for poster presentation at DDW 2015 in Washington DC in May 2015. The abstract title is &ldquo;<I>Lovastatin improves stool form
in Methanobrevibacter smithii colonized rats with constipation.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"><I>IBS-C: Intellectual Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An extensive intellectual property portfolio
including granted use patents and pending patent applications for SYN-010 has been licensed to us by CSMC. Additional worldwide
patent filings, including composition of matter claims, among other claims, recently filed by CSMC and licensed to us could extend
patent protection of SYN-010 to 2035.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Monoclonal Antibodies:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Monoclonal Antibodies for Infectious
Diseases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Acting as the body&rsquo;s army,
antibodies are proteins, generally found in the bloodstream, that provide immunity in detecting and destroying pathogens, such
as viruses and bacteria and their associated toxins. MAbs can also be designed and produced as therapeutic agents, utilizing protein
engineering and recombinant production technologies. The mAbs being developed under our collaboration with Intrexon are intended
to supplement a patient&rsquo;s own immune system by providing the means to specifically and rapidly neutralize and/or clear specific
pathogens and toxins of interest in a process known as &ldquo;passive immunity&rdquo;. Many pathogens that cause infectious diseases
are innately resistant to, or over time have developed increased resistance to, antibiotics and other drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Intrexon Collaboration: Monoclonal Antibodies
for Infectious Diseases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2012, we entered into a worldwide
exclusive channel collaboration (&ldquo;Second ECC&rdquo;) with Intrexon through which we intend to develop a series of mAb therapies
for the treatment of certain infectious diseases not adequately addressed by existing therapies. Utilizing Intrexon&rsquo;s comprehensive
suite of proprietary technologies, including the mAbLogix<FONT STYLE="font-size: 10pt"><SUP> TM</SUP></FONT> platform for rapid
discovery of fully human mAbs and the LEAP<SUP>&reg;</SUP> cell processing station, our initial efforts have targeted three infectious
disease indications.** To date, we have initiated development of mAb therapies for the treatment of Pertussis and<I> Acinetobacter
</I>infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">**mAbLogix<FONT STYLE="font-size: 10pt"><SUP>TM
</SUP></FONT>and LEAP<SUP><SUP>&reg;</SUP></SUP> are trademarks of Intrexon Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pertussis:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify"><I>Bordetella pertussis (B.
pertussis)</I> is a gram-negative bacterium that infects the upper respiratory tract, causing uncontrollable and violent coughing.
Antibiotic treatment does not have a major effect on the course of Pertussis, because while it can eliminate the<I> B. pertussis</I>
bacteria from the respiratory tract, it does not neutralize the pertussis toxin. Infants with Pertussis often require hospitalization
in pediatric intensive care units, frequently requiring mechanical ventilation. Pertussis in adults generally leads to a chronic
cough referred to as the &ldquo;cough of 100 days.&rdquo; The incidence of Pertussis is increasing due to the declining effectiveness
of the acellular vaccine introduced in the 1990s, exposure of unvaccinated and under-vaccinated<I>&nbsp;</I>individuals including
infants who are not yet fully vaccinated, exposure of individuals whose immunity has diminished over time, as well as asymptomatic
carriers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">According to the World Health
Organization there are 50 million cases of whooping cough and<I> B. pertussis</I> infection that are estimated to cause up to 300,000
deaths each year worldwide, primarily among unvaccinated infants. Recent news reports throughout the U.S. indicate that the pertussis
vaccine introduced in the 1990s does not provide long-term protection and, as a result, whooping cough cases have increased to
a 60-year high.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pertussis: Intrexon Collaboration and
The University of Texas at Austin Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In December 2012, we initiated
mAb development for the treatment of Pertussis focusing on toxin neutralization pursuant to our August 2012 collaboration with
Intrexon. Unlike antibiotics, we are developing a therapy comprising a combination of two mAbs, SYN-005, to target and neutralize
the pertussis toxin as a prophylaxis for high-risk newborns and in order to reduce the mortality rate in infected infants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">To further the development of
this potential therapy for pertussis, we have entered into an agreement with The University of Texas at Austin to license the rights
to certain research and pending patents related to pertussis antibodies. These research efforts are being conducted at the Cockrell
School of Engineering in the laboratory of Associate Professor, Jennifer A. Maynard, Ph.D., the Laurence E. McMakin, Jr. Centennial
Faculty Fellow in the McKetta Department of Chemical Engineering. Dr. Maynard brings to the project her expertise in defining the
key neutralizing epitopes of pertussis toxin to optimize the potential efficacy of antibody therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Pertussis: Preclinical and Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Working with our collaborator,
Intrexon, and our academic collaborator, The University of Texas at Austin, we established a combination of two humanized antibodies
designed to neutralize pertussis toxin, a major cause of pertussis-mediated infant morbidity and mortality. Benchtop studies demonstrated
high affinity binding to the toxin, as well as potent neutralization of the toxin. In addition, the antibodies were highly efficacious
in a murine model of pertussis in which they completely mitigated elevations of the white blood cell count that is characteristic
of the illness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In April 2014, and again in September
2014, we received positive preclinical research findings for SYN-005, our proprietary mAb combination therapy for treating Pertussis
(whooping cough), in three non-human primate studies (n = 19). In the latter two Pertussis studies in particular, SYN-005 rapidly
blunted the rise in white blood cell count that is characteristic of the disease and accelerated its return to baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In addition, during September
2014 we received U.S. Orphan Drug designation from the FDA for SYN-005 for the treatment of Pertussis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">We intend to seek non-dilutive
funding to support additional preclinical and clinical development of SYN-005 for the prophylaxis and treatment of Pertussis, including
the anticipated filing of an IND application, and the anticipated initiation of a Phase 1 clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2015, preclinical efficacy data
that support advancing SYN-005 toward the clinic were presented in two poster presentations at the European Congress of Clinical
Microbiology and Infectious Diseases meeting (ECCMID) 2015 in Copenhagen, Denmark. The data suggest that SYN-005 has therapeutic
potential to diminish morbidity, long-term complications and mortality from Pertussis in critically ill infants. In addition, the
data support a prophylactic approach for use in newborns that has the potential to save thousands of lives annually, particularly
in the developing world where the unmet need is greatest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"><I>Pertussis: Intellectual Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have patents pending on compositions and uses of SYN-005
and we have an issued U.S. patent and patents pending on other pertussis mAbs from UT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acinetobacter Infections:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"><I>Acinetobacter baumanii</I>
is a difficult to treat pathogen due to its rapid and well-established development of resistance to most antibiotics, making it
a multidrug-resistant pathogen. In addition, as a biofilm-forming pathogen,<I> Acinetobacter baumanii</I> has the ability to survive
up to twice as long as non-biofilm-forming pathogens. In the U.S.,<I> Acinetobacter baumanii</I> has been reported to be the cause
of up to 2.6% of hospital acquired infections, 1.3% of bloodstream infections and 7.0% of ICU respiratory tract infections, and
more than half of the<I> Acinetobacter baumanii</I> isolates are multidrug-resistant. According to published articles, mortality
rates associated with<I> Acinetobacter</I> infections as high as 43.0% are reported in hospitals and ICU settings. While<I> Acinetobacter
baumanii</I> is a well-documented pathogen in the hospital setting, this pathogen also poses an increasing danger to wounded servicemen
and women in military treatment centers and to those treated in trauma centers following natural disasters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">A treatment for<I> Acinetobacter</I>
infections represents a billion dollar market opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Acinetobacter: Intrexon Collaboration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In September 2012, we initiated
a mAb discovery and development program for<I> Acinetobacter</I> infections pursuant to our August 2012 collaboration with Intrexon.
This program is in the discovery stage and the generation of a panel of antibodies is ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Multiple Sclerosis Program</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Relapsing-Remitting MS:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MS is a progressive neurological disease in which the body loses
the ability to transmit messages along the central nervous system, leading to pain, loss of muscle control, paralysis, cognitive
impairment and in some cases death. According to the NMSS, more than 2.3 million people worldwide (approximately 400,000 patients
in the U.S. of which approximately 65% are women) have been diagnosed with MS. The diagnosis is typically made in young adults,
ages 20 to 50. According to the NMSS, approximately 85% of MS patients are initially diagnosed with the relapsing-remitting form,
and 10&nbsp;&ndash;&nbsp;15% with other progressive forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are nine FDA-approved therapies
for the treatment of relapsing-remitting MS: Betaseron<SUP>&reg;</SUP>, Rebif<SUP>&reg;</SUP>, Avonex<SUP>&reg;</SUP>, Copaxone<SUP>&reg;</SUP>,
Tysabri<SUP>&reg;</SUP>, Gilenya<SUP>&reg;</SUP>, Extavia<SUP>&reg;</SUP>, Aubagio<SUP>&reg;</SUP> and Tecfidera<SUP>&reg;</SUP>.
Many of these therapies provide only a modest benefit for patients with relapsing-remitting MS. All of these drugs except Gilenya<SUP>&reg;</SUP>,
Aubagio<SUP>&reg;</SUP> and Tecfidera<SUP>&reg;</SUP> require frequent (daily, weekly &amp; monthly) injections (or infusions)
on an ongoing basis and can be associated with unpleasant side effects (such as flu-like symptoms) and high rates of non-compliance
among users. Despite the availability of therapies for the treatment of relapsing-remitting MS, the disease is highly underserved
and exacts a heavy personal and economic toll. Annual worldwide sales of MS therapies have been forecasted to reach approximately
$17.8 billion in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Relapsing-Remitting MS: Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Research has shown that pregnant
women with MS tend to experience a spontaneous reduction of disease symptoms during pregnancy, particularly in the third trimester.
The PRIMS (Pregnancy In MS) study published in 1998, a landmark observational clinical study published in the<I> New England Journal
of Medicine</I> followed 254 women with MS during 269 pregnancies and for up to one year after delivery. The PRIMS study demonstrated
that relapse rates were significantly reduced by 71% (p &lt; 0.001) through the third trimester of pregnancy compared to pre-pregnancy-rates,
and that relapse rates increased by 120% (p &lt; 0.001) during the first three months after birth (post-partum) and then return
to pre-pregnancy rates. It has been hypothesized that the female hormone, estriol, produced by the placenta during pregnancy, plays
a role in &ldquo;fetal immune privilege&rdquo;, a process that prevents a mother&rsquo;s immune system from attacking and rejecting
the fetus. The maternal levels of estriol increase linearly through the third trimester of pregnancy until birth, whereupon it
abruptly returns to low circulating levels. The anti-autoimmune effects of estriol are thought to be responsible for the therapeutic
effects experienced by MS patients during pregnancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rhonda Voskuhl, M.D., Director, UCLA MS
program, UCLA Department of Neurology, has published that plasma levels of estriol achieved during pregnancy have immunomodulatory
effects. Dr. Voskuhl further postulated and tested in a pilot clinical study that oral doses of estriol may have a therapeutic
benefit when administered to non-pregnant female MS patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estriol has been approved and marketed
for over 40 years throughout Europe and Asia for the oral treatment of post-menopausal symptoms. It has never been approved by
the U.S. FDA for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Relapsing-Remitting MS: Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Trimesta (oral estriol) is being
developed as an adjunctive once-daily treatment for relapsing-remitting MS in women. An investigator-initiated, 10-patient, 22-month,
single-agent, crossover clinical trial to study the therapeutic effects of 8 mg of oral Trimesta taken daily in non-pregnant female
relapsing-remitting MS patients was completed in the U.S. The total volume and number of gadolinium-enhancing lesions were measured
by brain MRI (an established neuroimaging measure of disease activity in MS). Over the next three months of treatment with Trimesta,
the median total enhancing lesion volumes decreased by 79% (p = 0.02) and the number of lesions decreased by 82% (p = 0.09). They
remained decreased during the next 3 months of treatment, with lesion volumes decreased by 82% (p = 0.01), and numbers decreased
by 82% (p = 0.02). Following a six-month drug holiday during which the patients were not on any drug therapies, median lesion volumes
and numbers returned to near baseline pretreatment levels. Trimesta therapy was reinitiated during a four-month retreatment phase
of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion volumes of 88% (p
= 0.008) and a decrease in the number of lesions by 48% (p = 0.04) compared with original baseline scores. The study was published
by the lead principal investigator in Ann Neurol. 2002 Oct;52(4):421-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Patient follow-up is complete
in the UCLA-led Phase 2, investigator-initiated, randomized (n = 158), double-blinded, placebo-controlled trial which evaluated
our drug candidate, Trimesta, in women with relapsing-remitting MS at 16 sites across the U.S. Positive Phase 2 topline efficacy
and safety results were presented in April 2014 by lead principal investigator, Dr. Rhonda Voskuhl of UCLA at the 66<SUP>th</SUP>
American Academy of Neurology Annual Meeting. Dr. Voskuhl presented additional Phase 2 clinical outcome data, including more detailed
results on improvements in cognitive and disability measures, at the 2014 Joint ACTRIMS-ECTRIMS in Boston in September 2014. The
data as reported by Dr. Voskuhl for the UCLA-led Phase 2 study demonstrated the potential of Trimesta to have a novel dual mechanism
of action for both the anti-inflammatory effects that improve relapse rate, and a neuroprotective effect that improves standard
measures of disability and cognition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically, Dr. Voskuhl reported the
following results:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Annualized relapse rate:</I>&nbsp;&nbsp;A
    47% reduction in annualized relapse rate in the Trimesta+Copaxone<SUP><SUP>&reg;</SUP></SUP> arm as compared to the placebo+Copaxone<SUP><SUP>&reg;</SUP>
    </SUP>arm (active control arm) at 12 months of therapy (p = 0.02), meeting the primary endpoint of the trial. These improvements
    in annualized relapse rate were sustained during the 24 months of therapy. When compared to the placebo+Copaxone<SUP><SUP>&reg;</SUP>
    </SUP>arm at 24 months, the Trimesta+Copaxone<SUP><SUP>&reg;</SUP></SUP> arm demonstrated a 32% lower relapse rate (p = 0.11).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Cognitive disability:</I>&nbsp;&nbsp;Patients
    in the Trimesta+Copaxone<SUP><SUP>&reg;</SUP></SUP> arm who had Paced Auditory Serial Addition Test (PASAT) scores lower than 55 before
    treatment (PASAT scale maximum of 60) experienced an approximately 12%, or 6 point, improvement in cognitive scores within
    12 months of treatment (p &lt; 0.05). This improvement from baseline was sustained throughout the 24 month study. In addition,
    a significantly larger proportion of patients in the Trimesta+Copaxone<SUP><SUP>&reg;</SUP></SUP> arm demonstrated sustained improvement
    in cognition during the entire 24 month period, as approximately 33% of the patients showed sustained improvement of at least
    3 points during this time period, compared to only about 21% in the placebo+ Copaxone<SUP><SUP>&reg;</SUP></SUP> arm (p &lt; 0.05).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Physical disability:</I>&nbsp;&nbsp;Expanded
    Disability Status Scale (EDSS) scores in the Trimesta+Copaxone<SUP><SUP>&reg;</SUP></SUP> arm significantly improved during 24 month
    follow-up by at least 0.5 point (p = 0.03) compared to the placebo+Copaxone<SUP><SUP>&reg;</SUP></SUP> arm which experienced no change
    in EDSS scores. The between group difference showed a positive trend (p = 0.25). The 25 foot walk test showed a significant
    difference, while the patients in the Trimesta+Copaxone<SUP><SUP>&reg;</SUP></SUP> arm were stable during the study, those in the active
    control arm did worse. The between group difference (p = 0.02).</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In addition, adjunctive oral
Trimesta plus injectable standard of care Copaxone<SUP><SUP>&reg;</SUP></SUP> demonstrated a strong safety profile and was well tolerated
by women in the study. Further analyses of the MRI data are ongoing by UCLA, with topline data expected from the lead principal
investigator during the second quarter of 2015. We are engaging with the neurology community and potential strategic partners,
as we determine next steps for Trimesta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">This investigator-initiated Phase
2 clinical trial was supported by grants exceeding $8 million, awarded primarily by the NMSS in partnership with the NMSS&rsquo;s
Southern California chapter, and the National Institutes of Health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"><I>Relapsing-Remitting MS: Intellectual
Property</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In March 2014, we announced
that the USPTO issued U.S. Patent No. 8,658,627 entitled,<I> Pregnancy Hormone Combination for Treatment of Autoimmune Diseases</I>,
to the Regents of the University of California. The patent includes claims to the use of our drug candidate, Trimesta, in conjunction
with a gestagen for the treatment of MS and other autoimmune diseases. The patent also includes a claim for the administration
of Trimesta, a gestagen and a third standard of care MS agent, such as glatiramer acetate injection (Copaxone<SUP><SUP>&reg;</SUP></SUP>),
interferon beta-1a (Avonex<SUP><SUP>&reg;</SUP></SUP>, Rebif<SUP><SUP>&reg;</SUP></SUP>), interferon beta-1b (Betaseron<SUP>&reg;</SUP>, Extavia<SUP>&reg;</SUP>) or sphingosine-1-phosphate
receptor modulator (Gilenya<SUP>&reg;</SUP>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In April 2013, we announced that
the USPTO issued U.S. Patent No. 8,372,826 entitled,<I> Estriol Therapy for Multiple Sclerosis and Other Autoimmune Diseases</I>,
to the Regents of the University of California which includes claims to the use of our drug candidate, Trimesta, in combination
with glatiramer acetate injection (Copaxone<SUP>&reg;</SUP>). According to Teva Pharmaceutical Industries Ltd.&rsquo;s Form 20-F for the year
ended December 31, 2014, filed with the SEC on February 9, 2015, Copaxone<SUP>&reg;</SUP> continued to be the leading MS therapy in the U.S,
and globally, with approximately $4.2 billion in global net revenues. Currently marketed exclusively by Teva Pharmaceutical Industries
Ltd., U.S. Orange Book patents on Copaxone<SUP>&reg;</SUP> expired in May 2014 and, subject to further judicial review, in September 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 6.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Through our wholly owned subsidiary,
we hold the exclusive worldwide license to issued U.S. Patents 8,895,539, 8,658,627, 8,372,826 and 6,936,599, as well as pending
patents for MS and other autoimmune diseases covering the uses of our drug candidate, Trimesta. Numerous new provisional patent
applications have been filed based on the Phase 2 clinical results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cognitive Dysfunction in MS:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">According to the NMSS and the
Multiple Sclerosis Society of Canada publication,<I> Hold that Thought! Cognition and MS</I>, it is fairly common for people with
MS to complain of cognitive difficulties, such as remembering things, finding the right words and the ability to concentrate. Among
MS patients, 50&nbsp;&ndash;&nbsp;65% have some degree of cognitive dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">The major areas of cognition
that may be affected include complex attention and executive functions<I>.</I> Complex attention involves multitasking, the speed
with which information can be processed, learning and memory, and perceptual skills; executive functions include problem solving,
organizational skills, the ability to plan, and word finding. Just as the nature, frequency, and severity of MS-related physical
problems can widely vary, not all people with MS will have cognitive dysfunction, and no two people will experience exactly the
same type or severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cognitive Dysfunction in MS: Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">In the investigator-initiated,
10-patient, 22-month, single-agent, crossover clinical trial conducted by Dr. Rhonda Voskuhl, a statistically significant 14% improvement
from baseline in the PASAT cognitive testing scores (p = 0.04) was observed in relapsing-remitting MS patients after six months
of Trimesta therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders
such as MS. The PASAT scores are expressed as a mean percent change from baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cognitive Dysfunction in MS: Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">Our Trimesta drug candidate is
also being developed for the treatment of cognitive dysfunction in female MS patients. This randomized, double-blind, placebo-controlled
Phase 2 clinical trial to evaluate Trimesta&rsquo;s potential neuroprotective and therapeutic effect on cognitive dysfunction in
female MS patients is currently enrolling relapsing-remitting or secondary-progressive female MS patients at four clinical sites
in the United States, including UCLA. Up to 64 patients between the ages of 18 and 50 will be randomized 1:1 into the treatment
and placebo groups. Investigators will administer either oral Trimesta or a matching placebo, in addition to an FDA-approved MS
treatment, including Copaxone<SUP>&reg;</SUP>, Avonex<SUP>&reg;</SUP>, Betaseron<SUP>&reg;</SUP>, Extavia<SUP>&reg;</SUP>, Rebif<SUP>&reg;</SUP>, Gilenya<SUP>&reg;</SUP>, Aubagio<SUP>&reg;</SUP> and Tecfidera<SUP>&reg;</SUP>.
Each patient will be dosed and monitored for one year after being enrolled. The primary endpoint in this clinical trial being run
under an investigator-initiated IND application is expected to be improvement in PASAT cognitive testing scores versus matching
placebo. We and a private foundation pledged to equally support this new clinical trial, and we will also provide Trimesta drug
supply. The trial also received contributions from several other supporters. Patient recruitment and enrollment into this trial
is ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements
are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the
reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting
estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making
estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future
periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and
assumptions used are consistent with those described in the  Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations section in our 2014 Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Three Months Ended March 31, 2015
and 2014</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
to $1.7 million for the three months ended March 31, 2015, from $1.1 million for the three months ended&nbsp;March 31, 2014.&nbsp;
This increase of 53% is primarily the result of increased employee costs, audit fees related to the additional procedures required
under the accelerated filer status and stock compensation expense for the three months ended March 31, 2015. The charge relating
to non-cash stock-based compensation expense was $582,000 for the three months ended March 31, 2015, compared to $255,000 for the
three months ended March 31, 2014.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses
increased by 139% to $6.5 million for the three months ended March 31, 2015, from $2.7 million for the three months
ended&nbsp;March 31, 2014. This increase is primarily the result of increased program costs associated with expanded clinical
development programs, manufacturing and research activities within our pathogen-specific microbiome-focused pipeline,
including our<I> C. difficile,</I> IBS-C and Pertussis programs. Research and development expenses also include a $1.0
million expense for achieving the third milestone as set forth in the Asset Purchase Agreement with Prev ABR LLC, dated
November 28, 2012. Prev ABR LLC exercised its option to receive the milestone payment in shares of our common stock that were
issued in April 2015. The charge relating to non-cash stock-based compensation expense was $246,000 for the three months
ended March 31, 2015, compared to $107,000 for the three months ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Income (Expense)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense was $4.2 million for
the three months ended March 31, 2015, compared to other income of $1,000 for the three months ended March 31, 2014. Other
expense for the three months ended March 31, 2015 is primarily due to non-cash expense of $4.2 million from the change in
fair value of warrants. The increase in the fair value of the warrants was due to the increase in our stock price from the
previous period. There was no non-cash expense relating to fair value of warrants for the three months ended March 31,
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net loss was $12.4 million, or $0.17
per common share for the three months ended March 31, 2015, compared to a net loss of $3.8 million, or $0.07 per common share for
the three months ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have financed our operations since inception
primarily through proceeds from equity financings, corporate partnering license fees, laboratory revenues and miscellaneous equipment
sales.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash totaled $12.0 million as of March
31, 2015, a decrease of $5.5 million from December 31, 2014.&nbsp;During the three months ended March 31, 2015, the primary use
of cash was for working capital requirements and operating activities which resulted in a net loss of $12.4 million for the three
months ended March 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our continued operations will primarily
depend on our ability to raise additional capital from various sources including equity and debt financings, as well as, license
fees from potential corporate partners, joint ventures and grant funding. Such additional funds may not become available on acceptable
terms and there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long
term. We will continue to fund operations from cash on hand and through the similar sources of capital previously described. We
can give no assurance that any additional capital that we are able to obtain will be sufficient to meet our needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Current and Future Financing Needs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred an accumulated deficit
of $113.4 million through March 31, 2015. With the exception of the quarter ended June 30, 2010, we have incurred negative cash
flow from operations since we started our business. We have spent, and expect to continue to spend, substantial amounts in connection
with implementing our business strategy, including our planned product development efforts, our clinical trials, and our research
and discovery efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, the actual amount of funds we
will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.3pt; text-indent: -13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.3pt; text-indent: -13.2pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 25.3pt; text-indent: -13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the progress of our research activities;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the number and scope of our research programs;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the progress of our preclinical and clinical development activities;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the progress of the development efforts of parties with whom we have entered into research and development agreements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to maintain current research and development&nbsp;licensing arrangements&nbsp;and to establish new research and development and&nbsp;licensing&nbsp;arrangements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to achieve our milestones under licensing arrangements;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the costs and timing of regulatory approvals.&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based our estimate on assumptions
that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential
sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. We may seek
to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not
have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we
need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other
securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able
to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit
our operations and our business, financial condition and results of operations would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Several factors will affect our ability
to raise additional funding, including, but not limited to, market volatility of our common stock, continued market listing of
our common stock and economic conditions affecting the public markets. If our common stock is delisted from the NYSE MKT, the liquidity
of our common stock could be impaired, and prices for the shares of our common stock could be lower than might otherwise prevail.
These factors could be negatively impacted by the matters discussed under this heading and under the caption &ldquo;Risk Factors&rdquo;,
included herein; also see &ldquo;Risk Factors&rdquo; in our 2014 Annual Report on Form 10-K.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_008"></A><B>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2015, our cash and cash
equivalents consisted primarily of money market securities. Due to the short-term duration of our investment portfolio and the
low risk profile of our investments, we would not expect our operating results or cash flows to be affected to any significant
degree by the effect of a sudden change in market interest rates or credit conditions on our securities portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_009"></A><B>ITEM 4. CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-indent: 16.5pt"><B>(a)&nbsp;&nbsp;Evaluation
of disclosure controls and procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-align: justify">Pursuant to Rule 13a-15(b) under
the Securities Exchange Act of 1934 (&ldquo;Exchange Act&rdquo;), the Company carried out an evaluation, with the participation
of the Company&rsquo;s management, including the Company&rsquo;s Chief Executive Officer (&ldquo;CEO&rdquo;) and Chief Financial
Officer (&ldquo;CFO&rdquo;), of the effectiveness of the Company&rsquo;s disclosure controls and procedures (as defined under Rule
13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company&rsquo;s
CEO and CFO concluded that the Company&rsquo;s disclosure controls and procedures are effective as of March 31, 2015 to ensure
that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act,
is recorded, processed, summarized and reported, within the time periods specified in the SEC&rsquo;s rules and forms, and that
such information is accumulated and communicated to the Company&rsquo;s management, including the Company&rsquo;s CEO and CFO,
as appropriate, to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-indent: 16.5pt"><B>(b) &nbsp;&nbsp;Changes in
Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-align: justify">There has been no change in
our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during
our fiscal quarter ended March 31, 2015, that has materially affected, or is reasonably likely to materially affect, our internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.5pt; text-align: justify; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><B>PART II-OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_011"></A><B>ITEM 1. LEGAL PROCEEDINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_012"></A>ITEM 1A. RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following information updates, and
should be read in conjunction with, the information disclosed in Part&nbsp;1,&nbsp;Item&nbsp;1A, &ldquo;Risk Factors,&rdquo; of
our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2014, which was filed with the Securities and Exchange
Commission on March 16, 2015. There have been no material changes from the risk factors disclosed in our Form&nbsp;10-K for the
year ended December&nbsp;31, 2014, other than as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need to raise additional capital to operate our
business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 37.4pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">With the exception of the three
months ended June 30, 2010, we have experienced significant losses since inception and have a significant accumulated deficit.
We expect to incur additional operating losses in the future and therefore expect our cumulative losses to increase. With the exception
of the quarter ended June 30, 2010, and limited laboratory revenues from Adeona Clinical Laboratory, which we sold in March 2012,
we have generated very minimal revenues. We do not expect to derive revenue from any source in the near future until we or our
potential partners successfully commercialize our products. As of March 31, 2015, our accumulated deficit totaled approximately
$113.4 million on a consolidated basis. Until such time as we receive approval from the FDA and other regulatory authorities for
our product candidates, we will not be permitted to sell our products and therefore will not have product revenues from the sale
of products. For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt
offerings, cash on hand, licensing fees and grants. If our current cash, cash equivalents and short-term investments are not sufficient
to sustain our operations, we will need to seek additional sources of funding, such as additional financing or grant funding, and
additional financing may not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable
terms, we may be unable to complete planned preclinical and clinical trials or obtain approval of our product candidates from the
FDA and other regulatory authorities. In addition, we could be forced to delay, discontinue or curtail product development, forego
sales and marketing efforts, and forego licensing in attractive business opportunities. Any additional sources of financing will
likely involve the issuance of our equity or debt securities, which will have a dilutive effect on our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot assure you that the common
stock will be liquid or that it will remain listed on the NYSE MKT. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that we will
be able to maintain the continued listing standards of the NYSE MKT. The NYSE MKT requires companies to meet certain
continued listing criteria including a minimum stockholders&rsquo; equity of $6.0 million if an issuer has sustained losses
from continuing operations and/or net losses in its five most recent fiscal years, as outlined in the NYSE MKT Exchange
Company Guide. At March 31, 2015, we had a stockholders&rsquo; deficit of $1.6 million. The NYSE MKT Exchange
Company Guide also states that the NYSE normally will not consider removing from listing securities of an issuer with total
value of market capitalization of at least $50.0 million and 1,100,000 shares publicly held, a market value of publicly held
shares of at least $15.0 million and 400 round lot shareholders. Although the total value of our market capitalization
exceeds $50.0 million and we have 1,100,000 shares publicly held, a market value of publicly held shares of at least $15.0
million and 400 round lot shareholders, there can be no assurance that the NYSE MKT will continue to list our common stock
due to our lack of minimum stockholders&rsquo; equity. In addition, in the future we may not be able to maintain such
minimum stockholders&rsquo; equity and/or issue additional equity securities in exchange for cash or other assets, if
available, to maintain certain minimum stockholders&rsquo; equity required by the NYSE MKT. If we are delisted from the NYSE
MKT then our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board
securities market, and then only if one or more registered broker-dealer market makers comply with quotation requirements.
In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock
and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting from the NYSE
MKT could also have other negative results, including the potential loss of confidence by suppliers and employees, the loss
of institutional investor interest and fewer business development opportunities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.3pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_013"></A>ITEM 2. UNREGISTERED SALES OF EQUITY
SECURITIES AND USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 22, 2015 we issued 212,843 shares
of our common stock to Prev ABR, LLC in connection with an asset purchase agreement that we executed on November 8, 2012 (the &ldquo;Asset
Purchase Agreement&rdquo;) with Prev ABR, LLC upon the attainment of certain milestones in connection with the Asset Purchase Agreement.&nbsp;
At the time of issuance, the shares of common stock had not been registered under the Securities Act of 1933, as amended, and therefore
could &nbsp;not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
For these issuances, we relied on the exemption from federal registration under Section 4(a)(2) of the Securities
Act, based on our belief that the offer and issuance of such shares of common stock did not involve a public offering as the purchaser
of the common stock and its beneficial owners are &ldquo;accredited investors&rdquo; as defined under Section 501 promulgated under
the Securities Act and no general solicitation had been involved in the offering.&nbsp; On April 20, 2015, a registration statement
registering the shares of common stock was declared effective by the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_014"></A>ITEM 3. DEFAULTS UPON SENIOR
SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_015"></A>ITEM 4. MINE SAFETY DISCLOSURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_016"></A>ITEM 5. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_017"></A>ITEM 6. EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: white">
    <td style="width: 8%">10.1</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 90%">Employment Agreement with Steven A. Shallcross dated April 28, 2015 (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed May 4, 2015.)</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td colspan="2">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top; background-color: white">
    <td>10.2</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">Severance Agreement with C. Evan Ballantyne dated effective April 29, 2015 (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed May 4, 2015.)</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: white">
    <td style="width: 8%">31.1</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 90%; text-align: justify">Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) *</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.1pt; text-align: justify; text-indent: -34.1pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: white">
    <td style="width: 8%">31.2</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 90%; text-align: justify">Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) *</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.1pt; text-align: justify; text-indent: -34.1pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: white">
    <td style="width: 8%">32.1</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 90%; text-align: justify">Certification of Principal Executive Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 *</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.1pt; text-align: justify; text-indent: -34.1pt">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: white">
    <td style="width: 8%">32.2</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 90%; text-align: justify">Certification of Principal Financial Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 *</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="background-color: white">
    <td style="width: 8%">101.INS</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 90%">XBRL Instance Document *</td></tr>
<tr style="background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="background-color: white">
    <td>101.SCH</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Schema *</td></tr>
<tr style="background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="background-color: white">
    <td>101.CAL</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Calculation Linkbase *</td></tr>
<tr style="background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="background-color: white">
    <td>101.DEF</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Definition Linkbase *</td></tr>
<tr style="background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="background-color: white">
    <td>101.LAB</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Label Linkbase *</td></tr>
<tr style="background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="background-color: white">
    <td>101.PRE</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Presentation Linkbase *</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Jeffrey Riley &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeffrey Riley &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: May 11, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ C. Evan Ballantyne &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C. Evan Ballantyne&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: May 11, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v409108_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-14&nbsp;OR RULE
15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Jeffrey Riley,
certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">1.</TD>
    <TD STYLE="width: 98%">I have reviewed this quarterly report on Form 10-Q of Synthetic Biologics, Inc.;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">2.</TD>
    <TD STYLE="width: 98%; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">3.</TD>
    <TD STYLE="width: 98%; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">4.</TD>
    <TD STYLE="width: 98%; text-align: justify">The registrant's other certifying officer(s) and I are&nbsp;responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&nbsp;for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">a)</TD>
    <TD STYLE="width: 98%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that&nbsp;material&nbsp;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">b)</TD>
    <TD STYLE="width: 98%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">c)</TD>
    <TD STYLE="width: 98%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">d)</TD>
    <TD STYLE="width: 98%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">5.</TD>
    <TD STYLE="width: 98%">The registrant's other certifying officer(s) and I&nbsp;have&nbsp;disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">a)</TD>
    <TD STYLE="width: 98%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">b)</TD>
    <TD STYLE="width: 98%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-bottom: 1.1pt">Date: May 11, 2015</TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1.1pt">By:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid">/s/&nbsp;Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v409108_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT 31.2</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14&nbsp;OR RULE
15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, C. Evan Ballantyne, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">1.</TD>
    <TD STYLE="width: 98%">I have reviewed this quarterly report on Form 10-Q of Synthetic Biologics, Inc.;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">2.</TD>
    <TD STYLE="width: 98%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">3.</TD>
    <TD STYLE="width: 98%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">4.</TD>
    <TD STYLE="width: 98%">The registrant's other certifying officer(s) and I are&nbsp;responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&nbsp;for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">a)</TD>
    <TD STYLE="width: 98%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that&nbsp;material&nbsp;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">b)</TD>
    <TD STYLE="width: 98%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">c)</TD>
    <TD STYLE="width: 98%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">d)</TD>
    <TD STYLE="width: 98%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">5.</TD>
    <TD STYLE="width: 98%">The registrant's other certifying officer(s) and I have disclosed, based on&nbsp;our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">a)</TD>
    <TD STYLE="width: 98%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">b)</TD>
    <TD STYLE="width: 98%">&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Date: May 11, 2015</TD>
    <TD NOWRAP STYLE="width: 1%">By:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid">/s/&nbsp;C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Financial Officer)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v409108_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION&nbsp;PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.25in; text-align: justify">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics,
Inc. (the &ldquo;Registrant&rdquo;) hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">the accompanying Quarterly Report on Form 10-Q of
the&nbsp;Registrant for the quarter ended March 31, 2015 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section
13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Registrant.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.7pt; text-align: justify; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Date: May 11, 2015</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD NOWRAP>By:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/&nbsp;Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Executive Officer)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v409108_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION&nbsp;PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.25in; text-align: justify">Pursuant
to 18 U.S.C. &sect; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics,
Inc. (the &ldquo;Registrant&rdquo;) hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">the accompanying Quarterly Report on Form 10-Q of the&nbsp;Registrant
for the quarter ended March 31, 2015 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section
15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Registrant.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Date: May 11, 2015</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD NOWRAP>By:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/&nbsp;C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Financial Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`$D`F<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]N?\`@OW^
MWU^U9^P[??LC+^S)\1]/\`)\4[3]H,^.EOO`?@3QK_;#^!)?@<?"KPOXT\/:
MZVE'3/\`A,O$B.-,-K'?+J6;]+A[*Q>V_G=_X?Z?\%4O^CC-`_\`#%_`[_YW
M]?J[_P`'5G_'[^P/_P!>?[6?_HW]F>OY1/`W@CQ'\2/%_A[P'X.M-+O?%'BK
M4!I>AVFM>*/"/@G2KB^,$]R([[Q9X\UWPQX.T&$PV\I^W>(?$&E6'F!(/M7G
MS012?U#X:\-<+XW@G+LPS3(\HQ5?FS-XC&8W#QG/V5#,,5&+J5)35H4J2:NU
MI%:WL?@G&V?9[AN*,;@L!FF98:E".`A1PV$Q4Z<'.K@Z-1J%-0:4ISJVLGK9
M/1MV_5[_`(?Y_P#!5(_\W&:!_P"&+^!P_GX`I3_P7S_X*I#K^T7H'/\`U0OX
M'?\`S`5\]:A_P2[_`&R?#=YKUGX^\&_#;X=2:!\&_B-\=95UKX^?!#QE=ZEX
M!^&?@:X^(FKW6G:'\%_'?Q6\31/KGA>V:Y\(:KK6A:/X.UV>:SA/BNRCO;:>
M7\^@DAG%KY$_VO)!L?(E-\K&%;G:;(QK=@K:D73[H%*6^^X<+$CLOV."X=\/
M,R=19=DG#&.]E&C*H\)AJ=>,5B%6="U2G6<*CJK#UW"-)5)?N:EU>+1\YB,Z
MXTPCIK%9CQ%A_:R<*?ML56A.52,HP</9>Q=6+]I.$$YQBISG&,$Y-)_L3_P_
MT_X*I?\`1QF@?^&+^!W_`,[^C_A_I_P52_Z.,T#_`,,7\#O_`)W]?CH"IC>9
M49X8XY97FCC,L*PVYB%Q,9HPT7D6_GVWGS!S%"+NS,CJ+VT,TTD,L+RQS6MQ
M#)`@EGCEMY8I(8F)42RI(BM'$2"/-8"/C.[!4GN?!7!D7:7"^0Q:M?FP5.-K
MI-7YJT$M&GJU:ZORW2?-_K/Q/K_PN9WIO_ME?3WIPM_N^_-2JQLKMRIU$DW"
M7+^PO_#_`$_X*I?]'&:!_P"&+^!W_P`[^C_A_I_P52_Z.,T#_P`,7\#O_G?U
M^/`CD:X^QK;3O>Y9?L26\CWI98UF919HC7+.(724HL1;RY(WQMD0LD2M.D,E
MO#+<1W#M';26\+W$=U*A`:*VDA5TN)060>5"SN3)$`I,L89?ZF<%+5\,\/I<
MJG?ZK0MR.,IJ=_K-N1PC*:DFXN,924G%-@N)^)VU%9YG;E)M12QE:[<7",DE
M[!-N,JE.+5KJ4X)I.23_`&('_!?/_@JD>/\`AHS0/_#%_`[_`.=_2_\`#_/_
M`(*I?]'%Z!_X8OX'?3_HG_/X5^>_@']F3XE^-M1^")UJ;P3\&?!'[0Q^(A^%
MWQG^/7BRV^&GP5U:'X6IK$/C.?4/'D]OJ<.D1V&MZ'=>$[%+RP\_5_%E]I.E
M6,$L-X+M/GP!GC%PJ2M;-*84N#$_V=IE19&MA/M$!NQ$P=K57,^TLWDJ@)'/
M#A;@&I4J4J?#_#=2=%3]M&&%I24)1JUJ#BZJKNC[2G7P^(IUJ'/*O3=*=Z2Y
M6RY<1<60ITZLLZSN-*IR.$I8O$7G&I"E5ISC%8?F5*=.O0G"O)1H.-:FU4]^
M-_V*_P"'^G_!5+_HXS0/_#%_`[_YW]'_``_T_P""J7_1QF@?^&+^!W_SOZ_.
MCPA^S/\`'CQ]\$/BC^TEX.^&.KZ]\#/@KJNDZ'\4/B);ZGX6MM.\+:KK<VC0
M6-F-&U'7K+Q7XA:-O$6A2ZM-X3T#7K;P[::M8:AXCFTFPN$N3X:RLBEW@E5`
M8`6:!PN;J1XK5<[?O74L4\5LHRUQ);74<(=[6X$6E+A'@6O.K2H\.<.5JE"N
M\+7ITL-1J5*.)5*G7>'JPA7<J==4*M*LZ4TJBI5(5'%0E&3)<1<60C2E/.<^
MC&O1^L4)2Q5=1K4.>=/V]%NA:I1<Z=2"J0<H.=.<4W*,DOV)_P"'^G_!5+_H
MXS0/_#%_`[_YW]'_``_T_P""J7_1QF@?^&+^!W_SOZ_'E8I'N9+-+>9[V(L)
M+-('>\0HL<C[K55,X"130S.3'A()[>=]L5Q"\D:E&`9=K`]"-I!'4$$9!!'(
M()%:+@O@N3<8\,9`Y12;BL'3<DFVDVE6;2;32;23:=F[&;XIXF6^?9RM6M<;
M56JW6M%:JZNMUU1^Q7_#_3_@JE_T<9H'_AB_@=_\[^C_`(?Y_P#!5+_HXO0/
M_#%_`[_YW]?CO@>@_(4U@H'(_+C_`#_GO5K@G@RZOPMD:5U=K`0;2NKM+VFM
ME=_(%Q3Q*VE_;V<N[2LL?4N[NVG[K?L?L0__``7W_P""I\88O^T=X?4+@N3\
M#/@<`@8L%+'_`(5_A0Q5@I8@,58+DJ<.7_@OG_P52<`I^T7H#@@$%?@7\#FR
M&.%(Q\/SPQX4]">!DUZ7_P`$L/C-I?[/W[(7[<7Q8UOXN_&3X+Z/X3_:!_X)
M[ZGJGB7X#^'-$\4?$+7-+T[Q[\5=0U3P%;Z5XC\:^`]#DT+QS86T_AOQ'/JN
MJZEIUGH][=3ZAX7\46'GZ'>=AKNG?L1?''3OV,?B5XS_`&>OA5\'_"W_``4*
M_;Q_:BM_BK\3=0\4^-="\3?!_P""W@C]H;P3J/AGP;X>/AWQMX=^%W@R[\6:
M7XGMO`_B_P`=ZAX6U*S\.>%;WQ#/X<309S;>)=&^*Q.'X2P.99CA,3X=8"K@
ML%BGA(8W!8;#SG6Q%'*99MB,/&CBJE*%6NL/&52G#"3K.,8+#8A0QN(P\#Z>
MA6XAQ6!P->AQKBXXO%8>EB:F$KXW$0C0IU\94P5*7M:<)2M[=4HU)5HTH14Y
MRB^6FV_!/^'^?_!5+.W_`(:+T#(+`C_A1?P.R"N[<#_Q;_@KL?=G[NQLXVG'
M0:S_`,%QO^"O_AS3_#6K^(_B_=>'-(\::5-KO@O5O$'[-'PHT/2O&6A6VH7>
MD7.N>$=2U3X96EEXGT6VU?3]0TFXU;0I[_3X-4L+[3I;E+RSN88OJW3?V+_@
M!>_$S]G?0/VD/V4/@_\`LU_M$>*/BG^U]HW@3]D3PC\9O%5OX3_:/^''PZ^$
M,VO_`+,=YX_U?7_C/XVU#PQ=^+OCC!/X#TOQ?8>+_A_9?&N33B]EI4^CZAI6
MFZ?N_%[]G"U^.'A#X+_!7Q%^SU\.O`?[0^G?\$A/VA-;^"W[.G@SQU>:IIWA
M/]ISPM^UI:7FL>&_AK/X@^)'C"^/C>QT:3XDZ@WPGU_Q[XPUGP.R^)?!FJ_;
MKCP'?RZ?P3Q_A[[?#TJ?`^5.G*53ZSB)T\OE2A3C-THUL++#UYPQ>%A-PK8C
M,*,YX"CAU7A*M'%T9072Z'%T</6JRXLS&4U[-X:G#$8R,JG,YRG3Q%.K257"
MXETZ<X4<+54:]6O*BU#ZO4YCX6_X?Y_\%4B0!^T7H!R`1CX%_`XY!X!&/A_R
M">`1U/'6F+_P7V_X*GMOV_M'^'6,;%)`OP.^!A,;@`E)`/`!*,`02K8(!&0,
MBOKZ]_8<^&/AK4/BAI/P>_94^"_[4/[27@;X(_\`!.>[N?V?/$_Q>OH_!-MX
M9^*OPQO;_P#:<^/.C:AX2^-?@#3_`!E-?>.4T'1;OQ_IWCW5?`WPXLM?M_'$
MM@WA6]E.L_%__!16>/Q'^R]_P30\>>&?@?\`!OPIX!U+]EK1?"\_Q6^&B^(+
MB]D^)_@[QC\4]/\`&7P5N]2U/XF>+K>\L?"EF-'\8:H=8\-7OB>3Q-KNISR>
M-9M.DM/#>F^A@H\!YCF.!P6#X(R=TL9B:V%>*JPP$?93AEN,S*E/ZK&K]8J4
MJT,+"%.HDHU_:3EAI5?9R2X\35XLP>#Q&)Q'%69>UH8>EB5AJ6(QK<J<\7'!
MU(^WG2]BJU*KSRG2O*I1A!.O&"G%FI_P_P!/^"J7_1QF@?\`AB_@=_\`._H_
MX?Z?\%4O^CC-`_\`#%_`[_YW]?CL%&!P.GH*7`]!^0K[/_4G@W_HELB_\(8?
M_+#YK_6KB7_H?YQ_X7U/_E1^Q'_#_/\`X*I'/_&1>@<!F/\`Q8OX'<*H+,3_
M`,6_Z*H+,>@4%C@`FM/P]_P78_X*V^+M?T;PIX2^.$7BOQ7XDU.ST3PWX6\,
M?LZ?!_Q!XE\1ZUJ5W#8:=HWA_0-(^&UYJ^MZOJ-_<6]C8:9I=G=7U[>3PVMM
M!+/+'&WXKZD,6%Z5!R+2Y(QD#*PLVYL$?ZL*95R0`\:GDX4_W*_MGZ-=^._B
MO;^'OBUJ7Q6\)^#1_P`%/_\`@G)KWP:U#XT?%+POK7ASXO:#K[^'/`'Q0\+_
M`+#,O@:Z\#?%7X#VG@73]>F\>_%+6KO4?&%_J-UI^MS:;XCT'^U;A]$^0XGP
M7!_#V)RVA'@GA[$QQU/'U*E2I25%T5A:;]BZ=*G[:K7]I7<(U5&G)TZ3G53I
MPA.O2^CR+&\0YS1Q]1\4YUAZF#EA5"FL6Y1K*O4HJI*52<8JE&G2G5:E)J,J
ML(4M7-I_@AJ__!=O_@K3X>UC6/#WB'XZVF@>(?#VJZCH7B'P_KO[/7P:T?7?
M#^NZ/>SZ;K&AZ[H^I?#FVU+1]9TC4K6YT[5-*U*VMK_3M0MKBRO+>&Y@EB34
M\2?\%O\`_@L+X,;0%\9_%J^\'-XL\*Z-X[\)KXM_9E^%7AEO%7@7Q&+@^'/'
M'AA=<^&-@?$/@SQ"+2Z.@^*]'%[H&LBUN3INH77D2[/KSP)^QW^R[XJNK+7?
M%/P+^'7CWX`^*?B[_P`%%H?V\_VO/&/QL\80_$3]C_4?AW\5_B=HOP,TKPQ,
MWQ4TNP\,:C:Z-9^!?$]G+X[\"_%/6_CM<>+HWEN?LCS7$U/Q#\&=`^,O@/X4
M>(_#WP,^'W[6/[5GPX_X)"_\$OH_@+^S=X_\9:[8>'?$MKXKU[XH:7\>_'5S
MX2\(_$;X4^)/B%JOPRT&W\,6[:/'XZT^'0&\91>)=5M+B:*R#>2\P\//:TH1
MX(ROD::J2J8?"4FJDJ.&C3YY.O4H99!8ZI75?^UJM*=#+(87,IVHXNFST'A^
M+5&3?%F9)OEG"*Q&*G+V<<0HXA*,(.6*J+#2C4PZP2J0K5U4H7;HU5'XK'_!
M?+_@JF3@?M%:"2><?\**^!V<>N/^%?\`3KSTX/H:Z37_`/@M_P#\%AO"<'AF
MZ\6?%F_\*VGC;PY9^,O!5UXG_9D^%?AZU\9^#M2N+BTT[Q?X0N=9^&%E#XH\
M*ZA=V=W:6'B30GO]%O+JTNK:VOI9K:9$_1OX4_L"_L1OX@_:F^(GP\_9X\*_
MM#?#SX;_`+2_BOP1J7PXM?\`A?/[1'B#3=&T/]BCX<?%&?X-?LXZG\&O%6C:
M3=^*M!_:W\>:SX-UKQE\8;F^TGQ-\.]$N?#/A[Q,WB+P_P#:HOG'P]^S;\.O
MB'\+/A#X@\+_``1\)?M'?M/Z1_P2N_92\?\`P-_96^)?Q"^*%YX)\6>)_'7[
M5?Q7\-?M"ZYH?A>X^,?@GQ%+9_!CX:VIOM$^%VA^//#^A:'-J=SJ+^'[[7K>
MU>*89GX=U:CC3X$P,84IPI5G7PN!IR=?$9?AL90HJ4\53IX.,*N)5/%XW,7#
M`TZ-*K7A47NP'+"<7THI5N+L9[6I3=6DJ&,Q=:'LZ6*KX>LY6H\]2<HTE5HT
M<-[2JE)QKQ32;^33_P`%\_\`@JD!D_M%Z!@@$?\`%B_@=R"<`K_Q;_YMQX&,
MY[9H7_@OI_P51<!D_:-\/NK'"E?@9\#6!;.-H(\`'+9XVCG/&,UR_P#P3U\$
M:#X8_:D_:+_:*\?7O@7X`^$/V*/"/Q8^(EA=^()O$'Q1^&GPT^/7B?7;[X+?
MLX^"IM0\$6GQ*\6^.=(\%_%'Q9!KOA[7O#]MXZU/7(_A5:ZG$=;FOHKVOU-M
MOV./A!^U9^UG\3?VHM-TGX+_`!W\,_M#_LB_"G]H[P3J^M:#^T%-\`6^/5G\
M9?`'P+_:V+_"[X<0>`/VBM>E:ZT3Q;XE\,6^HZ18V?A?Q5X_AUGXA^&[>*UL
M4L_1S5\`Y/BL73Q7!.5?5L)E4,9+$4\)";JYE6HX/%T,JHS4/J-253!8ZEB?
MK$,;.5H5E'"3A#VCY<M_ULS/#4*E'BG,Z>)K8^IAWAJV.E!T\%2E7I5,PFDW
MB(05>A*DJ4\+&.L).O%SC%?FV/\`@OG_`,%4CR/VC/#Y&,@CX&?`T@CU!_X0
M#D>XXH_X?Y?\%4^O_#1>@8X.?^%%_`[')`'/_"`8Y)`'/)('4C/Z$?"#]D#]
MB_XA:M^TCXDNOV,O%NK7.B_MH^//A/XN_9XTSPSX@TSXG?L[?LR:#\//#\/P
MF\37.F?$7]MC]GV\^`.I_$M3J_Q)U/\`:&\<Q?&3P&NI2ZQI]EHGA#PS96D-
MG\MZ%\!?V4M5^`WP[\&I^SSX-OO%/C__`()%?M2_M>3?'G4_%'Q(M?BE%\7?
M@?K_`,4Y/A=J-IHNB>/K+X8:=:W%GX:N?^%AZ<?".H+XW2?3]/BNM'TKPS+;
M:MRX?&^'N(JRI0\/\/'V=;"4JLWALJ=.$*N&P=?$XB,XXZ3G2POUVDHJ-)RQ
M,8SEAYU4E,UGA^,J:AS\858RG3Q%2SS#,%R.G6K4J%.HG@HVE7CAL1)\M6]-
MJG&<(R<X+QZS_P""]W_!5K4;BWL],_:%T;4+R[O(M.L[6Q^!/P/NI[K4+B<6
MUO8V\,7P_9YKN>Y9+>*VC!EDF81(I<@5T?C;_@M__P`%?_AQXO\`$O@#Q]\:
M[+PEXV\&ZS>^'?%?AC6?@/\``F+5M`UW393!J&DZG##X%GCAO;.96AN(5F<Q
M2*T;D.K*OV5\0?#?AOQ)^UG^Q'^UMK?P&^$7@3]FC]GC_@GIX(_;@U;Q?\*8
M-:LK/XJ:M\!_ACX'N+#X0"\UOX@^.+*[3X??M`:Q\+OAWX5T6;1-.\:-;>)=
M=T_Q?K?CW4[:WO\`1/YH?%'BKQ)X\\4>)_'?C/4)M:\8^.?$6N>-/%FLSLTD
MNK>)O%>J76OZ_J4DDLLTCM?:MJ%W=;GFF=A*"\LK$NWL9%E/!^=U9.'!O#V&
MHT<!AZF+A/#X6O7P^9XG,<SPT<#[7"U71E[/"9<L16A5Y<53JXJC3J0C%P<_
M-S;,N(,KI0DN)\XKRK8JK##SCB<11A4PE'"X*K+$25:FIWG7QL:5)T^:C.%*
MI*,W*,E'];?^'^G_``52_P"CC-`_\,7\#O\`YW]`_P""^?\`P52/_-QF@?\`
MAB_@=_\`._K\=OEQG`Q]!7OWP)_9:^._[3*^/9?@EX*TGQ1:?"[2-$U_XAZK
MKWQ-^$/PKT/PEHOB/5)M$T+4-3\0?&#Q_P##_0VBU/5X7T^VCL]1NKC[5Y22
M0Q^=`9/HL1PCP+@Z$\5C.'.'<+AJ3C[7$8C"T:-&GSSC3CSU:M:,(.=2<*<%
M)^]4G""O*23\>CQ'Q7B:D:6'SG/:]6=^2E1Q5>M4DXQE-\M.G1E.=HQ<FHIO
ME3>FY^AG_#_/_@JE_P!'%Z!QZ_`OX'?_`#OZ3_A_I_P52_Z.,T#_`,,7\#O_
M`)W]?`OCC]E3XL_"A?CII_QH/@KX+>._V?C\/#XE^$OQ0\8Z=H/Q0\>0?$K7
MIM$T>^^"7AZQ&J:;\8=(TB.+_A)/$VO>$/$,F@67A![;7-+U/5TG51\XB*7S
MDM?LMP;J1!)':"WE:ZDC,4DP>.W$8GE0012SEUA&VWBDF<(D;LN>&X5X"Q<'
M/#</\-XB,7%.=+"TG3?/3IUJ<J<YXB*JTY4:U&HJU-RH24_=JJS4:K<0<789
MJ.)SC/*,V^7EGC*\9*7/.FH2A*ASTZG/2J0=*I%5%*$DXZ-G[$?\/]/^"J7_
M`$<9H'_AB_@=_P#._H_X?Z?\%4O^CC-`_P##%_`[_P"=_7X[+AHI9UC9H+=X
M8KB<)^XMY;DJ+:*XF_U<$MT9(Q;13,DEP9(Q"KF1`TCPRQ><)+:9#;(LMRKP
MNK6\;K&ZR3J5W1(RRPD%PH_?VXZW$`DZ%P9P4[6X9X?=W%)+"46[SG&E&-EB
M&U*52<*<8R49.<X04>:44\7Q1Q,KMY[G22=FWC*Z2=G*WO8>-W9-Z<VB=[6L
M?L+_`,/]/^"J7_1QF@?^&+^!W_SOZ/\`A_I_P52_Z.,T#_PQ?P._^=_7X[%2
M&9&AE1TM4OF5X70K9.KNMX2R@?92D4C&XSY2K&Y9U"G$S6URLAA>SNHYQ&9O
M(DM98Y_(4R*TX@=%E,"^3.6G"&)4@G=G"02LA_J9P5:+_P!6>'[2BI1:PM!J
M46VE)6Q+O%N,DI:*\7KHQKB?B=JZSS.VE-TVUC*WQI)N'\#XDI1;CNE)76J/
MV#_X?Z?\%4O^CC-`_P##%_`[_P"=_1_P_P!/^"J7_1QF@?\`AB_@=_\`._K\
M=P%(R`,'D<"FNR1J78<`9.%R?H`!DGT`Y)X&3Q5/@K@Q)M\+9$DDVW]1C9))
MMM_O-DDV_)-]"?\`6KB7_H?YQK;_`)CY]6DO^7:W;2WZKN?L5_P_T_X*I?\`
M1QF@?^&+^!W_`,[^C_A_I_P52_Z.,T#_`,,7\#O_`)W]?&/Q]_8)_:^_9?T`
M^*?CI\$KWP=H$7BC3?!6HZCI/CSX2?$P>'?%VM:#!XHT/PWXRLOA+\0/'FH^
M`]8U[P]=6VKZ!9^-K/P_+KEI<0MI(O))%C/R(`2'(B=ECM([^1UC9HX["9?,
MAOWD`*+931$3PWC,+:6V(N8Y6MR)3RX7A?@#'47B,%D7#&,H*4H.MA:.&Q%-
M2BXQE'GI8F2YHRG!-6=G*.]TSHKY_P`7X6JJ&)S7B'#UY*+5&OB,32JM3Y^5
MJ$\-=J7LY\K6_)*VL6C]BO\`A_E_P52(S_PT7H&.G_)"_@:/Y^`*/^'^7_!5
M+_HXO0#GT^!?P./\O`%?EU\'OA9XG^./Q6^&?P>\%/I4'B?XL?$;P?\`"[PQ
M?^(+F^L/#%MXI\;:S8Z'I']N:MINF:Q<V6GPW5_!-J$]EINIWEK;!Y(=/NYM
MEM)O_%;X(ZU\(;#PU<ZUXZ^$WBK4=?U;XH:)JOA;X<^-SXK\7_#O4/A-\0KW
MX;:Q!\5-!_LC3+CP-/XJU6QEU_P##>M/)XD\'20ZX\.FLS6E*IPOP%3Q5/`R
MX>X>6,JW]G0_L^3DG&<HRA5<:G+1DG"I'][*DE-*,DN9.27$'%\J$L5'-\[^
MJQWQ+Q]3V3;CSI1M0YYR<;RC""E*44Y+1.WZ3?\`#_+_`(*I\?\`&1>@<_\`
M5"_@=_/_`(0#\O6D_P"'^?\`P52SC_AHO0,YQ_R0OX'=?_#?U^7GAWX:W'B'
MX<_%;XCMX[^%_AV+X2S^!+:_\`>+_&EOX=^*WCMO'NOW>A)/\*?!%U9M<^-H
M/!ALWUGXBS_:M+A\)>'I(]0GENY)DC7SI8IVD2W6UNGNG@2[6W2UG:Y>U=@J
M7:6Z1FX:TD8A8[D1F&0L@21F9<ZTN$>!JTJT:7#?#\_85_J]1_45:-1T:6(2
MNZMIKV%>G-RI.I"S;YTG&^;XDXK@HRJ9SG<(S2E3;QU5\T&YPO*/L'*G+GHU
MER5%&24)*24J=3E_8G_A_G_P52_Z.,\/_P#AC/@;_P#,!2?\/]/^"J7_`$<9
MH'_AB_@=_P#._K\U=>^!_C/P[\!OA?\`M&7][X9D^'WQ>\=_$OX=^$[2QU._
MN/%46N_"BR\*7OB2ZUK3&T>#2;/1KV/QEI:Z'>6GB#4[N]>VOS<Z5IMNUC/<
M>0X'H/R%%#A'@?%4W4H<-9#4A&K6H2<<!;EJX>HJ=6#4IIWC)QVNG&<'=\R8
MI\3<4T^55<[SFFY0C4BGF$I<U.:DX33C3MRRY)\KZ\DGT=OV(_X?Z?\`!5+_
M`*.,T#_PQ?P._P#G?TO_``_S_P""J7_1QGA_\?@9\#1_/P!7XY2R1PH\DF`D
M:-(YVYVHH)8X`).`#P`2>PK]!-1_X);?MR>'?&'PR\'^./@[I_@,_%3XK?#3
MX,Z9XBU3XG?"WQ?X=\'^./BZVFMX!MOBG'\'_%_Q0\4_#2PU^RU2UU2QN/%7
MA2SNM2LF1-$L=3U&6&QFY\;PYX>Y=R?7LCX9PLJL*TZ-.OAZ4*M>-"/-66'I
M>U]I6E36LE3C)QZIW2EO0S[C#%1JRPN:Y_B8T.3VTJ.+JRC2]HXQI^UFJ3C3
MYW)*"FTYMI1O>Y]$?\/\_P#@JE_T<9X?_#X%_`X_R\`4?\/]/^"J7_1QF@?^
M&+^!W_SOZ_)/Q1X;U+PAXJ\0^#]62&76/#?B#6?#-X=/,]S:WE_H&LW_`(?O
M+G26E@M[J^TVZU/3KN/3KL6D!O`A46\%RLMK#AA7,EQ"+:X,UHLSW4`MIC/;
M);M&D\EQ`$\V".&26..225%1)'6-F#L%KK7!W!$H>TCPWP[*G[*-?G6&H<GL
M962JW>*_AMM1YFVN;W7[WNF/^LW%/,X?VWG?/&4H2BL96;C."YIP;6'MS1BG
M)I._*G*SBFU^Q'_#_3_@JE_T<9H'_AB_@=_\[^C_`(?Z?\%4O^CC-`_\,7\#
MO_G?U^.F1L641N8GN#:),(V,+7(A^T_9Q,`8O.:V_P!(2,N&>#]\@:,AC[?X
M4_9M^.OCCX,?$?\`:)\+?#'7-2^!WPEFT^U^('Q+FO/#VC^'M'O-2U70=$BL
M=-37=9TO5O&.HV>I^*O"]OKNF^!M-\2W_A>/Q)H-[XFMM(L-7L+JXFOPAP-A
M8QGBN&^'L-"=6E0A+$82E1C.M7J2I4*4)5:L%.I6JPG3HPBY2JU(3A3YY1DH
MU2XBXLK.U'.<^JOV4JUJ6*KS?L8QE.5:T:#?LHPA*4JGP*,9-R23/T<_X?Z?
M\%4O^CC-`_\`#%_`[_YW]'_#_3_@JE_T<9H'_AB_@=_\[^OQWP/0?D*,#T'Y
M"M?]2>#?^B6R+_PAC_\`+#+_`%JXE_Z'^<?^%]3_`.5'[$?\/]/^"J7_`$<9
MH'_AB_@=_P#._I?^'^7_``52(S_PT7H&/7_A1?P._P#F`_S^-?G)\"/V;OC3
M^TUXA\5>%O@=X,L?&6L^!O`VJ?$SQBNJ>/?AE\-M(\-^`M$U70]$U7Q/JWBC
MXL>-/`GA6VL;'5/$FBVTL1UIKXK>M=1VDEE9:A<VG?\`Q&_8G_:'^#O@?XH^
M-?BMX2L_`-Q\(OC-X#^!7B_P)K.J_;O',WC+XC^!?$/Q(\,:EX9M_#=GKG@_
MQ1X*NO!_ANXU1/%^C>-;K2]2M;VQN]`36K%[J^M?/K\/^'6&Q"PE?)N%J6+;
MH+ZK.A1^L_[2VL/>A&O[6$:UGR5)Q5-*TI.,91E+KIYUQI6H_6*.9<0U:#]I
M:M'%5E1DZ*O5C"LZ/LY3AU@I7O=6NFE]M_\`#_/_`(*I?]'%Z!_X8OX'?_._
MH_X?Z?\`!5+_`*.,T#_PQ?P._P#G?U^.2.KV\EV@:6TC,?F7:HS6T9F\KR4E
MN`##'),9X%AC=U>5IX$C4M-&K.)"QQRO&Z1S!C"\D9C6<+)Y+F`N%$WES8AD
M\O=Y<SQQ2;9)8U;O?!7!D;J7"^0)J3@T\+0TDH.HXO\`VK=4TZC6ZIKG?N>^
M^7_6GB;E4GGN=13@ZFN-JZ04U3<FU1M:-5^R<E[OM/<5Y:'[%_\`#_3_`(*I
M?]'&:!_X8OX'?_._H_X?Z?\`!5+_`*.,T#_PQ?P._P#G?U^1OA[P_K7BOQ)H
M?@[PYI%YJWBKQ+KNC>&-"T"WB6/4]2\0^(KVTT[0](A@NFM_+O-3OK^RM[=+
MEH$WW,;2O'&2X]P^//[)W[0O[,<'@:]^./PW'@_1_B;8ZYJ'P^\3:1XV^&?Q
M,\&^+X/#.IC1_$<.B^./A)XT\>^#[C5-`U)XK;6=#?7(]<TO[1:SWNG06UW:
MS385.%.`J5:AAJO#_#5/$8J,Y86A.A0C6Q,:;DJDL/3=?GK*#C)3=)3Y>6=U
M:$W#6/$/%LZ5:O#-\_E1PS@L16CBJ[I8=U.7V:KS5#EI.ISPY/:<O,YQ4;N2
M3_0+_A_I_P`%4O\`HXS0/_#%_`[_`.=_1_P_T_X*I?\`1QF@?^&+^!W_`,[^
MOQWP/0?D*BFEAMXI9YB$B@C>:5R,A(XU+NY`!)"JK$X!.!TKI7!'!S=EPKD;
M;V2P$6]TO^?G=I>K7<Q_UJXD_P"A_G'_`(7U.B;?_+OHDWZ)OHS]CA_P7R_X
M*I'_`)N+T#T_Y(7\#1_/P!2?\/\`3_@JE_T<9H'_`(8OX'?_`#OZ^=;[_@ES
M^W'H'B3X:^'?&OP;L_`T'Q2^*GPE^#NG>)=0^)7PL\7Z%X-\8?&^]TBS^''_
M``M.U^$OC+XD>*_AGI?B"/6]/OK&Z\7>%M/GU&":.STJSU#5I[;39_B/QCX5
MU;P-XT\5>!-<2V?7O"/BOQ#X-U$Z<]S<Z??:OX8\0W_A:_FT2>[L["ZU#3;K
M5=-G&G3FR@GGBDA\RWAF<PKY^%X=\.\;)PP>2\+8N2C*HOJM"C6A[*-54)2=
M6.(]FW&NU2:A*5I/6R]]]=?.>-<*D\3F'$>'C*2A&57$XB#E-P=11Y'A^=2=
M.,YI-:QBW?HOUF_X?Z?\%4O^CC-`_P##%_`[_P"=_1_P_P!/^"J7_1QF@?\`
MAB_@=_\`._K\=@K-)-"L$QFMX9;BYA$$GG6T$'E^?-<1;?,@C@,L2SO*J+"\
ML<<A5W52APJ&4QL(A<+:>;L_=?:W@2Y2U$@^0W+6TL5R(`QE^S2Q3[/*E1V[
MUP5P8[6X6R&7-*G&/+@J<^:56'/2BO9UJEY58-3II:U(^]!21RKBGB9WMGN=
M:*4G_MM96C"2A.3OAU90DU&3VC)I2LVC]BO^'^G_``52_P"CC-`_\,7\#O\`
MYW]077_!?;_@JI';7$J?M&:!NB@FD&?@7\#<%DC9EW!OA\V5#`$XP>.N,@_#
MOPP_8L_:@^-/PVUOXM_"OX2R^-/`OA^Q\8:G?W&G^._A58^++K3/A_;P77C7
M4?#?PNUOQWI7Q6\:V'AJ*YB34[WP5X(\0VT5V)M/CEDU"VN;6'Y2O&5["\9/
MNFRN2",8(:%B"/4$<@UA1X3X$Q%2O2P_#W#E6KA9QIXFG2PM*I4PU6<9RIPK
MT_:*=*<E"4H1JQ@Y*$FK\KMI6XAXLHTZ<Z^;Y[2IXBG.="=7%5X4Z].+Y)SI
M2E14:L(RDHRE!RBI-1E9M)_ZSGP%\0ZWXO\`@E\'?%OB6_\`[5\1^*?A3\.O
M$?B#4_LMG8G4M<UOP?HVIZOJ!LM.M[73[/[9?W,]P;2QMK:SM_,\JUMX8$2-
M2L?]F+_DV_\`9_\`^R(?"7_U`/#]%?Q7B8QAB<3"$8PA#%8J$(0BHQC&&*Q4
M8QC%:)1C%)+LD?T]AW*5"@Y-RDZ%#FD]92E]7P[<I/K*3;E)]6V?RW?\'5G_
M`!^_L#_]>?[6?_H[]F>OY$[J+S[>6'8LAEC=%C?9M=V1@B$R$1KN?:`\K)%&
M<22R1QJSK_79_P`'5G_'[^P/_P!>?[6?_H[]F>OY&F&1TSU!![@@@@]L$'!S
MQC/!Z5_7?A(^7@7)Y:^[B,SDK;WCFN(DK:QZQ75;6NKW7\W^(:YN*\VCH^:E
M@8V>SYLLP\6GH]&I-7L[73L[6?[H^&_VZO@1X)_;"UWX]^$_BI=:);V'_!)B
MR_9S\"^,[7X?_$'^T+?]IO1/V=_"/@30_#-MH][X)?5(([#XAZ2MK;>,-8TB
M#X;[8#J;>)7T>2:[;W?X8_\`!27]E\:KI_B_Q[\3[B7]H7QA_P`$U/V/?@SX
MM_:/\7Z/^UKH.J:-^T)\)OBGX[U[XW^#_&OQ._9ILO#?[3EQXB\>^"+SX:VL
M_P`5/A;>^(_#WBRX\'V/AWQAXCUG1$O=$OOYM"#C&WTQG:<<[B!V`W88`#[W
M/6C#8(*YR<G[N"W(R1T)P2,G)Y.",G/HXC@/)\5"+JU<:J\,%A\`Z]-X*-6>
M'PT*T:="<JM"=26%G.LJV(H>VA"M4@Y+V:E*G/FPW%F8X6I[2E1PBBL;6QBH
MM59Q4Z]3#5*C4(N$?:1]@U1JWYZ2F[2=K/\`HIUW_@I=\';BV73-&^/6L?#2
MQ^('_!5VT^.G[0*_LN>`/BU\,;7Q-^S++\!?A7X4\5>-_#R^/M!U6_'AWQE\
M4_`U_P",?%OP_P!>UN?Q_P"*M6C3Q?KGP]M?-TBQL?M3PE^UM\!/CM\1M4UG
MX&?M'3+XK^"?_!*?_@HQIGQ$^/&G>&?VOO&NM?"RVU#XN?!KQY\(_&$WB']J
MS3KSX_?%N7X>:?/J_BFWMO[:\1ZAH>N:7JEGX1TW0M.F\(Z7<?R`D,221DG)
M))!)+?>R2<G/?N>`2<"I$>:+>8GEA:6-X93#*T1EADP'AE*.#+"XSYD3[D?H
MRD5P8GPYRJI&,L+B<;A<1!8B,)NCEM7#<N)GE;G"KAZ=.G.K2C2RR%"%*K7K
M4(T%AZ,J,J=)J?12XRQWOPQ&'P]6A4G2FX0EBJ52E+#4L?2H3HU'7E&@Y/,:
ME6HZ%.E4E6A*JITY2:E_3IX:_P""EG[)6E>/?B9<3_&)M>^+U[^QM^Q%\%H_
MVV/&'A/]KOX=6?QK^*'P(\5?$#Q!\;]7UKQ!^S7'X;_;#\*VWCC1O%OPSTB/
M6]5T:`?$(_!\Z1\4K:7PY;Z#)JGFGPW_`&U_V,_%/Q5\$?$#XH_'C0O@[_PI
M+_@JUX^_;`AT[P'^S=\<;[P?\7/AGXW\"_#7PLWB+X?>'-)T;7=5\`7,GC'P
M7?>)/%VB_$O4-+\4V7A_Q!JVJZ+I'BKQ2;7P'>?SI_/SD'GK\V,YR&SSR6#,
M"3UW-G.:"#D97."#G/<+M!'0@@9`]`2!P:N/AUE--5W1Q>:4ZV(P^'PTZ_M<
MNE.%.A3Q=)J@JF%J0C3JT\=BH+#^SI4L)3J0AA4HT:481+C/,IQHQJ87+ZD,
M/5J58TO88I*I.I4PD^>;6)<IU(RP.&E*O.O*MB7&4Z_-.I-G](G[/'_!27X,
M:4O_``3$O/BA^UMXZT/1OV4/B?\`MH:;\9/AOKO@_P#:%\46-[X.^).F?'2V
M_9>^*>B7'ACPEXH\.:]X>^''@'Q9X8^$7ASPYA/B!X%TSQ0;+3?#6G>`]#U3
M4H/@C]I[]H_P)\3_`-D']F3X>_"W]J'7/#GAKX9_LW_`#X4>//V$V^%_Q$TO
M1H_CC\/=:\2W'Q*^.X\8QZ0GP2NAXVUF_NO'J^,++Q/J?Q4UJXUJT\,^(M%L
MM.?7?[)_+':<D[>2<Y)'7.2>,')YR<Y.22<FE^;.2"3C;RV3C&,<YX]NGMT-
M>A@^"LNP6-PV.I8C$JIA<15Q%*C.CE%7"J53$8G%U%4H?487G.KBZT*6)IRA
MC:--N$,7"#:ER8CB;&XC!XC!3H8?V>)H4J$ZBJ9C"ORT:-&A3Y:_UV4HP4,/
M2<\.XSP=2<74J86<WS+]]OV9OVU?V"/@U\*_V8/V8?&]W\7M<^'_`(M^`O[0
M?A7]KSXB^";G5=(^&VA^,/VQFL;?X@:+XQ^#>N_`W5OB5\7O$'P'T7X<?!K3
MO"GC'X6^*],TFUO=,>Z\('QHMKJ,=XWX+_\`!1'X,?#CXC?\$P_!WC?XOZYX
MP_9W_9E_9T\5>$_BM9:9X*^*C^#/!O[2M]<?'+P_X)^,[^#9-&\&^-_'S^!]
M%\5^#/$>@ZUX.EOO$_@+2M9U6?X?7FD_$!-5TVY_`O#=A[XR."#D$8Q@YYZ=
M1G-*`5SM4`';G!QNVXVC@#.W'&[..V!653@')Z[Q4JV)S.K]>J8S$8F-7%8:
M:EBL70Q>%GBJ:JX*H\-5IT,6Z=)0E5BUAL+:5+V<W/:EQ=F5*GAZ<</@8_5*
M>'H89TJ=E'#T*F$JJA5C)M5:<JF$C)N6JE7Q,N27M;0_I?\`"/\`P4._9:/Q
M[U?XC^-/VBK/2_%6@_LR_"#X<^#?B7\,9/\`@IGI7@_QUJGAK]HC7_%WC+P=
M\9/B'J^K6_[;WQ=\4Z!\-IK#5OAYJ?C/6?#GPJUV^UF]\$_$._UKPWH&@7]Q
M^'7[:'CWX=?%3]KW]IWXG?"&\M]2^%WQ$^.7Q&\;>`]2M=!U;PM!J/AKQ-XB
MO-7L-03PYKVEZ)K>C-?K=O=S6&K:/INH0SS2_:K.&5F6OF3#`[E&UN.00",?
MKQU')V]L4Y00#GN<]<G\3^%=N1\(9=D&-J8[!XC&5*E7+<-E<J5=X;V"H86J
MZU*<(T*=-PJ*4I^Y[].*J5'!QYG%89MQ+CLYPJPF+I8:,88^MCX3I1J.JI5X
M.$J<JLY)5(I6?,J--R<8N;DX\TE)P"?2O7?@/\"OB3^TI\4O#WP>^%.EZ9?^
M+O$$&LZDUUX@UW3/"_A7PYX=\,Z1>^(?%7B_Q?XGUB:WTS0/"_A?0-.OM7UG
M49WEG6WMQ;Z?9:AJ5S9V%SY$PR"/\]:^O?V'?VD/"W[,'QMU+Q;\1/".O^-_
MA3\2/A)\5_@#\7_#G@_4=-TKQU+\-/C'X9?PYX@U/P'J&L1OHUOXNT25+'5M
M+75V@L+]+.YT:XU#1X=5EU6U]O-*F.HY;CZN6T8XC,*>$JSP=&4>=5,1>E&$
M8T^>DJTXQE6JPH3JT88B5*%"5:FZRD>1@(86IC<+#&UGA\(\12^L5DVN2DG4
M<N::C.5*#:I*=>%.I.C"4ZD*<W#E=75OV'_C9J?B^V\-?`BW\*_MJ_\`%,1^
M*)O%_P"Q4OC7X^>'M!TV;7=3\/26OBJ.V\!^'/&W@;4?[2TV]>UL_&7@_0(O
M$.G/!K/A2X\0:3>6MY+YQX;_`&5OVE/&/AG4O'?A#]FOXX^*?!]G#XM?6O&'
MA[X/>.]9\.V<7PZO$TOQXNJZY8^';C3[1O`U[)_9WBR&^N(I-"NA=:=J,<$\
M5W;+^C'['_[5/_!/7]D+Q3XLU#2?"7[3_P`7CJEU\#/%OAGQ[\5O@3^S1XAU
MWPOXI^%/Q'\5>*O$>A>'/A+K'QTU_P"'WAZX\5^%KOPOIOASX]/XC\3?$[X:
MZ^OB34?!/A'2;;4[F>^]M\/?\%9O@KH?QZ_9D^)5KX=_:&M?!'PC_;B_X*&?
MM._$/PUING>"+:^\6>#?VLK_`,1O\+=)L-&3XLPZ%K7C'PSI?B&^T_QK;^)-
M0TO1]'.I:W9^%?$?BR.\>74?D99[QA#$8VAAN'\3C:%+"TI8?,\;DV-RS%8^
ML\'BJM=2P&$Q]6AA*DL1##Y?0:Q;BDX5L2Y4:M:D?2PRSA>I3PU2>;T,/4J5
M:OML%@\=2QD,-%8K"4Z3ABZT(.<O93Q6+F^2:<4E"$:D$G^:/[//[`OQ=^._
MPV^,/Q9B\$^,O`'P4^''[-WQ\_:`TGXM:Q\)/$US\*/B7J?P)TB;5K[X7:'X
M[D_L#PK'K_B.[M-<T]-775-8&D77AS6Q-HNIM:7,5OHR_L`_$?Q'^T`_P(^#
M/A;XL?&/1-)C^!M_\0OB#IO[*OQI\&Q_#32/C!HGAG5SXE\=?#7Q5HR>+-#\
M->%K;6M3N-/UW7WT?3_'?A_PW>>*/#LT&A7*7-O]J>$_^"B_[.UE\!K?1M;T
MC]I[3?C+9_\`!)WXB?\`!,>/P1X6M/AO)^S9<W>L:=XN7PE\<+Z[O/B-I/C2
MZUO6M1U/P_)XRTQO`(FT07&JZOIFI>+;W2;#3M;]#US_`(*B?LR^./$WC%_$
MOA_]K+P+X8@_:#_8A_:>^'^O?!VR^%NF_$+Q1XI_93_9N\(_!/Q!\)_B6VJ_
M$^QTWP[\/-?\0^%W\3>$_$OAS6/&FKZ<]R-8OO!\%]!#I5[S5<VXWCB,?6CD
M>*C05.=#"4?[.K5\+@Z2=>$*U2TGC<UJ4I_59_[)B<!0K3Q,IQH0PV&Q%%Z4
MLNX7]G@Z53-Z?M%[.>(KK&4Z5>I43H5*E.:DIT*5.LYXI2;C.I&-.FHSC.=/
MF_+CXO\`[#WQN^&_BK]H^P\/_"#XF?%+X1?LQ?%_XN?#'QC\>/#/P;\6_P#"
MKHKKX/\`B74-!\0>)=7U6UM/$&@>%5%I:6VNZO87WB34#X<M;Z%;[4[B&W2_
MDUOB?_P3U_;"^#7C7X2^`_%G[.?Q,D\=_'CP'IWC[X<^&_"O@/Q7XE\2^)-,
M33;;5M<\.R:3IN@OK*^.OAQ97VG2?$OP8]I-K/P^;4]/;Q!#9QW:RU^IWAS_
M`(*D?L7:/#^TMX@D^"_Q?T_XA_&_Q[_P41UF#Q*OPH^!_CK7]<\-?M=7FKS?
M"2._^(7C+XL6_B[X'+\/M/UF71OB)\._@W8ZOX3\?2H_B2^\1>);RRNM.U#S
MGX;_`/!3/]GCPEXN^$7C#7/`WQAU>[_X=@:3_P`$Z_C?IFL_#SX*_%+POX;U
M;P)8>!U\)?%/X:>#OB%X\70/C9X;\<WGAS4;+XC?#WXL:?\`#2./1;JU2WUG
M76ENECE9YQY3B^;A2=26#]I3=*O@L;*KF%6618!4*M2MA\2J&!G3QU?,^9X*
MC[&M0IT<-)4)*E`<LJX1E*E)Y]R+$3E5<J.,PTE@J7]IXZC5IPIXB@_;7H1P
ME5<_O^].K>?[U+\8/&'@WQG\.O$VL^"/B'X/\4>`?&GAJ\_L[Q%X/\:Z#JGA
M?Q3H5]Y$-TMKJ^@:U:V>IZ=/+9W-K>P1W=M$TUG=6MU&&@N(G;G:^K/VU?V@
MM/\`VE_CK<_$?1-1\0:IX>T_P!\-_A_X;N?$_P`+OAC\&=5CT;P)X6M-(BL(
MOAK\(=7\1>"/"NAZ5?"_T_PKI5CXG\27=CX6M]'LKW57:VCMK?Y3K[O+:^*Q
M.7X+$8[#PPF-K8:E4Q6%@ZKA0K3C=TXNO&%;S<:D5*#]UW:;/D\;3P]'%XFC
MA*SQ.'I5IQHUWR?O:5_<D_92G2;<=W"<D]]+I'TE^S'^R_XO_:H\1_$O0O"O
MC[X1_#'3_A!\%?&'Q_\`'_C;XU^(/%_AOP5H7PY\">(/"7A_Q#>O?^"/`/Q'
MUJ34K6[\8:7>16@\/"VDT^VU&=K^*Y@MK.\Z3QO_`,$]?VCO!/C+P[X1\%?#
M"/\`:#M/B'\.],^*?P^\=_LL:=K'QO\`A_\`$GX9:IXCM_!,/BCP]J7AKPY!
MK]MIMGXQO;;PKK6D>-/"_A77-"U^[L(M;T.P_M72;J^Z+]B'X^?!_P"!FJ_M
M/:7\;H/BM_PA?[1'[''Q;_9BAUCX.>%_!GC'Q=X7USXE>,OAKKMMXEDT#QW\
M0OAEH=[I.F:5X-U43(GBA;Z74+G3((K-K:6\O;#ZPO/^"B'P7\(?"'Q3^SM\
M&/#7Q]T'X9>&OV#?BM^RC\'?&7BB?P19?$SQ)\3OCI\?O!_QP^*WQ"^)T/A+
MQ=!IG@+P+X@ETG6-`L/#?@W7OB5JVC:;*EM</JJ:I>_8_FLTQW%5'.'2RK+Y
M8W!WP5&FJV62^J4Z>*H4%B,4LVH8BGC9UL/F$I*KE]"$4\+"=2=6/+357W<N
MPG#];+X/,,9]6Q,WBI3C2QJ=:K*A6<L/A9Y?6P\\)2I8G#1;ACJ]1M8ATXPI
MW<I0_,2^_9P^-.F7MS%JOP*^)NEWVA_"B\^.=\FH_#/Q/97FB?!#2KQM+O\`
MXO7B2Z*ESIGPQT[48KG3)_&\L</AVWN;:\MO[0412UI>-/V5?V@_AW\/M)^)
MWQ'_`&</C#X!^%WB.;29M#\>^.?A-XN\+^"=:G\1V4E[H,EAXBUK0K31KR36
M[$37>C[+MGU&U$EU8B:V8S/^FVG_`+>W[+VH_`\:7KGAW]H/3/CYJ/\`P2GU
M[_@F3(L&C?#6[^!%H]QK.K:GX9^+^I>)3X[C^)LT&H+)I?\`PE6DV/@-7\)6
MC>(9=&B^(<\6DQWOU7_P6I\=_"/QY\,;G4?A=\9OAA<V_B#]K27XHZMX(\-^
M,/AM\4-?_:`\4ZQ\%]&\`W'[0^B^+_AQ^U)\:I?"O@CPEX3\%>%_"LGA77/@
MG^S!I6NZGXJ378/A_:ZWY=O/Y[XLXAI9SDF48G(G@5FF,J4:^(K4,X4+8:GB
MHUJF$Y?K,:L*E6GAW2Q%?EI)5IQDE"G*I'KAP]E4\LS',*>9^WJ8'"8>O0P\
M9Y5%PGB/9WA5<H491=)O$1G##^T=Z4>5N52*?Q/\#H/VY_V??V7?!_C/PC^T
MO^S-^S_X&\36OQ+^.W[/'PG^-%Y\%[GX^>+(-)T%O#OC?XI_LXM\0/@[X^U'
MX1W?B&R\+7.C>$M3/Q4^">K^/->T19/`=KKFM:AI-[K/Y^ZU^RQ^T?IFC>!O
M%'B7]F_XX6/A_P",WB'0M(^&_B/Q!\(/'UII?Q2\6>.&5_#.F^$M5UCP]$GC
M'Q'XQ\^.7P_9V$]_JGB42)-IBWQ`=?K+XE_M"?LF_M#?!3]G*V^->E?M(^%?
MVA/V8?V;O^&;O#T'PN\-_";Q5\$OBSX6^'-SXKUSX%7OBS5O&?COPQXP^'-W
M::SXNO\`3/BK)HW@[XBG6=#$]_X?AT_55T\V7VIXS_X*G?LYW_Q)^+WQ9\->
M&?VJ=8U_]J?]I#]@_P"-7QD\%?$8?#C4/!'P-T#]D#XC^!?BEKNA_`74],^(
M]Q?_`!*U?Q!?^$+GP9X'N?%V@_!NRT+P+>6VC:A%;7*RFLZ&)XCR_%8RMAN%
ME/&9CF.,686R?^S*<I8;$8FGEE&&:8/&N&8.>!^KYG+'YGAE"57VN!I4XXC$
M<T;JT\FQM"A#$9_*&'P6&PCP%3^U95W_`+10I5,75C@\317U)RQE.M@(X/#R
MFE&%'&2DJ7-$_*>?]AW]LFTFLDN/V//VFH)U\/ZWXJL!-^S]\4(9(_#7AU[&
MQ\0:Y:^=X3B:#2=(:_TVWU+4E$5FBZA81FX?[=:K-W_P%7]N_P"!_P`,OB9\
M3?@;\)OBDOP.^)7@KPWX@^+7B35_V8M!^-'P)\7^!/!?B779_"GBOQ7:_%CX
M4?$7X876G>#O$NB>)?[`\5S645SX<O;?Q$MMJ%G;6^KH/OSPM_P5<^'^C?$S
MP%XLU(_M'7OASPS_`,%:?CW^WCJVE1S:%-=:G\#OB9X2D\.^!_`45A>?%2/3
M+CXA^'EN=8MK_P`,WMY#X$T72M9OK70?&-ZVHRV+]W'^VA^SS\"_V<?V)/&3
M>)?C+XX^+?AO]CG]M7X;^$_@MX#UOX:7WP2L]9^/_P`4?B=X;BC_`&A;.?QF
MOBSP-?Z%I&H:3XF?2-*\'^+9_&]M:^"I8W\/6GA<SZ_GC\VXGK8:G@<TX5P6
M.AC,2J.&PGU+,YT\4W3JXR;J.52/L*D_J\N3%8BK'#87E4ZE%Q5.E+;#Y7D$
M)5<9@^(L=A)8.BZSK>WRZE4HJ=2,8U+J$_:1IU*BC4I*$YUZE=<L4XMK\@/C
M+\/_`-K+XM6FH?MB_'3X8?&WQCH/Q:URRUB[_:+\7_"WQ/#X&\7ZSK<EMHNB
MSZ7XS?PS8>#A97[6-CH/A>TT"2#1?(T_3M#\/PK:6EA:)Q/_``S?\<FUS6O#
M7_"B?BBWB70?B1X8^%?B'05^&_B4ZUH_Q<\8BX7P7\/=6TY=)%Y8^/O$_P#9
M]ROAWPS=Q1:YJ+64JVMJ[V^%_3?XC_\`!0_X(>(O`'QC\0>%O#_[0)^.7QU_
M8Y^`W[(FN_"?Q6O@6']E#X9Z=\)G\"0:IX^^'VKZ9X\U3QOJ\TL'PXM]1\"^
M$[[X<>$8_!6N^-O'VJ3>(=2DU>,7OLWB#_@II^QLOQ4\2?&#P7X#_:J37_BK
M_P`%#OV2OVY/B7I'BS0/@Q_9/AK2O@8FMMXV^&W@!]&^)S:AX@U2YO-8O]3\
M'^)/%#>'K;Q+#K=OI&L:-\/_`/A&O[?\6]M+-N**&'IT(\(2H\DJE"E0IX7,
M%1H5*"BX4:T5B^1?5Z=&%"EC</AJ>!S"JZ%;"4J-*G9<E7*\DJ5O:PS^=:$8
MTIXBM4Q&&]M7]KM*BU:DG5G6G5J4YTO:T*<*T:C]I65ORGMOA)^V+\)+:;X*
M1?!GX^_#\_M>V7A?3XOAU>?!KQ=HFO?M`Z;X$U^R\;^&[#PSIFI^$HO$WBZT
M\.^()M/\226?A(R(LPLKO58KB`6F;W[2_P"R5X[_`&6/#?[.^I?$DZ[HOBWX
MZ_#+Q)\0=6^&WBOP'K7@+Q=\+;SPY\2O%'P^G\*>(['7KZ6^U*[N5\.PZ[;W
M\FD^'3%:ZFMD-+GAB@U2\_0+X2_\%/\`X;^#=3\&S^.=%^/WB?[+^TE_P4$^
M(7B/Q1IL_A:?X@>%_A;^VI\-K7P5X<U3X5ZWXB\?7"V_Q>\$:M'J.O:IHVHR
MZ'X4`OI[?3O&%\]_=7\/QQ^V7^T3\(OC9X,_8_\`AY\'W^..H:/^S!\!M3^"
MNH^)OCS;>#[?Q1XL9/B%KWB/1-9TR+P;XR\966G:-_8.HV5K:^%;F_D/@6U@
ML?!NGZQXML=$3Q5JFN!QO%$LWP='%Y*LMP5>MF%3,L9A<%BHTLPK0PE:.%J5
MJ]67LX0I8B>'H-5:/UBM6IU,1'$1PDN0RQ^%R199B*M'-:F88JC3PRPN%Q%?
M#R>!C.I0^L>RHTJ?/*?LXUI>TA65"G%TZ?L)5XQD_AG!V8[YQ^.ZOT)_8S^(
M/P,TOX`_M]_!#XS?&G0?@=??M'_##X'>&/AWXF\5?#OXP_$7PY<ZQ\./C59_
M$OQ%!JUC\&?AY\0]=TI(M"T;R;.ZO=.M8[B_U"V%FURUK=?9OSW'(]CG]2:;
MAAT!S@\@@'D@GDY.,A2.AR`>H&/J,SP$<RP<\(ZU;#.5;"5J>)P\*%2M0JX'
M&X7,:$XQQ,:E"4/K.!H*I&I3J*46TXN+E?PLOQCP.(C7]C2Q"5*O3G1KRJPI
MU*>)PU7"UHRE1<:MY4<15C%0G3?-)-5(-*2_H>O?V]OV5[;P/XT^#WA/XRW[
M6?PP^%'_``2+_9]^$/Q2^*?P/^)7BS1_C5%^QM^UEXS^+WQ9^+.N_"+2+6;4
M+/X9>&-!\8+=6GPG\?>*?"/C#QQX1\/KX-T.23Q'?VEG;]'X[_;Y_9J\4^._
MCCKW@[]LGX@?"_X\?%[]E;X9^"O#G[7EKHW[6'Q&^'_P'\?>'?VEM=^+/Q6^
M%WP8U+QKX";]L?P_\/?BSX1U,VEK;ZEX9UC1/`-[<OX/\):TGA"TTJPB_F]*
ML<9'0%<D@G81C;GKMQD$#`(.,4X@DDE02?O'/+$YR2<#)Y.?7=7RDO#[)Y3A
M5CBLTC*G3KTXN4\KJ5)QKRP-2<*L:N!JT*^'J5\&ZM?"UH?5ZZK2HSI_5[X>
M7T$>,LS]G*$\-@9SE*@^>,,32450^N0CR*&(C6C55'%1I4Z\*ZK4_8J4)*?/
M4J_T-?#K]OG]G?PO\-_A[!XB_:I\3Z[X%\#_``N_;6\%?M'?L=#X&?$BSLOV
M]/BU\;?$GQ1/ACX[Z]K$'AN\^$.FCXB3>-/!WCW53\4_%%AXP^%3>!+CPAX7
MT2^L=:/V[/;_`(*+_LGVWPE_9P^(/B.;7?B'^TA\7/&'[`_A/_@I!X)N?`>M
M:F=9^$?[!?B+Q/,^M6GB/Q3HVG>"/'FN_'.71?A;XGUWPCHGB;6]/O\`3/#L
MWA[Q-+ILNVVA_GU^;KM(.<YW<YVJN<^NU$7/7:J`<*,&#C&WC@8R.@Q@8QC`
MP,>G;':X>'^2\ZK3K9A*J\54KR?UC!X/GI5*.+@L+5GA,&ZE6FJ^,EB_K%:6
M)Q<*N$RJ$*WLL#0C2F7%V9NG[.%/"J*PD,/"-66)JNG7A5PTEBJ?UFIB'2?L
M<+&@Z<)1I2^L8R<J4I8NL?T\_$'_`(*A_`1?CUX=^(>A_'OP%XF'@_P%_P`%
M!1\/_B-X?\`?MQ>,O'?AOQ#\:/AQI^G?!?PAXFU7]JF'Q?J,.B^)_&MO;W47
MPT\!:1>_`?X77?AI+RVUC2_#FN-:P>(>#_VG[O7O^"5GCC]K#XM:UXT\5?M;
M^`'^.7_!-7X;?%?QK<:IXBUCQWX8_:TO/`/QI\2>(=2\<ZU)=:MJ/Q`^$7PY
M_P"%VZ%H%Q;7LUWHVD^,[1]0GDDU;2YD_GTPWH>F,;L#CGIQQGG''-2&28Q+
M;F24P([RQVYE8V\<KJ4>1("WE+)(AV22*@=T)1B5XKGPOA[E>`HT*.#KXF$J
M6-RZM4KU50G4K9=@JE>6(RU_5OJ\H4\QIU84\7"=2="HZ49*-*?OO6MQEF.*
MJUZF(A!*KALRI4X4E90Q&/IT:=+$U/:J4*DL&Z+E2E",:JC4<8S<5'E:@"JJ
M@``*``.`````!V`'`IDP+(5"EB>,`;C@\%MH^9]@)<H@:5PI6)))2B-*.@SU
M[TASVZC^H(_K7Z!HTT^9)IIN+:DE*,HMQ:E%J24G9J46G9III,^/ZK2+U3M-
M)Q=I1DE).,DXMQ2DG&2:O=/8_I$^)?\`P5>^`EU_P4FMO$WPPM/!7A#]DGQ1
M^U1^S3\>/CK^T9HWA;]H*_\`B1\;(O@E\%?#?A'0;C6_`WB]+C5O"?A[X?:U
M<ZWI(\*?#;X0Z%=^*;S0],U^87S:CXBU+Q1G_L=?\%0_A=X:^'/CR\^-/QMT
M[1/VA]=_:]U7XJ>*/'/Q@\.?MA^(]#^+/P-NO`6G^$O!?A%[+]D^]TNT\7Z-
M\,(K'4=(TC]F[X^Z3I_P'M-$\1VS:+#X>N+34H-+_G(VD$X7&?=>@&`.G0``
M`<@#@#@&CYL`8.!@`;AP`-H`Q@``8``'RC@8XQ\!+PYX>E@:>"5.O%1P^"HU
M*\(8>>(KRP>)KXGVM2IB)5'*6(=94L3%SA1E1H8>%*C16'I(^KI<:9Y#$/$R
ME1G*53$58TYSJ<E'ZQ0A05*G3HPITHPPZ@ZE"U.<XU*U9SJU/:U&?OE\-?VW
M_@1I6F_\$\]0T7]J?4OV?OA+\`-<^!*_M!_L1Z+\(OC+JOA7Q5XV\&_M:VGQ
M;\=_';3M7\,>'=<^'VH:9+X:ETOQ7I;C6]9^,6FCP19_#K3O#5TGBG6HH^\\
M.?\`!1K]G_P-X`DN?`GQSU;PS\4?#O[$G_!6#X=^!-1TSX>_%:'4-#^/'[0G
M[9FF_&O]FM-*U*3P#+I>G:AXA\.:9:^+]/\`%LMQ%H'@/5M,L;/QEK'A;Q+%
M8:>W\Z.#TV#&`,9_A'1>O3I@=`!CL,&#UP,\GKR690K-]2H"M_>`P20!74^!
MLJFHTY5\=[&-=U?9M93",X2Q5?&3HUG3P"ECE4K8FK&57'JO5>'<<-*<J5*F
M*'%^91BTJ&'<VTO:-XR$XU/JL<(J])3QE:EAHQHPB_J^%A0HNO?$*C[24T_Z
M-+[_`(**_LC:IH_BKQ'\1O&FI_%GQ'\0?`O_``1%U;XO>'+_`.&_CW4->^-O
MQ#_9%^*%]XB_:ZT_Q'?>*_">E^$_$&OZ7X6BTL3:MXQUVQ\*_$R)8M)\):_X
MCDL[Z*QZ#X8_MU?L^>&/VE?CU\6OBS_P4G^)OQSN_$$FBZM\"O%G_"&?MS?"
MKP)X/\$77[3&J^-?%/P;\5VGPJT'P/\`';6=4T_X<W6GZI\/O`.G3:=^R]:Z
MY<7'A+Q;?ZWIJ6$5I_-7\XZ9'&WJ/N@DJH_V022%Z9)(`R:7#9'&,'(YZ-@J
M".O121P!\ORG(ZX3\/<HE1Q%&.+S""Q-*=&>F45U"F\1A\12I477RRI/!THK
M#4\/76!GAWB,+"EA9R5"A1A'2GQ?F-.I"K[/!2G1J1KQ<IXZ/M*E/VK2J+#5
M:*K2G/$5*J>)4XQJ2J37+*K5Y_U8_P""@O[27[/OQH^'<'A+X)>*X]9DL_V_
M/V^?CC::1;>"?&GA&PM_A+\<_$G@75_AAXCLSXD\+>'],A'B.WT?59G\,Q3_
M`/"3Z-)!*^N:%I*RH@_*JHMK>@'0#[O&/<#/';'3M4M?5Y5E=#)\#2P&'J5J
MM.G*I/GKSI3FYU72<VI4J=-6;H0?O)RYG-N335OGLPQL\PQ+Q-6%*%248Q:I
M.3A:$JSC932:M[>:LM+*/5.].^B>:VNHHUW/):S(BY`W.R,%&20!EB!DD#U.
M*_HS^,'_``50^".I?M\:'J/PEL/!'AW]E_Q;^TS^PI\8OVC_`-HZS\-_'J]^
M)/QATC]EOPM\/$TA=5\`>-#+=>%O#OPPUO3O%.FVGA_X<_"/2-6\:77A_1/$
M=L;^74+J^\5_SK$'G`SD8[>_7/'?CK]/5N">HYSG)VL>,8//?(Z]>ASQ7%G'
M#V`SJK0JXSVSEAL+F&&HP5O8J680I1=>5.-2G&M4P\J,9T5B(UJ=.I:?LIN%
M)T^C`9UCLLHUJ.#5*,,15PM6M)RDJE3ZK452%.ZA+EISLH55"TYPT52%W?\`
MH7\$?\%#_@?X_P#%7P4\5_M%?M*?$B?QS\,?CY_P46U?PSXYLK#XZ^'M3\%?
M"7XR_#W1]+_9U\.WWC;X0>$;;XJ>%?@[JVK)KNCS^&/@5>6'Q6^'%A/IIM;#
MP7ID<SQ^[3?\%$?V.;O]H?XN^+)OVHI?"OPL^)/P3_95T'Q]XM^&?@3]MOPE
M^T/XV^(7P7^%?Q$\.:Y>_"[XI:EH'BC5/&"6.MW.@:'XC\"?MGV'C#X<?%_3
M=0\,ZKK?CC4=7\,^(M0N_P"7(@GJIQ@#&X8^4$#CD<`D#&!@G`&2*`&&>#D\
M$[NH`P`<=1MPN.F`!@8KYROX;Y)B*U2K]:S&C&=&I1IT*4,IIX?#4IXNCF$H
M8:C'!15)_6J$:E!^_&C4ES1IKWHR]JCQIFE*FH2P^"JR]K1KU*M6&,J5:U6A
MAJN#A*I46*C%KZO5E2DJ=.@IP?))\MV?OEXZ_;S_`&;=6_X)R^%OV?\`P!XD
M\`Z+KMI^Q+\._@)XN^`WCCPC^UQ>>(I?C9X8\2:?=>*OB=X+T;PQK<'[#NF>
M(]?U^&3XNZ5\=M0-I\98-]WX;UEM5M[V'18/C_\`8Z\2_LW:'^R[^VMX$^+O
M[5O@_P"$/CO]H[X?>!?AMX$\+>(O@[^TIXZ&B/X"^,?@_P"*-WXJUS6?A7\(
M?&OA"TT/Q-::)>:/9V=EJAUNTU6Q%YK.F6%C+"R?F;AO0\CD;A@_7U'Z].>!
M2_..0"",8(;&-HP,=^`!WSP,$5ZE+A+!T<%C,!0QF9488_.,/G=?$-996JRQ
M6$QKQ])U5.D_:SJ8B4_K%9<DYTN6E'EC%,XJ_$N+Q&*P^,KX3!U)X7+:N6TJ
M4*>)H4U3JT:]"I.'L\0E"3A7E[.,E.FIKFDHQO&38F?8GF(8G9$9XRP<Q,ZA
MC$SAY%8J25W*[!L9X)*K+3`&XXP.,\YZ8Y`Z#@``<XQV%/KZZUDE=2:BKR5U
MS/6[<6K0;_EBY1723N[?/.SU2M?7E;NX^3:W:[GZ!_\`!/[X]?!'X#']M*7X
MZ:9IGBG1/BY^PW\6?@SX1^'6LQ_%&#1_BMXX\3^,OAEK.G?#G5_$?PB:S\5^
M"=.\1:3X:UJ*;Q<=?\)66FF((/%&FWD]LL_VS\/O^"M/B-O`GB_Q7JGQ.A^`
MGQ<\6_MM_L6ZS;^"O@_X4^(-IX>\,?L<?`;P'<>#O%'AC2-<BTWQ?=/H&F:1
MINDV'B;0M0\6W7C;XA0:EK]C9Z)J'AO6;KPTOX0$')."0?<>F.A!_/T_*FX?
M(..1T)VDCIWZ]A^5?+YCPEE&:XK%XO&PJ5:^*E@FY35%PHT\%0E0C1HT:RKX
M5QQ$9*6*KRPL<76]G1I/$NA1IT8^[@>(LSP.&I8/#RIT\-0^LRC'GE&=6KBY
MPJ2K.4(\\9TG'EI)5(QBG-\LI3<C^F?P]^W7^P'H/PJ_;.\-:5\:_$=I:_'/
MQ?\`\%2GTSX5ZWX<_:UA\">(+#XYZUKTW[+6H?##X6_#_P`/V/[/.D:'KNAZ
MA8/XKUS]H7PO>_%GX?\`B8Z;::'#X,\)1+=Z55\.?\%#OV.[;QO^PKX^^+'Q
MLOOB9XE^#.H:[X4UO2OAU\-OVD](_9\^#_A6T_9>G^%WPO\`BY_PI#XDV]IJ
M7PZ^,7A#QS+X=3Q)HO[&7B[4_!FJ:?H>N_$OPXLGQ.MO"$L_\T>&Z[1G`&00
M.!NZCO\`>;\"0,9)HPV0<8(&%((!7Z'J`.HVXQ@'D@&O"?AKDW-7;Q^<R6(J
MU)34*V6PJ?O\GADE9O$?4W.*>$IQC)PI^TG",(WBU*=3U/\`7;,DH*&$RR,J
M$8PHOZK7E33AC_[4I3E!XA*:HXE_NHM0A&2<U1?,G'],?V\/CC\*OVK/V@?V
M?#<?%SX>W/@W2/A[X(^%?Q,^//@SP?\`M;^-7T'09?B?XJGU+7?%UY^U-<ZC
M^TK\>-8^'O@C7(?$7VS4;4ZGJ=O>'X?^'IM8&BV5_/<_X*&?$G]GOQ%X7_9^
M^#O[)'QY\'>._P!F#]G#3/$_@_X0?"W3/A]^T+X9^(NFS>.+Z+QE\3OCC\7?
M%_QC^$7PT\,>*?&_Q<\="6^U#0/`,C:)X*MCIFC:#HHL(-5UO4/S"`;N!W/.
M,$_A_7@^QI0O^R!D@GGG().3QC/+8QTW-_>-?18/AK#X"60*ACL=]6X>H8RE
MA,'+ZA+#U)8RG7ISQ-2V'=>EBH4\15P]-T:[C#"3J4Z/L)5L1+$>7B<]Q&)C
MF[J4L/[?.*U"IB<1[3%NK"E0C2MAJ,Z?LZ<Z4YT:=6:Q%!N=5<SG&+:3ZH:G
M')+87T4*>9+)9W$<41(`DD>"540DL@`9B%)+HH!RS*/F%^FG=G(]NA`(QGU]
MCU'/]?HM5JFTTTTUT<90G%VZKFA&\6TI*\6TI-KP&FTTE%O:TFXIIJ49*\4V
MFXSFD[?%9]#^B+XP?\%2_@E<_MS>$[SX.V/@?0/V;O&7Q_\`^">'Q)_:>_:0
ML_#'QYNOB=\6M!_9%LOAW>Z5INH^"?%Q9_#/AWX3Z[:^+HHM*^&GPHTS5O'L
MND:5J$5QJR7NK_\`"55_"_\`P46^!GQ%\7?"WQ5^T7^TG\3;KQ-\,?VM?^"@
M'BCP/XZL].^.>AZOX%^`/Q@^$VF^'O@!HJ>-?ACX1LOB9X.^$>O>)[>\TG4/
M!_P9U&P^,W@6V?3IM)TKPH8K2ZM/YY,<8VGGU(..GJ>V!CIT'2FE223MZDGJ
M!U()ZY(W%5)YY*J3]T8^&_U!R5X:CAZ4\90=##+"+$JG@I8RK#FQ#J5'7Q4<
M7[/V]/$RPU:G2]E3GA:=+#PI4:$(TX?7+C3-_:U:E2GA:D*M7VSHU/;RI1:^
MK2IPC"A4PTHTZ-3#*K27M).-2K5E*51S:?\`4M=?\%&/V.[C]I#XD^-8/VI$
M\+_#7Q[^S[^R/X.^)OC/X:>!OVY?"7[0?C3XD?!'PC\7M-UK4OA)\6=6\,:]
MXE\1SZ+?W'@VP\0^$?VR=+\7?#SXT:!J7A@>./&<FJ>$_%$C_,/BG]OC]FBZ
M_P""<_AS]GWX>:_X"\/:M:_L6:7\!/%_P*^(/@[]K?4/$-]\9K3Q;+J^O?%S
MP?H?@[5X?V'[+Q9KWBYK7XP:7\</$0M?C+H<W]J>&=0DU.QDM?#1_`?:202I
M)'`RP.!R,`XR."1QC@D=":7#9/R\'@@D'(Y&#ZC!(YR>>O4'FP_AOD>%J8.<
M<1F=6."Q67XFE1J2RSV3>70<*,9)8>,I3E'V<?:2FY0C32@H_;NMQKFM>&(C
M.C@N?$4,=1E65+%.K%YA*E*NX2J8FI&$'[*5Z<:?+*51N73V?[!_\$Y?C_\`
MLH_LY^#O&7B'XY?$CX63V7CWP+\;_"7CKX8^'_V8OBJG[;30^-?`LW@OP[X;
M^`'[9OA'3;;PM\._#FOPP:1J6I0ZQ\2?"MEI,M[XNTC4/"\MWK&D^*I_QJ=9
M$TF5)6C:4::_FM#&(H6E^RDR-%&J1K%&7+%(TCCC5"JQ1QQA$&D58YX!)Y+'
M!.>>I/)/)Y]SCTJO?_\`'E>`#_ESNN@_Z8L:^MP&38?+\?F>8TZU>I7S>="I
MB(U'05*DL-3KPHTZ<,/2IQE**K5'*O4_>S3C&48QA%R\#&9E5Q>"P&!=&C1H
M9?3K0H\CG.K)UZE.K5E.<V^12E2II4:=Z<>5R4FYNW^L#^S%_P`FW_L__P#9
M$/A+_P"H!X?HH_9B_P"3;_V?_P#LB'PE_P#4`\/T5_"F+_WO%_\`89C/_4O%
MG]88;_=Z'_7BA_ZCX<_(G_@KG_P3\;_@H]^T+^QK\%!\7?\`A3*>%/@S^V5\
M43XE'P__`.%BOJ']E>./V*_"?]B?V.?&O@86BSKXU-]_:7]IW1C:P2#["ZSM
M+'^=A_X-5E4%F_;TFP.N/V7$SSP,`?M"$DDX&`,\U_1CXV&?V_/V91D_\F@?
MMT$$=01\9O\`@GH!UX.,]#QD"M?]KWXH^-?AQ\/O"&C?#?5-*\-?$'XT?&/X
M5_`?PCXSU_3+;6]'\!7GQ+\2)8:QXZFT6[GMK+6]7\->%++Q'?\`@OP_JDAT
MCQ)\0(_"?A_5XI-)U"_CF^NRKC3BW)L%EF59+F_U/"*@ZD*,L)@:T(U*V)QU
M:M5G4Q&&KU7S<CG-0C4;Y;0I7:4OF<=PQP_F&)QV8YEEL<5B'4I*=5XC%0<X
MPPV#I4J<84:]*$4KQBG))+FO*I:]OYM4_P"#5E'.%_;UE)QG!_9;0<8ZC/[0
MG(Y'0\C--E_X-6HXMN_]O:5=P8@?\,NQ@D(-S'G]H-N%7))[#DG%?U/?"GX?
M:_\`#G3-0TC7_B[\3_B_-=WS7]MK/Q33X;-K>EQ-;VT$NG6,_P`-_AQ\-K&7
M3YIXOM[Q:GIVIWEI>W<]O;7]MIPL["#\[_B?^UM\2/%'Q/\`AKHFD-X2^'_P
M$U#]JCXG>`+[QA%XQUJ+XRZ[X6_8CT7XB_$+]HCQA/X9L?#TF@V/PBO_`(E?
M!G4/V>-:TVYUK[?>Z?KFDZ]J6IQ6OQ"L/"NF^G@_$7Q"QN(G2H<1\\:493=6
M>6992C*,88F7NTZF7*I.=\/*+C"C.W-2DYN+<EQ8G@_@[#1A*KDL(^UJ*G",
M<;CG>3EAX_$L5))+ZS3;ZKEFG%-1O^-Z_P#!J[`<C_AO:7((4@_LNQ@@G;@'
M/[0:]=RXXP<\$]`H_P"#5N)F*+^WK,6&>!^RY&<8SD''[0AY&"".""#QQ7VI
MK7Q/_;3\4>$'\2>"_B(/!=[X6_9__8T\#>$=(\2>._'VMZWX;_:H_;^UK1M`
M\3WOQ!EM6T31?BIK7P8M/B1X7U#P3I/COPW<^'/#6E#PMKUIX9;4[G48[#ZS
M^"_QB^-</BSQ+\#/@YIND>./&T7B/XKZB?%'[07QI^*_B[PCH?A']G6'X2_`
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M`_;`\#?L=?LH+;)HWA/6-<TKP%?Z'\*/C7\5KG1/"W@WQCJ6D:9+XGU;PEHG
MC;Q$]C!JWV)>_&CXRZE^P_\`M#_%KXK?#Z_^%WCCP=\+?C_K.@6/A_6-8\&Z
MUKGAOP?X+\1:CX/\>Z;::M97OC+X0:SXD@LX[^P\.^*8=1\8>#KB.UO]5LXK
M]AI%GAB../$J@\)[3B&G&.+KX;#4Y/"9)3E[?$UX8?E<)X2$G"G.<'.24E3A
M4IN?+)RC#HI<+<$595E#*$U1I5*TW]9S27[NG"51O2K%*4J<7.G'F;J1:E%*
M+4G_`#__`/$*RA7</V])RO8C]EI0",XX/_#0A[^QY[4B?\&K<4C83]O>5CW_
M`.,7$.#\PP?^,@5P<JXP3G*,.JD5^W>D?M:_&G_A9]]X-M_AW\.7^%FC?'[X
M9_LOP^+M4\;^*-0^)=YXT^)G[''PO_:*\/>,=1T!/"]MH4_A_0_%WCS2_`WB
M*W7Q2NM^(=!U.^\6V4VBZGX230_'?RA^S-^V-^TUX9T#X4^%;[X<Z_\`M#>.
M/'G@[X5?M#_%[Q'HZ?';QK<-H_[2/Q(\8>#;/1O`UPGA?Q+X#^$5AX%TGX:^
M,/&0T#7M5\'_``RGAM;+PCX/T706E\4^,-+(<;^)DZ%:K_K!03A"C5A36&R+
MF=*K3=6I*I4>"IT:<J,71C*/M92]K7A!:*4UG+AK@A5:</[#J^^ZL7)5,W5I
M0G"%-*DJLZLU6<W*$DHQ]E"4Y2C:Q^?!_P"#54#_`)OSF/T_9;0_I_PT)_7G
M/3BF1_\`!JS'+G9^WM(Q`5C_`,8N)D!@2IQ_PT)T8`D'/;'KC]E_'G[4'[67
MB;X56'Q3^&-G^SUX(\,^+_VG/A7\+?AU'XFUKQ=XH\<2>%+C]L'PS^SAXBB\
M;:-%X:M?#\=[XS_M*&[U^#P_J-OJOPLM-3O/"EI>>(?%K:7XLT[3\._M(_&Z
M?XL?$#X%?"[P_P"#=9^)VI_%W]H+5%U?XQ_$/Q;_`,*YT+P?\"OA_P#LLC6]
M*\)Z=H7A74O$>GPZ_P"+_CYX9L-`\-6S)I/A?28O&_CR^U#7]1M[3PAKLPXX
M\29T*E9<2X;DI.?/;#9,I48TJM"E6GB'++DH4X2Q$'S1G5]V,WRM1UT_U8X)
M4W3ED<X24*<XN57,KS56%2I#DA'%RF_=I-N\4DI0;:3ER_BS_P`0JG_5^DO_
M`(BXG_T0M1_\0K*%V0?MZ3EEQN'_``RTN0#T)_XR$'!YPWW3@X/!K]D?"O\`
MP4$^+/CI?!/Q$\/?"7P%8_!'6;O]@>V\3#6/'6NS?%*TE_;VU'X=>%?#\'AV
MSL/!P\'7UK\+/$WQ+\/ZIJNL7>JK#XX\-1:K;:59Z%?VUIJ-_P#6GP#UG6_B
M5\6/VD?BG<:QJT_P_P!-\:VO[/7PMT3^TKS_`(1B[A^`UQK5A\7OB!::"UP=
M/L?%FK_'KQ/\2OA3XBOX[&&YU#0_@=X.D%S/:>2D?-B?$+Q'P<*D\1Q!&')1
MA57^QY+53]HZ'LX-4L'6:E.&(C4BK7Y(RE?:)M0X1X,Q$^6EDO-:HZ;<ZN:4
MDN6-9RFO:8B#E",J$J;DEI.=-6:ES+^5S7/^#:W^QOCU\-?@@/VTY[G_`(6'
M\(_C?\4SXG/[.$<+:0?@WXQ_9[\)KH*:&/CG*=2/B/\`X7N=0;4SJ]@-&7PJ
M;<V&I#6?M.E^Q?\`$*H#C/[><O!S_P`FN)_/_AH3^GX5_19XS)/[=_[-[\;D
M_9(_;>V9`PO_`!>/_@GP@P,``A"5Z=\]17V9L'J?T_PJ<3XF<=4Z67N&?SC*
MMEU.O6O@,LGSU)XO,8.34L&DFX4:<;)17+"*Y4TW+2AP/PG4GBO^$>G:GB5"
M-\9F'NKZMA9M17UC1<\Y26K=Y-W3T7\@_P#Q"IK_`-'YS'Z_LO(?_?A/\_2@
M_P#!JFIZ?MYS#_NUU.G'_5P@)X'<U_7QL'J?T_PHV#U/Z?X5Q_\`$3^/+)?Z
MP:)W2_LK*+)O2_\`N6OSNO(Z/]0^%/\`H4Q]'CLS:?K'ZUROYQ?X*W\@_P#Q
M"IKW_;SE/_=KB?U_:$-'_$*FG'_&>4O'I^RY'ZY_Z.#_`,_G7]?&P>I_3_"C
M8/4_I_A2?B;QVW=Y_P#^8O*4ON6#2_#SWU#_`%"X3LU_9*2:LTL?FD5:Z>BC
MC(I:I/1+UU=_Y!_^(5-/^C\YO_$74Y^O_&0G/XYH_P"(5).O_#>4W_B+J?7_
M`*.$K^OC8/4_I_A1L'J?T_PH7B;QVML_:_[I>4_KA'_6FV@_]1.%;M_V5J_^
MIAFO_P`V:?*W??4_D'_XA4UQC_AO.4?7]EU./Q/[0?3W/3`/:O(I_P#@VI$'
MQXT?X(_\-K3,VJ_"'Q+\53XE;]F^-&MQX>\:^%?!XT/^Q1\=6$@N_P#A)3J'
M]I?VI&819"W%A,+@SP?VIN@".>>%8\XQP#[5\?W8W_MZ^$"QY/[('Q%!/?\`
MY+/\+B/R_EQT`KIPWB9QY4EB$^(*DG#!XS$)RP.6Z3@J$^?7"2<IJ\N7FERJ
M[5DGIS5N`^%(*ER9/2BI8K#Q:CB\>DXR^L<T;*O91DH1NDHWY5JK:_SD_P#$
M*FO?]O.4_P#=KD?KG_HX0]Z3_B%37M^WG*.__)KJ?T_:%`Q[8]:_KYV#U/Z?
MX4;!ZG]/\*Y_^(G\>O?B!O\`Q97E,ONYL'*WJK/S.C_4/A/_`*%$$NJ6-S)1
M?K%8KEE_V]&6MFK-)K^0;_B%37.?^&\Y<\_\VN)W^O[0I_+T_.D7_@U0B0DI
M^WC(I8Y8C]EN,%O3)'[0@Y&3@G)Y/K7]?6P>I_3_``HV#U/Z?X54?%+C^-N7
MB.<;.Z4<MRJ,5*SCS**P:BI6;7.HJ5F_>)_U!X1U_P"$:E:7Q+ZWF-I>J^LV
M?HU9=%W_`)!S_P`&J:'K^WE-W_YM>3O]?VA*/^(5)/\`H_.;CI_QBZGL!_S<
M)[?7WK^OC8/4_I_A1L'J?T_PJ%XF\=WO_;]WO[V5Y3*[O>[Y\')-WUNTWYE+
M@/A16ME*22LDL?FEDK624?KG*DEHE:RZ+O\`R#?\0J:]_P!O.4]>O[+J]_\`
MNX4].HXZT#_@U20$D?MXR`G&2/V7(P20`,G'[0?8``$Y(`&"._\`7SL'J?T_
MPHV#U/Z?X4WXG<>-R?\`K!+WOB2RS*E&6J>L(X2,&]%KR7LN6_+[K/\`4/A.
MS7]CTU=).V,S"+M&<:BUCB8O2<(25FM8K=73_D'_`.(5->W[><W;K^RZAZ=,
MC_AH3G_/I2?\0J8_Z/TF_P#$75`_(?M"BOZ^=@]3^G^%&P>I_3_"A>)_'D=L
M_P#LN#;RK)VW%N[3<L%)O79MMK:+BM!/@+A)R<GD]-R;;<I8S,92;>]W+$R;
M\ELMHJ*T/Y!O^(5)/^C\I?\`Q%Q/_HA#C\*7_B%33_H_.;_Q%U.#ZC_C(3CI
MCZ<5_7QL'J?T_P`*-@]3^G^%)>)O'D?AX@E'ORY;E<;KLU'"I-7ULTU?6U]0
M?`/"4K)Y1%J+;BGCLSY5S.[M'ZWRJ[Z6LMDDM#^*/6_^#:X:-\?/AI\#1^VG
M-<GXA_"#XY?%8^*/^&<8XCI!^#/C3]G?PB-`30O^%Z2'4O\`A)/^%]G4#JIU
M>P71AX4-LUAJ0UK[1I7LG_$*I_U?I+_XBXA_]^$%?T4^->?V]OV;'/++^R#^
MW*5X&%(^-/\`P3Q0$#&,[21R#Z]>:^S]@]3^G^%=N*\2^.J5++G#/YQ=;+J5
M>HW@,LGSU)8O,J;F[X2R;A0IQ:C:-H1M%.[EA0X'X3J2Q2_L>G:GB?9J^+S#
M1+#X634?]ITCS3DUJ]9-MZV7\@__`!"J?]7Z2_\`B+B?_1"T?\0JG_5^DO\`
MXBXG_P!$+7]?&P>I_3_"C8/4_I_A7)_Q%#C[_HHI_P#AMRK_`.9#H_U#X3_Z
M$]+_`,*\P_\`FD_D'_XA5/\`J_27_P`1<3_Z(6C_`(A5/^K])?\`Q%Q/_HA:
M_KXV#U/Z?X4;!ZG]/\*/^(H<??\`113_`/#;E7_S('^H?"?_`$)Z7_A7F'_S
M2?R#_P#$*I_U?I+_`.(N)_\`1"T?\0JG_5^DO_B+B#_WX0U_7QL'J?T_PHV#
MU/Z?X4?\10X^_P"BBG_X;<J_^9`_U#X3_P"A/2_\*\P_^:3^*7XX_P#!M</@
MSX-T7Q=_PVG/XC_MCXO_`+._PI_L_P#X9PCTA;;_`(7U^T'\,?@4VNF\_P"%
MZ:GYK^%1\1CXG&DBWB_MDZ0-).H:8M__`&E:>Q?\0JH('_&>DOH?^,7$()!Q
MD?\`&0@X/49SQW-?T6_MP$GX,>"<_P#1X/\`P3QSP!D_\/`_V91DXQSA1_\`
M6K[)5!M')[]_<^U=$O$SCM8'"5X\05$ZU?'P<I8#+)SDL/+`**E?!I)1]M+D
MLKM2E>^EL(\"\*O$UX2R>ERQI8248K%YARQE-8SG:_VA/WO9PO=M7BK)=?Y"
M?^(53_J_27_Q%Q/_`*(6C_B%4_ZOTE_\1<3_`.B%K^OC8/4_I_A1L'J?T_PK
MG_XBAQ]_T44__#;E7_S(;_ZA\)_]">E_X5YA_P#-)_(/_P`0JG_5^DO_`(BX
MG_T0M'_$*I_U?I+_`.(N)_\`1"U_7QL'J?T_PHV#U/Z?X4?\10X^_P"BBG_X
M;<J_^9`_U#X3_P"A/2_\*\P_^:3^0?\`XA5/^K])?_$7$_\`HA:/^(53_J_2
M7_Q%Q/\`Z(6OZ^-@]3^G^%&P>I_3_"C_`(BAQ]_T44__``VY5_\`,@?ZA\)_
M]">E_P"%>8?_`#2?R#_\0JG_`%?I+_XBXG_T0M>/?%;_`(-K1\,-9^">D']M
M636Q\8OC)IWPD^T']G*/2_\`A'CJ'@+XA>-QKPB/QSU#^UC$?`@TS^RS)IHD
M_M0W?]HH;,6MU_:SL'J?T_PKXW_:S0#QC^Q-UX_;(\.-^*_`?]H(CM7;E_B9
MQU6Q=.G5X@G.FX8J4H_V=E:O[+`YA75FL*G=2H0DM5[T8WTNGRXW@;A6GAJL
MZ>44XS3H\LEB\?=<V)PD'O7DM8SG%Z/236E[Q_G-7_@U6W!3_P`-YS#<H;G]
MER,8R`<$#]H4X/\`LY..NX]W?\0JG_5^DO\`XBXG_P!$+7]=\'S<'IL4\`#G
M:G7CGJ:L[!ZG]/\`"N"'BCQ\XJ_$52ZO%WR_*I-R@W"3;^IJ]YPFUILUWLNM
M\!<)IN^345K+;%YA:RE-+_F)[)'\@_\`Q"J?]7Z2_P#B+B?_`$0M'_$*I_U?
MI+_XBXG_`-$+7]?&P>I_3_"C8/4_I_A5?\10X^_Z**?_`(;<J_\`F07^H?"?
M_0GI?^%>8?\`S2?R#_\`$*I_U?I+_P"(N)_]$+1_Q"J?]7Z2_P#B+B?_`$0M
M?U\;!ZG]/\*-@]3^G^%'_$4./O\`HHI_^&W*O_F0/]0^$_\`H3TO_"O,/_FD
M_D&/_!JK@$_\-YS''I^RXF?R_P"&A>?T]:\@^&?_``;6I\1?&G[0G@\?MK3:
M0?@/\7]$^%7]H_\`#-Z7X\4#6?V?_@7\<QKAM#\=+(:,UM_PN<^&CIRW6JK*
M/#ZZM]NB?4GTVP_M5D4*C$9S@#GMD@9'3D=CV//6OCO]F-0WQI_X*&DD\?M@
M^"0.>P_8`_88_P`YZ_K77A_$KCRIALSJRX@FY8;#X"=.7U#+%R2K9K#"S<8+
M"<K<J=6,)<S?NIN*4E<SGP'PHI4+9/32=2JFEC,P7,EAY22E_M#NE)<RU5GK
M=['\YW_$*I_U?I+_`.(N)_\`1"T?\0JG_5^DO_B+B?\`T0M?U\;!ZG]/\*-@
M]3^G^%<G_$4./O\`HHI_^&W*O_F0T_U#X3_Z$]+_`,*\P_\`FD_D'_XA5/\`
MJ_27_P`1<3_Z(6C_`(A5/^K])?\`Q%Q/_HA:_KXV#U/Z?X4;!ZG]/\*/^(H<
M??\`113_`/#;E7_S('^H?"?_`$)Z7_A7F'_S2?R#_P#$*I_U?I+_`.(N)_\`
M1"T?\0JG_5^DO_B+B?\`T0M?UE^+_&_@[P#IL6L^-O%&@^$='GU+3-&AUCQ+
MJUAHFE/J^MW::?H^F_VCJ4UM91WNJ7\L5EI\$DRO=W<L5O`'ED1&Z2*6.0Q[
M7+"0%D(QAEVE@X(!!0@#:V0#G@G@5/\`Q%/CR[BN))2G%0<J<<NRF52$:GP3
MG3CAG.%.5G:<H*.CUT=DN!.$6W%911;BES+Z[C[QOLG'ZUS:ZV:BXZ-<R>A_
M%K\?O^#:=?@9\"OC/\:C^VO-XG_X5'\*_'_Q+'AL?LW1Z-_;Y\#^%M4\2C1C
MJQ^.VI_V:-3.F_8OMPT^]-H9Q.+2Y,?D2>M_\0JG)_XSSE'_`':ZA!'8@_\`
M#0@R/1N-WH*_H]_X*`J!^PG^V81_T:W\>NN#_P`TP\3^U?7*H"">G0<8'`'`
M_#)KJEXG<=+"4I_ZP5/:RQ=:#FLORO6$<+0G&#C]4MRJ4IRT2?,[MOX5@N!>
M%7BJE/\`LBER1P]&=GB\PLI2K5XMI?6-VHQ3;ELDK*UW_(3_`,0JG_5^DO\`
MXBXG_P!$+1_Q"J?]7Z2_^(N)_P#1"U_7QL'J?T_PHV#U/Z?X5S_\10X^_P"B
MBG_X;<J_^9#H_P!0^$_^A/2_\*\P_P#FD_D'_P"(53_J_27_`,1<3_Z(6C_B
M%4_ZOTE_\1<3_P"B%K^OC8/4_I_A1L'J?T_PH_XBAQ]_T44__#;E7_S('^H?
M"?\`T)Z7_A7F'_S2?R#_`/$*I_U?I+_XBXG_`-$+7*^.O^#7`>&/!7B_Q*?V
MZ9K\>'O"WB+7?L(_9D2T-[_9&C7VH_9/M0_:`F-M]H^S>6)_)F\HL&,,H!0_
MV1;!ZG]/\*\T^,Z@?"#XJXSS\-O'8[<?\4IJ_(XX/O5T_$_CUU*:EQ#-QE5I
M1DEEV5Q;C*K3C)7CA+J\923:ULW:VZSJ\"<)QI59+)Z:<:-:2:Q>/NG&C5E%
MKFQ#5U)1:NFKI735T^0_95FEN/V8_P!G.XF9&DG^`WP>FD9$*(TDOP\\.N[(
MA)*(6)VJ22H."3C-%1_LF_\`)K7[-G_9`?@T/R^''AH_U-%?"XEWQ.)?5XG$
MMZ6UEB<0W9:V5V[*[LM.A];ATEA\.E_T#X??5_[O06KZO35V5W=V5['FOC49
M_;\_9F'K^Q]^W2/S^,__``3SJ;]L/XH?`WP7X1\*>`/CS\,?^%P>!?C%XRT'
MPGXF\*7'AWPMXI\.^%_"5OKFB?VM\8_B)I7BO4+&TM/AI\+?$FH>"K[Q)XFT
M^+5-:\*ZEK7AO6=-TXRP->647C4X_;]_9E([?L?_`+=)_P#,S_\`!/.L#]H'
M]B;P9^TY\2/$7B+XQ>*/B%>^!+CX%W7P7\)>"/AW\4/C%\'9-'M?'NL^)+[X
MY:CXKU7X4_$+P;%\1]%^)VEV7P=T=/`_C'3M9\.:0/AC-=26M^?$]W%I_32E
MAX5\NJ8NK4HT*>"C4<Z/M/;*<<5B(4W2E3<9TZD)5G5C.$HR_<\BDN=RAQU(
MUG3QBP].%6I.O&GR5%!P<'0PLI*<9QE&496Y7&2:M-MI\MGH:!XO_88^`_Q;
MT+X.^%YO@?\`"_XRP:;IOPUT;P?H.F:+H'BJQTCQI>W?Q`T7PU<-8V4+:?:?
M$'Q#/J?B#08M2N;<_$3QHFK0:,^O^,+34;*'X]U3XY?L&ZOX/^*7[1OPW_9M
M^&'C:Y\4>&OVT7^*-_K?A/PS\-OB1XYE^"G@?Q8WQ(T)[76O#L^I^,M-^+.E
M:)?VFJ7T-U)%;:1KL6L>,+#^V;K5M)M?H"S_`&//'M]X=UV'QW\7-*\4^._%
MOQ'_`."?WQ,\7>,(O`MWID.L^(OV,_&7P6\:>,)VTQ/$%S]E/Q9U'X4:I)I4
M4=Y-'X)F\3H]Q%XBATJ4W_CGQ1_8YEC\$7?@/XD_M'_#'PEX?U[6/^"B&C_"
M^_UCPQ)X>UF?3?VQO!/Q=^(NHZ+J\VN_$)].\3^)O@[I.I^/_%NJW6@6VCV^
MO_#OP1J.M7&B^'(M+UK48O5PLLJBI*.;9A/%UOJU*K"%7&15:A"-:=>4E0<:
MU:$YTZ+HPJ.JJ,X5<14C.\XQYL1'%Q2_V7!TZ=-\].G*C12@ZGL(M^UK5%1A
M4A[.\I1A#VCE2A3=.48S>;X%M?@OXP\2?"SQ'X3_`&DM*^.,'B;]LSP]XT^*
MFEZ+??#+P=INO?%6'X'PP?`5+:RLM'GGNOAY\-?AS\)O"FL?#SPQX#G5_BG?
MZ98?%"/X@:]H.FZ_I^N>A>.?CC_P3"_X1@_%RYL/@I\3XO@!XXTSQ%IE_P""
M_!6B^-_$O@[7OV@/C3%<GXA^$EM['S[_`,,>/_C-9W_BZ]\>^'KC4/"_BOQG
MX7U35=-U77/%>APPBQHW[('BCXJ>)O"WQS\=_'?X>^/[K5/$'P3U;1M>^%'P
M_N_"_@KQ/\#?AA\+OVA?#7@U=&N)_B-X\N)_%'C"]_:>\7>,KOQS8>(+SPO!
MI,?AK0O#WATV]I=^(]6YZU_8'^*=[\-].\+^,_COX!U/Q+\*/@#X+_9]_9\U
MSPQ\&=7\+:+IFA^`OB%\,/B3:^+OC'H8^*.JR>-=4\1:G\$/A7INH:'X)U/X
M=:#X;TVR\>S^&@S^.K6#PK-3$9?*K'VN98M^S<Z<XQKSHS5.I5A>DY1I4Y5X
MRIQ=&<IT*?)"G+FIU(J4'E##XQ4[4\#A]5&I2FZ"K)2A1E&,U%UIJC*G4Y*U
M-0KSNW^[G3;3CWVH^,_V$8O!GQ5T[XG>!?@1X=^$]IX@^$WP*T^UU#2])\0S
M?$G1]!^&'A?]J_X8Z%)\/;+PZ_BC2=4\!_\`"Y_&7Q&T#P6^EZEKWA;2X-:^
M,KG0]/U:ZO+#Z,\8ZM^RU\%_@58>'/$UI\./"G[/WB?0Y?`VD>%;#0[;4/!O
MB[P]XQT;5=0OO#FA^%?#NG:BWBJQU_P]-XBU[6K;2=,U-+K0AXD\3:N3IMOJ
M^HQ_+FD?LX?$+Q%XG/[4WPA^/'P;U'QY\1OB)9?&_P`,>)6\!Z[X^^"7B'P1
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M1OV(Y/%6@:'I^O\`P/N/$GC?_A%_VD]"GTV;PY?V.L2:/\+(]+\#?&$>)[`7
M'AV.['P6^&Y7P9XCN]7@O=1^&O@*^O/#[W?AOPM?3V/D&O>*_P#@F#=^#/A;
M\6=?T_\`9YO/"?PUUA?A_P#!S7KSP3IMSJ7AK5O#UG;_`!(B\)^`]`_L&3Q4
M\&CZ)I=K\5+?3]'T:YTRQ\+V4'Q,A6+0(HM?KRS1_P!CSQ#\#K;]G6?4/CA\
M+O#/A/X7?!3X/_LL>*+R;X8_$F2X_:/UA?AIJG[/OP_\#_&'PA'\<S\-?B)X
M"U3XF>.]"\6^'],UOP7?_$#PK!#JO@+PY\1=%TOQ#KWC=-+X;?LH?%[P%JV@
M:I\/?VEOA/J'QK^#%]\1-+T[P!XI\)_$_P")7PL^%'P9^//A7X210_#K2/"?
MB3]H?4OC5X4CA\5?`/1/B%X"OM5^)1\.Z=HNN_$'X8>$/!VE>#+KP_=^&->3
M!N\H9ICITE&JZ=5UZT8."^L4US349*C&K*GA*4FX5(4_K,855*<8TS-SQ44H
MSP.&A.4:3J4_8TY3U="2C&GS+VTJ<93G&":E)TFZ:C"$ZD>\^(-[_P`$X-'D
M^(EM_P`(?^RWXJ\;?M"_#B?XL>(M#@T[P)+!\;?#T^GZ]\5/"?B'Q1XPT[2]
M6T"UT?QYJ_A#5?&?A/QEK=XEOXK\1Z%J?C+P_-KVN:'=WD-W5[S_`()X?$.#
M2/AG\4?!7[/FK^)-<L(?C=>_#76/#&B>-HX?%-_\&]/US6Y--U!-$NM,\2>.
MS\%-.CO;O1='=_%WB3X3Z9_;9\.W/@\^:?+/!_[*=Q\(/AG\4/A_\./VG_A'
M;_`R?X):+\'_`-H'5?'O@RTU3Q-X5\9_"W]G^V^#M]K?_"::#\4/"_@GX:Z5
M=^'+;P+XI\7>!/$GA;4CX.AT_6U\/W-A9>-;&[\*\EX-^`V@R?%CX(_M10_M
ME_#;XH_!'X2?$/X7Z1X;.A:AXY\8:38>*+GX`G]D#2/A=X;U/PS\<]8^!?A;
M1]?^(_Q&C^(<.JGX12>/(O$/C?4/#VM>)SH[R:O<]4/91E*<,USB,:,DZ=7G
MS'VSK4\(ZF#H6A%4J%>5>GAZ=*F\3STX3A7H\RI4U*'.LH0B\'EW//F<H<F'
ME3A!U:GM9*TOWMDZDYRC34'556,Y)N<U]`>'?VF/^"?WC?X1^`/BY=:G\-O`
MWA+XZR?#;Q?H">/O"^G>%-8_M;X*77@GQ1X$U_Q#I-]8366EVOP"UZ3X?W-O
MXYNWE^'GP^UP^$FB\5VZ7NB2W>WX%^.?[/OP!\5?L]_L.?#WQC;^.O'DGC&^
M^#>MV=SXHTFY\=Z'J&B?`7XG_M!^(_'_`,07L-'T[3O$?B_Q(?!5C=?$6UT*
MSTN]TKQ#\7_#/B?5],T:Q\0Z'::A\Y:Q_P`$TO'.M^"_@CX=U?XI_#;Q/=_"
M7X(:O^RUJUGX@\#_`!ST;P9X[^!\%QX>C\(W?B/PU\,OVE?AUJ-YXQLM*T2]
MLO'^CZIXCU7X>>.T\026]KH/A2/2+!I_?/#_`.Q_\1O#GQH\!>)+;XL^$I_@
MC\,/VH_C1^U-X8\!/\,M8C^)%QXH^.WPJ^/'@OQ7X8USXE'Q]-H5UX;T'QA\
M>_%/B3PE)8?#BTU%?#46A^#=1OG7PU'K.MX5_P"R%[>G#-,77I+ZY4HTIU6Z
M.(E2>)HX&K%SHRJ-TJ"PTY0E[%2^LS4'&6'DZFD?K\:E%PPF&C:="E/$4Z+N
MJ%5QJ8AN"G35/GFY)2O6Y.7WZ<O:)KT3QC_R?7^SAGK_`,,C_MO9[_\`-9/^
M"?'<\_G7V:YPI/H.U?&/C#_D^K]G#/7_`(9'_;>S_P"'D_X)[_3^0K[.?[K?
M0_GV_6O,QJ;P^5J2:;R>@I)/5-XO-E))Z:IMI.ZU5[G=A%[^.2=O]M:3WM_L
MN#2?GW/E']IO]I.X^`#?";1M*\)Z1XJ\6_&OXB2_#7P1'XR^(FG?"3X?IXEB
M\*:_XMMM*\0_$;4]$\2Q:;KWBB'P]/H/@#PU8^']7U?QAXHNH-.MX;2QAU+5
M-/XW_AL"%?B_)\`+[X=^(--^,$7Q&TG2)/!UUXBT[S8_@CJ7PSN?B;)^T@VH
M6=I<1/\`#ZSETCQ#\)I$MH+B";X\Z'<_#J+7FTV[M/%3>G_M*?![QO\`&WP'
M>_#[POXN^%WA_P`.^+=/UKPW\2-"^+WP+A^/GA/Q=X1URP6SFM(O"ES\0_AY
MI]GKNFRH+K2;[Q!)XP\*EI+B+7?`NO(;5K7`\$_LL:!X%^(WP]\?Z9XKUO69
M?A[^RG:?LJ6,_B^SM]>\;Z[H&FZ]X:UNR\6^*?'S2VM]JVLS-X;636;1M+AM
M]5U;4KS6C/;3YMFUP[RF.'3Q;D\3&&+DHPE5LZ[<)8*562Y53P[K2]C6I04Y
MOV%.I"K3A4K4W%=YC[::H<GLN:@X3]Q2HKFE[>$8.+]I.4(QJQJ3<H*,W15/
MGC&H>/\`[-/[??AW]H_3?V=Y[#X?>(O!OB+XV6GQ!3Q1X1US7K"\U;X2:WX'
M\">"_BAIFE:R]A:?8_$MIX_^'7Q&\$>//!^M:?)917W@KQ=X:UYK:-]2^Q67
M6?&']L>Z^&'C[QYI.E_"C6/&7PY^!\/PNF_:$^(EOXPT70I?A_%\5M2\G2O^
M$3\&WUC<WGQ!N?!7AJ>P^(?Q0BGUGP=%H_@;5-.D\$S_`!"\8_;/!UEYYX/_
M`."<'@+PQXS^`/B/4O%\GB?1/A7^RBG[+OQ/^'^K^#=+E\%?'NUT_P"'FC?#
M'0O'OB73)]1NQH>MVW@]?%/AS7]/5]?3Q9X9UCPQX>U?4#9_#[P^SZ_BG]@G
M2)M8\3>'?A?XRT#X1_L\?%+3OA7I/QH^!N@_"RRN4US3_A+J<UQIUE\+?%=C
MXI\/Z?\`"VS^('A\6'@+XK6VJ>!?B/%J_@[2K8^`#\-/%]SJ?B^_Z*O]B2Q$
MIT'55*=&I.-&HL5*-"H\744J/MURUZ]2&%C!X><*4Z$Y5$JTX5*;YN6,LWAA
MHQJJ#J1G&/M(5*$)SH+#T[590JIP4)8ER]NE45:,%^Z4E)<O0^"/VU8O$_Q`
M\*V>O?#6_P#!7P8^*/BOXU>!_@Y\9-6\<^'KB/Q5XD^`J>,;WQ?+XP\&):V\
M_P`/_#'BOP[\./B'XU^&.OMXD\3-K'@_PA>7OCO2OAMK6HZ5H-_Z=^S#^TA;
M?M+:5\4/$.G>#-?\&:/X%^)O_"%>'9/$-Y$]]XX\(:Q\-OAI\5_`WQ)BTA+>
MVN_"]AXX\%_$W0=:T_PQKB_\)+HUI/%!XBMM(UMM0T'2O`H/^"?&E>()9O`O
MQ6^)=Y\0/V;?#NH?'_5/AA\'--\/:W\./%OANX_:33QKI_CJT\7?&?P=\0;;
M7?%6D^$O"'Q,^(WPZ^%$7@_P]\+=7\.^!_%UU!XWUKXD^*-/TSQ5:^\?LZ_L
MK^$_V;_$7QUU_P`,>,/B?XI3XV>.O#/B^:S^)/Q:^,WQ6F\-6OACX9^#?A]:
MZ7;ZI\7?B3\0[S4-4NY_#>HZOJGB]&TO7]7TF_\`"_@K5YM1\-_#3P+!I7/C
M?[$5'$O!NI]87L?J[DL2XI4ZLVG)SJ)?6JN'G'ZS&=+V,9T_W2YIOEUH/-)5
M*#Q$81HN,_K/).E=U)TUM%0;^K1J)^PE3JJK*Z=5)+7ZED_U<G^XW_H)KX^N
M?^3]/"'_`&:#\1/_`%<_PNK[!D_U<G^XW_H)KX^N?^3]/"'_`&:#\1/_`%<_
MPNK+`_Q,7_V*\?\`^FZ!VXC:A_V&87_W:/L2FLP7KZ'W/8=!D]Z=44JY(//1
MAD?[6/J.W?TKB=[2MOROE\Y6?+NTMSHM?3S7S75;JUUI?IN?'WQ'_:,^(EM\
M2_&?PS^!7P+O_C;K?PJ\+^&O%'Q1EG^)GASX7V-A/XR@UO4/#/P^\!77B#3=
M4M/&GQ5U;1-%?7#HOB*\^'G@'1],U?PM+KOQ.TF36YH].S/#?_!0#]FCQ/HV
MBZIH&O\`Q*\1S:S\(OAU\;GT7PA\`OCS\0M?T/P'\7?#]AXE^&<GB/3OAS\-
M_&']C^(_'%C?O9^$?"%Q<?\`"3>+->TCQ)X?\+:3K.K^&-?L=,T/'O[.GQ3;
MXI>-OBC\!?COIOP<O?BYX?\`"?A_XKZ;XC^$=G\5XY;WP1;:MI'A[XB?"Z2?
MQQX)L_!/Q0A\+ZTWAZ]U+QOIGQ=^'NI6WACP//=_#&271=<7Q7Y?=_\`!/W0
M]*^$WQ%^$'PW^(FH>$_#'B?PC^R]X'\+:=XAT"^\9:/8>$OV7[+P]I.G>"?B
M796WC+PIJOQ7^'_Q8T+0O^$4^,'AG_A(?!-UXO\`!VN>)]`FUR+^VY[Q/64,
MHE3C&=5TY6PKA*A]<=3VDX4XXYXM582P[4<0ZTJ$,-.*<(P]Y04[^5.>90E4
M<8*;C[>RK.@H2C%U*U+V"I5/:*+7LZ,Y5H\R;E-+E2@_:/`?[5/A/XG_`!4^
M&W@KX?VE]K7A'XD_![XW?$V+Q;J]CXH\%^(?#>N_!'XL?"_X2^(_AYXA^&GC
M+PKH7BWP[XEL/$?C_6=.\5:7XJB\.>)O!6O>#+OP[K7AAM0N[E]+NZW^V5^S
MKX;\5^._!FN>.=3TS4_AOHGC'7?%.KW/@#XEGP(!\._#<_C'Q[X<\.?$^/P<
M_P`-O'/Q!\&^$[34/$7B?X7>!_%OB+XEZ%I6E:S=:IX2M%T75A9>7_LT?L26
M7[.FL?#36K/QSIFKQ_#SP7^U)X3CT#P[\.-.^'_A>1OVGOVC_#'[1-Z_AW0M
M-\0:M;>$M`\!7GAYO!?AWPW"VJM=:)<6=W>:M'=Z>R7OD>L?\$R?!U]XU_:`
M\0Z?JGP?M--^-MC^T%J>G^)=2_9QT?6OVA_A_P".?VC?!7BSPIXWOM*^/9\>
MV,FI^!;6Z\>>,]7TOPE_P@&F^,H;#6O^$&/Q4/@6UB\/L1I9+4Q+A+%8J&$C
M&E&E7I4N:<I/$0C6JSIR][]UAYSJJ$4W5E#V<;-W5<^:K#TYNA0]O*K4=>$J
MGN4:4:3<(P<6E-N<8Q;T2C>3OJG[_)^W_P#LPK\/_&'Q2M_$GQ+U?P9\/]0T
MZT\8W/AS]G/]I+Q-KFAZ3K/AS4/%VA_$&?P5X=^$>J>-KGX,Z_X9TK4=;\/_
M`!VLO#UU\%]>L;.:32/'EX0BMW;?M<_`!=&N->D\=3V]A:^-='^'4\-SX/\`
M'MKK$7C37OA-IGQVTW0W\-7'A>/Q*)'^#^K6?Q!N[X:/_9>F>'EOKG4[VSFT
MG5X+'P;XU?L7>,_B1>>*]1\%_&3PYX4?QKI7[,GASQ;H'C[X0ZE\2_!?B_PM
M^S;KGQ;\50^%_%FC:'\7/A9KFJ>&OB!XI^(N@:AXIT6R\5Z3;7VA^#;_`,%Z
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MG:QX7L?AA\2M?^'^KW2:/\0_#OP]\8^)]?\`A_K$5[I'C+3-$U'3M1MK7Y^N
M_P!AZ"\\*^+O"[?$^]0^+/V8?V1_V;Y=0/A&)C9Q?LJ>-OBUXQC\8BV/B3%U
M-X^/Q5ETVZT%YXD\/1Z(MRFK:W_:+P6;_@O^PEX5^#'[0?C3XS:6GP>U33_$
M7BKXM>/=#OI?@!HUA^T)HWBKXV>+-1\:>-K/6?VB(?&$I\1^![?5_$?BFR\-
M^'[7X8^&_$5IX<O-$T+Q%XV\56^@&75,ZD,GY,0J>)Q=.:IOZJIJG.56JW*R
MG-TH\L5:G>/*VU.5I1Y%>XU,T4Z$94L-*G*;C7J14H.E#W7S1C*=3GTE:W,G
MIV>GWX#G/L2/7TI:8G3\?Z"GUYNWX?DK_C<]+\/Q_KO\[=#\D_VZ/VFO#O[)
MW[67[(_Q&\3:)/KFE^(O@5^V%\-EAAU.'1H;"^\3?%#]AC4[35=1OY;+4!#I
M\4WALV<\@M7\J34+>YF*6]O/*B'_`(*L>#P2/^$%\-\''_)<O!W_`,I*[W]J
M+X/^$?C9^V!^S1X7\7Z+8:RND?LO_MM^+O#)U%)98-(\7Z=\6OV"-(TS6UME
MD2WN9[*QU_5XX([Z*YLXY;E;@P>=#!)'Y3+_`,$\_&[2RF'Q1X:CAWMY*'P=
MX1EVQ;CL'F2:*78XZEOF]:_./$'*?%O&9EE%;@GB?(<GR5<-Y;%X7,,ORW$X
MEXSZ[Q$\34D\5@,5.G&3]ERQ55I[V^%1^6Q%/B*OBL;/*\7@,-AHXJ,/9UJ=
M!U95%@\&ZE27M:3M&4FE%1<K6?,]4EL?\/6?!W_0B^&__#Y>#O\`Y24?\/6?
M!W_0B^&__#Y>#O\`Y25A_P##O'QY_P!#5X9_\(OP=_\`*6C_`(=X^//^AJ\,
M_P#A%^#O_E+7P7^KWTB?^B\X4_\`#-D?_P`YS'ZIQG_T,\K_`/!6#_\`E1N?
M\/6?!W_0B^&__#Y>#O\`Y24?\/6?!W_0B^&__#Y>#O\`Y25A_P##O'QY_P!#
M5X9_\(OP=_\`*6C_`(=X^//^AJ\,_P#A%^#O_E+1_J]](G_HO.%/_#-D?_SG
M#ZIQG_T,\K_\%8/_`.5&Y_P]9\'?]"+X;_\`#Y>#O_E)1_P]9\'?]"+X;_\`
M#Y>#O_E)6'_P[Q\>?]#5X9_\(OP=_P#*6C_AWCX\_P"AK\,_^$7X._\`E+1_
MJ]](G_HO.%/_``S9'_\`.</JG&?_`$,\K_\`!6#_`/E1YE\=OV__``E\9/!&
MA>$[;0/"7AZ71_C-^S=\56O;GXQ^$M2AGM?@-^T5\+/CG?:(D$&FVDB77B2S
M^'-QX=L[YI7BTZ\U:'4+B"Y@M9+:3VG_`(>L>#1P/`GAL#GC_A>7@['))[Z*
M>V/8=!D#)^<OVAOV./B9\+_A[HOB32/&WABVOM3^.?[*?PY\T^!?`]T&TOXQ
M?M6?!3X0^);<0W7ARYA5KOPKXXUNU6\PMS8&;[9ILUKJ<%K=P>X#_@GEX[.X
MCQ7X:QOD"Y\%^#N%#LJ@'^Q>0%`P>_7O6\N'?I&K#8=2X^X4=&-;&1I6R;(T
MO:+^SUB7_P`B;E]ZJXM6;]VR;;1E'"<8JM67]J99*JH4.=^QP<5R?[5&A:])
MWO&G4E+5V<[;IN6[_P`/6?!W_0B^&_\`P^7@[_Y24?\`#UGP=_T(OAO_`,/E
MX._^4E8?_#O'QY_T-7AG_P`(OP=_\I:/^'>/CS_H:O#/_A%^#O\`Y2UA_J]]
M(G_HO.%/_#-D?_SG-?JG&?\`T,\K_P#!6#_^5&Y_P]9\'?\`0B^&_P#P^7@[
M_P"4E'_#UGP=_P!"+X;_`/#Y>#O_`)25A_\`#O'QY_T-7AG_`,(OP=_\I:/^
M'>/CS_H:O#/_`(1?@[_Y2T?ZO?2)_P"B\X4_\,V1_P#SG#ZIQG_T,\K_`/!6
M#_\`E1N?\/6?!W_0B^&__#Y>#O\`Y24?\/6?!W_0B^&__#Y>#O\`Y25A_P##
MO'QY_P!#5X9_\(OP=_\`*6C_`(=X^//^AJ\,_P#A%^#O_E+1_J]](G_HO.%/
M_#-D?_SG#ZIQG_T,\K_\%8/_`.5&Y_P]9\'?]"+X;_\`#Y>#O_E)7BWQ>_X*
M`>%OB?K/P,U>#0/".D#X/?&O3/BU<V]U\8_"EZ=?MM/^'WQ'\$MH=M+%IT"Z
M?<RS>.H-0%[/'=Q+#ILT'V<23QSP^F_\.\?'G_0U>&?_``B_!W_REKPKXU_L
M<?$_P!K?[/&G:9XU\,6R_$W]H?P]\-]94^`?`=S]IT"\^&GQ7\774`DNO#5T
M]D1J7@[1YQ>6!M=040F".Y%K/=PS]6#X=^DA+$TUAN/>$U7<<0J;>2Y&XJ^$
MQO/S+^Q]8^R592U2L]7:YAB<+Q<J$W7S/+/9?N^>U+!WUKX=1:_<O55)4G\N
MFZ^CE_X*K>"U/R>!?#1PH7/_``O+P:"1[JNB;01@`X]AT`I__#UGP=_T(OAO
M_P`/EX._^4E80_X)Y>.3C9XM\-D`8`;P7X.)QVW'^Q`,XP20H'3@#@+_`,.\
M?'G_`$-7AG_PB_!W_P`I:Y%P]](BUX\><*J+47&^39'>SA3;O_PC+5R=1O2Z
M;:>J9LL+QHU=YGEB;;<DZ6#TDI3BUK2NU[B=_P"]\WN?\/6?!W_0B^&__#Y>
M#O\`Y24?\/6?!W_0B^&__#Y>#O\`Y25A_P##O'QY_P!#5X9_\(OP=_\`*6C_
M`(=X^//^AJ\,_P#A%^#O_E+3_P!7OI$_]%YPI_X9LC_^<X_JG&?_`$,\K_\`
M!6#_`/E1N?\`#UGP=_T(OAO_`,/EX._^4E'_``]9\'?]"+X;_P##Y>#O_E)6
M'_P[Q\>?]#5X9_\`"+\'?_*6C_AWCX\_Z&KPS_X1?@[_`.4M'^KWTB?^B\X4
M_P##-D?_`,YP^J<9_P#0SRO_`,%8/_Y4;9_X*L>#2"#X%\-XZ\_'+P=CCG_H
M"8_/^6:\9^%W_!0+PK\._'/[1WB^7P_X1U2+X[?&;0?BK96%O\8_"=G+X<M]
M'_9W^`GP/DT6^GDTZXCU2YFO?@S>^(4OK>.SB6RUZSTY[4W%A-=7'I?_``[R
M\=CKXL\-+[_\(7X.P`>.?^)+@=NOO[@^'_"C]CCXE^-_B%^U+X9O/&OAN>Q^
M#OQW\+?#GP]&/`/@2'[+I&J_LI?LQ?%^\A:6#PU!=7K-XK^*?B:?[3J%S>7"
M),EG%*FGVUC!#M3X=^D=*CC%2X^X5BEAZ'M5_8N2N,HO')T[I9.HOEJQIN,9
MS5YM.#52S,*F%XRYZ,7F>6J3JS5*2HX245-X.;]Y*FDU\5KM7E:+:NC]@?!_
MQLL?%GP%3XZ0Z=;P:?)X%UWQN-+3Q%8WMG]FT.VU:XE@7Q+%:P6#6UP-,<#5
MOL:V\".97B=(B&\<_9A_;(T;]I?Q)XE\/:3X>TS1&\-Z%9ZY+<:;\0]$\:&=
M+J_%@()K73-/LY;`!V#1W$KR13E6B2-64N?5?!GPRO\`PW^S[;_!Z:9)M4A^
M'^M^$&U&+3;2.P^U:G9ZI;17'V)((K$VR-?1N]NEK]F95='AVED/BO[+?[,?
MB#X#>)O$^MZYJNGZO#KWAZRT:WBTKP_HVER126NHK?.\SZ5IUDSQE%"()YG4
M,242.0EF_1,1@>.99KP=6AG.7T\GPF"G#C7#RPF#5?-,;+#4Z4,1@)5J7M\+
M"->55JG@?9JU2$FFH(^CE3S3ZSEO[^C]6A!QS2$HTXU*]3V4;5:$81;BE53E
MR0G&/+*TD[(H?&7]NSP_\(?C3/\`!R\\+Z9J-[;7?A&U?4+GXEZ!X?O)#XKM
MM+N8FA\.WNE76H2M;KJD:Q1QW&Z^>("%HA(]>Z_M)?'JP_9W^'EIX^U/2K;5
MK:X\1Z9X<-KJ'BFP\(P12ZC::C=BXDU748+NVWQ)IDJ"U\EI968L'5(Y,_.G
MQF_9'\3_`!.^-TGQ1T_6M*T_3Y[_`,%W+V=WX<T"YO53PS:Z;!<`WM[IEW?L
M)18NT.9CY)(6`Q#!D^@/VG/A%J'QQ^'5KX.T:]M=+O+7Q1IOB#[3J.DVVH0&
M+3[/5H'B6WU2RNK822/?H$E6$RQC<8V4,QK".6^(BH<<4Y9YE,L5C:]9\`U7
MA,)_PC47AU]7I9PJF%IT,15IXF[MB_K7/1Y93JN<FR/8YQR9K&>+H4ZM64GE
M%3V=&"PM.4$X.ORQJ*;A4=I*K&3E:S6[?XR_MT_MEZ3^U/\`LY>+/A'X:T'P
M?X>UV^U;PCXCL+^]^,/A'5(9&\(>)=.\0RV"V2V&GQ23W\5B]K;FZO;>U%P\
M2W$T<;,3\6?`;]M?XP?LS:=H3^"/B_X7B\)RV<$UY\%/BUXCLKWPM:PAI4F3
MPU;7VLZ3XE\%*Q6X:P;POJ5MH[R,;W4]#U<1I;K]D?ML_L8_%KX;?L]^)-=\
M+WH\3ZW>:[X/\-VVA>$O!^APZ]J-KXA\0VEAJ$%I<:+HT6HVD(M#(U_=6MW;
MO'8?:!*_D-.&_);X0_\`!/3QW\2_%TVJ^-],U'7O$$]Y%'+HULDB:=I"P[((
M=.DNPK11VVGVH6VC2T*.L<"[FWM(U?@>8\*^,6(XPP=;%<0U,3GV$P=&I#,^
M'<#A,!AOJDIUXTJ&.KXBE@,FQ5*$J:Q-2EBE7K)2ER89)+F^-K8#B6IFE&5;
M'.6-C0<U7R^G2HT:<9K^'7E&*I3C&;]I)3A4E*":22=C]N?BA_P4[^!G[3'[
M%7[6G@2\-S\/OBQJG[+?QX@M?"LVH6_B_P`*Z]>_\*L\52R)X4^(&@PG2[H;
M5"V^G^)K/PGKEU*Q@TW2M0*-*W[RPD,N5(8$*<CD'*YR#T/&.>]?SF_$+_@G
M@OP?_8E_:O\`%6HRPZ!/IW[+OQQO(=*T0&T#M!\,O$<B17<D2F2XW-&HD:7>
MS_(S%B.?Z*M/MEL[>.V1Y'2*.-%:5BSG`(.6/4\?A^I_JKA^CGM#AO`4^)<?
M@,QSB&88KZSB<NPL\-0FGEN!@HMN7L<1*$HMO$X6E1P]:<JCI4TH.4_M,%'%
MPK-8RM3KU_J>'C.=*/+%N.)Q%N9)V<[7YI*,8R;5DEHKU%%%>F>H%%%%`!7F
M?QH_Y(_\5/\`LF_CO_U%-7KTRO,_C1_R1_XJ?]DW\=_^HIJ]73_BTO\`K]1_
M]/43*M_`K_\`7BO_`.F*QQ7[)O\`R:U^S9_V0+X-_P#JN/#-%'[)O_)K7[-G
M_9`O@W_ZKCPS15XC_>,1_P!A&(_]2*X4/X%#_L'H?^F*!YMXT('[?O[,A/3_
M`(8__;G/X'XS_P#!/,C@<]Z^Q_,7U/\`WRW^%?GC^T+XR\6^!_VW_P!EC5?!
MOPC\;?&;4[C]E?\`;>L9_#/@/7OA?H&L6-C+\7/V`)Y=:GN?BO\`$'X<Z!-I
MUO/;V]E-!8ZM>ZL)KZVDAT][:.ZFA]/_`.&AOCM_T85^TA_X<K]C#_Z**NF>
M%K5*."G#V"3P<-*F,P=&:MB<<O>IUZ]*<7\I*UG?5(Y*>(A3JXJ#A5NL0E>-
M*O.+_P!FPCO%TJ=16UM[S3OLFM3Z[D<$#&20<_=;^ZP]/?'XU^$/CCP7\<O$
M/[0>E:WJ'AS]KC5?BQX._:8_:V\0ZEJYN?B+=_LQ^%?@M?\`[)W[7W@G]DW6
M/A+9F];X3Z5XVU#0/%_P]\-:GJWPETVT\?P_$O5?'>E_'K4X?$.O?#&+7_TB
M/[0WQV[?L%?M(9[9^)7[&//Y?M1#^OTJ'_A?_P`<C][]@?\`:/Q\W`^)?[&H
M'S'+9Q^U,-V3SE@2,GGYFSTY?/%Y;7G7A2P=:=2G[)*>88#D47#$PDI.&)ES
M1DL3*7+*=).=.E>4DI0GSXV&'Q]-4JD\91CS)R]E@Z\E.TL/-1DZD(MI/#1:
M2C=.4K-MQ<?SO\`#]JN7]IK]E:?4]&_:1T&QT/1?@GX8^+-KK+?M.^)/`?C7
MP!J7[(.HZAXV\<^+;O4?'UM^RAX*U;2?V@;RR\!ZOX1N_AEXH_::?QWX8G\>
MZIX[T#X?^(M,LQZE^S-\$?C$'_X)[GXH^-?VO+@K^R#XO^,W[2$?C'XV?'&-
M-3_:O`_8B'ACPW\5(Y?$UNMC%IRVWQB&G_`Z,:1X!UDVWQ'/B+P3KKZIXU;4
M_K\_'[XXGG_A@?\`:/!.,E?B7^QJI(4D@$K^U,"5!).TY7.#C(&#_A?_`,<@
M<K^P-^T;D]_^%E_L:>N<8_X:D(()Y(/!XR#@5TU<7BJE)4X8;+L.E"I!NEB\
MM4G[18B/-[2I5FVX?6:LH)5&HRDG&W)'V>-/"X>DYRGB,=B.:4'!5,%B+TE'
M:,53JT[Q=H*7/!MJ$4[IOF_*;P-\(/VN/@S^RKX!\$_#6_\`VF+(Z[^Q1^P7
MJ'Q5TWQ1??%_QYK7P[\2:%XYT'PS^TKX;^$WA72O%_@WQG\._&.E?`9]1TG6
M_A+^SSXH^&?CTZ=X:MM6^%5II?QUO;'Q)K=#XO6O[8.B_`CX0Z9\.]>_:J\?
M>,-&T+XZ^-_A7\3-.^'O[>/A'Q/=>)M'^(%O/\-O@W\1?A)?_&N+Q2ZZ1X92
MZU#P]\4?^"A&M_$W0O&WA/P_9:!??#+XD>,/%U]8:I^M(_:`^.7_`$8/^T=T
MV_\`)2_V-/NYR5/_`!E*,@G.0<[LD'(.*#^T!\<SC/[!'[2!VC"@?$W]C90`
M>N,?M38&>IX.X@%LX&-5F>-595JF"RZM4>)KXBI*6,R^+JSKNMS<[@JG,HJO
M*,6E!NFN5WYN>,/!8?V?LXXO,(Q5*G2IQ^JXAJC&G3I4TJ2<_=<O91<KNHN9
MR:L[)TOVIF\KXD?L*W\[SCPO:_MD`>+9A)C3XTU;]E+]JG0OA^=37RVAGMY?
MBYK'PW@T6&1E1O%=QX=E@,M^L<4WPO\`#*+]I[X/?$B#]LWQ9\`;K7=._:'T
M3XX:C\3/`OPRM?'NO_M#2:5<>&=6^,G[)VB_%_X?7'@+3+#PSXC^"'@#X6VG
M[*<6DZ5K.M&/XD_&1I;](/MNIW4/V[K7Q>^*7B6RBTSQ+_P3K^/'B+3;?6?#
M_B*WT_7?''[$FKV-OX@\)Z]IOBOPMKUO:7_[3D\$&M>&O%.C:1XF\/ZI$BWV
MC>(M*TW6].N+;4[&UNHM@_M`?''``_8%_:-X).#\2?V,`,DEB>/VH@<EB3GW
M(Z$@\=*=>AAEAHX?`U%.G6P]?VV-P+YZ%;$RQ,H1_P!OI<G-)P<ZD5.7/2I2
M@U*G8VKTZ>(K>V=;&0]G5A7HNEA\3&4*T,,L/SRI3PKA6Y$YJG3G.--PJ34[
MN5U^7>H_`7]JKX3_``2_:B^''C?X7Z!XMU']IK]COQYXS\7:I^S]'X_^(]AX
MB_:R\%WTE[\3/%/B;3I_`OA^YT_X@?M+V?Q?B7PEX?T2'7K3^R_@&GAW2[F>
M2UT?3]0]`_:2L!XX\%_\%`_CI\+?A?XZ^%?@+Q/^P7XP^$]IJGC3X8>)/@=X
MF^.?[2*/XN/P7U;1/AG\0M"\)?$:WUSX5:AJ5EX1\-^._&/@C0#XBUGXCZ+I
MW@W4?$>C>%/MNF?H$?C_`/'-E56_8'_:-*IMV@_$K]C1@-N-N?\`C*4$D8'+
M$DGELGFLG6OB_P#%/Q-:0:=XE_X)V?';Q!IUMJ_A[Q#;Z?KGC;]B35["#7_"
M'B#3/%GA+78;/4?VG;N"+6?"WBG1-&\2>&]4BC2]T+7])TW5]+GM=0L;6XB[
M5F&.]HJLL/@>95(3G.CFF&@I*,\$]<(L;4P]2HJ>7X:C"K/GE3A'G@E4C3<.
M:678)T'2C4Q2CR2A3C/`57*+E#&P:]K&DZT:<ZN/Q&(G3BU&4Y*,OW;=_M>%
MBB%9?]9N8OM5@I8G+%!EB$+$E`3G;C.3R9?,7U/_`'RW^%?'R?M"?'1%VK^P
M5^TA@$G'_"ROV,."3D_\W0\<DGOU_`._X:&^.W_1A7[2'_AROV,/_HHJ\+ZE
MB.^%^>89:G\T\9=/N>S]<IO51K.^M_JV,6^^GU?O>WDD4_&8(_;O_9Q7!W']
MDG]N#`[G_B\G_!/AN,]?EYXZ@''/%?9?F+ZG_OEO\*_)?Q?\=?C%)^VG^SYK
M$G[%GQ]M]5L/V8/VQK&U\+R_$#]D=M6U73]2^*W["DE]K]AJ$/[2DOAZ&P\/
M76FZ=8:S9ZKJFGZO/)XDTFXT&RU:WM=<;2_JG_AH;X[?]&%?M(?^'*_8P_\`
MHHJ[\;@L1[+*;+#J^44&^;'Y='7Z_G"=KXJ-U9)W5UOK8Y<-BZ*J8Y15:5L8
MKOZOC-W@\&VO]WZ77?SUT/K_`,Q?4_\`?+?X4>8OJ?\`OEO\*^0/^&AOCM_T
M85^TA_X<K]C#_P"BBH_X:&^.W_1A7[2'_AROV,/_`***N#ZEB>^%_P##CEO_
M`,V'5]<I_P`E7_PGQG_S.?7_`)B^I_[Y;_"CS%]3_P!\M_A7R!_PT-\=O^C"
MOVD/_#E?L8?_`$45'_#0WQV_Z,*_:0_\.5^QA_\`114?4L3WPO\`X<<M_P#F
MP/KE/^2K_P"$^,_^9SZ_\Q?4_P#?+?X4>8OJ?^^6_P`*^0/^&AOCM_T85^TA
M_P"'*_8P_P#HHJ/^&AOCM_T85^TA_P"'*_8P_P#HHJ/J6)[X7_PXY;_\V!]<
MI_R5?_"?&?\`S.?7KNI1P,Y*L!\K#D@^HQ7Q_=';^WIX0SD?\8@_$7L<\?&C
MX7`\8SU_QZ4X_M#?'4@@_L$_M'XP<Y^)7[&&,8YS_P`91#CUKY?OOCI\93^V
MIX6UEOV*OC\-47]ECQ[IL?A@_$+]D4ZS-9R?%WX<74NNK<)^TD="72K66"'3
MY4FU6'5VO;RU%II5Y9KJ%]IW7@L%B5/%.*P\G_9N.O;'Y<U&'+AE*3:Q>EE*
M^K5M[-'/B<937U>\*UGC,*KK#8QZOZU;;#^7IW:TO^L'F+ZG_OEO\*/,7U/_
M`'RW^%?('_#0WQV_Z,*_:0_\.5^QA_\`114?\-#?';_HPK]I#_PY7[&'_P!%
M%7)]2Q/?"_\`AQRW_P";#H^N4_Y*O_A/C/\`YG/K_P`Q?4_]\M_A1YB^I_[Y
M;_"OD#_AH;X[?]&%?M(?^'*_8P_^BBH_X:&^.W_1A7[2'_AROV,/_HHJ/J6)
M[X7_`,..6_\`S8'URG_)5_\`"?&?_,Y]?^8OJ?\`OEO\*/,7U/\`WRW^%?('
M_#0WQV_Z,*_:0_\`#E?L8?\`T45'_#0WQV_Z,*_:0_\`#E?L8?\`T45'U+$]
M\+_X<<M_^;`^N4_Y*O\`X3XS_P"9SZ_\Q?4_]\M_A1YB^I_[Y;_"OD#_`(:&
M^.W_`$85^TA_X<K]C#_Z**C_`(:&^.W_`$85^TA_X<K]C#_Z**CZEB>^%_\`
M#CEO_P`V!]<I_P`E7_PGQG_S.?7_`)B^I_[Y;_"CS%]3_P!\M_A7R!_PT-\=
MO^C"OVD/_#E?L8?_`$45'_#0WQV_Z,*_:0_\.5^QA_\`114?4L3WPO\`X<<M
M_P#FP/KE/^2K_P"$^,_^9SZ_\Q?4_P#?+?X4>8OJ?^^6_P`*^0/^&AOCM_T8
M5^TA_P"'*_8P_P#HHJ/^&AOCM_T85^TA_P"'*_8P_P#HHJ/J6)[X7_PXY;_\
MV!]<I_R5?_"?&?\`S.9_C3)_;U_9M7!!/[(/[<V`>I_XO3_P3P;@=?N\XZXS
MQQ7V?YB^I_[Y;_"OR4\8?'3XPR?ML?L]:S)^Q;\?;?5;#]EK]LJQM?"LGC[]
MD=]6U;3]3^+?[!DM]X@L-1A_:4E\.P:?X<N=,TZPUFTU75=/UBXD\2Z1/H%C
MJ]O:ZZ^E?5G_``T-\=O^C"OVD/\`PY7[&'_T45=^-P6(='*+?5U_PCT+\V/R
MZ.OU_.5I?%1NNMU?UL<N&Q5!3QJ@JTO]L?,WAL9I)X3!MI?[.E976U_-WNE]
M?^8OJ?\`OEO\*/,7U/\`WRW^%?('_#0WQV_Z,*_:0_\`#E?L8?\`T45'_#0W
MQV_Z,*_:0_\`#E?L8?\`T45<'U+$]\+_`.''+?\`YL.KZY3_`)*O_A/C/_F<
M^O\`S%]3_P!\M_A1YB^I_P"^6_PKY`_X:&^.W_1A7[2'_AROV,/_`***C_AH
M;X[?]&%?M(?^'*_8P_\`HHJ/J6)[X7_PXY;_`/-@?7*?\E7_`,)\9_\`,Y]?
M^8OJ?^^6_P`*/,7U/_?+?X5\@?\`#0WQV_Z,*_:0_P##E?L8?_114?\`#0WQ
MV_Z,*_:0_P##E?L8?_114?4L3WPO_AQRW_YL#ZY3_DJ_^$V,_P#F<I?MO_\`
M)&/!(P>?VP/^">!Z'I_P\$_9F/\`(@XZXK[+5U"CG]#Z_2OR9_;"^.?QCU;X
M3^$K75/V*_V@?#5M!^U/^PEJD=_J/CW]D>_@O-1T?]N7]G/5M-T*.#0_VE=1
MOHM3\47]E;^'='NKBWBT.UU74K2X\1:GHFA0W^KV?U*G[0OQUP"/V!_VCAR>
M1\3/V,3CD@@?\918([<C/K\V:ZG@\3_9F7P2PZC'$9HUS8_+HMN=3+.=>]BX
M_"TEI'J[MG/'&4OKF)M&LW['!7_V;&=5CVK/ZOKI>^NCTWL?87F+ZG_OEO\`
M"CS%]3_WRW^%?('_``T-\=O^C"OVD/\`PY7[&'_T45'_``T-\=O^C"OVD/\`
MPY7[&'_T45<OU+$]\+_X<<M_^;#H^N4_Y*O_`(3XS_YG/K_S%]3_`-\M_A1Y
MB^I_[Y;_``KY`_X:&^.W_1A7[2'_`(<K]C#_`.BBH_X:&^.W_1A7[2'_`(<K
M]C#_`.BBH^I8GOA?_#CEO_S8'URG_)5_\)\9_P#,Y]?^8OJ?^^6_PH\Q?4_]
M\M_A7R!_PT-\=O\`HPK]I#_PY7[&'_T45'_#0WQV_P"C"OVD/_#E?L8?_114
M?4L3WPO_`(<<M_\`FP/KE/\`DJ_^$^,_^9SZ_P#,7U/_`'RW^%?&_P"UDP/C
M']B?&?\`D\CPX.01R?@/^T$!U`ZGBK/_``T-\=O^C"OVD/\`PY7[&'_T45?*
MW[3'QR^,>H^*OV0Y=0_8L^/VA2Z5^UCX>U/3;74?B#^R//+XDO8_@K\=+4:!
MI,FE_M)7]O;:M);W<^I0/KDFEZ/+:Z9>0/JUOJ$FG6U[Z&5X+$?7J*_V9WIX
MR.F89<W:>79G!VMBV[I3;V>VIQYAC*:P=9\E;1T'_NV,_P"@O!?]0_\`7WV_
M5^#Y<%@0#&F."?X4[`$CH>M6?,7U/_?+?X5\?+^T+\=`,+^P7^T>PP,,/B5^
MQB=X`'S9/[463GKVX(X&:=_PT-\=O^C"OVD/_#E?L8?_`$45>;#!8AQ37U97
MO)J689<FG-NHU9XM/251I:;);[G:\93;;Y*N\O\`F&QG\\_^H<^O_,7U/_?+
M?X4>8OJ?^^6_PKY`_P"&AOCM_P!&%?M(?^'*_8P_^BBH_P"&AOCM_P!&%?M(
M?^'*_8P_^BBJOJ6)[X7_`,..6_\`S8+ZY3_DJ_\`A/C/_F<^O_,7U/\`WRW^
M%'F+ZG_OEO\`"OD#_AH;X[?]&%?M(?\`AROV,/\`Z**C_AH;X[?]&%?M(?\`
MAROV,/\`Z**CZEB>^%_\..6__-@?7*?\E7_PGQG_`,SGUW*ZF-N3V/W6[$'T
MKX\_9B=5^-/_``4,SG)_;!\$D<$\?\.__P!A?'0<=>AYJ<_M#?'7'/[!7[2`
MSQG_`(65^QAD9!&1G]J(<CZCO]*^5OV>OCI\8K'XN_MU76G_`+%OQ_URYU;]
MJ?P;?:QIMCX__9'M[KPGJ47[#?[%^F+H.L2ZE^TG:6=WJ-QIFG:=XE@N/#]U
MJ^D?V-XATJ*XOX->CUC1M)[\)@\2L'G$4L.U+"Y:I26/R]J-LZI5-9+%<L;R
MA".LKOG22N](J8VDI89.-:[JU[6PN-:TPC>K6':6^EVD^FNA^M/F+ZG_`+Y;
M_"CS%]3_`-\M_A7R!_PT-\=O^C"OVD/_``Y7[&'_`-%%1_PT-\=O^C"OVD/_
M``Y7[&'_`-%%7!]2Q/?"_P#AQRW_`.;"_KE/^2K_`.$^,_\`F<^O_,7U/_?+
M?X4>8OJ?^^6_PKY`_P"&AOCM_P!&%?M(?^'*_8P_^BBH_P"&AOCM_P!&%?M(
M?^'*_8P_^BBH^I8GOA?_``XY;_\`-@?7*?\`)5_\)\9_\SGU=J=I;ZG9W6GW
M*N]M=V[V\Z`.`\4H9)8VP,E'0E'4$%E8@,K89>2\)_#GP9X,0KX?T2QL-SO(
M[QVN)69SDDN5+$D\DL6)R>>1CY^_X:&^.W_1A7[2'_AROV,/_HHJ/^&AOCM_
MT85^TA_X<K]C#_Z**CZEB>^%_P##CEO_`,V!]<I_R5O_``FQG_S.._;_``I_
M85_;,VEB?^&6OCWP<@8_X5AXG/<`<8'?IZU]=JP4$'.<^A/8<\`\'L>]?E#^
MV]\=?C/K'[&7[66DZI^Q1\?O"NFZE^S=\;;&_P#$VL_$/]D6YTGP]9W/PX\1
MQ76MZE;:%^TAK&N7-CI4#R7]S;:-I.J:K<Q6[6^GV%W=2Q0M]0?\-#?'7/'[
M!/[1W1<;?B5^QCC`'&,_M19V]U)Y.23Z#IE@<1]1HO\`V;_?L0O]_P`NM_N6
M'>K^M66G6]KV6^AS1QE-8VK[E:[PE#_F&QFWUC$I?\P]MUWOY6LW]@>8OJ?^
M^6_PH\Q?4_\`?+?X5\@?\-#?';_HPK]I#_PY7[&'_P!%%1_PT-\=O^C"OVD/
M_#E?L8?_`$45<WU+$]\+_P"''+?_`)L.GZY3_DJ_^$^,_P#F<^O_`#%]3_WR
MW^%'F+ZG_OEO\*^0/^&AOCM_T85^TA_X<K]C#_Z**C_AH;X[?]&%?M(?^'*_
M8P_^BBH^I8GOA?\`PXY;_P#-@?7*?\E7_P`)\9_\SGU_YB^I_P"^6_PKS3XS
MNI^$'Q4`SG_A6_COL1_S*FK^H`_6O"_^&AOCM_T85^TA_P"'*_8P_P#HHJ\^
M^+7[0/QPN/A7\3+>X_86_:)TZ"X^'WC6":_NOB1^QLUI8QR^&=41[R[%M^T]
M-=?9;929K@VEO=72PHY@M;B0")M*6!Q+K45_LNM:@O\`D89<]ZU'I'%2?W1;
M_-16Q=-T:ZY*S_<5]%A\4F_W%=Z.5",5MU:7F?07[)O_`":U^S9[_`+X-_\`
MJN/#5%)^R;D?LM_LV!E9#_PH#X-':^W>N/ASX<!5]A*;E/#;69<YVDC!HKGQ
M*MB<2NV)Q*?758C$)V>S5T[-:/?J=.':>'P[77#X?Y?[/0=GYJ]GYGG'C7+?
MM^_LR`<?\8@_MS'VX^,O_!/9!_Z%Z<#/X_8FP^H_7_"OCOQG_P`G_?LR?]F@
M?MT?^KH_X)YU]DT\0N:&#;_Z`X=%UQ&-;WC+]#/#JT\4TVKXA-V=KOZMA%^2
M1%L/L?S_`*8KXA\;?MD:9\,/B/\`%#P3XI\#>+?$J^&O'OP:^&GP^TWX;:6W
MBCQEXZ\:?%WX?>)O'%AI#Z3>WVD:5I$"R^&KG2HM9OM5L?#VDQ2KK/BW5]#\
M/VNK:WIGW$2!C/KC^=?,.N?LK>`O$'Q3N/B]<^(O&EOXAF^)OPT^*K6%K?\`
MAX:`-?\`A1X`\7?#C0-/%M<^&KF_70KW1?&6IWFO0#5!J4VLVVGW.FZKI5I%
M<V%V\$\'&I6CC5.=%47R1I74_;.,W3UA3ERQ<U3YFX2O#G5DWS06+>+]G'ZG
M.*J^TC?VKBX^S3ASZ2Z\O.E;52<7TL_)=1_;0M-=\3Z#H?@;P9X\L+6V_:.O
M/V>?$>I>+O`E@^E>,/&^@>%?BSK'BCX>?#/6HOB=X=@_X2;3-0^'VGB7XAZA
M;:Q\++1[V3PM+J-SXE;73X(XS1O^"D/A+2_V8_A-^T]\8/@A\8/A/X.^(OAM
M_%6N?;;KX;>(=/\``GAVST+2?$.I^*+C68_'6D7?B[0GT_4+^_\`#/A_PEX?
MU#XS^+-'\-^)-5T[X.QPZ/>1Q_0]M^RAX`MF\+&+Q'XV<>$?VFO&?[6&F!K_
M`,-N)_B!X[7XBC5-!O57PNAD\"6S?$O79-,L+4VGB-)++26N_%=Z(=0&H_$O
MQ?\`^"=7[/%SX+^"WP;\>?M"?M`V.CW^@_&#]D[X0I]@^!&O:M)\./C'X/@\
M8ZC\%=)UC5?V:_%4?ANP\&^$?@>;_P`+?$^-]`^+%W;>'39?$+XO^.[Y]'LC
MZE&/#]6="E[+%P3JIUI>SJU*TJ$</4<E2G3A%2J>TC*K4=2BHJ%.*I_NXUK^
M=/\`MJDY5?:X9Q5%JTYPC259XB"BY6]]1]CH[27O2O92Y4_<?#W[;.?BG\6O
MA;XX\&^)='_X1_X\>,?@I\./B+8>$;V/X7:CXATGX+Z!\7?#O@OQ1XCO?$QO
MYO&VMZ;_`,);<1ZMH^C6?@'_`(EFF^$+W7]'\=:KI6E:WSOP=_X*3?"?Q18_
MLZ>%O'\WV'XG?%WX>?LX7OC6]\.Q:3;^`/`GQ8_:*^'/A[QKX,^'=U8ZWXOG
M^(HNO%-SXATRVT.;2?#OB[1_#\/B?P-:>.O%6B7GB?2KC4/66_8G\&7/Q4U'
MXF7OQ2^,MYI>L?%/6_CM/\&KG4_AV?A?;_%_6/AJOPDA\>6RI\-H_B6DV@^#
M,1:+X5E^)$_P^A\1LGC+4?".I^+X;?6XN8^&G_!/CX6?";QA\//&/@#XA?$O
M2X/!/A7X1^&M;\,WFD_`CQ)I?Q-U#X*?#S0?A-X-\8^,?$7B3X)ZQ\2?#?BN
M3P3X.\':/KQ^#7CWX4>&]7;PIIDDGAN&6YULZM,I\-NC/]UBE7G"-2/L83A!
MU%A<-2DG*K&4I+V\:M:7+!P<I6@XTY6IZ1CFT90]^ER<RA)SG"4E3^L8F<E[
MCC%OV4Z$:<W:I9-5$W%\VK^T)^UU<?L^_&CP_P"%-9\`^-/&?P\E_9_^*/QI
M\6WGPV\&ZAXI\6>%K+X9>,_AYI>M>(]1>37M,T5?!^B^%/%&N:OJ>A6=GJGQ
M#\27UE8Z?\/-&\3ZL)?#]SM7W[;WPJM_&[^$]+\-_$SQ3H/_``E5A\-[?XK^
M%_#.GZE\*=0^+^M^"+;XA>'/A+IOB*?7K+5;WQ/XB\.W^E6NF^(XO#Q^%L7C
M/6-,^&NI_$/3_B+<GPM'J_M`_LD^'_V@_$4'B.Y^+WQG^%NI-\+O&OP4\1I\
M)]6^'EC%XJ^%?Q*UCP]JWCCPKK0\<_#?Q]=:5+KK>%=-L;?Q?X/N/"OCWPS9
MB_?P9XK\.ZC?75^^#IW[$OPXTSXDVWC'2_B'\4;/P#9_$C1/C';_`+.=OJG@
M0_!!/C!X=\+Z3X5\/?$#8W@-_BY]JTR'P]I/B"T\&CXMCX8'QOIL'C9_`LGB
M97U$\U)9-]7INM&LL3##I3A".(C"I6C*HZCO&$H^UM&G&@TUA[3JSQ/*H4.?
M:H\T56:I2H^Q=2IR3E*FYP@W1C2:5TG&-Z\JJJ7JR<:4*+?-4M'X>_;Y_9_\
M71Q2>%KWQ/KWVSP?^R?XUTI;+0TC_MS3OVS/%&G^%O@]8:-/?7]G97NMV<FN
M>&-<^(FGB[3_`(03PQXP\):YJLSVFOV)?QF^_P""EWPN\;:=;I\$7&J:]<_%
M+]EC2M!F\71:;<:!\0_@W\</VNOA%^S?XN^)G@F+PEXRN]:L8M(L/B-/>:%9
M_$&R\&^);>^U+P3XFU#P-J_@W7M/EU3=T;]B3]G3X)?$3X&>(X/%OQ<75M!^
M,GQU\8^!-'OGM=<\"WU]\0?!-MKH\!>.KO1OAX^G^'OAC\$_!OP=\*0?!&?Q
M%KWA:?0KWX=>#=+U7Q?XW\5WXM?$G*_"O]D;]FC27TOX.?#_`.-WCOQ/X8ET
MW]G7]H?X6>#M*T[X(2>'?"'PI^#GQ^\&_&'X3P^"_BEX*^!.C^(/B!\/=;\3
M_#;PQX6GG^)_Q0^*?C>_^'UH9=`\2:/JNI-XUEZZ5/AU2C4]GFM>E"-*JW*@
MXWNZJJMJ--1;HOV<Y1YH1]E.3YU5A!RY9SSN4+1J8"E4;G3<?:J6LJ=Z*C*3
M3C)SB[2Y'&2G;EO%V_4:/,B[AQR1SUX^@Q],8XJ38?4?K_A3;;;Y?RL'!9CN
M4@@DG)^Z2.#P>3R#4]>`H16EK6;T2C9:RT5X-_>_\E[:;>O-+[_-KMV2]=^K
M/B_QFO\`QG;^SB<#(_9(_;@YQW/QF_X)\$D>YRW/OCI7V7L/J/U_PKXV\9_\
MGV_LY?\`9I/[;_\`ZN7_`()\5]F.Q5&90"0I(!(`)';)P/ID@$\$@<CT,<DZ
M.5:;931V2_Z#<W?52_"QQ8._/CO>DO\`;7UM_P`PN#\AFP^H_7_"C8?4?K_A
M7RSXD_;.^`/A+6OBCHVO>*]?M(?@MI-_K'Q1\60?"GXQZI\,?!<&C0:'>>(]
M/U;XO:3X!OOA9)XD\*Z7XCTOQ#XP\(6'B^[\6>#O"::IXM\5:+H_AK0M?U72
M-7Q7^UM\"/!'C73/AYXK^(6FZ'XLU;XP>"_@!9VEUHOBV;2C\:?B'X%E^)/@
M[X;3>*;709O"EIXFUSP6^DZU;VE]K=HL`\3^"M,U%[#6?'O@O3M=YOJ>)O:.
M$Q4_=E*\,.YI*--U6FXT]'[-*:CNXRC)+EES+=XG#Q5Y8NC%*<8-RKPBE*4X
MTXIMV2O.<8_XI);M)_2.P^H_7_"C8?4?K_A7`>$_BGX(\;:9XKUGP[K]I=Z7
MX(\6^,O`WBF^NK?4-'M=&\3_``_U"?2O&.GW,^MVFFQR0Z%?VMS#<ZM:FXT6
M9(7NK+4KJU!F'A?A?]N;]F#Q;X4\>>-['XH6VB>%_AOX;\/>-O$VM>/O"7Q`
M^%UG/X"\8W>H:?X&^(WA`?$SPIX0N/B-\-?B#J>DZGI7PZ^(WP\@\4^"/B#J
MUE/I/@O7M=U-19M,<-5FYJ%&K-TYTZ=3EI.7).JH2A&5J6C<:D';6RG%O247
M)RKTX)2E645)2E&]1)RC!5')Q5]4O95.UW%K=-+ZSV'U'Z_X4;#ZC]?\*^5O
M%?[:G[/'@KX>?"SXH:YXUU6Z\)_&;P-'\4/A[)X2^&?Q;\?:]JWPP&A^'O$F
MI?$S4O!7@;P)XB\<^$OAQX8T;Q=X3N?''CSQGX9\.^%/`,OBCP[8^-M6T#4-
M:TVTN?1]=^-F@Z=J/@'1_#>D:U\2=5^)/AO7/''A>V\`3^%KRUO?`/AN;P;:
MZUXWCUWQ)XI\+^&[O0;6Z^(G@B&TCTO6=2US7%\0VUSX?T75+.UU6YTT^K5>
M6,W1K1A-U%"<Z:C";I2G&HHRE32;A*G4C)734J=1:N$K"Q%)MQ5>,I146XQJ
M*4E&;2C)I-OEO*%W:RYX7MSQO[`Z$(YXX5CW[`^U?(%TN?V]/"&./^,0/B*!
MD^OQH^%I_I_AQ7V')_JY/]QO_037Q]<_\GZ>$/\`LT'XB?\`JY_A=71@(I5,
M8K+7*\PZ1O\`PJ"TM%?D_NT(Q#=J'O2_WS"]?^PKR/K_`&'U'Z_X4;#ZC]?\
M*EHKBY%_2C_\K.C7^:7_`($_\B+8?4?K_A1L/J/U_P`*EKYI^,G[6_P/^!'B
M`>%_B%XD\01:U!X<A\::]:>#OAA\6_BH/`7@6YN=5L;3X@_%BZ^$_@3QO9?!
M[X=W=[H/B**U^('Q3N?"'@ZZB\*^,;BVUN:'PCXC?3+A0G4ERTJ=2K.S?)2@
MIRLK7=E!:*ZNVTM4M6XQE$ZD::YJE7DC=+FG/E5W>RNUN[.RL_DDVOI'8?4?
MK_A1L/J/U_PK'T_Q'HNJZ98:SINL:/J.D:IIT&L:;JNGZG97FF:AI-U:0W]M
MJMA?6]Q):W>FW%A<VU]!?02R6TMG<07*2F&6-VY.X^*?A6W^)FB?",W<S^-M
M?\`>(OB;IUG'8W;Z?+X.\+^(/"WAC5M0;5U3^STFCUCQCH<-O9"9[JZ@GENX
M8S;0R2"8T^9R2A4;A&4Y?NVN6,(.<I-RHQ5HQ3O9NTERNS:33JQ5KU=Y1@K5
M(OWIRY8Q?+*33<M$FD>B;#ZC]?\`"C8?4?K_`(5Y_P"+OBAX3\$^(_AGX5UZ
M]E@UCXN>,K[P'X*AM[.XO(;OQ'I_PW^(GQ9NH-0N+8/%H]FO@GX6^,M0BU'4
M3!9W%W86^EPS-?7]I#)W`O82747%J3&)#(!.F8Q"2)3)\YV>401)NP4(^;&#
M0Z=E!M22J1YH/D?+*/,X\RDJ$HJ/,G&\I1UT*C.,G)*LKPERSBZB4HRLI<LD
M]5*S3MJ[-%C8?4?K_A1L/J/U_P`*@-_9K.ELUW:K<.$986GB65EDW%"D1;>0
MP1BIQAMC;>AQ;!SW!Z=.G(R,>WOWI.*4N5J2=KJ\4DUW3=.S2O9M;/0%-2UC
M4;UMI*^JZ:=;:V[:[$>P^H_7_"C8?4?K_A4M%'(OZ4?_`)65=_S2_P#`O^`?
M%GC0$?MY_LW=,_\`#(/[<WKS_P`7K_X)WY_'KV]/2OL[8?4?K_A7Q#\2-6TO
M1?VZ?V;K[6-3T_2K+_AD7]N*'[9JE[;:=:++-\:_^">/EQO=7<L4*LX5B@9P
MQ5&(!P<?6?\`PL#P/S_Q6GA'@X/_`!4FC<'T/^G=:ZLTQ&%HPRBG5KT*=3^Q
ML--TW5H<ZC/'9WR2E#VDIP4_9R<'*,%)1;C=)V\_!U(*6.O6C!_79:2JP@W_
M`++@K.TI1=K;.UMSJ]A]1^O^%&P^H_7_``KE/^$_\#_]#IX1YZ?\5)HW..O_
M`"_4?\)_X'_Z'/PCZ_\`(R:-T]?^/ZO+^N8'_H+PZ]:M!/[G),[O:1Z5HOS5
M:FU]_M#J]A]1^O\`A1L/J/U_PKFCXW\'@9/BWPN!C.3K^E8QZY^V=*3_`(3C
MP=_T-WA;_P`*#2?_`),JEB<&]5B:#_[BT/\`Y(7M(_\`/U?^#:?_`,L.FV'U
M'Z_X4;#ZC]?\*YH>./!Q.!XM\+$GH!K^DDG\/ME3_P#"6^&,`_\`"2>'L$`@
M_P!LZ;@@C((/VKD$$$$=0:3Q.#6^)H_*K0?Y2#VD?^?J_P#!M/\`^6'RI^W"
M0WP9\$G8,C]L#_@GB,GG@?\`!0/]F0`?FN[..#CJ>:^QTC.T=!UX^I.>@[]:
M^(OVV-=T.[^#G@R*SUO2+N6/]KG_`()\W4D-KJ5E<2I;6?[?G[,]U>7+113N
MZ6UI`LDUS.P$4$*-+*Z(K,/L%/%?AKA!XC\/ELD;1K.G$D@G(`%UDD8.1U&#
MGI7;5Q.#CEV`4\1057ZUFSFE4H[.KEG*[.<M'[UFK)^?3GA4@\7B>6K%KV."
M5U5A:Z6/TOS[K9KIV-[8?4?K_A1L/J/U_P`*RAXAT0]-:T<Y]-2LC^/$_3WI
M?[?T7_H,Z1_X,K/_`./UQ+$X1ZJO3:[J5)K[TSH]I'_GZO\`P;3_`/EAJ;#Z
MC]?\*-A]1^O^%98U_1B<#6-))/``U&S))]`!.2?PJ7^V-._Y_P"Q/N+NW_\`
MCU4L1A7M6A_X%27YL:FGM57_`(-A_P#)E_8?4?K_`(4;#ZC]?\*H?VQIW_/_
M`&/_`(%V_P#\>H_M?3R0!?6))(`'VNWR2>`!^^ZD\"G[;#?\_8?^!4?\Q\R_
MY^?^58?_`"9?V'U'Z_X5\<?M9*1XQ_8FSCC]LGPV>,_P_`?]H$GT[<>GK7UW
M_:=I_P`_-M_W^B_^.5\>_M77<,WC#]B@QRQ.%_;)\,ARCHP02?`C]H)06(8A
M03P"<9;"C)(KTLIJ4'CZ*56FG[/&\O-.C!<RRW-'"\G*"5YJ"2<E=M1U<DGR
M8]_['6O/2]"_[R-O][P7F_Z?F?8\/S!5'\*+@D\D;4Z^_/)J?8?4?K_A5$7$
M-NL4DL\$2RJJQM+(B*Y\L/M0LZAVV(6`4L2%9@-HR+$5W%,',4T,VP@-Y3AP
M"P!"L49]K8(.#@X.<=,^=3E3E:*OS7:C'DM>"7-2<;P=XN@Z34N:S:EJI*2.
MV35VHSN[R:BIIR=YS5U'>U]$[6TWT)MA]1^O^%&P^H_7_"H$O8)"%BGMY689
M18YHW9QC<<*CL?E&23S\H+<`$T/>0QOY;S0HV,A7D568`E254L&(!&"=I&01
MU%/GHO55(R7.Z=X<E1<Z2;BW3C42:NDU)Q:E[MKM)IMI7=2RT5W4BM7LKMVN
MWHE?5Z(GV'U'Z_X4;#ZC]?\`"F/<)&@=WB12`<NX53T'#$XZG@YZ8)P.2U;N
M%@2LT#8Z[9%;:3T#88X.`?;@X)"FCGI<T8<RYYIRA!^S5244DVXTVE-I7:;4
M'9QFG9PD%WMSN^FG/KKMIOKK9ZIV=MATB$(2<8QCCKR-O]:^//V8U+?&C_@H
M4,Y*?M@>"E4GLI_8`_87)`ZG!;DC/7GDU]=R7L!5T$]N7#^7M$R$^:'V^40&
MW"3>#'L*YW_)C<,5\B_LSMY/QG_X*$L^$$O[8'@EXV?Y%DC_`.&`?V&4,B%B
M`\8D5HRZEE$BLA.]2!Z.#JT%@,\7M*;7U?+DI<]%Q<UG>%=11DIJ'-"G%\\9
M6<4G=7VSJ/W\/^\O^]K:J::7^RS:NT[).SM?>TK;.WV+L/J/U_PHV'U'Z_X4
MU9E==RM&R@`DJP8<@G[P.!\O.2<`<DCI31<*Q.&0X&?E8,<9(!^5B,,>%/`)
M!YXKSG.DK7G%7BYIMTDG",7)SCUE!):SA&<;R@K^\C36R:E)WVM*][ZJVU]-
M=+W6JN2;#ZC]?\*-A]1^O^%-:=58J7C!!/RLP#8^A8'/0CCD8QP0:1KA%`8L
M@4@G<S!5XR3\S%5Q@$GGL3TSAJ5)\WOP]R_->5&T4E>4I/[,8KXG/DY7NA7>
MOO3=MVI:*V]W>R:6K3M9-/84JV0``0<<Y./Y4[8?4?K_`(5\7_M\?'OQC^S1
M^S'XS^-/@"+P]=>)?".N_#J&&S\36$^K:+?:=K_Q$\,>'M:L[NRL=3TB]?S]
M)U6\6"2UU.TGM[DP3I+F,JWS_P#L^?\`!5SX(_$E],\._%^S;X"^,+]8EM=0
M\0ZBNI_"O7'FB1[>;3?B*;?38=#^U*RRK;^.-,\-P*TL5G8ZMK$S)-+\WC.+
M^&<MSJAD&99KA<OS'&4(U\%3Q<X4:.+A*4XN%+%2B\*L1%TY.6'J5Z,XPM4<
MN1W7'6S/!4,53P5;%QI8BK352E&I/DC4C*7)'EJ-NFY.6BA=-MJU[W/I;_@H
M`I7]A3]LMN,C]EOX]8/<'_A5_B?D>A'8BOKD+GD8'3.>YP,D=>/;VKX^_;XO
M(+W]@W]L.XMI[>YM[O\`94^.]S;3VTJ30W$$OPL\32Q36\J$I+#)&RNDB$JZ
MD,IP:^PXSG</0C]0,U]@[/`4&EI+'8BUTKZ8'"U'T<;<LX--<R:E[LGN:1N\
M95:FVOJF'DFI7T>(Q"O=733O^0FP^H_7_"C8?4?K_A4M%<W(OZ4?_E9TZ_S2
M_P#`G_D1;#ZC]?\`"C8?4?K_`(5+11R+^E'_`.5AK_-+_P`"?^1%L/J/U_PK
MS3XSICX/_%;.#GX:^/`.XR?"NK=<CIC.?RZ9KU"O,_C1_P`D?^*G_9-_'?\`
MZBFKUI2BE5HM735:CMRK_E]1ZJ"?XHRK7]A7]Z3_`'%?1O3^!6\CBOV3N?V6
M_P!FL^GP`^#:X_[IUX;;U]\44?LF_P#)K7[-G_9`O@W_`.JX\,T5KB/]XQ'_
M`&$8C_U(KBPZM0H6_P"?%!_^4*!YOXS_`.3_`+]F3_LT#]NC_P!71_P3SK[)
MKXU\:<?M^_LR_P#9G_[='_JY_P#@GG76_M9_%SQ1\&/A-;^*?!^H>#]"U[Q!
M\2O@S\+[3Q?\1+2^U+P!X`_X6[\5/"?PVD\=>+]*T[7/"UWK&G>'AXF^T6&A
M1^*_"<?B'7VT?0;GQ3X=M=1FUBTT<)5IY?AX)>TJX2DH7:4;RQ..BDWTV;^5
MDG*48RRA-4UC*DOAA5<Y6M>T<-A6[<THQ_\``I17>22;7TVV.,DCG.1]#_GO
MS7X@?$3X+_%'PIXE_;B^)TO@/5OAWX0T?1_$W[2/ASX__&#Q!\)[3Q1K/Q3^
M!'Q,\*?&KX7^'M-\;_#GXO\`BS7?$W[,*Z=X$U73SI/QZ^%WPR\;_!#P#=2_
M#GPYK?C3P?XIU33/!?8^._VVOC;X-U3QC'I?Q<_99\<V_P`#_#GP.U;Q#H^F
M>"O$]CK?[56I_%WXO>,?AI<:)\$6L/CMXGM_AQJ-AJ?A@_"KPRD=O\<'\0_'
MVS\0^'-7M?#UCIL.ES6XOVKOVH;J?Q%J5_\`\,WZ]X8\9>)?^"DOPU^$?A+6
MM!\5>!TT#Q3^QU\6/BAX*^&6N?%KXG:Y\3-6\,:QX2\9:?\`#R?3_B+IUKX/
M\&1Z5<WNGZ]IGB.SL[?4M,;U,+@\=A>><8X24:U&BW&O5Y.>#JPQ,%"%7#1E
MSRH4I5).2M3IU*E"O3IXE5<)1X,5B\)B8\DGB%[*JHWI4U/E=6G5HJ4O98B3
MY8UI03LU*,HPFK12F_&/$_['OQH^,'PI\4?$K5?AUXGN_B[\0_V,?VEOC#X,
MTR[^(]AHVI_"_P#;;^./C&/XL_!OP;IK7?C31=,M?'OP"L;CPW\,/AQ\6=1L
MK+2/!NG>"#<Z?XF\,C7=9BO_`%VY_9O^,5]^V)H/Q!UKX"^(-;U/0_VM/%?Q
M4NOVHI?B?X#3PM>_L]:U^S!\3OAUX#^%>E^"I_B+_P`+"@OOAYXQ\2Z+X?O_
M``7>?#:U\#VNI2:Y\5_#'B/5M?\`%OBCRV_"G]I/XV_%7XT_LG:7+\<_`&@Z
M9K%C^U9X3^-_@+5/@:WA.7Q)\0_A9XH^!C2?#NS;1_VG_B;X1@\<Z!X8\87U
MCH/B[X;?$KXR>"+B6U\5^(K%?$]IJ0TSP9XY\%_VX_C+IGPJ_9Y@T+7_`(!Z
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M-^.7PZ\4_$GXJ?"./0/,^$'AK5=.\42W%KWJ?L,_$_Q/XO\`$OBWXM>'=7^(
MOCNY_:X_9IN[OXDVGQ*?1(?%O[/>@_L5_LX?"+]HJ\T[2=/\<:.^B>`_B%\3
M_#?Q3TOXF?#672-'U;XK6FGZ8WB;P?XL\,:?X,N$\N^)W[?W[07BO0OVQ_#W
M@3Q]X0\,:-X2_9N_:$^-7PB^+D?PO\)^']2\/:7\!?BQX8^'?B"Y'A>P_:Y^
M*/CO4K/58=6\4Z3;>-_C'\./V:Y-$\0^#+CQ)H7P_P#B%H<GB#0_"OONJ?M!
M?%+P=\;/%OPTT;QS\%=$\9_$?XR_`/X6W_QY\2:+\2=7^%%M?7G['WC+XRWV
MMZ-\']7_`&AVT'1[CQMJ'@*+P=X!\+>%/B#X0L-OB(^(/%&M?$KQ9I"?\)0W
M2SVG2IRE'+(57&OB)PY,1*MR-.I4;ARKDA.GBYKV=.-2K6JX:C)TI*C"2UA5
MRRM*HHT\3.-)4X3<O9.%1T^:C#18I*4XSA&I.=HPCS2UCS.!\]?$7]B_]J.]
ML?AMX3'A7XOWGPU\%ZQ^U?X0^%^C?"KQ)^SYKGC#]GRSU+]L+XB>(?V<_BIX
M?OOC;\8?!FG^&8M(_9KF^%FF_##Q5X`UCQ5\6/@QH7A2;P,O@6Q3Q%XBT"OT
M/_;2^"GQ4^(K_"G5?A1I5]J^I:I=_$#]GGXPOI_BS3_"USH_[,_[2/A[3]"^
M*?C_`$J74-4T59O%'P\\2^"/A;XYTR'1;F7Q0=+T/Q%IOA6SO=5U*&WF^/S^
MWI^U!KO@3Q?\3O#-S^SW#X:^"/[-LGQ[\>^9X-\?Z_:?'.V\(?M`?M#?">^U
M3X/Z[!\3-$M?`'P]^-'@CX(6WQ)^&WB76++XH/X;L_%WAX,?B)HTLVJ2_>O[
M4-U=S_$#]B;P-=7;+X:^(?[7MM:>*[7>R+JMM\,_V<?VDOV@/!6GNRC`6U^*
M7P@\`Z^5<K'/_8*V;>8;@!_/J/,*5?+G76!7LXX]P4%&M"=\)B:U;V\%"E*K
M6=*G"M&-^:,W2E4Y9PG%],88%TL4Z2Q+]M]1=YN5-WGB*-.DJ$N>M&E&FW.,
MVXI)\\;-24CX:\#_`+*'[0GB1?AE'\:O"DVMR0?%KQ5\*/B++XC\;>$M=TS7
M/V:OA=^PS\<_V:?AKXV\4:9IWB&]AUK1?C9\7_&6L_%Q_"T%IK?CC0HOC)I,
M7C?P[HUQX4U>'PSY!:_L,?$O5_V;=-L--_9DU7X5_%?X3_\`!-+7?AS\%O"<
M'Q!^%.BW?A?]N/PMJ_BK6?#7CCPO=?#SXLZIX%M_%NN?$2WTWXC^!/BOX@U6
MUGT*V\57<WB'5?!.N:WX^\.Q^8?&+QQ\=/%GP\^'5[X<^+WB'3?$>B?LQ?MZ
M?$:V\6^)?VWOC)^S9:^&?%?@']H[3]`\&_$:>P\,+?\`@G]H/6?AUI12TT'X
M7?'V_P!!^%5QH]NVA>(O$FB>'=1U.6'[/T;XPZGI'[4GACXH:A?_`!0^-&D_
MM"Z'O_9_^'7@/]H*Z\,>*_AUK&C?LIQ?%75_V<_C'^QIXG^('@?X#:?XC\4S
M>"?&/Q!\,_'W6]7N/%GAOXB>/=$^&_Q&UKX>?#32?#?B75?0Q$\PH1E[^!NZ
M6+J1P^'HUZ47[*5JT5">+I4G[2FII.K4ARTY55'F?NK@P[R^O*"Y,4TZN&E4
MJUZN%K2YY+VF%<VN2LFI.+]RDTZBC*UDF?L$)XT#;GV@MN'R_>W`,`N?O$YP
M%7)Z#&3BK*.&Z;LX!^9&3@]/O`?CCIWK\D_$/Q#T[XL_M">+]/\`VB/B7\8?
MV,='^&O[/'PH^+/PP^%^L?'[PM\%]:TS6_$7CGXU:1\2/BQXXUWX.?%3Q5\*
M?C3%X0/@?X<:0WP\\5^,/C!\&O!5CJ-C?_$#P->S_%&VL3]4?LK7]W:^-_VS
M?`">>GAOX;_M:ZG;>$K6=ED;3[;XM?L_?L\?M)>-+)92WFO')\5OC?\`$#5H
MHRI@LK75;738)62Q\J'Y>I@9T*7-*;<E0P^(E'DG*ERXJHXQC2Q495</7E2E
M.*JJC7JJG\#FY1=OH:6+C4J*$5>+J5Z,9)Q4N;#4^>HYTF_:TE.TO9^TA%S3
M51+V<DW!XS_Y/M_9R_[-)_;?_P#5R_\`!/BOLF<,89`H);:<8QG(Y&`2H)'7
M!8`]"0*^-?&1_P",[/V<<G_FTC]M_P#]7+_P3WK[.(#`@C(/!%5CE>AEBT5\
MHHK5<RUQF;K6-X\RUU7,KJZNKW3P>E3'>6-Z>6%P9^<FA?`OXBM^U;XN\0:5
M\,KGX<?!+QX?B##^T=INL?%+2/'WP@_:9MM=\)VWACP7K_AGX(S6NHR?#_XF
M,EGIS_%'Q7':?#ZU\0:)9ZAX6\46_P`;KG4/#OC#P7XSX3_X)^ZU??L\?LL?
M`GX@:)-)IOA_Q]\>M5^/FL?\)U+K'CG^SOB#\&OCU\/O!WC'3?'5Y/>:UK?C
MWPW=>*OA?#X5\0?:[O6?!)\.:!=Z1=6R^#M->V_8$*`<@?J:"H(P1D?CWK:.
M;XV"C&E*%.*A3@W!3YY.GA\5AHU:DISG.I6C2QE>,)RFN2*H4XIPH4[9RRS"
MRYKPYTYSJ*,K<J<ZV'Q#BO=?+!U<+3E))._-5OK-L_)OX3_L=_M+^(_V=?B!
M\/?C=\<M=^%WC[Q[XQ_:U;QWHWP@LOA#K?PN^,5I\:;S6M&T'QIXO'C+X4^)
MOB+X8M9[6X7QO8^%_A9X]^%^JZ%/K5SX>UW5==?3K6XCZOX<^!_VCK+Q#>_&
MCQ[\!=*T[Q3\.OV8_`O[._A3X3>$/BGX.UVX^)'BJU\86?B+QSXZT?Q-K3>'
MO#FA>`]!GTO0+CX7S>++C0_'6J6Y\67/B+PIX0U)="L-2_3C8OI_/U)]?<TG
MEIZ=\\DGJ,=STQVZ5,\VQ=2>(E*E@TJ]55>6-&5.%)2^KQK4Z,,/.@H0G2PT
M*<75EB)PO)TY05DE'+,/"%"$9XANA!4U.=6-2I4495Y1=2=6$^9IXFK*24(J
M;:YFTC\=?A+\'?VM?A%\/_V2O%.D_`;0_$GQ$^$O[$E]^QEXT^&^O?%SPAHL
M-AXLT>W^#\O@[XJ6_BC3CX@T:^^$^N:K\.-?@\<6MC)<_$O2-'U/PI?:+X%\
M2W\6LZ/8_<OPG_96\'^!/@[^S-\.O$&HZ_K7B?\`9N^"7A#X,Z'X]\-^*O%_
M@+6-2TO1O!_@?PSXF6YN/"&OZ/>76B^+[SX?^&=;U+0-4NM0T\ZCHFB7OD_;
M]*M+J/ZFV+Z?J1_(TX#`QZ<5%?,<37@Z<O9TXRK2KN-+VJ]YQQ$(QO5J5/<I
MPQ>(A!))M59<[FU&2NAE^'H2YHN=23IJ$O:<EF^:C*=5JG&"]K4EAZ+FXJ,?
MW<5"$%=-DG^KD_W&_P#037Q]<_\`)^GA#_LT'XB?^KG^%U?8,G^KD_W&_P#0
M37Q]<_\`)^GA#_LT'XB?^KG^%U3@?XF+_P"Q7C__`$W0-L1M0_[#,+_[M'V)
M1117&=`5\!^)_"_[1/PB^/'QW\??"/X0^&/C7HO[0FF?#6_TJ]U3XFZ7\.IO
MAK\0O`WA&?X?R:7\1SK&C:GJ4_P8N=,B\/\`BVTUGX<6OC;QII>M7GQ#@A^&
M5Y<7.E7>O??E-VJ23CD\_IC\./2MZ.(G0]HHPI5(5H*G5IUE4<9PC5IUX6E2
MJ4JD'"M2IS3C-<RC*G).$Y(Y\1AXXA4[SJ4Y4IRG"=-PYHN5*K1G>-6G5IR4
MZ56I!J4'R\RG%J<(L_#C_AW)XP\#_"/XC>&=%^'7PH^*_CBP^&'[$OP/\'^.
MO$_@_P"%GB3Q+K_PF^"W@WX9^#/CH/AYH/QLT;QY\-?!7C;6-,\+:YJW@+2O
MB'HNL>`=4\6Z;X&'CZ'6-$T.UGT_V3]AW]DWXT_`G6/@S/X_TG3;#3/`GP@_
M;(\"W"V^O>"-0GTA?BS^VAIOQ@^$>@1:?\/O!_PZ\#6UK:?":SM+>XL/A_\`
M#[P5X!\*75BGA;POX4\-Z#::1I%O^L>U<`8Z=.3_`#SFC8OH,\\]^1@_IQ75
M6S?'UZ->C5=&2Q,IRK5.6:G+FI2C:*YW&G#GE*U."C&,).,6U:*Y:6582E.G
M.G[6G[*,(TX1E'EC[-)1;ER1G.:LFYSE)N2Y]).Y^(_B/]B7XPZG\;)_%<7P
M0^&5YXBM/V@OVL?B9KG[4$_C/0H_B'\3?AE\</V<OVF/`/P7^&%YI1T#_A*#
MIWPDN_BCX!^$^I:;X@U^#0_#>@_#_P`)Z]X$BU[3]?\`%B>$:OQ4_8?^+?@O
MX#7?PT_9[^!OPSN;GXH?\$W_`(F_LF>,])M/&?A[X=V7A;XP^,?#6E&X^('B
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M`8QQ[]#^'\NM-:&-E*LI*G.5+-M.3DY7=@\\\CCM4@``P.@^O]:SQ^-6.GAY
M^R=)T,)1PMN=2C^[44W",:=.,(RDG)W3J3E)RJRE/4O!X1X2%:+J*JJN(G7C
M[C3ASWNG.52I.;2?*OAA&*4:<(P226BBBN`[#\5O^"E_P,\7?M`_'_\`97\&
M>"M<M/#FJ>'O@G^UE\0KS5[B-Y[B+1O"/Q9_87%_;Z7:>1/;WFJZA<:E96"6
MVH;-.DL;C4#=B8*L$WY]W?PV\7V5S/:RWNL&2"5XF,?P<\+-&61BC%&!`*%@
M2N.@(&%QM'[L^.$23]O']G!'571_V0/VYU=6`*LI^-7_``3Q!!!XP02"/>OJ
MU_!OAEV+-HFF,3U+6D.2<DDG"<DDY)/)[U\#Q]X0\%\=8_)LXX@PV-K8VGP[
M@<%%T:^&C25##X[/W#EIU\MQO).4J\G-TY4U*T7)2:7+\K/A[+LSQ&-KXR->
MI4CB_9P]G7C2C&G'"8))-2IU&Y-N3;326F[>G\N(^'_BGG==:TX.#M;X.>&0
M..F-DB$>O!Y[Y!(IA^'OBIL[9M77G@CX.>'LXR>#BY/'?MTZ>G]1W_"%^&/^
M@%I?_@)#_P#$4?\`"%^&/^@%I?\`X"0__$5\&_HV>%CU>7X]OSKY?_\`.`G_
M`%,R-_\`+G%)]']:IRM_VZZ"3]'^B/Y<_P#A7OBO!!N-6'&,-\&M"<8^GVA@
M/<`J3W/0A%^'_B9,^;<:@Q/"A_@OHZ#/7/[J]W'H002!SD'C!_J-_P"$+\,?
M]`+2_P#P$A_^(II\$>%V()T+3#CM]EAQ]?\`59S]&`_7,R^C7X7VM'`X^.J_
MYB,`K;_]2!]P_P!2\C_DQ?\`X.H+_P!PG\NI\`>)#_RVNQWY^#&G$>V/].R#
M[TG_``@'B7/-U=9SG!^#&G'!//`:]./PK^HO_A"/"W_0!TO_`,!(O_B*/^$(
M\+?]`'2__`6+_P"(J%]&GPP6OU3-;NU^7$Y6UW>E3(H67:S;[I+4B7!62NW*
ML6M=?WU%:?*B?RG>)M+O/`FD0Z[KUY>6VGW?B;P)X,26#X(6<\G]M?$WQYX7
M^&7A6W:.#48S]FO?%7B_1;*ZF(865O/)>%=D+))T1^'_`(BP=[$XZEO@M;'!
MR3@LVI<_-GG)5B2!D'%?N=^VMX8\/VGP:\&M!H^G1F7]KO\`X)YP2%+2`%XI
M?^"@?[,BRHW[O)5PBAEZ,HP<9.?L$>"_"[*/^)#I>WD8-G%ZGJ"GKFM_^)9/
M"Z."PF(CA,V_VBMCH23Q.4/7"_V=24K/)W9SC/FE9ZRU:,WP;DTJ]6DOKC5.
MGAYWE6H<SE76)E43:HJZ56G4E'32-2VC<D?RSMX"UHL29;4DGG?\$XB<^X6_
M*`_[HQZ=3D_X0+61_%8GZ_!!#CZ;=2C(/XGVQCG^I4^!?"A_Y@&E#Z6<'_QN
MC_A!/"G_`$`-*_\``.#_`.-5C_Q+5X7O_F#S;Y8G*%^63HK_`%(R9Z-XQ+NJ
M]&^GK1MZG\M7_"!:ST)L"#P0WP3D'7_=UCI^-(?`.M$Y\S3N<=?@E*QX`'4Z
ML2>GKQT&!@#^I;_A!/"G_0`TK_P#@_\`C5)_P@?A/_H7])_\`K?_`.-5+^C5
MX86]W"9NGW^M93MVNLGN"X'R;;GQZ71QQ%%2?JU1V_R1_+3_`,('J\?,C:4R
MGA<_!"\SD<Y(BU<<XZ\[1GIT(7_A!=6/_0#4>_P-OR3]"-7.,>O'6OZDV\`^
M$6^]X>T@XZ9LK?\`^-5'_P`*[\&?]"WH_P#X!0?_`!NI_P"):?#3_H'S?_PJ
MRK_YSC_U(R7_`)^YE_X4T?\`Y4?RW-X!U8@[9-%4^@^!E^>_J=7';_/-,L+.
M+P?XR^%<&N7FCP/XT^*?A'P1HBK\#M807NN7CW_B.*RGN(=7*6$4FE>%]7E^
MWSA[:WDMXS-&Y=4/]2G_``KOP9_T+>C_`/@%!_\`&Z^0OVJO!/A2T\6_L71P
M^'])1+G]L?PRLRK90`2+%\"/V@W57P@W("2=ARK';N!P*[LL^C3X;?VAA)PI
MYS2G0J_6X5*>+RV,XRP-.MF$7&5++*%12<LOC%<M:F[3:<E%S4L<1P?E&&I2
MQ%.ICW4I2HSIJIB*4J?.L3A5#GBJ<6XJ4HMI-/W5;56>7_P49LCKGP"L+.RF
MTR6:/XD>&;@I=>'YO%L"K#IGB4N7TJRO+293'E3'>^<!;L,JC2O&*T/^">=H
MVE?LZV]G?7>G_:#XY\6R$6V@S^$H5262R\M(M)O;RZG4JO\`R\B9A<-\X",&
M4?7%O\//!&?E\+:$IV`Y73;5."J$CY(A@8)&!P5RI&"14C_#3P+(Q9_">@.Q
M.2SZ;:NV?9FA)';`&`,#`%?HD."\G?&,N.Y1Q#SV>32X?G)UH/"_4(PEAVE2
MC2A+VEH74TXM)ZNWN+Z=Y9AXYG+-(NH\3]7>$46W[+V2G)IN*E\5[WM'9K6]
MS\2_V&/#M]I7[5-IJ5Y/H@MVTSXC;C#\/-6\-741DBD`?^V[W5;JVS]R.6+R
M-UY&RNHC4#/:?\%+M$O=:^+'@FYTZ?09(X_ADT3OJ'@/5O&$GFKXG\0-^[O]
M*U>P2R5%=5%HT;2.=TWF@,%'[`M\-?`SJ$?PMHCH`H"O80.N$!"?*\;+\H)"
MG&5!8`C<<D?PU\#1`B/PKH48))(33[=`2<`G"Q@=AT';BOGO^(1\+/A+&<$2
MGF-3(\=G53/*TJE:E4Q:Q=6O]:E&G4K*LXTO;MQ25925'W>;7E7#_J[@/[*K
M91S5XX:O6^L5)1G+G]K[95^52=1R5/G5K<ZTZ'RQ^T7"]S^Q/KVG6UWI@OF^
M&_P\A`N-'NM5M-\>H>$#+N\.VUW%?S1LB-LM!<B6WRIDE*Q.Q\/_`.":>GW&
MB^$/BRFJ7FCHUQXJ\.F!M/\`"VI^#XEVZ+<[RUKJ^I:C)>3<9^TQ2(B1J86C
M#$NWZ*CX9^!%<2#PGH`<-O##3+16#X(WAEA!#\G#`Y!.0<\TDWPQ\!W`/G>$
M]`D)7:&DTVU=E7.2JEHB0I/)`^]@9S@8^@?!.4RXGR/BV4\7'-<@R?$9)@Z=
M.K%8&6#K+D4J]!^_4K\KE+GC*$(S;<H55;E[GEV'^O87,>:I]8P>%6#I1YOW
M3HWB[S7,[S]U6DXR]=7?\4-'T353_P`%!S?>?H!L_P#AH'6KE0OP\\3+JS6_
M]H:BR*OBIM>;2F?#+G4AIYM)(`VRU564I[7_`,%.-'U"]UCX)G3KG28%CTSX
MCK+_`&UX,\2>+2[&\\#G-LVBZMI7]G@<^<DZSK=,RO$8FAF\[]0/^%9^"8@"
MGAO2$V@A=EC;J%^4C``C``QD8QCFODW]G'P3X7U3XP_M^0WNC6-TFF?M:^"+
M&R%S;I,+2U'[`_[#]S]FM1('^SVYGNIKEXH@B/=3W%PZM-+)(WDP\(.&\1PW
MQAD/UK-(Y;G^:4,^S9+$M8I8NMF6&C2C@JL:L84J2KR<YTVH1M"/NS;27!/(
M,`L)B\`I5E1S7&5,37DIR52-90J5VX/GNH)3E"*4HVO9QLV:?PCLKZ+]A&UM
M)9;!KS_A1WCB$2PZ'JEKIAD;2_%'D2)H$UY+JR6I$D9;3Q?_`&N:-3%#<!I8
MW7X__P""9NE:O9?$/XE27USH,T3^!=)C1=$\$>*O"CB3^WHW=KFY\0ZUJD-V
MK1C;%!!'#+"1)(SNC;5_64?#?P>$$8T'31&%VB,6T>P+M";`NW`3:`-@&S&<
M+RV6I\-/!:9V^'M,0,`K".VCCW*#D*Q15R`><'(R!Q7HU.`LFJYOPGG4JF.>
M,X*P%;+LE4JZ=&IAZV'IT'+'0@Z:JU5["E[SC5C9U&XN7+;K>5T)U\LQ$G/V
MF4P5/#)2ERRBJ2HWJKF2E+E5]8S][KU/Q5_;`TS7)_VRM0FM;KP[':?VU\(V
MCBU'X?\`C+6]4(_LOPVC_9==T[7;+2(M[PR+!(+"9+*X96OHY1$[#[G_`."C
M=K?W7P"TF.QETZ"8?$OPS(QU?0-<\169C72O$I:)[#P]>Z??&1V*^7<?:?(2
M0^6T;23PX^PC\,/`C$EO#&DNS8W,]K"[/@!5WLT19P@`V!B0F`4VD##G^&?@
M>4%9?#FFRJ3DK+"LBD\\E71E.=S`Y'()!R":Y(^&V10H\<X:.(S+V/B!6Q&(
MSM_6(^UI5<1AOJT_J#::H14/=C&,H)))ZR]XS628)4\VI<]=PSF=6>+?/+F@
MZU/V<_8>_P"Y9:JSA9^1_)K\5ISX9^'OB?6?%$7@37]'BL([6XT0_"WX@P?V
MO+?7<%A96(O;_P`8VMMI[RWUY;&/4'N8I+(HUS:L+R*W!_.73OC)\4O$%]%X
M"^&/P_\`"WB30=)C%A+JVOZ9K]ZKS[I7OOL]W;^(].MXM)MGE6RLFNX3)/!!
M]K2ZEBFC!_MK_:)_9+^%OQ\^$GB#X6ZUI<FBZ1K=]X<U.]NO#4.GV6LW"^&=
M?T[Q%%ID%]=6EREE;ZK/ID5A?SI`\XLYYO*:.0+(OPW\'?\`@F%X:\/ZD[ZU
M:6FD^&K6[8Z;H%@'\LVT<A:$W#,[S74S(@+RW#R2_-@R$<#\IJ?1VRE9K36#
MKU7D5+#TI5:V9XBMCL54Q4ZV(;HT,-2Q%#EJ4(5U*-7%5*E"*BU/#UZ:=-_/
M2X*POUA0IRYL$J5/]Y6YJDU*FN5N%YR7/RZPO.,;VOW/Q<\*ZU^U!X$_97_:
MAT<>--5A^'&H?LV_'*/7?A5X:TJZU7P"+>^^'7B-)WM5\5ZAK1\)3*93=75Y
MX)?19[ET'VLW_F-G^R;1;N:_L8+NXMWM99XHI)+>0`/"Y7#(VTL-P8'(!..G
MN?@O]L3X2>!_AS^P'^V+9>&=$LK$1_LK?'E!+'"AE(/PM\2@X<KO&2-W4,#T
M(K]!HP`#@`<]AC@#CI]37]#9%D6!X:X=R_)\NGCJN&PN88QPJYACL1C:UIY;
M@::A#V\ZBHT5*FY1HPJ2A33C&FHQO$^CP.#IX&O4P]&=25*&"PR2JSE.5WBL
M0Y.[;Y8Z148)N,5=)DE%%%>B>J%%%%`!7F?QH_Y(_P#%3_LF_CO_`-135Z],
MKS/XT?\`)'_BI_V3?QW_`.HIJ]73_BTO^OU'_P!/43*M_`K_`/7BO_Z8K'%?
MLF_\FM?LV?\`9`O@W_ZKCPS11^R;_P`FM?LV?]D"^#?_`*KCPS15XC_>,1_V
M$8C_`-2*X4/X%#_L'H?^F*!\X?M"?%OX<?!K]MW]EGQ+\3?%5EX2T6__`&5?
MVW]$LK^^M]1N8[G5)_BW^P%>I:*FF6=].':TTV]FW/$(@L1W.'*(_=:Q^VS^
MQAXATK5-"\0?%7P5KNAZYIUYH^MZ-K/AOQ'JFDZQI&H6\MI?Z7JNG7WA:>SU
M#3KZUGFMKRQNX9K:Y@FEAFB>.1U-[QF3_P`-_?LR#)P?V0/VY\CL<?&C_@GG
MC/K7V.2`,G@?Y%=G-@HTL%[:CC958X2G:>'QM*A!)8G&N"C">"KSBXV6L:NL
MDI*S2MQQIXF=3%*G4PRIRKI.%7#5:LG?#85-2E#%THSNM/>IWL^5W2U^!5_:
MF_8`6\\%Z@OBGX2K?_#>SGT[X=WR_#Z^6\\`Z?=6$>E75CX*N1X,$_A6SN=+
MAATV>UT)["":PBCLY$:W18Q>N/VNOV$KNS;3[KQS\,[JP=_%$CV-QX)U:>S:
M3QO+?S^-)&MI?"#0M)XOFU75)O%#E"WB"74K^35C=O>7!D^ZPZG&&')P/<^E
M&Y?4<=?SQT^M$L1@9-.<,WE)-V<LVI2DG*4ZDK.67R:<IU*E25FG*<ZE27-.
M<YSI8?%)M*>7IZ72P%9/96NEC5T2M?HET2M\"VO[4O\`P3_LM'\*>'K+Q/\`
M".TT#P'J]OX@\#Z':_#V]M]'\&:]:"^%KK?A33(O!:67AW5[8:GJ(M]2TB"S
MO81J%Z(YE^U3^9PF@?&3_@G;X<^)FI?%;3_'O@23Q+<:-X(T+P_%=^#[R73?
MAUIW@'P]KOA71H?AI!'X$ANO!:W6@^(KW2=732[Q8KS3H[73XH[6RADMYOTV
MR/4?G1D>H_,4UB\%:I%1S?\`>)QJK^UJ+YU*<:DHS_X3FVI3C&4[M.;^)N[O
M$L+7?)S3R[]W+FIIX"K:$E%P347C>72+:245;1JSC&WP-9?M3_L`Z=>>(M1T
M_P`5?":QU'Q>VKOXMU"S^'U_:WOBE_$,>GQ:^_B.Z@\&)/K;:[%I.E1ZP=3D
MNCJ::9IZ7IG6RMA'3G_:7_X)Y77A:]\#7.N?!FX\$ZEIVA:1J/@Z?X:W$OA:
M_P!)\+Q6<'AK2[WP])X);2+K3O#L&G:?#H5E/9R6VD16-G'I\5NEM"J?H('4
MD@$9'!__`%]*`ZG)!!QUI?6L"W?ES>Z<7=9O25G#X;?[`VN2UH:W@DE%QL/Z
MMB(V7/ERO>R^H54VGJW_`+XKWO>3^U>[O>[^&I_VP?V&KF"\M;GX@?#BXMM1
MT"U\*ZA;S^#=9F@OO"]D;LV7AN\AD\(M'=:!9F_OC:Z-.KZ=;F]NS#;(;B;?
MSOQ$_:E_8G^)D?@PZY\<-.LK[X?_`!%\)_$_PKJ^CV7B>UU33/$?A.YF'EQ3
MW'A2[B_LWQ)H&H:_X*\46Y@\[4?!_B?Q!IEI<Z?>7EMJ5G^@^]?7]#_A070=
M6`^N:E8C+HRC-4LT4HM\LGFF&;C*<90=N;+)6<XSG"V\DVFI+0IX?%2A*+JX
M'DE922P>(BG:49+6./6THP:ZW2ZGYZ:U^T=_P3J\2R>'9O$FJ_!/Q!-X0N[G
M4/"DNM_"^359/#&H7FHQZQ>7_AU[[P/</HEY=ZO%%JES<Z8;6:?48X[Z5WND
M64;MI^UM^P?8>+]4^(-CXV^&%EX]US3H='UKQO:>!]4MO%^L:3;BR%OI>J>)
M8?!Z:UJ&G0#3=.$-C=WLUM$+"R"1*+6#R_NW>AZ,#U_3@_D>#2AU/1A_G_\`
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M2E[;`\Z::DL'B+W<>1\UL>G+FIW@N9NRM;16/R7\7?MG?LPW'[:7[/WBR'XO
M>'G\/Z5^R_\`MC:!J.H+IWB40P:QXA^*?["^H:182Q'01<&2]M/#6N7,3Q6T
MD*C3I1+)'(T22?4W_#>?[)'_`$6OP[_X*O%O_P`SE5_&<CG]NW]G%M[Y'[)'
M[;^#N;(`^,O_``3YP`<Y`&3@=LGUK[,KLQD\K]EE=\+CU_PETG[N/PRT>-S6
MR=\LEM9Z^:[&&&6/G4QO[_!JV+LK83$K183!I7MF"N_/3;9MN3^._P#AO/\`
M9(_Z+7X=_P#!5XM_^9RC_AO/]DC_`*+7X=_\%7BW_P"9ROL2BN'FRK_H%S+_
M`,..%_\`G4=7)C_^@C"?^$N*_P#GB?'?_#>?[)'_`$6OP[_X*O%O_P`SE'_#
M>?[)'_1:_#O_`(*O%O\`\SE?8E%'-E7_`$"YE_X<<+_\Z@Y,?_T$83_PEQ7_
M`,\3X[_X;S_9(_Z+7X=_\%7BW_YG*/\`AO/]DC_HM?AW_P`%7BW_`.9ROL2B
MCFRK_H%S+_PXX7_YU!R8_P#Z",)_X2XK_P">)\=_\-Y_LD?]%K\.CW_LKQ;Q
M[\^',<>_%?+UY^VA^R^W[:?A?Q2GQ>T`Z#;_`+*WC_0YK]=.\2^1'JEU\8/A
MM>VUH4.A"Y:6:UM;F9"D#1A8)-SK\N[]8I"1&Y!P0C$$=0<'FOD"Z=S^WEX0
M4NQ7_AD/XBMM+$KN/QF^%P+8)QN(`!/7`QG%=6#>5REBH_5<P5LNQL[O,,*W
M[L,.[)K+%9.VMT^FFCOSXB&/M0MB,'_OF%_YA,2_^@GOF/X].SZ-_P"&\_V2
M/^BU^'?_``5>+?\`YG*/^&\_V2/^BU^'?_!5XM_^9ROL2BN7FRK_`*!<R_\`
M#CA?_G4=')C_`/H(PG_A+BO_`)XGQW_PWG^R1_T6OP[_`."KQ;_\SE'_``WG
M^R1_T6OP[_X*O%O_`,SE?8E%'-E7_0+F7_AQPO\`\Z@Y,?\`]!&$_P#"7%?_
M`#Q/CO\`X;S_`&2/^BU^'?\`P5>+?_F<H_X;S_9(_P"BU^'?_!5XM_\`F<K[
M$HHYLJ_Z!<R_\..%_P#G4')C_P#H(PG_`(2XK_YXGQW_`,-Y_LD?]%K\._\`
M@J\6_P#S.4?\-Y_LD?\`1:_#O_@J\6__`#.5]B44<V5?]`N9?^''"_\`SJ#D
MQ_\`T$83_P`)<5_\\3X[_P"&\_V2/^BU^'?_``5>+?\`YG*/^&\_V2/^BU^'
M?_!5XM_^9ROL2BCFRK_H%S+_`,..%_\`G4')C_\`H(PG_A+BO_GB?'?_``WG
M^R1_T6OP[_X*O%O_`,SE'_#>?[)'_1:_#O\`X*O%O_S.5]B44<V5?]`V9?\`
MAQPO_P`Z@Y,?_P!!&$_\)<5_\\3\DO%_[9O[,-Q^VO\`L^^+8/B[X??P]I/[
M+7[9?A_4=073O$OD6^K^(?BQ^P=J&D6,T3:"+DRWUIX9URYB>*VDA`T^5998
MY&B63ZI_X;S_`&2/^BU^'?\`P5>+?_F<JGXU=_\`AO3]FT[VR/V0?VYL'<<C
M'QK_`.">`&#G(P"0/3)]:^T*[\;+*_8Y5?"YAKE-%KEQ^&6CQV;V3OEDKM6>
MJM>^W0Y<-]?J3QG[_!KEQ;BK83$K187![VS!7?GIYW=Y/X[_`.&\_P!DC_HM
M?AW_`,%7BW_YG*/^&\_V2/\`HM?AW_P5>+?_`)G*^Q**X.;*O^@7,O\`PXX7
M_P"=1U<F/_Z",)_X2XK_`.>)\=_\-Y_LD?\`1:_#O_@J\6__`#.4?\-Y_LD?
M]%K\._\`@J\6_P#S.5]B44<V5?\`0+F7_AQPO_SJ#DQ__01A/_"7%?\`SQ/C
MO_AO/]DC_HM?AW_P5>+?_F<H_P"&\_V2/^BU^'?_``5>+?\`YG*^Q**.;*_^
M@;,O_#CA?_G4'L\?_P!!&$_\)<5_\\3\D_VP_P!L[]F#Q/\`"7PC8:#\7-`U
M&\L_VJ/V$-?G@AT_Q*CQ:/X6_;F_9S\2Z]>9N-!MXVBTW1-)U#4)51FGDBMI
M$MXIIBL;?5`_;R_9(`'_`!>OP[TS_P`@KQ:,@\@_\BYW';MT[9JM^W`S'X+^
M"<LQ_P",P?\`@GCU)[_\%!/V9P?S''TXK[+7[H_'^9KJD\K_`+-P%187,(QG
MB<TC&$<?A4HJG/+%URR5[\RZ*UNMSGA3QZQ>*3Q&#?[G`V_V3$JRY<?>]LPU
MN[OR6GFOCW_AO/\`9(_Z+7X=_P#!5XM_^9RC_AO/]DC_`*+7X=_\%7BW_P"9
MROL2BN7FRK_H%S+_`,..%_\`G4=')C_^@C"?^$N*_P#GB?'?_#>?[)'_`$6O
MP[_X*O%O_P`SE'_#>?[)'_1:_#O_`(*O%O\`\SE?8E%'-E7_`$"YE_X<<+_\
MZ@Y,?_T$83_PEQ7_`,\3X[_X;S_9(_Z+7X=_\%7BW_YG*/\`AO/]DC_HM?AW
M_P`%7BW_`.9ROL2BCFRK_H%S+_PXX7_YU!R8_P#Z",)_X2XK_P">)\=_\-Y_
MLD?]%K\._P#@J\6__,Y7RO\`M+_MF_LQ>(?%?[(5QI/Q=T&\A\.?M9^&]=UF
M2/3?$JK8Z4GP6^.FFM=R^?H<+-&;W4;*U`@6:0R7,>46/?(GZV5\<?M9,R^,
M?V)RK,I/[8WAY25)!*M\!?V@@RG&,@C@CH1P:[\KEE:QU)K#9C>-/&RUS#"M
M/ERW-)M-+*X[J+COIS7UL<F/AC_JE7_:,)O0_P"83$_]!>"[Y@_Z_%4_;R_9
M'"+CXU^'#\JC(TOQ:1T&,'_A&\D8P03USVQR[_AO/]DC_HM?AW_P5>+?_F<K
MZYMV8GEB?D4\DGG:G//?WJW7FPEE7*O]DS!6<HM1S#"I-PE*FY)/*W;F=-R>
MOVM;N[?9*GCTW_M&$WE_S"XG^:?_`%,%_7W+X[_X;S_9(_Z+7X=_\%7BW_YG
M*/\`AO/]DC_HM?AW_P`%7BW_`.9ROL2BKYLJ_P"@7,O_``XX7_YU"Y,?_P!!
M&$_\)<5_\\3X[_X;S_9(_P"BU^'?_!5XM_\`F<H_X;S_`&2/^BU^'?\`P5>+
M?_F<K[$HHYLJ_P"@7,O_``XX7_YU!R8__H(PG_A+BO\`YXGQT?V\OV2""/\`
MA=7ASD8YTOQ<!SQR?^$<XKY8_9\_;._9BT+XN?MT:CJGQ=T"ULO%G[4W@W7]
M`G;3_$\B:EI,/[#G[&7AJ6]B$.@RM&B:WX<UFP,<XAF#V3OY7E21._ZTRDA&
M()!XY'!ZBOCO]F(D_&C_`(*&Y)/_`!F%X*ZG/_-@'[#'^)_,UWX3^RG@\XE]
M5S#W,+EK_P!_PS;OG=&FDG_9B2LZO-?EE=)QTNFLZE/,.?#6Q.#2]K7NG@\2
MV_\`996L_P"T;JUK];Z:)ZC_`/AO/]DC_HM?AW_P5>+?_F<H_P"&\_V2/^BU
M^'?_``5>+?\`YG*^Q**X.;*O^@7,O_#CA?\`YU&G)C_^@C"?^$N*_P#GB?'?
M_#>?[)'_`$6OP[_X*O%O_P`SE'_#>?[)'_1:_#O_`(*O%O\`\SE?8E%'-E7_
M`$"YE_X<<+_\Z@Y,?_T$83_PEQ7_`,\3X[_X;R_9(_Z+5X<_\%7BW_YG*/\`
MAO+]DC_HM7AW_P`%7BW_`.9ROL+<O7([=_7I_.ER/7V_K4^TRF[2P^87N[I9
MEA+W6]U_95[][Z]PY,?;3$8.W2V%Q-OE;,;'Y.?MN?MJ?LO>*?V,_P!K/PUH
M/Q?T"_UK7_V;?C;HVD6$.F^*$FO=3U+X;^([.PM(FN-`A@$ES=S0P*TLL<:;
M]\DB(K,/J)OV\?V2%8C_`(75X=!!P<Z5XLSD<9('ASACCD9.,=:L?\%`&9/V
M%/VS&1F1O^&6OCV-RDJ<-\+O%"L,@@X925([@D'@FOK="2#DYY_PKJE/*_J5
M%?5,P_W[$>]_:&%YK?4\/I?^R[+7K9Z-JVMSFC#'_7*J^L8/3"T'_NF)UOB,
M0M_[1_KO;1?'W_#>?[)'_1:_#O\`X*O%O_S.4?\`#>?[)'_1:_#O_@J\6_\`
MS.5]B45S\V5?]`N9?^''"_\`SJ.GDQ__`$$83_PEQ7_SQ/CO_AO/]DC_`*+7
MX=_\%7BW_P"9RC_AO/\`9(_Z+7X=_P#!5XM_^9ROL2BCFRK_`*!<R_\`#CA?
M_G4')C_^@C"?^$N*_P#GB?'?_#>?[)'_`$6OP[_X*O%O_P`SE>?_`!9_;F_9
M1U'X5_$RQL_C-X=GNKSX>>-[6V@&F^*D::>?POJL<,*O+X>1%:21E4%F`&3U
MZ']!*\T^,[,OP@^*A4E2/AQXZ(()!!'A75B"".000"#V(!ZU=.>6*K2<<-F-
M_;4;7S##6O[:CORY7%V]))^9G6ACO8UKXC"6]A7_`.83$/\`Y<5NDLPE%_--
M'$?LF,K?LM?LV%#N0_`'X,LK%64E6^''AHJ2K`%<C!VGYEZ$"BE_9-_Y-:_9
MM_[(%\&__5<>&J*X\1_O&)\\3B6N]GB<19-]6EN]+O6RO8ZZ'^[X?O\`5\/>
MRLK^PH7LM;*^RN[*RN[7/-_&?_)_W[,G_9H'[='_`*NC_@GG79?MC_$_Q5\%
M_P!E[XV?%/P1=VUAXM\$>![_`%O0;V[\.WOB^*UU"*>VBBG'A/3734O$]Q&L
MS-:>'M-)U'6;H0Z=8I)=7,*-QOC/_D_[]F3_`+-`_;H_]71_P3SKZ2^)'P]\
M)?%?P/XC^'?CS2GUOPAXKL5TW7M*CU+5='>]LA<07/E)J>AWVFZM9L)H(I!-
M87]K."FT2A68'?FIPGETZT%4I0H8>56FTFITXXK&2G!J7NM2BI1:EIKKH<_)
M4J4L?3HS]G5G*<*53_GW4EA,,H3_`.W9-2^1^5GA7_@H?XC\&_#7Q#K/C:2U
M^+%WJW[3>L_`3X&^)?$'@;Q;^RYJ?B:U\._!W3OBEX^N?CI\.O%NA^+?B+\&
M=2^'.M:9\1O!,(U/X8:9X@\9_P!F>!]:L?AU9^#_`!)'\1=1Z.Q_;_UEM2^(
M?C\:78Z?X(U/X/\`[&?B?X;_``Z^,7B'0O@Y?>%O&/QUNOVA3XIT;Q1KL7AS
MQAXLU/Q'<#X?:!I5KX8\)>&/B+J=_J%C!<^$]!_L#4=9\21_27Q?^"/[*4FN
M:YK7Q2U>S\`>*_B/X^\'?$"7Q%I?Q[\=_`[Q7>?$_0?!EO\``[PYXL\$>(/"
M'Q&\$Z_X5\7:S\/]2TWX0ZW?^!;_`$J_\=^$KC2O`WBQ_$&F+ING5C:A\`/V
M2/B+.]])K%WK'B#2/$OP^^&*^.?#7[2WQ8LOB;H_Q!^!.D?$G1?"OA:+XI>&
M?BU9?$72_BOH?AGXH?$_0_'B)XFM_'_C31/&'B;2_B1-XDTN\>%/1A5R=THU
MG@,6JM9R59PHN<%!UL,Z3IJ,:4+QA1K0J3IRBW&K*I:*O"/!.GF/-44,?12I
MKFI1E4I1DINC6HWE&;E4DW7K4)1C4;@E&.K;E,\?;_@I/'J7@2/XI^%?@'XS
MU_X>^&OV:/AE^U?\8M:F\9>#-)O_`(<?"[QOXD^+_AOQ)9:1H=P;J^\?>./!
MW_"G?$_B&UT/3#INA^*_#FEZO)%XJT+Q)#X6\+^.MSQ9^VOJFHZK\5O!=CH=
M[\-]9^%O[1'[-?PJ9&\3>#[CXMZCHWQ*_:Y^'OP*F\4^)/@UXP\)F\\+?"7X
MK6&L:EJ'PT^(VCS^+]/\>_#:ZUG5_#?B/P-\1=(M]/TWYX^('PL_8%^%'Q=N
M#\5/%,OAWX+^"_V9?@_X6T/11\3/BC:?"_2M.^$O[4GQ=\.ZQX7^)FM>'?BO
M+<?&>U\3?%/XN>&_#NL_"OXI^&?&OAK3+KP/JY\32DW-_I<'TV/`O[&VNZ_\
M4/B?XNO=1DM=-\=>`O$,?Q,^*O[2GBSQ'\.[F?3-1^%'[:GAO6_@9=^)/C=X
MBT#X;_#-O%^D>`O&'B#POX5L/AQX9\7/\/=.BU3PQK_PQT/PQ=W6V)I951EA
MZL,OS-T:F%IUE-4,3+FG4?M)4N6I5C2DX<RA*K"/N1C:-*=ZE598>IF-1U%4
MQ>%YG4=-*,L.I>Y>E[135%3Y925.:ISD^>4W>HERP6.?^"B"Z5IWQ!\3^,_@
M5XOT#P-X6\#_`+8GC7P;KNG^,?"'B35?B#%^Q3\19/A]\3;*3P[:BQ_X1"/Q
M)+-9:UX`OM6U>X^TV%IXC'C&T\('2=*E\3>@?L^?MT>$/BWX=M];\:V?@_P5
M%XK^+E_\(OA)K/P[^(5]\>OAU\8K[3;#P>+KQ/X`^)GA7P#H7AK5/"Z^)?%W
M_"''5Q(VGVOB/0/$6D:I>:;JVAZSI>F^2_&?X7_LT>./"GQE^!V@:UIOPFUG
MX:_`;6?BJGQD\8:[J&I?"CPYX,_;K^+WQ.\6^,M1EUB[^)VA2W<'BWQQ\`_$
MNIZYJT.M^$]9^'&CZSX<U7X(^._!NKOI]SH/T'^RI\/M=^"WPW\;:SXY^-&F
M_$G1O&NOO\4-#U.R\6?$#Q#\-_`?@4^!O#-A;V?A+QC\9_BE\5O&&H^&]3AT
M"]^(FKZS>^.+7PG_`&IXIU:ZT/0])@.H:EK''C(99##.K'"UZ&*G4I>QI5)8
MI3>'J4G5HO#JK*=)UL3#6<(R<I.-H4J3Y5';#SQKQ48?6*%7#NC4<ZR6'BW7
MARJ4*CBJ<U&E*2Y);6DI.I42FW\K:Y_P5%F\._##X-_$;6/@!KME??'?X<>(
M?CEX`\"2_$/1]0\0ZA\%?"F@_#J_U'6YKGPWX2UW3H/'WBK6OB-I^F?"[X?^
M>^G>(-(CM]<^('COX4WT]_X<TOTS7/V\_%"?$#5O"G@G]F[Q;XR\/6_QK\$?
ML\:1XOE^('@OPC+J'Q/^)7[.7@C]I+PC+J7A/Q!!%KGAWP%IWAGQC;Z#\1]=
MOVF\8^%]5:R_X1'X?_$B2ZU"TT#J]2^%7[%VJ_#K]FW2+3XBZ5X7\$>%]#M?
M@Y^S%XP^&_[5'Q"^%FM:YX?O+#P_H`^&/@[XM_#7XM^$_&GQ2T_6AX(\,-JO
MA6X\7>*DU_7_``?H>L7]A>>(M!TS5-/D^'EQ^RA\0;#P%\3;)K;PKKGQN^,\
MWQR\":+\0/'MSH/C/QC\:?A=X`L?V?3K6A>&Y/'&H+X@N]*^'/@71](NO"_A
ML:IX;N+2.V\5:KHK^(=6N=5FW4LH:E4CD^/=*,JT'4E5Q;ITIRJXUX?GA[9N
M7)0HX:=O>GS4<9&K&+E!0'3S!UHPEF.%3DX<DDL,Y1ART/:5/:U*;<8^UJ.,
M>6-FJE&5/G3<CYO\=_M^_%)-!O/&?PM\$(_B[3_AGIB:O\&OB3KOAJ'P/HOQ
M!T+]M`?LK?%*,>//"&B7?B/7-4T/Q'IGB32O#&H6FIV'A#Q#HL6C^)GT&RU%
M[O39O1-=_:J_:&M?%GQC\.>,_`OA?X=^&/AK^T/^PC\+-(\3_#OQO8>,_%=S
MJ'[1/Q/_`&7]#\4>#?$.D^-/`$6@ZAH5W#\6?$VEZGXQT>+PYKUCX1VQ^&M)
MLO&!TWQ=9=[K_P`'_P!A&S\._%A/$>O_``XTO1(M#\6>%/BMJ5_\?-8T'_A#
MK3XP_'/Q9\8=8_MCQ#'\1K#4/AUK^L_'N]\6:_X3\0V.I^'_`!%X=\1Z:^A^
M"-3T>#PU9:?I_1:U\$OV5H/'&F?VSK;WOCWQQHGPB\5:-X7U;]HGX@W>L_$]
M/V5O%G@_XI_"[XC+X+UCXI?8_B-XR\%:[\.?!E[K'Q5U+3-7\4^)?#NF)X>^
M(GBW7O".H:KIDU2Q614TH+*,4H<LTZLJ%=XB&M'$MJ2:IQC2H1=-N=&<H?6*
MTI.HWS4X5/-)N-1X^BFXTYNG&M2E33C3Q/M>9J$G)3JU$K0GH\'%+E22K>60
M_P#!11M/TSQ]XL\9?`GQ?X:\#^'OA]^U?\0/`NLV?C#PAX@U3X@VW['GQ*L_
MAK\3+&?0;=+,>"H]>O-6TG7/`M]J^LWYO=#A\1R>)[7PE<:-IZ^(/H;]D?\`
M:0U7]I[P-XH\=3^$_"FA:%H_CW6?!?AGQ)\/OBE9_&3X>?$K3=$TS0[F\\<^
M`/B)I?A'PCHGB7PH=9U74?"T5]I-K=PIK_ACQ%I=Y-:ZGI=[8V_SSXH^!O[/
M?QZ^$/AOX;_#W7O#_P`*?BG\1/@G\0_'WPT\+>+?%[^)_'?A?P5^TUXZ\+?&
M+XKWFN^!M`^*SZIK&F>)O'>A66G:KXS\%>+_`+;\/]22XF^"7Q)\(:C8:3J]
MO]*?LK?`WX@_`_PSXTT[XA?$V?XA7_B_QY<^+M+TR+5_B?KGAOX=Z2_AOPQX
M?7PIX2U3XR?$?XL?$*YL=2O_``_?^-=9;4?&*:2/$WBG5QHGA[1[<32ZACF$
M<F^KU_JN&Q&%QJQD(>QQ=2NZD*-&I.+G1BJDZ$O@=/$5.9PE4A/V<;-<V^%6
M8.MAU7K0K8?V"E4G1E3E&5:K13J0FXQ4XJE4:=%1<9*,X\_,KM<OXR_Y/K_9
MQYS_`,8D?MO<^O\`Q>7_`()\<_C7V:[K&C2.<(BEF."<*HR2<9.`.2>PY/%?
M&7C+C]NS]G$?]6D?MO\`_JY?^"?%?8U[;6UY9W=I>6T%Y9W5M/;7=I=11W%M
M=6T\313V]Q!,DD4\$T3O'-#*CQRQLR.C*Q!XL<[4<L;TME%%NR3:_P!LS=NR
MDU&ZULI-+9-I7:Z<'?FQUK7^MNU[VO\`5,':[5W:]KVN[7M=V((M4T^<[8+N
M"=@"Q2"6.9@H."VV-F)3=\H<`HS<*QJ+3=<TC68[B72-1LM3AM;[4=+NIM/N
M8+V"WU/2+Z?3-6TZ>:VDEBBU#3-2M;G3]1LG=;JQOK:XL[N*&Y@FB3\/M!_9
MGT7X<?&[XAV/[/OPRTG]F&?QO_P4.L?A9J'Q0^!OP.^&GA+Q9IW[-3?\$ZO`
MGCC7_#/A?Q)>_#35]-\-_#3Q%\8/!>G6]YK&E6L.F6OQ!6:YL;R'QJH=EUZ[
M_:?DT[Q?H_@CQY\8OA-;^'/"W_!8;XL6S?#?X:^"]/E\8_$;X4_M=^#H?V:$
M\11:O\+M9L=;.M>'=?\`$?B"PL],M-/UKXUV;7VI:YJ7B_2;KQ%_:?6LIC4G
M-T<?0C2C2HS<<4H0JIU'"#7^SU)J;G4K4HTXQ?,E"I*IR*R7.\QK0253!U)3
M<YT[T.90<E&I434L0O=4*=)RJ.=HMSIQ@W)V/W3#K]/K_P#6S3'F1%9VW;4!
M9B%+'`&3A1EFXZ``DG@#/%?AA\4?'?[9_P`,--\6^'=`^(?Q?\>>%]4A_8Y^
M(7CWXE^,-)CT/Q!\/=%^,.G?M#67QHT7P;K_`,)_V;?B+<^&O#%MXR^%WP6L
M-=71_@QX_P!6^$?AOXF^*]>.H_#S1)+7QWX(W_`GQ2_:+D^(7[(^C^/OBY\4
MO']OX[\'IH>L:#\+?!GC[P=<6\6J^/\`XR:9IOQF\6:W\1?V2/"7A3XI:(?A
MS9>`(?'^I:AJ'[.VH>";OP2WQ;^&W@S7H/C)X1\/WJEDU6,546-P56,^9TXT
MO;SFZ<,-#$RFXV3BG"4TE4J0LZ4N97E"#%FB<O9_5,4I+V?/*?L(4X^TK5:/
M*YN=FXRIQ<G"G+2HK-\LVOVQ$JG'#+DD892I&#CD'L>Q[CD9R*\SLOC=\&=1
M\2ZEX,T_XM?#.^\8:-J.KZ1JWA2S\>>%+KQ+I>J^']._MC7],U'08-6DU6QU
M#0M)_P")IK%E=6D5SIFF_P"GWD4-I^^K^>CQ-\6OVB_@;^P[\#_"_P`%_$?[
M5E_\8?"'PK^/6I:W-XDTSQ5,N@_'[X/Z-\/[/1_@GJ/AS3/V1?B]XK^(FI)K
MNI:AJ7@OP%K>L?#KX7^,?!5K\3=;USXH>(+31-)\0^#/W/\`'7[+W@;XB:[?
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M_P"S0?B)_P"KG^%U?2_@[PG9>!O!?A;P7IL]Y=Z=X/\`"^A>%M/N]2FBGU*Z
ML/#NDVNDV=QJ$]M;65M-?36]HDEW+!:6L$D[R-%;0(1&OS1<_P#)^GA#_LT'
MXB?^KG^%U<^"_C8Y+6*RW,5!]904*/+)KHVM;79TUFW'#N2LWBL&VNS:Q3DN
MNST_5GV)1117&=0UG"*S$,0JEB%5G8]3A54%F8XP%`))P`"3BJD6H6LQ(AD\
MT!WC+Q#S(Q)&"7C,B;E5T`RRL5(&#SD5\O\`[;>F?$#6/V6_C9IOPRMO%FH^
M*KOP64.C^`KB\M?'FN^%8M6T^;XA^'O`5QIEU8ZM;^//$GP]3Q1H?@NXT>]L
MM:B\2WVF/HE[::J+6=?R]\66_A+1-:\9^/\`_@FO\.-<^!?A;3_V<]?\-_$S
MQ-\+/V=-9^$?AC5/BMXG^.G[.9^!Q3X<^+_A]X8T/X@_$[X<^`[;]H*Z\43-
MX/UF^\#^&?$T'ASXAS6@\4>'K2#MPF#CB8.;KJBW5G37/&'L::I*DY3Q-1U(
MU(0JJM^Y5"E5JSG1G!1?-)PXL1BY4)N,:7M>6$9N,9256HY.:<*4%!INGRQE
M.4Y)*,XI:N[_`'GGNK>VB>:>18H8T>225R%CBCCC>6221V(6.-(T=W=B$55)
M)Z9@T[5-.UBPLM4TF^M-3TS4K2VU#3=2T^XAO;#4;"\A2YL[ZPO+9Y;:[L[N
MVDBN+6ZMY)()X)8YHG:-U8_B7XA^(G[1'AS]LO1O@GH_B#]H7Q-\--'U'Q;\
M,O&E[\2_M/B'2_&_@-OV+_'_`,2].\?06OA/]E'PY\--&\.ZC\;;;PMX:TOX
MF7O[1<GQ#U?X@Z1X[^&MOX/B\*&'PYX9[WQ=XC^.GPL_X)O_`+$L'PLL_$'A
M:_@\"?LL>$?C7J-O!XIT#Q3\//AI_P`*:@3Q!/*WA[X._'/Q9X+G/C;3?!7@
MSQ=KMG\&O$^I^!O"_B+Q#K5Q<>`(=.N_B-X-Z'E-1/!P^M8=3QM6G&G*?[NG
M"$Z5:IS5;RE*#?LX67OV]K"+;GS*/.LTC_M4IX>LJ>$HU*DVHMRJ2C6A3BJ-
MU&,XRC*6[BU[.4VHQ:;_`&"DE2)&D<D*HRV%9C]`J@DGV`)SQC-1M=0H&+L4
M"8+EU9=@()RVX#``!)/3&#W&?Q3\!_%+]HJ7XA_LDZ)X^^+GQ2^(%OX\\&IH
M6L:'\+O!?CWP9/:IJGCGXR:=I_QH\6ZU\1/V2?"7A3XI:(_P\L/`$7CO4[[4
M/V=[[P1?^"3\5_AMX*URV^,GA7P]>0?L7:3\59[']B?X5O\`%O\`:8TGPKX,
M^"/[1.N_M`:)XKT.*SO'^-WP@\>_L=^'=!^#7BS7_&GPRAU*T\%:7;>+OB9)
MIFG^&M0L[_QM8'7CI_CK7?#NFZTDU/*7"G.53&8?FBYN*A&K*-6G#ZQS3IRO
M!NT\/["*G3ASU*T))\D9#AF;J2Y*>$KR:]R?/.E#V=22HSAS12JN2=&HZCY*
MC:4;-1DXJ7[3Z=K>DZSIFG:UH^HV6KZ/K%A::II.JZ7=0:AINJ:9?P17-CJ.
MFWUI)-:WUA>6T\-S:7MK++;7-O+'-!+)&ZL7:3K.DZ]9C4-%U*PU:P,]Y:K?
M:;>6U_9M=:=>W.FZC;+<VLLT)N-/U&SN]/OH-_FV=]:W%I<)'<02QK^`/PB^
M*?[4=A\./V8M'O=>^.?@7XI:;\%_^"<=K\%_@GX.^`UGIGP<^)V@>+?!OPQC
M_:=OOBHVG?"9]`\*:AX?NKOXE^&_'?A]/%OPV@_9Y\&>!?`7BGPKX2\*:AXF
M2]\<?J=^PGH^H:#^SQ;Z7J>E:EH]S%\:OVK+N.SU;3;O2;UM/U3]JSXU:KI%
M\;*^AM[E;;5=)O;+5;"X:%8[_3[ZUO[9YK:YAF?#$9;+#T:N(GB\//EKTJ-+
M#4TIU)QF\0ZE>53GMR0A3HI<D&G4J5(N2=.SWH8WVU2%/V-2/-3K2G4DI1C&
MI2G2@J=G'>3E5DKRNX0C-:22/L*BBBO/.T^+O&X*?MZ_LVAN"?V0?VYL=_\`
MFM7_``3Q;D]N`<YZ$8ZXS]E_:(O[Z_\`?2_XU^)__!3_`,9?'?P-^TC^QMK7
M[/@UEO%\WPK_`&M=.\2#14MT9?AY-\0/V,+OQ-/J.J7=G>0:#86]U8Z-<+J[
MH5CU---LW@O(KV2UE^:7_:?_`&KU8A_'GC=&R=RO\3OAK&002"-C:#N7!!!4
MA2K`KCBOS;Q!\6,)P7F63Y1B.&.)<WG+AO+L7];RFE@)X2^(QW$+=&^)E"JJ
ME-48.5W)>_HTK(^6Q6?4LKQ>,PW]G9EBFZ\*KJX:%&=*]7"82:A>HXR4HI6D
MK=4[]OZ1OM$7]]?^^E_^*H^T1?WU_P"^E_\`BJ_FV_X:A_:N_P"A^\:_^'1^
M&G_RAH_X:A_:N_Z'[QK_`.'1^&G_`,H:^"_XF%RW_HA../\`P1E/_P`M,/\`
M6^E_T)LZ_P#!6%_^3/Z2?M$7]]?^^E_^*H^T1?WU_P"^E_\`BJ_FV_X:A_:N
M_P"A^\:_^'1^&G_RAH_X:A_:N_Z'[QK_`.'1^&G_`,H:/^)A<M_Z(3CC_P`$
M93_\M#_6^E_T)LZ_\%87_P"3/Z2?M$7]]?\`OI?_`(JC[1%_?7_OI?\`&OYM
MO^&H?VKO^A^\:_\`AT?AI_\`*&C_`(:B_:N_Z'[QK_X='X:?_*&C_B87+?\`
MHA../_!&4_\`RT/];Z7_`$)LZ_\`!6%_^3/V`_;@!'P8\$Y&/^,P?^">![?]
M)!/V9C^'!'7WK['2XBVCYU[_`,2^I]Q7\Q_C/X^_'KQ9HMMI?C[Q;KVI:#:>
M+?A]XFLH-:^*GPQ@M(_&O@SX@>%_%_PRO[>5M,MB-6TGXDZ'X2U30X?,;[;K
MEEINF^3>"^-C<]4W[47[5V>?'OC4-@;@/B=\-$`/H`=$<D8P=V[G/0'-;OZ1
M67/!83#OP_X]I>QJXRJG5PV3Q<_K:RZKIRXJLGR*"C+6/+.ZL]UE'BVBZ]:K
M'*,XE"I3P\%;#TH-.B\9%MJK-.TU4A.#2LXR5];I?TD?:(O[Z_\`?2__`!5'
MVB+^^O\`WTO_`,57\VW_``U#^U=_T/WC7_PZ/PT_^4-'_#4/[5W_`$/WC7_P
MZ/PT_P#E#6'_`!,+EO\`T0G''_@C*?\`Y::_ZWTO^A-G7_@K"_\`R9_23]HB
M_OK_`-]+_P#%4?:(O[Z_]]+_`/%5_-M_PU#^U=_T/WC7_P`.C\-/_E#1_P`-
M0_M7?]#]XU_\.C\-/_E#1_Q,+EO_`$0G''_@C*?_`):'^M]+_H39U_X*PO\`
M\F?TD_:(O[Z_]]+_`/%4?:(O[Z_]]+_\57\VW_#4/[5W_0_>-?\`PZ/PT_\`
ME#1_PU#^U=_T/WC7_P`.C\-/_E#1_P`3"Y;_`-$)QQ_X(RG_`.6A_K?2_P"A
M-G7_`(*PO_R9_23]HB_OK_WTO_Q5?''[6,B/XQ_8GVD-_P`9D>'!P0>6^`W[
M06,X)QTK\??^&H?VKO\`H?O&O_AT?AI_\H:Y+Q3\?/CUXBN_!=UXN\6Z_?WW
MA7QE:^)_`<NJ?%7X:1RZ=XY@T'Q%H]G?:/&--LS>ZL/#NM>)K>/3R+M)[.XO
M9FLV-LMS:].#^D9EF&Q$:\N`>.ZL84\4G3I8?*'4FJN!Q]"T$Z\$Y?O[I.45
M[KN]->?%\5TZN'G3CE&<0E.5%*4Z.'<5;$X25VHS4GI!I).]VC^FZ%ECVLY`
M#(H&2!R%3(.2,$8JQ]HB_OK_`-]+_P#%5_-N?VHOVK.J^/?&H!Y_Y*C\-#P<
M$<_V&03[C((YSR*3_AJ']J[_`*'[QK_X='X:?_*&N2/TA,N2L^`N.HR3O*,L
M/DZ:E-*K)6CB*JLI5FE:<M$M=->C_7&E-*?]C9U:2<E^XH1LN>JK.,Y\R?NO
M?NK'])/VB+^^O_?2_P#Q5'VB+^^O_?2__%5_-M_PU#^U=_T/WC7_`,.C\-/_
M`)0T?\-0_M7?]#]XU_\`#H_#3_Y0U7_$PN6_]$)QQ_X(RG_Y:'^M]+_H39U_
MX*PO_P`F?TD_:(O[Z_\`?2__`!5'VB+^^O\`WTO_`,57\VW_``U#^U=_T/WC
M7_PZ/PT_^4-'_#4/[5W_`$/WC7_PZ/PT_P#E#1_Q,+EO_1"<<?\`@C*?_EH?
MZWTO^A-G7_@K"_\`R9_2.\L;J55E+'&`"#G!SV)/05\>_LR.L?QI_P""AN\A
M?^,PO!/4XY/_``3_`/V&#CG`SQTSGKQQ7X]?\-1?M6#KX^\:D?\`94/AIV'7
M_D!`]<=/TKD_#GQ\^/6@ZS\0-4\,>+-?L->\:>+K#Q/\2KG3OBM\-)+S5_&M
MK\/?`?@W3]0UZ+^S;A;/5D^&WA+X>Z;%;""Q\W0M/T/4C:,^HOJ>J=%+Z1F7
MTL/CJ2\/^/)1Q5/!4IU%A<H<(>SS*&)BW+ZW%Q]^C%2_<SO&22=VW'.7%])U
M**63YRN6I4=GAZ+;3PDWI)3Y+^3U6[T:/Z=?M$7]]?\`OI?_`(JC[1%_?7_O
MI?\`XJOYMO\`AJ']J[_H?O&O_AT?AI_\H:/^&H?VKO\`H?O&O_AT?AI_\H:Y
M_P#B87+?^B$XX_\`!&4__+33_6^E_P!";.O_``5A?_DS^DG[1%_?7_OI?_BJ
M/M$7]]?^^E_QK^;;_AJ']J[_`*'[QK_X='X:?_*&C_AJ']JW_H?O&O\`X='X
M:?\`RAH_XF%RW_HA../_``1E/_RT/];Z7_0FSK_P5A?_`),_:[]K3]I+3OV4
M?@_=_&/5_"U]XOTG2?%?@KP_JFC:7J=II6HBR\6^(;+09=0L+B_@ELKBZT[[
M6+N.PNI]/MKX1-;2:IIPE6[A3]GW]L'X"_M*6S1_#3QI$?$]I;FZUGX=^)H#
MX<^(>B1IM2XFNO#%\XGU'3+::1(9/$'AV;7/#;S`PPZS-*C"OYY?VB_C/\4?
MB+\'/%OAGXX>+/%NI_#R1=.U"_@G^(W@*_F35].U&"[\.SV-AIND1WFI7T6L
M):?9=-C+QWLI$=S$\&[;^7-Q^T1X6T[5M%\.Z=X3\8>(_&?A@::+7Q1X0U&'
M2-0TS6+>)&MGL-3MKG^U['6-.CEBMY[O3;E)H[EI6683_:7KP<3X^9K/.J%3
M*N$\UK9$\+AH8O+LTIX?!9E1JQJXAU,9@\;"NL)RRIT%'ZOC;^UJ--2C2;D<
M-3C+$RQ5/ZKE.(^J.G'VE'%TUA<3SJ5ISH2=5QG'EMR4^2\Y*RE[R9_:)_P4
M`=6_83_;+`SS^RW\>N<'_HF'B<<]QSZ@&OKJ,@@CZ'\"./Y&OY-[/]N;]J?Q
M+^R#^U%\//B_:6GBOP#J7[+WQTT^U\0>/;EX/BWI"2_##Q+':)_:OABRN[#Q
M9%N,0>+Q9:6&M7#>=<7?CEY#%:-_5_87,=W!'<1;_+ECB9=ZE&^X,Y5@I4^N
M5'/8=!_2>0YU3XAX<R_-Z.`S3+:>)QV*MALWP,\#B8VR_!23C&<Y>WI.4ZD:
M>)I+ZOB(P=3#RE33D?4X'%+&5YUXTJU*,L'A[PQ%)TJD)+%8A-<K;YHZKEJ*
M\9J[3T+M%%%>B>J%%%%`!7F?QH_Y(_\`%3_LF_CO_P!135Z],KS/XT?\D?\`
MBI_V3?QW_P"HIJ]73_BTO^OU'_T]1,JW\"O_`->*_P#Z8K'%?LF_\FM?LV?]
MD"^#?_JN/#-%'[)O_)K7[-G_`&0+X-_^JX\,T5>(_P!XQ'_81B/_`%(KA0_@
M4/\`L'H?^F*!YOXS_P"3_OV9/^S0/VZ/_5T?\$\Z^QI/NGZK_P"A#-?''C7(
M_;\_9E*@DC]D#]N7L3U^,_\`P3T/3/1L''/TK[$+.1C8>?;_`.O3KV]GA-$_
M]B@FFTD_W^.TUTL[]+HC#J\L3U_VA)JZ33^K81V>J=]MOO1^>O[77[(6M?M&
M>,O$FO6ND?#+5K6Y_8?_`&MOV<_#;^/8[F>[TGXE_'JZ^%K>%=:A6+POKR:;
MX4@T_P`&:Y9>*M;T^:3Q#:I>6%MIWA_6XKJ^:T\S\3_L6_$KPGXU7X@_`_PY
M\$--;PEJ?['GBGP-\-+S5M;^'/@_Q)X@^`_A/XV?#;X@6/B/6?!WPO\`%:^!
M%N_`7Q,\-VW@KQ5I'@WQG<7W_"$:1X7US0="T*WLKV#]4PK#LY^N/_K?YS2D
M$]48_4#_`!KIH9OC\+3HT:4Z'L*%)4(4I1YXRH^RJT)0G"=11<ITJ]6G*:G"
M2;C4A*-2$)+&KEF'JRJ2G"3G4G.JZJ=-3C.;IR3BW>5H2I4W&+?)[K7)RRDI
M?B\/V!_V@M3\&>/8M;O/@A+XO\4^$OV@[F'2K?Q#XSE\&W/Q!^)O_!07Q3^V
M9X5TB\OM2^'LNK:?X0E\/:GIWACQ#X@_L35M8\-^(9[R33O"OB:PT^*ZO+_Q
M6^!'QUTCXN_#+Q[;?!OX,^/O$'Q!_;DT3XY:=\/-2\4^,KGX8>#8O"?_``2O
MUGX'ZA!XI^)%M\"=>O?"JZ'\3?`E_%\/?&(^$U_%K"7/@:-](\,>)?$CZ-X<
M_9(`C_EF?R_P84?/G(5QR#@8QQ]2?K]>F*Z5GV.=6=6K]7J.K2J4:D/9RI4_
M9U(5::A&-#$0=-0C5]UTZD)>XKS,I9/AE",:7M:4H3A4BXSI-N491DW)SC)2
MYG'F:E%QO9J*:5OP[N_^";7QTTWPAH-IH'BWX=G5O!OPZ_8EM=&\,:-XP\7?
M#_PUJ7B[]GCXM_ME_$;QCX&L?$,?PT\>7G@'X;>#K?\`:8\&CX!>($\%>-M9
MTW6/A;HLNM>"/#BZ;IU]7VEX>_9CDTC]B+6_V:[_`.'7AO6KSQ%X4^(=AJ_P
MUU7XY_$";PIJ.I?$7QIXF\9ZWHH^/FE_"C0/'6A6D]_XFN[C3/%7A[X0Z:_A
M2=K.ST+PD-)T/2;,_>6&QC:WUP,_J<<]^*7+YSM;ICHO2LL5G>8XOV'MZ\9>
MPQ%/%1<;TY>UIRE..M*<$N64Y.%16JQYI)U7S-E4LIPM#VGL82BJM">':;HR
M48U%%2DN=2O?D3Y'[BU2BDVC\H?AK^R]^U'X-\1_"WQMXXT?]F[XS>(U\&^/
M/ACX\M/'6M7MK%\+_"OB+]H;4/BWI/B7X>ZMX/\`V;/#?A[XO>,M1\,7NBZ3
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M-X)^`/C;QS\/?VM?VO/V@]>\`>-_$?B'P/\`#[Q_:?M&>/?CYJ?A+Q1>^.M&
M^$GQ"U?3/BWX`\'?%31+.&_U3X8^)K>."?Q[X.L=:M+&_P!+\5R<A\+OV'OC
M9\+/&?[/-UX5B^$>D:1X&^'.G^"/C+XIL/&6N7EMXC\/Z7_PO'7?"?P@^'WP
M+\2?`O6+'PCX8^$/B+XSZEH?PE^+?A#XX?#?QQ8>`)IO#WC+PGXLT'2K+P5/
M^O95CU5_IA<?K^/YF@*1_`WUPO'Y4O[:Q_+.$I4:BG[3FYX*3DZGM;WE]9IM
MJ#KU'!.":3A&3J*E15,_L;"IQ<(5*2A!0BH5HM)>SA3E[C@X)U(TX*4N=M/F
ME%*52JY_E)^R]^QU\<O@9\1_V?K]K3X2Z!X1\$?`_P"#W@/XY:MHGQ#UWQW=
M?%CQK\+OV9M(^#-CK'A7X<^,OV?]%O?A3K.AZ]86NG:=\1_!7QQTBQ\9_"G1
M3H'C[X.ZIXE\1Z;K'P__`%C48`'IGI]:@4,ISM<GW"_TQ_GWYI^]_P"X?R_P
M-<F)Q>(QM9XC%2IRK2Y^:5-<BFYU:M:4Y1<Y\LG4K5'RPDJ<4U&,5&,4N[#X
M>.'@X4XN,92YVFZ3L^6$59P4$URPCK).3>KDSXV\9_\`)]O[.7_9I/[;_P#Z
MN7_@GQ7V:1D$=,U\:>-48?MY_LW1X;:_[)'[;Y'!+'/QB_X)\,,`<XWK@MM*
MJ#ARIY/V/O?^X?R_^RK?&V]CE>S3RFBK/3_F-S=-6DE=>ET_,SPL)1J8V]FW
MC+Z2B[7PN#:OJM=-A&B)'#[3C`.W)`[`<]`<''J!2&%B`/,(Q]W"\+SQ@9[+
M\HYX'Y4[>_\`</Y?_94;W_N'\O\`[*O.E&,FF]TK:2LK:=%)+3E5M-+:6N[]
M;3::MI)-.SBM]'LU9ONK/S$$1!SOSUQD'(W,6;!W<9R,\<[03G`PXQY!4G*L
M#N!!YSSG@C!]>Y[\4F]_[A_+_P"RHWO_`'#^7_V5#A3=[QB[WOKH^:+B[I22
M:Y6U9K1;6LFG9]D[[WY'>_>[_P"`((CW?..%V@KA1T4D.20#R.V>U2J,`#K@
M`9Z9P,=.?YU'O?\`N'\O_LJ-[_W#^7_V5-**=THIV2T:6BV7Q-)>B^;%9Z^Z
ME=INW(KM*W1KHOUW'2?ZN3_<;_T$U\?7/_)^GA#_`+-!^(G_`*N?X75]?,S%
M6!0@$$$XZ`C'8YKY"O%=/V\_"#;&Q_PR%\1E&1P2OQH^%O`)QDA2K,`>-RDX
MW+GLP<E&>*DWH\NQL%;7WI0H)7LFDKO5MI+<Y\0K>P3LF\9A;)M:_P"\[:[^
M5[GV'146]_[A_+_[*C>_]P_E_P#95R77=?>O\SHL^WXQ_P#DAY7/H.G;/3/7
MVY_GZT@4C^+/7MR"?0YS_CWIN]_[A_+_`.RHWO\`W#^7_P!E0K)MWWM>\DUI
MV3=D^[25^MQ<K?3K>]XIZ>:E>WEMY#MA_O'_`#^-(8^X(!]=HSSC/((.3@$\
M]0/2DWO_`'#^7_V5&]_[A_+_`.RI*,5=I13;O>ZWUU^)VW>UMQM-[J_JXO\`
M4!'C^(D9SCG!.<G.6(.3WQ[T[9D`$YQC&><<$=SWS^7'<TW>_P#</Y?_`&5&
M]_[A_+_[*A1BG=))WOH^MI1U]YWTDUKIK>U[-'++;5^LE?[^9/\`X&@[9QC/
M'.1CJ3G)///)YSU_$TX#'N?6H][_`-P_E_\`94;W_N'\O_LJ$DK;:*R]Z]E>
M_5O[W=]+VT#E?;\8_P#R1+146]_[A_+_`.RHWO\`W#^7_P!E3NNZ^]?YA9]O
MQC_\D?$?Q.TRSU[]N7]G73-1A66RNOV._P!NF"XA).)8W^-'_!/-#N(P1]_)
M`X..O<=K)^QS\"99))9?!VFO)([.[-&Y+.Q+,?F+'EB21G`[>_.>-D8?M\_L
MUQX;#?L@_MR[>"6.?C/_`,$\&X`R<!P06VE0"`Q7[U?96]_[A_+_`.RKOQUG
M1RA?RY/AXJSE#2./SII73IN23J2M=R2N[-(Y<-"2GC>90DY8QRNN23L\+@TD
MWILE;EZ>5]?E7_AC7X"_]"7IG_?IJ/\`AC7X"_\`0EZ9_P!^FKZJWO\`W#^7
M_P!E1O?^X?R_^RKS[+N__!D__EIU<O\`<C]T/\SY5_X8U^`O_0EZ9_WZ:C_A
MC7X"_P#0EZ9_WZ:OJK>_]P_E_P#94;W_`+A_+_[*BR[O_P`&3_\`EH<O]R/W
M0_S/E7_AC7X"_P#0EZ9_WZ:E'[&OP&R/^*+TSK_SR:OJG>_]P_E_]E1O?^X?
MRS_[-19=W_X,G_\`+0Y?[D?NA_F?E3^V-^RK\$M$^#_A.>R\&:;')>?M6_L!
M:5,2A):SU7]OG]FBPO8P?^FUG)<6YR"")V(VL%8?5A_8W^`QY/@W36]S$?4G
M''IG'X=`<U@_MQ(5^#/@CAL?\-@?\$\`>#C<?^"@?[,AZXQP2WN%Y..37V,K
M.%`V'C/8^I]3G_/'%=DW&678#FE.555\SYY2J5K\KJ9;*G&\JBV7-HE[NS?1
M<\+/%XE)1:5#`Z)05O<QD$[:6;C3@KVU44W=W;^5_P#AC7X"_P#0EZ9_WZ:C
M_AC7X"_]"7IG_?IJ^JM[_P!P_E_]E1O?^X?R_P#LJX[+N_\`P9/_`.6G1R_W
M(_=#_,^5?^&-?@+_`-"7IG_?IJ/^&-?@+_T)>F?]^FKZJWO_`'#^7_V5&]_[
MA_+_`.RHLN[_`/!D_P#Y:'+_`'(_=#_,^5?^&-?@+_T)>F?]^FH_X8U^`O\`
MT)>F?]^FKZJWO_</Y?\`V5&]_P"X?R_^RHLN[_\`!D__`):'+_<C]T/\SY5_
MX8U^`O\`T)>F?]^FKY1_:>_90^".D^*OV.K>U\&Z8L>K?M@>%K.]PC*9;./X
M'_'ZZ>WS@X$LL,+$C!'ECD#(/ZL;W_N'\O\`[*OCG]K`2R>,OV)PJ-D?MD>'
M"<*20@^`W[01D;`)P%4$DGA1R>`:]#+(Q>.HIM_!B^7]Y4TFLNS-TWI5;TJ>
MS>S6B;329QX]6PE5VC&SH:^XK?[7@NJ=UV^=NNNQ'^QS\!G`'_"%::`%4C]W
MQT4XP.F,\`=,8.>M2?\`#&OP%_Z$O3/^_35]21*R!2%;)C4$$="%4$=L=/4F
MIM[_`-P_E_\`95YT7S*[E)MMM.52K?EN_9I\U52TI>SCJK^[9W:;?;)<TF^6
M+UEM&"7QU'HM-->BMKYGRK_PQK\!?^A+TS_OTU'_``QK\!?^A+TS_OTU?56]
M_P"X?R_^RHWO_</Y?_94[+N__!D__EHN7^Y'[H?YGRK_`,,:_`7_`*$O3/\`
MOTU'_#&OP%_Z$O3/^_35]5;W_N'\O_LJ-[_W#^7_`-E19=W_`.#)_P#RT.7^
MY'[H?YGRH?V-_@,H)'@O3>.PC(/IW^OY9Q7RO^SU^RG\$M9^,'[>MM=>#-,\
MG0_VL?`^DV"A&(CLU_8(_8AO2A'=FO+V\G+9/^O*#"JJC]4'+LI&P],].N.<
M<$\GMQ7Q[^S+O3XT_P#!0L>6W/[8'@EL[3C/_#`'["X."2!PP8<9Y!`Y5@._
M"J#P>;W<^98;+G3M4K<J<LYI1FW:JX*])5(WE;5QVDXLRJ13EADXPNJU:27N
M)W6$DKZ/7W=+-M=;7U-O_AC7X"_]"7IG_?IJ/^&-?@+_`-"7IG_?IJ^JM[_W
M#^7_`-E1O?\`N'\O_LJX++N__!D__EIKR_W(_=#_`#/E7_AC7X"_]"7IG_?I
MJ/\`AC;X"_\`0EZ9_P!^VKZJWO\`W#^7_P!E1O?^X?R_^RHLN[_\&3_^6AR_
MW8_=#_,_+?\`;`_X)X^!?BM\$-9\%_#6TT?P3XDN=<\+ZJWB:XM[FY>QTC0]
M8M]3UF"QM;:"1[C4]0LK>2RL8Y&M[7SI@US=6\2;G^!_V<?^"4+Z=>&2ZTQ-
M'TV.X?S-6U)5?7M37S!(\[3/N\B2=RTTH@?RQ*TB[I%!!_H]8,X*LA(/!!5?
MK_.FQQB+`CBV@#`"J`,?@1ZUXE?AW)L7FT,\QN7T,;F=&A1PN'KXR7UB.%I4
M93J1GA:56K4I4:JK3E753V+JJKRRC-627//!8:==8F>'I3KJG&BIS4)I0@K1
M4:<FZ<91Z34%4OKSMZGY=?M0?LP_#/X0?L'_`+8<NC:+:SZK!^RM\=A_:4Z^
M9<F1/AAXF.\$LZ*<C/')/7(Z_J5$JHFU0%4'`4#``````'0>U?(_[?PDD_85
M_;,01N2?V6OCV0%0LQV_"[Q0QPJDD\`GIVKZW!9>`I8$`]#C..<$D?E^/-?3
M3?\`L5'56^O8AV6B7^Q89:67)%6224>5*VD8W]Z8W6-JK5_['AHI73LEB,39
M?%I%:\JT2Z(FHJ+>_P#</Y?_`&5&]_[A_+_[*N6Z[K[U_F=5GV_&/_R1+146
M]_[A_+_[*C>_]P_E_P#9477=?>O\PL^WXQ_^2):\S^-'_)'_`(J?]DW\=_\`
MJ*:O7H^]_P"X?R_^RKS3XSL[?"#XJ#8PS\-O'>,*2<_\(IJ^.A/T'')(`Y(!
MTI?Q:6J_C4>J?_+ZCVN_P,JZ?L*^G_+BOUC_`,^*W]XX[]DW_DUK]FS_`+(%
M\&__`%7'AFBC]DW_`)-:_9M_[(%\&^V/^:<>&O\`.**K$?[QB/\`L)Q'_J17
M_KH_)"H?P*'_`%XH?^F*!\W_`+0?PB^''QH_;@_98\,?$[PO:^+-"L/V5OVX
M==L]/N[S4[*.#5K;XM_L`Z=!>"32KZPG=X[+4[Z!4DE>';<,YC,BQNGJ/_#`
MW[(G_1%M%_\`!]XR_P#FCJIXV./V_/V9B.W['W[=)ZXZ?&?_`()YGKV^M:FA
M_M)^)?%WQ0\7>'?!7P8UGQ#\(OAOX]G^%OC_`.,\WCCP?X>CL/&NF:78ZCXM
MN_#7@K7+FSOO%'@#X=W.IVWAWQ[XK?7-&U>S\367B#3O"O@_Q?:Z#<ZC)V^U
MQBHX6%"M6A2HX"G)J.(5*$5+%8V,8QC*K!RG4F[0ITXRE.3M%.5SB]EA)5*T
MJ]"E4G4Q/)!RHQJ2;6%PLY.4N5N,(Q7-*<O=C%:M*Q6_X8&_9$_Z(MHO_@^\
M9?\`S1T?\,#?LB?]$6T7_P`'WC+_`.:.H-(_;S_9@\0^&?%/BS2/'NM7.E>$
M[3P/JDULWPK^,MKXC\7Z!\4=>?PK\+/%7PA\&7GP[M_&/QU\'?%+Q5&_ASX9
M>,O@KH/C[PK\0M9CFT_P?K.M7D,EN,6Z_P""B'[)ECX<\-^*=0^(/BK2=,\5
M:9X_U_3X]6^"7Q^TK5],\*_"GQA%X"^*/C?QEX9U'X76?B7P!X!^&OBF:'3_
M`(@>/O'>D>&O!G@N!UU7Q'KVFZ,PU(O_`(6FY*,<SFX-QER^W:4^24^5M2T:
MC&3>EHV=]4XI..4)0;CET>>*G#F]A%2IN<8<ZDTE;FG&*75RBD[RC?H?^&!O
MV1/^B+:+_P"#[QE_\T='_#`W[(G_`$1;1?\`P?>,O_FCKG=1_;:\"^%_B]I_
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M``?>,O\`YHZ/^&!OV1/^B+:+_P"#[QE_\T=>A_"G]I7X-_&KQ!XE\+?#KQ7>
M:UK/A>TBU.Z2_P#"/CGPOIGB'0)]0O-)A\8?#?7_`!?X;T#0?BUX`DU73[O2
MQ\0_A;J/C#P/_:"169U];BZM(I_"OBC^W[\$/AU\5_"/PI6^U77=1F\?>//"
M'Q-UJQ\-?$I/#OP^L/AU^S3\8?VC_%=QHOB73OAYK/@_XJ^.?#NF_"_1M"\4
M_"'P-XFNOB'X7@\=:=K6LZ;:W%E;^'=>4)9O4G*E%YA[:$/:3HMUO:0@DVY2
MC>Z6CM?5M62O>,;E2RN$(U)4L`HU)JG3DHT7&<Y-)1C*R3EKJK:=7JF^R_X8
M&_9$_P"B+:+_`.#[QE_\T='_``P-^R)_T1;1?_!]XR_^:.MSQO\`MD?L^>`+
MN#3M<\::KJVK7FE^!-:TW0OAW\//BE\6_$FLZ9\3-+\?^(/!=YH'AOX5>"?&
M6NZ_#?\`AKX6^/?%>J?V+I]])X5\(>'IO%7BN/1?#U_I6I7WF?@/]MKPYXQ_
M:+^+/P7OO"^L>$_#/PY^(OA3X(>&_''B7P]\<-'U'XD_&?Q#X!_X65<^'/#N
MF:[\"=&^&<OA.V\)V^IZGI'BW2_C7X@U'7++3[/Q2/"6F_#SQI\,_&WCA0EG
M%2%2I'^T.2E3=2;E4J0?*JRH>Y%RO-^TYH^[I>$[M6;C#CE,73BZ>"O5J.G!
M1ITI>\J4ZLN:R7*HQBKM]91T=TGV'_#`W[(G_1%M%_\`!]XR_P#FCH_X8&_9
M$_Z(MHO_`(/O&7_S1U'XJ_;O_98\%R6D7B#XG7$7VAOB%)=36'@#XHZ_;Z!H
MGPE^)^J?!KXI>-/&%WX>\$:M;>!_AM\.?B1H]_X=\<_$_P`93:!\._"J?8M<
MUKQ19^'-4TO5[W*^,?[>_P``O@QIOQGN=2'Q1\;:C\"/#FIZYX^T_P"&7P7^
M,'CO2;+4=)L-&U*^\$Q_$?P]X&O/A1'\0=/TWQ#HNM:]X+O?'MIX@\(^%[YO
M&7B^QT'PE8ZEK=FX2SBJZ<:<<SE*JHNE%^VCSJ=3V4;.4K:S3BM;.2LFVFD3
M63THSE4CE\/91<JMXT7[-12E+F:72+3V5TTTK-7V?^&!OV1/^B+:+_X/O&7_
M`,T='_#`W[(G_1%M%_\`!]XR_P#FCJ@_[:7POTB?QK?^+;G5-#T'0[[X5:5X
M/T.R\"?'?6?CIXOUOXI^`KOQ]IWA6;]FX_!33OBO9^.;71-,UG65\">%=)^(
M/BRS\+:#XA\1^,M,\$CPYKVGV#[_`/;\_9-TP>#3+\68KNW\=>%M!\<Z1?:1
MX.^)'B"PTGP1K_BW5/`2^,_'NI:#X.U.P^%OA/P]XXTF]\'^/_$7Q.NO!^D_
M##Q&D.B_$F\\):C=V-M=IO.5]G,I)ZQ=.5:HG'V,:[;<96BU"7PMMNUTVFKO
MERG3]W@$[N+4HT824N=4U[LHIM2FTE+1)[H^7O%W[&'[,,'[9OP!\+0_"32(
MO#^J?LP_MB>(-0TU-;\7+'=:SX<^*_["VFZ+?/./$/VM7L+'Q/KUO'%%<1V[
MKJ,K30R.D+1_5O\`PP-^R)_T1;1?_!]XR_\`FCJAXRR/V[/V<0PP1^R1^V_D
M'D@_\+E_X)\9!/L:^SZVQF-QGL<JMBL2E_95%V]M46KQV;MZ<V[>K\]R,+@\
M)*ICN;"X=M8Q[T:;_P"83!K^7LK>BMHM#X__`.&!OV1/^B+:+_X/O&7_`,T=
M'_#`W[(G_1%M%_\`!]XR_P#FCKZ_R/4?G2Y'K_G_`"17%]=QG_07B?\`P=4_
M^2.SZC@O^@3#?^":?^1\?_\`#`W[(G_1%M%_\'WC+_YHZ/\`A@;]D3_HBVB_
M^#[QE_\`-'7V!1D=<\>M+Z[C/^@O$?\`@^I_\D'U'!?]`F&_\$T_\CX__P"&
M!OV1/^B+:+_X/O&7_P`T='_#`W[(G_1%M%_\'WC+_P":.OL#(]111]=QG_07
MB?\`P=4_^2#ZC@O^@3#?^":?^1\>O^P/^R($<_\`"E=%X5CSKOC+'`)Y_P"*
MD%?+=U^Q9^R]_P`-J>%O"H^$>D+H%S^RSX\U^?3EUOQ<(I-6M/BU\-["VNRY
M\0F4-%:7EU$L:R"(^<SNC.$9?UCD_P!7)_N-_P"@FOCZY_Y/T\(?]F@_$3_U
M<_PNKLP.-QCJ8N^*Q#ME>/:_?5-'[/#O^;>Z3^2,,1@L':@OJF&M]<PNGL:=
MO^8K7;?SZ=-V2?\`#`W[(G_1%M%_\'WC+_YHZ/\`A@;]D3_HBVB_^#[QE_\`
M-'7V!17)]=QG_07B?_!U3_Y(W^HX+_H$PW_@FG_D?'__``P-^R)_T1;1?_!]
MXR_^:.C_`(8&_9$_Z(MHO_@^\9?_`#1U]@44OKN,_P"@O$?^#ZG_`,D'U'!?
M]`F&_P#!-/\`R/C_`/X8&_9$_P"B+:+_`.#[QE_\T='_``P-^R)_T1;1?_!]
MXR_^:.OL#(]:,CU%/Z[C/^@O$_\`@ZI_\D'U'!?]`F&_\$T_\CX__P"&!OV1
M/^B+:+_X/O&7_P`T='_#`W[(G_1%M%_\'WC+_P":.OK_`"/4?F*,@]"/SH^N
MXS_H+Q/_`(.J?_)!]1P7_0)AO_!-/_(^0/\`A@;]D3_HBVB_^#[QE_\`-'1_
MPP-^R)_T1;1?_!]XR_\`FCKZ_P`CU''7GI2T?7<9_P!!>)_\'5/_`)(/J."_
MZ!,-_P"":?\`D?'_`/PP-^R)_P!$6T7_`,'WC+_YHZ/^&!OV1/\`HBVB_P#@
M^\9?_-'7V!11]=QG_07B?_!U3_Y(/J."_P"@3#?^":?^1^1_B_\`8Q_9AM_V
MT_V?O"D'PETB+P]JW[+7[97B'4=,36O%JQW>L^&_B[^P?INB7TDX\0?;%>PL
M?%&O01Q17$=O(NHS--#(Z0M']8?\,#?LB?\`1%M%_P#!]XR_^:.LWQK_`,GZ
M?LV_]F@_MS?^KK_X)X5]I5W8[&XM4<I_VO$+_A(H/^/46KQ^<-OXMV]7W>K.
M/"8/"2GCG+"X=OZ[+5T:;_YA<$OY>R2\DK'Q_P#\,#?LB?\`1%M%_P#!]XR_
M^:.C_A@;]D3_`*(MHO\`X/O&7_S1U]@45P?7L7_T%XC_`,'S_P#DCL^HX+_H
M$PW_`()I_P"1\?\`_#`W[(G_`$1;1?\`P?>,O_FCH_X8&_9$_P"B+:+_`.#[
MQE_\T=?8%%'U[%_]!>(_\'S_`/D@^HX+_H$PW_@FG_D?'_\`PP-^R)_T1;1?
M_!]XR_\`FCH_X8&_9$_Z(MHO_@^\9?\`S1U]@44?7L7_`-!>(_\`!\__`)(/
MJ."_Z!,-_P"":?\`D?DA^V#^Q?\`LP^&/A-X1U+0/A+I&FWUS^U5^PCH,\\.
MM>+)#)I'BO\`;E_9W\+^(+(QW'B":)5U'0M5O["258UN(5N/.MIH;B*&:/ZM
M7]@?]D3:/^+*Z+_X/O&7K[^),_4FJ7[;Y_XLQX)_[/!_X)X'_P`Z"?LS_P"-
M?9J?='X^W<^M=CQN+_LG+9?6Z_-+%9OS/V\[NU3*TKOFN[7=K[7=MV8+!8-X
MS%/ZIAF_8X&_[FGT6/7;MH?(/_#`W[(G_1%M%_\`!]XR_P#FCH_X8&_9$_Z(
MMHO_`(/O&7_S1U]@9`ZG%)D>H_,5Q_7L7_T%XC_P?/\`^2-_J."_Z!,-_P""
M:?\`D?('_#`W[(G_`$1;1?\`P?>,O_FCH_X8&_9$_P"B+:+_`.#[QE_\T=?8
M&0>AS11]>QG_`$%XC_P?4_\`D@^HX+_H$PW_`()I_P"1\?\`_#`W[(G_`$1;
M1?\`P?>,O_FCH_X8&_9$_P"B+:+_`.#[QE_\T=?8%%'U[&?]!>(_\'S_`/D@
M^HX+_H$PW_@FG_D?'_\`PP-^R)_T1;1?_!]XR_\`FCKY4_::_8L_9?\`#WBK
M]D.VT?X2:19P>)/VL/#^A:W&FM>+'^W:4WP5^.FJ?9'>37WDB4:AIMA=!X'B
ME\RVC!<H71OUKKXV_:T_Y'']B?\`[/'\._\`JAOV@J]#+,;C/KM/_:\1I1Q[
M7[ZINLJS=I_%T:37FCDQ^"P7U2K_`+)AMZ'_`"YI_P#07@O(6#]@K]D5L`_!
M71`-BMQKOC+NB<9/B0DCGOD^_6K'_#`W[(G_`$1;1?\`P?>,O_FCKZTMNO\`
MVS3_`-`CJY7FPQN,Y?\`>\3I*HE^_J;1K58Q7Q;*,8I=DDNAVSP6#YG?"8;=
M[T:?\T_(^/\`_A@;]D3_`*(MHO\`X/O&7_S1T?\`#`W[(G_1%M%_\'WC+_YH
MZ^P**KZ[C/\`H+Q'_@^I_P#)$_4<%_T"8;_P33_R/C__`(8&_9$_Z(MHO_@^
M\9?_`#1T?\,#?LB?]$6T7_P?>,O_`)HZ^P**?UW&?]!>)_\`!U3_`.2#ZE@O
M^@3#?^":?^1\>O\`L$?LB(I8?!;1,C&,Z[XRQU`_Z&.OE;]GC]BO]E_7OBY^
MW5IVK?"72KRR\)?M4^$/#_AVW?6_%J)IFCW'[#W[&7B:6RC,7B!'G5M<\1:S
M?++=M/<1F^>WCE2TB@@B_6>7_5M^'\Q7QW^S%Q\:/^"AN?\`H\+P5_ZP!^PO
M7H8/&XSZCG;^M8BZPF66?MIW5\^PL79WNKQE*+M:Z;6S9G4P."<L-_LF&=JM
M>W[FGHWA9)VTT;22=MUH]"Q_PP-^R)_T1;1?_!]XR_\`FCH_X8&_9$_Z(MHO
M_@^\9?\`S1U]?Y'J/S%>%>+OVE?@AX#^*^B_!/QM\1-`\'_$3Q+X9T_Q7X<T
MGQ-<2:'8Z_IFI:SJV@6EOI/B#4(X/#]UK4FIZ+>PIX?_`+336[A/(FL[&ZB=
MFC\BOFU7"PC4Q.8SH0G4IT8SKXQ482JU7)4J49UJM*#J5'&2IPY^:;344VFB
MI83`02<L-A(IR44YTJ44Y2NHQNU:[::2ZV/-?^&!OV1/^B+:+_X/O&7_`,T=
M'_#`W[(G_1%M%_\`!]XR_P#FCKZ]C;<BD\$YX)YZG\?S`(Z$`T_(ZYX]:V6.
MQC2:Q>(U2?\`'F]'YJ;3]4VGT;*^HX-:/"8:_6U&FU?UY=?4^/\`_A@;]D3_
M`*(MHO\`X/O&7_S1T?\`#`W[(G_1%M%_\'WC+_YHZ^P**?UW&?\`07B?_!U3
M_P"2#ZC@O^@3#?\`@FG_`)'Y._MP?L3?LM>$_P!C']K/Q/H'PAT:PUSP_P#L
MW?&S6='OEUKQ;,;/4]-^''B.\L+M89_$$MO,UM=0PSI'<12P.\86:*2,LC?4
M/_#!/[(TA+/\%]%+$G).O>,LG/))_P"*DY))ZGFI?^"@7_)B7[9G_9K?QZ_]
M5?XGKZY3H?K_`$%=$\;C/J5'_:\3_OV(?\>I9/ZEAU=+FLFUHVM6M+V.>.#P
MGUNM'ZKA^7ZIAWR^QIV_WG$/:W?7UUW/D+_A@;]D3_HBVB_^#[QE_P#-'1_P
MP-^R)_T1;1?_``?>,O\`YHZ^P**Y_KN,_P"@O$_^#JG_`,D='U'!?]`F&_\`
M!-/_`"/C_P#X8&_9$_Z(MHO_`(/O&7_S1T?\,#?LB?\`1%M%_P#!]XR_^:.O
ML"BCZ[C/^@O$_P#@ZI_\D'U'!?\`0)AO_!-/_(^/_P#A@;]D3_HBVB_^#[QE
M_P#-'7GWQ:_84_9-TWX6?$K4++X-Z/!=V7@#QG=VLRZ]XRW17%MX:U2>"0#_
M`(2/!*2QHP#`KD#(R!C]`:\S^-'_`"1_XJ?]DW\=_P#J*:O5TL;C/:TO]KQ/
M\:C_`,OJG_/ZC_>,ZV!P7L*_^R8;^!7_`.7-/_GQ6\CB?V3%`_9:_9LP``/@
M#\&E`'``7X<>&L`#H`,G&**7]DW_`)-:_9L_[(%\&_\`U7'AFBL,1_O&)?5X
MG$MONWB,0VWW;>K?5G3A],/ATM$L/ATEV2P]!)+R25D>:^-AN_;[_9G7.,_L
M??MU#)Z#/QF_X)Z#)^E<-XF_9_G\#>*O'^BWG[1GA3P3^S9^TI\1-<N/%GPE
M\7>#M'C\>:Q\3/C%I!T+Q'\/OA#\9]5^(&D:9H/A_P"*>KVMSK][X&O/A-X^
M^(ESXEU[Q<?`7C_PO:ZAHMCX4[KQJ"?V_/V9@.I_8^_;I`^I^,__``3SKH?V
MH(OB!)%\!S\/HO%LDT?[3_P5F\:?\(G'J<AC^'4>L:F?%LWB0Z;'*(_"$=E)
M&=>?4-NE1PO";UH=Z25UTIR4\#3]JJ-.K@X1JSE&$U%4ZF:UZ<ESIJ,E6I4H
MPDES*51<OO.)QSBFL1-PG-T\1S15.4XR]^CE]*:3@TVG2J5'*+]UQIN^BDSX
M#^.G[%'QXE^%%JT_Q!UG]H7Q]X6L?V>OA3X5M?A-X/\`!/P4\9:'\#?@]\5=
M!^)]YX@^Q^-OC;IGA?QO\==>\1^%O!U]XC\6:3\6?V>O"NG+X:TSQ!\+/!OA
M#5](O_"_C[O/AC^QUXX\:_`2^\-_%!M+^"/B#Q#^RM^U!^RA;^#M+\+^'[J[
M\/>"?C3\0+B]\#_$CQQ!X8^*/C;PIJ/Q>M_"FF:5K/Q4TGPSX]\1^&O%OQ%U
M_P`3:QIWC?38[P6*:7[$/@SX]^"O$'P+OOB+X@_:.\1_\+4_8Z?Q9\>!\;_%
M'CGQ;IWAOX]^&?%'PNL?"ND:?IWBUWTCX3^(_P#A$O%?CO2=6\*^$['PU-XX
MM/"MMXJ\=VGBKQKI.I^,-1X&Y^#OQQ\:_%_2M4\0^//VP-&\.^._V[?CS\,/
M'5EX;^+7Q=\$^$],_8\3]GGXN>.?!H\/Z=H&HZ?IO@#POJWQP\'?#S3_``_\
M>?"1\/?%NROO%4G@#P7\7]"\*:WIG@VW]BK7Q:A7RN69Y8Z6%<\92Q=*C7Y:
ME7_:[X:C3IU52BE++G.#ITY<SQ>"Y)*GB91.2%*BZD,7'"8IO$7PU6G*M&,:
M5.$*2]K4]H^62E[>4.5)N].I9MPL?33?LDZUI/Q(T_XH>#_BOINF>(;']J]?
MVBKBTU_X;3>(M#O/"VM?LT>%?V8?&WPS%K8?$#PSJ-OJ^J^&?#EQXH\*_$.#
M57A\+>)[NQCU?X?^-=&TZ\TO6_,OA;^Q9X`TWQ#^S-XK\._'G3/%6A_LU:9X
MI^'WQ5T31-,T"?1OC/XH^$OB?QA>_#6W\;75GXNU5O!VL_LO_$KQM\1M<30(
MI-7FM?%_B"Z@UM='N-)BA7YFG\9?M=>$?A%J'A_Q#H?[7'B+X@_$3]C[X`^"
MOA?JGACP?\2O$.KZ5\8?A7\:/CQ#\9/$7C[6/#UC%IOPM\?ZY\)_%'P;\2Z]
MXJ\=3>$]5^,&GZ)=:5X)D\<^+-%3PL_2>"O@KK.A_M.?"/XH>./!/[0VF64'
MQQ_X*6^'=%U+P3=?M"67ANUUGXG_`+37@OXA_!74_B!X1^%FJ1>'7^%_Q`\/
M:%XUU6[\;_%'PY+\)/$%MI'@NP\<:U<?8?AI!';P^/C3QGUK/<-5E&$X8=X:
M%&HJZ]GF$6H2G5524>5*$'\252[O)P9S*MAY3PE&AEM54Z?+*<:OMJ<:4H5:
M56-DX*FGS/GD[W]RZTYT?3/[!W['_P`-?V==.T_Q7\,?%'P`^(WPVUKX9^'=
M`^"'Q'^&7P=TGP[\0O$?P=U"33]>\,7OQ"^.FC_$[QIX>^-T>LZ+;^%K[3O%
M/@;P5\*_#OB:6WD\67VB:S>:GI]SIKO`O[+SZM\5/!_Q1\(?M'>&_&O[/GA'
M]I3XS_M%^$OAOHG@/0/$-U=?$SXK>`_CM\)/C!X;UWXS6'CB]L]>\):!XZ^+
MOCO7?#^A6'@31==\(:O%KO@?Q9KOC&V@T./PC^?/PE\0?M%WNH_!KP?K>L?M
MCS_M"^$?AM_P2LGTC01=?%P_"OPUJ^KZ)X0N_P!M&3]I"'3@?A_8:AJGPWTS
MQ?\`\)SI_P"TKMOKC5%BN_V=(8_C_/J%[%'#X+_:ZT34_@UX9T[Q#\=O@CX+
MM;SX@ZI\+I/"WP2_:>^(=JOQCU?]M+X]Z_XMA^+7AGX&^-O"/A/3_#GB?X6:
MC\%)_#UW^U]H.L_`*Y\.:YXKUSP]J7AN[M/$.IR:5<#BXU<55>=X?ZSC8M3F
MW2Q#K86-#&5?:2ASRJQKM8N5.A6HJ'+*OF$8I*"3=#%T(4J5&&7UJ=*@[1A2
M<XQC74X4_9N:CR*"Y4ZD9N3<?9[N4DOI3X?_`/!/CQW<?LN7WPON_%>@?#CQ
MKK/QK\4^*M(UCXF_#R+XH>,OA1\*O`F@7?[/_P"R];_"[Q/\+OC)\+=3^&'Q
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MV%XJ^./_``TS\/=3EMY8?C'J7[*L/[.WA[]OSX$>+/@U=_"W1+:[/[/%_P"*
M-,_9\T+0];\6:O\`#S1M2^+GAW4-"^-=Y\8]1TJVFLS?\6&GC<75H5J^/I4*
M.*K5E6Y*%"])5Y>QJ7E6JQBJ;I>Y*<Z+P_+6J)IU-8/$+#4(UJ-/!2K5<-2I
M.DU4J6KO#KVM.+C1HU)2E"K.4O9^U553I1M:G=/WF/\`X)]2M\*_C)\-]5^.
M%WK.H_&#]GG]K+X"ZQXMN/A_I=I<6^H_M4?&#XF_%C4O'TVAZ7XIL=*N+SPG
M??$N[T=_#5G_`&#IVO-IPOK.\\*V]XND67<>*_V/O&_B7PU^T[\*[/X]V^A_
M`K]H;3?C)J=AX/M_A5IE[XY\"?$?XV:=,OB77)?B3<^-5LO%G@32/%=UJOCC
M0?`?_"`>&O$4.M:S<Z-JWQ1UGPG;:=H5C^?XTG]MN]F_:SN9_B=^TCI/Q4O-
M!^,EG<>"_"OP?_:<B\/VM[<_M$>'(/@9XR^!/Q3\?>+/&W[,+S^$_@W;WTGA
MSP[^S;X(TS4_%_A'Q7J%W^U#X9UCXC^$KA[?W/XC>$?C%X)^.]UX-\$WG[8]
MQXA\.?$']F6/]DV_LO&_[0WQ`_9\N_@HWBSP9=?M0S?M'^/M;U_Q5\/O%'BI
M[*3XQV?BB3]J?7]6^(,'PVC^&</[*<=O\2(;&63?$QS6=2:J9Y@ZLG*-9QAA
MJ;BGA73K4JT4G1O3]IB5.G5BN7V"Q-:-*I[%4$8;ZE##PA3RS$4Z7+&C&*FU
M.U6,H5*2<E=25/"T:4HMJ]64*3DN93/9?'/[-GB/2O&>F_&K6?VFOA=X%_:`
MUKXL?"+6_!7B+Q'\*9[7X/:S\6++X!^,/V=]:\'0?"K5OCU8^,/$VE_$[PSX
MX\5:QX0\&^'_`(UZ-XV\,>)[#P[CQ5XVL-)U_3_$C[3]@*VC^'?QM\"K\6]4
MO+WX[?LY^+_@[XN\27?@RTF*^-?B/\6?CY\9_B#\4[31=/\`$&FV(L]:\;_M
M`^)9-&^'4#V]OX4TBPLM)3Q7JL3/=#YS^'#?M`KXQU[2M,C_`&J?&6EV_P"V
M1\!?$7B#XM^/M-_:<\$0:]X5UOQA\5YOB+X#M?@[\9L^&_!_A'X4>'+7P3:>
M,O'/[/"P_LI?%*QUOPS?^%]%T#6=&\2:=%]0_P#!.ZX^(,/A+XDZ)X\'QP\2
M+HWB?3#8_&#XYVG[17@[7OB[J]]H=J_BW6]/^#'[3LESXT^#3Z1J$5EINN>&
M/A;?7_[,VIZA)#XB^"</AV#4O%'@_P`-\V)>:83#JM#-*4I4U2O1HTL,YQH8
M;%X&6%I<_LXU5"$H0J4Z,[UER2E*/(IVZ*$\)5K*FL'4C[6552G*<YKVU7][
M6<O=2?M)0M*M']U*2Y(/F23]/\9-N_;L_9Q;&W=^R1^V^VWKC/QE_P""?!Q^
M'2OL+4(#=6%[;"XN+0W-K<0"ZLY%AN[;SHFC^T6LKI(D5S#N\R"1T=8Y55RK
M`$'X\\9?\GU_LX_]FD?MO=1@_P#)9?\`@GQU';Z5]FNN]&4Y&Y2,J<,,C&0>
MQ'4'L:\O&I^PRM7=_P"R*"YK1O?ZYFRYN62<+WUY9)POHTXW3[L)9SQ_-L\8
M^9:[/"X/F7NM/J_A:?9IV:_%[P]XL^/_`,,OBM\0?"_A+XP>-?C1KU]^VE9_
MLA>!-(_:*\4Z;<?#_P`)>$-7_8C\#?M.:I\0=8L_AYX!\.^(?$_BWP_XBM/%
M2Z9IJ:IH]OK^D:O_`,(I+JGAZ26S\5Z-;NOVO?CEX+TKQ+8?#3PKX&\5WVC0
M?\%3/C%XIO/BYX^\?ZC)_8?[&?[4_A_P/IW@SPH]G9ZK>:;:^/=/\<2:5H,%
MW-_8/PCTRVTXZ3I/BO3?#\7A'6?U7_X57\-_[6;7QX"\(#77\<K\3GUD>'M)
M_M1_B0G@E?AJGCYK[[,;A_&2_#N./P(/$CNVK_\`"(1IX=^UG24%I65)\#_@
M[)_:!/PJ\`%M6TOXGZ)JA_X1+0,ZCHOQM\1V7B_XR:1>DV/^DZ;\5_%>FZ=X
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MQHO?&WQ%\!Z)X)AO?"ZB3X,1ZK#X6\#_`!$\$0_&_3M)A^*=I\3],^#VE>(_
M"WQ4T6XM]1^V_$WP!^"'C;2_$.A>,OA!\-O%>B>+="\&>&/%.D^)/!/AK6]-
M\1>'/AQJFI:U\/-"UJRU'3KFWU+2/`FL:OJNK^#K"[CEM_#6J:G?W^CQV=W=
MW$TF%I'[+'[-6@:[X$\4Z#\`/@UH?BCX6Z&/#/PS\3:3\-/!MAXA^'OA]6UR
M1-'\%ZS:Z/'?^&M/CG\3^)KB.UTB>UB2Y\1Z_<JHGUG47N2>,RMTX<N5^RFH
MRYY1G*;]LZ%."J1BZKBH^WC*HT^;24M=8J)3PF91FG+,'-+D:O&TKJK5E-^T
MC2A)2=&<(1DHQ2Y(I)N,I2_*NY_X*`_M'?!_]C/X(_%[QLOPO^,GQ6U[X"?$
MG]I;QAH'A7X<_$VVOM=^$OPET#P?J.O3WDGA!+WP9\-)+O4?$G]F:W\4M>N8
M_#NAZEJOAV'PY\)O&>FQ>+=5\,?=?C+]G#XDS^//$'C3X=_$.?PBNO>--?UM
MH8_$7C>:*/0O&WA;X6>"]<SI"37&CR:KX9MK7XU>/_`=DL2Z'IGQ+UOP1J5P
MD5E-XC>#TS6_V,/V1/$NG)HWB+]E[]GW7M&C\2^,_&4>DZS\'OA_J>EQ>*_B
M-]B/Q`\11V%]H$]JFL>.6TW39/%M^L0N/$$VFZ=<:H]S/86DL/TPHP`/0`?D
M,5G6QV&YO:8#"K#59U,14K>UHTIT)1JU)3HTXX=_NG&C&24;ZZ6;=H\NM+!X
MAMQQ>)=:FJ=*--0E.-6G.$5"I45=I5'*M;FG*]^9NR2;///A?X:U;P9\,?`G
MA#7M0?5]<\*^!O"7AO6=9DO=4U)]8U70?#NFZ5J6J'4=;EN-:U#[?>VD]T;[
M6)Y=6NS*;C49'NI)';Y_N?\`D_3PA_V:#\1/_5S_``NK[!D_U<G^XW_H)KX^
MN?\`D_3PA_V:#\1/_5S_``NK'!.];&OK++<QD_64*#?XG16CRQPZO>V*P<=D
MM(K$Q6B\D?8E%%%<9U'S!^V9\4O$WP8_9F^+WQ(\'7>D:3XB\-^&[1K'Q+X@
ML8M4\/\`@B'6->TKP]J?Q%U_3;FXM+74-#^&NEZM=^/=7L;RZM;.ZT[P]<P7
MES!:R2RI\2?%WXK?%S]BWQ_J'A[PW\5_&/[42ZW^S?XY^+<G@SX]ZQX$L;_P
MUX]\&?&O]G;X5^$=0@\8_"[X:^$[[PCX6^+]E\:_&L&JV6J>&_$V@6>L_#*U
MU?X:^'=)BTOX@:;KWZU:GIMCK%C>Z7JMC:ZII>IV=SI^I:;?V\%YI^H6%[#)
M;7EE?65TDEM=V=W;2R6]U;7$4D%S!(\,T<D;%3X;X*_93_9F^'/AOQ-X/\`_
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M0K:_O-:M/MN[_9P^`%_\29?C-?\`P2^%=[\8+B$P3_%2Z\!>%9_B)-&WAN\\
M&2"3QG+IC>(&,W@[4+WPC,YO]\GA:ZE\.LQT<BR&QKOP4^$?BGX;6_P;\3?"
M_P``^(?A%9Z1X=T*R^%^N>$M`U7X?V>C^#Y-.F\):7:^$;ZQGT.WLO#$VCZ1
M+X?MX[%8M&ETS3Y--%J]G`T>KQ66S6#C++Y<E*K"KC%>,?K#6$KX>5E=M1<Z
MD*BA&?+:E&#^*<WS1PN/4<7?&I3J49TL')4W)T7*M"I%RO",6U&$ES2@KSJS
M<E91BOACP_\`M;?M$:AXC^`>F_$7X,:/\!]`^*FBOX>U7Q'X_P!`^(&OZ9J/
MQJO?&/Q&\$:1X(@OO"ZK)\'(]2A\*^!?B'X)@^-VGZ-#\5+'XH:=\(](\2>%
M?BKH-S9ZCR'[,7[1G[5WCSP[^Q'X3\8S_!7Q9XF^/GP(^)/Q\^(OQ"ATKQ5X
M6ET[P/\`"WQ)^S)X>;3-#\+Z+=2Z3J/Q!\62?&_7(S?I=^&O"&B2V.GZQ:Z5
M?PZ7<>'M>^ZM(_99_9M\/Z_X"\5:#^S_`/!O1/%7PMT,>&/AKXHTCX;>#-.\
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MZ_\`M`>/+;QEX.67X>ZEHZ^*]?\`OS]B;Q'XE\6?`6'6_%^NZMXDU_\`X7!^
MT[HLNK:W?76HW[Z5X7_:>^,?AKPY8&ZO))9S9:-X>TK3-&TJ`OY=II5A96<"
MI;V\2+W47[+O[-T&O_#GQ5#\`?@Y%XF^#_ASP[X.^%'B%/AOX-&M_#;PEX/A
MGM_"/AGP-JG]C_;?"^A>%(KJ[3PSI>C3V=IH`O+L:1%9BZN!)ZMX6\(^&/!.
ME?V'X0\/:-X7T47^LZJND:!IMGI.F+J?B/7-3\3>(=16QL(8+87VN^(]:U?7
MM7N_+^T:CK&IW^H7<DMS<RR,\5B\NJT:T<+EM/#5L1B*5:=9V=2$:4L1)X>F
MW>2I3GB)3;3AI&$.64:<&KPU#%0JQE6Q,JE.G2J4U3;FU+VDJ3A4;DH^]"G1
M5/E]]+FG+F3E9='1117EGH'XV_\`!17]IC6?V6/VI?V.OB#H/ANQ\57/B7X/
M?M<_#*XL+RVU:_-I:>)OB1^Q)JDFJ6FGZ)/;ZAJ%S8W'AJV5K."7S#837D\:
M2RVZ1/Q/_#T/Q]@$^&_A\<Y/R^`_C<V.>C9A4ANA((!P0>]?87QS\#:%\0OV
MT/V=?#^O:?8WR+^R1^W/?Z9->V-K>RZ3JP^+W_!/_3XM6TUKI)/L>H166IZA
M:1WD!BN4M[VYA618YI5;DI_^">]I)-+(GQ)\80J[LPC36=0$:!B6VHBWH2-5
MSMVQJJ9!8#YLG\V\1>$?$/.\SR?%\,<?U>&LKAPUEM%9?3IJM"6)AC>(G7KV
M609G*$IN=-23Q,D[)QC'6*^4Q."SW&XK&U<!G57+J$<3&G&A3=*SE'!X/GJ-
MSP]:3E.;U5U%6]W=V^:?^'HGC[_H6O`'_A`_&[_XW1_P]$\??]"UX`_\('XW
M?_&Z^D?^'>EO_P!%.\9?^#G4?_DVC_AWI;_]%.\9?^#G4?\`Y-K\_P#^(<>,
MO_1WZ_\`X2/_`.A`Q_L;BK_HJ<3]]#_YA/F[_AZ)X^_Z%KP!_P"$#\;O_C='
M_#T3Q]_T+7@#\?`7QN'ZB)OY&OI'_AWI;_\`13O&7_@YU'_Y-H_X=Z6__13O
M&7_@YU'_`.3:/^(<>,O_`$>"O_X2/_Z$`_L;BK_HJ<3]]#_YA/F__AZ)X]_Z
M%KX?_P#A!_&__P"1Z/\`AZ)X^[>&?A_GM_Q0?QOZ_P#@/7TA_P`.]+?_`**=
MXR_\'.H__)M'_#O2W_Z*=XR_\'.H#_V]H_XAQXR_]'?K_P#A(_\`Z$`_L;BK
M_HJ<3]]#_P"83X=^+/[>WBGXO>%=+\)ZWI'A72K32OB;\$OBC;W6E?#[XR27
M,NL?`KXT>`/C?H.FRK?V<T/]FZSK?P[L-'UGRHTNTTJ^O)K*>&\C@D3T]?\`
M@J/X^89'ACP'_P"&_P#C@WZB$@U;_:>_8NG\`_#'P_K6C_%GQ]I]]J7[1?[&
M7@EKJP\1:Q:3G2/B1^V;\`?A]XELI9;>^61['5_"WB77='U*S+^1J6GWUS8W
ML<EI<2*?HH_\$];8D_\`%S?&7+.1G6M1)PTCLO\`R^XX4KQSCIVK>?AMXU+"
M8:4O&;$U:,JV-C1O@U92H_V?"O+3@^UZE1JIY*UK+181RGBCV]6G'B3$1G&&
M'<YWHKFIS^M*BE_L-O<ITFI+I.;6R1\TM_P5&\?@97PMX#;U`^'_`,<`?K\T
M0!],=><]C2?\/1OB#_T*?@3_`,('XV?_`!%?2O\`P[TM_P#HIWC+_P`'.H__
M`";1_P`.]+?_`**=XR_\'.H__)M8+PX\9?\`H\&(_P#"2W_OH&_]C<5?]%/5
M?^*&&F_O>"3MV70^:C_P5)^(*@_\4GX'/&1M\`?&PCO_`+'7CIUZ>HIH_P""
MIOQ$[>$O!0_[D#XV_P`B%'YD?TKZ7_X=Z6__`$4[QE_X.=1_^3:/^'>EO_T4
M[QE_X.=1_P#DVJ_XAWXSI67C%B;+I]5?_P!!X?V-Q3_T4U5?X:>&B_O6";MY
M'S1_P],^(W_0I>"L>O\`P@7QJ'\G8_H*3_AZ;\1O^A.\%?\`A#_&,_F'E3'Z
M^^._TQ_P[TMO^BG>,C_W&=1_^3:<?^">=J?^:G>,/QUC43_.\/Z8I_\`$.O&
MA_\`-X\0O7#4U_Z<X2A?_MV_G;0?]C<4_P#13U_G[!_^Z6O^1\PM_P`%3_B*
MK`?\(9X,/&<KX$^,1'?C(GV@\?WOUKS#XC_M^>+OB;JGPHU/5O#NB6$WPC^*
M6G_%?1(M,\!?%-HM4UC3O!_C7P9%I>J_;))G&F2V7CB_NI3:&"Z-U9VBK*86
ME5ONS_AWG:_]%.\7_P#@VU#_`.2Z^<_V@/V*[WP;K_[,%CI/Q<\?62^._P!I
M[PWX,UM;+Q#J]K'J'AZ?X2?&CQ!>:=J"P7Z+>V+ZCX>TB[>PN5EM9IK*"62-
MI((A75@_#CQNEB8*AXSXBG6Y,0X3^KX=\G+A,;.;=N%')I4X54[)NS=EH<^*
MR?B2&'J.MQ+5G37LU.$:>'2DI5\/!>ZL"U)J<X25_P"1)Z)F4?\`@JA\1P!L
M\"^$7![_`/""_%P\<8P3?$A2""%Z<YX.12?\/4_B0/\`F0_"I]E\!?%DY]L_
MVG@'Z\#(-?3Z_P#!/>S<X'Q-\8<`$`:OJ&,87&"UV6(`(Y;D]^0:?_P[TM?^
MBF>,?PUB_!_,7>1]17-_Q#OQGE[T/&.O&+46H^PHKE?)34HM5.%(S34XU%)-
M:232=EIN\EXI=G/BGDE9J47AZ4O>4IQOS+`M--1C+?JUI9'RX?\`@JK\2E4D
M?#_PP?8>!?BJ,\X_Z"F>G^S^G-1_\/5OB6?^:>^&?J?`GQ5/\]47^9^GI]3?
M\.\[7_HIOC3_`,'>H_\`R93A_P`$];8<#XG>-/\`P=ZC_P#)E'_$.O&G_H\F
M(_\`!.%_^A8?]B\3V_Y*R3\G0BX_*+P%H_+T/EC_`(>K?$L=?AWX;..FWP+\
M4"#^#:TI'TP3ZBF'_@J[\3QT^&WAXCU_X0;XFCGTP=:!].<8.>.0<?57_#O6
MW_Z*=XT_\'>H_P#R91_P[UM_^BG^-/\`P=:C_P#)E'_$.?&?KXQ8B7_<.C'_
M`--\,1O\[VZ6UO+R7B>W_)5='_S"T_\`Y@/E-O\`@JY\4"O'PST%FY(5?`_Q
M)!XSR"=>4\=3Q],\9\Q\!_\`!0GQ[\/?%?QN\7:9\/K6]O?CG\3M'^*?B"VU
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M`(*N_%A<?\6HTAL_W/`_Q#.,>N?$B^IQQ7YG_MH?&W7/VD_BS\.OBWXMT&+P
M\ND^%_\`A5VH>'I/#NMZ+I6K:4VK:UXE2[AN-?O=32YO(7U2[:]M=\1MX+.S
MOX"QAD6OW<_X=XVG_13?&'_@YU3_`.3J_([_`(*(_P#!/SXL'XB>%+7PEJ7B
M/4_AM%\,DA\0^,]7U2>XCMM;USQ;KL&H>&?#MK->S7ESJMUHVFZ1<:J]G;;(
M+*YL6NYXO]%<?+\5>''BK+):]+,^/,9Q7A:];#4*F2T<,L3+%RJ57R3J4O[(
MRV/LZ$H^UE4J8I4Z4U2J3IU.5<G+F.2\1U<)5IXC.:V9TIN$981T9OGO-6E[
MN$I6]FTI)N7*OMIQV\,^!/\`P4Z\4?LYW5EX?^''QNT[XF^`[61+6+X5>/['
MQMXAT6"TA8(+3P=XF72AX@\&M'$3!8)I^I:CX4M8F6<>%+]HT:3^DC]DC]L[
MP;^U9X7EU?3_``?XO^'NO6/D0ZCH7BRP(T^\GFB9FN/"GB.*"V@\1Z;&\;(T
MT^G:)JD3-%]KT6U66)Y/PM_99_X)8WUP+*]C\-)H]L8X?.UW68/,U"53@$V\
M;*8H`68_<#N&)VD*I-?OQ\"/V4_!?P3@@GT[S;K5A&GG7<CN=SA>>&D(7G@;
M5``XP!7Z7X;<(<8\,X:%/.N)\;C,M]FZ6&R7,O8YMC,->*4;9MR1K83V=1-O
M#TYUZ%.FHTZ<Y4XQD_H\CR[,L#2Y<7CJE:E9<F'KJC6J0V=HUHO]S!1M&,*=
MW%14;)),^K001D$$'H0<@_B*6D4!0`.@]:6OUP^@/D/_`(*!?\F)?MF?]FM_
M'K_U5_B>OKE.A^O]!7R-_P`%`O\`DQ+]LS_LUOX]?^JO\3U]<IT/U_H*Z)?[
MG1_[#:__`*AX<Y8_[[6_[!,/_P"I&('T445SG4%%%%`!7F?QH_Y(_P#%3_LF
M_CO_`-135Z],KS/XT?\`)'_BI_V3?QW_`.HIJ]73_BTO^OU'_P!/43*M_`K_
M`/7BO_Z8K'%?LF_\FM?LV?\`9`O@W_ZKCPS11^R;_P`FM?LV?]D"^#?_`*KC
MPS15XC_>,1_V$8C_`-2*X4/X%#_L'H?^F*!YMXU(3]OS]F5CT'['W[<[''/'
M_"YO^">;8^H&<CV.,U]?/-;N060L1G&Y#QD%3CK@E6921R59E/RDBOS[_:$\
M%^+?'?[;W[+6D>#?B[XT^#&IP?LJ_MP7]QXF\#:#\,/$.J:A80_%O]@*UET*
MYL_BKX!^(6A0Z?<SW=O?2W-AI-GJPGTZVACU%+.6\M[CTO\`X9O^.O\`T?G^
MT+_X:_\`8V_^ACKK>'H5:.#E5S"EA9?4Z?[N>'Q=:7^\8[>6'H58*VGVDW>_
M0X?;XBG4Q,:6`JXF/M]:D,1AJ27^SX1+W:M12;>K^&RM;6Y];I+;1DE(RA.<
M[5/.0@Z8`QA%`]`H`[TADM>/W70$?<((!*L1T/!95..@*KC[HQ\D_P##-_QU
M_P"C\_VA?_#7_L;?_0QT?\,W_'7_`*/S_:%_\-?^QM_]#'6?U'!WO_;-'T^I
MYI;[OJGZC^MXVUO[)Q'_`(68&_W^T_0^LV-L6W"%`3@D^7R2``#]SKM51GT&
M.E(6A)W%`3GC*L-ORE"5(4D$J2I(QE25.03GY-_X9O\`CK_T?G^T+_X:_P#8
MV_\`H8Z/^&;_`(Z_]'Y_M"_^&O\`V-O_`*&.D\!@9)_\*^&3?VEE^8<WKS/!
M2=[:7U=FU<?US&VM_9.(VMKCL&U;T=9Q7RBOQ=_IJR\.^$]-UC7/$>G^'-$L
M/$7B=-+3Q+KUEH]E:ZSXB30[::RT1-=U2"W2]UA=&L;FXLM)&HS7`TVTN+BV
MLQ#!-)&VL/LZ8$<:@`@_<*;<8("A4Q@%0P'`W@/]X9KY/_X9O^.O_1^?[0O_
M`(:_]C;_`.ACH_X9O^.O_1^?[0O_`(:_]C;_`.ACIO`X)_%G&'G963G@<RDT
MELH\V#?*ENE&R6EE9))+%XU.ZRC$*[;:6-P<8MO2\E&M%2?F[_B[_6;O`[,3
M'N#``AU+!@#D`@JPPK<J.@P,8P,,(MF.6A1CDDDQDDE@H8DE.=P55.>J@*>.
M*^3_`/AF_P".O_1^?[0O_AK_`-C;_P"ACH_X9O\`CK_T?G^T+_X:_P#8V_\`
MH8Z/J."U_P"%?#ZVO?`9B[V]<%):];)7NVU=W&L9CEJLJQ*[6QV#C;TY:\?Q
MN_.VA]8*8!MS$O[LYCX<[2!MR/D&/E^7!R-I*]"07.T$@VO&"F`-NPX&.1CY
M<\=N?ER<=37R;_PS?\=?^C\_VA?_``U_[&W_`-#'1_PS?\=?^C\_VA?_``U_
M[&W_`-#'1]1P-N7^UL+RO1Q67YCRM/=<OU-QL^JY0^N8WIE%=.]U)8W!\R?E
M+V_-_P"3'UB3;D@M$I*XVY0_*!T`&S``Z8]``>``'K+$I#!.0"OW6X4\D*=N
M0"<$],X`.0!CY+_X9O\`CK_T?G^T+_X:_P#8V_\`H8Z/^&;OCK_T?G^T+_X:
M_P#8V_\`H8Z2P."3NLXPZ?E@<Q5NG3!1O;I?F2:3M=7!8S&K?*,1+REC<))?
M)/$.SWU5GJ];:%;QGQ^W?^S?'D%G_9'_`&WR"#D`?\+C_P""?+\G`/0$'`)W
M8_A8-7V+]KB_V_\`O@U^3/B_X%?&6/\`;._9_P!)?]M3X[W&JW7[,/[8>I6W
MBJ?X=_LG#5=(L-*^*_["]GJ&@:?I\'[.T'AZ:P\1RZSI][JM[JFD:AK5M-X8
MT:WT'4M&L+KQ%:ZY]5?\,W?'7_H_/]H7_P`-?^QM_P#0QUZ&,PF%='*^;-L/
M"V544K8/,I.26.S:TG_LLK771V>[:5TEC2Q%:%3%^PR_$5D\7[]\1A*?))83
M!72<JWO)MO562Y>J:9]>?:HO]O\`[X-'VJ+_`&_^^#7R'_PS?\=?^C\_VA?_
M``U_[&W_`-#'1_PS?\=?^C\_VA?_``U_[&W_`-#'7#]3PG_0YH?^$.9?_,9M
M]<QO_0HK_P#A9@O_`):?7GVJ+_;_`.^#1]JB_P!O_O@U\A_\,W_'7_H_/]H7
M_P`-?^QM_P#0QT?\,W_'7_H_/]H7_P`-?^QM_P#0QT?4\)_T.:'_`(0YE_\`
M,8?7,;_T**__`(68+_Y:?7GVJ+_;_P"^#1]JB_V_^^#7R'_PS?\`'7_H_/\`
M:%_\-?\`L;?_`$,='_#-_P`=?^C\_P!H7_PU_P"QM_\`0QT?4\)_T.:'_A#F
M7_S&'US&_P#0HK_^%F"_^6GUTUS&RLHWY92HRI`R1@<]J^1+UA'^WGX09N0/
MV0?B+G;D]/C3\+5X&`3R?R[4-^SA\=54L/V]/VA1M&[_`))?^QJ3\O/&?V8^
MO'%?+]Y\"?C,W[:/A;1#^VI\=VU*3]EGQYJ47B=OAS^R8-6@LHOB[\-X)]"6
MU7]G3^PI-,NYYX;Z22;2'U6&ZLH!:ZG!:S7EK<=6#PF&4\3R9OAI-Y=C>=RP
M>9)QARX=2<4\*DVHMM))RNM.SSK8G$RITY2RZO"<<9A>2G[?"3]IIBG\:K)0
MUM'5/?FV3/U=^U1?[?\`WP:/M47^W_WP:^0_^&;_`(Z_]'Y_M"_^&O\`V-O_
M`*&.C_AF_P".O_1^?[0O_AK_`-C;_P"ACKE^IX3_`*'-#_PAS+_YC-/KF-_Z
M%%?_`,+,%_\`+3Z\^U1?[?\`WP:/M47^W_WP:^0_^&;_`(Z_]'Y_M"_^&O\`
MV-O_`*&.C_AF_P".O_1^?[0O_AK_`-C;_P"ACH^IX3_H<T/_``AS+_YC#ZYC
M?^A17_\`"S!?_+3Z\^U1?[?_`'P:/M47^W_WP:^0_P#AF_XZ_P#1^?[0O_AK
M_P!C;_Z&.C_AF_XZ_P#1^?[0O_AK_P!C;_Z&.CZGA/\`H<T/_"',O_F,/KF-
M_P"A17_\+,%_\M/KS[5%_M_]\&C[5%_M_P#?!KY#_P"&;_CK_P!'Y_M"_P#A
MK_V-O_H8Z/\`AF_XZ_\`1^?[0O\`X:_]C;_Z&.CZGA/^AS0_\(<R_P#F,/KF
M-_Z%%?\`\+,%_P#+3Z\^U1?[?_?!H^U1?[?_`'P:^0_^&;_CK_T?G^T+_P"&
MO_8V_P#H8Z/^&;_CK_T?G^T+_P"&O_8V_P#H8Z/J>$_Z'-#_`,(<R_\`F,/K
MF-_Z%%?_`,+,%_\`+3Z\^U1?[?\`WP:/M47^W_WP:^0_^&;_`(Z_]'Y_M"_^
M&O\`V-O_`*&.C_AF[XZ_]'Y_M"_^&O\`V-O_`*&.CZGA/^AS0_\`"',O_F,/
MKF-_Z%%?_P`+,%_\M*7C3G]O;]FQ.,M^R!^W,1@\8/QH_P"">+@G@$'`((P2
M#C^$@U]C>?;_`-UO^^#7Y,^+_@7\98OVT_V?=(D_;4^/%SJUY^RW^V1J=KXK
MF^'G[)ZZKI&G:1\7?V#[34/#]AIT'[.T/AV?3_$DVL:??:K>ZKH^H:U:S^%]
M$@T#4]%L;GQ%::]]6_\`#-WQU_Z/S_:%_P##7_L;?_0QUW8S"89T<JYLVPT+
M9312M@\R?-%8[-[2?^RRM?6R=GO=;(QI8FK">+]AEV(K7Q;Y[XC"4^27U7!-
MI<U7WDVVM-%R]4TSZY\^W_NM_P!\&CS[?^ZW_?!KY&_X9O\`CK_T?G^T+_X:
M_P#8V_\`H8Z/^&;_`(Z_]'Y_M"_^&O\`V-O_`*&.N'ZGA/\`H<T/_"',O_F,
MV^N8W_H45_\`PLP7_P`M/KGS[?\`NM_WP://M_[K?]\&OD;_`(9O^.O_`$?G
M^T+_`.&O_8V_^ACH_P"&;_CK_P!'Y_M"_P#AK_V-O_H8Z/J>$_Z'-#_PAS+_
M`.8P^N8W_H45_P#PLP7_`,M/KGS[?^ZW_?!H\^W_`+K?]\&OD;_AF_XZ_P#1
M^?[0O_AK_P!C;_Z&.C_AF[XZ_P#1^?[0O_AK_P!C;_Z&.CZGA/\`H<T/_"',
MO_F,/KF-_P"A17_\+,%_\M*'[;DBM\&?!04'/_#8'_!/$]#T7_@H'^S,>O3H
MW`SOX.5`&:^QQ/!CYE;/?Y#_`)Z5^3G[8?P(^,>E?";PC=:G^VG\>?$]M-^U
M3^PCIL>FZK\/?V3;*UM[[6?VY?V=]'TS7DET']G/2;Z34?"NI7MKXHT:VFNY
M-(N]:T;3K;Q%INN>'9=5T+4_JE?V;_CJ0/\`C//]H7'./^+7_L:@XR3SC]F/
M&1TR,`X!QG)/4\+AY9;@+YKAH4UB<T]GRX/,I-R<\M=6[>&E+1\MDTE;6+>I
MBL5C(XS$I9;7J_N,%=_6<%3MIC[67MG?=]M=-=SZ[\^W_NM_WP://M_[K?\`
M?!KY&_X9O^.O_1^?[0O_`(:_]C;_`.ACH_X9O^.O_1^?[0O_`(:_]C;_`.AC
MKE^IX3_H<T/_``AS+_YC-OKF-_Z%%?\`\+,%_P#+3ZY\^W_NM_WP://M_P"Z
MW_?!KY&_X9O^.O\`T?G^T+_X:_\`8V_^ACH_X9O^.O\`T?G^T+_X:_\`8V_^
MACH^IX3_`*'-#_PAS+_YC#ZYC?\`H45__"S!?_+3ZY\^W_NM_P!\&CS[?^ZW
M_?!KY&_X9O\`CK_T?G^T+_X:_P#8V_\`H8Z/^&;_`(Z_]'Y_M"_^&O\`V-O_
M`*&.CZGA/^AS0_\`"',O_F,/KF-_Z%%?_P`+,%_\M/KGS[?^ZW_?!KX[_:OD
MC;QC^Q.(U8?\9D^&U/RX^]\!_P!H/!Y[#!)_0$D"K?\`PS?\=?\`H_/]H7_P
MU_[&W_T,=?*W[3'P&^,NE>*?V18KW]M+XZ:[/JO[5_A_3=,NM1^''[)L+>&[
M]O@I\=+H:_ID.E_LZ:=#=:I':VMUI<,>L+J6E16FJWMQ_9CZE%IM[8=^683"
M+&TFLWH3_=8V\?J>91O%Y;FBG[WU16M!SE?O%63;2?+C<7C'AJBEE5>$7*A>
M?UK!3Y?]KP6O*JR;]%KV/U>C:.,`O\P**!@$G(5,G'!QD'&?RJ3S[?\`NM_W
MP:^08_V=?CK+@?\`#>?[0PPH(7_A5_[&VU5*@A1G]F1FPN[`R2<#KZR_\,W_
M`!U_Z/S_`&A?_#7_`+&W_P!#'7FT\'A7!.6<8=2;DY*."S.RDYR<TKX66U1U
M%NUII[O*WW5L5BHU)1AEE>K%-VG]9P=.]Y3;7(ZUU9Z>>Y]<^?;_`-UO^^#1
MY]O_`'6_[X-?(W_#-_QU_P"C\_VA?_#7_L;?_0QT?\,W_'7_`*/S_:%_\-?^
MQM_]#'5_4\)_T.:'_A#F7_S&9_7,;_T**_\`X68+_P"6GUSY]O\`W6_[X-'G
MV_\`=;_O@U\C?\,W_'7_`*/S_:%_\-?^QM_]#'1_PS?\=?\`H_/]H7_PU_[&
MW_T,='U/"?\`0YH?^$.9?_,8?7,;_P!"BO\`^%F"_P#EI]<-+`X(52#C.2I`
MXY/7V''O7Q_^S,\:?&?_`(*%^8"0W[8/@E@`,X_XU_\`[#&,XX]>F1^8S,W[
M.'QU0;O^&]/VAQCKM^&'[&P//'!_X9C!'7J".,U\L_L]_`7XR:G\6OVZ+2R_
M;1^.NBW.A_M4^$-,U;4[/X=?LG7-WXNOY?V'OV--7CU_68=2_9UO;"PU*VTS
M5=-\*PVWANST31VT/PQHL]SIMQXAEUS7=9[\)A,.L'G"CFV&=-X7+?:2>#S%
M2BEG=)II/#)N]548^[!M*4F_=YG$GBL3:A)Y;B%/VN(2I+$8-II81V;J>W2C
MS-R5K-KEULI)GZP^?;_W6_[X-8NL:-H6O)#%JMA#>Q02++''<0+*JR+N`8+(
MK*&`9@&&&VO(FX))(K?,'_#-_P`=?^C\_P!H7_PU_P"QM_\`0QT?\,W_`!U_
MZ/S_`&A?_#7_`+&W_P!#'7!]3P?_`$.*#]<#F3_/!A]<QO\`T**__A9@O_EI
M]8VJ:?90I!;6R011C:L<4(1`.P```Z`=N.@XJV+J(#`#X'`^0U\A_P##-_QU
M_P"C\_VA?_#7_L;?_0QT?\,W_'7_`*/S_:%_\-?^QM_]#'1]3PG_`$.:'_A#
MF7_S&'US&_\`0HK_`/A9@O\`Y:?7GVJ+_;_[X-'VJ+_;_P"^#7R'_P`,W_'7
M_H_/]H7_`,-?^QM_]#'1_P`,W_'7_H_/]H7_`,-?^QM_]#'1]3PG_0YH?^$.
M9?\`S&'US&_]"BO_`.%F"_\`EH_]O^>.3]A3]LQ5W9_X9:^/9^92.!\,/$^>
MOUKZY\](_E;=GKP">H'7W_,>AK\HOVWO@%\9]$_8S_:QUC4_VUOCKXHTW2_V
M;_C9?:AX9U?X;?LF6NE>(;&V^''B.:[T/4[K0/V==%UZUL-5MTDL;NZT36-*
MU>VAG>?3=1L[V."XC^H3^SE\=Y"2?V]?VAR,G`;X8?L;'D\DY_X9C/7@=NG.
M>*Z)X3"_4Z*6;X:WU[$7D\'F7-;ZEA]H_55L]/A=T^EKF<<3B/K%:?\`9V(5
M7ZK07L/;X1IKZU72?M?;<JO%N5K.W+R[L^O/M47^W_WP:/M47^W_`-\&OD/_
M`(9O^.O_`$?G^T+_`.&O_8V_^ACH_P"&;_CK_P!'Y_M"_P#AK_V-O_H8ZY_J
M>$_Z'-#_`,(<R_\`F,T^N8W_`*%%?_PLP7_RT^O/M47^W_WP:/M47^W_`-\&
MOD/_`(9O^.O_`$?G^T+_`.&O_8V_^ACH_P"&;_CK_P!'Y_M"_P#AK_V-O_H8
MZ/J>$_Z'-#_PAS+_`.8P^N8W_H45_P#PLP7_`,M/KS[5%_M_]\&O-OC+.DGP
MA^*JKNS_`,*V\>'E2.!X4U;_`!'0&O#/^&;_`(Z_]'Y_M"_^&O\`V-O_`*&.
MN`^+'[/'QPLOA;\2[J?]NG]H"^@@^'OC:2:QG^&7['L=O>1)X8U1Y+6XDM?V
M:;:Z2&95*2&VN;>;:2(YHV(=:IX3"*I2:S>C-JK1:@L'F$7+]]1TYI82,5ZR
MDEIOJB*F+QCI55+*J\(NC73E];P<N5>PKZ\L:MWT5EKK?H?0?[)O_)K7[-O?
M_BP7P;Y'3_DG'AJBD_9-W?\`#+7[-FYBQ_X4#\&@6(4$G_A7'AHEB%"J"Q.2
M%50#T`&`"N3$?[QB?+%8E)]TL3B+/YK6VZN=]#_=\/T_V?#Z=O\`9Z&GRV/.
M/&?_`"?]^S)_V:!^W1_ZNC_@GG7V37QMXS_Y/^_9D_[-`_;H_P#5T?\`!/.O
MLFKK?!@_^P.G_P"I&.(H?%B?^OZ_]1\*%%1K*C.8QDLI8-\IPI7:=I;&-Q5E
M8#.2I#=",J\BIC.3G)X&>%&2?H.![9R<*&(YSH!V90Q5=[!<A00"QSC`+%5'
MXD<]Z^:O@=^US\"?VBKR;3_A9XMUG4+]/"ND>/-/L/%WPS^*GPIO_%'P^UZ9
M[;1_B-X%LOBQX,\$W7Q`^'5_=JEK#X]\"Q>)?!ZW-S8VTNN)/J-@EQ]+$$\C
MKE>OH&!;N.2/RXZ]*_"[4O\`@FI\06_8L^#'A"\UGX@>+_C?X6^'_P"SYX-^
M)G@_5?&OPE\4VD?PN\!G2-9^(GP!^$.G?%KX;>._V>;?P_<>,+#1_%L-C\2O
M`/B32_BG=?#SP)X*^(WCJW\/Z-X6\4>"^O"4<)752.*Q4L+.=:E1H2]YP@N2
MI.=:JHQD^2\%3E;>52FE;WK<>)JXFDXNA15:,8U)U$W:6CIJ,8*S4G9R:3MM
M+75'[?:EK%AH^GZAJVJW=O8:9I5C<ZEJ5]<MY5M9Z?8P275Y>3R.0$MX+:*6
M=Y&X$<<C<A&Q#H7B+1O$VB:+XCT#4K/5]"\1Z3INNZ%JEC();/5-'U>T@O\`
M3-2M)N!+:WUG<07-O(!^\BE1A]X"OQ]^%/\`P3LTF6&QLOBK\*M'\3Z%I/[)
MOBSX6_#V#X\P_!/XCZO\._&GC[XP_'/Q5>:*WA?X4^`O!WP:\/:9X6\#_$/1
M/"?AZS^%WP^TKPMX$\"-??"[P=J.H:#%J=WKGFVH_LB?M":1^SM?_#;X:?LN
M>`?"M[\6O^"?B?LG>)O!&E^/OAEX2\-_"WXE^$O$_P`4];\0>-=2;P]:7&E>
M*O#OQANOB=XC\8^';OPQ;-KM]XTFM(OBCIG@O_A*_$7BOPAU?4<#)<M/,XNI
M*5.,IU%2H4J:E1G-\JJ3OS0DE&I:4TY<L4DY1YL/KF*3YYX.:A9VA35:K-R4
MHQ;DX4K*+<TXW2Y4I*\N25OW>,Z!<ET4G;@,"&^;.`4)#@G#'E0,*S9V@D<M
M;>,K.Z\9:OX*33O$4-YHWACP]XLN-;NO"OB&W\&76G^)-1\2Z79Z?I7CB:PC
M\)ZMXDT^?PK?W/B+PMINKW7B'PUI.I>%]9UW3;#3/%OARZU+\@_&O[&7C;6?
M'?[9DL7P`N=1^'OQQMY]6UO5TU[]FNY^./C[Q?%\:?`'BWPU:?"_XB^*/"EY
M!XN^#4'A?1/$7B3QA\"?VW]*\;^"K368?#OP(\'27/[/%WJGARSP=3_8F^+W
MB+X;^)M'^)7P/\+WNF:Q^SY^R%X!M?AO\`G^!'ABSLM1^!W[1?[4GQ)A\/Q?
M#3XMZ7KW[.VM6OAWP?\`$;X7R^/_`(?^(=-?X,:[KNH>-HOAE):IX<\&O!,,
M#@_W;EF4>24::<G%<U-U(T:BFX1D^>49^UHU8.<%&*C*\W-*"EC,7=J.#J+E
M<FDTVY\E65-W;22IS@E4C9.33^S9M_N0C%LYQQ@\`C@Y`R"<CH>N#[4^O'O@
M!H'C+PI\$O@_X6^(6B_#_P`->./#?PN\"Z#XN\-_"C3Y])^&/A[Q'HWAS3=.
MU;0_AYI=PSRZ;X)TF[MY-/\`#.GL<6>D6UK;H?+1`OL#':"QR0H)(`))P,\`
M<D^@')/`KSII1G4BI1FH5*D(S@[PJ1A.4%4B[*\9\KDM%HT[*]EZ46Y0A-QY
M7.$9N+T<>9)\K5W9K9J[U6[%HJ'ST/0N1ZJA8`C)(;"L4*J,D/M."H`+'%2(
MP=0PS@^O!&#@@CL01@CJ#P0#Q4)MMKEDK=7:S]-;_@4?&?C/_D^W]G+_`+-)
M_;?_`/5R_P#!/BOLZOC'QG_R?;^SE_V:3^V__P"KE_X)\5]B7L\EM9W=S%;7
M%Y+;VT\\=I:"$W5U)#$TB6UL+B6"W-Q.RB*$3SPPF1U$DT2;G7OQG\+*[;_V
M30M=I*_UW-NK:2]6TENVDFUPX1VECWKIC&]$V],)A'HEJWIHEJW9+5HM45^6
M/P\_X**ZCK/P3\&_M'_$OPA\)O!7P:U/XE>'_`OQ7USPE\<=6\<:]^S+!XK\
M.SK:6O[0WAG7O@O\.KOP!\0?!'Q2O_!'PR^+W@2[G8_#P>,X_%NI:W)HV@ZD
M)+.G?\%#/%MA\2/#/@#XD?`&^^'4/C;]FKP_\<-`U/5/&TUQJNC_`!`^(5U^
MT;XA^%GP$\?>'9/`>G-X2\6^)_A1^SAXO\0ZUK@U+5-.\/?$:TU#X6P6.L7C
M^&-;\56LIS!N7+AU)0=>,IJM14'+#<KKTZ4I2C[>K2C4HSG1HJ57V=>E4BIP
MFF/^T<&MZSB_=NI4JL7%3<U"4KQ:C"<J52,9.2CS0E%N+B[?J+17QCXD_:MO
M=._9X^#WQ;\/>#=*U_XB?'%?@!HW@KX7W7C5='TFT\:_']O#*Z79>*?'$/A?
M6M1TCPCX3MM>O=<\0>)+;P)J.M77A_0+U]!\'ZKK=[INC7/C>G?MI_'7Q3XH
MO_@WX)^`'@#4_P!H[P1>_&B/XI^!=<^/.J:'\+]&T[X0VWP5U/3;CP1\5++X
M%:_X@\6ZK\4=`_:&^%FM>%=,USX7^";/1/-\:Z?XJU?3KSPQID7B?.CEV,KQ
MG.G1BH4IU56E5K4:/LJ=&?LZF(J*K*,HX>%9QHNK9I5)PO:,E,53,<)2G&$J
MJYYJ#A&"=1RE4INM"FG!22J.A&=?E=OW4).]URGZ945^7OPR_P""ATOQ6^*O
MPG\-:-X;^&W@WX7_`!B\$_!CQQX$\5_%?XE^-/!7Q)\=Z?\`&?X16'Q9T33/
MAUX+L_@=X@^%GB[Q-9PZHOAZ;PTOQYTW7KV]T/Q'<V>DK#I]K_:GM7Q:^/GQ
M`\*^'?VF6\-ZW\-M$\6_"."2_P#ASIWB[PWJOB(>,+;2?@MX:^)GB'3[O1-,
M^(7@S4M:OK/4-:F$E_X?U"PMM%T$6[ZCIU[+OU%RIEV,HUXX:O1]C7E"$W3J
M3A[BEB(X62G.+E34J6(<J=:/,Y4W3J.22C8<,PPLZ+KPG*5-2E&ZIS<G*-"6
M(LH6Y[NG%J-XQYY.*C=24G]JR?ZN3_<;_P!!-?'US_R?IX0_[-!^(G_JY_A=
M7UAIT>K1:9;Q:W>6%_JD=E$E_>Z7IUQI%A=7JPXNKBRTRZU36[C3[2:7+V]G
M/J^I3VT9\J6^NF7S6^3[G_D_3PA_V:#\1/\`U<_PNI8'^)B_^Q7C_P#TW0-<
M1M0_[#,+_P"[1]B4445QG0>/?$KX[?"_X1>*?A1X/^(7B^Q\+Z[\;_&)^'OP
MPM+[3]<N8_$WC46$^IQZ&=0TW3;S2]%DN[:#[/877B*]TBQU#5[G3M"L;JYU
MO5=,T^[+3X[_``OOOC9JG[.UIXLL[CXQ:)\/K+XIZMX-BT[7&FT_P+J&LQ^'
MK76+C6_[-_X1H79UF:T@G\.)K+^)K6RU31M9N](@T?6-,OKSYH_;5_9D\8_M
M*:W\(M.\.7EMH%AX:T;XW&7QR;FW&I_#GQYK/@2UD^"OQ`T739&6YU34_!'Q
M8T3POXOLHK821P7V@6DM[%+:EXV^,-<_8R_:K\=Z/J7Q$\4Z#X(L_C+\:?@G
M\4=<_:%\+V'C^YL?"FN>.?&?QR_93\31?LP)XOTZWFUA?`^K?LQ_`JZ_9DOO
MB+8:7<Z>+"VN/$]_IER=9-A/ZU#"9;4PU*I4QZHXB4*L9T:E2BDL1/$Q^KSL
MUSK#1PD*WME)J2Q$L.HOV4Y2CYE;$9A3Q$H0PL*E#GC*%2+DI.@L-)5H-7M[
M;ZRZ<J3BI)TO:MQYH*+_`&^%U!A2UQ`"RAA\ZX*DD;@2_P!TD$`^H(Z@@*9U
M4,6*@C/R]6RJ-(4V@EB_EJ7V`%MH+8V\U^-?@W]@JW\4^+?!\OCK]F'X2>!O
MV;+O]J+QI\6H_P!E'4X/AYXB\#_#CP7=?L?M\%XY-;^'_AY=1^$4NJ>.OB]8
MW'CW4?`W@0>)/"6GW6K6'Q`U*]N/B!J'BB?3?+HOV%?CW=>&_A5H7B[X1>"O
M'GQ,L?V?OV0?AW\._P!H7Q!XZT:^\4?L5^-O@7=WEQ\3M<\,W]_Y_C$W.K(^
MG^)O"VL?".YU34/BOXP@;P/\8+WPWX`TS1O$ZQ]0P4DG_:U.BI).?M(T5[)S
M51OWI5%3DL,H.==QD^:/LU0]I*I%$?7\7",F\OJU$N=QE3=6I*4:;@HR<(P5
M2+Q#E:C>+=XU?:^S4-?VF^(7Q0\+?#'2M&UOQ9?266F:[XZ^''PYT^XM=.OM
M5,GBKXL>.=`^'/@>REATZ.>6V@U/Q9XIT.SN-0F5;'3K6YDU&_GM[*"6=.^2
M?*J6>$ONV,%;`61OF1#N;(9D*,HR2X(9,HRL?QVT_P#9$^(UIJ'B*VA_9O\`
MAG8?$8_M>?#7XN^+_P!JJ/Q7X.F\>?'+X;:9^WGX)_:)L=.N[I-(M_B!J$/@
M'X/Z4VB:EX<^(.J:98^"O$'@O0/`'P?T_P`<>"I;#Q!I?B,/_!/_`.--U\.O
M&_A&/X*>!/!OC^3]EWXW?!;XS?%_2?'.AIX@_;K^+/Q&\<?#76O#?QB\3:MH
M[VGB17M8?!OCKQS>ZW\7[O3/&?PR\8_%"_\`!'PM:\\+W'B'Q'J.U/+<%.=.
MF\TP].4JCC.K.K0J484Y5</&G6G&G.4J=.4*LIN$?:5X13=2$.62&\=BN:7+
M@JTX\WNITJ]%KW;\KE.%I)-7E4?+&UXQO)P3_?8W42AB9(QM"EB6`"J\C1*6
M)(VY='09ZLC+P5-<)X:^)WA?Q1XV^(/P[TV\EE\6_"YO"*^,[$V%]!;:<?&^
MCS:]X>%OJ$\26>HM<Z;`\LZV4TS63[$NA&TD:O\`D3\</V#?&%UH'Q0^%WPI
M^!'PG/P#\6_M7Z?\3/#GPYT#P9^S#<Q>&?"5U^R;\-?!4WB+X>>#OVA_A3\6
M_@3\/[?4_C]HGBFX^+$\GPFU[QW=>$M=\7>+?`6DZEXM\1W2:U]:?L,_`GXQ
M_!Y?$MY\8(;9]:USX+?L=^$KO5D\2IXFO=7\9?"3X%V'@SXF7&H7[SW-]=RQ
M^,([Q(=7OYYI==B8:BDTP=I7RJ8+!4Z%6NLQHUJKI1EA\/3J0C4YIRP$Y1JT
M;.3G1I5ZT)I-1C4IS<9SA9O2GBL7/$0HRPKIPNO;55=TERTJ_-[&;LY1G4]B
MUS0B^5M-)I<WZ#T445Y9Z)\6^-?^3]/V;?\`LT']N;_U=?\`P3PK[2K\J/VT
M_P!HKPO^RY^UG^R/\0_%NFW>J:=XI^"/[8'PJL;:UOK+35BUWQ5\0?V+/%.G
M7-]J&I,+.QT\P^`[W3S/*=HU'4-,CD,5O)/<0VO^'HO@/_HG]_\`^'$^'W_R
M77R'%?BCP'PSBLLRK/N(<-EF8TLDP=2IA:V%S2K.,*V+SBK2DY8+*L?2M.FU
M)?O8NS2LVGR_/2SK*LLQ6.PV-QL*-=8I5'#V.)J>Y4PF$E"7-2P]2+4DGM)[
M-/70_4VBORR_X>B^`_\`HG]__P"'$^'W_P`F4?\`#T7P'_T3^_\`_#B?#[_Y
M,KY?_B./A5_T6."_\(,__P#H;'_K5P__`-#*'_A-C?\`YD/U-HK\LO\`AZ+X
M#_Z)_?\`_AQ/A]_\F4?\/1?`?_1/[_\`\.)\/O\`Y,H_XCCX5?\`18X+_P`(
M,_\`_H;#_6KA_P#Z&4/_``FQO_S(?J;17Y9?\/1?`?\`T3^__P##B?#[_P"3
M*/\`AZ+X#_Z)_?\`_AQ/A]_\F4?\1Q\*O^BQP7_A!G__`-#8?ZU</_\`0RA_
MX38W_P"9#W[]M_\`Y(QX)_[/!_X)X?\`KP3]F>OLU/NC\?YFOQ%^/O[=G@_X
MQ>!M!\):9X3.BW&D?&O]FCXJRW>H^/O!-Q;R6'P'_:2^$_QRU?28X[2],RWW
MB#2/AYJ&AZ7,VZWM]5U"REO?*LEN)4]N7_@J)X#`_P"2?7XY/!^(OP^)P"<$
MXO,9(P<#.,X[5TR\=/"=9?@</_KE@74HXC,YS7U#/[*->I@?9O\`Y)N_O?5Z
MCU2TLU=.ZQ7%&0K$UYO,:?+.C@U%JABY)N$<6Y*\<-)7C[:">NC;70_4ZBOR
MR_X>B^`_^B?W_P#X<3X??_)E'_#T7P'_`-$_O_\`PXGP^_\`DRN;_B./A5_T
M6."_\(,__P#H;-O]:N'_`/H90_\`";&__,A^IM%?EE_P]%\!_P#1/[__`,.)
M\/O_`),H_P"'HO@/_HG]_P#^'$^'W_R91_Q''PJ_Z+'!?^$&?_\`T-A_K5P_
M_P!#*'_A-C?_`)D/U-HK\LO^'HO@/_HG]_\`^'$^'W_R91_P]%\!_P#1/[\_
M7XB?#_'XXO,X^G-"\</"IM+_`%QP.K2_W'/ENTMWPXDM]VTENVDFT?ZU</\`
M_0RA_P"$V-_^9#]3:^-OVM/^1Q_8G_[/'\._^J&_:"K4_9L_:LT/]I*[\:6F
MA>'KC07\&6_ARYNFF\2>&_$"W2^(I=<BA4+H<LSV?DG1)<F[Q]I\T"V),$^/
MF#]I/]H71]>_:3^`GP<73(;35/A#^U)\,O$FHZG=>)O#T/\`;D/B?X<>)_!L
M5AIVD-.=4AOHKSXN:7=QPW$"&]M=*O$MG6:[L=_UV`\2N!:&`R?B6MQ)@H9%
MG>,Q.3Y5F7LL?.EC<RQ&%S7+Z6%I4J>`EBHREC:E/#<]3#TZ7/.,O:.G[YIC
M,UR^IEM/%4\3&>'QN(PV&PM10J)5J\L5AVJ<5*G&49+V-1/GC!)Q:NNOZD6W
M7_MFG_H$=7*^7_VCOVD]"_9MTOPEJ>M:#/KB^*[_`%'3($M_$&@Z$;=],LK:
M[>1I==EBCN1*DRJ$M@73&]P%85T'PT^/&G?$GX'S?&^RT:?3]+33/&>J+I#Z
MOI.HR&+P9?ZWI]RBZQ8,^E,;R71)G27S/+M%E"76V2&4"Z?%O#\L]S#A=9A#
M^WLKP-3-\PR[V&-]IA<MDGB8XJ5;Z@L'5BX5HQ]G0Q]:NIJ2=!6L>C_:."GB
M\1@HXB+Q>&I.O7H<M13IT7SS51MP4)1<=?<G-]&D]%]`45\0?L[_`+:GAO\`
M:'\>W'@;1?#%WHMQ:^%-1\627DGBSPGKR-;Z=J6AZ:]HUEHLDMY'YDFN(ZW9
M/D1&V,<K;[B`/C_'C]NOPO\``;XA:Q\/]:\)W>LW>D:;I6IO>Q>,?!^B+/%J
MNG_;H8TT_5YH[V,H"(?,DRLKJ\L>(1D>54\3."*7#U+BIY]1?#];,GE$,R6$
MS1T_[14JT%AO8QRJOB^9U*,Z?M%A/8QEK.O&.KYWG64K!QS#Z]2^I2JNA'$*
M%?D=92Y?9<OL?:<[::7N<KM\5['WN3@$GH.37,Z9XO\`#.MZEX@T;1?$>@ZM
MJ_A'4+;2_%NDZ;JEE?ZGX8U&]L+;5;.P\0V%M<O=Z+=WFEWMGJ5K!J$,$ESI
M]U;7L*/;3Q2OY3\?OCGIWP&^'MOX_P!6TB;6;&YUC2-%-G%JVDZ)(DNL1S21
M3&^UATL0(5MW#1%C++G]T#@X_EK^.'Q/\5ZK^V?\2OV@?!?B/6/A</B3_P`(
MYJ_@_P`3^%/'%A_;'AZ?PQX*\.^&]8T37]2T&Z^QOIVH/H`OKS1]9BN=!U*T
MDMI9K:]CLM36V\3CSQ;X=X&K87!UZD<?F=7ZKBL1D]&5:ECXY1BXU/9YCAI3
MPZPM62G3M'"5,31KUE>FH0J3II\>:\0X+*I0I3;K8ANG4GA8*I&O]5FF_;T7
M[-TJC5M*?M(N:4HW4FK_`-A+N&B)!5LXP5.1P1GGV_SWKX^_9A_Y+1_P4-_[
M/"\%?^L`?L+U^5GP+_X+"Z_X0>T\+_M-6_ASQ]I"$01?%'X77?AFS\5Q0H@'
MVGQ3\/5U*WT?79&<O=7NI^"[GP_)%:(D-AX(O9HI+J[_`$>_8?\`B'X,^*GC
M7]N;XA?#_P`06OBCP=XO_:O\':KX>UZSCN8;;5+.V_81_8FT:\EBAO;:TNHI
M;+6M*U;1M1M9[>&YTW6=)U32+Z"VU/3;^TM_M^">.^&.,\HSFMD>94ZU=8/*
MW7R^O&>$S'#N.=X*K4]I@\1&%24*:E%2J476I\STFTG;KPF:X#,EAI82NIRY
MJLITI1=.M3OA6VITYI25DTFUS13?Q:H^_:***]\]0****`"BBB@#Y#_X*!?\
MF)?MF?\`9K?QZ_\`57^)Z^N4Z'Z_T%?(W_!0+_DQ+]LS_LUOX]?^JO\`$]?7
M*=#]?Z"NB7^YT?\`L-K_`/J'ASEC_OM;_L$P_P#ZD8@?1117.=04444`%>9_
M&C_DC_Q4_P"R;^.__44U>O3*\S^-'_)'_BI_V3?QW_ZBFKU=/^+2_P"OU'_T
M]1,JW\"O_P!>*_\`Z8K'%?LF_P#)K7[-G_9`O@W_`.JX\,T4?LF_\FM?LV?]
MD"^#?_JN/#-%7B/]XQ'_`&$8C_U(KA0_@4/^P>A_Z8H'F_C/_D_[]F3_`+-`
M_;H_]71_P3SK[(;H><<'GTXZU\;^,R!^W]^S)DX_XQ`_;G//''_"Z/\`@GGS
M7V,60]64CCN/7COZT8EI4L(FTF\%"UY*/_+_`!RTNU]Y%!I3Q.J_WA=NF'PM
M^I^4'BW]H+5O@I\3_P!KKX]>*-0T@_#KX7?M>_LY_L]?%B_U2#5I]0\(_LX:
MM^RG\(O%GA>_\*K9:C96.GZCHG[3?[59\7>*=>U/3]=TU_AO<>,M/N[6UN;#
M3==\->#Z]^U9^T_\8?AO:^$]1M_A]\*_C'\*/BY^Q+X9^--GIT/CB33O#OQN
M^)/_``4+^'G@KPIX75;7QQ9:Q_P@&K?!+PFWQ`\9>!;[4)M8\:>%?C)X(L%\
M6:%I5[?QZG^NH^"/P^_X3#XJ^+;S3H]8A^-&F^!K'X@^#];M-*UKP1K5]X"M
M-5TK3O$<_A^^TZ9)_$&K:!=Z'X;U^[O;J[M+W1/`W@BWMM/L;G1Y[N_[)O`W
M@N:XU>ZD\+^&9+K7]?T'Q7KUS+X?TDW.M^*O"\6B0>&?$^K7!M?.U+Q'X<A\
M,>&X?#^MWKW&I:)%X?T6/3;BV32M/%MZU#-\KP\*<IY;0Q&(I2I2A7J2I.DN
M2G3I.G.@WR5;Q>(O*4)<U26'J-?N9NIYM;+\;7<TL?.A0G[12IQOSOFK>U4X
MUHU8SAHHP48V48RKQ3Y9P5/\I+W]LK]HA5C^'E[\1_V6_AA\0?"&G_MI:WXT
M^+GQ.\$>/A\)/&MG^R9\3O!7@JPT[PGX'A^.GAW7/`CZ]X;\<V/C'XDZQJ7Q
M/^(\GP^L](D32/#7BRT\0G4/#-OPY^W/\9?&'B3PSXJAB^$O@3PE)\7_`-D#
MX,^)/V:/%>E>*KW]I'4+W]J;X9?!#X@:OXNT;QI#X]T+2]"M?A4?C9J=Q=>&
M+OX&>(V\0>%_@?\`$?5;SQAX:%S,O@W].]=^$GPK\4V=MIWBCX=_#_Q)IUGX
ML/CVST_7?!WAO5K&T\=&:YG/C6UM-0TZY@MO%S37EW,_B6!(]9::YN)?MHDG
ME9[ES\/O`]UXUT[XCWGA3PE>_$#2M(E\/:7XZN_#&B3^-=,\/S23RW&AZ=XK
MDLVUVSTBYFO+V:XTRUOH;&66\N7^SJ9I=_/+,LEE&:AE=+G<)\MI4+J3BDTY
MRE&<X3G*HXPG*V&;3PWQ2Y-5@L8E"/\`:=104W*5^>+E%.,J<'4C*4VX^SA3
M;E=5+SE4NWK^'^I?ML?&3Q[\'M/U/QEXC^`?CC3OBO\`!*^^+EMX:^$4GQ9\
M#>(/@]K?PS_:=_9\^$]SX>\>>,/"O[0`\2ZS_P`)K-\3==DABT./X2R^%?$_
MPX\4>"M5B^)FA76OM:^WZW^VG^TAX'LO&GQ+\3)\$->^&H\5?\%&/!'@3P=I
M7ASQ]X<\8Z5JO[%^K?&V^\'>(_&WCV^^(GB;1-:TOQ=HOP8U+0?&.@:%\.M$
MN--O=3T[Q/H>OP1?:O"5M^@OPH_9C^#/P=\!VWP_\+^$/#]_I[:/X8T7Q'KG
MB+PYX6OO%'CV#P86_P"$5NOB!JEEH.F1>++_`,/JQ31;K4[.0Z2H!TY;5R[/
MO_$3X%_#/XG_``^\8?#7Q'H-A;^'?&FA_$+1=2G\/6]MX>US3V^*>G:SIWCO
M6M`UG3[>.[T7Q%XEA\0ZU-K.LVI%UJ]SJ5Y-JYOUOM02\[ZF:\.NI.G')Z53
M#RQDIJLW"E+ZI*M4DX1P]/$*%*I5INA><9RFW149N\JCGST<#F,*<?:X^K4J
MJA!/FJ.I%8B-&4>?VE7WY0=67-R."CHFDVE;YE_82^.OQ?\`VAO!GQ%\=_$C
MQ=\)/%GAJQ^)4'A+X8:U\*O"-IX*N-2\/:9X'\):AXHU/QKH>D_M+_M.V.E:
MLGC_`%SQ+X<TW2+CQ3H>H?\`"/\`AG3O%+Z9<:7XMT/4Z^=_#G[9WQO\5_#[
MX+^*8OBW^RAX?\0_M3_$/P3X9\(>&+_P=XQU*?\`9(TOQ#H7QO\`%5W8?M`-
M%^T3IMY\4O&#:M\*(OV>;.STJS_9ZTV']H:ZU#0V.I+;1>%E^_?@;^SIX?\`
M@G/XYUS_`(3GQO\`$WQ[\2;[0+OQK\1OB%;_``ZTWQ#K-MX1T>30?".D)X?^
M$?P_^%7PUTC2_#6ESWD%DNA>`M+U"^EO;B\US4-6O/*GC[FZ^"WPAN[+QMIU
MQ\,/AK<:=\3=035?B7IL_@/PK<:?\1M3B:.2+4O'EI-IDD/B[48I(89([[7U
MO[M)(HV292IW>9/&90\7C91P].>'Q-6'L*<88:$:%*%'$4O8\M24J;Y:M6%1
MSBJ4:LJ%YQC[6\.F&&QKH8:,\7.->C%*I/VM>7M)*I3G=>^K1<82ARU'4M&H
MUS2Y?>_*/7?^"C?Q'\(_!CXY^.O$FL?`JW\0_#']DS]KCXG^"/$)M]?TCP'\
M6_BK^S-\=OB1\$-#U_PI8:E\0I+J\^&_Q'N?#_P\UH>!='\4Z[KVD:G\1='\
M.:=\3/$*:AH7B#6,_P"(W[8_QU\??%[]K#X,>%/%OPCT?X;_``F^&7[5%KXG
MTFSTN2U^,VD6?P^^%)M/!_BCP]XZ3]I'3O$QUW5OB%JUU=:C:_\`#,6GV'AC
M1O#\K6GC*\L]5\#^.?%7Z[:W\)OA9XETWPWHWB/X<_#[7M(\':?=Z5X3TO6?
M!GAK5-.\,:5?:(_AF^TSPY8WVFW%KH6GWWAJ27P]>66EQ6MK=:%++I,\,M@[
M6Y^>])_8H^&6F_%B3XG:EXN\?^*M,A\;_$?XG^'OA/XH_P"%?:G\./"WQ(^+
MWAWQ/X3^(WBRQOXOA_:?%KQ&OB#P[XZ\=:+!X/\`B)\5/&_P\\.Z5XJGTOPO
MX/T73O#W@NT\,>C1S+(83J3>5TX5N3F@G["O14U5A-^S@ZD%3=3DUB^>%)S?
ML8^R4H5.*>7YK[2DHYC*I2CRJK%5\13JN*H2IN\VY*34I<\>7E;4??O-Q</A
MCQ%\7_C=;_!CQCX;^*&L>!/$OCKX$?#W_@G-^U?\-?%WPYT'Q;X4O9HOB?\`
M&3Q9X9E^%/B9O%7CGQYJ7C#5[Y?@?XH\+:]\0[*Y\$Q?$#PM\6;_`$9_`?A*
MZT^ZU#5?VSC&U`N2V"XR>N`[`9X'0<9Q@]1P:\;\??`_X?\`Q&M-$LM9L([&
MTTCQ9\(O%<\>A6VE:9+K_P#PHOQK#\2/A;X9UZ\&F37\_@[PIX\MK;Q38:!8
MW.G0QZA'<VZ31Z5K/B#3M7]BBVI&B-(K,J@,V0-Q[G!9B,G)QDXKQ\5C<-BE
M2=.E3P]2,\3.I&,8TX_O5AX**BJC@HN5%UHP5U3<YJ+CSR3];"T:M!RC4JRJ
MQ5.C3A*<Y2E)0<W>3E)MSBI*G*;]ZK92;LDCXV\9_P#)]O[.7_9I/[;_`/ZN
M7_@GQ7U_JMK/?:9J%E:W]UI5S>65S:V^J6*6$E]IL\\+Q1:A9)JMAJNEO>6<
MC+<VJZEI>I:>9XXQ>6%Y;^9;R?('C,_\9W?LXCN?V2?VW\#N?^+R_P#!/CH.
M_KQVYZ<U]F;T_O+_`-]#_&KQLX>RROWX?\BJA]J'_0;FW>3\MUVTL]8PGQ8Z
M]M<8UKL_]DP:[K3H[/N?`EU^PG9>)/!W[36D?$SXQ^+_`(@^.?VJ_AMX0^$W
MQ!^),GA3X<>#[ZS\'?#^S\9V_@V/2?"_@WPKH_AJYUK3[CXA^+[W4?$6O6NK
MZOJB7NDZ+]IL_#?ACPUHVD]Q\;_V//!7QVN/CM=^(_%?BS1KWXW_``@^#?PL
MBU+PW-IUCJ?PVUCX!_$3XQ?%3X7_`!5\#WLUA=&/QUX7\<_%S^WK2+6DU;P[
M-<^"O#T%YI%S87FO6.I?8>]/[R_]]#_&C<G]Y/S';I^59QS#$0G&I#%.-2GK
M3<9THJ$K4(IQBM$DL+ATTE:2I14E)))4L%A>25-TH.E--3CS3O.\JLUS/VFO
MO5Z[=[W<]U96^(=<_83^#5WX`\/>'O"^F:5\/?BCX2TKX(VNA?M'>$/!?P_M
M/C2VJ_L_'P:_PZU/Q#X@O?"E_!XMTV%/`VB:3K7A3Q';7V@:IX6:]\-00:9;
MFQNK'ES^P=<65[:^,_"'[1_Q9\&_&S5)OBX/B;\;-,T#X2ZCXE^)%E\:W^'(
M\4VESX8UWX?:EX%\.2>$-/\`@_\`"K0OA%?Z-X>6Y\%Z!X$TW3_$!\=S:OXI
MO-<_0;<G7<N?7(_QHW)_>7\Q_C5T\TQE*,HQQL[5'4=1.I"49JM-5:M.49.2
MEAYU4JCPTN;#\\82=%RA!Q)X+"3:?L:4;0A3CR7A)<D/9QGS0E!^T5+]VJG\
M10<XJ:C.:E\8']CJR1OA)X/M_BQXXL_V=?@D_P`%]0\`_LZVFD^`(?#=CJW[
M/T'AUOA7!>_$`>$6^)NI>&/#_B'PAX8\<RZ/<>)1JVI^,-&MXM1\2W'@.>]\
M!77UV=#T>74=-UN?2].EUK2K#4M-T[5GL[=]0L+'6Y],NM:L[*\9&GMK75;K
M1M)N-0@AD6*\FTRPDG61K6$IJ;T_O+_WT/\`&C>G]Y?^^A_C7/5Q4Z\E.M7]
MI->V;E*<.:4L15E7KU)R3YZE6M5G*=:I4G.=64I2J2G*4I2VI4J=+GY(QC[2
M4)22<FKTX*G!14YR4(0@DH0BHQCK9*XDG^KD_P!QO_037Q]<_P#)^GA#_LT'
MXB?^KG^%U?7\C*8W`9<[&[CT/O7Q_=$#]O3PAGC_`(Q!^(IYX_YK/\+AW]^/
MK6^!G#VF+]^/_(KQ_P!J/_/NA_>\U]Y&(:M0U7^^87JO^HKS/L6BF[T_O+_W
MT/\`&C>G]Y?^^A_C7'SP_GA_X''_`.2.BZ[K[U_F9^JWD&GV%]J%S((K:PLK
MF]N92DTHCM[2&2XF<QV\<UQ($BC=MEO%).V-L2/(54_AG\)_^"A?[27Q3L?%
MFD:2OPGAU^^\5?L(7?PM\>>(_ADN@>'[[X;_`+:?Q!^(OA>T\1ZY\)OA]^V-
M\=?$3'2_"'@"S\<^#[#QQ\2?@O\`$'6SXEBT#QM\)_AS##9^*M=_=ERCJR[P
M,J1N5@&&?[K`A@?0J0PZJ0<$>:Z#\'/A'X6BD@\+?#3X=^&;:;4[#6Y[;P_X
M)\+Z+!/K6E:OJ'B#2]8FBTW3+:.75=,U_5M4US3-2=&O;#6-2U#4K6>*]OKN
M:;MP>.R_#JJL7AJ>+E)0=&,ZD?9TY0E?GE%-<SW7)SI-/WHR2./&8>OB?9*C
MBY8:$5-5.3FYY\\7'W9PFN2W>S>]I1N[_E]H'Q\_:5\<?%GX1:9XB^*OPCT3
M04\$_P#!1GP9\3/!>E?#;Q=I5A\6?%O[*'[1G@3X16_B7P3J%S\?XM?^'^K>
M)?#5U;ZWX=TJ.Z\?W/PY:7XA0W>I>-TU?0==\#>#?`#]I_XL^&+C0?$NE?$'
MX52>&O$&F_\`!*CP[X@^"'BW5?BCXP^)6N6O[3WP[^$/PZU*Z^$WBKQ?\9]1
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M3K?7ZDY0J*HN:K7Y>:+HI:1JJT?94G%P:<)3G*<HOFJ<_P"0TO\`P41^-NC^
M!E^*&H:A\`O$>E_$;X"?'GXQ>%/`&@Z/XTTCQ+^S1=_"GXG_``Q^'5K;?M&>
M*9_B5KUMXR\/>$Y_B1<6OQMOM*\%_!6X\&>*_`7B/0]+AU"PN[S5O#/.-^T1
M\1OAS\0?B/XK\5>*/"?[2/B'P%^VIX_TAQ\(M0^*G@CPEJO_``KO_@CEXO\`
MC%-X-\$?#[3_`(Q_$?2=(U^_\4^%9M"U?P5XSU'XO>&;?Q%K.L^/=.\*:7\2
MX_#VL^$/VIT[X:?#K1-0\9ZSHO@?P3H^L?$65)OB!JNE>$]`L=2\=31V\MFD
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M_P#@I/\`$%OB5-X*C\`^&O$&EZQ+^T3\.?$7C_X;^*/&NM_#[X/^+O%/PM3P
MIXU_9'X=>*+'QQX(\(^-M*U.UUK2?&/A7PUXITO5["RU33+#4]/\0Z+9ZO::
MC8Z9K:IK&F65_;WD=W:Z=JZ+JME#,EMJ`6YC=$X9_P!G?X`2Z%J'A5_@E\'G
M\*:OXFC\;:QX8?X7>!CH&K^-8E"1^,=4T=M".G7WBE(QY:Z_-:MJJ(65+I05
M">U*R\DE02<GD>@]37GXW%8"NU+"X.A@DJM:2C"5-_NJG+RPG*5:I4E.,H)N
M:DHM72@N9L]'#4:]!)5:_MU[.,6Y_$JD6_?B^?12B^5Q<6[^]SO1$E%-WI_>
M7_OH?XT;T_O+_P!]#_&N#GA_/#_P./\`\D=5UW7WK_,_,;]KOX/>'OCC^UC^
MS3X+\0Z1I^K/I?[,7[:OC3PR-2@%Q#I?B[2OB=^POX;L=92!W^SSRV^A^+_$
M=LL-U%-$XU`2*J3P02Q_/TG_``3M^(TCN89_A\L88A=W@OPVQ*Y)4Y_LZ/)"
MD*3@EB"Q.37W5XT_Y/T_9MQU_P"&0?VYOKG_`(77_P`$\#_+GZ<]*^S]T?JG
MYK7G9]PKPIFL\KQF8Y#DF.QM3)<)"MB\5@Z56O55+&9W"FIR6,HJU.G.,(KD
MORI7;O&WEPP>`Q=7&5<1@L-5JK%\KJUJ;J2E&&$PD8I7K4XQC'6RC&UV[ZGX
MA_\`#NKXE_\`/S\//_")\-__`"%1_P`.ZOB7_P`_/P\_\(GPW_\`(5?MYF/U
M3\UHS'ZI^:UX/^HG!'_1+\.?^&ZG_P#/(T_LG*O^A=@?_"=?_-1^(?\`P[J^
M)?\`S\_#S_PB?#?_`,A4?\.ZOB7_`,_/P\_\(GPW_P#(5?MYF/U3\UHS'ZI^
M:T?ZB<$?]$OPY_X;J?\`\\@_LG*O^A=@?_"=?_-1^(?_``[J^)?_`#\_#S_P
MB?#?_P`A4?\`#NKXEC_EY^'G_A$^&O\`Y"K]O,Q^J?FM&8_5/S6C_43@C_HE
M^'/_``W4_P#YY!_9.5?]"[`_^$Z_^:C^=OX^_L9_%?X7>`M%\2Z?>?#>&]U/
MXW_LN?#M6F\!>&+B.;3OC-^U'\&O@WK]N8I=,D17E\.>/=86WNODEL;DQ7L$
ML<]O$X]H_P"'=GQ*;)%Q\/0`=HSX*\-YPN`"<V6<D<L>[$GG.3]W_MOD?\*8
M\%>W[8'_``3P]L?\;!/V9NOX8X/(&.U?92-%M'S)WXRH/4]CS77/@#@5Y?@J
M\>$^&X3JU\RISY<MC=QP\\NC2YF\SD[PA4E%;+63M=N_-3RG*X8C$4G@<#**
MIX6<%+#TU:55XZ52RC7@K2E&+V;7*DG9)+\1O^'=7Q+_`.?GX>?^$3X;_P#D
M*C_AW5\2_P#GY^'G_A$^&_\`Y"K]O,Q^J?FM&8_5/S6N3_43@C_HE^'/_#=3
M_P#GD=/]DY5_T+L#_P"$Z_\`FH_$/_AW5\2_^?GX>?\`A$^&_P#Y"H_X=U?$
MO_GY^'G_`(1/AO\`^0J_;S,?JGYK1F/U3\UH_P!1."/^B7X<_P##=3_^>0?V
M3E7_`$+L#_X3K_YJ/Q#_`.'=7Q+_`.?GX>?^$3X;_P#D*C_AW7\2QS]I^'O'
MIX)\-Y_](O\`&OV\S'ZI^:T9C]4_-:?^HG!'_1+\./R_LZGKY:9E?7;37736
MP?V3E/\`T+L#\J%G\FL5=/S6JW6J1\%_LA?L]^)/V>KWXBR^)%T6Y_X2^U\'
M160\,^'],THK_8$OBN2Y^W'3HK;S@W]M0_9C,66/]_M(\PAOE/\`:D^"WQ%T
M?]K/X`_&'PX_A5=%^)G[7?P;T+4=/U'PGX>NO$5YX=\-_"_Q-XJU6T@UF^LY
M[G3]0FU+X66HL-4CN8KJRA:&*&XAA+!?VAW)_>7CIR./UKXV_:S*GQC^Q/@@
MG_ALCPX.,$Y/P&_:"QT_'%>]E_#'#=98#*JV4996RS!5,1C,)ETZ<GA<-B*&
M%S'&4JN&A'&QJ4:M.O1ISHUHU:E2G.,+0DKJ48[#82&`]E'#T(TL/4H5:%-K
MW*-7ZW@TJM.\DU-<\M9N5W.7-S.6O.?M5?!+QG^T5HW@O3=*T33=$?PMJNJZ
MC-)XHL-!\0Q7":C8VUHB6D<WVO[-,C6Y,KXC+(40LQ&%ZSX3?#+Q7\./V?/^
M%*W/AN"]O/['\>:4=3TJ/1=.T)F\8:MXBU*"7^R%>%8XK>/6XTOHE@(N)8[A
M]LHE!?ZUM\#K@`QIUP`?E3U_&K>Y/[R?F*R63Y-]=JYK'`8&&:8G#K!XO,73
MC+%XO"T[TE3JS=>,/9U*<$G[*E2YJ<DE*6E1]KPN&CB*V)5*E[>M%TJM5ZSE
M"+G%4V[W4+:2BK7>ME)N1^9G[+W[+/CS]G[XB7WC?4]/\.ZU!=>"M5\++:^&
M=%T#0+]+C4=8\-:F+B6[B@M#)9JFA2I+:^8`\T]L[(XM$:/"_:0_9!\?_'/X
MFZ[X]TVQ\+:3;:OHVDZ8MEXBT#P_K>HI)INFBP=Y;^6"[9H'RWDQB5BD3%%\
MM&9#^J&Y/[R_F/\`&DW1_P!Y/S6N5\,<+O`PRIY)E#RFGB98R.6.AS86.+E4
ME5GB81>,<X59SG-2:GR\LYQ4%S-O'^S\#]76%^J8:.'53VJH1C+V2J7;]IRS
MG-\]VW=-)/5).S7R%^TI\-O%7QW^&<?@*P\-PZ5-'K^B:Q]K\1IHFMZ:T6E+
M=+)%]A9[E&N)!<`0S&(&+YVW+]T_R>_M<?LS_'"]^//Q.^&XMWL/"/AR_P#"
MWA;4/$]EI$6B^')+2;POX?\`%-UH6A0Z;:0V-Y<WNH:M;RZ\;99I3+;BSNG2
M#;:V_P#;_N3^\GYBO+_&7PE\$^/-6TO5O$^G6^ISZ3AK-+@"2.-]Q+/M.5^8
M8##(SC)ZG/C<3\"9%Q3/!UL9[*AB</6H.MCL-3HQQ^)P>&A45'`^WE6G3ITX
MSG&4:OU:K5IJ*E2<:JC-<V8Y1A,Q=*<U&E5I3@_;T[NO*G332I*4I2A&*;;7
M+!6>K3EJOY6/V6?^"75YJLEG>6GA223+1O)XA\068**R&-A/:V4XQ&5QYB,Z
ML58*P`PN/V^_X)Z_!]OA1XY_;BT!]:NM0DT7]IWP#I+Q[ECM=Z?L&_L3WF8X
M(ML:B$WK6D0V+BVAB("ERJ_I#I^D:9HUHEKIEM:V<$2+&D5M%'$NT'@87DX!
M/<YY)KY1_9B('QI_X*&Y('_&87@KJ<=?V`/V%\=:^MX<X>X?R'+LWIY1@,)A
M)4\'@$\1^[J8ZO&IG&"I5%B<7.4J]>_(ZCDY0TWIQ4>9[4,#A,%+#.A3C&HY
MUXRJOE=2HI82SYYM<S;Y$[*2BM>6"NV_LFBF[T_O+_WT/\:-Z?WE_P"^A_C7
M7SP_GA_X''_Y([[KNOO7^8ZBF[T_O+_WT/\`&C>G]Y?^^A_C1SP_GA_X''_Y
M(+KNOO7^8ZBF[T_O+_WT/\:-Z?WE_P"^A_C1SP_GA_X''_Y(+KNOO7^9\B_\
M%`O^3$OVS/\`LUOX]?\`JK_$]?7*=#]?Z"OD7_@H"RG]A/\`;,`92?\`AEOX
M]="/^B7^)_>OKA'3!&Y<YSR1T(&#]#V/3K73*4?J5%\T;?7L1KS1M_N>'Z\U
MOQ.:+7UVMJO]TP_5?]!&(\R6BF[T_O+_`-]#_&C>G]Y?^^A_C7-SP_GA_P"!
MQ_\`DCINNZ^]?YCJ*;O3^\O_`'T/\:-Z?WE_[Z'^-'/#^>'_`(''_P"2"Z[K
M[U_F.KS/XT?\D?\`BI_V3?QW_P"HIJ]>E;T_O+_WT/\`&O-/C0RGX0?%3#*?
M^+;^.^A!_P"94U>M*4HNK12E%MUJ-DI1;?[ZCLE)M_),SK->QKZK^!7ZK_GQ
M6\SB_P!DW_DUK]FS_L@7P;_]5QX9HH_9-_Y-:_9L_P"R!?!O_P!5QX:_P-%:
M8C3$8A/1_6,1H]'_`+QB.CLPH?P*'_8/A_\`TQ0/*OC[X'_:-7]H+X'?&WX"
M>`/@[\1D\#?!S]HWX4>+=`^+7QL\8_!-+=OB]XV_9@\6>'M:T/5?"'P"^/DF
MMK9Q_!#7[/5+"]TG0?L[:CID]M>7H>X@BA_X33_@HA_T:M^QC_XGQ\;/_I;U
M?;;,$5F8X55+$^@`R3^`%,$@)P59?7<,8ST[\CD#(R`3@D'BM%BDH4X5,+AJ
MWLH>SC.JL5S\OM*M1)NAC<-#1UI+X&^7EN[)WS^KRC*I*GB:])59J<H4_8\O
M-[.G3;7/0J2U5*+WW;MNCXG_`.$T_P""B'_1JW[&/_B?'QL_^EO4?\)I_P`%
M$/\`HU;]C'_Q/CXV?_2WJ^UC,N2`DAP<<+D'G&0<X`SG.2"`I)`49I'N$1=S
M!^02`%W,<#)``/)`R?H#Z4+%4I)-8#`M/9I9AKZ?\*OZ>>VHW3JI-O'8JRM?
M7#:7=E?_`&;3737J?%7_``FG_!1#_HU;]C'_`,3X^-G_`-+>I?\`A-?^"B/_
M`$:M^QC_`.)\?&S_`.EO5]KB4'=\K#:VT\=_4$$@C'.0?4?>#`(957J&'S*N
M2/XF(4#KW8A1ZL0HR2`3ZS2O;ZA@;ZZ6Q]]+7T_M;S7WZ7UL_95KNV-Q>B3>
MN'T3V=_JMM;=WZ'Q1_PFG_!1#_HU;]C'_P`3X^-G_P!+>H_X33_@HA_T:M^Q
MC_XGQ\;/_I;U?:RSHTC1[9`456+,A5?FS@#/.[@DC'`P3U&22XCB0N^[:`3P
MN?NC<>>@`&222``"20`30L32>V`P/3[.8+?;?-42Z=5)MX[%66[OAM/6V%=O
MN/BG_A-/^"B'_1JW[&/_`(GQ\;/_`*6]1_PFG_!1#_HU;]C'_P`3X^-G_P!+
M>K[4-R@QE).20/DZD-MX!().<@C&5(PP!9`T@D!`)##.>"!GC/'!//'3MWQ@
MT+$TGM@,#M?;,-KM?]#9=4_/R*]C6V^NXNZ\\-Y?]0WFOO/B?_A-?^"B(Z?L
MK?L8C_N_CXV?_2WJ/^$T_P""B'_1JW[&/_B?'QL_^EO5]J?:8\N/F.S(;&TX
MQC(X8G//W<;N#QP:<TZ*5!#9=E50!G)+`<<\[<[FQDA06QA3@>)I+?`8)?\`
M;N8__/7^O347LJK=ECL4WVYL*_\`W7_X/D?%/_":?\%$/^C5OV,?_$^/C9_]
M+>H_X33_`(*(?]&K?L8_^)\?&S_Z6]7VN)06*A7('\87Y#\H;(;.""#@'IN!
M7.X8IQD7&<$\D'`R1@XR?;WH^LTKI?4,#=[*V8:Z7_Z&W;T'[&M_T&XO[\-_
M\S'YD:UH7_!1#5OCU\,_C6?V<?V.8!\/?A!\<?A8/#B?MR?&:=-3'QC\:?L\
M^+#K3ZR__!/6VEL'T%?@6UC#ID>CZC'JW_"2R7$^IZ.-'B@U;U[_`(33_@HA
M_P!&J_L8_P#B?'QL_P#I;M?:JW$;;P`^4.U@5*G(Y(`;!88P0PRK*0RD@@U)
MO`SPW'7BJGCJ4E!2P.`_=4W332S"_)&M4?O6S9W<:E6<;[]-;-DJA42E)8W%
MVD^:3YL._><8ZZX;2\5%V2MUW9\3?\)I_P`%$/\`HU;]C'_Q/CXV?_2WJ/\`
MA-/^"B'_`$:M^QC_`.)\?&S_`.EO5]KO*J+N(<@#)VKDX'7CN1Z+DGHH)P*2
M2>.,9;..I(QP.Y//11U/3TS4+%T6F_J&!LKZ\N8].BOFJN_))M[)-Z#]G5O;
MZ]BKV3M?#;/9_P"[;,^*?^$T_P""B'_1JW[&/_B?'QL_^EO4?\)I_P`%$/\`
MHU;]C'_Q/CXV?_2WJ^V?,'HPZ'D8ZY]^V,$'D&D,JJ"QR`.IQTSP.GJ>`.YI
M_6J*CS?4,#RVO>V8>7_4V;ZK2UT]&D[I/V-=?\QN+^_#?_,Q\3_\)I_P40_Z
M-6_8Q_\`$^/C9_\`2WJ/^$T_X*(?]&K?L8_^)\?&S_Z6]7VLDZ.0`'!)(PRE
M6&%W?,IPRC&1DJ,,-IP2`9"P'KWZ>U+ZU1O;ZC@;ZO59@MM7OFJ6BWU$Z59;
MXW%Z>>&?Y85GQ+_PFO\`P41&2/V5OV,L@'&/V^/C9G/8#/\`P3>`YZ<G'KQ7
MD=QH?_!0Z;X\:/\`&G_AF_\`8Z632_A%XE^%9\/_`/#<WQG>VGBU_P`9^$_&
M"ZR=9;_@GFES#<6LGAN2P.F?V'/!<17BW?\`:UO);_9+C].**UAC8T^?EP&`
M7M*52C*\<>_<J>SYK?\`"OH_W:L];7?E:98>I/EYL;BWR3A4BN;#JTH>TY6[
M875?O'=/1\L>SO\`$?\`PFG_``40_P"C5OV,?_$^/C9_]+>H_P"$T_X*(?\`
M1JW[&/\`XGQ\;/\`Z6]7VY14?6:7_0!@?NQ__P`]BO95O^@W%_?AO_F4^(_^
M$T_X*(?]&K?L8_\`B?'QL_\`I;U'_":?\%$/^C5OV,?_`!/CXV?_`$MZOMRB
MCZS2_P"@#`_=C_\`Y[![*M_T&XO[\-_\RGQ'_P`)I_P40_Z-6_8Q_P#$^/C9
M_P#2WJ/^$T_X*(?]&K?L8_\`B?'QL_\`I;U?;E%'UFE_T`8'[L?_`//8/95O
M^@W%_?AO_F4^(_\`A-/^"B'_`$:M^QC_`.)\?&S_`.EO4?\`":?\%$/^C5OV
M,?\`Q/CXV?\`TMZOMRBCZS2_Z`,#]V/_`/GL'LJW_0;B_OPW_P`RGQ'_`,)I
M_P`%$/\`HU;]C'_Q/CXV?_2WJ/\`A-/^"B'_`$:M^QC_`.)\?&S_`.EO5]N4
M4?6:7_0!@?NQ_P#\]@]E6_Z#<7]^&_\`F4^(_P#A-/\`@HA_T:M^QC_XGQ\;
M/_I;U'_":?\`!1#_`*-6_8Q_\3X^-G_TMZOMRBCZS2_Z`,#]V/\`_GL'LJW_
M`$&XO[\-_P#,I^8>MZ#_`,%$-7^/OPR^-I_9Q_8Z@'P]^#OQT^%(\-Q_MQ_&
M:>/5!\9?&_[.GB\ZW)K+_P#!/:VEL)-`'P'-C#ID>CZC'JW_``DLEQ/JFC#1
MHH-7]@_X33_@HA_T:K^QC_XGQ\;/_I;M?;E%5+&0FJ:E@,!^[IJE%VQ]^15*
ME1)_\*^K3JS2>]K7N]6E0JJ]L;BUS-REKAW>323>N%TT2T6G7=L^(_\`A-/^
M"B'_`$:M^QC_`.)\?&S_`.EO4?\`":?\%$/^C5OV,?\`Q/CXV?\`TMZOMRBI
M^LTO^@#`_=C_`/Y[#]E6_P"@W%_?AO\`YE/B/_A-/^"B'_1JW[&/_B?'QL_^
MEO4?\)I_P40_Z-6_8Q_\3X^-G_TMZOMRBCZS2_Z`,#]V/_\`GL'LJW_0;B_O
MPW_S*?$?_":?\%$/^C5OV,?_`!/CXV?_`$MZC_A-/^"B'_1JW[&/_B?'QL_^
MEO5]N44?6:7_`$`8'[L?_P#/8/95O^@W%_?AO_F4_,+XX>'_`/@HA\8_!FB^
M$3^SC^QQX?\`[&^,/[.OQ474(OVY?C1K'V@?`C]H/X8?'$Z*;27_`()Z:.(8
M_$O_``KI?#LNJ?:9IM&BU236(M+UF6PCT;4?8?\`A-/^"B`&!^RO^QGQZ_M\
M?&W!]1_RC?.1SC)&3[=:^W**T>.BZ5.B\!@'"G*K."Y<PNI5_8NH[_VOU="#
MV5M>^B6'FISJ+&8OGFH1D^:AM3=7D5OJUO=5:26]THWUNW\1_P#":?\`!1#_
M`*-6_8Q_\3X^-G_TMZC_`(33_@HA_P!&K?L8_P#B?'QL_P#I;U?;E%9_6:7_
M`$`8'[L?_P#/8?LJW_0;B_OPW_S*?$?_``FG_!1#_HU;]C'_`,3X^-G_`-+>
MH_X33_@HA_T:M^QC_P")\?&S_P"EO5]N44?6:7_0!@?NQ_\`\]@]E6_Z#<7]
M^&_^93XC_P"$T_X*(?\`1JW[&/\`XGQ\;/\`Z6]1_P`)I_P40_Z-6_8Q_P#$
M^/C9_P#2WJ^V/-4$@Y&#CM^G-'FKZ-_WR:S^NX;_`*!,M[?%C=UNO^1QNNJZ
M#5&L]L;B_G]77YX57^5SXG_X33_@HA_T:M^QC_XGQ\;/_I;U>._%?P]_P4/^
M)FL_!/5F_9P_8XTC_A3_`,9-.^+*V\'[<WQGU#^WI-.\`?$/P5'HDTTO_!/'
M3CI,$C^.AJ,FIPPZM,ITU;)=,*WKWUC^G7FKZ-_WR:/-7T;_`+Y-:T,THX>K
M&M2PN6*<%-1;>,DOWE*M1E=/.+/W*]1:]6NVL5<)4K0E3J8S%RA)P<ES897Y
M*E.HE=8:Z]ZE"]M;75U>Z^)AXS_X*'J-J_LK_L9[5^50W[?'QLR5'0D#_@F^
MP!]?F.#D#(YI?^$T_P""B'_1JW[&/_B?'QL_^EO5]L>8I[-^6/Y_Y].]+YB^
M_ICCKZ=>IJ%BZ#U6!P#4GHU_:#BVK)VE_:[5[K;FO=NR;T+=*M=MXW%;Z^]A
MGK)MJ_\`LSMO97MHEKNW\3?\)I_P40_Z-6_8Q_\`$^/C9_\`2WJ/^$T_X*(?
M]&K?L8_^)\?&S_Z6]7VR)`>Q_3^AHWCT/Z?XT?6Z&WU++_OQW_SX#V-;_H-Q
M?WX9_EAFOQ/B;_A-/^"B'_1JW[&/_B?'QL_^EO4?\)I_P40_Z-6_8Q_\3X^-
MG_TMZOM9YTC&Y@Y&0"57=MS@`M@\`D@9YQD$X7)$NX8!/&>.>O\`GWZ#O3^M
M4KV^H8"]K_\`,?MWO_:UK+KKIU%[*MH_KN+U_P"P?\OJM_O2/B,^-/\`@H@>
M/^&5OV,AGC(_;X^-@.#[_P##M[./7'->/_#+0?\`@HC\/O&O[1'BT_LX_L<:
MJ?CM\8]$^*OV"3]N+XSZ?%X:&C_L_?`SX&?V)#>I_P`$]]3DUZ.X'P73Q,-5
MFL-`EAE\13Z'_9,D.BP:[KOZ<O(J+N/(RJ_+@D;F"@D9Z9(R>BC+'`!(<KAN
MS`XS@@9'L<$C//K51QU)*I".!R]JJH1EICV[4Y^W23_M=I.Z3EN^5):=5["K
M*49/&XMNFYR6N'23G3]FVU]55[1;:OI=MN]DE\2_\)I_P40_Z-6_8Q_\3X^-
MG_TMZC_A-/\`@HA_T:M^QC_XGQ\;/_I;U?;9(&,]\_I3!*I!/.!WXQGTSGJ.
MX.#4/%T5_P`P&!ZWM',96M;1\N:RL]5H[-WT3Z5[&MM]=Q5][7PU_N^K7?R3
M/B?_`(33_@HA_P!&K?L8_P#B?'QL_P#I;U'_``FG_!1#_HU;]C'_`,3X^-G_
M`-+>K[7,R#.<\=?N_CSNP,>I('O1YJ;=W.W`.>,`'OG...^,_J*;Q5**3>`P
M2NKKW<Q;:O%:16:N3UE&]HNUTW9:A[&M_P!!N,]7]72[:-X1)_)O[M3XH_X3
M3_@HA_T:M^QC_P")\?&S_P"EO4?\)I_P40_Z-6_8Q_\`$^/C9_\`2WJ^V#*H
M!)R,`D@X!P!GG)&/J<`=R!S2"9"0,-DC.,#@8SD\X_(GJ*%B:3VR_!.U_L9B
MEHTGJ\T2W:V;[ZJ[1[&O>WUW&?)8=[^:PC2^_P#S/S,_:`T3_@H?\;?@3\:/
M@T?V;?V./#W_``MGX5^/_AL-?MOVY?C-K,VB'QOX6U3PW_:\>D7'_!//0H-4
M;31J1O5TV76=)COV@6S?4]/68WL'KI\:_P#!1$G/_#*_[&>#\V#^WS\;>"W4
M8/\`P3?(!&.0I*CD*2*^UVD"@$JYW':`JY).TL.,]#C&>F2,X&2!9%8\9Q@$
M$XVD'I@@G/X5H\=#V2HO`X!4XU9U%=8]6J5*=.#LWFZ5^2DK)7ZWOHE"P]15
M)5/KN+YY4X4W[V'LHPJRFI**PUDW*HXMV=X\NBMS'Q/_`,)I_P`%$/\`HU;]
MC'_Q/CXV?_2WJ/\`A-/^"B'_`$:M^QC_`.)\?&S_`.EO5]LEP/7\,?XTUY51
M2[!@HZG&<>_';U/0#DX`)&:Q5%NRP.`;[)XY_EG#*]E6W^NXO_RW_P#F4^*/
M^$T_X*(?]&K?L8_^)\?&S_Z6]1_PFG_!1#_HU;]C'_Q/CXV?_2WJ^V!(&S\K
M#'7<-OH>02"#@@X(&<X'(("F0#L?T_J>U#Q-)7;P&!T5W_O[LN[2S9M+U71]
MG8]E6U_VW%Z:?\PZU]7A4NG1O\K_`!-_PFG_``40_P"C5OV,?_$^/C9_]+>K
MF?&FK_\`!1'Q3X0\5>%_^&7/V-[7_A)O#6O>'3=P?MY?&BXELQK>E7>FF[6W
MF_X)SV<=P;?[3YHA:YA$FW;O7.X??_F*>><'('3G'XT@E4XX;)QQCD9&1GG`
MX]^XI+&T(RBU@LOYHRA-)?79.\9PG!V>:U$TW&+LX233VMJIG0J2A*,L;BU&
M<94W?ZNM)PE%K7"I_#)_.VM]'Y;\"O!>L_#CX*_"#X>^(GT^77_`7PL^'O@O
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M&Z7KWB#6_#W@;6M`ECMIK'0-*\1_''C7X:_MQ^+OV?O$?@OQC<_$OQMJ?CSX
M-?&W0-7\-:)!\%O!6OZ?\8/$GPG^&/AKP9I&IZMXA^+/C?PWXD^#VN>*?^%Y
MWNMRPZOI-I8Z[XE\-VN@^"M/\&Z+X5FTK['^)W[5U[\,_B;XC\`2?#^\\7O;
MQ>&H_#2Z%J>E:5<S75S\)OCC\8?%#Z]>Z_J%K:6]I#X<^"]WI/AL:7;7TM]X
MGUS3;35SI.AMJ7B/1>;T;]LN]F\0>*;35?A[&_AA/BVG@SP?XBTG7HI#!X`L
M_P!ECP-^U!KOCWQSI]W;1WUI<6OASQ)J&G:=X>\+6OB'5-1UJ?0]'>UL],BU
M;QA%Z5*GF5.%.K#`T*E+V="M3G6<9737)&%):\F[E4A#E<9*3ES.2:\ZJ\(Y
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M:_#V7Q3H$WAFVUCQ)XD\.^`O'.ALH\3Q:#>OH*>!?%7C'4=<\76]E-X/L/%_
MPB\7_#+1_$/B+QMXO^#&F_$^OHW[>.C^)7\!V'A[X3^+M3U[XK>&OAG\0/AS
MI;Z]X0LK?4OAO\8OA?\`M!?%?X?^)?$.K7.I"W\/:E>Z%^S3\0M.UOPY;PZY
M+HNL7OA2.'4M5T[4]5U'01TLQJQBJ.6T8S5--3I4E)WPM2*J5HU'5;E*#ER5
MI/W>><5*$G"/*H?4U*4GCZ]1)N=2,ZE2,(QK1:A345&/+'2,X:<R2=I6JN_E
M7P_^&G[4G_"1>#(K[PCI?PL\,WDOPU\&^--2^$>C?"_X=W4OPQ\,>-/VW=1U
M.".SC\3>._%7A*/4M-\1_L\ZYJO@_P`->+M;M_!>N^-=8_X5IJ&C:@/',.C8
MNM6'[</C/1M/\,^)?AWK%S+=_L\1^'_'<_B'Q=\$/$OA3QM\4G^'7P7URWU&
MW^'MXMMX>T2\TWXHS_%7PM?W$/V_2K^XL-3U&]G7PQJ?PNM-#^O[CXZ>(?'&
MO?`GPW\)+?0M._X79\&?&7Q_L?$7C_2-3U&&R\%>$Y?@W:6OAEO#6A^(]"N$
M\2^(+GXV:!-<:NOB&YTWPK:Z)J2S:3K\^IZ<(^-O/VT](2_T;3].^&?BO4I/
M'6O7FB_"Z1=:\+6T7B^+1/CKX=_9\\4:UJ[2ZF6\'Z7H'C+Q?X7\0-%>IJ6N
M:GX%U@7VG:+-XQT[5_`M@X2QG.[9=AJE2'M%*E.+E.BU+$4Y2FN=/G4L-B)6
MG.?+*C*5HV7,5:.&M%2S#$TDY4WS*3C3K.]*T8M1:Y7*<(M)1O[7E;E=V\J^
M,'PB_:)G_:9\?^/_`(9Z=K9\(?&#P5\,/V>?%>K0^.-'T:S\)_#N_'C/6/%O
MQL\/:;=:ZNH+XW^#-Q)J&C^&=+TS1[;4?$FH_%QK\RW^G^%YYM+\T\"_#K]N
M?P+\-_"OA;PWJ>L^#W^'O[-7@/P;X,\(6UM\/O$VG7&KZ'^S5;>'-7\+:MXX
M\2_%>XT[3_BMH_Q[B;Q#IGBS4_AIXR\/ZKI6D>$=+N_%DWA#Q#\19-%^G-+_
M`&T])U;6M&\-P?#7Q+;:]XW\5^,O!WPPL[_6O#44'C'5?AY\6O$7P@\;7FHW
M]KJ-]!X/T;1]2\.S>+[.34EN]=U[P3=;M)\/3^-K&^\#Q/T/]M+1_$F@^*?$
MFE>!9M)TWPK9>';&YG\>^.O`_@N'4?B'KUC<7UQ\--*GGU74H[W6_#SZ5K>F
MZEJMF;S1-4U.UTUO"5UXDT.^U37_``]<I9G&C"E++J3A3C0IQ<Z$7SV4*5&4
M_>E>3YG0YHI7DYQ=JBE-1R8#GJ3688BG4K.M5475<.1SA[:MR)J\8PBHUFI-
MN$7!J\)*!\XZ-\,OVC/"_B/Q'XG\,>"?'EGI6N^/?B'?ZK>ZGK7P4NOC/>?#
MGQ)\7/V4S<:+I'C*VUYY[#5=6^%O@WXGV\*/XAL_$,FE^';.]\1ZLWQFB\-^
M)[CI_B#X<_:?^('Q!L/#L/P_\>P?"?3Y/A3J=W=>-/B7\)];G\2:OX"^/7['
M'Q`T/Q$WAW3+RRF\+:YX9\,:5^T1#XF@T>]U&#7=3\,7=S=3ZU<ZM\+[$[[?
MMZ6O_"/^(_BGK/A_^QO@KHGBRTNM&UFRL&UWQAXJ^&[?L`7G[:^JC4]$NO$/
MAFQ\#^*-/T^.*VM[IKSQ?I]Z\<7AB;1;(Z@WCO2^\\2_MN67A'6/%WAK7_A)
MXNC\1?#71OBGXI^*%MI^N^$[W3/"?A/X0^%?V>_'_B?4],U274[.;Q7?W7@C
M]I+P1J6C:/8Z;9/=:QI/BG1+N[L8K+3-8U?.4\<ZG.L!AY5/9^S:;<HPY(TX
M.=N9<U2-HI]*<WRM+F5Q0PD(*/UVO"#K7U7+S3J3E)1YG%OEJ.3<+OWEJFU%
MVQOB!X'^,MGXO_:B\6>%?`MQXL^+OB'2M2O_`-D3XLW<O@35_#7PEMHOV=-$
M\*Z3X,GMO%7BK2-:\.7$OQPTCXB>)-?LK'PU?^&O%-A\2_##:UK^JVMGK>G>
M!N6TGPK^V3::IX=NO^$J^(VJ:)H]S\.K^TL=3C^''AB=K74?VG=)/Q#\/>+]
M,G^(7Q.U;Q'-X:_9SN_$ECINLW7CB=]5T.XL+WRY/B[H^C:Q8?2OQ/\`VD=&
M^%VM?$VPU+PKKFKZ1\%/@G#\>?BGK>F7FAPOHW@W58OBS_PC=KH.EZIJ&GR>
M(=:UB^^"_C*PN(KFZT'3=),V@7DVIW-I>ZD^C?/?C3]KSQE8_$C3O`6D>#]$
MT#6]#\=Z+\/_`(FZ+KXO?$K:=X@UCXU?L$Z%:3>%/$.A:MHT&I:7J/P8_;!F
MUU9I](6XLO&L6F6US:3VGA_5]/\`$<X2&+Q$7"CA*57]RZLJE11GRTJ--*_-
M)_NERZ1C"W-.:T<IIKKK?5HRYIUZ\;-QY(Z*,IR<KRY4HSFY0:YY<TO=Y5HI
M)\/\,_AM^UWX.N/A;X5MM9\>>'/!7@W14CU,:E)X<^(]WX@\4V?Q6\?S>/X_
M$NO:O\9]'NK#PKX]^&<G@*V^&FIIX?\`'EYX8:X\1:D_AOPCXUTV#3-9]\DT
M;X\Z3\`?@'I-Y?\`Q#\4^.1=?#>X_:*?3_$?@VU^+.IV6H>&;VZ^(4/AO6DN
M_#W@>PO4^(LVBC5X/!U[X?M++X?P>*+3X:_9-0C\-V\GG6N_MS7%UXK\-Z)\
M//!FD>+[6'QQKVC^+K?2?%WA'Q%'J_@\?LY_$KXY>%=9\)^,=.\46OA6RUFZ
MG^'SZ#J^G3#Q+8Q:C)':VM^_A[4%\?:5U^H?MW>#HM)L_$VB^`/&7B/POXHU
M'5?#_P`/=2LKGPWIU]XT\5:%XJ\!^$-7T)]'UW6-,G\*(FJ^/2FFZOXEN+.R
MO!X,\6_VDNAK>>`9/'&N(HYE4G1J/+:,54K<\8QI1IR<IQKP5*:34DY^TGB*
M4)WTI1J*WLU!<L)Y=2A4BL;5<?9JFJDIR<?W<Z,G*#LX2E!48T:BA;6;4O>J
M<S\L\5>"OVJ_&>K0Z9K.C>-=5T-/B;H.M^(;;Q%XB^%1\(ZCX.\(_M'?`/QQ
M\)Y_"FG:-K-O=67CCPG\-/#OC:\^),HM-+TC5?%">.["WG\6PO\`"![7Q[XB
M_"G]KW4_@WJGP*\%_"_Q'%H&M_!']H_P-XGG'Q(^%\_A77&^)'PD_:13PIX7
MB\(7U[!'H^NI\5=1^#BCQ8-9N9?[/U^2WO)],\'V_BLVGU7\3?VR;WPMXAE^
M'_A?P=X5\0>/XO$WP?TL6'_"Q=+U314M?%_[1?PG^`7Q$T_6;SPY9ZC?>&?$
M?AC4?BGI-WX<LM7TYFUFUF-_JMAI=_I&K^$UOZ'^V-I4.L:EHFK>']6U9M"^
M(VB>"?%?B#3M.TW0+/P[%\5?VO/B[^R1\%ELO#\_B[Q1?^(?M?CWX6W=KXOU
M1-3T<PZ,]KXRMM#LIM4G\!>&"-7'TH49K`X1P35:E&46ZB?N<E;ENDM>25.<
MUK**:4G"(2IX2=2KRXW$W@N6IOR+EJ34HJ7*TN646I1@WRI)NT7KY)J^G?MJ
MN/%,'AS_`(6=9Z0;GXE/\$TU_P`2_!U_$^B>,QX7^`L7P[U/X^7&GZY<6>N_
M#@_$E/VB]4O-$\)7^O11?#?6-'LW\*MJ>G?#O3_#W2ZO:_M<Z>OPYM-)T;XD
M>(=8UCX]:KXF\<>+;SXE_#/3=(\%?"@?M/\`A_2XO"]WX*CM;*T\0Z'?_LK2
MZZ=&.FW1UG29]&?5[J/4/C9J*:S+]'_L\_M%Z=^T#I,6IVW@_P`0>")K[X=?
M";XM:3IFO7V@ZC=77@'XTZ'JVL>"[Z[F\/ZAJ-E8ZVDGA[Q!INN:()[N/3[C
M3XI[74]3M+^"9/I`#&<$\G/;K^5<=3%5:4W"K@,-"I"?-)-+FG*49WE-Q5M7
M-SDEI.I%3:C;E-XX2-:"G3QF)G3G%Q3C47)925^5.UFG%Q3U:BW%7OS/\F_A
MU\*_VC?`.B^"]/3PSX[33=$\*?#;P/\`$?6+/Q1\.K_XO^(=#T;XG?'&Y\7Z
M?X*^(&M^(KCQ`^ARQ:K\*]?T^.]\2Z"MI\/M2\52^#[/PW\4KNYTL^I_"'0O
MVR;?Q?X'UWXIZSXJN["#QEX0T?Q3I+ZS\,)/#S_#*;]F+Q#/XCUO4M.\.1HU
MQXRD_:`M/!EMXEO-!G>*'Q%;ZN?AY86/PKU77Y=8_1`H"<DG]/\`"DV>X_[Y
M!J*F/J34_P#9L)>HI1GS4[NTG)OEDXMQ=Y.-XI>ZHI6Y;RVIX&-*--1KXINF
MDHWJ))6A&'O+:?P\WO7]]N6[LGT445Q'<%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%(3@$]<`G'TI:*`/YROBG\5
M/VSO"?QC^.EOX@\2^/=`\&'XS_$9?A4VJ?%?4OATDWP_M_$NH0Z*;+3+BSGL
M[G0DC0CP[?VPMVNM'%NS1W5N+6_FXK_AH3]I?M\1_$W_`(DO(?U_L_FOZ%?'
M'P=\`?$6ZCNO%WAZTU::!&CADN85DV)O+`*2&(YPP'`R,CC`KA/^&4O@=W\#
M:3_X#)_\;K\(S#P2JYAF&.S!^(?'.&ECL7B,4\-A<YS"AA:'MZU:JJ.'H4^(
MZ=*E2I1JQI0C3ITTXTXOV<&W&/RE7A;GKUJ\<ZS>E*M.4Y0IXBLZ<5*<YJ,(
M?7:4(*//RKECJDDTDD?A+_PT)^TO_P!%'\3?^)+2_P#ROH_X:$_:7_Z*/XF_
M\26E_P#E?7[M?\,I?`W_`*$;2?\`P&3_`.-T?\,I?`W_`*$;2?\`P&3_`.-U
MR?\`$!ZO_1RN/_\`P_9E_P#1*1_JM/\`Z'V=?^#:O_SQ/P#\7?M"_MA+X7\1
M/X$^(5Q-XVCT/5G\(0>*?VF;U/#4WB1=/N#HT>O/96UK>+I3ZA]G2[\BZL]\
M3-$^HZ6'&I6OT5^SQ\?OCY\5_P!@[]F'_AI.Z^,=CJNAZW\(/#W[;GB?P#-X
MOMOBVGAI?`OBU?%&K7M_\)C)XUT71+OXZVWPTL?B?XA^&]Q`^C_"/4O%NN/J
MUCX$CUO7K?\`7+_AE+X'?]"-I/K_`,>R]?7_`%=>H^"/AIX0^'MO-:^$])M]
M(@G8&2.VC"*Q&[K@+G);/(/05^C^'O!+X"K8^I+B#/.)5CG0FO[>QF*Q<\+.
MBI0:PE?$9CFGL5*$E-I4)1E4C%-Q6IZ>`R:6!HXND\QQN*>+C&*J8F<YSH<K
MC>T:E:O'EFHN,E":DX2:7*V?F-8?'WXA>'?BA\,OAQ\#+[QM<_"2?5O@QI7P
MV\$?$3X2?M#>/O%7QJ^%/CWQOJFG?&SXOW7[1WQ1U674?"%K\#M!76/$7AG3
M/&Z7;W>@>"-&2\E\2>'OCQ\%9])H_"CXV_MSSZM\(-;^)/B3PEK7ASQ-X=_9
M!\5^-/"V@_LY^)?!]_;7/[3]EX]T3QQX6/B2\^)'B1M%M?@9J/A+P]XMEU&X
MT1[^2XUW5M+\9+::)>:)#HO[![#TW>YXZGU///XU'+`LT;1.<JX=6#*KJR2*
M4='1PRNK*QRIX.?F!&0?TSZ_124/[/PTTXJ-6K55*M5J7YDY.4L/2DIWDINH
MFY.2M;EY%#JG@:KYW'%U8W3Y84W.G"+TLHKF:44H\JCR\J3OOS.7X$_#O]JO
M]J?XR^`/A3\4[+2Y?C/K7AW0O`7QP\+6OA[X%_$SX.Z!=?&[QI^PM^VSXBU_
M]G>Z37-1O9/%?AK1/%.A_!"YTWQ4LT(U#4?C!HEM!JUU<:GX/L[+T'X??'O]
MKSQ6WP%^(/BSQW;7NFR?$+X[>$[7PQ\.OAG\2;/PY\:KF/X3^`_%OP[\"_$#
M5O'GP\^'*?#WQ-?>-;;XD^$=`\1V_AR+PSHBV6G:1J>N7?Q&L/$]@_[.^&O#
M&@^#O#VA>$O"VDZ=X>\,>%]%TKPWX;\/Z-96^FZ/H/A_0[&#3-&T72=.M$BM
M+#3-+T^UM[*QLK:*.WMK6&*&&-$10-S9GJQ/3VZ>_OSD'@D]*VEF=!*LJ658
M2,'.<J?._:5/92C5C[!?NZ=*G%N<&YQIN;<%:4;-RR>6UW.,WF.)]VFDX*35
M-SYH6G=MUI2C%3M&<W3;?O)JT3\#K7]K']L7QI\`Q<>/-7\,>$YO&NH?$30C
MX[\"?LR_M*?$V_TWQ%#\'/#FOZ!\!=<^%0\*?#+QCX?\2>(O'^N^*=(TS7=-
M&H:UIUCX6L_@Y>ZI!\;-13Q)=?M'\$8KJ'X-_"2.]BNX;R/X8>`8[J&_+F^A
MN4\*:0D\-Z9`)#=QRJZW!<!_.#[QN->FB,C!WL<8'X#)Q^OZ#.:?SGKQCI[^
MM<N,Q=+$1C"C@J&#IQKU*RC0;M[T'35W)<[7(TN5R<;Q4E&,G*^^#PE3#7G5
MQ5;%5)4Z<)2K<J:Y8IRM&%H?Q'-W4;V=FY14+?)7[<C?%_\`X9@^*,?P#;Q&
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MZ:4TU>*?16_*C]JCXI?&#0/VMK[PYX8\;ZQI7AB+5OA@%T>U^.FI>$X5@O\`
M2O#\FHK%X*M]/FM]EY++.98C.R:@7:9U!OF*?5?_``4-\8>.?!?PN\!:CX$\
M0WGAS4KKXDVUA>7-I\1KOX9M=:>?"?BJ[-I+K%G;73WT;W5I:2-I9C3[GVT3
M`V6R3Z:US]G_`.&WB7Q`?%7B'1(M9\1E["0ZQJ"":],FEB%;!C($4$VJ6\*P
MDJ67R_O$$K6WXL^$GA;QYI]MI/C5;OQ1IUI=KJ%K9ZO(L\$&H);7%I'?1HD,
M82XC@NKB-&7";)I$*&-MM>=/P\7U/CC!KB//.7C;%5<5*M&M5C5R*4U!0I9/
M.GFE.MAJ=.5.,E[*IA.;9QNY(P>3+V6;4ECL9S9K6=7VDJ]:2P>B2AAE[5NE
M&]Y6IJFE>UM#Q7]C[Q!XI\3?LN^$=;\5ZQ?:QXDO$^(HN=5N?%]QXQO)/L7C
MCQ996`'BNYAMY[XV]G;00Q,8A_9BPIIJM(+`2/\`SX:K^TQ^W5X4^-W[)?B3
MPIX[N]?^#6G_`!9:3]HK1(_CMJ_Q`\2:QX9OO!7B.S\+V_\`8FHG3K=_!<'C
M"XLKOQ9=:;I^K:W)=P>&Y2FG>%K+Q6NH_P!0WA_X:Z+X4T2W\.>&KB_T30;/
M[9]ETG3Y(X;*`ZA=W%_>E8?LY!-U>W=S<S!RP9YG`"J<5YS#^RK\$;=XG@\$
M:8C0%3#MA`,>S`0*Y0G:H&!N+'&1NYKIJ\!TZE;@JNL]S=U."Z*HP=6M5JK/
M']7IT)5,W4\PI>VJ3E2A6525'%SISO*"]I9/2651G+*9RQ.)4LKA&+4:M3EQ
M3C3C"^(_>Q=2\H^T?.JCU:W>OY2^/O`W[0OQ/O/V[?C9IVL>,/#?A#2/!WQ7
MM=&T[3_BW\<_$NJ?%&SUK_@G[\--(TKX7>$OV>;VSA^#'@[PKH7Q6\2S_%'3
M?BAX&O/$7Q'UCXB^&KCPE;6.E6FM^-;_`%GTF\_:P_:YUCXS?'WX?^$=-@TS
M1M*^(W@CP1\.M7\4?`GXAW'_``@?F?M@?#3X`^(]3U_28KG1=#\9:-KGPN\:
M:U\7M%.E?%W5M4U[P7IWA[XJSV_P?\,>*;7P3I?[&:9I=MI-A:Z=8H+>TLX8
MX((4Y6..-=JJN>@[D#`SSBM#;TY/``]CC_)R/?ZY_4UFD)*2K9;@ZMHQCAXN
M.F'<)4I*?O)JM)NFT_:\WN5)0LHZ%3RZ7,I4L56IJ4YNJE*3=2$Z=2GR*3DI
M4U'GY[TVFYQB[WU/R0TSXY?MGR>(](L+G5=!;1/AYXI\!^'/'DC?`?Q&MW\7
M[*]_;W^)W[+>O>(-/U./QE':>`TN/@7X6T?XOWL.A:?X@M+/7M1T+Q=9SZ1\
M-TN_#?B[R_P?^V%^V-JNG>.;[XBCP?\`"_0X/C#X)\(Z_KND?!?XV_$?Q1^S
M9HVI3?&-M5L?%?@J3P1X3TWQG!J^H^#?A+\/=-\2:)XE\90Z+K7Q(U?XJ:G>
MWOPXO_!=E8_M\%/'S$X.>WIC_/;GI04);.X_3^GM^&/?-3''X=0Y7EF"<N6D
MH5805*<.2<IU+I0G3G*M*5VYTWR\J@E[)R@W/`5I5(2AF&+A&/M%.',I0J*4
M(QIZO]Y#V:BTG&2<G4E-OVBC-?GW^SYJG[2^C_LG?LT'X?\`P]^&WCCQ7<?#
MFS;X@1?&WQ]\5?V=+^PO]D,MM<:?X7?X+_'CQC8W5[<S:DVI>%/&LVDZYX2C
M73].O=3UW4/MKVW"?MY>+8[3X(?#;1?B3J/CWX8_&?Q_-J&B^$O%'P1^)G[0
MD/P^^#'CHZ!]MU[XJ>*/%OPRTOX?7OCWPM\+[>(ZIX/\,>/O!5LGQ+\32:1X
M37PEI=AKGB76_#_Z?;.,;CCW&3QTYS_+'Y4NPXP&(Z\CKT`^G&/3'M6$<6EC
M7B_J]&/^TSQ,8PO&3<ZE>HJ-22BX2HTG5BH05)1E&FX2CR2<37ZI+ZJ\.JU5
MR^KPH*=:U9/EC1BY\LFDYOV+]Z4E)2J.:E&237XX:7XG\1W'[3%]?:AXQ_:+
MT3QS;?&3]H2;XU1B^^,!^$/AO]BFP^`_CVX^#GC#P=X?U2ROO@=:WA\6'X!Z
MQX?USP5HES\2K_XCW7Q7TN4ZFFF_%32['P?X@>,;[Q/^RC\'_&'@CXN?%S6_
M%'PK\7?M.V7A7X8>)/#G[=/BGQ#^T;JVF^.9]6^&?PQO_B!\(?BS\*OB)I?Q
M`UWPB_A'2?AWXN^*%_\`%K1KK1_%VO\`B,?#WQV_A36;C2?Z!C&3C+L<'/4C
M^1'\J`F,?,QQU)).?S/\\CT%=,,U<%%+"QNG35W4HSBXQHXJE44H2P$6U4CB
M/9Q49QE3252,_:PA4ASK+7*W-7?)>?-3Y*T6^:I1JPM*.-J*\)T(MN2DIIN$
MHNFYQG%9R236UO--";>66W@DEA:2*8Q2/&'DB,T!,$IC=BADA)BD(WQDHRFB
MK-%>2M;Z<NKLKWLKNVNO?].AZJV7HK^;LKOY[G*>.8_#-QX/\36'C/13XD\)
MZGH6J:5XD\.?\(QJ/C5=?T+5+233]6T:;PEI.EZUJ'B.VU*QNIK.[T:VTG4'
MO[6:>%K2:(R+6!\-OB%X,^*?AC3_`!AX#NM;N_#FI")])U+5?"OC#P@FJ6DM
MG:WMO?:79^,="T"]U+1Y[6[A>TU6RM;C2II1<PVUT]S;7L47HSQQL0[1H[Q@
ME"P!VG@X!(.T%E4G`/*HV"47'AOP\^$.H>`?@_\`#CX60>-M2BN?`/ASPYH3
M^+/#MEINB7NL?\(_;Q6[?Z!K-IXOM]/T_541X[VT$U[=I$P%OJ,+@NVEH.GJ
MW[2-1."YI64)P<:LN6*;;LH1=OBC[O16SG?G24%).G*[6DTXRC*"3>EG*[L]
MI)/UX#XI?$+]E_P5XK\3M\4?#4:^*/#'@CQ%\0_$.O7OP*\>^*%A\!>"_!.L
M67B7Q)%XOT[X?:QI>K:3H7@SQ[K_`(7U"?3-8OF@3QEJ_@8C^T=?O-#N_3-)
M\*?`;2M3TGQ%H6@_#"PU?6-5BCT+7-*TWPM:7^K:_P"'_"T_P]5-%U&SACGU
M'6]'\#Z7/X(D339IK^Q\)Z8OAR41Z381V</G_P`>OV<IOC=#X[MG\66F@0>-
M_P!F;XW_`+.T@NO#K:\EBWQB?PNR>+9H/[9TJ'4H/#R>'G2?PRRVO]N+=JCZ
M[IB0,)O+=;_8=TW5OB[)\23XITZ7P^_CN3Q?;_#MK'QWH6@:)#'J/[/_`(CL
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M]8\2^/\`7/$5GXWTO3/!_C'QQ\!?B+XM\,3>%KB^U]O$OP`\3Z-XKT"/PWXJ
MB\2Z?IVE:3XBO/"?@VQUNUU/PEKMU;6&EZW_`&=>I<^(+*7PWX#X>_X)T>%;
M#PW\-/!&O>+-)U;P5X/^"_PK^#OC+0=)\!1^'E^($7@;X#_M5_`WQ;XE,\/B
M:^CT#5?'UG^TS#KTTDEKK]YI+>!AIEQJ.M/XAAU/P[5..'Y*;GF&*BU&/,HP
MDI.]&/.FE.*YO:NI9:)KE<Y--**<L1S22P>';;DN9RTY8RE[/EDX-<KC:Z3T
M<I-)V9]?:YX$^`FLV?A+P)XE\)_##4['PI'-8>!?!VM:/X9N;;P_;:#H%IIU
M[8>$_#U[;/%IEEI/A>^LK+4[/1[.&TL-"N[>&]BAL)HU.,=#_9RT*[O==T_P
MG\.9M:UWQ1X<US49?"7@O3/$/B/5/$L_Q+33=&\5:C8^$M&U/791I'Q3U2YU
M'5_%DULMAX5U[_A(?%'B/5-*&GZ_JEM\KZ?_`,$^[^77?^$P\9?%BS\:^-->
M\'1V7CG7W\+^-_"MCJ7Q-@\2_&[Q1#\3O#?A/PK\8=.\.Z>TS?&V]\*W/A?Q
MM;?$:W3P)X,\)>&+;58[*VN!+V*_L3-:ZQX1N-`\;^'?"?ASPWX;_9XT;5O#
M&@>`;M+#Q7??L[?%+X*_$/PIJUQ977C2;0O#,]MIOPL\0^$-.?P5H7AV:33/
M'.D/XQE\;+\+?!=O2A2PBE%1S3$RY>;F_=RC&[3E)-PGSR4ZDII.:NY2<Y)<
M\V*4\9:4G@:#?NV7MHN;M[J:O!17)%0;Y6K15DY.,;]C\&/A5^R+J'@#6;WP
M!8_#/XC>&?'7C#7?$WB/Q=>:?X-UN_\`%?B#Q!\7_$_Q$TY-?U2VT;3Y-1G\
M/?$[7]6;P$M_"=2TV^MK.XTVYN]8$FI77:?$'1_V6/A[X)\43^/_``W\(M$\
M&^!_"%C\2/$FD7WA7P_+'I/@[X8:.VB:'XD'A2QTRXU&ZT_PGHMA'X9\-/I^
MDW4L5HD'AC1(IC<Q:=-\Z:/^R!XA\.?%W]G@)J>EZK\./`MM\0]4^)LUGX>T
M_2-,\=+X.\?/X_\`V4_"_B;1;KQ'JFHS>(OAGX[^(7C;XEZ/XHTJQ3P__P`)
M3X3EOVM?#%]JV@:/<;_QC_8DO_BKK?Q8NS\2-)T/2?B3JGQ"\466/`DE_P"*
M-&\2_$#]DJ[_`&2I=(U3Q$/%EE%XA^&NDZ+>_P#"PX_"$>D:-J=[XPT[0HO^
M$GLM/TA%N=:OL77IU)YGBI4IJ-:=N:56$HU53=->\XNHZ-*$HJFDK."7+*$@
MBJLJ$HQP5&-2/[J"UE"452<HSC'DYE%5*CB^9W]V3?,G&WHEU<_LI>$;KX=6
M;_##3+)_B3IOAJQ\`PZ%^SMXPU:QU:VL_AGXK\,^&]"6;PW\.]2TG3;_`$+X
M-2>--`B\/ZM-9:EH'PNDURPN;*R\(2W"'T33_AG^S?:Z3J>C:9X%^#BZ';Z/
MX_\`"&LZ?;:!X/EL(]`UAO#-A\4O"^K11VK1?V1J'_",>#+#Q[HU\6M)H_#W
MABS\00&/2M)B@Z/QO\-!XN\4_!;Q);ZI'I$7PC\>:WXV.GIIWVAM<BU;X1_$
MKX61:1;W27EJFB"S_P"%A1ZVMZMIJ*.FBG2ULH?[0^WV7P3HO_!-J+1/!7PC
M\+6_Q.L5U;X1^)OAMXNC\57/AWX@^(+[XB:G\(=!\*>%_!^E_$.R\:?&3Q18
MS^#M?T+P_.GQ*\)^$8O"-KXJU?3_`(<:O87>@CX;:;I^I94_83C%RQ>(I3M)
MR3E4JWE[2LX-ZQLO9\FRE)5)W^"#M;C6BY<N%HUKRARW<824?945/=-N2JJI
M))\J5.,4KU&C[I\0>'/@9XKUE?$OBC1_AEXB\06K7OPO77M;LO"^KZK%+J\=
MYI][\.Y;_4(KB=KF_AUO4[*;PC<2O<7*:UJ-N^G2?VM>I<\MK_AO]E_X6Z'=
MZGXA\._"#P=HWPX\.:S\2;D7/AWPM:OX4\,Z#KWACQUKGC2*P6P>^M+"R\6_
M#_P/XDN]8M;;GQ9X+\'WJS-KFA:(UO\`-<'[#_Q!;Q%>^,=5^/&BWWBV;Q7\
M+/$.E>(K'X1P^'IO#L/PZB^(&AZR-.\/:)XWL_`VIWGCKP#X^N/`VJV_BGPG
MX@\/V>F:?IUZ^BZIJVC^&[[0NO\`CW^Q]XK^/'C34=8O_C%IWAOP3=>&_'V@
MV?@ZQ^%^D7>IV5S\0_@#\2_@=K5]/XS@UO2-5UB"&;X@67C"#3=9MKZU,OAB
MST*,6BSVNK:2<F#C4C!YK55%1]^<:=:#IS<:4G0A%.*=W5E",I.-Y*[BH2U.
M;%.G.7]GTU7=2T8RK0:Y8\SC.;LVU=0=DV]5J^5V[+Q=\.OV)?"?@[P[>^*?
MAS\`;+P'XQ\4>#]!\+O)X`\'WWAOQ!XF\5:;=>"O!]OIT5EHEW97<5UX:UK5
M=`M;I(SH^G>";O6+6ZGLO"D&H^1ZO?\`PW^`<&J>(/%>I>"/A5;ZS>02:AXH
M\17_`(=\)PZA<0^%[WPOK<]_K>KW5K]I`T#4?"7@K5KR\NIU;3;OPQX3O[F2
M&;0]$EM/&OCQ^RC>_M$:#X&\+^-/BAJ7A7P[X8\`?$GP]J^G?#/PKX=TJ74?
M''Q%^'Z?"Y/'F@7GC6W\?KX6B\)>"/$'Q3TG0=&M[.^UD2?$".\7QE:R^'`N
ML^:77[$GC'7]4U+4O%WQ9\'>(DU+0O&[7$%I\-_&7A.]E^(/Q&\6?LR^/_$/
MCBV\0>%/C5I6NZ!'HWCC]GN\\0>!-)\/7EC?^'9?%7AZ'4?$7B#_`(0*YF\:
MVO83I*I/,,3"O&<HSBU7G'V7->E.$W/EYHI2E5U3<G%P:M(EQKPJ33P%&5)T
MX<K@Z<5[2TO:QJ1Y;Q4Y2M!\JO%3<F[Z>TMI7['WB/Q7XXTJ+P=\(_$?BZ?Q
M0G@_XG26/P_TK7KZP\0:AX=TKX^Q/\0]9L-`NX]!T^_L]"\/>/H?%?BB^T_0
MI_&=EX>\K63X];2;5_0/^$"^`.ZW^()\(_"G?X:O/$6J6WC9="\)B/0;^7Q3
MKWB/Q3JB>(OL@BTZ]7QMJGBC7-;OFNXIH?%>H:_J=Y*NMWFISR_(WB_]@;Q+
MXU\`^-O!6O\`QIT2_O?'"76H:OXN?X0:;I^H7GBG6?V"?$7[#WB+5;K0M`\7
MZ+X9@TF^.IZ9\5]/\.:%INAV.CS1Z]X"M'_LS5].U[0?9M;_`&6GETSQO8>&
M/$?A?0H-?_:#^&'Q\\-:'=>`XK_P3H$_PV\'?"#PO%X.U;PI9:_I*:YIU]J/
MPNN?&&G:KI]_X;N/#WBO6M%U>VLKRZ\)!]?F?U;EC[/'U9<O+%R:?*J<4U**
MDY1:O[BBN6RCI):V1&6(7,I8&E:4Y3=I<UY<T7%Z1:U<ZDIZ[Q36LKGJ3:S\
M"/@MH^L:O8P^!_!.G^%_`7@^WU.W\)Z%9QW^F_#3PPUSH_@*UAT#PMITVL/X
M,\/C5;[3?"EI8:=+H^EQW=_;Z3%`C78&Q+\</A9!X3\1>-I_&-C#X>\*VGQ/
MOM;EEM-3BU:"S^#.N:_X:^)EY9^&7L!XFU>U\+ZWX7UNQGGT?2+Z+4C;0W&C
M/J-KJ&FSW?R9XB_8>U+Q++XE6;XB^%]'MM9U#QMXAL9_#_PN?3];AUSX@>`?
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M;Z0+?SO-.J3V]I=7,5@$-T]M;3W`B\F)W7\[]4_X)]:SJNE^)[%_B=X*TMO&
MG@/XC?"C6=+\/_!^72?!OA_P/\1?A/\`L^?"6;5?A_X83X@W`\,_$CPMH_[/
M>C7GA;Q++J&HZ%8Q>)]6T:3PI+9Z;IT[=MXL_8O\1:MHNA^&O"OQ6\/>#]&3
MXW_$_P"-GC*.'X1:-J6I^,-<\<_M6>%?VF?#07Q`_B"TU[0K_P`'6_AV[\"W
M>IZ?J1_X2JYU+2O&=Y:V$O@[0_#ISE2P'.HK&RC&4X\LI4)-<K5:<XR45?GC
M&G%>ZN6<I-Q<8Q;*=7'.$>7"0<E%.4?K%G=<JM?N[R>ND>6SNVCZH\,?'/X4
M>-+.74_"WC73-;T.VLO%>H7GBBQAU&3P?86_@?Q"WA?Q5'J7C![)/#&FWVD:
MRLD<NF7VKV^I7%A!<ZU9VMQHMM/J$?>1>*/#D][8:;#K^C3:CJMG)J&EZ?%J
M5FU]J5A#!;W,M[I]H)S<7EK%;7EI<27%O%+"D%U;RLXCFC9OAJ?]BC64N-`U
M#3_B-X82Z\&^+?&/BKPSI]W\,9Y=`O%\0?M-Z)^TEHNF>*]-A\<1'4ET"^TJ
M30DOM+ETEGUV'P[X\L+33)_#Q\-ZG/\`#O\`8=@^'_C7PKXWA\<Z3?:IX=\3
M>`_$A,'@%-'E6/PII_[2$&H^%O#U['XFO;GPWX,:?]H[7-/\$^'8WU&'P5X)
MT5?!\L_B./6;_5$*E#`I3E3QE5M1;A3='>2<K1<K))-*+<O[S5E*+;<*N-<X
MJ>&I1@Y)2DJ[DXQ:BVTFKMIN22O]F[TDDOOL'(R.AZ?X_C2TU00H!_F3U.<9
M/)QTR>3U/)IU<1W!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%)@'J`?P%%%`"X'H*,#ICCTHHH
M"PF!Z#\A2T44!8*3`]!^5%%`!M7(.!D<`X&0/0'M2D`]0#]:**`"BBB@!,`]
M0/RI<#THHHM_G\^_J`F!Z#\A0%4=`!]`***`%I,`=`!^%%%%EV7W(!:***`L
M%)@>@_*BB@!:***`LNR^Y?Y!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
F1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>syn-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 11-May-2015 [02:53:45] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:syn="http://www.syntheticbiologics.com/20150331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="syn-20150331.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2014To03_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_08_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-05-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn03_31_2015_ComputerSoftwareIntangibleAssetMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ComputerAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_ComputerSoftwareIntangibleAssetMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_ComputerAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_ExercisePrice14MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_ExercisePrice175MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice175Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_ExercisePrice222MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice222Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_ExercisePrice330MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice330Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_ExercisePrice375MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice375Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_ExercisePrice180MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice180Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePrice14MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePrice175MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice175Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePrice222MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice222Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePrice330MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice330Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePrice375MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice375Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePrice180MemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice180Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_20_2007_StockPlan2007MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2007-03-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_StockPlan2001MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2001Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_StockPlan2007MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_StockPlan2010MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_02_2010_StockPlan2010MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-11-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2001To12_31_2001_MaximumMemberusgaapRangeAxis_StockPlan2001MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2001Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2001-01-01</xbrli:startDate>

      <xbrli:endDate>2001-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2007To12_31_2007_MaximumMemberusgaapRangeAxis_StockPlan2007MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2007-01-01</xbrli:startDate>

      <xbrli:endDate>2007-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To03_31_2014_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To03_31_2014_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_PrevAbrLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:PrevAbrLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_PrevAbrLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:PrevAbrLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_10_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-10-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-10-01</xbrli:startDate>

      <xbrli:endDate>2014-10-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_MoneyMarketAccountsMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">syn:MoneyMarketAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_MoneyMarketAccountsMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">syn:MoneyMarketAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-10-01</xbrli:startDate>

      <xbrli:endDate>2014-10-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-10-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-10-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2012To10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>

      <xbrli:endDate>2012-10-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_StockWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_StockWarrantsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To03_31_2014_StockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To03_31_2014_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_StockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To03_31_2015_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_22_2013_MinimumMemberusgaapRangeAxis_StockPlan2010MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-10-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_22_2013_MaximumMemberusgaapRangeAxis_StockPlan2010MemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-10-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2015To03_31_2015" id="Factid_1">10-Q</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2015To03_31_2015" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2015To03_31_2015" id="Factid_3">2015-03-31</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2015To03_31_2015" id="Factid_4">2015</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2015To03_31_2015" id="Factid_5">Q1</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P01_01_2015To03_31_2015" id="Factid_6">Synthetic Biologics, Inc.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2015To03_31_2015" id="Factid_7">0000894158</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2015To03_31_2015" id="Factid_8">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityFilerCategory contextRef="P01_01_2015To03_31_2015" id="Factid_9">Accelerated Filer</dei:EntityFilerCategory>

  <dei:TradingSymbol contextRef="P01_01_2015To03_31_2015" id="Factid_10">SYN</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn05_08_2015" id="Factid_11" unitRef="shares" decimals="INF">73179307</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_12">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"&gt; &lt;strong&gt;4.&lt;/strong&gt; &lt;strong&gt;Selected Balance Sheet Information&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Prepaid expenses and other current assets (in thousands):&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Intrexon prepaid research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,060&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,067&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Prepaid insurance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;140&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;228&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;374&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;253&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,574&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,548&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The anticipated Intrexon research and development expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Property and equipment (in thousands):&lt;/i&gt;&amp;#160; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Computer and office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;111&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;93&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;11&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;11&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;122&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;104&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(47)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(39)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;65&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Accrued expenses (in thousands):&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Accrued manufacturing costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;247&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Accrued vendor payments&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;225&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;176&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Accrued milestone payments&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;350&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Accrued clinical consulting services&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,347&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;525&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,646&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,298&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>

  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_13">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"&gt; &lt;strong&gt;5.&lt;/strong&gt; &lt;strong&gt;Stock-Based Compensation&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -37.4pt; MARGIN: 0pt 0px 0pt 37.4pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Stock Incentive Plan&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;During 2001, the Company&amp;#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &amp;#8220;2001 Stock Plan&amp;#8221;). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt;. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&amp;#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &amp;#8220;Awards&amp;#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of March 31, 2015, there were &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 682,449&lt;/font&gt; options issued and outstanding under the 2001 Stock Plan.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On March 20, 2007, the Company&amp;#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &amp;#8220;2007 Stock Plan&amp;#8221;) for the issuance of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,500,000&lt;/font&gt; shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt;. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 428,657&lt;/font&gt; options issued and outstanding under the 2007 Stock Plan.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&amp;#8220;2010 Stock Plan&amp;#8221;) for the issuance of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,000,000&lt;/font&gt; shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company&amp;#8217;s 2010 Incentive Stock Plan to increase the number of shares of the Company&amp;#8217;s common stock reserved for issuance under the Plan from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,000,000&lt;/font&gt; to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,000,000&lt;/font&gt;. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,420,000&lt;/font&gt; options issued and outstanding under the 2010 Stock Plan.&lt;/div&gt; &lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In the event of an employee&amp;#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 100%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%" colspan="6"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;131&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;126&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;2.03&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;1.57&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Expected life of option&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;10 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;5 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Expected forfeitures&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 6%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 4%"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 90%"&gt; &lt;div&gt;immediate vesting,&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;half vesting immediately and the remainder over three years,&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;quarterly over three years,&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;annually over three years,&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;one-third immediate vesting and remaining annually over two years,&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;one half immediate vesting with remaining vesting over nine months,&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;one quarter immediate vesting with the remaining over three years,&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;one quarter immediate vesting with the remaining over 33 months; and&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;monthly over three years.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.6pt; MARGIN: 0pt 0px 0pt 80.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;During the three months ended March 31, 2015, the Company granted &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 550,000&lt;/font&gt; options to employees having an approximate fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;817,000&lt;/font&gt; based upon the Black-Scholes option pricing model.&amp;#160;During the same period in 2014, the Company granted &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 587,500&lt;/font&gt; options to employees and consultants having an approximate fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.4&lt;/font&gt; million based upon the Black-Scholes option pricing model.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Average&amp;#160;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Balance - December 31, 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,909,580&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.59 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;785,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,382,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.36&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(6,583)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.58&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(304,391)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.93&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Balance - December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,981,106&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.80 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;685,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;550,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.54&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Balance - March 31, 2015 - outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,531,106&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.97&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.79 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,628,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Balance - March 31, 2015 - exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,168,043&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.89&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.98 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,939,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Grant date fair value of options granted - March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;817,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Weighted average grant date fair value - March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.49&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Grant date fair value of options granted - December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,974,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Weighted average grant date fair value - December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.09&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees and consultants for the three months ended March 31, 2015 and 2014 were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;826,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;362,000&lt;/font&gt;, respectively&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;As of March 31, 2015, total unrecognized stock-based compensation expense related to stock options was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.0&lt;/font&gt; million, which is expected to be expensed through February 2017.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_14">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"&gt;&lt;b&gt;7.&lt;/b&gt; &lt;b&gt;Stockholders&amp;#8217; Equity (Deficit)&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;During the three months ended March 31, 2015, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 212,843&lt;/font&gt; shares of common stock to Prev ABR LLC, with a fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;350,000&lt;/font&gt;,&amp;#160;&lt;font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt; that was&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt; &lt;font style="TEXT-ALIGN: justify; WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal"&gt; recorded as research and development expense,&lt;/font&gt;&amp;#160;in consideration for achieving the first two milestones as set forth in the Asset Purchase Agreement dated November 28, 2012. In lieu of receiving any cash payment for achieving the first two milestones, Prev ABR LLC exercised its option to receive the milestone payments in shares of the Company&amp;#8217;s common stock. The number of shares of common stock issued upon achievement of each milestone was based upon the average of the opening and closing prices of&amp;#160;&lt;font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"&gt; the Company&amp;#8217;s&lt;/font&gt; stock on the date each milestone was achieved as specified in the Asset Purchase Agreement.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2015" id="Factid_15" unitRef="USD" decimals="-3">12049000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2014" id="Factid_16" unitRef="USD" decimals="-3">17525000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn03_31_2015" id="Factid_17" unitRef="USD" decimals="-3">1574000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn12_31_2014" id="Factid_18" unitRef="USD" decimals="-3">1548000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn03_31_2015" id="Factid_19" unitRef="USD" decimals="-3">13623000</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2014" id="Factid_20" unitRef="USD" decimals="-3">19073000</us-gaap:AssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn03_31_2015" id="Factid_21" unitRef="USD" decimals="-3">75000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2014" id="Factid_22" unitRef="USD" decimals="-3">65000</us-gaap:PropertyPlantAndEquipmentNet>

  <syn:DepositsAndOtherAssetsNoncurrent contextRef="PAsOn03_31_2015" id="Factid_23" unitRef="USD" decimals="-3">18000</syn:DepositsAndOtherAssetsNoncurrent>

  <syn:DepositsAndOtherAssetsNoncurrent contextRef="PAsOn12_31_2014" id="Factid_24" unitRef="USD" decimals="-3">6000</syn:DepositsAndOtherAssetsNoncurrent>

  <us-gaap:Assets contextRef="PAsOn03_31_2015" id="Factid_25" unitRef="USD" decimals="-3">13716000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2014" id="Factid_26" unitRef="USD" decimals="-3">19144000</us-gaap:Assets>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn03_31_2015" id="Factid_27" unitRef="USD" decimals="-3">1559000</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn12_31_2014" id="Factid_28" unitRef="USD" decimals="-3">996000</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn03_31_2015" id="Factid_29" unitRef="USD" decimals="-3">2646000</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn12_31_2014" id="Factid_30" unitRef="USD" decimals="-3">1298000</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn03_31_2015" id="Factid_31" unitRef="USD" decimals="-3">15341000</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2014" id="Factid_32" unitRef="USD" decimals="-3">9588000</us-gaap:LiabilitiesCurrent>

  <us-gaap:Liabilities contextRef="PAsOn03_31_2015" id="Factid_33" unitRef="USD" decimals="-3">15341000</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2014" id="Factid_34" unitRef="USD" decimals="-3">9588000</us-gaap:Liabilities>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn03_31_2015" id="Factid_35" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2014" id="Factid_36" unitRef="USD" xsi:nil="true" />

  <us-gaap:PreferredStockValue contextRef="PAsOn03_31_2015" id="Factid_37" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2014" id="Factid_38" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn03_31_2015" id="Factid_39" unitRef="USD" decimals="-3">73000</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2014" id="Factid_40" unitRef="USD" decimals="-3">72000</us-gaap:CommonStockValue>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn03_31_2015" id="Factid_41" unitRef="USD" decimals="-3">111702000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn12_31_2014" id="Factid_42" unitRef="USD" decimals="-3">110526000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn03_31_2015" id="Factid_43" unitRef="USD" decimals="-3">-113400000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2014" id="Factid_44" unitRef="USD" decimals="-3">-101042000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2015" id="Factid_45" unitRef="USD" decimals="-3">-1625000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014" id="Factid_46" unitRef="USD" decimals="-3">9556000</us-gaap:StockholdersEquity>

  <us-gaap:MinorityInterest contextRef="PAsOn03_31_2015" id="Factid_47" unitRef="USD" decimals="-3">0</us-gaap:MinorityInterest>

  <us-gaap:MinorityInterest contextRef="PAsOn12_31_2014" id="Factid_48" unitRef="USD" decimals="-3">0</us-gaap:MinorityInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn03_31_2015" id="Factid_49" unitRef="USD" decimals="-3">-1625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2014" id="Factid_50" unitRef="USD" decimals="-3">9556000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn03_31_2015" id="Factid_51" unitRef="USD" decimals="-3">13716000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2014" id="Factid_52" unitRef="USD" decimals="-3">19144000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_53">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;Prepaid expenses and other current assets (in thousands):&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Intrexon prepaid research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,060&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,067&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Prepaid insurance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;140&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;228&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;374&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;253&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,574&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,548&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>

  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_54">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;Property and equipment (in thousands):&lt;/i&gt;&amp;#160; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Computer and office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;111&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;93&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;11&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;11&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;122&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;104&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(47)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;(39)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;65&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>

  <syn:AccruedExpensesTableTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_55">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;Accrued expenses (in thousands):&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;March&amp;#160;31,&amp;#160;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"&gt; &lt;div&gt;December&amp;#160;31,&amp;#160;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Accrued manufacturing costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;74&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;247&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Accrued vendor payments&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;225&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;176&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Accrued milestone payments&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;350&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Accrued clinical consulting services&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,347&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;525&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,646&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,298&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:AccruedExpensesTableTextBlock>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_56">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"&gt; &lt;tr&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 100%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%" colspan="6"&gt; &lt;div&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;131&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;126&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;2.03&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;1.57&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Expected life of option&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;10 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;5 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"&gt; &lt;div&gt;Expected forfeitures&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_57">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Average&amp;#160;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Balance - December 31, 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,909,580&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.59 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;785,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,382,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.36&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(6,583)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.58&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(304,391)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.93&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Balance - December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,981,106&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.01&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.80 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;685,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;550,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.54&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Balance - March 31, 2015 - outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,531,106&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.97&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.79 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,628,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Balance - March 31, 2015 - exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,168,043&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.89&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.98 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,939,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Grant date fair value of options granted - March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;817,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Weighted average grant date fair value - March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.49&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Grant date fair value of options granted - December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,974,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Weighted average grant date fair value - December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.09&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn03_31_2015" id="Factid_58" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2014" id="Factid_59" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn03_31_2015" id="Factid_60" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2014" id="Factid_61" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn03_31_2015" id="Factid_62" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2014" id="Factid_63" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn03_31_2015" id="Factid_64" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2014" id="Factid_65" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn03_31_2015" id="Factid_66" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2014" id="Factid_67" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn03_31_2015" id="Factid_68" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2014" id="Factid_69" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn03_31_2015" id="Factid_70" unitRef="shares" decimals="INF">72725987</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2014" id="Factid_71" unitRef="shares" decimals="INF">72594626</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn03_31_2015" id="Factid_72" unitRef="shares" decimals="INF">72807469</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2014" id="Factid_73" unitRef="shares" decimals="INF">72513144</us-gaap:CommonStockSharesOutstanding>

  <syn:PrepaidExpensesResearchAndDevelopment contextRef="PAsOn03_31_2015" id="Factid_74" unitRef="USD" decimals="-3">1060000</syn:PrepaidExpensesResearchAndDevelopment>

  <syn:PrepaidExpensesResearchAndDevelopment contextRef="PAsOn12_31_2014" id="Factid_75" unitRef="USD" decimals="-3">1067000</syn:PrepaidExpensesResearchAndDevelopment>

  <us-gaap:PrepaidInsurance contextRef="PAsOn03_31_2015" id="Factid_76" unitRef="USD" decimals="-3">140000</us-gaap:PrepaidInsurance>

  <us-gaap:PrepaidInsurance contextRef="PAsOn12_31_2014" id="Factid_77" unitRef="USD" decimals="-3">228000</us-gaap:PrepaidInsurance>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn03_31_2015" id="Factid_78" unitRef="USD" decimals="-3">374000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2014" id="Factid_79" unitRef="USD" decimals="-3">253000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn03_31_2015" id="Factid_80" unitRef="USD" decimals="-3">1574000</us-gaap:OtherAssetsCurrent>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn12_31_2014" id="Factid_81" unitRef="USD" decimals="-3">1548000</us-gaap:OtherAssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2015_ComputerSoftwareIntangibleAssetMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_82" unitRef="USD" decimals="-3">11000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2015_ComputerAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_83" unitRef="USD" decimals="-3">111000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2015" id="Factid_84" unitRef="USD" decimals="-3">122000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2014_ComputerSoftwareIntangibleAssetMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_85" unitRef="USD" decimals="-3">11000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2014_ComputerAndOfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_86" unitRef="USD" decimals="-3">93000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2014" id="Factid_87" unitRef="USD" decimals="-3">104000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn03_31_2015" id="Factid_88" unitRef="USD" decimals="-3">47000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2014" id="Factid_89" unitRef="USD" decimals="-3">39000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <syn:AccruedManufacturingCosts contextRef="PAsOn03_31_2015" id="Factid_90" unitRef="USD" decimals="-3">74000</syn:AccruedManufacturingCosts>

  <syn:AccruedManufacturingCosts contextRef="PAsOn12_31_2014" id="Factid_91" unitRef="USD" decimals="-3">247000</syn:AccruedManufacturingCosts>

  <syn:AccruedVendorPayments contextRef="PAsOn03_31_2015" id="Factid_92" unitRef="USD" decimals="-3">225000</syn:AccruedVendorPayments>

  <syn:AccruedVendorPayments contextRef="PAsOn12_31_2014" id="Factid_93" unitRef="USD" decimals="-3">176000</syn:AccruedVendorPayments>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P01_01_2014To03_31_2014" id="Factid_94" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P01_01_2015To03_31_2015" id="Factid_95" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2014To03_31_2014" id="Factid_96" unitRef="pure" decimals="2">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2015To03_31_2015" id="Factid_97" unitRef="pure" decimals="2">1.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2014To03_31_2014" id="Factid_98" unitRef="pure" decimals="4">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2015To03_31_2015" id="Factid_99" unitRef="pure" decimals="4">0.0203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2014To03_31_2014" id="Factid_100">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2015To03_31_2015" id="Factid_101">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod contextRef="P01_01_2014To03_31_2014" id="Factid_102" unitRef="pure" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod contextRef="P01_01_2015To03_31_2015" id="Factid_103" unitRef="pure" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_104" unitRef="shares" decimals="INF">3909580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_105" unitRef="shares" decimals="INF">2382500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_106" unitRef="shares" decimals="INF">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_107" unitRef="shares" decimals="INF">6583</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_108" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_109" unitRef="shares" decimals="INF">304391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_110" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_111" unitRef="shares" decimals="INF">5981106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_112" unitRef="shares" decimals="INF">6531106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_113" unitRef="shares" decimals="INF">4168043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_114" unitRef="USD_per_Share" decimals="2">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_115" unitRef="USD_per_Share" decimals="2">2.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_116" unitRef="USD_per_Share" decimals="2">1.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_117" unitRef="USD_per_Share" decimals="2">0.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_118" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_119" unitRef="USD_per_Share" decimals="2">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_120" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_121" unitRef="USD_per_Share" decimals="2">2.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_122" unitRef="USD_per_Share" decimals="2">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_123" unitRef="USD_per_Share" decimals="2">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2013To12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_124">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_125">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_126">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_127">P4Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_128" unitRef="USD" decimals="0">785000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_129" unitRef="USD" decimals="0">685000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_130" unitRef="USD" decimals="0">2628000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_131" unitRef="USD" decimals="0">1939000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_132" unitRef="USD" decimals="0">4974000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_133" unitRef="USD" decimals="0">817000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_134" unitRef="USD_per_Share" decimals="2">2.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2015To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_135" unitRef="USD_per_Share" decimals="2">1.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2013" id="Factid_136" unitRef="shares" decimals="INF">1632501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2014To12_31_2014" id="Factid_137" unitRef="shares" decimals="INF">7029808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2015To03_31_2015" id="Factid_138" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod contextRef="P01_01_2014To12_31_2014" id="Factid_139" unitRef="shares" decimals="INF">232619</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod contextRef="P01_01_2015To03_31_2015" id="Factid_140" unitRef="shares" decimals="INF">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2014To12_31_2014" id="Factid_141" unitRef="shares" decimals="INF">454896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2015To03_31_2015" id="Factid_142" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2014" id="Factid_143" unitRef="shares" decimals="INF">7974794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn03_31_2015" id="Factid_144" unitRef="shares" decimals="INF">7974794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2013" id="Factid_145" unitRef="USD_per_Share" decimals="2">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2014To12_31_2014" id="Factid_146" unitRef="USD_per_Share" decimals="2">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2015To03_31_2015" id="Factid_147" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2014To12_31_2014" id="Factid_148" unitRef="USD_per_Share" decimals="2">1.47</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2015To03_31_2015" id="Factid_149" unitRef="USD_per_Share" decimals="0">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2014To12_31_2014" id="Factid_150" unitRef="USD_per_Share" decimals="2">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2015To03_31_2015" id="Factid_151" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2014" id="Factid_152" unitRef="USD_per_Share" decimals="1">1.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn03_31_2015" id="Factid_153" unitRef="USD_per_Share" decimals="1">1.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2014To03_31_2014" id="Factid_154" unitRef="USD" decimals="-3">1122000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2015To03_31_2015" id="Factid_155" unitRef="USD" decimals="-3">1713000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2014To03_31_2014" id="Factid_156" unitRef="USD" decimals="-3">2717000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2015To03_31_2015" id="Factid_157" unitRef="USD" decimals="-3">6494000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:OperatingExpenses contextRef="P01_01_2014To03_31_2014" id="Factid_158" unitRef="USD" decimals="-3">3839000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2015To03_31_2015" id="Factid_159" unitRef="USD" decimals="-3">8207000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2014To03_31_2014" id="Factid_160" unitRef="USD" decimals="-3">-3839000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2015To03_31_2015" id="Factid_161" unitRef="USD" decimals="-3">-8207000</us-gaap:OperatingIncomeLoss>

  <us-gaap:InvestmentIncomeInterest contextRef="P01_01_2014To03_31_2014" id="Factid_162" unitRef="USD" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>

  <us-gaap:InvestmentIncomeInterest contextRef="P01_01_2015To03_31_2015" id="Factid_163" unitRef="USD" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2014To03_31_2014" id="Factid_164" unitRef="USD" decimals="-3">1000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2015To03_31_2015" id="Factid_165" unitRef="USD" decimals="-3">-4151000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:ProfitLoss contextRef="P01_01_2014To03_31_2014" id="Factid_166" unitRef="USD" decimals="-3">-3838000</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2015To03_31_2015" id="Factid_167" unitRef="USD" decimals="-3">-12358000</us-gaap:ProfitLoss>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P01_01_2014To03_31_2014" id="Factid_168" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P01_01_2015To03_31_2015" id="Factid_169" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2014To03_31_2014" id="Factid_170" unitRef="USD" decimals="-3">-3838000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2015To03_31_2015" id="Factid_171" unitRef="USD" decimals="-3">-12358000</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2014To03_31_2014" id="Factid_172" unitRef="USD_per_Share" decimals="2">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2015To03_31_2015" id="Factid_173" unitRef="USD_per_Share" decimals="2">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2014To03_31_2014" id="Factid_174" unitRef="shares" decimals="INF">58324260</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2015To03_31_2015" id="Factid_175" unitRef="shares" decimals="INF">72673959</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <syn:WarrantsExercisePrice contextRef="P01_01_2015To03_31_2015_ExercisePrice14MemberusgaapRangeAxis" id="Factid_176" unitRef="USD_per_Share" decimals="2">1.60</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2015To03_31_2015_ExercisePrice175MemberusgaapRangeAxis" id="Factid_177" unitRef="USD_per_Share" decimals="2">1.75</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2015To03_31_2015_ExercisePrice222MemberusgaapRangeAxis" id="Factid_178" unitRef="USD_per_Share" decimals="2">2.22</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2015To03_31_2015_ExercisePrice330MemberusgaapRangeAxis" id="Factid_179" unitRef="USD_per_Share" decimals="2">3.30</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2015To03_31_2015_ExercisePrice375MemberusgaapRangeAxis" id="Factid_180" unitRef="USD_per_Share" decimals="2">3.75</syn:WarrantsExercisePrice>

  <syn:WarrantsExercisePrice contextRef="P01_01_2015To03_31_2015_ExercisePrice180MemberusgaapRangeAxis" id="Factid_181" unitRef="USD_per_Share" decimals="2">1.80</syn:WarrantsExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePrice14MemberusgaapRangeAxis" id="Factid_182" unitRef="shares" decimals="INF">316522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePrice175MemberusgaapRangeAxis" id="Factid_183" unitRef="shares" decimals="INF">7029.808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePrice222MemberusgaapRangeAxis" id="Factid_184" unitRef="shares" decimals="INF">517257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePrice330MemberusgaapRangeAxis" id="Factid_185" unitRef="shares" decimals="INF">61207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePrice375MemberusgaapRangeAxis" id="Factid_186" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePrice180MemberusgaapRangeAxis" id="Factid_187" unitRef="shares" decimals="INF">7974794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePrice175MemberusgaapRangeAxis" id="Factid_188" unitRef="shares" decimals="INF">7029808</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePrice222MemberusgaapRangeAxis" id="Factid_189" unitRef="shares" decimals="INF">517257</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePrice330MemberusgaapRangeAxis" id="Factid_190" unitRef="shares" decimals="INF">61207</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePrice375MemberusgaapRangeAxis" id="Factid_191" unitRef="shares" decimals="INF">50000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePrice180MemberusgaapRangeAxis" id="Factid_192" unitRef="shares" decimals="INF">7974794</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePrice14MemberusgaapRangeAxis" id="Factid_193" unitRef="shares" decimals="INF">316522</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2015To03_31_2015_ExercisePrice14MemberusgaapRangeAxis" id="Factid_194">P2Y6M25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2015To03_31_2015_ExercisePrice175MemberusgaapRangeAxis" id="Factid_195">P4Y6M11D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2015To03_31_2015_ExercisePrice222MemberusgaapRangeAxis" id="Factid_196">P1Y7M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2015To03_31_2015_ExercisePrice330MemberusgaapRangeAxis" id="Factid_197">P1M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2015To03_31_2015_ExercisePrice375MemberusgaapRangeAxis" id="Factid_198">P10M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2015To03_31_2015_ExercisePrice180MemberusgaapRangeAxis" id="Factid_199">P4Y2M16D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn03_31_2015_ExercisePrice14MemberusgaapRangeAxis" id="Factid_200" unitRef="USD" decimals="0">187000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn03_31_2015_ExercisePrice175MemberusgaapRangeAxis" id="Factid_201" unitRef="USD" decimals="0">3903000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn03_31_2015_ExercisePrice222MemberusgaapRangeAxis" id="Factid_202" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn03_31_2015_ExercisePrice330MemberusgaapRangeAxis" id="Factid_203" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn03_31_2015_ExercisePrice375MemberusgaapRangeAxis" id="Factid_204" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn03_31_2015_ExercisePrice180MemberusgaapRangeAxis" id="Factid_205" unitRef="USD" decimals="0">3280000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_20_2007_StockPlan2007MemberusgaapPlanNameAxis" id="Factid_206" unitRef="shares" decimals="INF">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2015_StockPlan2001MemberusgaapPlanNameAxis" id="Factid_207" unitRef="shares" decimals="INF">682449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2015_StockPlan2007MemberusgaapPlanNameAxis" id="Factid_208" unitRef="shares" decimals="INF">428657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2015_StockPlan2010MemberusgaapPlanNameAxis" id="Factid_209" unitRef="shares" decimals="INF">5420000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn11_02_2010_StockPlan2010MemberusgaapPlanNameAxis" id="Factid_210" unitRef="shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2001To12_31_2001_MaximumMemberusgaapRangeAxis_StockPlan2001MemberusgaapPlanNameAxis" id="Factid_211" unitRef="shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2007To12_31_2007_MaximumMemberusgaapRangeAxis_StockPlan2007MemberusgaapPlanNameAxis" id="Factid_212" unitRef="shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2014To03_31_2014_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_213" unitRef="shares" decimals="INF">587500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2015To03_31_2015_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_214" unitRef="shares" decimals="INF">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue contextRef="P01_01_2014To03_31_2014_EmployeesAndConsultantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_215" unitRef="USD" decimals="-5">1400000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue contextRef="P01_01_2015To03_31_2015_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_216" unitRef="USD" decimals="0">817000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2014To03_31_2014_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_217" unitRef="USD" decimals="0">362000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2015To03_31_2015_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_218" unitRef="USD" decimals="0">826000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="PAsOn03_31_2015" id="Factid_219" unitRef="USD" decimals="-5">4000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2015To03_31_2015_PrevAbrLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_220" unitRef="shares" decimals="INF">212843</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure contextRef="PAsOn03_31_2015_PrevAbrLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_221" unitRef="USD" decimals="0">350000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2014To03_31_2014" id="Factid_222" unitRef="USD" decimals="-3">362000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2015To03_31_2015" id="Factid_223" unitRef="USD" decimals="-3">827000</us-gaap:ShareBasedCompensation>

  <us-gaap:Depreciation contextRef="P01_01_2014To03_31_2014" id="Factid_224" unitRef="USD" decimals="-3">3000</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P01_01_2015To03_31_2015" id="Factid_225" unitRef="USD" decimals="-3">8000</us-gaap:Depreciation>

  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="P01_01_2014To03_31_2014" id="Factid_226" unitRef="USD" decimals="-3">-259000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="P01_01_2015To03_31_2015" id="Factid_227" unitRef="USD" decimals="-3">26000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

  <syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="P01_01_2014To03_31_2014" id="Factid_228" unitRef="USD" decimals="-3">2000</syn:IncreaseDecreaseInDepositsAndOtherAssets>

  <syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="P01_01_2015To03_31_2015" id="Factid_229" unitRef="USD" decimals="-3">12000</syn:IncreaseDecreaseInDepositsAndOtherAssets>

  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="P01_01_2014To03_31_2014" id="Factid_230" unitRef="USD" decimals="-3">631000</us-gaap:IncreaseDecreaseInAccountsPayable>

  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="P01_01_2015To03_31_2015" id="Factid_231" unitRef="USD" decimals="-3">563000</us-gaap:IncreaseDecreaseInAccountsPayable>

  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="P01_01_2014To03_31_2014" id="Factid_232" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="P01_01_2015To03_31_2015" id="Factid_233" unitRef="USD" decimals="-3">1348000</us-gaap:IncreaseDecreaseInAccruedLiabilities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2014To03_31_2014" id="Factid_234" unitRef="USD" decimals="-3">-3470000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2015To03_31_2015" id="Factid_235" unitRef="USD" decimals="-3">-5458000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2014To03_31_2014" id="Factid_236" unitRef="USD" decimals="-3">4000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2015To03_31_2015" id="Factid_237" unitRef="USD" decimals="-3">18000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2014To03_31_2014" id="Factid_238" unitRef="USD" decimals="-3">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2015To03_31_2015" id="Factid_239" unitRef="USD" decimals="-3">-18000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <syn:ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises contextRef="P01_01_2014To03_31_2014" id="Factid_240" unitRef="USD" decimals="-3">4000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises>

  <syn:ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises contextRef="P01_01_2015To03_31_2015" id="Factid_241" unitRef="USD" decimals="-3">0</syn:ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2014To03_31_2014" id="Factid_242" unitRef="USD" decimals="-3">4000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2015To03_31_2015" id="Factid_243" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:CashPeriodIncreaseDecrease contextRef="P01_01_2014To03_31_2014" id="Factid_244" unitRef="USD" decimals="-3">-3470000</us-gaap:CashPeriodIncreaseDecrease>

  <us-gaap:CashPeriodIncreaseDecrease contextRef="P01_01_2015To03_31_2015" id="Factid_245" unitRef="USD" decimals="-3">-5476000</us-gaap:CashPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2013" id="Factid_246" unitRef="USD" decimals="-3">14625000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2014" id="Factid_247" unitRef="USD" decimals="-3">11155000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:InterestPaid contextRef="P01_01_2014To03_31_2014" id="Factid_248" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>

  <us-gaap:InterestPaid contextRef="P01_01_2015To03_31_2015" id="Factid_249" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>

  <us-gaap:IncomeTaxesPaid contextRef="P01_01_2014To03_31_2014" id="Factid_250" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>

  <us-gaap:IncomeTaxesPaid contextRef="P01_01_2015To03_31_2015" id="Factid_251" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>

  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_252">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="justify"&gt;&lt;b&gt;1.&lt;/b&gt; &lt;b&gt;Organization and Nature of Operations and Basis of Presentation&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -37.4pt; MARGIN: 0pt 0px 0pt 37.4pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; Synthetic Biologics, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Synthetic Biologics&amp;#8221;) is a microbiome-focused,&amp;#160;clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of &lt;i&gt;C. difficile&lt;/i&gt; infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 26%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt; Therapeutic&amp;#160;Area&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 26%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt; Product&amp;#160;Candidate&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 46%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;Status&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;i&gt;C. difficile&lt;/i&gt; infection prevention&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;SYN-004&lt;/div&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;(oral enzyme)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; Initiated Phase 2a SYN-004 clinical trial during 1&lt;sup style="font-style:normal"&gt;st&lt;/sup&gt; quarter 2015; Phase 2b proof-of- concept SYN-004 clinical trial is expected to initiate during 2&lt;sup style="font-style:normal"&gt;nd&lt;/sup&gt;&amp;#160;&amp;#160;half 2015&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Irritable bowel syndrome with constipation (IBS-C)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;SYN-010&lt;/div&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;(oral compound)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intend to initiate Phase 2 clinical trials during 2&lt;font style="FONT-SIZE: 10pt"&gt;&lt;sup style="font-style:normal"&gt;nd&lt;/sup&gt;&lt;/font&gt;&amp;#160;&amp;#160;quarter of 2015; Collaboration with Cedars-Sinai Medical Center&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Pertussis&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;SYN-005&lt;/div&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;(monoclonal antibodies)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Positive preclinical research findings reported at ECCMID in April 2015; Seeking non-dilutive funding to support clinical development of SYN-005; Collaborations with Intrexon and The University of Texas at Austin&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Relapsing-remitting MS&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;Trimesta&lt;/div&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;(oral estriol)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; The lead principal investigator presented additional Phase 2 clinical outcome data, including more detailed results on improvements in cognitive and disability measures at the ACTRIMS-ECTRIMS Joint Meeting in September 2014; Partnership discussions ongoing pending data from University of California, Los Angeles (UCLA); MRI data review underway by UCLA&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Cognitive dysfunction in MS&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;Trimesta&lt;/div&gt; &lt;div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"&gt;(oral estriol)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Patient enrollment underway in Phase 2 clinical trial&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (&amp;#8220;GAAP&amp;#8221;) for complete financial statements. The accompanying consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&amp;#160;31, 2014 (&amp;#8220;2014 Form 10-K&amp;#8221;) as filed with the SEC. The interim results for the three months ended March 31, 2015, are not necessarily indicative of results for the full year.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>

  <syn:WarrantLiabilities contextRef="PAsOn03_31_2015" id="Factid_253" unitRef="USD" decimals="-3">10908000</syn:WarrantLiabilities>

  <syn:WarrantLiabilities contextRef="PAsOn12_31_2014" id="Factid_254" unitRef="USD" decimals="-3">6756000</syn:WarrantLiabilities>

  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="PAsOn03_31_2015" id="Factid_255" unitRef="USD" decimals="-3">228000</us-gaap:AccruedEmployeeBenefitsCurrent>

  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="PAsOn12_31_2014" id="Factid_256" unitRef="USD" decimals="-3">538000</us-gaap:AccruedEmployeeBenefitsCurrent>

  <us-gaap:FairValueAdjustmentOfWarrants contextRef="P01_01_2014To03_31_2014" id="Factid_257" unitRef="USD" decimals="-3">0</us-gaap:FairValueAdjustmentOfWarrants>

  <us-gaap:FairValueAdjustmentOfWarrants contextRef="P01_01_2015To03_31_2015" id="Factid_258" unitRef="USD" decimals="-3">4152000</us-gaap:FairValueAdjustmentOfWarrants>

  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="P01_01_2014To03_31_2014" id="Factid_259" unitRef="USD" decimals="-3">-885000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>

  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="P01_01_2015To03_31_2015" id="Factid_260" unitRef="USD" decimals="-3">-310000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>

  <syn:AccruedMilestonePayable contextRef="PAsOn03_31_2015" id="Factid_261" unitRef="USD" decimals="-3">1000000</syn:AccruedMilestonePayable>

  <syn:AccruedMilestonePayable contextRef="PAsOn12_31_2014" id="Factid_262" unitRef="USD" decimals="-3">350000</syn:AccruedMilestonePayable>

  <syn:AccruedClinicalConsultingServices contextRef="PAsOn03_31_2015" id="Factid_263" unitRef="USD" decimals="-3">1347000</syn:AccruedClinicalConsultingServices>

  <syn:AccruedClinicalConsultingServices contextRef="PAsOn12_31_2014" id="Factid_264" unitRef="USD" decimals="-3">525000</syn:AccruedClinicalConsultingServices>

  <us-gaap:SharePrice contextRef="PAsOn03_31_2015_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_265" unitRef="USD_per_Share" decimals="2">2.19</us-gaap:SharePrice>

  <us-gaap:SharePrice contextRef="PAsOn10_10_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_266" unitRef="USD_per_Share" decimals="2">1.75</us-gaap:SharePrice>

  <us-gaap:SharePrice contextRef="PAsOn12_31_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_267" unitRef="USD_per_Share" decimals="2">1.46</us-gaap:SharePrice>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2014To12_31_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_268" unitRef="pure" decimals="0">0</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P01_01_2015To03_31_2015_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_269" unitRef="pure" decimals="0">0</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_270" unitRef="pure" decimals="0">0</us-gaap:FairValueAssumptionsExpectedDividendRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2014To12_31_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_271" unitRef="pure" decimals="1">0.9</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2015To03_31_2015_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_272" unitRef="pure" decimals="1">0.9</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_273" unitRef="pure" decimals="2">0.95</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2014To12_31_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_274" unitRef="pure" decimals="4">0.0159</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2015To03_31_2015_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_275" unitRef="pure" decimals="4">0.0126</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_276" unitRef="pure" decimals="4">0.0139</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2014To12_31_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_277">P4Y9M14D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P01_01_2015To03_31_2015_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_278">P4Y6M18D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapFairValueByLiabilityClassAxis" id="Factid_279">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2014To03_31_2014" id="Factid_280" unitRef="USD_per_Share" decimals="2">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="P01_01_2015To03_31_2015" id="Factid_281" unitRef="USD_per_Share" decimals="2">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>

  <syn:StockIssuedForMilestonePayments contextRef="P01_01_2014To03_31_2014" id="Factid_282" unitRef="USD" decimals="-3">0</syn:StockIssuedForMilestonePayments>

  <syn:StockIssuedForMilestonePayments contextRef="P01_01_2015To03_31_2015" id="Factid_283" unitRef="USD" decimals="-3">-350000</syn:StockIssuedForMilestonePayments>

  <syn:DisclosureManagementPlanTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_284">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"&gt; &lt;b&gt;2.&lt;/b&gt; &lt;b&gt;Management&amp;#8217;s Plan&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company has incurred an accumulated deficit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;113.4&lt;/font&gt; million through March 31, 2015. With the exception of the quarter ended June 30, 2010, the Company has incurred negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials, and research and discovery efforts.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company&amp;#8217;s control. These factors include the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 6%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 4%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 90%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the progress of research activities;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the number and scope of research programs;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the progress of preclinical and clinical development activities;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the progress of the development efforts of parties with whom the Company has entered into research and development agreements;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the costs associated with additional clinical trials of product candidates;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the ability to achieve milestones under licensing arrangements;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;the costs and timing of regulatory approvals.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company has based its estimate on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company&amp;#8217;s shares or debt and other sources.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company may seek to access the public or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:DisclosureManagementPlanTextBlock>

  <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_285">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"&gt; &lt;b&gt;3.&lt;/b&gt; &lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -13.2pt; MARGIN: 0pt 0px 0pt 41.8pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 6%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 4%"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 90%"&gt; &lt;div&gt;Level 1 inputs: Quoted prices (unadjusted)&amp;#160;for identical assets or liabilities in active markets;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 6%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 4%"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 90%"&gt; &lt;div&gt;Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -13.2pt; MARGIN: 0in 0px 0in 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 6%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 4%"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 90%"&gt; &lt;div&gt;Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;If the inputs used to measure fair value fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant to the fair value measurement.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Cash and cash equivalents include money market accounts&amp;#160;of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8.5&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;13.6&lt;/font&gt; million as of March 31, 2015 and December 31, 2014, respectively, that are measured using Level 1 inputs.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>

  <us-gaap:CashEquivalentsAtCarryingValue contextRef="PAsOn03_31_2015_MoneyMarketAccountsMemberusgaapCashAndCashEquivalentsAxis" id="Factid_286" unitRef="USD" decimals="-5">8500000</us-gaap:CashEquivalentsAtCarryingValue>

  <us-gaap:CashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2014_MoneyMarketAccountsMemberusgaapCashAndCashEquivalentsAxis" id="Factid_287" unitRef="USD" decimals="-5">13600000</us-gaap:CashEquivalentsAtCarryingValue>

  <syn:StockPurchaseWarrantsTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_288">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"&gt; &lt;strong&gt;6.&lt;/strong&gt; &lt;strong&gt;Stock Purchase Warrants&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On October 10, 2014, the Company raised net proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19.1&lt;/font&gt; million through the sale of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 14,059,616&lt;/font&gt; units at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.47&lt;/font&gt; per unit to certain institutional investors in a registered direct offering. Each unit consisted of one share of the Company&amp;#8217;s common stock and a warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0.5&lt;/font&gt; shares of common stock. The warrants, exercisable for an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7,029,808&lt;/font&gt; shares of common stock, have an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.75&lt;/font&gt; per share and a life of five years. The warrants vested immediately and expire &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;October 10, 2019&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The warrants issued in conjunction with the registered direct offering in October 2014 include a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date and changes in estimated fair value will be recorded as non-cash income or expense in the Company&amp;#8217;s statement of operations at each subsequent period. At March 31, 2015, the fair value of the warrant liability was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.9&lt;/font&gt; million, which represented non-cash expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.2&lt;/font&gt; million for the three months ended March 31, 2015. In accordance with authoritative accounting guidance, the warrant was valued on the date of grant and in subsequent periods using the Black-Scholes valuation model. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The assumptions used by the Company are summarized in the following table:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;March 31,&lt;br/&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;December 31,&lt;br/&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Issuance&lt;br/&gt; Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Closing stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2.19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.46&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;90&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;90&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.26&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.59&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.39&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Expected life of warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.55 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.79 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table summarizes the estimated fair value of the warrant liability &lt;i&gt;(in thousands)&lt;/i&gt;:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Balance at December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,756&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Change in fair value of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4,152&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Balance at March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;10,908&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;As of March 31, 2015, all of the warrants remained outstanding.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 635,855&lt;/font&gt; shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.60&lt;/font&gt; and a life of five years. The warrants vested immediately and expire &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;October 25, 2017&lt;/font&gt;. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. Warrants outstanding as of March 31, 2015 were &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 316,522&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Balance at December 31, 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,632,501&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.99&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,029,808&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(232,619)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(454,896)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Balance at December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,974,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.80&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Balance at March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,974,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.80&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;Contractual&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Intrinsic&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;1.60&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;316,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;316,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;2.57 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;187,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;1.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;7,029.808&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;7,029,808&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;4.53 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;3,903,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;2.22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;517,257&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;517,257&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;1.66 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;3.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;61,207&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;61,207&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;0.16 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;3.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;0.88 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;1.80&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;7,974,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;7,974,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;4.21 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;3,280,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:StockPurchaseWarrantsTextBlock>

  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_289">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The assumptions used by the Company are summarized in the following table:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;March 31,&lt;br/&gt; 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;December 31,&lt;br/&gt; 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Issuance&lt;br/&gt; Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Closing stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2.19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.46&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;90&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;90&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.26&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.59&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.39&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Expected life of warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.55 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.79 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>

  <syn:ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_290">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The following table summarizes the estimated fair value of the warrant liability &lt;i&gt;(in thousands)&lt;/i&gt;:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Balance at December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;6,756&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Change in fair value of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4,152&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Balance at March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;10,908&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock>

  <syn:ScheduleOfWarrantActivityTableTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_291">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Balance at December 31, 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,632,501&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.99&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,029,808&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(232,619)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(454,896)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.88&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Balance at December 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,974,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.80&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"&gt; &lt;div&gt;Balance at March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,974,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.80&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantActivityTableTextBlock>

  <syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_292">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;Contractual&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"&gt; &lt;div&gt;Intrinsic&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;1.60&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;316,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;316,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;2.57 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;187,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;1.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;7,029.808&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;7,029,808&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;4.53 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;3,903,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;2.22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;517,257&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;517,257&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;1.66 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;3.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;61,207&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;61,207&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;0.16 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;3.75&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;0.88 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;1.80&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;7,974,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;7,974,794&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;4.21 years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;3,280,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_293" unitRef="USD" decimals="-5">19100000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_294" unitRef="shares" decimals="INF">14059616</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>

  <us-gaap:SaleOfStockPricePerShare contextRef="PAsOn10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_295" unitRef="USD_per_Share" decimals="2">1.47</us-gaap:SaleOfStockPricePerShare>

  <syn:IssuanceOfWarrantsToPurchaseOfCommonStock contextRef="PAsOn10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_296" unitRef="shares" decimals="INF">0.5</syn:IssuanceOfWarrantsToPurchaseOfCommonStock>

  <syn:IssuanceOfWarrantsToPurchaseOfCommonStock contextRef="PAsOn10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_297" unitRef="shares" decimals="INF">635855</syn:IssuanceOfWarrantsToPurchaseOfCommonStock>

  <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber contextRef="PAsOn10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_298" unitRef="shares" decimals="INF">7029808</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber>

  <syn:WarrantsExercisablePricePerShare contextRef="P10_01_2012To10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_299" unitRef="USD_per_Share" decimals="2">1.60</syn:WarrantsExercisablePricePerShare>

  <syn:WarrantsExercisablePricePerShare contextRef="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_300" unitRef="USD_per_Share" decimals="2">1.75</syn:WarrantsExercisablePricePerShare>

  <us-gaap:FairValueAdjustmentOfWarrants contextRef="P01_01_2015To03_31_2015_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_301" unitRef="USD" decimals="-5">10900000</us-gaap:FairValueAdjustmentOfWarrants>

  <syn:WarrantLiabilities contextRef="PAsOn03_31_2015_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_302" unitRef="USD" decimals="-5">4200000</syn:WarrantLiabilities>

  <syn:InvestmentWarrantsExpirationDate1 contextRef="P10_01_2012To10_25_2012_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_303">2017-10-25</syn:InvestmentWarrantsExpirationDate1>

  <syn:InvestmentWarrantsExpirationDate1 contextRef="P10_01_2014To10_10_2014_StockWarrantsMemberusgaapStatementEquityComponentsAxis" id="Factid_304">2019-10-10</syn:InvestmentWarrantsExpirationDate1>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn03_31_2015" id="Factid_305" unitRef="shares" decimals="INF">316522</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2015To03_31_2015" id="Factid_306">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"&gt; &lt;b&gt;8.&lt;/b&gt; &lt;b&gt;Net Loss per Share&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive at March 31, 2014 and 2015, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2015 were 6,531,106 and 7,974,794, respectively, and for the three months ended March 31, 2014 were 4,490,497 and 963,168, respectively.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2014To03_31_2014_StockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_307" unitRef="shares" decimals="INF">4490497</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2014To03_31_2014_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_308" unitRef="shares" decimals="INF">963168</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2015To03_31_2015_StockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_309" unitRef="shares" decimals="INF">6531106</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2015To03_31_2015_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_310" unitRef="shares" decimals="INF">7974794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="PAsOn10_22_2013_MinimumMemberusgaapRangeAxis_StockPlan2010MemberusgaapPlanNameAxis" id="Factid_311" unitRef="shares" decimals="INF">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>

  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="PAsOn10_22_2013_MaximumMemberusgaapRangeAxis_StockPlan2010MemberusgaapPlanNameAxis" id="Factid_312" unitRef="shares" decimals="INF">6000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>syn-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 11-May-2015 [02:53:45] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.syntheticbiologics.com/20150331" elementFormDefault="qualified" xmlns:syn="http://www.syntheticbiologics.com/20150331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>102 - Statement - Consolidated Balance Sheets</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>104 - Statement - Consolidated Statements of Operations</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>105 - Statement - Consolidated Statements of Cash Flows</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation" id="OrganizationAndNatureOfOperationsAndBasisOfPresentation">
        <link:definition>106 - Disclosure - Organization and Nature of Operations and Basis of Presentation</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ManagementPlans" id="ManagementPlans">
        <link:definition>107 - Disclosure - Management Plans</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>108 - Disclosure - Fair Value of Financial Instruments</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation" id="SelectedBalanceSheetInformation">
        <link:definition>109 - Disclosure - Selected Balance Sheet Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>110 - Disclosure - Stock-Based Compensation</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrants" id="StockPurchaseWarrants">
        <link:definition>111 - Disclosure - Stock Purchase Warrants</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
        <link:definition>112 - Statement - Stockholders&#39; Equity (Deficit)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>113 - Disclosure - Net Loss per Share</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables" id="SelectedBalanceSheetInformationTables">
        <link:definition>114 - Disclosure - Selected Balance Sheet Information (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <link:definition>115 - Disclosure - Stock-Based Compensation (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables" id="StockPurchaseWarrantsTables">
        <link:definition>116 - Disclosure - Stock Purchase Warrants (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual" id="ManagementsPlanDetailsTextual">
        <link:definition>117 - Disclosure - Management&#39;s Plan (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual" id="FairValueOfFinancialInstrumentsDetailsTextual">
        <link:definition>118 - Disclosure - Fair Value of Financial Instruments (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" id="SelectedBalanceSheetInformationDetails">
        <link:definition>119 - Disclosure - Selected Balance Sheet Information (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" id="SelectedBalanceSheetInformationDetails1">
        <link:definition>120 - Disclosure - Selected Balance Sheet Information (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2" id="SelectedBalanceSheetInformationDetails2">
        <link:definition>121 - Disclosure - Selected Balance Sheet Information (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails" id="StockbasedCompensationDetails">
        <link:definition>122 - Disclosure - Stock-Based Compensation (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1" id="StockbasedCompensationDetails1">
        <link:definition>123 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual" id="StockbasedCompensationDetailsTextual">
        <link:definition>124 - Disclosure - Stock-Based Compensation (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails" id="StockPurchaseWarrantsDetails">
        <link:definition>125 - Disclosure - Stock Purchase Warrants (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1" id="StockPurchaseWarrantsDetails1">
        <link:definition>126 - Disclosure - Stock Purchase Warrants (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails2" id="StockPurchaseWarrantsDetails2">
        <link:definition>127 - Disclosure - Stock Purchase Warrants (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails3" id="StockPurchaseWarrantsDetails3">
        <link:definition>128 - Disclosure - Stock Purchase Warrants (Details 3)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual" id="StockPurchaseWarrantsDetailsTextual">
        <link:definition>129 - Disclosure - Stock Purchase Warrants (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDeficitDetailsTextual" id="StockholdersEquityDeficitDetailsTextual">
        <link:definition>130 - Disclosure - Stockholders&#39; Equity (Deficit) (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual" id="NetLossPerShareDetailsTextual">
        <link:definition>131 - Disclosure - Net Loss per Share (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20150331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20150331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20150331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20150331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_DocumentAndEntityInformationAbstract" />

  <element name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_DepositsAndOtherAssetsNoncurrent" />

  <element name="WarrantLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_WarrantLiabilities" />

  <element name="AccruedExpensesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_AccruedExpensesTableTextBlock" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />

  <element name="BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_BalanceSheetParentheticalAbstract" />

  <element name="ScheduleOfOtherCurrentAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="syn_ScheduleOfOtherCurrentAssetsTable" />

  <element name="OtherCurrentAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_OtherCurrentAssetsLineItems" />

  <element name="PrepaidExpensesResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_PrepaidExpensesResearchAndDevelopment" />

  <element name="ComputerAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ComputerAndOfficeEquipmentMember" />

  <element name="LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_LaboratoryEquipmentMember" />

  <element name="ScheduleOfAccruedExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="syn_ScheduleOfAccruedExpensesTable" />

  <element name="AccruedExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_AccruedExpensesLineItems" />

  <element name="AccruedManufacturingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_AccruedManufacturingCosts" />

  <element name="AccruedVendorPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_AccruedVendorPayments" />

  <element name="AccruedMilestonePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_AccruedMilestonePayable" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />

  <element name="ExercisePrice1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice1Member" />

  <element name="ExercisePrice14Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice14Member" />

  <element name="ExercisePrice175Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice175Member" />

  <element name="ExercisePrice220Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice220Member" />

  <element name="ExercisePrice222Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice222Member" />

  <element name="ExercisePrice330Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice330Member" />

  <element name="ExercisePrice375Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice375Member" />

  <element name="ExercisePrice199Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice199Member" />

  <element name="WarrantsExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_WarrantsExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />

  <element name="StockPlan2001Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPlan2001Member" />

  <element name="StockPlan2007Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPlan2007Member" />

  <element name="StockPlan2010Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPlan2010Member" />

  <element name="EmployeesAndDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_EmployeesAndDirectorsMember" />

  <element name="EmployeesAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_EmployeesAndConsultantsMember" />

  <element name="EmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_EmployeeMember" />

  <element name="ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ConsultantMember" />

  <element name="GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />

  <element name="CdfourBiosciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_CdfourBiosciencesIncMember" />

  <element name="EpitopeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_EpitopeMember" />

  <element name="StockPurchaseWarrantsAggreementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="syn_StockPurchaseWarrantsAggreementsAxis" />

  <element name="StockPurchaseWarrantsAggreementsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPurchaseWarrantsAggreementsDomain" />

  <element name="CommonStockPurchaseAgreementWithSingleInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" />

  <element name="StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" />

  <element name="CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" />

  <element name="ConsultingAgreementForFinancialAdvisoryServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ConsultingAgreementForFinancialAdvisoryServicesMember" />

  <element name="StockOptionsAndStockAppreciationRightsSarsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockOptionsAndStockAppreciationRightsSarsMember" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />

  <element name="StockholdersEquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="syn_StockholdersEquityTable" />

  <element name="IntrexonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_IntrexonMember" />

  <element name="PrevAbrLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_PrevAbrLlcMember" />

  <element name="CedarssinaiMedicalCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_CedarssinaiMedicalCenterMember" />

  <element name="NrmViiHoldingsILlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_NrmViiHoldingsILlcMember" />

  <element name="EquityOfferingSalesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_EquityOfferingSalesAgreementMember" />

  <element name="DisclosureManagementPlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_DisclosureManagementPlanAbstract" />

  <element name="ManagementsPlanTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="syn_ManagementsPlanTable" />

  <element name="CantorFitzgeraldAndCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_CantorFitzgeraldAndCoMember" />

  <element name="ManagementsPlanLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ManagementsPlanLineItems" />

  <element name="StockPurchaseWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPurchaseWarrantsAbstract" />

  <element name="StockIssuedForMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_StockIssuedForMilestonePayments" />

  <element name="IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_IncreaseDecreaseInDepositsAndOtherAssets" />

  <element name="ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" />

  <element name="StockholdersEquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockholdersEquityLineItems" />

  <element name="AccruedClinicalConsultingServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="syn_AccruedClinicalConsultingServices" />

  <element name="StockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockWarrantsMember" />

  <element name="DisclosureManagementPlanTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_DisclosureManagementPlanTextBlock" />

  <element name="MoneyMarketAccountsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_MoneyMarketAccountsMember" />

  <element name="StockPurchaseWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_StockPurchaseWarrantsTextBlock" />

  <element name="ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" />

  <element name="ScheduleOfWarrantActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ScheduleOfWarrantActivityTableTextBlock" />

  <element name="ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" />

  <element name="ExercisePrice180Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_ExercisePrice180Member" />

  <element name="IssuanceOfWarrantsToPurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="syn_IssuanceOfWarrantsToPurchaseOfCommonStock" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" />

  <element name="WarrantsExercisablePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_WarrantsExercisablePricePerShare" />

  <element name="InvestmentWarrantsExpirationDate1" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="syn_InvestmentWarrantsExpirationDate1" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>syn-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 11-May-2015 [02:53:45] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformation" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails2" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" />

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_syn_WarrantLiabilities" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidInsurance" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" use="optional" order="10" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockIssuedForMilestonePayments" xlink:label="loc_syn_StockIssuedForMilestonePayments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedForMilestonePayments" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="60" weight="-1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" use="optional" order="70" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="80" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="90" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="100" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" use="optional" order="10" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedManufacturingCosts" xlink:label="loc_syn_AccruedManufacturingCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_syn_AccruedManufacturingCosts" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedVendorPayments" xlink:label="loc_syn_AccruedVendorPayments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_syn_AccruedVendorPayments" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedMilestonePayable" xlink:label="loc_syn_AccruedMilestonePayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_syn_AccruedMilestonePayable" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedClinicalConsultingServices" xlink:label="loc_syn_AccruedClinicalConsultingServices" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_syn_AccruedClinicalConsultingServices" use="optional" order="40" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>syn-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 11-May-2015 [02:53:45] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#DocumentAndEntityInformation" roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails2" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockbasedCompensationDetails" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockbasedCompensationDetails1" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetails2" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails2" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetails3" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails3" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockbasedCompensationDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockholdersEquityDeficitDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDeficitDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ManagementsPlanDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#FairValueOfFinancialInstrumentsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#NetLossPerShareDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetails1" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_978" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_978" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_979" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_978" xlink:to="loc_us-gaap_ClassOfStockDomain_979" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_979_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_978" xlink:to="loc_us-gaap_ClassOfStockDomain_979_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_13" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_14" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_14" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_15" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_15" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_71" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_68" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_71" xlink:to="loc_us-gaap_StatementTable_68" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_69" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_68" xlink:to="loc_us-gaap_StatementScenarioAxis_69" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_70" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_69" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_70" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_70_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_69" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_70_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_72" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71" xlink:to="loc_us-gaap_AssetsAbstract_72" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_72" xlink:to="loc_us-gaap_AssetsCurrentAbstract_73" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_75" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_75" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73" xlink:to="loc_us-gaap_AssetsCurrent_76" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_77" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_79" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_72" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_79" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_72" xlink:to="loc_us-gaap_Assets_80" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_82" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_82" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_83" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_us-gaap_AccountsPayableCurrent_83" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_84" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_84" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities_861" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_syn_WarrantLiabilities_861" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_862" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_862" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_us-gaap_LiabilitiesCurrent_85" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_86" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_Liabilities_86" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_88" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_StockholdersEquityAbstract_88" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_89" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_PreferredStockValue_89" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_90" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_CommonStockValue_90" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_91" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_91" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_93" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_StockholdersEquity_93" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_94" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_MinorityInterest_94" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_96" use="optional" order="30" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_204" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_StatementTable_201" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_201" xlink:to="loc_us-gaap_StatementScenarioAxis_202" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_202" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_203" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_203_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_202" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_203_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_205" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_206" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_206" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesIssued_207" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_208" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_210" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_210" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_211" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesIssued_211" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_212" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_OtherCurrentAssetsLineItems" xlink:label="loc_syn_OtherCurrentAssetsLineItems_231" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfOtherCurrentAssetsTable" xlink:label="loc_syn_ScheduleOfOtherCurrentAssetsTable_228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_syn_ScheduleOfOtherCurrentAssetsTable_228" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_229" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syn_ScheduleOfOtherCurrentAssetsTable_228" xlink:to="loc_us-gaap_StatementScenarioAxis_229" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_230" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_229" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_230" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_230_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_229" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_230_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment_232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment_232" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_233" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_us-gaap_PrepaidInsurance_233" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_234" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_236" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_us-gaap_OtherAssetsCurrent_236" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_239" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_239" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_239" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_240" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" xlink:to="loc_us-gaap_EquipmentMember_242" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember_243" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" xlink:to="loc_syn_ComputerAndOfficeEquipmentMember_243" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_244" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_244" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember_245" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" xlink:to="loc_syn_LaboratoryEquipmentMember_245" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_247" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_247" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_248" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_248" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_249" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_249" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedExpensesLineItems" xlink:label="loc_syn_AccruedExpensesLineItems_255" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfAccruedExpensesTable" xlink:label="loc_syn_ScheduleOfAccruedExpensesTable_252" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_ScheduleOfAccruedExpensesTable_252" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_253" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syn_ScheduleOfAccruedExpensesTable_252" xlink:to="loc_us-gaap_StatementClassOfStockAxis_253" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_254" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_253" xlink:to="loc_us-gaap_ClassOfStockDomain_254" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_254_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_253" xlink:to="loc_us-gaap_ClassOfStockDomain_254_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedManufacturingCosts" xlink:label="loc_syn_AccruedManufacturingCosts_256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_AccruedManufacturingCosts_256" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedVendorPayments" xlink:label="loc_syn_AccruedVendorPayments_257" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_AccruedVendorPayments_257" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedMilestonePayable" xlink:label="loc_syn_AccruedMilestonePayable_877" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_AccruedMilestonePayable_877" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedClinicalConsultingServices" xlink:label="loc_syn_AccruedClinicalConsultingServices_878" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_AccruedClinicalConsultingServices_878" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_259" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_259" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_263" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" xlink:to="loc_us-gaap_RangeAxis_263" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_264" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_263" xlink:to="loc_us-gaap_RangeMember_264" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_264_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_263" xlink:to="loc_us-gaap_RangeMember_264_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_265" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_264" xlink:to="loc_us-gaap_MinimumMember_265" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_266" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_264" xlink:to="loc_us-gaap_MaximumMember_266" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_267" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_267" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_981" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_267" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_981" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_981_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_267" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_981_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember_982" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_981" xlink:to="loc_syn_StockWarrantsMember_982" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_269" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_269" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_270" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_270" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_271" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_272" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_272" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_273" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_273" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_276" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_276" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_277" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_276" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_277" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_278" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_277" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_278" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_278_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_277" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_278_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_279" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_278" xlink:to="loc_us-gaap_EmployeeStockOptionMember_279" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_281" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_281" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_282" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_282" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_283" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_283" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_284" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_284" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_286" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_286" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_287" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_288" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_289" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_289" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_290" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_290" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_292" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_292" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_293" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_293" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_294" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_294" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_295" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_295" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_298" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_298" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_299" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_299" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" use="optional" order="21" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_353" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_353" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_354" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_353" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_354" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_355" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_354" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_355" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_355_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_354" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_355_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_357" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_357" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_358" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_358" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_359" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_359" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_360" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_360" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_362" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_362" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_363" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_363" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_364" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_364" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_365" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_365" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_372" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_StatementTable_369" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_370" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_369" xlink:to="loc_us-gaap_StatementScenarioAxis_370" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_371" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_370" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_371" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_371_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_370" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_371_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_OperatingExpensesAbstract_373" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_373" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_374" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_375" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_373" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_375" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_373" xlink:to="loc_us-gaap_OperatingExpenses_376" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_377" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_OperatingIncomeLoss_377" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_863" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_863" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" xlink:to="loc_us-gaap_InvestmentIncomeInterest_379" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_381" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_381" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_384" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_ProfitLoss_384" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_385" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_386" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_NetIncomeLoss_386" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_938" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_938" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_390" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_390" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_387" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_391" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_391" use="optional" order="20" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_395" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_395" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_396" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_395" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_396" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_396_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_395" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_396_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_397" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_396" xlink:to="loc_us-gaap_WarrantMember_397" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_398" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" xlink:to="loc_us-gaap_RangeAxis_398" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_399" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_398" xlink:to="loc_us-gaap_RangeMember_399" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_399_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_398" xlink:to="loc_us-gaap_RangeMember_399_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member_400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice1Member_400" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member_402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice14Member_402" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice175Member" xlink:label="loc_syn_ExercisePrice175Member_401" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice175Member_401" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member_403" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice220Member_403" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member_404" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice222Member_404" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member_405" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice330Member_405" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member_406" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice375Member_406" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member_407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice199Member_407" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice180Member" xlink:label="loc_syn_ExercisePrice180Member_956" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice180Member_956" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice_409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_syn_WarrantsExercisePrice_409" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_410" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_410" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_411" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_413" use="optional" order="22" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_417" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_PlanNameAxis_417" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_418" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_417" xlink:to="loc_us-gaap_PlanNameDomain_418" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_418_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_417" xlink:to="loc_us-gaap_PlanNameDomain_418_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member_419" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="loc_syn_StockPlan2001Member_419" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member_420" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="loc_syn_StockPlan2007Member_420" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member_421" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="loc_syn_StockPlan2010Member_421" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember_920" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="loc_syn_StockWarrantsMember_920" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_422" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_422" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_423" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_422" xlink:to="loc_us-gaap_RelatedPartyDomain_423" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_423_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_422" xlink:to="loc_us-gaap_RelatedPartyDomain_423_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeesAndDirectorsMember" xlink:label="loc_syn_EmployeesAndDirectorsMember_424" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_423" xlink:to="loc_syn_EmployeesAndDirectorsMember_424" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember_425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_423" xlink:to="loc_syn_EmployeesAndConsultantsMember_425" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeeMember" xlink:label="loc_syn_EmployeeMember_426" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_423" xlink:to="loc_syn_EmployeeMember_426" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ConsultantMember" xlink:label="loc_syn_ConsultantMember_427" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_423" xlink:to="loc_syn_ConsultantMember_427" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_428" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_428" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_429" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_428" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_429" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_429_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_428" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_429_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_430" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_430" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_431" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_430" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_431" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_431_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_430" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_431_default" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_432" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_431" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_432" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_433" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_RangeAxis_433" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_434" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_433" xlink:to="loc_us-gaap_RangeMember_434" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_434_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_433" xlink:to="loc_us-gaap_RangeMember_434_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_435" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_434" xlink:to="loc_us-gaap_MaximumMember_435" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_436" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_434" xlink:to="loc_us-gaap_MinimumMember_436" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_437" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_dei_LegalEntityAxis_437" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_438" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_437" xlink:to="loc_dei_EntityDomain_438" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_438_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_437" xlink:to="loc_dei_EntityDomain_438_default" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CdfourBiosciencesIncMember" xlink:label="loc_syn_CdfourBiosciencesIncMember_439" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_438" xlink:to="loc_syn_CdfourBiosciencesIncMember_439" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EpitopeMember" xlink:label="loc_syn_EpitopeMember_440" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_438" xlink:to="loc_syn_EpitopeMember_440" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_441" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_441" xlink:to="loc_us-gaap_EquityComponentDomain_442" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_442_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_441" xlink:to="loc_us-gaap_EquityComponentDomain_442_default" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_443" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_442" xlink:to="loc_us-gaap_WarrantMember_443" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAggreementsAxis" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsAxis_444" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsAxis_444" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAggreementsDomain" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsAxis_444" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAggreementsDomain" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsDomain_445_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsAxis_444" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsDomain_445_default" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember_446" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" xlink:to="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember_446" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xlink:label="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember_447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" xlink:to="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember_447" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember_448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" xlink:to="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember_448" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xlink:label="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember_449" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" xlink:to="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember_449" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_450" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_AwardTypeAxis_450" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451_default" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockOptionsAndStockAppreciationRightsSarsMember" xlink:label="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember_452" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451" xlink:to="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember_452" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_454" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_454" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_455" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_455" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_456" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_456" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_457" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_457" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_458" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_458" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_977" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_977" use="optional" order="53" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquityDeficitDetailsTextual">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockholdersEquityLineItems" xlink:label="loc_syn_StockholdersEquityLineItems_871" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockholdersEquityTable" xlink:label="loc_syn_StockholdersEquityTable_475" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syn_StockholdersEquityLineItems_871" xlink:to="loc_syn_StockholdersEquityTable_475" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_476" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_476" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_476" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_476" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_478" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477" xlink:to="loc_us-gaap_IPOMember_478" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_479" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477" xlink:to="loc_us-gaap_PrivatePlacementMember_479" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_480" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_480" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_481" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_480" xlink:to="loc_us-gaap_EquityComponentDomain_481" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_481_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_480" xlink:to="loc_us-gaap_EquityComponentDomain_481_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_482" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_481" xlink:to="loc_us-gaap_WarrantMember_482" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_483" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_483" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_484" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_483" xlink:to="loc_us-gaap_RelatedPartyDomain_484" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_484_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_483" xlink:to="loc_us-gaap_RelatedPartyDomain_484_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember_485" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_484" xlink:to="loc_syn_IntrexonMember_485" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_PrevAbrLlcMember" xlink:label="loc_syn_PrevAbrLlcMember_486" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_484" xlink:to="loc_syn_PrevAbrLlcMember_486" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="loc_syn_CedarssinaiMedicalCenterMember_487" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_484" xlink:to="loc_syn_CedarssinaiMedicalCenterMember_487" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_NrmViiHoldingsILlcMember" xlink:label="loc_syn_NrmViiHoldingsILlcMember_488" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_484" xlink:to="loc_syn_NrmViiHoldingsILlcMember_488" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_489" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_PlanNameAxis_489" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_490" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_489" xlink:to="loc_us-gaap_PlanNameDomain_490" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_490_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_489" xlink:to="loc_us-gaap_PlanNameDomain_490_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EquityOfferingSalesAgreementMember" xlink:label="loc_syn_EquityOfferingSalesAgreementMember_491" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_490" xlink:to="loc_syn_EquityOfferingSalesAgreementMember_491" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_492" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_492" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_493" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_492" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_493" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_493_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_492" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_493_default" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_872" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_493" xlink:to="loc_us-gaap_EmployeeStockOptionMember_872" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_495" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockholdersEquityLineItems_871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_495" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_504" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockholdersEquityLineItems_871" xlink:to="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_504" use="optional" order="27" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ManagementsPlanLineItems" xlink:label="loc_syn_ManagementsPlanLineItems_732" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ManagementsPlanTable" xlink:label="loc_syn_ManagementsPlanTable_728" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_syn_ManagementsPlanLineItems_732" xlink:to="loc_syn_ManagementsPlanTable_728" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_729" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_syn_ManagementsPlanTable_728" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_729" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_730" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_729" xlink:to="loc_us-gaap_RelatedPartyDomain_730" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_730_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_729" xlink:to="loc_us-gaap_RelatedPartyDomain_730_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CantorFitzgeraldAndCoMember" xlink:label="loc_syn_CantorFitzgeraldAndCoMember_731" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_730" xlink:to="loc_syn_CantorFitzgeraldAndCoMember_731" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_ManagementsPlanLineItems_732" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_738" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_735" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_738" xlink:to="loc_us-gaap_StatementTable_735" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_736" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_735" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_736" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_736" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_736" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_MoneyMarketAccountsMember" xlink:label="loc_syn_MoneyMarketAccountsMember_947" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737" xlink:to="loc_syn_MoneyMarketAccountsMember_947" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_948" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_738" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_948" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_779" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_772" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_StatementTable_772" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_773" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_772" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_773" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_774" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_773" xlink:to="loc_us-gaap_EquityComponentDomain_774" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_774_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_773" xlink:to="loc_us-gaap_EquityComponentDomain_774_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_775" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_774" xlink:to="loc_us-gaap_WarrantMember_775" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember_957" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_774" xlink:to="loc_syn_StockWarrantsMember_957" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_776" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_772" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_776" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_777" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_776" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_777" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_777_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_776" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_777_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_778" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_777" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_778" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_958" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_958" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_959" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_959" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_960" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_960" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_961" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_961" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_962" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_962" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare_963" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_WarrantsExercisablePricePerShare_963" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_964" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_964" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities_965" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_WarrantLiabilities_965" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_InvestmentWarrantsExpirationDate1" xlink:label="loc_syn_InvestmentWarrantsExpirationDate1_966" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_InvestmentWarrantsExpirationDate1_966" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_967" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_967" use="optional" order="20" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_971" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_788" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_971" xlink:to="loc_us-gaap_StatementTable_788" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_789" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_788" xlink:to="loc_us-gaap_StatementClassOfStockAxis_789" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_790" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_789" xlink:to="loc_us-gaap_ClassOfStockDomain_790" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_790_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_789" xlink:to="loc_us-gaap_ClassOfStockDomain_790_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_791" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_788" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_791" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_791" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_791" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_973" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972" xlink:to="loc_us-gaap_StockOptionMember_973" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_974" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972" xlink:to="loc_us-gaap_WarrantMember_974" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_970" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_971" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_970" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_797" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_794" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_StatementTable_794" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_795" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_794" xlink:to="loc_us-gaap_StatementScenarioAxis_795" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_796" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_795" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_796" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_796_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_795" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_796_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_799" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" xlink:to="loc_us-gaap_ProfitLoss_799" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_801" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" xlink:to="loc_us-gaap_ShareBasedCompensation_801" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockIssuedForMilestonePayments" xlink:label="loc_syn_StockIssuedForMilestonePayments_939" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" xlink:to="loc_syn_StockIssuedForMilestonePayments_939" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_867" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_867" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_805" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" xlink:to="loc_us-gaap_Depreciation_805" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_813" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_813" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_814" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_814" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_815" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_815" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_816" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_816" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_868" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_868" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_817" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_817" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_818" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_818" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_819" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_818" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_819" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_818" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_821" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_821" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises_822" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_821" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises_822" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_825" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_821" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_825" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_826" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_826" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_827" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_827" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_830" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" xlink:to="loc_us-gaap_InterestPaid_830" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_831" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" xlink:to="loc_us-gaap_IncomeTaxesPaid_831" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_975" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_975" use="optional" order="30" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_881" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_881" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_882" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_881" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_882" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_883" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_882" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_883" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_883_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_882" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_883_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember_885" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_883" xlink:to="loc_syn_StockWarrantsMember_885" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_886" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_SharePrice_886" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_887" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_887" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_888" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_888" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_889" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_889" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_890" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_890" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_893" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_893" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_894" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_893" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_894" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_894" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_894" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities_897" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" xlink:to="loc_syn_WarrantLiabilities_897" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_899" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_899" use="optional" order="6" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>syn-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 11-May-2015 [02:53:45] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DocumentAndEntityInformationAbstract" xlink:to="lab_syn_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders&#39; Equity Note [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and Other Assets Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_syn_DepositsAndOtherAssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders&#39; Equity (Deficit)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantLiabilities" xml:lang="en-US">Warrant liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantLiabilities" xml:lang="en-US">Warrant liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_syn_WarrantLiabilities" xml:lang="en-US">Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_syn_WarrantLiabilities" xml:lang="en-US">Ending Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantLiabilities" xml:lang="en-US">It represents value of warrant liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantLiabilities" xlink:to="lab_syn_WarrantLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity (Deficit):</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 72,725,987 issued and 72,807,469 outstanding and 72,594,626 issued and 72,513,144 outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable To Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders Equity Attributable to Noncontrolling Interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total Stockholders&#39; Equity (Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule Of Other Current Assets [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedExpensesTableTextBlock" xlink:label="loc_syn_AccruedExpensesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedExpensesTableTextBlock" xml:lang="en-US">Accrued Expenses [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AccruedExpensesTableTextBlock" xml:lang="en-US">Tabular disclosure of accrued expenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedExpensesTableTextBlock" xlink:to="lab_syn_AccruedExpensesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options and Warrants Vested and Expected To Vest Outstanding and Exercisable [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_BalanceSheetParentheticalAbstract" xlink:to="lab_syn_BalanceSheetParentheticalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfOtherCurrentAssetsTable" xlink:label="loc_syn_ScheduleOfOtherCurrentAssetsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfOtherCurrentAssetsTable" xml:lang="en-US">Schedule Of Other Current Assets [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfOtherCurrentAssetsTable" xlink:to="lab_syn_ScheduleOfOtherCurrentAssetsTable" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_OtherCurrentAssetsLineItems" xlink:label="loc_syn_OtherCurrentAssetsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OtherCurrentAssetsLineItems" xml:lang="en-US">Other Current Assets [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OtherCurrentAssetsLineItems" xlink:to="lab_syn_OtherCurrentAssetsLineItems" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Prepaid Expenses Research and Development</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Intrexon prepaid research and development expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Sum of the amounts paid in advance for research and development expenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PrepaidExpensesResearchAndDevelopment" xlink:to="lab_syn_PrepaidExpensesResearchAndDevelopment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid Insurance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid insurance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Manufacturing equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ComputerAndOfficeEquipmentMember" xml:lang="en-US">Computer and Office Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ComputerAndOfficeEquipmentMember" xml:lang="en-US">Computer and office equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ComputerAndOfficeEquipmentMember" xlink:to="lab_syn_ComputerAndOfficeEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xml:lang="en-US">Computer Software, Intangible Asset [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xml:lang="en-US">Software [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_LaboratoryEquipmentMember" xlink:to="lab_syn_LaboratoryEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfAccruedExpensesTable" xlink:label="loc_syn_ScheduleOfAccruedExpensesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfAccruedExpensesTable" xml:lang="en-US">Schedule Of Accrued Expenses [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfAccruedExpensesTable" xlink:to="lab_syn_ScheduleOfAccruedExpensesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedExpensesLineItems" xlink:label="loc_syn_AccruedExpensesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedExpensesLineItems" xml:lang="en-US">Accrued Expenses [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedExpensesLineItems" xlink:to="lab_syn_AccruedExpensesLineItems" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedManufacturingCosts" xlink:label="loc_syn_AccruedManufacturingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedManufacturingCosts" xml:lang="en-US">Accrued manufacturing costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_AccruedManufacturingCosts" xml:lang="en-US">Accrued manufacturing costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AccruedManufacturingCosts" xml:lang="en-US">The manufacturing costs incurred in the production of goods for sale.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedManufacturingCosts" xlink:to="lab_syn_AccruedManufacturingCosts" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedVendorPayments" xlink:label="loc_syn_AccruedVendorPayments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedVendorPayments" xml:lang="en-US">Accrued Vendor Payments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AccruedVendorPayments" xml:lang="en-US">Accrued vendor payments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AccruedVendorPayments" xml:lang="en-US">Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedVendorPayments" xlink:to="lab_syn_AccruedVendorPayments" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedMilestonePayable" xlink:label="loc_syn_AccruedMilestonePayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedMilestonePayable" xml:lang="en-US">Accrued Milestone Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AccruedMilestonePayable" xml:lang="en-US">Accrued milestone payments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AccruedMilestonePayable" xml:lang="en-US">The carrying value of accrued milestone payments payable as on balance sheet date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedMilestonePayable" xlink:to="lab_syn_AccruedMilestonePayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividends</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of warrant</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of warrant</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">Expected forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">The number of shares under options that were expected to be cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuers Equity, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuers Equity, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options, Ending Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Options, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issuance of common stock for exercise of stock options (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Options, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options, Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life, Balance Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Life, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Grant date fair value of options granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, By Antidilutive Securities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Warrants, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Warrants, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of Warrants, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Number of Warrants, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Exercises in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Number of share warrants exercised during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of Warrants, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from Operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense):</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Loss Attributable to Non-controlling Interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Net Loss Per Share - Basic and Dilutive (in dollars per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Continuing operations (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries (in dollars per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per share - basic and dilutive (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net Income (Loss) Per Share - Basic and Dilutive</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice1Member" xml:lang="en-US">Exercise Price 1 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice1Member" xml:lang="en-US">Exercise Price 1.14 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice1Member" xlink:to="lab_syn_ExercisePrice1Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice14Member" xml:lang="en-US">Exercise Price 14 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice14Member" xml:lang="en-US">Exercise Price 1.60 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ExercisePrice14Member" xml:lang="en-US">Exercise Price 1.60 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice14Member" xlink:to="lab_syn_ExercisePrice14Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice175Member" xlink:label="loc_syn_ExercisePrice175Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice175Member" xml:lang="en-US">Exercise Price 1.75 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice175Member" xml:lang="en-US">Exercise Price 1.75 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice175Member" xlink:to="lab_syn_ExercisePrice175Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice220Member" xml:lang="en-US">Exercise Price 220 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice220Member" xml:lang="en-US">Exercise Price 2.20 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice220Member" xlink:to="lab_syn_ExercisePrice220Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice222Member" xml:lang="en-US">Exercise Price 2 22 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice222Member" xml:lang="en-US">Exercise Price 2.22 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice222Member" xlink:to="lab_syn_ExercisePrice222Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice330Member" xml:lang="en-US">Exercise Price 3 30 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice330Member" xml:lang="en-US">Exercise Price 3.30 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice330Member" xlink:to="lab_syn_ExercisePrice330Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice375Member" xml:lang="en-US">Exercise Price 3 75 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice375Member" xml:lang="en-US">Exercise Price 3.75 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice375Member" xlink:to="lab_syn_ExercisePrice375Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice199Member" xml:lang="en-US">Exercise Price 199 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice199Member" xml:lang="en-US">Exercise Price 1.99 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice199Member" xlink:to="lab_syn_ExercisePrice199Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Warrants Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Exercise price of the warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExercisePrice" xlink:to="lab_syn_WarrantsExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Warrants Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">Warrants Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Aggregate Intrinsic value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2001Member" xml:lang="en-US">Stock Plan 2001 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2001Member" xml:lang="en-US">2001 Stock Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2001Member" xlink:to="lab_syn_StockPlan2001Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2007Member" xml:lang="en-US">Stock Plan 2007 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2007Member" xml:lang="en-US">2007 Stock Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2007Member" xlink:to="lab_syn_StockPlan2007Member" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2010Member" xml:lang="en-US">Stock Plan 2010 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2010Member" xml:lang="en-US">2010 Stock Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2010Member" xlink:to="lab_syn_StockPlan2010Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeesAndDirectorsMember" xlink:label="loc_syn_EmployeesAndDirectorsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EmployeesAndDirectorsMember" xml:lang="en-US">Employees And Directors [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmployeesAndDirectorsMember" xlink:to="lab_syn_EmployeesAndDirectorsMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EmployeesAndConsultantsMember" xml:lang="en-US">Employees And Consultants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmployeesAndConsultantsMember" xlink:to="lab_syn_EmployeesAndConsultantsMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeeMember" xlink:label="loc_syn_EmployeeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EmployeeMember" xml:lang="en-US">Employee [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmployeeMember" xlink:to="lab_syn_EmployeeMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ConsultantMember" xlink:label="loc_syn_ConsultantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ConsultantMember" xml:lang="en-US">Consultant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ConsultantMember" xlink:to="lab_syn_ConsultantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xml:lang="en-US">General and Administrative Expenses and Research and Development Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:to="lab_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CdfourBiosciencesIncMember" xlink:label="loc_syn_CdfourBiosciencesIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CdfourBiosciencesIncMember" xml:lang="en-US">Cdfour Biosciences Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CdfourBiosciencesIncMember" xlink:to="lab_syn_CdfourBiosciencesIncMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EpitopeMember" xlink:label="loc_syn_EpitopeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EpitopeMember" xml:lang="en-US">Epitope [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EpitopeMember" xlink:to="lab_syn_EpitopeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAggreementsAxis" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAggreementsAxis" xml:lang="en-US">Stock Purchase Warrants Aggreements [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsAxis" xlink:to="lab_syn_StockPurchaseWarrantsAggreementsAxis" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAggreementsDomain" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAggreementsDomain" xml:lang="en-US">Stock Purchase Warrants Aggreements [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain" xlink:to="lab_syn_StockPurchaseWarrantsAggreementsDomain" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xml:lang="en-US">Common Stock Purchase Agreement With Single Investors [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xlink:to="lab_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xlink:label="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xml:lang="en-US">Stock Purchase Agreement With Three Institutional Investors [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xlink:to="lab_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xml:lang="en-US">Common Stock Purchase Agreement With Institutional Investors [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xlink:to="lab_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xlink:label="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xml:lang="en-US">Consulting Agreement For Financial Advisory Services [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xlink:to="lab_syn_ConsultingAgreementForFinancialAdvisoryServicesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockOptionsAndStockAppreciationRightsSarsMember" xlink:label="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockOptionsAndStockAppreciationRightsSarsMember" xml:lang="en-US">Stock Options and Stock Appreciation Rights Sars [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember" xlink:to="lab_syn_StockOptionsAndStockAppreciationRightsSarsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Stock Options, Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockholdersEquityTable" xlink:label="loc_syn_StockholdersEquityTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockholdersEquityTable" xml:lang="en-US">Stockholders Equity [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockholdersEquityTable" xlink:to="lab_syn_StockholdersEquityTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IntrexonMember" xml:lang="en-US">Intrexon [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IntrexonMember" xlink:to="lab_syn_IntrexonMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_PrevAbrLlcMember" xlink:label="loc_syn_PrevAbrLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PrevAbrLlcMember" xml:lang="en-US">Prev Abr Llc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PrevAbrLlcMember" xlink:to="lab_syn_PrevAbrLlcMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="loc_syn_CedarssinaiMedicalCenterMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CedarssinaiMedicalCenterMember" xml:lang="en-US">Cedars-Sinai Medical Center [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CedarssinaiMedicalCenterMember" xlink:to="lab_syn_CedarssinaiMedicalCenterMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_NrmViiHoldingsILlcMember" xlink:label="loc_syn_NrmViiHoldingsILlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_NrmViiHoldingsILlcMember" xml:lang="en-US">NRM VII Holdings I, LLC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_NrmViiHoldingsILlcMember" xlink:to="lab_syn_NrmViiHoldingsILlcMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EquityOfferingSalesAgreementMember" xlink:label="loc_syn_EquityOfferingSalesAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EquityOfferingSalesAgreementMember" xml:lang="en-US">Equity Offering Sales Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EquityOfferingSalesAgreementMember" xlink:to="lab_syn_EquityOfferingSalesAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xml:lang="en-US">Equity Issued in Business Combination, Fair Value Disclosure</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DisclosureManagementPlanAbstract" xlink:label="loc_syn_DisclosureManagementPlanAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DisclosureManagementPlanAbstract" xml:lang="en-US">Disclosure Management Plan [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DisclosureManagementPlanAbstract" xlink:to="lab_syn_DisclosureManagementPlanAbstract" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ManagementsPlanTable" xlink:label="loc_syn_ManagementsPlanTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ManagementsPlanTable" xml:lang="en-US">Management&#39;s Plan [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ManagementsPlanTable" xlink:to="lab_syn_ManagementsPlanTable" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CantorFitzgeraldAndCoMember" xlink:label="loc_syn_CantorFitzgeraldAndCoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CantorFitzgeraldAndCoMember" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CantorFitzgeraldAndCoMember" xlink:to="lab_syn_CantorFitzgeraldAndCoMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ManagementsPlanLineItems" xlink:label="loc_syn_ManagementsPlanLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ManagementsPlanLineItems" xml:lang="en-US">Management&#39;s Plan [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ManagementsPlanLineItems" xlink:to="lab_syn_ManagementsPlanLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAbstract" xlink:to="lab_syn_StockPurchaseWarrantsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockIssuedForMilestonePayments" xlink:label="loc_syn_StockIssuedForMilestonePayments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedForMilestonePayments" xml:lang="en-US">Stock issued for milestone payments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_StockIssuedForMilestonePayments" xml:lang="en-US">Stock issued for milestone payments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedForMilestonePayments" xml:lang="en-US">The value of stock granted for milestone payments during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedForMilestonePayments" xlink:to="lab_syn_StockIssuedForMilestonePayments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Increase Decrease In Deposits and Other Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) In Accounts Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" xml:lang="en-US">Proceeds from issuance of common stock for stock option exercises</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity for stock option and warrants exercises.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash Period Increase Decrease</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net decrease in cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xml:lang="en-US">Accrued Employee Benefits, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xml:lang="en-US">Accrued employee benefits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Accrued employee benefits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockholdersEquityLineItems" xlink:label="loc_syn_StockholdersEquityLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockholdersEquityLineItems" xml:lang="en-US">Stockholders Equity [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockholdersEquityLineItems" xlink:to="lab_syn_StockholdersEquityLineItems" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedClinicalConsultingServices" xlink:label="loc_syn_AccruedClinicalConsultingServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedClinicalConsultingServices" xml:lang="en-US">Accrued Clinical Consulting Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AccruedClinicalConsultingServices" xml:lang="en-US">Accrued clinical consulting services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AccruedClinicalConsultingServices" xml:lang="en-US">The carrying value of accrued clinical consulting services payable as on balance sheet date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedClinicalConsultingServices" xlink:to="lab_syn_AccruedClinicalConsultingServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockWarrantsMember" xml:lang="en-US">Stock Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockWarrantsMember" xlink:to="lab_syn_StockWarrantsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Closing stock price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividends</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected life of warrant</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common share - basic and dilutive (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DisclosureManagementPlanTextBlock" xlink:label="loc_syn_DisclosureManagementPlanTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DisclosureManagementPlanTextBlock" xml:lang="en-US">Disclosure Management Plan [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DisclosureManagementPlanTextBlock" xml:lang="en-US">The entire disclosure related to Management&#39;s Plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DisclosureManagementPlanTextBlock" xlink:to="lab_syn_DisclosureManagementPlanTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_MoneyMarketAccountsMember" xlink:label="loc_syn_MoneyMarketAccountsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_MoneyMarketAccountsMember" xml:lang="en-US">Money Market Accounts [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_MoneyMarketAccountsMember" xlink:to="lab_syn_MoneyMarketAccountsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="loc_syn_StockPurchaseWarrantsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">The entire disclosure related to Stock Purchase Warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsTextBlock" xlink:to="lab_syn_StockPurchaseWarrantsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" xml:lang="en-US">Schedule Of Estimated Fair Value Of The Warrant Liability [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" xml:lang="en-US">Tabular disclosure of estimated fair value of the warrant liability.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" xlink:to="lab_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Schedule of Warrant Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Tabular disclosure of warrant activity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfWarrantActivityTableTextBlock" xlink:to="lab_syn_ScheduleOfWarrantActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Schedule Of Warrant Outstanding and Exercisable [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Schedule of Warrant Outstanding and Exercisable [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Tabular disclosure relates to warrant outstanding and exercisable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:to="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice180Member" xlink:label="loc_syn_ExercisePrice180Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice180Member" xml:lang="en-US">Exercise Price180 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice180Member" xml:lang="en-US">Exercise Price 1.80 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice180Member" xlink:to="lab_syn_ExercisePrice180Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Issuance Of Warrants To Purchase Of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Issuance of Warrants to Purchase of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Warrants issued to purchase common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:to="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercisable Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">The number of exercisable share warrants that may be converted as of the balance sheet date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsExercisablePricePerShare" xml:lang="en-US">Warrants Exercisable Price Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExercisablePricePerShare" xml:lang="en-US">Warrants exercisable price per share.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExercisablePricePerShare" xlink:to="lab_syn_WarrantsExercisablePricePerShare" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_InvestmentWarrantsExpirationDate1" xlink:label="loc_syn_InvestmentWarrantsExpirationDate1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_InvestmentWarrantsExpirationDate1" xml:lang="en-US">Investment Warrants Expiration Date1</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_InvestmentWarrantsExpirationDate1" xml:lang="en-US">Investment Warrants Expiration Date</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_InvestmentWarrantsExpirationDate1" xml:lang="en-US">Expiration date of warrants held.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_InvestmentWarrantsExpirationDate1" xlink:to="lab_syn_InvestmentWarrantsExpirationDate1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure for non-cash items:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>syn-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 11-May-2015 [02:53:45] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#DocumentAndEntityInformation" roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ManagementPlans" roleURI="http://www.syntheticbiologics.com/role/ManagementPlans" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#FairValueOfFinancialInstruments" roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformation" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockbasedCompensation" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensation" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrants" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrants" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockholdersEquityDeficit" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDeficit" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#NetLossPerShare" roleURI="http://www.syntheticbiologics.com/role/NetLossPerShare" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationTables" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockbasedCompensationTables" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationTables" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsTables" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ManagementsPlanDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#FairValueOfFinancialInstrumentsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#SelectedBalanceSheetInformationDetails2" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockbasedCompensationDetails" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockbasedCompensationDetails1" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockbasedCompensationDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetails1" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetails2" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails2" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetails3" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails3" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockPurchaseWarrantsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#StockholdersEquityDeficitDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDeficitDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#NetLossPerShareDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="syn-20150331.xsd#OrganizationAndNatureOfOperationsAndBasisOfPresentation" roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation" />

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract_2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DocumentAndEntityInformationAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_978" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_978" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_979" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_978" xlink:to="loc_us-gaap_ClassOfStockDomain_979" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_4" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_13" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_14" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_14" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_15" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_15" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ManagementPlans">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DisclosureManagementPlanAbstract" xlink:label="loc_syn_DisclosureManagementPlanAbstract_940" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DisclosureManagementPlanTextBlock" xlink:label="loc_syn_DisclosureManagementPlanTextBlock_941" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DisclosureManagementPlanAbstract_940" xlink:to="loc_syn_DisclosureManagementPlanTextBlock_941" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_943" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_944" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_943" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_944" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_30" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_30" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_33" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_33" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrants">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_949" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="loc_syn_StockPurchaseWarrantsTextBlock_950" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_949" xlink:to="loc_syn_StockPurchaseWarrantsTextBlock_950" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_36" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_35" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_36" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_968" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_969" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_968" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_969" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_104" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_104" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_105" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_104" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_106" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedExpensesTableTextBlock" xlink:label="loc_syn_AccruedExpensesTableTextBlock_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_104" xlink:to="loc_syn_AccruedExpensesTableTextBlock_107" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_109" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_109" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_110" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_109" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_111" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_951" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_952" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_951" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_952" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock" xlink:label="loc_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock_953" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_951" xlink:to="loc_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock_953" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantActivityTableTextBlock_954" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_951" xlink:to="loc_syn_ScheduleOfWarrantActivityTableTextBlock_954" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_955" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_951" xlink:to="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_955" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_67" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_68" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_67" xlink:to="loc_us-gaap_StatementTable_68" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_69" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_68" xlink:to="loc_us-gaap_StatementScenarioAxis_69" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_70" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_69" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_70" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_68" xlink:to="loc_us-gaap_StatementLineItems_71" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71" xlink:to="loc_us-gaap_AssetsAbstract_72" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72" xlink:to="loc_us-gaap_AssetsCurrentAbstract_73" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_75" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_75" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_73" xlink:to="loc_us-gaap_AssetsCurrent_76" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_77" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_79" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_72" xlink:to="loc_us-gaap_Assets_80" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_82" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_82" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_us-gaap_AccountsPayableCurrent_83" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_84" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_84" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities_861" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_syn_WarrantLiabilities_861" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_862" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_862" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_82" xlink:to="loc_us-gaap_LiabilitiesCurrent_85" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_86" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_Liabilities_86" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_88" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_StockholdersEquityAbstract_88" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_89" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_PreferredStockValue_89" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_90" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_CommonStockValue_90" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_91" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_91" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_93" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_StockholdersEquity_93" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_94" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_MinorityInterest_94" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_96" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_DisclosureManagementPlanAbstract" xlink:label="loc_syn_DisclosureManagementPlanAbstract_727" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ManagementsPlanTable" xlink:label="loc_syn_ManagementsPlanTable_728" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DisclosureManagementPlanAbstract_727" xlink:to="loc_syn_ManagementsPlanTable_728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_729" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_ManagementsPlanTable_728" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_729" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_730" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_729" xlink:to="loc_us-gaap_RelatedPartyDomain_730" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CantorFitzgeraldAndCoMember" xlink:label="loc_syn_CantorFitzgeraldAndCoMember_731" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_730" xlink:to="loc_syn_CantorFitzgeraldAndCoMember_731" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ManagementsPlanLineItems" xlink:label="loc_syn_ManagementsPlanLineItems_732" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_ManagementsPlanTable_728" xlink:to="loc_syn_ManagementsPlanLineItems_732" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_ManagementsPlanLineItems_732" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_734" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_735" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_734" xlink:to="loc_us-gaap_StatementTable_735" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_736" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_735" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_736" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_736" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_MoneyMarketAccountsMember" xlink:label="loc_syn_MoneyMarketAccountsMember_947" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_737" xlink:to="loc_syn_MoneyMarketAccountsMember_947" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_738" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_735" xlink:to="loc_us-gaap_StatementLineItems_738" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_948" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_738" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_948" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_227" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfOtherCurrentAssetsTable" xlink:label="loc_syn_ScheduleOfOtherCurrentAssetsTable_228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_227" xlink:to="loc_syn_ScheduleOfOtherCurrentAssetsTable_228" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_229" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_ScheduleOfOtherCurrentAssetsTable_228" xlink:to="loc_us-gaap_StatementScenarioAxis_229" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_230" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_229" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_230" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_OtherCurrentAssetsLineItems" xlink:label="loc_syn_OtherCurrentAssetsLineItems_231" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_ScheduleOfOtherCurrentAssetsTable_228" xlink:to="loc_syn_OtherCurrentAssetsLineItems_231" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment_232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment_232" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_us-gaap_PrepaidInsurance_233" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_234" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_OtherCurrentAssetsLineItems_231" xlink:to="loc_us-gaap_OtherAssetsCurrent_236" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_238" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_239" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_238" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_239" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_239" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_240" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_240" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" xlink:to="loc_us-gaap_EquipmentMember_242" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember_243" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" xlink:to="loc_syn_ComputerAndOfficeEquipmentMember_243" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_244" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_244" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember_245" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_241" xlink:to="loc_syn_LaboratoryEquipmentMember_245" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_239" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_247" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_247" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_248" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_248" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_249" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_246" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_249" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_251" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ScheduleOfAccruedExpensesTable" xlink:label="loc_syn_ScheduleOfAccruedExpensesTable_252" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_251" xlink:to="loc_syn_ScheduleOfAccruedExpensesTable_252" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_253" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_ScheduleOfAccruedExpensesTable_252" xlink:to="loc_us-gaap_StatementClassOfStockAxis_253" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_254" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_253" xlink:to="loc_us-gaap_ClassOfStockDomain_254" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedExpensesLineItems" xlink:label="loc_syn_AccruedExpensesLineItems_255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_ScheduleOfAccruedExpensesTable_252" xlink:to="loc_syn_AccruedExpensesLineItems_255" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedManufacturingCosts" xlink:label="loc_syn_AccruedManufacturingCosts_256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_AccruedManufacturingCosts_256" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedVendorPayments" xlink:label="loc_syn_AccruedVendorPayments_257" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_AccruedVendorPayments_257" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedMilestonePayable" xlink:label="loc_syn_AccruedMilestonePayable_877" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_AccruedMilestonePayable_877" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_AccruedClinicalConsultingServices" xlink:label="loc_syn_AccruedClinicalConsultingServices_878" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_syn_AccruedClinicalConsultingServices_878" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_259" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_AccruedExpensesLineItems_255" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_259" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_261" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_261" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" xlink:to="loc_us-gaap_RangeAxis_263" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_264" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_263" xlink:to="loc_us-gaap_RangeMember_264" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_265" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_264" xlink:to="loc_us-gaap_MinimumMember_265" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_266" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_264" xlink:to="loc_us-gaap_MaximumMember_266" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_267" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_267" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_981" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_267" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_981" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember_982" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_981" xlink:to="loc_syn_StockWarrantsMember_982" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_262" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_269" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_269" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_270" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_270" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_271" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_272" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_272" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_273" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_980" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_273" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_275" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_276" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_275" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_276" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_277" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_276" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_277" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_278" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_277" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_278" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_279" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_278" xlink:to="loc_us-gaap_EmployeeStockOptionMember_279" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_276" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_281" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_281" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_282" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_282" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_283" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_283" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_284" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_284" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_285" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_286" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_286" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_287" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_288" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_289" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_290" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_290" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_291" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_292" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_292" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_293" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_293" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_294" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_294" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_295" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_295" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_297" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_297" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_298" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_298" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_299" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_299" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_280" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_415" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_415" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_417" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_PlanNameAxis_417" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_417" xlink:to="loc_us-gaap_PlanNameDomain_418" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member_419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="loc_syn_StockPlan2001Member_419" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member_420" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="loc_syn_StockPlan2007Member_420" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member_421" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="loc_syn_StockPlan2010Member_421" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember_920" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="loc_syn_StockWarrantsMember_920" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_422" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_422" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_423" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_422" xlink:to="loc_us-gaap_RelatedPartyDomain_423" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeesAndDirectorsMember" xlink:label="loc_syn_EmployeesAndDirectorsMember_424" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_423" xlink:to="loc_syn_EmployeesAndDirectorsMember_424" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember_425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_423" xlink:to="loc_syn_EmployeesAndConsultantsMember_425" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EmployeeMember" xlink:label="loc_syn_EmployeeMember_426" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_423" xlink:to="loc_syn_EmployeeMember_426" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ConsultantMember" xlink:label="loc_syn_ConsultantMember_427" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_423" xlink:to="loc_syn_ConsultantMember_427" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_428" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_428" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_429" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_428" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_429" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_430" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_430" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_430" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_431" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_431" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_432" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_RangeAxis_433" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_434" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_433" xlink:to="loc_us-gaap_RangeMember_434" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_435" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_434" xlink:to="loc_us-gaap_MaximumMember_435" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_436" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_434" xlink:to="loc_us-gaap_MinimumMember_436" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_437" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_dei_LegalEntityAxis_437" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_438" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_437" xlink:to="loc_dei_EntityDomain_438" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CdfourBiosciencesIncMember" xlink:label="loc_syn_CdfourBiosciencesIncMember_439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_438" xlink:to="loc_syn_CdfourBiosciencesIncMember_439" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EpitopeMember" xlink:label="loc_syn_EpitopeMember_440" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_438" xlink:to="loc_syn_EpitopeMember_440" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_441" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_441" xlink:to="loc_us-gaap_EquityComponentDomain_442" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_443" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_442" xlink:to="loc_us-gaap_WarrantMember_443" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAggreementsAxis" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsAxis_444" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsAxis_444" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAggreementsDomain" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsAxis_444" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember_446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" xlink:to="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember_446" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xlink:label="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember_447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" xlink:to="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember_447" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember_448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" xlink:to="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember_448" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xlink:label="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember_449" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_445" xlink:to="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember_449" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_450" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_AwardTypeAxis_450" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_450" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockOptionsAndStockAppreciationRightsSarsMember" xlink:label="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember_452" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_451" xlink:to="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember_452" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_454" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_454" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_455" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_455" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_456" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_456" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_457" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_457" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_458" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_458" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_977" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_977" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_880" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_881" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_880" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_881" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_882" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_881" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_882" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_883" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_882" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_883" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember_885" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_883" xlink:to="loc_syn_StockWarrantsMember_885" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_881" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_886" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_SharePrice_886" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_887" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_887" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_888" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_888" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_889" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_889" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_890" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_884" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_890" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract_200" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_BalanceSheetParentheticalAbstract_200" xlink:to="loc_us-gaap_StatementTable_201" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_201" xlink:to="loc_us-gaap_StatementScenarioAxis_202" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_202" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_203" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_204" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_201" xlink:to="loc_us-gaap_StatementLineItems_204" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_205" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_206" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_206" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesIssued_207" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_208" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_209" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_210" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_210" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesIssued_211" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_204" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_212" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_892" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_893" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_892" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_893" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_894" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_893" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_894" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_894" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_895" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_893" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities_897" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" xlink:to="loc_syn_WarrantLiabilities_897" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_899" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_899" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities_900" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_896" xlink:to="loc_syn_WarrantLiabilities_900" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_352" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_353" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_352" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_353" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_354" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_354" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_355" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_357" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_357" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_358" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_358" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_359" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_359" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_360" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_361" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_361" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_362" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_362" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_363" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_363" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_364" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_364" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_365" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_366" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_366" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_393" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_393" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_395" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_395" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_396" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_395" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_396" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_396" xlink:to="loc_us-gaap_WarrantMember_397" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_398" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" xlink:to="loc_us-gaap_RangeAxis_398" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_398" xlink:to="loc_us-gaap_RangeMember_399" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member_400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice1Member_400" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member_402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice14Member_402" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice175Member" xlink:label="loc_syn_ExercisePrice175Member_401" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice175Member_401" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member_403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice220Member_403" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member_404" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice222Member_404" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member_405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice330Member_405" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member_406" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice375Member_406" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member_407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice199Member_407" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ExercisePrice180Member" xlink:label="loc_syn_ExercisePrice180Member_956" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_399" xlink:to="loc_syn_ExercisePrice180Member_956" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_394" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice_409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_syn_WarrantsExercisePrice_409" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_410" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_410" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_411" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_408" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_413" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual">
    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_771" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_772" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_771" xlink:to="loc_us-gaap_StatementTable_772" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_773" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_772" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_773" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_774" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_773" xlink:to="loc_us-gaap_EquityComponentDomain_774" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_775" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_774" xlink:to="loc_us-gaap_WarrantMember_775" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockWarrantsMember" xlink:label="loc_syn_StockWarrantsMember_957" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_774" xlink:to="loc_syn_StockWarrantsMember_957" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_776" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_772" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_776" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_777" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_776" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_777" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_778" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_777" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_778" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_779" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_772" xlink:to="loc_us-gaap_StatementLineItems_779" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_958" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_958" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_959" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_959" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_960" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_960" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_961" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_961" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_962" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_962" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare_963" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_WarrantsExercisablePricePerShare_963" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_964" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_964" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_WarrantLiabilities" xlink:label="loc_syn_WarrantLiabilities_965" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_WarrantLiabilities_965" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_InvestmentWarrantsExpirationDate1" xlink:label="loc_syn_InvestmentWarrantsExpirationDate1_966" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_syn_InvestmentWarrantsExpirationDate1_966" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_967" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_779" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_967" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquityDeficitDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_474" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockholdersEquityTable" xlink:label="loc_syn_StockholdersEquityTable_475" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_474" xlink:to="loc_syn_StockholdersEquityTable_475" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_476" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_476" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_476" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_478" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477" xlink:to="loc_us-gaap_IPOMember_478" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_477" xlink:to="loc_us-gaap_PrivatePlacementMember_479" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_480" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_480" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_481" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_480" xlink:to="loc_us-gaap_EquityComponentDomain_481" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_482" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_481" xlink:to="loc_us-gaap_WarrantMember_482" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_483" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_483" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_484" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_483" xlink:to="loc_us-gaap_RelatedPartyDomain_484" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember_485" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_484" xlink:to="loc_syn_IntrexonMember_485" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_PrevAbrLlcMember" xlink:label="loc_syn_PrevAbrLlcMember_486" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_484" xlink:to="loc_syn_PrevAbrLlcMember_486" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="loc_syn_CedarssinaiMedicalCenterMember_487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_484" xlink:to="loc_syn_CedarssinaiMedicalCenterMember_487" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_NrmViiHoldingsILlcMember" xlink:label="loc_syn_NrmViiHoldingsILlcMember_488" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_484" xlink:to="loc_syn_NrmViiHoldingsILlcMember_488" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_489" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_PlanNameAxis_489" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_490" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_489" xlink:to="loc_us-gaap_PlanNameDomain_490" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_EquityOfferingSalesAgreementMember" xlink:label="loc_syn_EquityOfferingSalesAgreementMember_491" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_490" xlink:to="loc_syn_EquityOfferingSalesAgreementMember_491" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_492" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_492" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_493" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_492" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_493" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_872" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_493" xlink:to="loc_us-gaap_EmployeeStockOptionMember_872" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockholdersEquityLineItems" xlink:label="loc_syn_StockholdersEquityLineItems_871" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockholdersEquityTable_475" xlink:to="loc_syn_StockholdersEquityLineItems_871" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_495" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockholdersEquityLineItems_871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_495" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_504" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockholdersEquityLineItems_871" xlink:to="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_504" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_787" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_788" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_787" xlink:to="loc_us-gaap_StatementTable_788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_789" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_788" xlink:to="loc_us-gaap_StatementClassOfStockAxis_789" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_790" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_789" xlink:to="loc_us-gaap_ClassOfStockDomain_790" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_791" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_788" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_791" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_791" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_973" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972" xlink:to="loc_us-gaap_StockOptionMember_973" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_974" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_972" xlink:to="loc_us-gaap_WarrantMember_974" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_971" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_788" xlink:to="loc_us-gaap_StatementLineItems_971" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_970" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_971" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_970" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_368" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_368" xlink:to="loc_us-gaap_StatementTable_369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_369" xlink:to="loc_us-gaap_StatementScenarioAxis_370" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_371" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_370" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_371" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_369" xlink:to="loc_us-gaap_StatementLineItems_372" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_OperatingExpensesAbstract_373" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_373" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_374" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_375" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_373" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_375" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_373" xlink:to="loc_us-gaap_OperatingExpenses_376" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_377" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_OperatingIncomeLoss_377" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_863" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_863" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" xlink:to="loc_us-gaap_InvestmentIncomeInterest_379" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_381" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_378" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_381" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_ProfitLoss_384" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_385" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_386" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_NetIncomeLoss_386" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_938" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_938" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_390" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_387" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_391" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_391" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_793" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_794" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_793" xlink:to="loc_us-gaap_StatementTable_794" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_795" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_794" xlink:to="loc_us-gaap_StatementScenarioAxis_795" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_796" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_795" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_796" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_797" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_794" xlink:to="loc_us-gaap_StatementLineItems_797" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_799" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" xlink:to="loc_us-gaap_ProfitLoss_799" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_801" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" xlink:to="loc_us-gaap_ShareBasedCompensation_801" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_StockIssuedForMilestonePayments" xlink:label="loc_syn_StockIssuedForMilestonePayments_939" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" xlink:to="loc_syn_StockIssuedForMilestonePayments_939" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_867" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_867" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_805" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_800" xlink:to="loc_us-gaap_Depreciation_805" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_813" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_813" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_814" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_814" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_815" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_815" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_816" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_816" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_868" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_811" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_868" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_817" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_798" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_817" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_818" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_818" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_819" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_818" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_819" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_818" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_821" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_821" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="syn-20150331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises_822" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_821" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises_822" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_825" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_821" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_825" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_826" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_826" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_827" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_827" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_828" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_828" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_830" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" xlink:to="loc_us-gaap_InterestPaid_830" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_831" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_829" xlink:to="loc_us-gaap_IncomeTaxesPaid_831" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_975" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_797" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_975" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_840" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_841" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_840" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_841" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#*#;D0WP$``!85```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-%NVC`4AN\K[1TBWT[$
MV&R4381>=-ME5ZG=`[CV@40XMF6[';Q]3T)!$Z(@5*2=&R(2^_Q??/%)^:<W
MJ]86+Q!3XUW%1#ED!3CM3>,6%?OS^&LP847*RAEEO8.*K2&QF]FGJ^GC.D`J
M<+=+%:MS#M\Y3[J&5J72!W#X9.YCJS+^C0L>E%ZJ!7`Y'(ZY]BZ#RX/<S6"S
MZ0^8JV>;BY\KO+TAB6`3*VXW"[NLBJD0;*-51E+^XLQ>RN`MH<2=_9I4-R%]
M1@S&#R9T3]X/>-OW&X\F-@:*>Q7SG6H1@Z\L_^OC\LG[97E\R`%*/Y\W&HS7
MSRV>0)E"!&52#9!;6_;7LE6-VW(?R>\7)]Y?Q(5!NO?K!Y_)(8EPC(AP?"'"
M\94(QY@(QS41C@D1CF]$.,20"@@5HPHJ2A54G"JH2%50L:J@HE5!Q:N"BE@%
M%;-**F:55,PJJ9A54C&KI&)62<6LDHI9)16S2BIFE53,.J)BUM'_,FO&U@=X
M__MQA'[,B=HAY;6%=.%/A<W04\FUBF`><L1^[.(`_\X^P:&5U;<U%D47/H3=
MW&/YV%[=1Q\2]G@1S@?8%G7=[D'`01!S`[NJ[E#EM4O$#O#\P+W.#;J6T8`Y
MD,W[5G/V"@``__\#`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R
M96QS+RYR96QS(*($`BB@``(`````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````(R2ST[#,`S&[TB\
M0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?
M'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+
MBQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J
M/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C
M`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/
M5%\```#__P,`4$L#!!0`!@`(````(0!]X;,$Y@$``/43```:``@!>&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````"\6,MNVS`0O!?H/PB\U_0N$R<I(N?0(D"N:?H!A$1;
M0F1*(-F'_SZ$X5`UT$XOPEX$<`4M![.[,Z3N'WX?ANJG"[$??:UHM5:5\\W8
M]GY?J^\OCY]N5163]:T=1N]J=711/6P_?KA_=H--^:/8]5.L<A8?:]6E-'W6
M.C:=.]BX&B?G\YO=&`XVY678Z\DVKW;O-*_7&QW^S*&V%SFKI[96X:DEHZJ7
MXY2W_G_R<;?K&_=U;'X<G$]_V4/_&L-K[)Q+.:D->Y=J54)1G]Z0667,2O\#
M3N9#%LXM@L,;83B\07"D:P5+Q23-#4%NKI:$$SL;7/LMA3RH,2<^-_-%&*&Y
M61),&:$92`F=I^H&@2$61D,,X4B30Y`=OA9FAZ\1.V;1(8_I.&1+F1OXM$;[
M2_<*;A5I_26HOYSM6]2=>`U+=2<-YP[!D?8#:`?2C0/[AL2I@=SPHE99K&A6
MF1(ZNQ-?H;XQBTI.RF=C-T,Y+?7I"3F1-@'H`22-AB`<7M222G/,12JA]W[!
M!T_I.P+#.P))FP)!4R!I4R!H"D9:^@P<<VGE@\(G72E8*)*FAB`WO*@I%($!
MF@,/HBQ]9V%X9S'2FF.@YIA%_:JQ0_.EL[V?BU5"Z!PA;0O%%?3%S[KM&P``
M`/__`P!02P,$%``&``@````A`&M>G<LS`P``<`H```\```!X;"]W;W)K8F]O
M:RYX;6R4EMMNFT`0AN\K]1T0]PTGQSDH=M2<U$AM8LEN<KG:P-JLLNS2W:5V
M^O0=EM@>#+'B*SQ@/F;^^6?@XG)5".\OTX8K.?*CH]#WF$Q5QN5BY/^>W7T[
M]3UCJ<RH4)*-_#=F_,OQUR\72Z5?7Y1Z]0`@S<C/K2W/@\"D.2NH.5(EDW!E
MKG1!+81Z$9A2,YJ9G#%;B"`.PV%04"[]AG"N/\-0\SE/V8U*JX))VT`T$]1"
M^B;GI?''%W,NV%-3D4?+\H$6D/=*^)Z@QMYFW+)LY!]#J):L=4)7Y57%!5P]
M2\+$#\:;(B?:R]B<5L+.H+PU'?2*!W$\K/]92_'$V=)L;ZI#;_7,9::6]5]!
MVK=-E$`"2W?IF6<VA^MA&&[._6!\D=OU2<`'B.\4A.>XHR==>6M%R'>9D5MI
MN7TC][)1GRMH8:WZ/506^9X^Y_!#WV=1G3BF7(.(2O",@D3DB@HJ4T:F]:T&
M(9(8,>(#&&1",091G-@?9C*UD%#=;T/4G#R6#%$&B#+8FTN;<DUQ22#\1I7C
M7<JC7E#)_SF/$9@$\D!MI5DWER1!&.<*7-(O*NG"E4$FH"Q^?(*K.-E]_AWE
MFCQ14;E'WG$);>%40'^-U172HO;4IHS37<R4"99V&KMV"<8,$>:L@[$J?;VB
M!AQRK0J8<N.$P?>?H/NCL!=`)I5.<Z"09ZHUA=9B`.R<31U1QZ73.H-<B0QF
MG-S^J6JOWS#8"]QBR!F&=&SZP"SYJ8PA)=-@<:I;IH)1W2;0,>=^)6'"7-OK
M:1NTQJWC3U=)5TLRHR\"]BSBX)&+.@YUG*ZD/1SLT&B/18WS*,AJ*1>&S-C*
M8J<-L&&C`QW;$@A;-CK0LR#*5FELVJCKVKWF!U6V(.Q>V-D[*W)_[T&6+0B[
M..YW<4_O&\D1)\:]AV`WH?YY?&\=UCK&S8?@(!#6.L;=AZ`/U./&;F6X^?&G
M7=UP6I7AYC?O8]>&]Y?C1^/1@%J5M9K?\?5^$'91W&I^U]=UTSZ4"+LHQFL,
M@CZM^W<A.`"Y*,$K#8(=3G<=XMG''+S1$N?JP&D-'R0I%2E\*=4']ZDQ.!XV
MO@_6'XOC_P```/__`P!02P,$%``&``@````A`-*7>B;E`P``GPT``!@```!X
M;"]W;W)K<VAE971S+W-H965T-"YX;6R45UUOHS@4?1]I_P/B/8`AA"1*,AKH
M=F:D76FUVH]G`DYB%3#"3M/^^[GFDH!-F](^I`$?'Q^?>WU]L_GZ4A;6,VT$
MX]76)HYG6[3*>,ZJX];^]Y_'V=*VA$RK/"UX1;?V*Q7VU]UO7S87WCR)$Z72
M`H9*;.V3E/7:=45VHF4J'%[3"D8.O"E3"8_-T15U0].\G506KN]Y"[=,664C
MP[J9PL$/!Y;1!YZ=2UI))&EHD4K0+TZL%E>V,IM"5Z;-T[F>9;RL@6+/"B9?
M6U+;*K/USV/%FW1?P+Y?R#S-KMSMPXB^9%G#!3](!^A<%#K>\\I=N<"TV^0,
M=J!LMQIZV-K?R#HAD>WN-JU!_S%Z$8/OECCQR_>&Y7^PBH+;$"<5@3WG3PKZ
M,U>O8+([FOW81N"OQLKI(3T7\F]^^4'9\20AW"'L2&ULG;\^4)&!HT#C^*%B
MRG@!`N#3*IE*#7`D?6G_7U@N3UL[6#AAY`4$X-:>"OG(%*5M96<A>?D_@DA'
MA21^1Q*`^F[<GTKBHJ!V?P^I3'>;AE\L2!I84M2I2D&R!N+KQE#&;:OO[12V
MJ$B^*9:6"S8A(#S/NS#:N,_@:-9!8H3`@;A!B(Y(K@@5"%!WDPC[-B4&$,&W
MO;\J4I,,14M]O7@,\75$,D:$JQM$TPC6#37>UZ;`6WL^L&+AW6A;0V.$8"HI
MAY/!"VUA8)F^L`)#Z@T7-H(0(V35QI!$)-!U)=HP\7O#-%&0T]-%*;`AJJ=%
M-Q"R:$4MYJNY(6HX[$>DSSQ-U.(SHA38$&58$2,$12U]KU^UU9P,AX-E\$[>
M1)\1I<"&*,.*&"$H:O:&*FW\?5GJWAI4A?OIK,!&.H=ZA&*$#-)Y\$(+TNHS
M"RNPX<?"6!@AG1]S$AJ9E>!XV&96?P8U201JS70S6K0ARDB-N,/@JL8!3-X9
MU"495?M^?`@65NW8F[6PP_1&C60AB:E9EV54Z@]D87759/6G!`\^04PGB_A!
M:`A/=`1D=`_0M:D".DAI==%]?(L0-4N/9M2G2:<1,68.817H",Q!79I1PR=*
M&Q?SR`A:3(;E>O:F?1KBCGU&29^H<5S;(^,$QJJ-`HLA[57;,/.<0?WN/-01
MD>/I?]'OLYY4=]:H^4KU'-@^2,QQ\8_,XD\0<T^UCOB,:N-2F*AZ?#M$YNT`
M+;+R&H]3Y"^B8#5H:#JWAYAP&?AS?]"=H+W8)V,?6=+F2!-:%,+*^%GUP`0B
M>7N+_7FL^O.VP[X-0'M<IT?Z9]H<626L@AY@JN=$$)X&&VQ\D+QN^[@]E]`8
MMU]/\$.(0E/D.0`^<"ZO#ZISO/VTVOT"``#__P,`4$L#!!0`!@`(````(0"J
M@;R;E0,``)`+```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)267V^;
M,!3%WR?M.R#>"QA""%&2J4W5;=(F3=/^/#O@)%8!(]MIVF^_:RX!3-,L?8&`
MCT]^/M<V7GQZ+@OGB4G%1;5TB1>X#JLRD?-JMW1__WJXF;F.TK3*:2$JMG1?
MF'(_K3Y^6!R%?%1[QK0##I5:NGNMZ[GOJVS/2JH\4;,*6K9"EE3#H]SYJI:,
MYDVGLO##()CZ)>65BPYS>8V'V&YYQNY%=BA9I=%$LH)JX%=[7JN36YE=8U=2
M^7BH;S)1UF"QX077+XVIZY39_.NN$I)N"ACW,YG0[.3=/+RR+WDFA1);[8&=
MCZ"OQYSZJ0].JT7.800F=D>R[=*])?,UB5Q_M6@"^L/940U^.VHOCI\ES[_Q
MBD':4"=3@8T0CT;Z-3>OH+/_JO=#4X$?TLG9EAX*_5,<OS"^VVLH=PPC,@.;
MYR_W3&60*-AX86R<,E$``%R=DINI`8G0Y^9^Y+G>+]UHZL5)$!&0.QNF]`,W
MEJZ3'906Y5\4D=8*3<+6!.ZM"8F]21@GL_>X1*T+W$\NTZM=?!Q7$],]U72U
MD.+HP-P#<E53,Y/)')Q/^>!HNL3>"@R2,B:WQF7IPJ*!+!14^6D5)9.%_P25
MR5K-'6K@VFF(K5B_5D1DVFE\(.ZP(<HA]OERGNB,V-"9\AK<.WPQ1`F[OVD4
MZS.*7F*10&A#$A/@Y,T)=B(RG4`WR"(BX[Q0@Y/24*\'+RP"L!D31+!0+F=B
M.L%D'A(DL1W"'6JF33V3-)DDZ8AQ/520:13&05]3BQ$2&3)>9C/B,5L_#["$
MJ(D;ML#F7F-;RQV$Z2R8=0J+:OH>*B,>4R6=+U*AYCP5MB'531B%4Y)VO2VJ
MY#U41CRFZD>+5*@Y3X5M+=4DGLS2/FF+RGP1!QO%Y0H:\9BJ'RU2H>;2[+JD
ML-A2F\VLP?^O`--IQ!B.5P!J2-!,,^*-@EV/FM-^B!8>]+>RNXZOZ34&[(N#
M(;:B].PZ:!OA9G9DX@T6N,UG-MY!;:_DP^W:VD+"\8(@*'J##QL[ODG?V^8;
M[?97\N$>;O.-*GA'4/0&7_L5..4WZWO;?&9G?G]^IM>XOOT,:NN+HBZBGJ!I
M-V<G8W*F'0GQ8(1?_)+)'5NSHE!.)@[FT$-@8G1ONP/9;=@<J;H&.`_5=,>^
M4[GCE7(*MH6N`<PFUY%XHL('+>KF/+$1&DY"S<\]G'P9?+L"#\1;(?3IP9S9
MNK/TZA\```#__P,`4$L#!!0`!@`(````(0"B`@@[MP(``-<&```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;(Q576^;,!1]G[3_8/F]?(1`FBBD:JBZ
M3=JD:=K'LV,,6`6,;*=I__VN[<"`M%U?$HS//3[WW.O+]N:IJ=$CDXJ+-L6A
M%V#$6BIRWI8I_O7S_NH:(Z5)FY-:M"S%STSAF]W'#]N3D`^J8DPC8&A5BBNM
MNXWO*UJQABA/=*R%G4+(AFA8RM)7G60DMT%-[2^"(/$;PEOL&#;R/1RB*#AE
M=X(>&]9J1R)9333H5Q7O5,_6T/?0-40^'+LK*IH.*`Z\YOK9DF+4T,V7LA62
M'&K(^RE<$MISV\4%?<.I%$H4V@,ZWPF]S'GMKWU@VFUS#AD8VY%D18IOPTV6
M8'^WM?[\YNRD1L](5>+T2?+\*V\9F`UE,@4X"/%@H%]R\PJ"_8OH>UN`[Q+E
MK"#'6O\0I\^,EY6&:L>0D,EKDS_?,47!4*#Q%K%AHJ(&`?"+&FXZ`PPA3_;_
MQ'-=I3A*O'@51"'`T8$I?<\-)4;TJ+1H_CA0>*9R)(LS203JS_N+]Y+X3I#-
M[XYHLMM*<4+0,W"DZHCIP'`#Q'UB3L:0ZFN90HJ&Y-:P6"Y(0D%U'G?1*MSZ
MCV`I/6/V#@,78L#,$%F/,)4`>8-&2'RN,8(2OFQ^+\D$324M9N?M7X!,-6>7
MB'@]0"8:P;NYQN6K#=)K-$$I7HXLB9+K@=]:NW<8UU3&ZVST8J(`:,8*WG;'
M@*$)QR>O%K.3'69MRYFLXF2ZG;EM*VRB`[(>ZS`=]?]JF:"IGNM@>M[>01(K
M9QG&,[69VX[M]K_0B;)DJNQMAPQXJBA:13-)#N,<"H-U,*L=3"3#,;+(#1AW
M`1LF2Y:QNE:(BJ,9'B&(']ZZN;:'N6:G@#]LP%SI2,F^$5GR5J&:%1`:>"LP
M0+K)Y!9:=+;_#T+#1+&/%7Q`&/10X`&X$$+W"W/CAD_2[B\```#__P,`4$L#
M!!0`!@`(````(0!\2P,:10,```4*```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;)1676^;,!1]G[3_@'@O8$(^B))435BW2ILT3?MX=L`$JX"1[33M
MO]\U3@@V3=3P$()]?#CGWFM?%O>O5>F\$"XHJY<N\@+7(77*,EKOENZ?WX]W
M,]<1$M<9+EE-ENX;$>[]ZO.GQ8'Q9U$0(AU@J,72+:1LYKXOTH)46'BL(37,
MY(Q76,(CW_FBX01G[:*J],,@F/@5IK6K&>;\(QPLSVE*$I;N*U)+3<))B27H
M%P5MQ(FM2C]"5V'^O&_N4E8U0+&E)95O+:GK5.G\:5<SCK<E^'Y%$4Y/W.W#
M@+ZB*6>"Y=(#.E\+'7J._=@'IM4BH^!`A=WA)%^Z#VB>Q*Z_6K3Q^4O)0?3^
M.Z)@AZ^<9M]I32#8D":5@"UCSPKZE*DA6.P/5C^V"?C)G8SD>%_*7^SPC=!=
M(2';8S"D?,VSMX2(%`(*-%XX5DPI*T$`_#H5594!`<&O[?U`,UDLW='$&T^#
M$0*XLR5"/E)%Z3KI7DA6_=,@=*32).&1!.Y'$C3VHG`\G=W",CJR1!U+"$/7
M)?C:3AN=!$N\6G!V<*#B0+!HL*I?-`?"4UBTB2Y0E^($`5(D#XIEZ<)6@1`(
MR.W+:C2)%OX+)"0]8M8:`[\]S-C$;(889"*2(6*$)AW&!U>=-8ARW]K[F3XY
M4&#E0&5>65KK`5/N^44M9C/$A)V4%I&\@SA##+60PH^K56"H0".64_/5:XW1
MM:P<;>R!I#=@2($ZZ$M1-1%=W"JG`*I%@#,DS2Q)&M.39`\DO0%#$KR^+^EZ
M+A78C$X8V='1&!2TQ8J\J5V)QGSHH=BTDACSR(O.I6'HGMRB6X%-W6AFAU!C
MXKC5'9BB-M<FDPN3AMSI+7(5V)(;6XK6&G.2Z\5VF.UYTU!R<=I0K5IT[PR[
M7AP*;*NV#IFUQAQ5(V\TBXWKR]UY#^N#P%H03@:0Q(*,XZ!_H?X"PUQ\BSD%
M-LV%D5U!&@/UVYW#*+;.ZLT0,YK8.^`=S/2<?NU!MV/=<"K"=V1#RE(X*=NK
M5HN@B+O1[BO@(6P;>3<!7;C!._(#\QVMA5.2')8&L&-=A^L^KA\D:]IVMF42
M^F_[MX#/+0)'7^`!.&=,GA[4EX+Z?FC[X>H_````__\#`%!+`P04``8`"```
M`"$`"DHVF'0'```%)0``&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R<
MFMMNXD@0AN]7VG=`W&_`-A""DJP&]VFE76FUVL.U`R98`QC9SF3F[;?:W>#J
M*D^`F8M)^/)7X;^[NKL,?OSUZWXW^))7=5$>GH;1W7@XR`^K<ET<7I^&__RM
M?ID/!W63'=;9KCSD3\-O>3W\]?GGGQ[?R^ISO<WS9@`9#O73<-LTQ\5H5*^V
M^3ZK[\IC?H"_;,IJGS7PLGH=U<<JS]9MT'XWBL?CV6B?%8>AR["HKLE1;C;%
M*A?EZFV?'QJ7I,IW60/77V^+8WW*ME]=DVZ?59_?CK^LROT14KP4NZ+YUB8=
M#O:KQ6^OA[+*7G;@^VLTR5:GW.T+EGY?K*JR+C?-':0;N0OEGA]&#R/(]/RX
M+L"!'?9!E6^>AI^BA4EFP]'S8SM`_Q;Y>XU^']3;\EU7Q?KWXI##:,,\V1EX
M*<O/5OK;VB(('K%HU<[`G]5@G6^RMUWS5_EN\N)UV\!T3\&1-;98?Q-YO8(1
MA31W\=1F6I4[N`#X?[`O;&G`B&1?VY_OQ;K9/@V3V=WT?IQ$(!^\Y'6C"IMR
M.%B]U4VY_\^)(I_*)8E]D@2NWO\]OCG)Q">!M^V2Q/-I-)W=<"DSG^4>9[G5
M#RR.=E#@Y_E2+@W&R`UL.T\B:[+GQZI\'T#QP]#5Q\PNI6@!"4\3Y(;S/&7?
MFS&8*IODD\WR-(1XF(P:RNS+<S*)'T=?H#167K/DFBA4I">%K0.;5IP`2AO-
MPB!YTIR"E`.N!&P638%!8`3#<!X+*!0\%OU%>K)LQ=;RZ7V7#D#N\QB0$4BY
M8OH0NA%<DDR24"/[-)-0H_HTTU"C^S1D=$V?YOZ<)Q@]6%YX]&PE3;Z[U$^C
M:(-`AP8MB8B7I=.X[<%.:$J!H$!2H"C0%!@$`EMP;=36#/;!CXO#!L%>A6U-
MYN=A:XM[Z30/[6J9C-M_H2)UBLZXH$!2H"C0%!@$`I\P5=3GY>FS0=0G*>FE
MTW0N4@H$!9("18&FP"`0V((=]W9;-NA253H-LD6!H$!2H"C0%!@$`EMP@%!;
MR<6JM$%DMJ;CL.:63C-KJW(>SZ`L0T&*!<D,^BDB$$[0#8RD0%&@*3`(!+;A
MA,&V/UZ$5DSMDB-GZ33=Q:84"`HD!8H"38%!(+#S$-JY;LNT09>*TVF0+0H$
M!9("18&FP"`0V(J@$O$T7>>KC:+S18[0I1<A9YZXBIW.[Z>L(%F,9$0QHADQ
MF(1^;4-!FJC+9T3DVI#@D)B2LW[I1=BO"W-^(W=PA$M4L"#)B&)$,V(P"0W;
MM@`9_G@=1JZ)"(W20]Z+L%$7UA'!-)(1Q8AFQ&`2^K)-`/)U9>':J$LK,G*B
MSDW*B&!$,J(8T8P83$)_]O"_W9]K&<+Y8PO3B?PRA$5(EV$:H<[#M_>42*91
MC&A&#":A7]L5$+]7+$S72X1^V<)T(M>^S:/['K^H)?%^*9'V7AA*IZL*Q8AF
MQ&`2^K7M`O)[85VZYB+T26X2EA'J0%H7*2."$<F(8D0S8C`)?=E^`/FZ<EVZ
M+@**['Q'QF\N(M1J>'^4"*:1C"A&-",&D]"?;1!N]^?:BG#^R`W<,G(BMRYG
M\W@R(?UYZA5=#0I&)".*$<V(P23T:SL'XO=R^QJY?B/TV]V,MK.W]*+.3<J(
M8$0RHAC1C!A,`G_Q#S5`;=2E<\2+D#]&!".2$<6(9L1@$OKK:7@NWRS&?0T/
M/4>\"/MS81T17N-J.NXY:R3+HAC1C!A,0K\W]3MQ7[]#[_Z]J'.5,B(8D8PH
M1C0C!I/0%ZPEN@ZOF$<;=;%.G0C[HT3$E$A&%".:$8-)Z,\V&&2?N<*?:TO@
MXKIS8TKWU=B)7`U.XOEL2G:BU"NZ$1",2$94D-?5-KG!UBS(8!(.@.TOR`!<
MWFCM!]HPP>$`D&-CZ46=O901P8AD1#&B&3&8A/Y(PW-=8Q"[GN;CQL"+L#_:
M"@FFD8PH1C0C!I/0WP\U/K'K8,+Y8QLM;7-2']8Y%HQ(3[Z_]2H6HQDQF(1^
M22/T<0,;]S1`,[):EE[4N4H9$8Q(1A0CFA&#2>BKI^&Y8B-R#<^%.G4B[(\2
M$5,B&5&,:$8,)H$_NZ?0?>:ROS:*[C-TH_4B5W'3B?W`D4QQZB7=$`A&)".*
M$>V)>ZO$OA%]*X.#PA'H:8FL^.,*3GI:HAG]C-*+.GLI(X(1R8AB1#-B,`G]
MD1;HNITV<:W0QQ7L1=B?"^N(8!K)B&)$,V(P"?W97N3FDS*Q4:2"9W2G]:+.
M3<J(8$0RHAC1C!A/7`G;3^]Q"8>&;0-SNV$;10W3ST82)\*&*1%,(QE1C&A&
M#":AOY[6YXHMR;4^<+E=[\>_D'0B[(\2D5`B&5&,:$8,)J&_GM;GB@W']3!!
M:\`+EC8Z*3PC8J>]<RP8D8PH1C0C]ND3F[E_SW6&W=,E[JF%?5Z]YFF^V]6#
M5?EFGQQ)X*NJ,ST_U?(IME_,$[Z,%FG[7`#A(EK`8P2@'YW_``^A'+/7_(^L
M>BT.]6"7;^"MQG?W,*N5>XS%O6C*8_L,Q4O9P.,G[:];>-PHAZ^IQW<@WI1E
M<WIAW^#\`-/S_P```/__`P!02P,$%``&``@````A`!\:S\(;!0``Z1,``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE%A=;ZLX$'U?:?\#XKT!0SX@
M2G)50-V]TEYIM=J]]YD2)T$-.`+:M/]^9QA([8&V21[R88Z'<V;&/L2K;Z_%
MT7J159VK<FV+B6M;LLS4-B_W:_N_?Q_N`MNJF[3<ID=5RK7])FO[V^;WWU9G
M53W5!RD;"R*4]=H^-,UIZ3AU=I!%6D_4299P9:>J(FW@9[5WZE,ETVT[J3@Z
MGNO.G2+-2YLB+*MK8JC=+L]DHK+G0I8-!:GD,6V`?WW(3W4?K<BN"5>DU=/S
MZ2Y3Q0E"/.;'O'EK@]I6D2V_[TM5I8]'T/TJIFG6QVY_#,(7>5:I6NV:"81S
MB.A0<^B$#D3:K+8Y*,"T6Y7<K>U[L4P\WW8VJS9!/W-YKK7O5GU0YS^J?/M7
M7DK(-M0)*_"HU!-"OV]Q""8[@]D/;07^KJRMW*7/Q^8?=?Y3YOM#`^6>@2(4
MMMR^);+.(*,09N+-,%*FCD``WJTBQ]:`C*2O[><YWS:'M>W/)[.%ZPN`6X^R
M;AYR#&E;V7/=J.(7@407BH)X71#X[()XTZLG^]UD^.PGP]<K[PRW:>G#9S\9
M2'P^V:$4M!E-TB;=K"IUMJ!-061]2K'IQ1("]JDDX9?D?I1;2"H&N<<H:QO6
M%Z2MAH9XV?ABMG)>H(A9AXD(`^\7C#`1\5B4N8E)>@SV!TBXZ(`,Z#K&6Z&G
MBV"DBZV!_",:T+EYYGWC$02#)$.(+Q:7,`9;*/;U;!$,+:HESA?!)2X)(`PU
M.RJ*^4"B#1A4H.@Z%6R`Z8=KJ4\@3@*<06G**!%&H\0'$FW`H`2WURE]7DL$
M\^R$C`IAYFUCSL)`")>U5:PC_-`-9X%KQD@(T<HQR,YO(8M@1M9C-XH(TY&=
MN?`RF<0ZP/,##S`F(B'$D.OB%JX(YES9BHT(,VL3RTC$=(UTW,UG@<](]G/Y
M2D:7UG:DSZN/8$Z2K<N(,.,DZ5I'TG>G?L@D)OUL3C.\A2:".4V6CX@P1&4^
M\T>:5$>,MG&B(W@;&UTKP'2OSW*+YOSY>N]`)&`JY@%DTRQYW$'>]X1$'S$)
MXD:OM0'N2SZ0_KP=!-F#L5=Z`R,B$-P:C<J;N&ZHO]C6&G<Q.[B8+!@@Z0##
MY2;0$6[70#YB:F#[5=2&!L\F#6(R8]6(38`W\5F$I`.,L$:GN)TU^8O)^MW]
MR*4$@<+1_:*[V$ERX8%,KTH8#@10L!$!Z"NW"R`W,@6P4D>"0!\(H(N7FH2L
M_9-N]@AC-)?;&9,EF8RY]>%S,6P][Z1836(3\-5J2$RXL1K,]8L>=+LD<BY#
MDL^,)1($ND@*F.:X`[1Y;ALOT4=,FNA"M],D[S)I,N.(1&]P[P^\OL^\*1X%
M#?IF+-+[@C<%H5_=+HA<SA0TV#=[*]0%L549BQ[4/ULG^HA)%=WJ=JKD<295
MUM21(!"MTWF`3U'<BG3$8@21=#&&J]5CWGF=-;6SF(?Z?'_I0.2AWMP+AL0-
MR)BTQ$`P:48!/.:QGWMKB^8"V-*+.A`)$"$\@PPRWT&TU:F/F`29@7Y!<,0X
MIZSND4<@ZHQ`+$;XZ8AIN)@.($D79*0UH"WUEOZ",*)91J=\&X&#%&,#G[*4
MQR8`-G`&P*,8C*"QI9,5.@<H9+67L3P>:RM3SWAJXH$]7T8O)SKW'OY=9N,Q
MG/2TQR+.Y0(<M)S2O?R15ON\K*VCW$%(=[(`'ZKHJ(9^-.K4GCX\J@:.6-JO
M!SA2D_#G%;S?MG9*-?T/?/:^'-)M_@<``/__`P!02P,$%``&``@````A`,ZC
M;;&8`P``<0L``!@```!X;"]W;W)K<VAE971S+W-H965T,2YX;6R45MN.HS@0
M?5]I_@'QGH`AETZ4I-6AU3,C[4JKW9F=9P=,@AHP8SN=[K^?*AL(=E8C\I)P
M.3YU?*K*U.;QO2J]-R9DP>NM3Z:A[[$ZY5E1'[?^]V\ODP??DXK6&2UYS;;^
M!Y/^X^[3'YL+%Z_RQ)CR@*&66_^D5+,.`IF>6$7EE#>LAC<Y%Q55<"N.@6P$
MHYE>5)5!%(:+H*)%[1N&M1C#P?.\2-DS3\\5JY4A$:RD"O3+4]'(CJU*Q]!5
M5+R>FTG*JP8H#D59J`]-ZGM5NOYZK+F@AQ+V_4YF-.VX]<T-?56D@DN>JRG0
M!4;H[9Y7P2H`IMTF*V`':+LG6+[UG\@Z(3,_V&VT0?\5["('UYX\\<MG461_
M%C4#MR%/BA[^925+%<L@<[Z'&3EP_HI+O\*C$()(#<`@\F<7YBG"*$$?9GC=
MA7S1:?M;>!G+Z;E4__#+%U8<3PHBS<$&=&.=?3PSF4(:(-8TFB-KRDN@@%^O
M*K">P$;Z;M05F3IM_7@QG2_#F`#<.S"I7@JD]+WT+!6O?A@0::D,2=22P/_%
MO(^B*9F%BSLXXI8#_EL.$H[D",R>M%W/5-'=1O"+!\4*JF5#L?3)&GC_WQ,P
M`[%/"-[ZT$RP70F)>=N%F^`-K$];Q-X@X+='$!N1=`C,'FCHA8`QXX4@&(5@
MLE#9WCP8QHV<N`81:=6SB,37]Y8,\&"\#`1O_=E@M[$==6\0IJI0:#)X8,4%
MDO%Q$0Q5.(@[<^(:!)1GGX>YC4@ZA)L'6#->"()M(0L[S-X@YMKVA]6,S!]L
M0-(!7!V+>W0@V-:QM,/L#0)UY+O)A$23&`HSQQ*>D)6-33JL*VEYCR0$VY*<
MG>\-`O;?Y\@5TB%<(?@Y&]VT"+:%$+=K#62HA+AMVT%<*2M;"IZM,1SKOS]'
M<)$CZ=J.IJ$-9-`XYL%"%](R)LM5'%YS;+42@?CC[=%H1XS;Q2W&,LCIN*3'
MN`X1//%&9TNC'3E.Z^Y;C)%ST(XX&4UZR(V:N\Y98D[-X4E#W`YO,4NM8Q:%
MJQMG#(G.I9TH/`S'.V..3DO+M0),U1"#L1+EM%W28VZLN>L,AC'GIHB=_MVW
M&'/Z12%Q$HFC$G(,G#$#C?E"5TP<6<+*4GHI/^.`0L#C_FD_<;6C4/\"9I>&
M'ME?5!R+6GHERV%I.%V"*\),/^9&\49__P]<P=2B+T\PVC+X3(53`.><J^X&
MO>J'Y=TO````__\#`%!+`P04``8`"````"$`)'K1CE,%``!%&```&0```'AL
M+W=O<FMS:&5E=',O<VAE970R."YX;6R465UOJS@0?5]I_P/B_0*&?!$EN6JW
MZNZ5=J75:C^>"7$25,`1T*;]]SOV.!@;)T`?VB8]GC,SGG-PW,WWSR)W/FA5
M9ZS<NL0+7(>6*3MDY6GK_O/WZ[>5Z]1-4AZ2G)5TZW[1VOV^^_FGS955;_69
MTL:!"&6]=<]-<UG[?IV>:9'4'KO0$OYR9%61-/"R.OGUI:+)02PJ<C\,@H5?
M)%GI8H1U-28&.QZSE+ZP]+V@98-!*IHG#>1?G[-+?8M6I&/"%4GU]G[YEK+B
M`B'V69XU7R*HZQ3I^L>I9%6RSZ'N3S)+TEML\:(7OLC2BM7LV'@0SL=$^S7'
M?NQ#I-WFD$$%O.U.18];]XFLGV<SU]]M1(/^S>BU[OSNU&=V_;7*#K]G)85N
MPS[Q'=@S]L:A/P[\+5CL]U:_BAWXLW(.])B\Y\U?[/H;S4[G!K9[#A7QPM:'
MKQ=:I]!1"..%<QXI93DD`-^=(N.C`1U)/L7/:W9HSELW6GCS91`1@#M[6C>O
M&0_I.NE[W;#B/P01&0J#A#((_)1!PFAHL8^)B+I>DB;9;2IV=6!8@*J^)'ST
MR!H"W@I"^K;$>Q5":3S($X^R=6'*(?D:MN5C%ZV"C?\!K4PEYADQ\+W%D!;A
M0S9M2I!&-R5[;V_,',R9>:]Y*L_X1I<FM--`S\;3<#!L5B?Y:*721V;$B&W7
MZIGI1+S%L[LS<ZN++P)<EY#,VD*0$#%]0@@^OC(.-BM3'4,BQ)!`["SQ%FT>
M6IV+*;0<;-)&;5RD1<P"YXDLYJ'*2R->3B'F8)/8;"QBAHFYK1OBB<!3'D\L
M7V0F,#<J1PRTO=5*M+K3]5C/X3$W!YO<2X,;,3'N]6H9!$K(6M=A'+3J'S,+
MM$F],J@EJ#_1A)N'T>EA#8E50R*2(`OG)!\BZ#NZ0ZAYQ8&6H%9(2[7O>FNY
ME73*'6@M&H].;6J)((@$*.)E$,;>*E`;H/,;EC7`CSZD\YN2(@A"37'V^^2&
M?7&_'%85?PKW1ENU5_8?0;JNXG8(]1Y,LC-B\S-361(D?24.HOO:FF1IQ.)I
ML5*MK!U!ECFWN-@(;:%%P:XJB^H]H,C-Q_B9JON()Y-<2Z!-[^AI"WU+:BOT
M0C@:=[X47$LDG&1B`FTF8BI-@G"7YV09SM4<Z-R&J3U66<C1)K>I,@D:P6V8
MVSB1A3:3,T4F09K(8G56TEO`76FTT?%C;J\%JKDXYQ(T%\\O)0*==I*_A19_
MB]4\25H$]>7%#_;=$L<=_\2JH4>7!%DX)WE7:/.N7GT(DO**/#7U>F<G&5=H
M,:Z5BBP[BR"<Z04)`[7C.K7A8P-R0FMZ_-`*$31,;=C92#6A8^DI]-2$(%U-
MJD5:!_A3LCMJCSL@T*:AJ-YB\R7HH9JB23XFT`9M;/J8!/4G.[+XUO##2JP:
M4I,$63@GF51D,RE331+4JNG>03":9%0";;2V)R<)DH\(_H2TGW\BP[<&AHFC
M3>K>KB)HF-JPKW%RBFPV9LI)@G0Y*9`NITE>%MF\K"<G!#V6TR0?BRP^%JN/
MBE+%"+*,ML6X1L@)/0EF\\'9+[H9EWGVFTUR*8$V!\N4DP2UGZON?*R933(J
M@3:9E?-B9R4(1WH9+V?+CI=ITS0SG.NQG@3:)#?U)$%CR`T+&Z>HF<W*E%AD
M!Q"D*TK-O=Z#278&%[E]3U&1)3V"\+HB"E<60\/;7+SU+&AUHK_0/*^=E+WS
MFUH"!\7VW?86^2D4]\#M'^`2]Y*<Z!])=<K*VLGI$98&WA+*KO`:&%\T["+N
M5/>L@>M;\>L9KNLIW$P&'H"/C#6W%UP8[3\`=O\#``#__P,`4$L#!!0`!@`(
M````(0"TB/^5!`4``/`2```9````>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM
M;)18VV[C-A!]+]!_$/2^EJB;+</V(KJU"[1`4>RVSXI,VT(LT9"4./G[#C6R
M30ZWB?/BR]'AT1P..4-I]?6U.5HOO.MKT:YM-G-MB[>5V-;M?FW_^%Y\6=A6
M/Y3MMCR*EJ_M-][;7S>__K(ZB^ZI/W`^6*#0]FO[,`RGI>/TU8$W93\3)]["
ME9WHFG*`O]W>Z4\=+[?CH.;H>*X;.4U9MS8J++M[-,1N5U<\$]5SP]L!13I^
M+`>(OS_4I_ZBUE3WR#5E]_1\^E*)Y@02C_6Q'MY&4=MJJN6W?2NZ\O$(OE]9
M4%87[?&/(=_452=ZL1MF(.=@H*;GV(D=4-JLMC4XD--N=7RWMA_8LF"Q[6Q6
MXP3]4_-SK_RV^H,X_];5VS_JEL-L0YYD!AZ%>)+4;UL)P6#'&%V,&?BKL[9\
M5SX?A[_%^7=>[P\#I#L$1]+8<ON6\;Z"&069F1=*I4H<(0#XM)I:+@V8D?)U
M_#[7V^&PMOUH%LY=GP'=>N3]4-12TK:JYWX0S;](8I,4BGB3B`_13]>]3XL$
MDPC<]B(2S@(OG"\^$THTJ<#W1<6;>8N0A=''AAR<G'&NLW(H-ZM.G"U8P&"_
M/Y5R.[`E*%\F&:?D.NW_-^LPW5+D0:JL;=AY,*$]+)67C1\O5LX+I+>:.(G)
M83HCO3!D+J5LA@!\*K*Q/BC_"2<*=4YQX<CE!KZOYB&[JOF?KZR+1TF6'B_1
M)0BHT7GZ?5.3$9+P,Y,2N*XNDYL</XIT3F%RO%LTFFE8RO>;EF38.$H&`I>D
M+4%./*8]8"&426(@51GD6H;7<`/+I.<4*!1`,P+;ZGXCDJP;\7U]"A.D1*,/
MYL;NPC2"E%NP&05R"A2J:C0/(U54LP/5X7X[DJS;"=Q;OL?=DR`'_?@L"I4%
M,1)2)"AN*)!3H%``+7@H'?<'+\DT>)H,Y-QB2RF042"G0*$`6K!S/5A9\WQH
M3^]O?SF(!AV0%80<)6@*9`A@3B(_7(2D5.5T1*$`F@EYS%$*]_O!2S(-GMPY
M08X2/`4R!)B+.V1&2E!.^84":*''GPE=DFGHY,X)<I30*9`A,,<:Y;MT[^=T
M0*$`6NS@_A/S/K+UZ/UH3E;-1%+"-Y#,0'(#*51$CUGV/V6MW+?@&79-J+[7
M[ANX1NQ(4F.G2#8)W3CYA$RE-F90$VG/*-11NAO9ZC[O!AND[L8XHB#I%FG*
M*)(92#XADYO`#>.(D15:J*-T-[*[*6[>W\<,>Z'N@APIDHFDNL!A-R0S./F$
MP"*2QS<V"TBJ"W6(;D&V.,7"G<L+&Z-NA1941MMI:B"9@>171#IQ9Z30%=?+
M]#@HGRZHD0"P#W*"/5$SPL@I)QFEU_8M`ZF!9`:23PBNK+GKQ0N7+-E"':1G
M178_)2L?F,!>J9EPR<0E3&FH>((PD,Q`\@FY+JPYD2W4(;H%V?ONMX"=4K=`
MSZH,2=->A4.>67G2B7/+568@N8$4*J*[D&WP?A?8-%47M%DE##G3B5N>MVGU
M3">*ZD'IQF/R<H-3J(CN0;;#^SU@\U0]!"ZIB`F\.I"-_19A:B"9@>03<FGD
M\\#8#XHL6L`7#/C0V_!NSU-^//96)9[ERP,/RMT5O;[8>/#D8Q[!$[:$1U19
M-*X7X'W#J=SS/\MN7[>]=>0[D'1G<R@)';ZQP#^#.(V/VH]B@#<-X\\#O%GB
M\+P#]<FV=D(,ES_R!M=W59O_````__\#`%!+`P04``8`"````"$`+_N>"HL"
M```Q!@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R<5%MOFS`8?9^T
M_V#YO1@32-,HI$I7=:NT2=.TR[-C#%C%&-E.T_[[?;83FLLVM>,!,!R?[YSO
MXL7UD^K0HS!6ZK[$-$DQ$CW7E>R;$O_X?G<QP\@ZUE>LT[TH\;.P^'KY_MUB
MJ\V#;85P"!AZ6^+6N6%.B.6M4,PF>A`]_*FU4<S!TC3$#D:P*FQ2'<G2=$H4
MDSV.#'/S&@Y=UY*+6\TW2O0NDAC1,0?Z;2L'NV=3_#5TBIF'S7#!M1J`8BT[
MZ9X#*4:*S^^;7ANV[L#W$\T9WW.'Q1F]DMQHJVN7`!V)0L\]7Y$K`DS+127!
M@4\[,J(N\8K.;Z:8+!<A/S^EV-J#=V1;O?UH9/59]@*2#67R!5AK_>"A]Y7_
M!)O)V>Z[4("O!E6B9IO.?=/;3T(VK8-J%V#(^YI7S[?"<D@HT"19X9FX[D``
MW)&2OC,@(>PI/+>R<FV))].DN$PG%.!H+:R[DYX2([ZQ3JM?$41W5)$DVY'`
M<T="BR3/BLO9*UA(5!0,WC+'E@NCMPB:!F+:@?D6I'-@WCN+.D:O?[,*'CW)
MRK.4&+H=7%@HS^,RIW1!'B&G?(>YB1BXCY@7!`$UHR20<2CISTG>1_9@']DG
MW4NYB1\.PV2CD*,PD[>$\6"HVH'XG+[PQL@1$^I_%"A_2R`/+C'<QRSE=#(:
MB($BYCP0]-)AXGPM)]#K_TZ@WW3J+#\)&#'34-B,9K/\1=&1T^G_"/";3@44
M)P(BYBH(F!0I7",@"HBC&SM;"=.(#Z+K+.)ZX\>2PL;QZWABK+(P].,/F-B!
M->(+,XWL+>I$#5O3Y!+<FSCS<>'T$.9FK1W,:GAMX6@6T'UI`N!::[=?^%-E
M/.R7OP$``/__`P!02P,$%``&``@````A``*'<^WF!```\1(``!@```!X;"]W
M;W)K<VAE971S+W-H965T,BYX;6R46%UOZC@0?5]I_T.4]Y+8^6H0<'5)U=TK
M[956J_UX#L%`U"1&22CMO]]QQN"/T#:\E)(Y'A^?&1\<+[Z]U97SRMJNY,W2
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MA30S&HE,!:^``/QUZE*T!BB2OPV?YW+;'Y9N$,^BQ`\(P)T-Z_KG4J1TG>+4
M];S^#T%$IL(D5":!3YF$T+N3!#()?*HD]#$B4?PU%0^7-:CTE/?Y:M'RLP.M
M!\2[8RX:F<PA\VU90`^!_2[`PQ!8<0>U?%U1?^&]@OR%A*P1`KM'04Q$=@-!
MKQ`/:%VY@5PZ-U&Z`!K@<XYBD,617-,/RU@CY'$HD5A7ICTP"(`@.H'/)Q;@
MI1OJ*P^LB1&";39,K#TP)H8LTR<68%!&GSBT)D9(.I2,4#],S7AFQ).(1M>X
M00LZ7J<UK2!BD$5/I<>"("1&>E%BL<_,</AXFUQLDON\6`)LD8JO:9$40B2I
M(*96,3,CGOJ)BAN:)??0$F"+5F+10D@T:)580F9Z,%9!@Y#X99N\XP78(J3D
M1YT0@H2(%<STH!+8X)/>PT>`+3Y6+Z\1<JE;0M2T`]_,B*<D5-UFT"+@---U
M&M#F[@]&UB@R+EUM^\M1PQ-S\OML&2U5=X#`]CR"F,L>BRS5,AG',J:I$LWD
M95GRYYN,H*\:O)358_=(#/*B<:@FQFH9<4)3U6`F,>&DD[N:"+391H':OI(8
M8J1@?NJKF24S'1`GD6)N,KO+R\G8S`/5H)(98K!4E(YXZ>$H4&&3EN7E7U1R
M;.*!LA=)R[3I(+1:,!/'+E`=%4VCQX^8W67D9.SD@:J$9&98=72#F0[XA-E=
M7D[&9A[89BXQ(,SUN*053/;9Q=1O8LRBWN7M!,T9VD5-;MG"6F)TS[I8NCAU
MZZ<U8AFY.!V$L+(O.FOLZ.'(.!&##6\%LV%:X:KB.*J"!C5J>;F@EGQ);1AE
MNH3=TVN)P=FU(P"6SHPJZS/)W>7U=.SUH4J,_2XQTKH(27P+D5D(/Z)JSYCD
M[C)\.C;\T/95B4%R#X0$H:^J)F7#-!>(3WQMB28]R_:GG4CIV/ZU4X#44'?W
M!P*O6.8Y+)-)+F[VD?U3X<:3?Y@&M-5RUL1KB;$;7DJGF[_2U11-^/!T2@)M
M45+-(L5"S*5@-\32`6GTH5B6]4\LY_@G(+2-%JX8Q"KD&U`P/A6:@!O'0KQA
MP'?GFK5[EK&JZIR"G\3M`07[N3[%FXTUF<.;)KBD]3P3-Q[BN7<-P(7#,=^S
MGWF[+YO.J=@.4OHS85$M7EG@EYX?AU?;#>_AJF'X]P!72PS>8?T9@'><]Y<O
M8H+K9=7J?P```/__`P!02P,$%``&``@````A``PCB@S?`@``XP@``!@```!X
M;"]W;W)K<VAE971S+W-H965T,RYX;6R4EEUOVC`4AN\G[3]8OF^^R`=!0%7H
MNDW:I&G:Q[5)'&(UB2/;E/;?[]B&4@?*@`L2X_>\>7S.P<[T]KEMT!,5DO%N
MAD,OP(AV!2]9MY[AW[\>;L88246ZDC2\HS/\0B6^G7_\,-UR\2AK2A4"AT[.
M<*U4/_%]6=2T)=+C/>U@IN*B)0J&8NW+7E!2FJ"V\:,@2/V6L`Y;AXFXQ(-7
M%2OH/2\V+>V4-1&T(0KX9<UZN7=KBTOL6B(>-_U-P=L>+%:L8>K%F&+4%I.O
MZXX+LFI@W<]A3(J]MQD<V;>L$%SR2GE@YUO0XS7G?NZ#TWQ:,EB!3CL2M)KA
MNW"RS+$_GYK\_&%T*]_<(UGS[6?!RF^LHY!L*),NP(KS1RW]6NJ?(-@_BGXP
M!?@A4$DKLFG43[[]0MFZ5E#M!!:DUS4I7^ZI+""A8.-%B78J>`,`\(U:ICL#
M$D*>S77+2E7/\"CUDBP8A2!'*RK5`].6&!4;J7C[UXK"G94UB78F<-V9A-'5
M)J.="5P/)M$X"9/T_RB^79;)TCU19#X5?(N@\P!<]D3W<3@!9YV>$23Y='H@
M+SKF3@>94%!+*.G3/!Y/_2<H0[&3+(XED:M8GE`<)#[@O3)"VJYGU$&P%HP.
MC+E+L+"2,#`K"#_=C-SYY?OS#AX\XRW>^=1IL8N5!.YC%U:26JK`?ES)\JS$
M@8NO@=/B`5SH/GEA)8F!&X`O3\\Y./"?N3Q76CS`.72(Z<2%E9S&.3WGX*0N
MSF7=KX,&6(/.65C)^YWU_KR#E[EXYSM+BP=8\:!X5N)VUK"(YS4.GCXBW^P=
MY_&T>("7#/"LQ.)E418E^3AS)4M7DN1Q&J6O$@<NOP9.BP=P!UO;:5:RAQL'
M69P.]A,XQK3+7I*$HS`^5,#"V7/*[L`]6=/O1*Q9)U%#*]BG`B^#IA7VE+(#
MQ7NSTZZX@M/%W-;P,D%A&PX\$%><J_U`GX.OKR?S?P```/__`P!02P,$%``&
M``@````A`-JNYUC^*@``AID``!0```!X;"]S:&%R9613=')I;F=S+GAM;.Q]
M6V\<27;FNX']#P%!AB6@6"K>J;[0H"BQ05L7CLB>\:#AAV15%IDS59DUF5FB
MV/##P-A]\B\PL`L(?M[W?>?^D_XE_KYS(C(C(S.K2MV6/9CQ8*:G6167$R=.
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MN##OEJ7(%`8,NU4[<'6_:"UE>[3UJ[##"21C(M)Q-HOZA[N(\R2C]'0SJ9K6
M<M0V/X/D%>&,O]H./PE[RWYT]CW-TB*;)1-A](MH%J7C&%S!N2C,D^\O7YK'
M3\/!SU-S=9LM"YQ!2,TRG<5%83+(4WZ7%+$I%O$XF29M07\9CRM!WPL'=0)T
M4A28NO5M5-P:S&?&_)?X#\OD0S2#O+4:7N3Q(DHF)OZ(,U]@9]E):#-C*Z)1
MYPQ760FY74W%10Y-DN.L<U`2L>`V#TP:ER'!+^-%5B3@83W_JGE[5FTI?IU$
MU\DL*9.X^"J<".>$^JDPB^@^NIZU)!3?YTN<(<>0L/]OHERTQ*R>(VQ2#3%?
MS++[.#;7<1I/L;BP89.''M7=#5<T.,4A34IR5SD(*2UQ-F$(P(-PM(=/#Y_"
MS^1XWV:S"0S)WYA7V"MLVY.7('N<E$];7(383&-HL`E,B^B%QZ/A:+0-IN8&
MDK:,OS;;H\%H)/\SA2J-:%G>9GGR8SR!",`6F:0HR&K9\GZ%PK5!`:V8:.5,
MASN#PYW]P?.C0W\^?'HT.ASL'3PW63VUD(*O]I_O#0YV#H(.^]N[@^V]/;]#
MR,:3R01BEZ4X&CQ66TF*$[A(<%1:+<<PB<N9J)&)LCELHN+1:WJ$V,OE=9%,
MDBC'/K>V+1SP;99NC2$9>3:;T10D:1E#F[<.HYV8.]LK$N'8VL<3427/&^/_
M_]M/__Q_?_J?_V;)#`=8J5@O8'6L!8YF3_L4;4LJ*W$T3[`3$RP[RG'R849%
M)%N:NC5`2W)#JOMZJ&AOVMH3P;!+4_H_=T'-WFM7T]5\8$_!:L+LT"L7XAG.
MRQ*"K^HJFYIWV)&(QV9#$QI_',>+4GT1`TL<?8Y5]=W'EE6UE.!LG&:%U:6O
MK&EL*<'OH-;IY%%_19-YDHH'628?6D;E?5S`P1NK29[$'^)9)J8PY*D>HE5$
MA#U>9_`EIGDV]Y@8MGE'5X/>:C:/S1.[G+9./[V-8#&@%,PT2JP:-]B=N\#B
MM5S/<ZM&T)53A-/;1742$;9]&Y>&2^K[W)R499Y<+TN:;E-F)E1ICI:-!]A<
MO?8."5?3RN*6>1$5"!(H$2^3V9*RL*'J<2LW]6CA6C<G=<,Y?Q,G-[<,&"+$
MCQ'V/EW.K[$8;'K[/)O),J?1P#Y2@](7[UVN]FZIUX:*;ZJ`4_JI9[/LKE<%
M>"W./'D'12=C\+G'VYO\;EE8OPC2DL<P?V-$1W1!S8QG!Y_RW\5/7A;@!>2?
M7BOT$8:.^H<6CVGK.F(?B#W=9]%AH9A(.^=)(.0U<\P/9P;^#UQ0T8%AETU/
M8H=O!S\:BTPZ*=%ABV"%XMV+Q'HN;4O7.9_6:Q-230F63?J>+#E/G49J[%#8
M*=S5\_0#F$/6K]C5BR5T*1B/*&IJ%IU!1CA/B[BNB<).(7%G28IP;QUQ>3:.
MXXG5RO0#)$0$I9"2RI$UE`1Q:2%M-'T(..)\C'BP4_<))0BG/B0`1,R+>X3X
M;5)"\KGF23P&<(,H$V(]QAD+V\C`48D0Y29)4RZ-+)7CW=<4T7I_H\OE8C$3
MRP[#.`&X@4.V)&+`]?.,3W'&04R%_;0D32B2F)0LZG-1FZW*Z&.;;^_RFRA-
M?I2C(/+]-BI!"BGQ'`ZJ:BIMH1#>7`$_L_/T^,,-X!XX;X9[QT'\OIS#[A#8
MX&FZ'TZNB3*-RQ8.]1\R_,N*X>:'J_AC:5[,X,,'<^5$Y+8M<H4_^-\+_*/X
MD:$;(,31HV?'WXP!<^54]G-@AMO\)#]#Z*!-KI(YMO1M?&?>9_,HY;?3"'KM
MWH[`#Y[)H`(Q?E4LHC&&@6HJXOQ#_.C8J'!YLU^CRY>AX-AG[<\6!)#J(90O
MXV*<)WIPL=<OE@40QM!M09>>Y?=;\B<TKS_]\7^?PJ)$Z?U/?_P_!MN`#SJZ
MX,NG,"PF@DD9Y]EU`N=K:TK`"Q'VPZ<Q8KP$X.(6D#K8=MHHC`B-(.XGCSI=
MLF@1PTT9BR&$*BWC<2DFOA[2W-W28I91?@,$%-T6$>)X8`M;%KD:\Z!3R11#
M`%TQSH;.!-*\R2+857K+(%,`5%I>?\*;9>FMPSRYB7!2,IY_V@-T?/+=^5-M
M`1V21T_5[46#'.Y+"GS-/#G_]5-L<)E@#ED3-0@9"L%#$U&SV*V6["5?3O9.
MAV#.E"B*@YH\F?\R\DY0O^/$0>=B;YVV<KL!V0!W30DC(6X2=P6PSA*@)AF7
M8"<A$&#:/"X1'Y"5&;X50R'ZM9A#<Z8FR7.@''3*K[.[>&:*^W0"+RTV=TEY
M"]E+L8F0&T[_Y/S%Y=;ITR%=A,CB)0.9K4=P#*QF!D-"(9#=S2;W%.=KB(6,
MZ+:Y7@4(AA]=+@LJ=IH^AO[7D!II+S0A4LCCCZ#G-,L7[ILG;W][^>HK\P_O
MWCX=8"YXQN:"GH;94>&%+,+SA67+ES=BPLFDQK1Y/(L6T`8W6WD,2$X.#'`>
MK!Z\@3F,<^"<$-4WEQ15NHXW*7Q7Q`F3^V*Z3'6+0/*;RUI%>YH'!\R=V8=/
M)]BVT$S#2\`&E0^?3C&\X-1A"]JC$!2GKCK^4Q36^NA6Q];C!M(66Z-1*XQ_
M(IHF3G^$?QU$(;+0<[)<H#>[NY&Q(QFG-;&K">3-!CTV8>"=741,Y<DLN4G5
MY!5+.$UJ$VC\OLS)/G90G4?'EYFI1X?\81GE@`PE\_:U.QG7U`G9=`O_Y4%7
M:$;W)>0F!)^X^I@Q)Q0-[)-L@^/R3K7%7"!]DO\2+J>3%AU?ALO'1.)OH]G4
M2V5BT9Y\GW^V6FT==N[$]BC\6$\(?0)D0R;=9Z2DI^]ODU.%S3,"*Z_(P%_D
M]KDC`8O#?/37,"<M4W,:3X`[;UW"7B7F33RA5V:8(G99VN:F5Y8KW#354?OA
MQT_:]A'(0+"GY?$%#(\8&JC4:@?ID0LR.4U@+=*;`M8?UE!`H=*\.CU]<_Z2
M!O1DD2<SN\++./X]'0#D<+8F#N6"Z6)_R@MT(8>H#[^'>-*5L,L(6%6HJU"9
M91I'&#OS?0KCB.H&Y*/0%U%-!(\7E01+NH4A*]YW6-\WEV&KJYSQ2]DRG=9L
MJ(UO\8_$S%`$`74'H!/>S`R,$;3B)BKA:(*M#!ZAVIQ7@Q:M(P.$'*<.UEY@
M:PPT6PK?YAE"TTE<1G`4)]B$`CZ#>E9SJ-</%BP75\8Y#.00/&_-==[#0XLT
MU`9WZ):<G%Z]/W]SN?5*_]_\'9UIB)\Z\1CI$B!Z+(`?)'</^AS*'8AV<9LL
M)'2G]T1,/DMOT!5^/_0!_Y^DJ_/=W)O3:);`%4L3X/$`<5'L<8.2!`)ZIZ]/
MGGYMWKP_U[[PQA/$CI`8I,"C>W-];]@DW*;3?M<H;'H!QPZ\-W'*W!9!M7IT
MK+2U"V+<PT$V@@$H!1%RR!+BD!OT;:N"`)PB(D38>#K6=M-N$9\`8(E3B@@R
M.-C?Q3(G+H2-RF2O\B49Q0W-XQMF!97Q."LQTO`XMO;;5Q\!?!&E/V7"5_;'
M/&%T^.I4HL$*,DGFIJ;%@UN&P-7&6<Y]G-V+UXV($!!H5D*8*8M8W6S&DT81
M\CH*<6@&0G*F\KD*[MOP<FAL(@3A/P:G4$UDEJ7DH`&,R'$120"IWYV<7%2T
MDH^SN(P]8FO&:33YF<SV5Q'5Z.\`^X2#A#A5P*N4I4TSK`3<%50[:)HBJ8K4
MZ`38\!AQ?92+D`+J0"0MTH5]8Y8$2Q9ZD1/.,9H]M%.'($,T!M[2I,3!16`5
M&E;H.FO0V8WCPAH<6P!R<PO+04R@*;AACC;B+M3>8X@-)`U[YT9`R(:@FB<L
MKATO#DL@0*L\FH,CRJG"FND2@G`/ZR#T(09:+^D%REQFD(L8%$!1BK9*?^>"
M&@F[*%;K!^))4&%#^SP&M^V^*CX/9I^DZ1([^%ZL%2/0,VPIB@ZV_KY:`&F'
M1IA@&U%*(YKNX9,M'-N38T.]5W<4J81UF8H*KJC%V=(=<JQRW'7[4][F*/*`
M$6;)FLZ')".R?:Y(#:'DQEOF!JVY_TU0'4<-M`$',>/"J1O="`R-B/1>[:P>
M7)S%`?$=$&M/-8`@C`\(B7)$Z`4E@#&D^'?+R8TF;+DWJ,U9S@7^8GL(630E
MNB!]H[D6V*"_EO"(ZO`2!S3?G$0]#6M1H'<P+C_V^@MLL]2O7$$.I8K-%*1&
M-A_;(69W:'Y#-3M+@/6@A9V$ZL,JHFHU)M;*'*P#7(H6,+!0#5AG18-N,4F[
MUA(O/76$T@%#`.;XVMP"YX!C,H#WB^E4C2<II56,SQCQ802)H>8&Q?-(7*::
M!,`JE%\G2R`2!X=0$<(KR>=RC:B6`2R/9E6_@=TGDN;I+$L`=JVB%Y-.EP)X
M6TY9.*$NLWQ3J[,+U+&U$@\>FAPT-?TX]JI.JR'IG1KO<.'?EPF[>H);/6><
MV@:?7Q"2KOGYTQ__M3!D?S6]%_Y=009@Z1=4UX"AJ`19X@:Y!736+B#BD7V\
MO;T[W&.2<49+`]V4+6]N35,AX:@0EJ.(:2T%FZ(S/W`!C2JROUL"\]L=2;$M
M_LD&G02E,9Q@6I_*K*D46ZM&-Q*@V!@N14F+*0$&![NVR+EJ6']H@,NL%:16
M4,Q`(&HH/KC]>N+8`J5D!4J@4-\,)`'PH-4]JO!@(&N\#U"F)J9X=%AIZ*8&
M/2R;O8$[I$:&#4C;`KN2@ME0#T34')@M]C^>0IN6T(M5)"4N)3X@P51)=;T'
MDC)PX.%"V$ZM@WB%R:P^T`5P+QA0J3)V7+G#GL+H@R*H&V4L^`G&+J]_)\HW
M@YJ!I$PQ5I:#E(*!!H92!4]==QW?9U;-VE%%_LA5.,[.T-L!+#L4"9["K\[N
MP)I6PNZG?_E?H8D2[N79#?@@>;6:']@03=5_W=7'UA^0A>#9PODRRDMLPTT>
MS8O.GO*EG0T6H=H5#E7]X<>AX-$J2OSQN!J_J]U&<A;>O&AX<1;N;E&&P\9N
MPWAD:9IX8F$*B*S[<J&)&!&G"*S2:*%S=6,M1BJ*C*E]C";S>6%FM4250B'-
M2NT8+!`8N)MQ+GH$=2SHI\VJ*G][R9TE8Y0[B`UB-:SZQ!J_8!P8*YC(!,G>
M%%%>[R#<FNZ!.GG@$1J-;\7(5Y44A49[GS.<LA0!?#;[(-O#8UX@'H!Z@6D%
M;3&3U&/^A<0%C?IX%B7(=O"[VG>>S7#T:,G1'886[A5L]FU9?,UV73)N]Q*#
MP+?BZ!`C&_2AK%^]$>1ABTXMX4N6EIY0DSGO@&YPRS.C^P_:Z!-E],SO<L3S
M377+)I5>N181\&1+%5&1H6(%I4%,R1M(*UB",,*J6Z:&J-G%.J4EXA'J8V(D
M\!V'Y@)AH^KG`G$2`BJNV8:G8(!U[9T>1OT4DR@2`@.*@!Y;+"%.8\X--^T#
MQC0%JMEE%.^XB28KM-0832?Q-=S2:J_LS"NY2CX4`+?(*9A7JA/19*WI&0!C
MI^=1_GO6_=_=(K:'#M7:7W45I]$')"&8$+/^(?)7-UM@VAPF4BJ"L4J)H\6K
M;F[(),/J4H1X`AU0IX^EP)M'OY.%XNS"%$"D8C5!V`W\C=!+_5#2B+5@R^H*
M90?9B5V!9$0?`#X)R;(@2@3FHQ,!JLD*S%*UE4!?&H-9"0PU6([O`1X@L:>>
MA!/6/&)9BS5HP`R*6,N//5+<M@5%,AA33QH/IH5!P&<84^1XP5I1JF0-B)1B
M&O50LCL'8Z$!M&\A&4QN9?P1-9H\=-+:%C=7BQ(P,YZT%@!&<C/<:C,](K4`
M>^R"#U%%W$N)%"A,8Y10(N!&AIM$5(X''0P`,A`8:DD`?DT'B^(H`H`1"F2:
M<$D$RIRG:P;-@?V%Z'G^%67=]VM\Y*$23CD1.IF<'Z__G8O=&?$Q^86)<)KF
M8$BHQ\Y8(/IKUOGS))]5H-<YTKSY4@1Z19<Z1"A6!!+>'(T.JX.(74NKY\;_
MV081'H=6[P*8$005T[K"UPN0Z48C4P&WDS<2X/C[S5076O]4=8$3&/A;,7Q_
M\4MYN"%D&OJ+RN;U(D@PG.RT8'0;07R=,8<M05O@D3&A-&E"QPS'^3HN[PB9
MJHY51XL&!3=<Y,@4R_$M)+Q>!PXIX'-H*A`."`I)^XE9+KHM(M5V8TBCPD_8
M`R3!RHC=]Y=1T3PTPG>8:$B_Q=Q%X@5,8"0A.C/"48=/MP7W,#=P5W+&`["+
MT(/B2;=O)CW\O_#,O*:':+9!T@)W5+XROUK"D$K^@3;T"?2+`)SQY.G#)_@J
M!I@ES2Z<$0N\X#-'M\4AQ.T%W6JY6HZ6SKA3S7@N,T.YB^T0,_^'!A'6=M._
M-8Y<$0Y&&]DUR[U$;<:(-\&("7#C,348J86]U+\Z?24=;;<BY?O4&TXY(DB?
M!C<<78(A7/LJ81DP?DJ/5G9:<RT-F$L4<0U`D6\PZ!!3Z^BK<KUK^%,M-6CM
MG"4&PB.";F7"E\TI,75P2/$=^I(S;FWEP7AB7(F*VH+J3^U!F^Z)-JT)HC(:
M.!F0VEBH46.-QI[=D$.(#MYDGOBV%B<5EK0I$M'358'(@W1!(211`*L;.R=(
M<B)+?/OP"30\/AKN5Q`$QW@,4.*@_D06_J:!D8IA<C"M0T[W"'>QRHS0@N8K
MZ&-@IRWE..(2ACC1TZUHK>42>2@I.GCA7]A$`1).#:P=]$UX]!IUK,U>GV&-
M]BPE?PG6:%,>-XW1!2'J3>Z?RI4&U!WJ-=KV[161)H'W'SYU7@SW,P#2I%4U
M=.XJPA:6*,B>!^-XX;K#HD.I>1Q^X):7I,42]F_<NASC&O2-*)=GPE&O<(KK
M`&L".;:E;&L)KG(C*:N#86$1_+K,!8\50EPD%7D9F98J<@&=VI-FC$+O5,TM
M`S)J(KDG9/-C/*8(6QB/R,FV+@*'9!4XKH\"WJ*Z8D=4R@%VH%MNT6MHBG3)
M2!L&TV43[E2[NK4&9QQ2A0H'%X)3Y5!C+01<X=V_EN1\\2.)XA[C[MDV99YQ
MT1*L$\9D+`Y%8.*H#??Z,IN6N('5$IS7C$Z;&/`"3.Z^^7$27&I>=YA<>\")
M2X*!B+VP.8)<A/2YIJBOG<#H]EUI<<TJR&9MRPK20NS"V$BB-K@3X%8K4W')
M:Z9;R-]#1LC=OKLXM>JFZ/DM#2M'Z%R=$FJS[QS8VST7]IK.BF#EEPZ\.JC9
M_TLR(RNWLGF09-NA_0!&2NZA3J/42:Z7*KMXL00OAE#9<->A6`0M>I$AVJ$H
MO!1/%*"YG,D&.!!-<$&'N@=].8J^A!',:ES=OM>"U#"EK&JSE/<2VA?L<-6.
M*U9$USH[]-346]7O](:01YN@A.ZP6\`1SJ[D^8&12Q$2QJ#^Y#TSF^Z48-UC
M`9WD2-(G<H,<A2#**]MM2_+GFCRT^&K``ZZ0-P69E@`^PE02&+6S+_?Q$:4Q
M$H3N0CP9UKL$;+*#U.9$`C?.YC[R$E2ZP%@V4%<F6IX!$"G7'"UFUYD=N&AY
M*`XE0'+Q!A5U0IY$=H!YX("G@![C7'Q$IJXL2.5\8JL=[`J=`.BT];Z'*X4V
M(\!:&`?,T9#;,CH$JT1J$RV[$JN%S>/-!<HHMDKH+!:(<1S1$R0Q$/5!B!U4
MYM#%.CL,0-!%]!*GD:\*/5TU95KV4RB8$*\3\<!Q81E[7`F/GAE(E^R#8S.9
M(M&3;I@Z!.Y*FP34P"7=U3ZV&3"KE]B"?`1HZB90E&RL*9BC\+H&5JV_H#SV
MTW61>_W&DQ,W&UF7*IV"4%JW1%`$?-<,0T1'P!&Z8SAY<+0SV-M[;F_H(?#I
M?*^B_VP$/DIY_`YE_1+U[$A&%0]0;*22()C`[RL5=+A6!;D63@55;I]_'7&Y
MX([AL8OF*QU@R=A#5-GF.M;-%A(TGXQC995N0T7)PQ[((*,0D#YD\-V*<U;)
M<1UH6KW6/+$\`>U/L`5$/BDM%B]FN^8!Q3K4UV)F5%LYO8@/%(IP!L"Z'`2;
M>/)X8*S9D#DX%[/.[N$-:GC$VCQ3N"T/.MR&$>PF)0YHQ@%_RUI.7K+>84Y]
M=*C6H7E2.&>#=4T1\W>7@(`/>\'E!K'8P,H'JE('P0G&')75@X8`ZZP!P0X`
M02*[\BK1(\@/1Q;P8*ZPBD)@3?[8='*-R$O^`!WEB',$>]T5=%M+]>=G'P]5
M%/HMXSM;.G6-^^@(D.SN"U#&2@%<*<$M(P1`MG*G+@@2+H+CPCK=-5S$`[A(
ML%X4*DUF*F5[D,,I-*T(A.IJ]EZM]A@#[NT<#0[V#S]+Z_DBV:7UFE*/IX&$
MJL]WO[9'/;H/A:6(^MVW&^B]W?!U(G#UO_6>AEJ;ZST8M'?C,A-])@H-3R3)
MUC;47J4/J66</TUP'8Z;OOP&;>,I65$BLIVU;W\IOH]X*&@,\T,_3]V,+J<Z
M'*VQM81)<`UY(F:Q,HD`).QID5FD"*^6$DQZX$3F\W5V0S+_+'3VG[0*VQ_L
MP</"\V.?H\0:>]128N=:=5I[XWBQP;[O)N*J?J]@R0VG3I/+8Q56?8$$F=P?
M`QMMX3_KIP$\<V.+J$$IPUPBGX&TG+ZZUC#PB%J80;/I+KU4-U,3(6:7CG)1
MHB!;"?/P?VN[Y;!:;\D".)R0XPJM*&C#E8]KIFUHG7BVD"ID4.Q\;#54+:9=
MH>6IQMM2OPA%@/)<G+LZ;0?/W=7G2L"!`$#B+)OF<.38*`M@/P(Q_D,LJ!Y$
M;S0L*$9UD',RX,&XUXNLL\%UN7(9.(NZJ0VK:C,*7.2+600O\G(,]PWQD'5<
M7')PGDUBK9@+VOD5.)(3LH'<VC)Q<<*D))UF>$6F\(J9Q8=/;Z3B_.'3*Y:X
MXT]&%H*`AQC=*W?GTGG9+0#MKWN[H#X*0HV(\SYL\CXI?@_/!)%A567![&?8
MK)H<,8&XH,K'L!E.'_&&%F7[W1]7HT)HID@N+J'3PR%]Z=,S`K?="PP:ARC(
MJGGR#7EM1^52H81OZL(]E<7J0-1Q/,4:T@1C53?6N@[GYE%WP%OK3PTG<U1A
M2(&Z'7\0KE5ND;K)J^8XL32YE&7%V&GA[!GFQ@G'6V/9"N#ZN/<W18$L@H5-
M6@*'VBIO$\!M%765]B"-=0X@&/,NZR&3R)8LNSV@E$?6(SJ^R,J19W`IC];*
M.:2K?^X9M>8E`>FUO/QY(^[NVJ1,9V9<;IIT\+RE?BWV29+7*I^FT7+:<E^Q
MO,J,P@MREJF@#),'=.08\'Z4JR*^;H<V?GRT?2B&.#A?&ZC6AT\>_05\11L.
M0=WP(BIRPUR8,R\5Q4>'1#2Z*::@^;']1BO8]LKI/W\5X4$]`7(P1P`-6]H,
M\ED!;BN2J0KPK4)%WB4B4&^5B1P)5*C2ZG<DS6'D5F@3]^Q;BS08=]QO"S]^
M[[)SX1<G-Z@#1=E_J\>)#@3+]%'?M`I[GK+>G'FE]KNHS._!74G&81_K<(8?
M7P#+;1'P&J8F;/AK%NR$'[K,_E:+B[MAT_WA_O-N6_2=(NYA![?X5A7PF9JL
M]H//_=2T<M7[PZ,>@[D5TE&/VA0H/-^WXKG._>%ASW)7C.<!&2$5>\/G1RO8
MI_A0TY-31Z'"B4!O<P'A%$ZNJ^<,12>T1EXWC&QGJQ?.8YN>UM'[V22M'4GB
M7^NC-QP7%SK`*695CB#\%A,2X]]\F90@4?W0]_IZ`:W$AI:'YA??J>*"!<,;
M%B'4KTY;K;4^M>LKP/OCHQT)MN7CQ[L'.Q)YPT>H:X%"3I]TJDS-NBU3+Y3I
M]0`=(YUKUUHQH=W'>\.1JV-R-R<94C@/&YV`EMNAZ'DI7'X67^=+*GT8KL.6
MG9:]->Y50_,;?7"UY<_V-%N1EN[ML3K??&`I_.(U$G\"-_%Z6*3BU4PW>V`7
M$<RV#R*%[KPSCN)2]PHD?:#MY\-M)S252-!YX34&6GHX,Z/]YX.#[0.7R4#Y
M#,9@98@,,-P#I@S?G7D.'D67/&1@C^"'%6S`[/4Y"B8QX"*QIIR_:8%$%B^6
MX@0PBPC\`#[;T+QBE"RCT1]B,T3#4'%P@#7\QA^>>]6&]7G4HRJZ!DE(\8[E
MJ:P1:O]D##F1T%55=;Z&2#8B1]+%,Q?BV-"3=#X%J8'GN/,<[[0?]8PWT#`*
MW>Q(<!$]GAWN"\]T/4JOBT&GO*HHT4^3)@E)J$-=P&4C*!QH<+#".NWV/V^=
MY"MLJEL?H`9YWAY[`1ZW;\'W;P^WKX)5>47=ZG:1"9L?IO<+G"AI;).F+;$9
MR,U!6A"7HPB@$A:OO+HK)5Q%I^I85\NH[@6X'887R@=X*1Z:V)*T*EB/!\^6
M<R08`.GX+TQ4/KH&X6`ONU;C0ZOZ)>%8%+[&_8(:IO'=`D5L*M!6H!LQ._(N
MADA^9T=W<:6B`=/R`1LI1P-_Y:HD)E7SR!T@D3:Z$/$72$!*#7A0<!KUBA(7
M+Y@3,X+(G3%;;^$PO%8=N"S*6G\]NG^6&56U-B[IT]ALCX;/G>)PU@:UB33;
M4N-1+<"1#<I@H79<GRI<6&N`]34^V3AYKE8O&.H/-@#JXW'QD+J;)6X4`H1K
M2(J0+#G!'F"-VP2^MOB$:TI2Q$N&-^-"CB9<1CA<H6TM?`U95F^OI#Q88RS^
MU(3;R>K^*AZRQ-6AUBW6RK4,'0O?,PN_.[>O^X:?O^P(BD[Q$J[4L$DB0_14
MV.V5\R*<FK)B$;;;&^[WP&)[/5X[#%G/4Z178'K`&QNA@GMZYZ/S/%G[T!9<
M)=9S';[@ZYK-RL[6S%_FYL^QE9VF<^"B(F@#7V+$2PCWSVM;B1T;[H<-3SJ=
M6BF2:>@-8O4LH:41KW_-I&6=/`<&OXC"&9&S\X^.F`TY,V(XH/UHNP,7Z<3=
M5=::->>*0#W`TTCH2%1^B"2;%[@C36L.]`^:WG5N3FQ-9643?'_B8'=_<`2!
M[_8IZ`UQ"2B^P!,O5+Z`,/AP`%!7UFE`%4O]$KP55#;?I$5@\.T-RVX/XF"D
M(13TLF+7O]!OL%Q'T<<E<Q@D'+!PM6J)?1R0!?WO.$<'!_7!O%O,JY1-UO&2
MN;Q`"L9CO#F1GRAT^."!%*6N',8#U;2Z(:"`M[*(/&&?.1*23.XI%W@1,BD>
MB[`!B2]<G1B5^A^[VP>#_1WWG$==BMF`OISBL*@77BU0F-R9W.KOM:9+MLCU
MEIK%'ER,N1\LL>_^E8,/\*QJ-Q#V5GX=@1=<'CXYEH0GUH$^#Y\Z@2GOY(=:
MH@4X-=@E9[X^VK)FWWVN9`@+Q%EKJI4U"W<TAVOI6^.[FHZPBQV*%C;\RL/\
M'CYU`705\O?PJ1.KVQFB**4S1P1[N-O]S?;PX*#[F]$0P5;G:*/A40]2!<]J
MN[N/J$A;Y=7^^:R0%9VMW^)NW[I0/IQ!^GBUYVL>?7?(@V><OXR)_%.)ZRV_
MX+[W_#:6;\/Q[ST^DI>'6*N-FLK9VK4=&-JCO=T5)NP"3UV9DQ?OS>O7I_#T
M^3H/WEBLT^1T['<U&8.GW:'HX6<@1,"_JG"MV=+\YOK;1V=GJ(C`?_A`\<][
MS/_8CY[6@8<VN[:&,IJL7_8+`[AHHR&VO-FGX0+-@;X20I>;_L$TR7%+LD0V
ML;J"(M8`OYY(4P-^VY#OA#^(4H-QM;?#4'/BU6\>J0<ED1.J&I;4N^`/;D)K
M5@R/-O"JDZM@V(RD`7]'HI*$RBN!3\525"EZH,>C\VCY4[4>-Y4$P;6WQ-7[
M<2Q"W0"1Z2J@\ELY)$.O4^OC*RX0EM"W)H%A:Y`DP^N7\N-"X@("SP+^K`Q"
M+L[&1!(-T7"):#?)+21>@GO"=4BXWS&E?1&&3E[]>YKK=K1&.;W;\?S1%#Q>
M*HZCN>1K(J'V?A7AB5.^E'L!B$5:K%#;78U7@Z]'-5D\.G_6O\S1QVPL/-@2
M"(INB<@U'1H(*&_1R2ND4M="H2+T*DTM)G#7_PM73L#M@S&U3S/4G^["R/^)
MDT)6W4O`E',\,:5X+9<IIY5DBD,.3`3Q#<*8$Y1*V6_IJ.OGSL1(*.%=+2%^
M$X!1>^)$,NP4-)`/*O",81IP%W%`P;=JH?,LIVO%:I])"=BCT46M2ERVC*A/
MY9TZ-]U!B=29;H4\Y[2>M&RD`M>)-*%5H8UHB2T70L3+K78;05XUC##*S;/6
M7-N+'H-]I-FW1P?"DL/!\\.]P2%^`Q1ZMLXX:;GUIB/OZ<A[@[WG(_SO4$9^
M?H!?$#V`X?#';87IZV]2FR=7=+';;WRC5@T_WJ%)A7?<S.`7>O&S0.QH>E50
M?8D6E@CW&1!.8_]>N=NI&_0'^BL_H$LP2WY1>/V4X@]W7-_L7R8WV29#3_V[
M#B?U<V1\G5BTLVUG;W':BT#O;`4^5^?B'/-K(%TX]K)B!\7!V/)C_Q>O;0,I
M;1!NKE_A%<YT$]ILH9C6_5@OL22/N2<!.E?$L[XL^(SP&8:+KF)>+3L&P.ZE
M".5^@XW6GJVL9>^FG=&;E<@.CY#+4^7T(9`&>E^_PHREX1<=X=WHL\P#::^:
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MWC$X.7P:7>K4P_4`!AVZYWY:$&CG1.$(E>UZ4?V&I859>UOV5.Q5(SE$M%6Z
M5[4XZZOAJUI@M3SIZTA9@9@Z0-I8/-HXLOB3"DR^KEWPVA%Z&+&VGZ.DQ:"U
M/7L9M[;G:H:N[ZZUJ'380KEH]:U*7@&<5)6J,.53,MT^(>59UG`\FYPUR-VK
MY,-9FT3W+3W6;G>TLMVA&V^GL]EG+6.%W.TIQFVV4;2D]._L=DY8%0#C-0Q;
MM:N6;0/17-%W]4:OZMB_Q9L6=89;6?'4H5B2G@,W$!?7\&S8:[T:7><^>6IQ
M9']\KDZD^5\>AG/#&QHB/M#;Y>&7N(<[-".]J=GZ33"4'*&GO<89]GQE+[OA
M%VGD#9Y&;-4,*>#!\\8%W.*3.[[^P5_+]>ZCO\53(??PU^#VV^ME01023FU_
M7D;\UY,)GH9"N1J+;X!I5$$F@Z+W2*;*ZPK\XZ7W7)=M59FJ<`(@*1E^/`4$
M]\5);J*PI^,*?^R(;P?)2T5R?=8YH6&/WADV#5T'^/5BIFO!5A%J07L!1>('
MV7O<I2\[9>VZATMUS.GE>_@VRG\&SSRU/3":T0WI[B/+_!-"#=QR6<Y7K<B_
M"O_9[3::HG%1=<44W>TVF`+'%8I?H0$<7OM<M8A1(:>LNCQ]IK\PTE<'!9AB
MY,I'^#B&VV#2@&.\BI/J^G6@"\XQ-D^TB8UTUX=]HY5^J"@_5]8;2D3/3&&S
M^BC\8H1C1<S@S#/>T[3>1;?7X-JM\T+6<7I%V+?6`5UMRM?.W!]EZ<DE?.SV
M?P.?HZM3CP?<U;37Z>UJW.OG=C7^A6S:[0U&'<D:,1B40XRJ0QA*;[-M^*UC
MLP^$]K99X5Q6#I4+:OI][7#X'>N75H*_L[^Q6PH4IGW[J[EB<`<5XTY%A9.[
MTU1-#N^XRZ</QMP9[NSTCJG%)*9VZ[L/<C#D[G"W?Q.MRVYV-AQJQ8JANIV"
M.=QDJ=N\DK:.?2A-MDKKH'/,M2IAG>.\O5[+N]K'<(L]]7U2_7*@KV+"#J=\
M+=5KP)K#]_SU#_AH=3XQ[&5/4B^KG#$U-8P+N#6K2Q+PN6^A>\8'WE*'0_;\
M5QGKL,^Y>.R2TZ\..KQF]S[;2SC'K2@$R!W?^T-!'6\#5%1#):^B[M)>>9&-
M=AX8>6C="XX#1QS9D*NZ-#$D-QA$X)`Z'=]J+2G!%ZW708WO<K^PV2+$]WQ%
MM)DM\GA29WU4D;<F8SXEK-,":HY77I,2>KJ-GVO!QW5N7L_&E5#TH6F=C5?1
MX`J?UJ)^LH-8N2UV<A&%;@LV"C_E(WO30C$(<J,TM=ZX%_8WO2@'U_AM"$8K
M`S]%4E>LA92W"P+:'`O[V/DU*JH8&+8ZP3.+U8\5>[^JBE]4];+,H-AEF"F3
M[>H-9,CD0>)Z^&=%41[_NP````#__P,`4$L#!!0`!@`(````(0">;B#1D`T`
M``"(```-````>&PO<W1Y;&5S+GAM;-1=^V^CV!7^O5+_!\2TU:[4!#]P;&?C
MK":>T!UI.EWMI&JE;E41C!-V>'@!SR1;]7_O.3S/-08NY@))H^[8V)SSG>\\
M[KF7:[CZ_LFQI2^F'UB>NY+'YR-9,EW#VUCNPTK^^YUVMI"E(-3=C6Y[KKF2
MG\U`_O[Z][^["L)GV_ST:)JA!"+<8"4_AN'N4E$"X]%T].#<VYDN?++U?$</
MX:W_H`0[W]0W`9[DV,ID-+I0'-URY5C"I6/P"'%T__-^=V9XSDX/K7O+ML+G
M2)8L.<;E^P?7\_5[&Z`^C57=2&5';PKB'<OPO<#;AN<@3O&V6\LPBRB7RE(!
M2==7[M[1G#"0#&_OABMYDAV2XD_>;U;RA2S%)J^]#8#XTZ][+_SN#_$_;_[\
MYLWH/]]^]Z^?S,V_?_ZF^-G/W\I*JH;(!!]4RSP?58J%CV/)2F+!]=76<XDA
M*M"$;%U^=KVOKH:?03"`>?BUZZO@-^F+;L.1,<(S/-OSI1"\#/9%1US=,>-O
MK'7;NO<M_-I6=RS[.3X\P0-18"3?<RQP$QY48@W]ZKE'-*E-"X3!V#3%(]0F
M!TS2\6"U3?HO1VQB=,WJ=;7AC]$565%MES!=Q;@H<-A&5^8KHL=_N%_)F@8U
M9#P:(:W481TI6ZY'H*\W91>SWBR;:E-M+M0R)A:+?D.%4TTDE34*M;?S=[W1
M*5Y9F75)&>XK`S#AQ+)H0>I6Y/=<P[\^XJ3G`:T;CT52F:(?I5Y>&^\LQPRD
MC^97Z2?/T5TDE@YJT;>9,9D)O&[$,R$@7D7'XJ%Y#M_:UH,;MSK!?@?=M.%;
MNQ#)S4);O%W'1&>C8C%-&W@^"H``(L.R[:S;G<ZP'X0CUU?0>(>F[VKP1DI>
MWSWOH!MT88Z`5BOQ]VJ^_>#KS^-)U!/QG1!XMK5!%`_KJ`=-K%U?W&KKVT@O
M0<:+HD2HIJWG'0B]O5FNQ2-=+Y>BA4XT^!,L].T,_P0+U>!_:V&<)J.`*@ID
M)D\*+9PSCL[GR^5R,;Y8+!9+=3I6U8CD^R2B+7=C/IDXC11&4Q'!#!`LIXOE
MQ02`C-1%I*I7!%,`,)_-%K/Q<J+"_Z-AIWL$HCF=R4-[E2`8R*L$P4!>C:8M
MBH#*GV0*K.`,G*L$P4!>)0@&\NI<<`6>#^Y5@F`@KQ($`WDU6FP3F*NP,CIP
MKA($`WF5(!C(J\*:SZ0"+P?W*D$PD%<)@KZ]FDRKL+'6HJ678F<FK#].IW#K
MV]OFNJ)9(\Q3[SU_`Y/N]+K,>`YSQ/C8]95M;D.8D?K6PR/^&WH[^.^]%X9P
MP>?Z:F/I#YZKV_!22<](_ZTX$RZ)P=6OE1P^6L9G4,:LN,3<Q"JZTI!5/15G
M$^I<'<W5V>0BGK`)4NV8&VOO%*W+=!^-2Z`1N:TWG'#H9DJ2<,A7_13T0N(^
MSC,B5T>>YCP!8B(-"<XS1-B8KX#SVDC.X+.1G,!I(SF#UT9(G6/)E3*Y\?9P
M-?;0P9JV&(WBQ49>/=4""?`C$7,<!#FGR&?M*4<8K3VGJ:U07PJY<3/!OZ@[
M/F)IS1E%.VM..&)ES1F\-K)QDWJ7$9XM76!Y/H+D@&_FZZ?!`$7QB2F>@R*8
MU"=<78TO@W"7N^/FUHHG5H.$9L,5MPU$27K.`;5#VIU"JN5*D,L[-KU6//'&
MR2YOHB3EM_:<*GZ3[@F:,<.T[4_8'OUSFW5DL,AY??6T)5M:8)\1[OG`'3/X
M$JXD)"_C[BM^`^:7G30I/4G2=SO[^>/>N3=]+=I\%*F(CN(5B_S=3=0VYN^C
MJSB.&2W3RK&8'WTO-(TPVAP57<$IPS,MP3-.!/'@::,?=O`<)1%XXN:CC7Y8
M!CRJ'W@95#\$%[=^D?&`V\"2H`87T*"NPB,2`2SVI`C`"4,@P&UK"0<0GD,@
M@$ETB@`"-$<`<"JBHDT>C$DU@QC(58+^KE1"C4FM9%1V:&59^07]%59J3/EM
M13.IMQ#H.<WPI@)`*Y5E)7:H$D/<#IF64P!O*BC08-05,^2-RVK^8(20H@L8
M<D:@#%0Q(BXJ2<T%G3F`:D9N!/8A)"BP%`T-`>`,`H$X8CS0^`NKD%E9'@\T
M`M-H&&@(IA"8,;C'G*">8$;(@3``GD&R@@0D,V+T2`.!,%2%)-$P&:I$4@Q#
MU<C<%9.A2B2!,%2%I)X8JD12#$/52.**H4HD@0",#%(AJ2>&*I$4PU`U,G?%
M=*@222`,52&))Z8=ETB%+IO&BZAD_70,U\K*UT+!0^G\_]!93]O:E=1QV:P)
M9*6GQ].G>.H(SH@F4V0NC>!TW`*/BZ?2H^=;O\$L$W\Q:,`!TY?Q%Z:A9=`C
M7WU]=V<^P5PTO@SXM#TP,)I>)DO$_!C9==84:[_(T1^U:]L'W):RF3,'UP5D
MJ98VHIR?-4Y^6F!!6,E:(+QD:CL;9*5$U%J.2T)-:3\>+J=CH$'+;;)H$%V&
M@*#DQIHSM*]@?!\<`W45C/5\*<*9K;4)0Y4C&5SYV87R,LMQ!8NM#JSVFV3A
M+"WSI7E[+&H'I>=5`&I1[L>BXZD%%OAUB=C8IL[#+3BTO2D,TA+^I`>7W$O:
MG"Z3D`)-.[%!P[Z%%X5'%"5'I!?1H5R5M+1:-7%1>VUM?%)6N&OJMA#+>P@(
MZH@LC^,?D16F*R2/<561+P38X>QETD))@`TY2I7EU"?3PQ6]JI%<BZ[!U8[C
M;6*5C$A=0*/EY)=]$%K;Y\IQH0F5$$\5,R;.(*(`XWI'/9N%=_QK.EXG]XDL
MWO/*BZQK'[<=3UE\=9TNFQ^#]+W3P]5Q`?E<'9--4J0?='G]:>U^ADVXL5;E
M1$>`^XLI?Y1>LHC"%/,:N,>7,-C*),"(:/MZPT6P'NL^)\>D56`X[F#`+":8
MP!#N&&];9[,A"Z3S%ZR3"FQ+[_<-MRV]C/=QD\W+H+>L@-7`?8T%[-4U#3T,
M<V*C^L47#3:JNX?;EEZVR+V8HE$V(O<-EY?>LB+'X"U$0_,:5[HB0?L*7M!<
M)!=`5_600N&5<5J38LU)/:FYX"6YS`HF,HJC]0NS@H2*\-5[NNIQ=`I$E(_)
M`B<[81<?IZUGE&R@=C^C;`V8C<GN`<<->E<3(-SCW7$++)AQX+]CP)Q3(KZB
M58#[PHI6F15,7A;J1G,CA(YZM-B5KI3@KI:7$2DO!2[O<,R'MQ`454W/2>U#
MQZ6OD)H=&5`[=G/EX+@`MWD2GN2%ME$#N.^C+2^XJ?/E)V7?<,72^^J3\M4W
M5-T;T#9BF*&]A]4MSGZJ;-1A$[)0!3LJV@(;[KX-$!L??751`@EG`QQV[;Z,
M-I!OF"_`?27#/$MZ]VG:-LK9K"RPWE%9:=(+3C!@DDUY[$X!_(T$&].O,D@*
M5@@G_;4%25N\3!(VZ@6YYN=MEW(`43X5J(''!:C86F1;PN+'OE5O_",+I<*A
MG<15&:"ZBZ8G3>Q.0DB76]@2VM=UL7:-0D51[:US/\$"TCLTL>"5#`ML('7O
M!^[(!V#;]-><-/*KZVQSUKF*7=O!@6&YIOJRV]ZXX'&32F*9V4G&X"M6O.:L
MGE05V[+,A$;QFN6+:W'ZQBMZ45?XP%W54T0W,*[<S%TV@M?D&U>&%9'57@HF
M1:L'HH["P4Q.BRB^Y/J9T?%D+V6I=EI%"GF?&*(;),`M$<@-9MG;RV8W4)#P
M:8?P=.;1'Z4SZ:V!Q30;!_&"_OW>LN&A(;B&CC>W,.#'&IYS$Q],?J97)2MK
MSK![H+*`F*:R0$(\^9S@#4\(+@BVIK)`?2QK"M8267#OW<:RLI4J>.@?(POF
MF4UQ95/3*<O]C)-[]9@?HQLW$;[`9!Y<5%;N1QPMB2PPN:FLW(_@."H+3&XJ
M*_<C("2R5%#25%;N1_`"E07AUE16YD<5'$=DS3BYOSCJ1S96\2XK/+BHK-R/
M;*Q..6.5RLK]R,8JFMP45^Y'D$KX4N&#IK)R/[)U0N6L$]3&W(\L]S-.[@\K
M*AOQ$\Z(CZ7DOH-7A"/<:\7#42PE]QH;Y5/.*(^EY/YBXUOEC.]82NXID$<L
M4N$#?HLR'TU9=E5.=F_T33H:L`&#XPP/C+5N&WM;QQN?IX+P\A8Q".\9QR7I
MT30^2VNX*7PFB,T''$9Y!-T^[6S=U4//?Y;PQD&9.-;I,TYQ?_&\C"-6P@3>
M\@#ZP=0WEOL@`2_)(,X0A"O+3<1DN<#2@[<1;2(&SH[1L/&'T\,F8N#L6`Q;
M5+%_XA'SWMWM,P^QM12';AX1'RSWL[EA(X>M$A,`R2/IH[D/?3V+/S:E)IS$
M?,1'"60RV!(1/]LY?>Y!TG]^A"<'I"3B7@V2.]C'\P#_VSXD-.)91`ANC.41
M<F>%\/R=Q)ML#B,L+A$>W,PK$W%043AE_$/W7<P6)G4/8K3$HOS>:-#];Y[R
MQTI$O(<Z/%\H>N!$-A\`HC;F5M_;X5WVX4K.7_\U>K(5!%/RK1^M+UX8B5C)
M^>L/^,@PR&*8BD&Y^1#`8ZC@7VGO6ROYO[<W\^6[6VURMAC=+,[4J3D[6\YN
MWIW-U/7-NW?:<C09K?\'E#FV&UP^C=65_!B&NTM%"8Q'T]&#<\<R?"_PMN&Y
M`4\B\[9;RS"58.=#40D>33-T;&4R&BV5I>+HT4.`0,AE8,.W_,38!/RG_-A*
M)F]B^-$T&V###_=3(Y0`G\[Q"95<_Q\``/__`P!02P,$%``&``@````A`/MB
MI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@
M=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0
M`KMTGR9;AZT#^A7V2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK
M7:YZB,0^'],X:'MWAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX
M[85*)9N5BO1A&,O+/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[
M,J$^04--TMO*B/<8O,9*Z@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/
ME(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R
M^@;`U#*NU^MU>[6<G@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]269
M6YU.I]%*9;%$#<@^UI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9
M=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z
M`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZ
MKYY__^KY4_3J^9/CA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S
M\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$
MHEOD"!WP"'0SAG$E)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#
M7I_==V0=A&*F:`GG&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMC
MQ[6]60)5,PM*Q_;=D#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=
M3$M-,J0C)Y`6BW9I!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>
M*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7[
M'IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!
MQRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF
M%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E
M\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M"
M>-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV
M&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;
MS8AFBJ+#+5=9F]B<R\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;C
MA8MTD0SQF*0^TGHO^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO8
M9=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`
M?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_
M6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T
M8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF
M6[@I2+D,YJT@'NA6*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E
M[7&A0@Y5*`FIWQ?0.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@
ML!^I4!"R#V7)1-\IQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)
M6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ
M=KU9GNV]147TQ*+-JF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0
M)7"1A/0?V/^H\)G]X*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2
MI*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9
MDRD*0Y/L(&,<8[Z4%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_
M````__\#`%!+`P04``8`"````"$`6Y_<AK8"``#C!@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6R,55UOFS`4?9^T_V#YO7R%D!*%5&FJ;I4V:9KV
M\>P8`U8Q1K;3M/]^USA0(*N4EP2;XW///??ZLKE[%35Z84ISV60X]`*,6$-E
MSILRP[]_/=[<8J0-:7)2RX9E^(UI?+?]_&ESDNI95XP9!`R-SG!E3+OV?4TK
M)HCV9,L:>%-()8B!I2I]W2I&\NZ0J/TH"!)?$-Y@Q[!6UW#(HN"4/4AZ%*PQ
MCD2QFAC0KRO>ZIY-T&OH!%'/Q_:&2M$"Q8'7W+QUI!@)NGXJ&ZG(H8:\7\.8
MT)Z[6US0"TZ5U+(P'M#Y3NAESJF?^L"TW>0<,K"V(\6*#._"]3[!_G;3^?.'
MLY,>/2-=R=,7Q?-OO&%@-I3)%N`@Y;.%/N5V"P[[%Z<?NP+\4"AG!3G6YJ<\
M?66\K`Q4>PD)V;S6^=L#TQ0,!1HO6EHF*FL0`+](<-L98`AY[?Y//#=5AA>)
MMUP%BQ#@Z,"T>>26$B-ZU$:*OPX4GJD<270F68#Z\_OH6A+?">KR>R"&;#=*
MGA#T#(34+;$=&*Z!N$_,R1A2_2A32-&2["Q+AJ'9(0D-U7G9QF&R\5_`4GK&
MW%]BPBEBWR-L)4#>H!$2'VO\O^F]%`NV4FP1K+9[MP'<@[9H%O<2L4P'R$0)
M.'2]$@N&0H\"Q^%JX'7B',:UC%6['VU,(L?3R+9.\8<-V'MA#\T5W,X4.$S2
M%2U9+L(PF!5N/T;$<1K$Z7L6$XV@YWIW+'BF+5C,M#G,R)W1QB1R,HU\G3OV
MT$Q!.'?'89P[JW05K])XJA&FCF5QB#19A,D[A9/HAHJ[=(*IDNU976M$Y=$.
MC`B,'W:'6;:+;/_.]N]AQG43P1]>P(QI2<F^$U7R1J.:%4`9>"OP2;DIY19&
MMMU5/T@#TZ5[K.!CPJ#C`@_`A92F7]C;-WR>MO\```#__P,`4$L#!!0`!@`(
M````(0#VYA3E^@(``$<(```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;)16VVZC,!!]7VG_`?'>@"&0BY)4)55W*^U*J]5>GATP8!4PLIVF_?L=>Q("
MM.HF+R5XCL^<.3/87=V^U)7SS*3BHEF[9.*[#FM2D?&F6+N_?SW<S%U':=ID
MM!(-6[NO3+FWF\^?5@<AGU3)F':`H5%KM]2Z77J>2DM64S41+6L@D@M94PVO
MLO!4*QG-[*:Z\@+?C[V:\L9%AJ6\A$/D.4_9O4CW-6LTDDA640WZ5<E;=6*K
MTTOH:BJ?]NU-*NH6*':\XOK5DKI.G2X?BT9(NJN@[A<RI>F)V[Z\H:]Y*H42
MN9X`G8="W]:\\!8>,&U6&8<*C.V.9/G:O2/+[=SU-BOKSQ_.#JKWVU&E.'R1
M//O&&P9F0YM,`W9"/!GH8V:68+/W9O>#;<`/Z60LI_M*_Q2'KXP7I89N1U"0
MJ6N9O=XSE8*A0#,)(L.4B@H$P%^GYF8RP!#Z8I\'GNER[8;Q))KY(0&XLV-*
M/W!#Z3KI7FE1_T40.5(A27`D@>>1A`17DX1'$GB>28)Y1*+X_U(\+,NZ=$\U
MW:RD.#@P>2!<M=3,,5D"L[$G!)/?MP=\,7ONS":[%=`*6OJ\"0E9><_0A_2(
M21`#7U&'"8:([3N(,\0#?9U(\.UZD6;34&0PUH@0.WVVL&UO82``G.D+^-@=
M`UZ[TU[E,"S#VA/$X,`92[>]A4%FH+D\LP%#_WJ9R2P<94;,PG9M-AT&M_U@
M,)UUT8$DF/O+)1GP6-(H:X*8R$H*@JC+BCWI1\DL[J(#3?$UF@QXK&F4-4%,
M;#41W_>[M"@*PR@YC,[1@:C9-:(,>"SJ7*S-FB#F*"KL]0=%81A%13T?!Z+,
MO=;[X#\>90,>B8K'HA"#`Q7$TU$8SG9#@6$2+.:=D:@*#VX\DFHF"[9E5:6<
M5.S-H1R`_]TJWA<)62:!.5U'ZUNX1^RZUP7@'&]IP;Y36?!&.17+@=*?S&"B
M)-X$^*)%:P^*G=!P@MN?)5S8#+Y+?P+@7`A]>C%W3?<OP.8?````__\#`%!+
M`P04``8`"````"$`'5R@C?("``!`"```&0```'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6R4E5UOFS`4AN\G[3]8OB]@2-(0A51-NFZ5.FF:]G'M&!.L`D:V
MT[3_?L<X,"!-E>8B"?;KU\\Y/APO;U[*`CUSI86L$DR\`"->,9F*:I?@W[_N
MK^88:4.KE!:RX@E^Y1K?K#Y_6AZD>M(YYP:!0Z43G!M3+WQ?LYR75'NRYA7,
M9%*5U,"CVOFZ5IRFS:*R\,,@F/DE%15V#@MUB8?,,L'XG63[DE?&F2A>4`/\
M.A>U;MU*=HE=2=73OKYBLJS!8BL*85X;4XQ*MGC855+1;0%QOY`)9:UW\W!B
M7PJFI):9\<#.=Z"G,<=^[(/3:ID*B,"F'2F>)?B6+#9S[*^637[^"'[0O?](
MY_+P58GT450<D@W'9`]@*^63E3ZD=@@6^R>K[YL#^*%0RC.Z+\Q/>?C&Q2XW
M<-I3",C&M4A?[[AFD%"P\<*I=6*R``#X1J6PE0$)H2_-[T&D)D]P-/.FUT%$
M0(ZV7)M[82TQ8GMM9/G7B<C1RIF$1Y,(Z(_SX:4FO@-JXKNCAJZ62AX0U`QL
MJ6MJ*Y`LP+@-S&%TH9Z+%$*T)K?6)<%0[!"$AM-Y7D4D6OK/D%)VU*Q/-62H
MV+0*>Q*`US%"X'W&MY/>HEBQ1;&'8-G6;@"\.[9PM.^I8AIWD@$)9*A/8K,U
M.5L&+9%=!+H>0$0FG;^#=!I7.I9ZTQL8$(!-G^#]7%@QE%IO9S*?CW9VFCAN
M3BT83F[.3`Z((/[+B:QX1!2/-ET[S9&(>-&X3$;SX:R#'G#-/L)EQ6.NT;YK
MISERA5X0QH//EZMQ70T6$&\Z&^CC_H(!^?5'R*UX2!Y.QF?L-)"W[A4@\>CU
MW+RE^5^E`SY[J?5ZQOLU:,5#/A)/NQ-SU>\T9VKPS*0C<AW;=;22JQW?\*+0
MB,F][<8A%'4WVET4MZ%M#J/Q-5P@3;OUNPEHX#7=\>]4[42E4<$SL`R\:\BC
M<E>`>S"R;OKH5AIHW<W?'&YJ#J]QX($XD]*T#[:U=7?_ZA\```#__P,`4$L#
M!!0`!@`(````(0#-<<KAS`(``+P'```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;)1576^;,!1]G[3_@/Q>/@-)44C54'6KM$G3M(]G!PQ8Q1C93M/^
M^UW;*042=<T+8/O<XW//M2_KFV?6.D]$2,J[#`6NCQS2%;RD79VAW[_NKU;(
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MI/-*RY<[(@LP%&C<,-9,!6]!`#P=1O7)`$/PLWD?:*F:#$6)&R_]*`"XLR-2
MW5--B9QB+Q5G?RTH.%)9DO!(`N\C21!>3!(=2>#]1A*NXB!._B_%LVD9E^ZP
MPINUX`<'3AX(ESW6YSA(@5G;$X')Y^T!7W3,K0XRH8"64-*G3>0OUMX3U*$X
M8K86`[=HP(131'X&\0;Q0-\@$GR[7*0.FHH,@ZF"K86L3*UT8OEH8B(`G!D+
M>-\=#<[08I1YY,>SG2W&'CBS\VABLC/0C'?^6'UT$-1QI"!(WJPU-=Q:S+6I
M7N`G_E1@/EM>#LL3=7`%QNK>]T6#YZKFI\9B8JMJ,1<U7@W#U7E-R26:-'BN
M:5XKB[&:HN5,<3Y>#>/HO*;E)9HT>*XI&7AM]2SF6+WX1-1T>3%WRG9+VP<8
M$37)2=M*I^![W0E#<'^8M4UZ&Z1P6:`[SN9S:-YFWAL6H'GVN";?L:AI)YV6
M5$#INTNHG;#MUPX4[\WMW'$%;=-\-O"7)'`-?1?`%>?J=:`;_/#?W?P#``#_
M_P,`4$L#!!0`!@`(````(0#A>O8;00,``%0*```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;)Q6;6^;,!#^/FG_`?&]@"'O2E(U5-TF;=(T[>6S`P:L
M`D:VT[3_?F<[)3;ITF1?0C@_]_#X[GSGY>US4WM/A`O*VI6/@LCW2)NQG+;E
MRO_U\^%FYGM"XC;'-6O)RG\APK]=?_RPW#/^*"I"I`<,K5CYE93=(@Q%5I$&
MBX!UI(65@O$&2WCE92@Z3G"NG9HZC*-H$C:8MKYA6/!+.%A1T(S<LVS7D%8:
M$DYJ+$&_J&@G7MF:[!*Z!O/'77>3L:8#BBVMJ7S1I+[79(LO9<LXWM:P[V<T
MPMDKMWXYH6]HQIE@A0R`+C1"3_<\#^<A,*V7.84=J+![G!0K_PXM4A3[X7JI
M`_2;DKVP_GNB8OM/G.9?:4L@VI`GE8$M8X\*^B57)G`.3[P?=`:^<R\G!=[5
M\@?;?R:TK"2D>PP[4AM;Y"_W1&004:`)XK%BRE@-`N#7:Z@J#8@(?M;//<UE
MM?*323">1@D"N+<E0CY01>E[V4Y(UOPQ('2@,B3Q@02>!Q(47TV2'$C@>22)
M9V,TGKPO)33;TE&ZQQ*OEYSM/2@]$"XZK`H9+8!9A2>!(+\='HB+\KE33MH5
MT`)R^K1.HLDR?((\9`?,QF#@&/68V$6D;R".D!#T]2(A;M>+5$ZNR!BY"C8&
M,M.Y4AM++8,C`")SO0#EM/)'5@22:#I08#"F\+0"R^`H`!I;P?G\*##DT?GR
M;/!E@YGK[*'X&'B=X=19C4:]KZ,)#L#EFA38U82FPWP8S%AKNAD-8I4ZJ\G\
M;4V3:S0I\$#39%C'!F,T3<?]1TV8[,7)<=&)TM15=-D)4TZNLB0Z[EA_?&,P
M5NU8!D>!FF57GW'E]%[U&HREP#(X"N:N@O/5J\##O0^KUV!,5A`:U%%JK\Z3
M/F>.)`1=SH[*>4T:/1"%HI[9).0`LN)A6]RO_U_?-2T3#F??5$];"C(@6X5E
M<54,&NL[,3#=\7Q;@5FNLG?H*\/$_&O5J#)#W(RGAO"2I*2NA9>QG1K0,;2%
MWFHN#QNT@!X.0WM@3^%2H>UAOP`SO<,E^89Y25OAU:0`RBB80E/AYE9@7B3K
M]-#8,@G37/^MX/9&8#I$`8`+QN3KB[IW]/?!]5\```#__P,`4$L#!!0`!@`(
M````(0`!+CS<`PD``+4H```8````>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
MK)I=;^)*$H;O5]K_@+@?P%^0H)"CX&_IK+1:G3WGFH`3K`&,L#.9^?=;[>ZR
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MS<!S57U5H?E.(1@\%:.3=@;^?1GMBI?-VZ'Y3_6>%>7KOH'I#B`CE=AR]R,J
MZBU4%&0F;J"4MM4!;@#^'1U+U1I0D<WWU=B%-RYWS7XU]N:38#'S'`@?/1=U
MDY1*<CS:OM5-=?Q+!SE&2HMX1@1>C8CK3^Z"P)_?+4#ERDC?C(17,_)Z/%QM
M;Q=>3;SC31Q_-E=W>^5]YF8<O/[D'2[,2'B]Z0YA8;5W"*\_=8?W9AR\WG:'
M4SV3;6-$FV;S^'"IWD>PVF"NZO-&K5UG"6K8$;HZ78_\78M`;RB1)Z6R&D,6
M,/LU]/6W1R>8/TR_02]N3<QZ((9&A!BA&D_)1AS$'"0<I!QD'.06F$(1NDI`
M4_\?*J%45"4PAS6"OC0N2QLC<$C$0<Q!PD'*0<9!;@&2-BQ#GK8/RV-X2\#Y
M5H-68UB'W7S?W]&LUCK$U6M?S68H2"1(+$@B2"I()DAN$Y(NW+.=[O4T53#L
M=E"Z+D\G6+!$31"\HQ7$JA%V0=TD"Q(+D@B2"I()DMN$Y`[3>GON*KC-'>]X
MK4G@=[T="A()$@N2")(*D@F2VX1D!;OT[5FI8)J5)I"5/7WW=([#+@B+$0D2
M"Y((D@J2"9+;A"0*#Y7;$U7!-%%-[.D3)!(D%B01)!4D$R2W"<E*>4OQ`)HH
M)]#LR^W7=06K"K;L@87JP8-&/WZ4!DU6$\_:?02)-/')S,]G=.;C+@AG/A%"
M:1=CM=#<H4)9%X1"N2U$2@+/85X2=ZX<V5`5`&,9U#A:!DW`4MIWQI\_)JA?
MUY$A:@ZZY_G<HPG%)FBN'_<S7KE$R*:WR&9<EFVWN2U+JN:`';;+-M`Q5JW:
M:%HL@SQH52MMGZ8=8E3_B(\0+;J=,49TKZOCL[9*\'JODB+J53)$6L5UV5,E
MQ^NM"BV&<CF_NJP<;97@^8<]NS:(=53`:Z0'>E9+F8%^^P&E7;4Q(J>MD;=@
ME4[PO7J5%(?T*ADBK>(&K$USHD)KI"S1+]=(^RI2(XU8'S$['#HFJN^`R"`?
MKE@-R!**,4IM?\IGR[H)Y13'7%7.,`J5?=%OMC*MI3)<5VKY1W7^NVW<7I3&
MMMD-9]"\Z\'0$2B2*)8HD2B5*),H)XCFK<P6R]L-)K!S_NPG*./:[-0-`D-@
MM0/;#T.GB\)%&DD42Y1(E$J429031*L!>=O5^&`+5M%L"S;(GFV!(G5DH0;V
M4;%$B42I1)E$.4$T/^7-K-G^(#_MY,C6T)D[>TK9,@N=+JJ?4H%B&95(E$J4
M29031%-6QNWVE+7-(RD;U$]6Z`@4211+E$B42I1)E!-$\U,NS,I/'X#\I/]T
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MMW!/CE%]!T0&^;"=7]F(,$I_4%NPST.)U$UQQ%7=#*.T[ISIYD27UG'`ESI!
M_UB[S8^[TI0BZK>"4*)(HEBB1*)4HDRBG"":M[*&5O]\L+L8(VDWBD;T/'#!
MMHI0G<7`DK,.TR*)8HD2B5*),HER@FC*RAK>GK(VDK`"\?F_!A_-D@DEBB2*
M)4HD2B7*),H)HODQ!_JY;5,:4U<CRXZ%$D4&?>#0^BBL:B*UTC[*WDO81IWU
M4:B5$RU:'&4S;Y]\;4K)Y&M$-\8%,SRA:Z+LC=$@6`G7-D8=99ZYXJA"ZJ:(
MKNIF)LKHNOPYE:/*P%-8><;;*Z8=)JF8L:;0/GWB/+/0-5'VX[8;B!,;8Q0>
M\+$-/L'KO4J*R#HF1*15G`5[K.5XO54A[>,QNWI]NVRCJ2\UB+4/2R/$**M]
M$+6_=M#G@08%,^U+9S-F;Q,<T\NDB'J9#&7,L6+`5'(<(EL#M@+2&I_::5H1
M5B1S'$H[ALU2:`9Z_5Q'!EG6*C8H<'61/-[YB91)I4R&2#NTP&4SEA,5VC+*
M(5KKYW-%TC;37E:>1K23YJ)()JIO@<@,_,"AF:A`GVVZ<Y\I)_C^O7)ZDW)&
ME1V7?Q.>$V5:2]OM0F:\EK>Y-%4R=HYF4/NQ1;^C_DV0_NG'L;B\%F%Q.-2C
M;?6F?N\#1O+QH</ZQTAKUU\JIP6;E;@2P)567%R9PY76&[(K\-.FI]9S,+Z&
MGSRUW])Q[H+0T'M[\!.I`?[D+Y\@ZX&;A2P&DX`<!E.`#(826"^6\"7F@+X#
M=P0'Q/)*=+>$KP\E3^^6\&V@Y'`:M(SA,$9>@;.=939X!?S),@9[,#`&KB@O
M(:^L'2@)'.(.78&BP/'GT!4H"YP2#EV!PL#Y&ER9=G,(/QH[;UZ+?VTNK^6I
M'AV*%VBR6?OQXZ)_=J;_:,S7`L]5`S\7:[\AV,//`POXN#Y3A^@O5=7@'^H-
MNA\</OX/``#__P,`4$L#!!0`!@`(````(0#OF*YH3`0``!H/```8````>&PO
M=V]R:W-H965T<R]S:&5E=#@N>&ULK%?;CJ,X$'U?:?X!\3XAD)`+"ADE03T[
MTHXT&NW./!-P$M2`$78ZW7^_5;X0.S#I[.6EZ1R7CT\=EPNS^O1:E<X+:5E!
MZ]CU1V/7(75&\Z(^QNY??SY]7+@.XVF=IR6M2>R^$>9^6G_X;76A[3,[$<(=
M8*A9[)XX;R+/8]F)5"D;T8;4,'*@;95R^-D>/=:T),W%I*KT@O%XYE5I4;N2
M(6H?X:"'0Y&1A&;GBM1<DK2D3#GH9Z>B89JMRAZAJ]+V^=Q\S&C5`,6^*`O^
M)DA=I\JB+\>:MNF^A+Q?_6F::6[QHT=?%5E+&3WP$=!Y4F@_YZ6W](!IO<H+
MR`!M=UIRB-V-'R7^W/76*V'0CX)<F/&_PT[T\KDM\C^*FH#;L$^X`WM*GS'T
M2XX03/9ZLY_$#GQKG9P<TG/)O]/+[Z0XGCAL=P@986)1_I80EH&C0#,*0F3*
M:`D"X*]3%5@:X$CZ*IZ7(N>GV)T$HV`1^N$,XIT]8?RI0$[7R<Z,T^JGC/(5
MEV0)%`L\%0MJN#-AHB;`4TT(1M,@G"]\7/7.Q*F:"$^M=S8*Y^.)F'A?KB=S
M%U8F*4_7JY9>'*A/2(XU*5:['P&Q]E#*Z%S]E:G@)I)LD"5VX6"!70PJX67M
M3\.5]P*[EZF8[4",';'3$;A52)L8@`=Z.]'@]?\@&EE0M%YNJX%K%L&-0AVA
MIR0&8"F$S345#I>D=@^#8Q?<-]R;V2MO94P@:P_-V?60Q$0L-4#]N!H,CMT`
M,C/DS&_DJ"!8T0A:V$&[+JBSRT0LA5#YCRO$8*%0\VX5,NOV<M=#$A.QUI[9
M:^,1F,/!TF?QX4.`/+8LA<##<&EYXU(7I+-)3,12.K>5WJ\J#+;E*&1Y=:F'
M)"9BK8UOS9M&,5E@8_U%O]7%C?-L&1+QC<WJ$,.G<&S[E`P&^5V0)79IB[UO
M%`;;"A5B*.PAB8E8:_OP(OM73HF)MA`%F5Y=H7MF#4==VYFM&/NLL;?W[?)E
M5X8&H0MVJZ")>%^+UKWK0XD%V0*PC1H"\`B&L,P[0F3SM81(R/*K@^[Z-1@U
M&:XN'QNM(?<=F:HMFWXIR"@PP0F;?X42"[+]PCYJ"$"_U&'\IR]NU9%-<0JR
MNE8X[:Q0^]M%Z2I(?!.R]6+O-?2^8YCJU*8F!5W=V>$M"X_M%4HLR!:`+=40
M\!\,4\W9%-?U:[/";JX_.ZC)GEX3LO5B&]9ZH33?,4PU;5.3A,2U5S++:[2\
M^U6D/9(=*4OF9/2,5V2P;KWJ8'E_AV,-%WAQX^B-3&!D@@V@-S*%D>G@2`@C
M0E!OS@Q&Q#[>C,`7Q$8D=8-O4=C0&D$$-[(!52!W2.UF&FWD%\KM`I#%8!*0
MPV`*D,%0`MMY!&_4`4'+"%X@@'O=PO!ETJ1'\C5MCT7-G)(<8%O&HSF4>2N_
M;>0/3AMQ:]]3#I\DXM\3?(,2N!*.\=)RH)3K'[A`]U6[_AL``/__`P!02P,$
M%``&``@````A`(X6]FSU!```7A,``!@```!X;"]W;W)K<VAE971S+W-H965T
M-RYX;6RLF%V/JS80AN\K]3\@[D\(D$^4Y&@3M.V1>J2J:L^Y)L1)T`*.@&QV
M_WUGP)@98$FVZLVR>1D/CU_;8\SJZUL2&Z\BRR.9KDU[-#8-D8;R$*6GM?G/
MW\]?%J:1%T%Z"&*9BK7Y+G+SZ^;77U8WF;WD9R$*`S*D^=H\%\7%LZP\/(LD
MR$?R(E*X<Y19$A3P,SM9^243P:%LE,26,Q[/K"2(4K/*X&6/Y)#'8Q0*7X;7
M1*1%E203<5``?WZ.+GF=+0D?29<$V<OU\B64R052[*,X*M[+I*:1A-ZW4RJS
M8!]#O]_L21#6N<L?G?1)%&8RE\=B!.FL"K3;YZ6UM"#39G6(H`=HNY&)X]I\
MLCW?<4UKLRH-^A&)6T[^-_*SO/V618<_HE2`VS!..`)[*5\P]-L!)6AL=5H_
MER/P9V8<Q#&XQL5?\O:[B$[G`H9["CW"CGF'=U_D(3@*:4;.%#.%,@8`^&LD
M$4X-<"1X*Z^WZ%"<UZ8[&TWG8]>&<&,O\N(YPI2F$5[S0B8_JR!;I:J2."H)
M7%42>SJ:.-/YHLPRT-)5+>&J6CJ/-9RHAG#]-+=5>5!:Z@=%L%EE\F;`/(5>
MYI<`9[WM0>+:RXI?N_N1N>`J)GG"+&L3%ACXEL.,>-W8SGQEO<(HABIFVQ/#
M(W9U!`X9IO6)8`&OA@;3_P=HS(+0]>.VM=#TPFD1UA%U$Y\(C!`&MTWHPD3O
MGZ*UB]AH;<(H$!<7G&!;Q3C59$23=AW%IPJC@M24:I@&@]>F`STD.,L6C@J"
M)S9![I@'[720MHTJC!`6X..$&%P2UGFW2IGI,=UU%)\J[-DS_FQ<"HLEEA!5
M!QY>#9B(<RD%+L0FNV63#JJ[XU.%H<XYZO!`8C#'40JQJ:/X5&'/QFVT53'<
MQ7^Q"1-Q+J5PF]IK4`=IFZC"4)<<==@F#.8X2B$V=12?*NS9-BQWZM/PP\MH
M_O1:FC>3N9'H/'+Y//+K*+"%S+:)CN*86&/)<-[!K"HR%(7:_*VM)(JI)0K0
MP511''/Z`2866H*)B].9CF!MW@&N"C0#5A(%UM(@L(KBP+,/@+$(MX#5,KE#
MK*HWM5A)E%A+@\0JBA,W&S.?"5B46\0/6:R*.056$@76TB"PBN+`S1[(@;&2
MMX"G,*GN^*OJ/\55$L75TB"NBN*XS1[)<;&:MW`?\E?M`A1821182X/`*HH!
M3YK]F@/C%M`"?FP*J[V#$BN)$FMID%A%<>)FZ^3$$$6)[\P$C&[57"513"T-
M8JHHN#0U=])L71P3-PUB[!U,M<50-^FN4[XJ[^R.Y#.)`3BMO0FKZ<P=S6$Z
M?_+%O\S$/:PEF&K$BE;UWS51]4[B,XGSXE;QL&'P<MP>UUHB6WE7\IG$`;#T
M$X#JF`35];-VJ2V$C"6^8.,LY'8UNW4UO$U48Y=N"!*GQ;)/:(?G%QS5.W95
M4GEXKC)7A_'JY)B(["1V(HYS(Y17/&C#Z7NSTG+U%6"[].#E"-#:N@TW8&KV
MW''&\.&@//NWVSCX2:$\\W3N.'"GM+-U![Y"//7I6TC5GPD2]5&Y'ARHNK1/
M$\C?=V,[\?Q)3X/MU(.S1S?1=N;!BWZ//O?@);Q'7WA^>6BU=(_AZ\8E.(GO
M07:*TMR(Q1$&95RNYZSZ/E+]*.2E//'O90'?-<I_S_`=2\`Q<HSO4D<IB_H'
M/-C27\8V_P(``/__`P!02P,$%``&``@````A`.:_IEP_!P``!Q\``!@```!X
M;"]W;W)K<VAE971S+W-H965T-BYX;6RLF=]OXS8,Q]\'['\(_'Y-[*1I$S0]
M-+:U#=B`8=B/9S=Q&J-)'-CN]>Z_WY>69(NB[RX9]G*]?$11)$61LOWP\?/Q
M,/J45W51GE9!>#,)1OEI4VZ+T\LJ^.M/]>$^&-5-=MIFA_*4KX(O>1U\?/SQ
MAX?WLGJM]WG>C*#A5*^"?=.<E^-QO=GGQZR^*<_Y"2.[LCIF#7Y6+^/Z7.79
MMIUT/(RCR60^/F;%*=`:EM4E.LK=KMCD2;EY.^:G1BNI\D/6P/YZ7YQKJ^VX
MN43=,:M>W\X?-N7Q#!7/Q:%HOK1*@]%QL_SEY516V?,!?G\.9]G&ZFY_"/7'
M8E.5=;EK;J!NK`V5/B_&BS$T/3YL"WA`81]5^6X5/(5+-8V"\>-#&Z"_B_R]
M=OX_JO?E^T]5L?VU..6(-O:)=N"Y+%])])<M(4P>B]FJW8'?J]$VWV5OA^:/
M\OWGO'C9-]CN6WA$CBVW7Y*\WB"B4',3W9*F37F``?AW="PH-1"1[/,JB+!P
ML6WVJV`ZO[F]FTQ#B(^>\[I1!:D,1INWNBF/_VBAT*C22F9&"?X:)>'BYBZ<
M+*9W4/*-B7,S$7^O7GVL/6D#DV1-]OA0E>\C9!MLK<\9Y6ZXA&(;$6U&%Z.O
MA0BQ(25/I&45X)C`^QK[^NEQ<?<P_H2MV!B1M10)N41L)2CNI#7Q0>H#Y8`Q
M'.J\P@;]#UZ1%O+*&K2VH'<S\GRP$G9*XH/4!\H!S(>I]&'VU5RU&T&35@%2
MJ]^(>V[B6HM$.BDISK$@B2"I(,HES'"L[@9_^'!9@TD8!PI!Z"U>>!8;&2S8
MR823"1>*.Z$N](*D@BB7,"<0Z<N=(.'6";OVVI!9ESNQ((D@J2#*)<P^G-7+
M[2-A;I\A4.^$U#^0G9!U*Q$D%42YA)E\=XW)),Q--F3>AU201)!4$.429A]U
M>:\4WJ&\VYI\<3$D/=QT0Q`9)]I^Z>B$NF@+D@JB7,*\67!OOGT*29B;;(@3
M;4$205)!E$N8?2&ZMQ_N\/:&>F"S+S:OZQ*Q0GT?,'R*#F/Z#BGAAK=Z,9-7
MBZE7+:Q4?T`3B_C$&9^86JE^HK*(3[SM)G*WJ64Y63;@'NX2G7^ZP:$\VJ18
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M:[E&"%=_+`1*J"KH8V&E4HD40SS`U`X=,]NR==\VE6LKEVFLK@L&\>3R&D2,
MC1#)91#?C[Y!M!N9RHG*(IY<?<GCOE.K=7S_SODG:>_P&.0FET8LN0SBSGCU
M.PW%1&613*[(NPI\V_)6FEMND)M<$B42I1(IAEB`\<C$`DS)M<"C.R)Q97*U
MFCP73*?GR>4UA-A,=/?#(KX??7?3R66EG,IE$7:J+WE17_*X[]2/+TXN>ISS
MDLLB)[D,8LZ8ML^<B;SZG<J)RJ*!Y*).>[GENB]#G2U`ZZAKU1;%$B42I1(I
MAGB`J:U>;J9NPLQ,@U@"15[1CR/3O?L\2"QB,0]%`HF)RD[D"?25UD?]_0K_
M2-H[(`:Y":012R"#\,=):I%`8J)J[<.=8""!J$]>OC.ZJ[*=,<AYEHH$2B1*
M)5(,\02BUGFYF;K1,C,-XJ'SVUO42=G3D$B42J08XI93>[S<<M.%W1-JD!M@
M@9)(H%0BQ1`WDUJ:8R:5_W""@G5M\=>MD87>(&2%D[7>!2&..JD^]`*E4DHQ
MQ'R:7M5Y6VE^*BUR0B]1(E$JD6*(FSG0>>?3_])YIZ;-.MEC$0^^=Z&)>ZDN
M^!*E$BF&N%=7]51\%_%+HD'ME5IKUE\^]`O^8UZ]Y'%^.-2C3?E&7S6F=WBQ
MT&']R64=W2WI;,(K,7*/D;91B)$%1MI*Z8],)_B"TY9H,4+?=MJ7SO[([1*O
M.0?6GR_Q+G&`P^!!>V'NH+4P=M#6"`N@G@ZL$,V6:S0$.8+^N8P'1U*,I(,C
MZ)-89T@;/G<]M8GH1P2A&HQ4!$4#5JVG".T`?YHMG_3G-'\!6-2^P/)Y>+]<
MZQ;HC>"Q9AD/CN"Y94G7?1DL/+[`CZ&1=10BP$.NX(:+``^-I!BAF]_`.ABA
M"Z`<68<1_!D*#5XPP9^A$;Q!@C]#(WB1!'^&1M;A+=892J48(_'@"%XF8)VA
M.7BG@'7:D7&W#?@,><Y>\M^RZJ4XU:-#OL.!GK0EL-(?,O6/ICRC+>%C9-G@
M`V3[WST^..?XSC.A=]F[LFSL#P1LW'W"?OP7``#__P,`4$L#!!0`!@`(````
M(0`<D3'P\00``'P3```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULG%A=
MCZLV$'VOU/^`>$^(34A(E.3JPFK;*[525?7CF1`G00LX`G:S^^\[]CA@FWS1
ME]V$.1X?GQD?'*^^?1:Y\\&J.N/EVB7CB>NP,N6[K#RLW;__>AV%KE,W2;E+
M<EZRM?O%:O?;YN>?5F=>O=5'QAH',I3UVCTVS6GI>75Z9$52C_F)E1#9\ZI(
M&OA:';SZ5+%D)P<5N4<GDYE7)%GI8H9E]4P.OM]G*7OAZ7O!R@:35"Q/&N!?
M'[-3?<E6I,^D*Y+J[?TT2GEQ@A3;+,^:+YG4=8IT^>-0\BK9YK#N3S)-TDMN
M^:67OLC2BM=\WXPAG8=$^VM>>`L/,FU6NPQ6(&1W*K9?N]_),J:AZVU64J!_
M,G:NM<].?>3G7ZIL]UM6,E`;ZB0JL.7\34!_[,0C&.SU1K_*"OQ1.3NV3][S
MYD]^_I5EAV,#Y0Y@16)AR]W7"ZM34!32C&D@,J4\!P+PURDRT1J@2/(I_Y^S
M77-<N_YL',PG/@&XLV5U\YJ)E*Z3OM<-+_Y%$%&I,`E527Q@K^+TV20>$I+K
M>TF:9+.J^-F!IH$IZU,B6I`L(?%E84BC7>JME<(219+O(HO,!8NHH3P?FWFP
M\CY`T51!(H3`AF@AQ$3$%X0H!+!K*<*Z;8H^5/"Z]A=&8I#)B%KS15<@%J,^
M(EBT$(,C2*=SO,]-@-?N5)-B/FO32D$CA&`K"85C[8$Q,61Y?F(!AM;3)IYU
MZ\&)$;*0-1P1Z@>AR2PV`'[H=W&#%[2USDOTU>.BB4&6,'-S^@@AFC#:`X/`
MS"1POR(";`HS[]:%PB`DD,*$U*(5ZU%_1EO2!J7Y$$H";%&R:X40I.0'DW92
M23C6HUW,("1>3];F?UPD,<@D%G;I42N$S*164Q)T<B`S#"/O;JC!;&$RNU\]
M`;88V7L=(:IZEE!ZS&]C!AT"?C-<*3G*[.?0TB)2&*VA]2<FB2M>_;A<!&U5
MW_2TY\V(07E&U#*C6*7`,+UE@<3RZ?LUDVBS:-3><@JC:!%+NM@,=U%3-&&<
M6H\_8(4VJXOEVZU$$(.L@EG7,=C<1GBFC39I#?)MTC?NT)HW4AC<=,2?6F+&
M*HZT;^PZ<:09(!9:KR'6M-T_Z`0RX]I5)?1)-[%2ZV+?XLPP"L.N,TVY!KDY
MZ=MYV".&&)1K%$Q[[SF51`'\Z;RC;E(;Y.H$71GJV1Z#M#4KS2[.+<Z1\N6O
M1DF3,">W'/Q!=U^Q;FNO1T0WYQ'I=9$1[D0U60UR;W+%OJW7:Z0P%R?HL=(M
M?'2#%;4\_+Y6$FUYMS5MI#":=^M/#$GH__)N.<HTR=`^!"B,O:^Q<8S@+5TL
MWW[NJ$;Q;*QO_D6W0["1%>8&-4R`P5O4A-4^;=X4C=F@9)NWPK3;WCYXQR;@
M]K:G@PQ<HLU"+KH7EE(+35X9^#RPW]*Q2J(`TYD&,'MMD(N+'Z#6Z6EAOUL4
M1LU,)U.K"6,30$APP\>IY>-/]AIZM6Z:BZYCE'J(T?>B]L349Y!C4W1CHZNZ
MU:G)+XXMWF+6+HA5`GL7F)0&^3C<=/1*9ONXPN`/N1XE3&`'D1)>@N`E0<&J
M`XM9GM=.RM_%!0>!0WW[%"]?(KA\D3<57AN`NX]3<F"_)]4A*VLG9WL8.AG/
MH=<JO#W!+PT_R1_I6][`K8?\>(1;+@:_>"=C`.\Y;RY?Q+5`>V^V^0\``/__
M`P!02P,$%``&``@````A`!C7$'JM$```-U0``!D```!X;"]W;W)K<VAE971S
M+W-H965T,3$N>&ULK)S;<MLX$H;OMVK?P>7[D46*.E:<K5@\G[2U-;M[[=A*
MK!K;<EG*9.;MMT&@"31^1K:R,Q<CYT.C078WP&[P\.$??SP]7OR^?3WL]L_7
ME\%H?'FQ?;[;W^^>OUY?_OO7])?%Y<7A>/M\?_NX?]Y>7_ZY/5S^X^/?__;A
M^_[UM\/#=GN\(`W/A^O+A^/Q975U=;A[V#[='D;[E^TSM7S9OS[='NF?KU^O
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M1Q8E-:-PJC3=[1_I`.C_%T\[%1IDD=L_NM_ON_OCP_7E)!J%BVDPG9'\Q>?M
MX9CNE,[+B[MOA^/^Z;]:*C"ZM);0:*%?UC(;3>?C2:"4G.@X,1WIUW0,IJ-Y
M,%Y.YJ<[1J8C_9J.[QN0M';G2[]\I.-1%$[GB[<.=69ZTJ_I&=(D.G%N<].!
M?L\Z1-+:'2+]FG[OM,G2=*3?,\\MH+C38:`"4'MX.0JB<1<$)\XQZ..'_N!!
MW^>)@(-&_6&ZOK,G1TU@PR8,1XOI-)HMWHB;@`-'_6%&?<./:CIIXSA!$YX*
M[RL]R;HY&]\>;S]^>-U_OZ"%D(QT>+E5RVJP4FIYMFH+]_/W1].7YJW2\DFI
MN;ZD^*")>:`UY_>/X63^X>IW6B?NC,P-R@128LT2:E%0:F,?)#Y(?9#Y(/=!
MX8/2!Y4/:A\T/FA]L''`%=FZ-SB%UE]A<*5&&9Q-=</`\8!G79;@+K$/$A^D
M/LA\D/N@\$'I@\H'M0\:'[0^V#A`6)>FG[#N\$6'HU9)7U_2M'.B=B&M=J-E
M0GUU44&Y!A(#28"D0#(@.9`"2`FD`E(#:8"T0#8N$48E`YUA5"5]?1F2AQRK
M+CVK&B$:T@I%8RFT[H7ZB`62`$F!9$!R(`60$D@%I`;2`&F!;%PB#$WK[QF&
M5M*=H=D\-X;,^E5A#20&D@!)@61`<B`%D!)(!:0&T@!I@6Q<(DQ(N9`PH;J>
MA=,1R9]Y15.*I'4-H1\G9OU+6"_$3HF!)$!2(!F0'$@!I`12`:F!-$!:(!N7
M"(-3+BD,?GK%5=+2JH8X,0LD!I(`28%D0'(@!9`22`6D!M(`:8%L7"),2&F3
M,*&*V<E"54?G!JW2),UK"+G/"=K06VA[H3YH@21`4B`9D!Q(`:0$4@&I@31`
M6B`;EPB+4STB+'XZ:)6TM*HA3M`"B8$D0%(@&9`<2`&D!%(!J8$T0%H@&Y<(
M$ZH"[0P;=N+2B`8M]"9`EUHABBUR(W@B(SBQ4AS"*:(,46Z1JSZ2Z@LKQ>I+
M1!6BVB)7_52J;ZP4JV\%DH97E066;"-59AX?=G>_W>QIJI/00%!/J#0S!9NN
M3RA-XR%O5.5,<2[\`2AFJ9FN\L:!=S*)%6#-*2/KZ0Q1SJC7#%XP1V.G7<E]
MK.8*4<U(KH(SWPN@ON6.G7KI!56!N%X8L#8MX+VY=<$BS*W11.;`7M&\5EL1
MY)1)U/LI9J3\S=5V,(,9H3M&ZABH&A\%7@J>LIIN*[`+BHR1'2QG='*PPDB9
MP8)1Y-FV9#5VL(J1':QF='*PQA]L[D5@RVJZP:375(USAM=,2>1.$HTF=#&W
MQE]X1>-:;0,IK]GZ/&8T[QV9,%IV+O*JGY1;Y4B>%S.6LB/EC.Q(!:/!D4IN
M/3E2Q5)VI)J1':EA-#A2RZT_&DDZ2]5)9SC+E%6NLS024RQ8>H9>JWTW?XKU
M'7D-2XS4-.B<Y2M)60DYWHD+\!8,E=N./%1Q>JC2]C@Q5,52[O2"LVJ\H6`F
M]3V&AY+^HFE[CK^4N)<1:"0GU](OL=0VI3^Y^HYLQ(2E="`&H]!;DE(6^%$L
MFB41!LMM1QZL8,2#33W'ERQP<K"*I=PI!F?6L!0/-O$&:UG@1X-)KZG*[HQ9
M9@I!=Y9I)&99&,&2:*1L/,9!WY$-F1A$L\P&7!AY)YABQXR159\SLM><8E#]
MU%L02NQ8,;+J:T96?3.D/EAZ:4PK.DI?D,?.\842]V:01DN;(JT#0#&B!%&*
M*$.4(RH0E8@J1#6B!E&+:".0-*FJ`<\(;U,RNN&M$9G4"<DI+$J]%,=R'`!*
M$*6(,D0YH@)1B:A"5"-J$+6(-@))*ZLR\0PKFZK2M;)&(G`!Q0&@!%&**$.4
M(RH0E8@J1#6B!E&+:".0,&EX7GW=B<NUP""Y+D_]O1^6LBM;S$CD,E!@&*GI
MN$N(9O.I?X%E-9UF>6ZJTG+#1=]U/+.$I7LR_O)GD$@@9MYQK5G(7F5C@R*[
M;"8&3</N]*+`-UPJU,C34Z77_W]ZNH!S2T9U4T5E/JYCPJE7^:U9RO6H*09I
M1;+9*7I42]'#(:IDI$<>QMY%/!6JY3FKBN?4.?^Z?_G1KH13)X=*C1?&&KDK
M@Y%R4(PH090BRA#EB`I$):(*48VH0=0BV@@D3:V2<M?4I[<>0IW#BSC2R+ND
M>7G*VG045NX[\E4N0:D4488H1U0@*A%5B&I$#:(6T48@:665>)]A99VG"RMK
MY-AOK;;T*;P=%"-*$*6(,D0YH@)1B:A"5"-J$+6(-@))DZI\WS7I3]^<"W7E
M(*QMD$S3O()VS1WM0A\C2A"EB#)$.:("48FH0E0C:A"UB#8"20><5U^$6%\P
MLO9;(XH1)8A21!FB'%&!J$14(:H1-8A:1!N!I$E5DN_&]!N+L:X)1.`:)`,7
MDI9>BE?>6#TDIJZ5UA<)HA11ABA'5"`J$56(:D0-HA;11B!I997WGV%E728(
M*QMDC;4.`<6($D0IH@Q1CJA`5"*J$-6(&D0MHHU`PJ23\^J+3EPF9@9-W$>C
ME%)*4"V*42I!E"+*#%K(9->[/Y);*9X7A=`ES_DOJ3OH[/P<U2#GO->(8H,B
M2J+Z+#R<>CEV8J7XC%+4E5DI5Y>W499;*=95"%W2.BK]?_\DF^AJP9UD!LGZ
M9.9MKZVM%!]4;-#4WDA(6$K?#:3[6^%T[&VZI"QC*YV,$25:O8WAYEANI/K[
M54O/<`6KP=I5G=PY5L*"IM-`DX2NKOTAAJ%W;FLK9:VD=3EWE1(C-=-W)>;C
M<+F`HHTUV7HW8^0>PH"5S'B\T>S?:"M83:=9QI(J%,Z()5U7B%C22`WA6,G?
MO:#[HMV"8S=A8T8V*!*#S%;%+^$DG,'M4.R6,7(/8<!*^A#,C2&Z]^DM406K
M&8@E50ZX5OJI?9")+BJ$\33R0LS?*#`=2<J&F.XX<XVGD=D(^26:1HNEEYVD
MK,D-,=V-ME2L_P:,9Z3F>LMAY-])+81F&6(JX7>-=SKSFBAQ[P*FD0PQ?Y]G
M;3J2E+62[BB6*Z-++U?SY3R:^QO_*6NRQLT8D1GZ*!^PDE;>+U?>):-@+0,1
M=E[&KP+&-Y)&7BC!:M5+62,99&,B,>HGE'CU9QO"C3F6LATS1J2R[SA@)C/B
M2?4%ZQI8M%1"?49$F?S;V<6FI=DL1_8XPQ`6K5[*&LL@&QJ)T25OA:&QH&,V
M=!`#QM(=3ZLO6-=`9*GLV376SZU=)@=W;:B1<E/OZS"$M:N7LC;42*Q=&D52
M%ZQ>1I<;<*8C3;S^(`9L^![UA0IWE11CP$5^#OY3-NRTR)7-(&]E\VUHI7H;
M&K2PEX3$(+,K/+RRL28;OIE!$879"0NR%*<8_LHF%(OE/WHKEW_?AG.GQC.>
MR>^=4I&E+(H1)8A21!FB'%&!J$14(:H1-8A:1!N!I*G/*PPB+`P8N=.)<C#Y
M`-[:2MEX-+JLX1.42A%EB')$!:(2486H1M0@:A%M!))65MFVNZ">SF<BG9R[
M61\C:ZPUHAA1@BA%E"'*$16(2D05HAI1@ZA%M!%(FE2EYF>85&?RPJ0:T28$
MA^1:E>^TG#LH-HA*:Y9*$*6(,D0YH@)1B:BRR"ZX]!:QG&.UE>)#;1"UB#8"
M22NK'/X,*^N47UA9([G5,_/3)DI_P?`:"</W4HX9_%N=*>K*#')TY5;JA*["
M2K%)2]156>3H"KR]D=I*L:[&JG<[>FMG:Z6XXT;HDAY3]83KL9_+.W15(ARI
MD8J5_J(?!EZ^M58U(<T@DN)CC0URC)]8*4?7S+M)F5HIUI6AKMQ*N;J\FT.%
ME6)=)>JJ&-&5R9ZC_Y!!S5)V26BL>K>C-T%;*\4'L1&ZI"-5Q>,Z\HUKABZ0
MA,<T4F5V?S:0Z*Y5`JT\IA\F#T:>1V/3[M3(B4%.C9RRE*Z1)\%LZI=&&8O8
M]38W:&&S\X*1SAJ'%)6LR,989="2DN[^5,.9EW'6V+%A=-)&+4N9#<O%?#SV
M9O>&1;":4FGR.8[4Q9MPI$:B;!IPI)'B?-O?THN[`^DV)SG\$D;6`:E!2[OM
M.()]QXS[V5HB9V15%0:=VL$LL5O%B')UQYG>-F[-4G:\AA%%=-\1[-0:*7-4
MD^5X,N!-8\M.N9R6JN([8UKJ`E%XT]2,)[<>UY&6,EN/X2BD3]TX_WD7T-B(
MBUEJQK'3)&6E^KFN:3"')")#13DCJZAX6U&)O2J#EF)YG7LSJ<:.#:.3)FN-
MU.EMCPWKPHE*>\CGN+83E^6E06],5)8R2]S(J]UC;K>3*V%D@STUR(3Q+`C'
MWN4FXTY63\[(ZBG>U%-BIXJ1F*)S+W&I6<J.UC`Z/459BB*XG\BPF;AA*9RD
M*@3$)/VI)*C3XCE8[Q^HK8O^P&"%69N.5'6KA^TF].RCS-1C(^#.5D9VDJ4&
M+?4S>U,U^Z6>C#LYEU2#9LL^`2O>U%.R'CMXQ9WD7/66G1H[-@:=-E'+4B*`
M_!W0C5`OEF&Z9?%7>%AI\3RLD:KE3WE82RTCOK<A'1-WAR<OM8SL9$@-HB)7
MQ<G@]EO&W=Q);`:W+T86[]!4LB9[`!4CX86YMQ[5+&4[-CS>22NU+*7/;Q(N
M,(0W0KETL;]IXD_B]^T"TN8F^%@CY\U/_<4S_?6DI^WKU^UZ^_AXN+C;?U-?
M,Z-+QL<//=:?6KL)%ROU5`NE4M"RI)9N_ODM$7V?C5:%@3Y12"W=3CGTF5!+
M-\']EH#&H8?,![2%U(<>,AUJB:BEF^:^MG!*+9U)H&5&+=W&$[3,J:6+3+^%
ME`WJ(E6#FDC1H!XR\J"-Z=0'SSP@1?3&R,"91[.5JDZQA:K1E:HUL85JRY6J
M'+&%"KZ5*N>PA3[!]VG0C^3Z0<^3XP?ER85#'OP4K3Y12./`-^39(<?2Z^8K
M];(S]J#'<%;J(1MLH<=95NIA%6RAAU.HSU#+3121@8>.X"::4LM0."34HO9K
M<!S:GR'3#[70I@F9?JCE)J!HH1=9!K21#=2+_D,M`;4,G0]]!6"EWD''/O0Q
M@)5Z%1U;Z)L`*_7&_U!+0"U#?6ZHCWH_'_NLJ64]V$)?3EBI[R)@'WJ'GUJ&
MM-%'$U;J;7WL0]].6*F7]JGEJI_']-G&E]NOV^;V]>ON^7#QN/U""^&X>XWC
M57_X4?_C:)[]_[P_TO<:N]<`'N@#G5OZFM98?9KGRWY_Y'^H`?I/?G[\GP``
M``#__P,`4$L#!!0`!@`(````(0"F<2N/.!,``%AE```9````>&PO=V]R:W-H
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M</D'C><[)W,S(J,E-BQA!J\QFX0@#4$6@CP$10C*$%0AJ$/0A*`-0>>!2PKM
M$%_*BO^/^!HS)KX<F1L&$O`X""9+L$H2@C0$60CR$!0A*$-0A:`.01."-@2=
M!U0P::!`,&<T*XPO`9R;1NOZG'+;R\V5#M:-E8GM9&]2;P,D`9("R8#D0`H@
M)9`*2`VD`=("Z7RB0DGA4*$\'D(C32LG]8L7PW400R=$38K0:J*%-H/0D)9`
M4B`9D!Q(`:0$4@&I@31`6B"=3U18*1E/"*N1[L/*P;AQ9#8,]`V0!$@*)`.2
M`RF`E$`J(#60!D@+I/.)"A@5)"<$S$CK@#E"]KVDBX*D&X0XS@F0%$@&)`=2
M`"F!5$!J(`V0%DCG$Q5#JLU.B*&1UC%T9"%)!R0!D@+)@.1`"B`ED`I(#:0!
MT@+I?*("9K:$8=$SIQ7\Q*+'F-&1=(1ZRLO&<&$>A(9L!)("R8#D0`H@)9`*
M2`VD`=("Z7RB@DMUNPKN\97%2.L8.N)E(Y`$2`HD`Y(#*8"40"H@-9`&2`ND
M\XD*F-FOJ(B9&GPQO9`=Y?O+<&-*A[.W3DCGY#28(45J2$I$*:(,48ZH0%0B
MJA#5B!I$+:).(1UN4ZK[H_]X@IH=81A2A[P492E!":(4488H1U0@*A%5B&I$
M#:(64:>0CI^ISOWXF73]A=DSLE4^%96<<C>,=*[.PEQUBGZL`:5BB\UGB')$
M!:(2486H1M0@:A%U"NE8F_K=C_4;N>K*?3^D#DFP-N:\P62TH`11BBA#E",J
M$)6(*D0UH@91BZA32,?/%.HGQ,_5]7[\'-(I.0]3<I#B9$O,88J.<HHH0Y0C
M*A"5B"I$-:(&48NH4TB'U)3R)X345?Y^2!V2_-N8<UP=K`11BBA#E",J$)6(
M*D0UH@91BZA32,>/,DG%STR?\?R"(G!B^1D92\%B[Y#.UD68K8.49"N@E,U+
M-V6(<D0%HA)1A:A&U"!J$74*Z6B;/<`)V>JV#'ZV6D0#@H*E;9L2^`3;KF+V
M;?M%='_BN8D`)8A21!FB'%&!J$14(:H1-8A:1)U".GZF(O;C9\^>^[KW\/!X
M]_O-CH8&U5HCB]Z4SIC=R;.KJ_VP6C2W3X'ZT[P(4.+0C.9I:L8=6J^"0^M4
MI'BL9(AR1`6B$E'ED'5512<>VQ5$\Q.CTUO1<X1#?G00)8Q6_6%^/(F")2\5
M@2$PC&3&R!$5C`;+07U7B@!;KACU/:K#=%HU3R>\X9SIT)2J(B\/@@/BC4BQ
M4XE#\^50P*8.T9FT>002G'UF8L-O*3A&S46*6RJPI?)H2Y78&&])AS`LZ$?&
M&SU[XP%G3H&#9<>A*4V5$L)U</L;D>(;2QC)@XV4T;H/830-SO(ROJ[:6D$0
MK9/D$;=5L**T53)R;<7!0EGQ]9^UI<-HRFI_.GLCC*X*]^:MV"*=B>L@`!N1
MXEM+&,FQ<>H0[<M,)L87DWCM_Q>D=\86]""`J`X.<M,%*TK3I6XZHL?%NOZH
M6.=GC>FPFCKZA+"ZLML/JT5!=H:G<O$@Q?>6,)*,21G1<N)E>G":DK&49%^.
MJ&`DYDM&VGPP058LU9O7P3)U]`G!<F6W'RR+@AP,)O^->11/<P!)2;`<DD1(
MG93+P6`ZR,2&%TH<R-!2P8K24GFTI8H5WI=OIA(^(82N</9#"+7TQIR^!?L;
M1"FB#%&.J$!4(JH0U8@:1"VB3B&=@J9>/B%^1CPH4!RBF'EC+)B;-_$@)2D(
M*$6I#%&.J$!4(JH0U8@:1"VB3B$=TM,V&C%N-!A)9;9!E"!*$66(<D0%HA)1
MA:A&U"!J$74*Z?B9XO^$E+1[!5K\.;-N8HMHG\EH(\C+TFFP$B2C4FM9$)6?
MT[&2WQX-'*\E>D4]B!SR/19TS.-1J;74"]KCTZKO*5;?#BD_K939U,OXA\B*
MHB>UEHI%^WE:B3O%$M<AY:>5>LO/$2EZ<W0HB;2?IL#R,U4.A][(`%N9^3EK
MEG":697'`_)BAI$=D:(-X$\\#LNS=WN,A=K4(N7Q@(YZ/"(53Z3"TS$V%<4O
MQ=B6(BK&%BF/!W34XQ&I>"*SA_;85`^_Y+$K.[R9;&J1\GA`1ST>D8HG4IIJ
MC\U*['O\1O:ZA=OWTR+EYX".^CDB%4^D@-5^GK:R3G%E=6A%&3A,5E.9+>VA
MG@CQ\I$@2A%EB')$!:(2486H1M0@:A%U"NF(AFNMS`<G'F]/<1EF1*DX!#N>
MA)6A2$FTG2U9OU.4RA#EB`I$):(*48VH0=0BZA12T9Z%%</Q<=:+ZSJ!D41F
M@RA!E"+*$.6("D0EH@I1C:A!U"+J%-+Q.ZU^F6']PDBGI!1X=@(0J2$E$:6(
M,D0YH@)1B:A"5"-J$+6(.H5T2$\KM698:C'R4]))"4I0*D64(<H1%8A*1!6B
M&E&#J$74*:3C9ZJO]R^=,UNL^46)0U0@<[)M$"6(4D09HAQ1@:A$5`GR9^]@
MK:Q%BKUO$+6(.H5T2$UY>$)(;36I0FJ1"BF@Q#Q*,J=B$O@4488H1U0@*A%5
M@OR0RB:HGWUJD9*0@JLM2G4*Z9":^O6$D-IR5X74(B]8&_,JOXY?@BA%E"'*
M'5K1\/!*A2#9"I'BR)1HJQ+DV8ID"^>B#-XW8MY7E)U4K]B*%#O128N$=.!-
M&7Y"X&W5K@)OD0H\H&0&*$64(<H=TH&/9"_6WW,A4GS/)=JJ!/GQDUV2"SRX
MVHAY7U$V*R[P5I%<92<Z:1$";_85?N!_Z6GUS.Y.5']8I/H#4.(4S8B4?(:'
MLB+%=Y0YY)G/1<JW%931A4BQK1)M58QH@?;\"NJ?FJ5D9FS$O*\8#-!6I-B)
M3MG28^.TW=P,=W,.><':($H<FDLUDB+*4#%'J0)1B8H52M4HU:!4BZA3BCI^
M8WNWDU\YF.&^S2'U4"F.@F5J(U+<UPDC>=23.C2?]`\VI^O)>AY^R"A#M9R1
MOQY$BV`J*=BX?6H:72R#?"S9C#A4B8Z7R#&L#C8J=,3%-]>P(ET9A@ZXU#JI
MA;W?Y6H^\0X/^WFL4TZI'J4H'9^T_KG[]K-7;.BI&3_R[\WH?:-#ZJ%J'`=+
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MEI)W(EI&HM@QZA5UWYB-KE]_'3_JFAOQ8,JRR'MI8>.D/)0XY+_5Y1`5Y7PW
M&2M*O^2,1*I`Q9*E1+%RB-*2S=<HU3#R<]O>D*?8L=1(;IL=GQ^_7\MMNV_T
MZ]>YVTKZTW`<![7V1J3X)A-&DB2I0VXEF*]7410>[V:HEC/R78"5M&`I7@DF
M$S4-A4L]BXM[%2-_Q8YC>;9@]R,L)8J-0PO:(OY\\+4LM>@'WV)LJ5>V]?@P
MV\]C_?O.I=[N8E4'NXTM9=O@_,A2/TA)!SLDN9[26Z=F6+I59FZ*&5CI02MW
M6FJ=&^E?9YN+MWF0@R6;$7\J]L<?>]!^XZ06_MQEI1;2R9TRK_O&;#3]OGEC
M[K+[4M4'%@4+"*ST@Y3T@4/B9TK[EOZ816=QL`AG+"6*.:,WAME[S)=L2\Q7
MC&0YJ!F)5,/([XNA1;[MCJ5Z1=T7Y+WJBU^;!XV58'FQ2"5I'`?KYX;6E3[X
M,HTG#BWDOE.'S"F[-^2@BYPMR>><%:GN'Q1'1HI5/&Z^9%?%?.60M^+4*-4P
MDGML4;%CJ=Z\[J+3]O%SW,<[1,.%,V*#*'%HV7_O5#]WIXQD/LA847(P9RFI
M_`M&HEBB8L5(NKIF).8;1N)]RT@4.T8C*6[VFOYT\VLI;JP$*6Y1D.+!8<]F
M/DAQ\!.'EI(1J4-N7[N83\>6>F=),C!W:N;'L02WBLL9E[&!CZ4SXVV`*K:L
MQUQ0%=2HV+#B49=:)^7N-U[$*UCZ.F5<#0E2.]ZE[UO=>S.Z3QWRAPJBQ"'Z
M2#KW:>K00OHT8T7)Y9REO*'"2!1+5*P82<;7C,1\P[;$?,M(S'=*4<?5;#7_
M]E"A>C4<*@X%0R4\\A(I#FOBD#]4'**[,)NR6;18T9XO.!]A2]Y0<<@DU9&A
MPNWQ4`G?P"[1<L66U5"9!H5<C8H-*QYUJ752[GZC-1WRA55BIXSK+AW;Q,=+
M^>`4#Y7W?\:,CGB@?]T.EU;2(;AQ^&&5C5/T!E?BD!I)UI8:2<Z\I'K.BE3L
M#"WBTLY2=@._BI80NI*=$ML5(W^P@0>-DZ(?G*TM(W^P^8JZ9\Q^]=A@XYXY
M7AY3G*`W+*+1QIYMG)2'$D8R1E*'O((F0ZG<(:_^+QA)$$M4K!SRS-<HU3`2
M[UM4[%@*ZR4Z'<*XFM?)3\APW-?W5NEIML[P<,LA4ASYA)&$)F4D^94Q$JG<
MH>.[Y,))+>WG!Z.+63"IEFBY8B3MUXRD_8:15W<Q$L6.4:^H\]OL"</\_ILS
MC]UF^EM!$QZJR_3*$K[$NQ$IZ1>GZ*>_15Y^9JPH4KE#RZ.S=N&D5FZ56B]G
M(U,/N%`Y-<^%&EUH&/E#!'SO6&IDB)@M8M@U$7T#JQLD//.<,&+LIE/UC-N'
M2OYL%H`21I)X*2/)LHR12.4.+>6Q8^'0RMMUH&+%2,S7C,1\PTB\;QF)8L=H
M)/O-IC(,\=_,?F,R*%<M"K(_..G9T$SMQHADOT.2UZF3\E(O8T61RAUZ*_NM
M^94]E:?/6\*L!.U7V'Z-[3>,_-2WMCS'.Y8:2?UP-QWN!CGWWUAU<9=-AU]]
M]TA";A`EB%)$&:(<48&H1%0AJA$UB%I$G4)ZMJ?I4.7[&_$SXD$N.T1SQ%#1
MQ=/@.'E#YT)!E!-$*:(,48ZH0%0BJA#5B!I$+:).(152.HDY):2]N`XI(R\E
M$26(4D09HAQ1@:A$5"&J$36(6D2=0CI^X6[V>$HN<=O*2*=D</"X$:EA>D64
M(LH0Y8@*1"6B"E&-J$'4(NH4TB$UNQE_57LCI';SXU<%])WX9OQZ7UUAO^+>
M?@WW\_;UZW:S?7K:G]WMOINOKZ=3V8\?!FR_6_]FL;XRXX;"'5Y93NAK]_L3
M3+ABOI"_KPS"*]/5E?D(QXBU*;5#'S<8N3*C=NA%^K$KU`XY/78EIBO];C'T
M8$$>T-0ZHA.1#GTAVMB5*5WI5\'06C2C*_W*!U?F=*4//5Q9T)5^FH`KY!M]
M:\V(!Z0RJK&D0(_)DZ%1.Q3DT1A'%&/ZXL*1EB.*,7TE'UZA%P.O4GI<CU?H
M-;\K\Q(?7J%W[Z[,FW5XA?Z&PZ?QV%/S(_(WU%FC\M158SWU:7;UR?Z-B##H
MU(.C'4C]-]9]].T]5^;[=/`6Z)MKKLR7T^`5^N:9*_/E,GB%WA:F4(VU0Z_P
M4JC&KM"+KJ0SE@[T]BGIC%VYB2F#Z*/SZ,%-3#E$6_:Q*Y1%]-EFNG(Y!(W^
MKL6WVZ_;]O;UZ^/+_NQI^X4FCDE_Q/5J_S*&_<?!O=[U>7>@OVC1O^GU0'_!
M9$M?<$ZOX9R??=GM#OP/T\#P-U$^_D<`````__\#`%!+`P04``8`"````"$`
M_MC6_)$"``!H!@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R45<MN
MVS`0O!?H/Q"\1Y3D)+8%RX'3(&V!%BB*/LXT14E$1%$@Z3CY^^Z2CFHU:>->
M)',UG-G97=*KJP?=D7MIG3)]2;,DI43VPE2J;TKZ_=OMV8(2YWE?\<[TLJ2/
MTM&K]=LWJ[VQ=ZZ5TA-@Z%U)6^^'@C$G6JFY2\P@>_A2&ZNYAZ5MF!NLY%78
MI#N6I^DETUSU-#(4]A0.4]=*R!LC=EKV/I)8V7$/^;M6#>Z)38M3Z#2W=[OA
M3!@]`,56=<H_!E)*M"@^-KVQ?-N![X?LG(LG[K!X1J^5L,:9VB=`QV*BSSTO
MV9(!TWI5*7"`92=6UB7=9,7UG++U*M3GAY)[=_2;N-;LWUM5?5*]A&)#F[`!
M6V/N$/JQPA!L9L]VWX8&?+&DDC7?=?ZKV7^0JFD]=/L"#*&OHGJ\D4Y`08$F
MR2^029@.$H`GT0HG`PK"'\)[KRK?EC1?)/,L7<[FP+*5SM\JI*1$[)PW^F<$
M90>J2)(?2.!]()E=)A?S=):!YBLD+"84_-UPS]<K:_8$9@8DW<!Q`K,"B%\V
M!$X0NT%P26&F(5<'3;A?Y_/EBMU#Y<0!<QTQ\!PQV8A@(#HJ@]KIR@A&92PM
MIG(=`\<R^<LRL_^107!)SX^2SQ?IR!N5(R9T>>('=IWN!\$P!.!B+%.^^%VH
MJ!1!V<3DXB\V80).5T=P4!_+&2,@A:?@N$N74UX<_'P6IOR56<&-4XT8R::>
M9V-U)[+SJ>R_QQ+!4ZD8.>I1/-EQ\K6TC7PGN\X1879X:G.8Y3$Z7BB;'*OQ
M9_R\V(2+AHT?X*`/O)&?N6U4[T@G:Z!,$SS9-EX5<>'-$,[;UG@XXN%G"S>Z
MA'%.$P#7QOBG!;9A_(]8_P(``/__`P!02P,$%``&``@````A`-N\Y2Q_`@``
M\`4``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULE%3;;MLP#'T?L'\0
M]%[+ER1+C21%DZ);@0T8AEV>%9FVA5J6(2E-^_>CI"1-T@YK7RR+.CHD#TG-
MKAY51Q[`6*G[.<V2E!+HA:YDW\SIKY^W%U-*K.-]Q3O=PYP^@:57BX\?9EMM
M[FT+X`@R]'9.6^>&DC$K6E#<)GJ`'D]J;11WN#4-LX,!7H5+JF-YFDZ8XK*G
MD:$T;^'0=2T%W&BQ4="[2&*@XP[CMZT<[)Y-B;?0*6[N-\.%T&I`BK7LI'L*
MI)0H4=XUO39\W6'>C]F(BSUWV+R@5U(8;77M$J1C,="7.5^R2X9,BUDE,0,O
M.S%0S^EU5JY&E"UF09_?$K;VZ)_85F\_&UE]E3V@V%@F7X"UUO<>>E=Y$UYF
M+V[?A@)\-Z2"FF\Z]T-OOX!L6H?5'F-"/J^R>KH!*U!0I$GRL6<2NL,`\$N4
M])V!@O#'L&YEY=HY+2;)^%-:9`@G:[#N5GI*2L3&.JW^1%"VHXHD^8X$UQU)
MEK^;I-B1X/I,DD_'V7CR_U!83"NH=,,=7\R,WA+L/`S<#MSW<58BLY=G]$]Y
M4!=_Y]I?"E<1;;&D#XLB36?L`>L@=IAEQ.`4'3#Y*6+U"N(9PC"^0Y"HVW&0
MK]=N'YP'GP>7G;I>1LPT%,EGM#HRG'A&2=[NV8.Q/XY2+M+GC()TRXB)G18\
M'QE./(_>X]F#SST79SE'3):&>DV3\>DQSF"0+1YG13(YG,>PXH3%WE%@&EA!
MUUDB],9/3XZL!VL<[&56HLXX46?V%0Y\L+/#`0[<P!OXQDTC>TLZJ)$R33YA
M(YHXLG'C]!`JN]8.1RW\MOBR`E8P31!<:^WV&_\H'-[JQ5\```#__P,`4$L#
M!!0`!@`(````(0`59T-/@@(``/L%```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;)2476_;(!2&[R?M/R#N8XR3M+$5IVI3=:NT2M.TCVN"L8UJC`6D
M:?_]#I"D^:BV]B8.^#T/Y[R'X_G5L^K0DS!6ZK[$-$DQ$CW7E>R;$O_Z>3>:
M860=ZRO6Z5Z4^$58?+7X_&F^T>;1MD(X!(3>EKAU;B@(L;P5BME$#Z*'-[4V
MBCE8FH;8P0A6A2#5D2Q-+XABLL>14)CW,'1=2RYN-5\KT;L(,:)C#O*WK1SL
MCJ;X>W"*F<?U,.):#8!8R4ZZEP#%2/'BONFU8:L.ZGZF$\9W[+`XPRO)C;:Z
M=@G@2$STO.:<Y`1(BWDEH0)O.S*B+O$U+9833!;SX,]O*3;VX#^RK=Y\,;+Z
M)GL!9D.;?`-66C]ZZ7WEMR"8G$7?A09\-Z@2-5MW[H?>?!6R:1UT>PH%^;J*
MZN566`Z&`B;)II[$=0<)P"]2TM\,,(0]A^=&5JXM\?@BF5ZF8PIRM!+6W4F/
MQ(BOK=/J3Q31+2I"LBT$GEL(S3X,&6\A\'R%9+,IG5[\/Q42RPHNW3+'%G.C
M-PAN'B1N!^;O,2V`[.T9@\EOVP.^^)AK'Q1"06VAI4^++)_-R1/T@6\U-U$#
M4_2J.58LWU!D>PF!_/9)@F\?3]('G21)]_A0QTV4S$*O?&'+@XVC!,"9PP3^
M[8X7EWAR6'F>GYP<-?'"A9,/-HY.!LS[3_9BZ-_!R9/QR<%1DH>FC2@=3]+T
M6`'#Z"$[14K3R6E7XK#%:Z2$:<12=)U%7*_](&7`WN_&&;^A!7@-PW6ROX39
M#_MD_P)F;V"->&"FD;U%G:@!F2:7,&PF3F]<.#V$YJZT@ZD+?UOXR`KH8IJ`
MN-;:[1;^^[#_;"_^`@``__\#`%!+`P04``8`"````"$`097W@GD"```@!@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6R45%UOVR`4?9^T_X!XKXG=
M)&ZL.%6ZJENE59JF?3P3?&VC&F,!:=I_OPNL5MQ&4_9BF<OAG'ONO;"^?E8=
M>0)CI>Y+FB8S2J`7NI)]4]*?/^XNKBBQCO<5[W0/)7T!2Z\W'S^L#]H\VA;`
M$63H;4E;YX:",2M:4-PF>H`>=VIM%'>X-`VS@P%>A4.J8]ELMF2*RYY&AL*<
MPZ'K6@JXU6*OH'>1Q$#''>9O6SG85S8ESJ%3W#SNAPNAU8`4.]E)]Q)(*5&B
MN&]Z;?BN0]_/Z9R+5^ZP>$>OI##:ZMHE2,=BHN\]K]B*(=-F74ETX,M.#-0E
MW:;%34[99AWJ\TO"P1[]$]OJPV<CJZ^R!RPVMLDW8*?UHX?>5SZ$A]F[TW>A
M`=\,J:#F^\Y]UX<O()O68;<7:,C[*JJ76[`""XHT2;;P3$)WF`!^B9)^,K`@
M_+FD&0K+RK4EO5PFBWQVF2*<[,"Z.^DI*1%[Z[3Z'4%I2"IRA=1NN>.;M=$'
M@NU&M!VX'YZT0.+3N6`2'KOUX)+B.**,Q?H];;)\OF9/:%K\Q=Q$#'Y'3#HB
M&(J.RJAVOK('>V5?%9_*30P<RV2G92[_1\:#2SH_2C[+%R-O5(Z8T*")'SQU
MOA\/QDZBB[%,6;Y\HQ1!JWP"RD?01!TGX'QU#P[J8SEC9!4*/.%=3GG]S&9S
M+,&_!\6?F@K$2#HU?'7:"QH^WXL'3Z5BY*A!\4;&L5=@&O@$76>)T'M_VS(<
MY#$Z/@3;S,_:V_B\V(8'@HT;>$$'WL`#-XWL+>F@1LI9DF-!3;SB<>'T$"[;
M3CN\FN&WQ9<8<)9G"8)KK=WK`H79^+9O_@```/__`P!02P,$%``&``@````A
M`.>$"/,P"```#B,``!D```!X;"]W;W)K<VAE971S+W-H965T,30N>&ULK%I=
MC^HV$'VOU/^`\GZ!A"1\:*%:\BVU4E7=ML]9R"[1`D%)]NZ]_[[CV":>&0IT
MMR_+<CP^R1R/[1.'AU^^'_:#;T7=E-5Q:=G#L34HCIMJ6QY?EM:?7^,O,VO0
MM/EQF^^K8[&T?A2-]<OJYY\>WJOZM=D513L`AF.SM'9M>UJ,1LUF5QSR9EB=
MBB.T/%?U(6_A:_TR:DYUD6^[3H?]R!F/_=$A+X^69%C4]W!4S\_EI@BKS=NA
M.+:2I"[V>0OWW^S*4Z/9#IM[Z`YY_?IV^K*I#B>@>"KW9?NC([4&A\TB>SE6
M=?ZTA[R_VVZ^T=S=%T9_*#=UU53/[1#H1O)&><[ST7P$3*N';0D9"-D'=?&\
MM![M1>;,K='JH1/HK[)X;XS_!\VN>D_J<OMK>2Q`;1@G,0)/5?4J0K.M@*#S
MB/6.NQ'XO1YLB^?\;=_^4;VG1?FR:V&X/<A()+;8_@B+9@.*`LW0\033IMK#
M#<#?P:$4I0&*Y-^7E@,7+K?M;FE-_*$W'4]L"!\\%4T;EX+2&FS>FK8Z_"V#
M;$4E25Q%`I^:9.C,/-OS!<F5CM#:71T^5<?9<.9YKC^;7N\X51WA4W5TA[8[
MOG4]J/KN>O"INMGCX=0>SR>7KS>2:G7BAWF;KQ[JZGT`%0UZ-*=<S`][,;<&
M6G69ZGD<_FT80']!\BA8EA;<#"C<0.U\6SDS]V'T#<9[HV+6/,;&$8&.$(,K
M:$,*1!2(*9!0(*5`9@`C$.&L!!3._Z"$8!%*Z!S6&C"D(6GK"-TEI$!$@9@"
M"052"F0&@-*>\+1=*-G+TTZ/M^BTM&"6G,=[/L-9K66((^>7&,V`(2%#(H;$
M#$D8DC(D,Q&4+MRS.<K7TQ3!L**`=.<\834@B<H@SQ3#]N8X*#@'G0>9(1%#
M8H8D#$D9DID(RAV&]?[<17"7N[[CM40@48T$#`D9$C$D9DC"D)0AF8F@K'R<
ME5S!AF(9;'?EYG5=R57_PDA/8*62ZY?@P,E*9&*4+T-"B;B@][D\;'^,1SXZ
M!VG58D:4G&-,(K(ZIN<@39291$@2V$S,@1:2.+[8-F],:]$/RR"1"4PG(T4'
MIQBHH+XP0H6(,=`;@NU/<+=(!?G=?F&/J7(QHTWNH4TI[11?-C-ID6K"21I;
MX86"`05UQ8A@+)5$)D!OY$PVP4`%]?M#>.ZFAS52R%SJXI*"BAE%PBA21.$X
M9&W.3`HD`3@`4X(/S27!@961""DBLHP&*L@H(HFXG6WLIFFD$+M39C(EXL:,
M(F$4*:)P/%*3F4F!E+'!T'Y:FHX$:Z,@4C8^KME`1QEUHR#7W)SX'--18JG[
MMK(]IAEG3G2?J\RICM+,+BTRQ(RU%!;,F&FTS+Y6I\Z87I^!MC1RL#OKF;-6
M4/=X@*\HW(]QQ1O,(KH;IGXJ.S,R)FM;1N&-WR<J!'V4OLN00Q&'8@XE'$HY
ME"$(JR!<T?TJ*`]EZJL@_RQY8#,HY%#$H9A#"8=2#F4(POD)YV/D1^OJ+BM@
M2_N$RDI"IAE04084*NB&'>BC=#W$G"OIH_H*M'WJ"/HHS94A+BR.,%"&.#>F
M@(@F*Y6$R#).C:YX9(>.$V,=UQ"T&#LC67DC%07/'MU*99-D8\W2$R<:NDJ<
M8N(YN6ZF23I>K)CP5X9B'RLG:=)0.2G?AIS"E&SS@:VBS"5?0FX__2(5Y4Z5
M:GC?B#E)HGOT)*F&+I-DB`0K)+R4H="-FI+."TDA(:@I7<&!K:!^G$,-R6,?
M\2P9*4A7BT,L::R[]"R)AGJ6E+",B:'(=)<+M2$LE)'YQVI#^C`DB+)F($(_
M5Z9D+@2V:>#448F$4&TH2`[K%Y<8X9BS)`HR6%(-*98)F?`98L'5(<S4IS62
MC@QII$P:[#R]1C[9G@/;M')*(PFYH(O1D2P(D>KH2O\])3XUYKR)[G&5-]51
MDM<GO!GB13HZ-ZSG?7:I8\$KNH*X78)3&S1RU^=U%\WL$JFVM8K"=FE*YFW0
M1^D%(>10Q*&80PF'4@YE",*Z_R?3"!5*=TP%F2<F'`HY%'$HYE#"H91#&8)P
M?L*Z?79^.LK_&2Y1088W"C@4*NB&7>JC=#W$G"OIH\R)35;-M(_27!GBPN(0
M+WEC"G#3Z"C3B%:I*5EL`AW5[U.AAJZZFDA%J0V0/=9IDIXWT=!5WA3S.G33
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MA[YBRA`SUE(XO2M:WFF9I%]$8DK(L$SRA;9\IWHHZI<B*/;[9K"IWL3+:G!U
MJX<SK-^D.XM'\%XPUTD+G"DMQ/G-I98)M'23D?1Y=&Q@ZU[,DQ:P7/#*OGN#
MP5K@.C(MT@)O^1\O7Q\N?^F^!-$E'&[WXMVZBT<XI;N0H+N`%U<7<&\!KWXX
M'OH+>+7"\<1?P)L2CL/QS"*"TQ'>`H<MB_1B"WB41006X4(?:!%^`EI&9P7A
MUPBG_*7X+:]?RF,SV!?/4`#P5AZVM5K^GD%^:=7QYE/5PN\0NI/.'?SNI(#G
MVO$0@I^KJM5?Q`7.OV19_0,``/__`P!02P,$%``&``@````A`$6^&0&/#@``
M<$4``!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&ULK)S=D^(X#L#?K^K^
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MT@-+#Y^?]C`"Y?:[T^[YOO/H3=>#8:?W\+ERT'_WNY]GY^^[\\OQ9WK:/Y7[
MMQUX&^9)S<"7X_&;$LV?%`+EGM!.JAGXU^GN:?>\^?YZ^??Q9[;;?WVYP'0/
M841J8-.G/Z/=>0L>!3-=O^K&]O@*'8#_WQWV*C3`(YL_JL^?^Z?+RWTG"+O#
M43_P0/SNR^Y\2?;*9.=N^_U\.1[^IX4\U:G:B&^,P"<:\;KCX7`0CD=@I44S
M,)KP:30'W8$_'(VKYEL4!T81/HVB?UV+T)]JP/!I%+W`#KBEQ=`HPJ=1A#74
M(C\R\O!9#ZUV;(L>6*TZ")_8P?YU0YL83?C$'G9'7G\2?#`)'D2=#@(5?GJ"
M_:M\XM7A`W]@;\.N-^B'*GQ:1NEAS*@_4/.Z87H8-.H/H^K$;%NC&#6>#9OV
M251+2;O&QLND-4)[>H%5ZS7:7#8/GT_'GW>0!,%#Y_>-2JG>5)G%E:K[6Z_=
MOUNZL-R4E4=EYKX#O895>89\\^/!G_B?>S\@1VR-S$S*>%1BCA)J%2NS$0<Q
M!PD'*0<9!SD'!0<+#DH.EARL.%@[H`>^KAT.@?7_<+@RHQR.KIHA<&:`>1<E
M4"7B(.8@X2#E(.,@YZ#@8,%!R<&2@Q4':P<0[\+:(]YMON%@U"KI^PZL.ANU
MP9AZ;:9E?'UK44$Y%R02)!8D$205)!,D%Z009"%(*<A2D)4@:Y<0IX*#;G"J
MDK[O^#!#UJN3@'G5",%=RQ$:4*%Y+51'K""Q((D@J2"9(+D@A2`+04I!EH*L
M!%F[A#@:\N\-CE;2E:/1/3-#PCHKS`6)!(D%201)!<D$R04I!%D(4@JR%&0E
MR-HEQ(4043>X4$E3%VHRUD5IM=P%B6KB!.^`17A<"^'L)(*D@F0U<4VS=9'7
M0FBZ$&0A2%D3U_20+KEE+82F5RXAGH8*DGA:5PY=5=5=7O;;;[,C+&VX"S:D
MX``J!%TW*"-T`C1Q)T"0R)!0%QI]CXTBKJ_C*!)A(Q4DJ[6J\J7O<;?7U]%J
M(6PL!"EK+=?M(7-[+82F5ZXAXG:HL8C;&]P+12[Z5TE3_VH20+*WF7<PHOV9
M&Z%!G4@B0]3D8H7GA3SFM1!L+"L/=KT)-9O4;>,P4]%0=DU#.6G(ZPZ8/PO1
MT$(T5%[3T)(U-&*1MG(;(M,$NYT;IDE)TVG2)(`PL/X>L]ID;H1L%1C5:NCA
MV)!)-2=]-B&UN-L*F[54M)+5:MA*WM9*48NWM+(0K92U&K:R;&ME58LWMT)F
M1^TM;YB>2IS.CT%D'7D3YM\Y2CD+"5%0KZW8H*%7S1$WDEB-YI%5F31%*=M4
MAL@VE;<W55B-EJ86*&6;*A'9II:L*;YRK$9S4W2^U&[*W::V9SUU`,#6DT%T
M04W$!E0K!LZ*LHH8AC$BO::\KL_23X("=/7R=852MK$,T:@.CAP1-C9D9@H4
M:&UL@5*VL1*1;6R)"!L+6&,K%/B[QNBLJ5W:#;.F-W6P<T!/S]0Q#$PD667^
M@*=!E++Q&"&R\1@;!*O,!IP_8`-,I&**R)K/$%GS>:/Y(4L(A51<(++F2T36
M_++)O#=A)<J**-*Y4+N[&^;";`;=N="HJHRI:;6?N<&TV?[0#2)+#S-U%@8S
M/X'RL[X!^D.Q7FLI#)G(*B**)4HD2B7*),HE*B1:2%1*M)1H)=&:(.IXM0NZ
MP?%FT^3.J4;@97367!T":L<CBB2*)4HD2B7*),HE*B1:2%1*M)1H)=&:(.I2
MM=VYP:5Z=T12ED8T90W96>C<,U)VT4>(W,I<EMA&:MBO:H5P-!3W'M<R'1LD
M;3*V7]JQ><H*JX4T(O?6D/5K;O3(K57K#6STQ49JZ%?#&WC<<0DQ0X>G:G%W
MZGYM>+JB)S-:%_EN*F)[G[EGI-P9U6@`'W4.:YA1+354F^(?#_#%2)_=WQ)B
MFHY9%;UM8_[]^/YWFW!GE^CIVID,6B.9[?W;2N=*O`H7ZP-_PH)CAE(0N[6G
M?![:<RM5IR:)8HD2B5*),HERB0J)%A*5$BTE6DFT)HC,-1Q!T[ENKX$K<;I.
M$=GU-I<HDBB6*)$HE2B3*)>HD&@A42G14J*51&N"J$MO*U!A??#49U#@?#T@
M4211+%$B46K0V+TGP/?0=!>?62E<%SFQ1<>LRKBVE''5N9VOBT%H!IN<&41<
MH:4<%!FI`11NSDIG&2^V4F@^D>93*^7:8A5]9J705DYL4>^H@M+US@>+3->?
MQ`T:T?M_R/8!<[^6PDY%!@WM=BQ&*7W0";<.?]AG)7"",O:^DR*"2J[VL;CO
M9$;*G-9YW0ES7(YF*LO42ZI&O,%+NJ0D7M*(E`R^S\8V5]_6J^V?=4F$R.YC
M8X-"?7PRZON3L;B%2K44$10A;5XR7<`=,3\!S-%,U2'J)56)W>`E7;@1+YE:
MCBQ_G]>2?BUE8\D@&Q2QD3*%XR<_\$-Q/HN6K%J*R.U"0RSI]LP)%AS(LA25
MHYF&6%)%H.NE7RK;?%U*$N=IQ$*,EVU&D8285@RM%V(C9<K23X/A8,QKF`0M
MV<A,#8("MS7$='N#D2X`N_R8-R>6:8BIVM%UW@?I2I>:Q$L:T73%J^ZY7TO9
M$-.(I"LCI=/5:#(:C/@)18*6K'-31+#2VA:B-EZG*W;+R-%*0X3Q(OD#)\EB
MV->(A9+(5K64=9)!-B9BM`57ZM'ZX@01I:QBB@BBI59L6(FFQ5;S.=J222NX
MK;ROQ&F5:1"-*)&TK%3M+$0V-&*#Z)F=<)943!&UIZVKS.=H2T86%#9T^?U2
M[JJL,!^:<VAWKGV?YRZCZ.8N@]S<91"D%QLW,N#0EA-PJ-B>O5"JU7Q.S),4
M%O`:_-=\*$OSRC`_.QX*'VI%B%8;AQJ-;=41&UMFC]Z<V;`]&[ZI0>T'`!E*
M88G!,QLQ3'VGZFLW_7/?7;?]5TN5'>D8)+?_P6T%<B4NMO^L.IBAE!MI4)[0
M;<[<2MFI,O6WW='&4BJ1*)4HDRB7J)!H(5$IT5*BE41K@NA<JT+4G>OVNUB@
MZU;W5H_(.FLN4211+%$B42I1)E$N42'10J)2HJ5$*XG6!%&7JJKU!I<J<9:G
M-8+].8;D/!`H,@AR($K%$B42I1)E$N42%1(M+')N`_PHH;12V-6E1"N)U@11
M+\.=X18O*W'F98WH*4C(MT&J.@-%9RXB@XCC:RG'#?Q!ED3:2J6MS$JUV,JM
M%+JTD+86%CFV/'9L4%HIM+6TYEU%ECM75@H5U\06G3%5:KOK@M]6KCHB@I-^
M,9&FAH>L79>POL<.@^=&$8Z(L*^1060BFVR%[`O11-I*I:W,2CG]"ME7DKF5
MPGX5TM8"$101=HS\VY`2I6Q*6%KSKB*[5:ZL%'9B36S1B52;`7<B/[AGZ+T#
MN6>8[43KWFP>:*EZ;\9F-#+7G2(K-LC9/B8HI;>/@1<.^:XA11&;;S.#QK9P
MS1'I@JK)4(&&;(PM#)K`!LB9.%:,E5)QB:C51RN4,F=YXU&_SU;W&D7D1F-P
MVZZL$J<YU""UZ.O1B=WC'*6P%.6G71$*.+4Q(CL!B4$3>R+7%4=R*>I94QDB
M:RHWJ.UPKY!J"T3D88^0G7"6*&7;6R)J]=/*2)E>!9-^(&<3+57&R;(<\&UC
M^[*LQ-ELFOUAZ_9V;A3-J9S?]>$M2.<_=@.-C+B[2A'999*@4?T%]-`;B>\C
M4M1R5BDB:RC_V%`AM18&34AZ';&55$K%):)6EZV,5/N!PQIM-2Q4M7>\/N,.
M]%;3S;@&?;10M2)D#/6E<=!EV]K(6L';1(S(!GMBD`GCT//[[':3HI*[2$W3
MUD[^H9T"[5BE!2*R1$>L<"E1RBHN$7VP1&L/V80GCCW6:*LR3Q?I1WOKJXJ@
M@=Q:&Z320ULFUHH0:7J"92;6`F2U&F0766(:F^B'"X9J]=-==6HD'#N90>&D
M+L#R#^T4:,<VOD`EF(EZI/Z(I9U2*BX-:G?1"J5(`/'#P34Q3V>8'V7\4IFK
MOLED^Q6#5&S5XVZXUVK%R0"/_>G$1,8*)`*[A+4*%'R($FQ+3W#CR50J+64&
M3>Q[+OD5E@JT9#NP0$1F8<3R48E25G&)[;5Z:852>GR!/Y8AO";&Z13S0Q,^
MQ=<=D$%A*^98(^>`3+\,KU^N/>Q.7W?SW>OK^6Y[_*Y>=*\6<HW-6_C!8/H(
MMF$RV14X$9NJLZ"F*T.XTJ@#%YKXHP>MP!,^#;;@BGJ\L.D*&(.GY.251[\_
M?=3)@O<9KJC'5Z3.S(>?&X"G,!JN!..IVN_)*S%<4;LW>05V:U.U%Y-78`LU
M51LD>05^[^"Q>E2!]QDZUM@O'SK<8&<6@/,;^*-R<=.%&7BXR<&K<`JO^,B.
MPA,?4_4\A[P"3TY,U7,1\@H\!P$Z35=F00CNK<[[^,"#$5QIZD$,5]3YAVP'
MSCO`\4U7X!`"'-]T)0NG\+I:@RTPU21?A%-XJTK*+\(IO%LE>1E.X9VU!CZ:
M+IOD9^%TUL3GX*@F'H53>)-/VH]&4WC+3/(DG,*[9I*GX13>.`/>JR<"?N_B
M??-UM]R<ON[?SG>ONV=($_WJ_;F3_L4,_8^+>83OR_$"OW11/<WW`K]LLH-7
MD?M=R$+/Q^,%_Z$:J'\KY>$O````__\#`%!+`P04``8`"````"$`==B'B<@-
M```D0```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RLFVUSVS@.Q]_?
MS'T'C]\WMN1G3]*=QGJ6K+FYV;M[[3I.XFD<9VQWN_OM%Q0!@01<-^YU7VS;
MG_X`*1`D05FZ_>W/W4OGC\WAN-V_WG6#FWZWLWE=[Q^VKT]WW?_\GGR8=CO'
MT^KU8?6R?]W<=?_:'+N_??SG/VZ_[0]?CL^;S:D#'EZ/=]WGT^EMWNL=U\^;
MW>IXLW_;O,*5Q_UAMSK!/P]/O>/;8;-Z:(QV+[VPWQ_W=JOM:]=ZF!_>XV/_
M^+A=;Z+]^NMN\WJR3@Z;E]4)^G]\WKX=R=MN_1YWN]7AR]>W#^O][@U<?-Z^
M;$]_-4Z[G=UZGC^][@^KSR]PWW\&P]6:?#?_4.YWV_5A?]P_GF[`7<]V5-_S
MK#?K@:>/MP];N`,3]LYA\WC7_13,ZV'8[7V\;0+TW^WFV]'Y>^?XO/^6'K8/
MU?9U`]&&<3(C\'F__V*D^8-!8-Q3UDDS`O\Z=!XVCZNO+Z=_[[]EF^W3\PF&
M>P1W9&YL_O!7M#FN(:+@YB8<&4_K_0MT`/[?V6U-:D!$5G_>=4-H>/MP>K[K
M#L8WHTE_$("\\WES/"5;X[+;67\]GO:[_UE1@*ZL$U`V3N!/=#*YF8Y&P_%T
M\GXG8W0"?Z*3\.J.3-`'_*E]7+@!F`W-#<"?:!<$-\-P-)DV8;A@.4-+^!,M
MQX[A.^,7P+`W[9N_H)O9]1$,8!"M&Q[-X"?<#,@-_`5[\_[Q[-D$:_(U6IU6
M'V\/^V\=6`0@A8YO*[.D!/-@V.U0IMK@MKG[O=2%G#5>/ADW=UT8*,C*(\RW
M/SZ&T^EM[P^8(VO4W&M-X"L6I#`3PKB-)(@E2"1()<@DR"4H)"@EJ"182E`[
MH`>A;>,+8_XKXFO<F/A29.X).`$7P20%F402Q!(D$J029!+D$A02E!)4$BPE
MJ!W@!1,R7P5S"&O9^665<M-8W74AM]O<#"8R-ZTFM`NH2;V%(I$BL2*)(JDB
MF2*Y(H4BI2*5(DM%:I=XH81P>*&\'$*CAMT(QJ6-83B=^0EWCR+8*5@TZ_NB
M12MJTU*16)%$D5213)%<D4*14I%*D:4BM4N\L$(R7A%6HV["2L&XMP068B">
M8XCJ%8Z-VG>,9-RN(`M%(D5B11)%4D4R17)%"D5*12I%EHK4+O$"!L6&%S"[
ML=V8TN?TO%U_N=]#EL*J?2;Q!["!V6W-./'C:,G(%FW-0J%(9,D0DJ2=",%T
MXD^$N!71V">*I(IDBN2*%);8+GHA,:<+O==?&1+CQ`^))6Y(%(F03&UIT`]&
M(AKM]38:2#AA4T6RUJHI./K!T/>:M]?):X&D&3XO-E`I>K$YDQ90>E->&+4?
M!$L&L-XZ8RYVF44KHOY$EHPF[;2,+8%=S=R36#V3UH';BEB'TU9$K62JE?Q2
M*T7KX'PK7MQ,;7Q%X!JY'SE$`TA;#IW:-UA%=Q41XJHH)C1KHA<,1(&9T'6O
M+;F1I:RBMC)"W%9."-L*QW[R%73]>VWY833UHSLW+^=?8,M-V)"IA_>(_`R<
MB0`L6$6&$:%FSVF6O1C1*+#3]:8?SMS_1%HGY,%/?IF6K**F,T+<=.XW'<!9
M4X;5WKI_G\X0^F$UE>058;6%IQ=6BT1VAGZG%N:,!PL"J.C>(D*<,3$AF%].
MI@]\7PFIV%>J44:(W>>$?/=B32Q(U;CW@V6*Q2N"A;6EFX,6^6,S$VO](FA5
M'"Q$G`@QJC`'Y4+(/IQ0.EG0Y''**FHI(\0MY1=;*L@`>LB#YK3DA]`4AE>$
M$.M(-X06Z0W*/#ZZQG5;6W*W0[D<W#=.83F&*JJ]N;`OIMR"513&2*-8HT2C
M5*-,HURC0J-2HTJCI4:UA_P!-/7D%0.(Y:<[@&Y%VJ3A(E`HTBC6*-$HU2C3
M*->HT*C4J-)HJ5'M(3]^IOB\(GY&+LH!BP;.43Q0*-(HUBC1*-4HTRC7J&#D
M3A6Q%9:LHJE2:;34J/:0'U)3LUX14EOB>GN815Y(%8H"A6*-$HU2C3*-<HT*
M1FY(1=U0LHI#JKJZU*K:0WY(385[14AM0>R%U"(OI`I%@4*Q1HE&*:*IN^F$
M?9%L&:LH,KGV53!RHAR(#;5D%?FJV+UK*"K*):O(L/9\>8$/KSLM-')_>4#D
M!EZC2*-8HT2C%)$?^$"4>QFKZ)YS[:M@Y,9/E'LEJ\A7Q>Y=0U'(+5E%AK7G
MRP^\/%_\U.,0>#XJEVM$WGA@A<XK>(0J[Y%(J!X"L(KN*-'N4U:YT1&GKXQ5
MY"O7O@I"4+YS_1.(^J<D%=]0Q>Y=0S%!EZRB3M2>+W^(S!GB_8L2K$9J+/`4
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MAXU20C^85;8U>A`!3Z3<9V&SF1H1U;N">L<+<TEM<W<J0AS^I3:L2=48^B,B
MSZYRNKSK)P_S+$`.E$5BMH@`+]#0?0:&:,PW&2,:A<T"^&'0'P[D4XF$/'&V
MIHB&T)-+L\5V=#BQCW]O9J*/N?9<$')G"]XOMU^1BA_*+0FQ84VH,?3'QAQA
MW<WI\O/=T)YXO5T(#\&<'0M4P03BJ6%5[@\*J()?%$B5D"&/2TJ(59DVS$G%
MA@4BF![DOM2JBA!W=:D-:U*=R6USXG/C]W.Y;<^-7ECQ*`EQ:Q,K#$6MO0A;
M%=UD1(B3)$:$.\%H-@V"OE@=$FV6$G*[H';2C%2T$_3[WC(D2L^<Y-R]@I"[
M8X>A>#I;DHH-*T1C6-C:&*D.+DDU;B;?^.Q6CV$\,S_,2?G2^+YSJ[<';F^`
M+1*[C-KJ6Q4/,"+.]3BT"'>9D2EFU$ZOK%*T\GJ@PI>1;RK>1B('<W+#_2G8
MAGI=:E6%:.RN7;:78Q[DVC/TUJ[!=8?V1NX?VA&)#43N]*RBNXD(<3]C0G`'
M;3*&\L>WA%1LF!*Z/,U(==%]3BIV7Q#B[:`DQ*J*D#,6A-BP)M08^F/Q2\[Q
M<!R4>SPB+TG#4.R?"U;Q$%E?8^Y^C*HA7+DT1-;0J>)2,H2$:PWU3"'51?<Y
M==69+HC<K4JK*D+.5J4-:U+IK6IPW3F^D8OI@N=X3I(%JMSB"M&D>1/9_FY+
MB/?BA`PY!U-2<>6?$6+#7!L6A'BH2T+LOB+$O5\28L.:T)D4-\?M2UO!N\I8
MD\BBC$4D4EP\[%FPBE/<^IIP1L2HPG/M>#0XL]63)\[`%-'(75W.)#BV-Z0R
M5O0QUYX+\NQ/"E$5E-JP(L.+75JB"N\W'(=3M?75GG-_U?HU!WE8*M28XGF<
MDVV!*F^J6!6\^T5C&J-JS&.:D"'G<DHJ=ZI87XYAK@T+0ISQ)2%V7VGW2T+<
MK]HS].-JCIK__U2Q!U:W:!K@&182L5V(PU`^\F(5A35"Y$T5ZPM39QB,IW#F
M$\]'R),[5:S9CZ:*54UHJC@_S#=+8JX]%XA@&W!N;B`*N5(;5F3X@ZGBW6\P
M@X=\LDJL/>?^D)JSIQS2<,(OZ5$A_/Z7&`?V..N-+YYPW5HHE&]++=#0FTG6
MT)M)%CD3(B%#3O44T03$;4:=6?G0O3W`3X.)"EVN?1>$W,EF'3G/Z2I4N0^\
M"+F3S37T1P:"I48F&.F1N7RT-T6PW)@L@O63YM$"50Z*"/$<B1$Y!4VB52DB
MI_[/"/$`Y=JP0.2X+[6J(L2]7VK#FE1GZB5S*-09#WGR[M=T89A53-L3.^=;
M.%!'CE9%D8_0EY,Y,2'.KX00!S!%=/F4G*%J8M^$A<^9Q**::\\%(6Z_),3M
M5X1X*UP28L.:4&/HYS<L:V?&0>?W%>-B7(K:UB)3*[3K0#@0^\%BT*IX7!"Y
MZ6^1DY\)&;(J130!<=OBF97'^IK:'RJ&L\GPS-*CNE"@<Z<+I>Y"1<B=(JKO
M-:GT%!G*$WCS]`N^",1)<OV>T'CT1P813%2*^4*CB!`G7DR(LRPAQ*H4$6P`
MY#Y#-'5.'=JP(,3N2T+LOB+$O5\28L.:D,Y^<UC]Q=G?N!0Q-JW`>Z)^]HLG
M/0LT=!=_0IS7,2(G]1*M2A'](/M1-;5/Y<.;OER5M.<"D=-^J545(2?UM6%-
MJC.I+T_3\L$OY?[E71<^]I4K$2+G34O[.:_]/'*W.3QM%IN7EV-GO?]J/M6%
MERL^WK:8OB,>S3_9#XG%%7BU<F[>,X1D5U?&<*69!N(*O"8QC^$%`6T#+SW,
MS2L-^@J\B3`W[QGH*_"-\Z?FW"):N8=OG\_I[\,Y?'BG_=P/YO`9F>:?AO-/
M]D,EV<`0/JX^8W`/]WWVMB=S^(I%-Q!-YW$S487_;#J'+SNT'MZ:FIMWHO05
M>)5I;EY4TE?@A1\(;/,(1;0";^%`8.UGWNTE^$;[;?6T6:X.3]O78^=E\PB)
MT6^VR(/]RMO^XX0_3'_>G^#K[.8WZF?X&G\#'Q;VS:K]N-^?Z!_0J5[[??_'
MOP$``/__`P!02P,$%``&``@````A`!R$&OZ5````J0```!````!X;"]C86QC
M0VAA:6XN>&UL/(Y!"@(Q$`3O@G\(<W=G];"()%E0\`7Z@)`=32"9+)D@^GOC
MQ4M#T5#=>G[GI%Y4)18VL!]&4,2^+)&?!NZWZ^X(2IKCQ:7"9.!#`K/=;K1W
MR5^"BZRZ@<5`:&T](8H/E)T,927NS:/4[%K'^D19*[E%`E'+"0_C.&'N`K#:
MJVK@/(&*_0.H]$NT&O\C]@L``/__`P!02P,$%``&``@````A`*_Z+\^]`@``
M[P@``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@``$`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````G%9-3^,P$+VOM/^ARAW24K1:H30(6A`K\5&I
M!8[6X$Q:"]?.VDX%_/J=)+1-J!-6O3F>>>,W\V;L1.=O*]E;H[%"JU$P..X'
M/51<)T(M1L'C_/KH=]"S#E0"4BL<!>]H@_/XYX]H:G2&Q@FT/0JA["A8.I>=
MA:'E2UR!/2:S(DNJS0H<?9I%J--4<)QHGJ]0N?"DW_\5XIM#E6!RE&T#!E7$
ML[4[-&BB><'//LW?,R(<1Q=9)@4'1UG&=X(;;77J>E=O'&44UHT1L9LASXUP
M[W$_"NN?T8R#Q#$%CE.0%J-PMQ'=(!1%FX(P-H[6[FR-W&G3L^*#RG82]%[`
M8D%G%*S!"%".:!5NU4>YEIEU)G[6YM4N$9V-0G*H-LMEW;>^%J?Q<%!ZT*KI
M642HF)"AR7$NG$3[D$[!.`_EX:#.N611,:X(;51D%RIA5\I1O=@?5:DM=)WY
M-H>Q5E9+D8##A%V"!,61S?8R_1]_-H7OCY@Y.JGH-,MTRAXR$FP;NRA]E4B#
M51,RAH8$6\B#68`2'V4[,9H-=@\N-]AURATH6)1DV)02]\>]IN9A3R#S,M2U
M4%0A`9+J2GV1>]G/4%*??:WG1@D_Q&G^>DG=F+"Q7M&4VC*1=E\VS0U?$H`]
M@S'4N7[VLR+N4LN$;A-V]3<O.F*"-/'">6/?HV.WVEI&]PBU`1B_/MT95FW_
M.2-;@4HJ^RFR.;Q0RWO9E)#]3+L@.TUM*2IEZT!(R^9TJ?GEZE:X)9E.B4_\
MV71BA@=@3OT8?R]]5N(`2$L).H]I*4&!\0A:B=1.K1720:T5<PBU%G4ZT^E0
MQS^1I)"W!/M#6>_J.J3QLGQY2VZ%>K6/V5Q/Z`;>/);-S:B<^&2B^<:^VXAN
MZ)TTL@@R7H):8++QV3<43_M3]?\2#TZ/^\,^O=JUO2C<_:G$_P```/__`P!0
M2P,$%``&``@````A``WM[8TR`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM
M;""B!`$HH``!````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````)R174_#
M(!2&[TW\#PWW+:7+_"`M2]3LRB4FSFB\0SA;B8420-O]>UG7U1F]\I*\+P_/
M.92+7C?))SBO6E,ADN4H`2-:J<RV0D_K97J%$A^XD;QI#51H!QXMV/E9*2P5
MK8,'UUIP08%/(LEX*FR%ZA`LQ=B+&C3W66R8&&Y:IWF(1[?%EHMWO@5<Y/D%
MUA"XY('C/3"U$Q&-2"DFI/UPS0"0`D,#&DSPF&0$?W<#..W_O#`D)TVMPL[&
MF4;=4[84AW!J]UY-Q:[KLFXV:$1_@E]6]X_#J*DR^UT)0&R_GX;[L(JKW"B0
M-SO6O[DF\;XN\>^LE&*PH\(!#R"3^!X]V!V3Y]GMW7J)6)&3>9K/4T+6!:'%
M-267KR4^ML;[;`+J4>#?Q".`#=X__YQ]`0``__\#`%!+`0(M`!0`!@`(````
M(0#*#;D0WP$``!85```3``````````````````````!;0V]N=&5N=%]4>7!E
M<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`````````````
M````&`0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`'WALP3F`0``]1,`
M`!H`````````````````/@<``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L!`BT`%``&``@````A`&M>G<LS`P``<`H```\`````````````````9`H`
M`'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0#2EWHFY0,``)\-```8
M`````````````````,0-``!X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M+0`4``8`"````"$`JH&\FY4#``"0"P``&0````````````````#?$0``>&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0"B`@@[MP(`
M`-<&```9`````````````````*L5``!X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L!`BT`%``&``@````A`'Q+`QI%`P``!0H``!D`````````````````
MF1@``'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`"````"$`
M"DHVF'0'```%)0``&0`````````````````5'```>&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0`?&L_"&P4``.D3```9````````
M`````````,`C``!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!`BT`%``&
M``@````A`,ZC;;&8`P``<0L``!@`````````````````$BD``'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+`0(M`!0`!@`(````(0`D>M&.4P4``$48```9
M`````````````````.`L``!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L!
M`BT`%``&``@````A`+2(_Y4$!0``\!(``!D`````````````````:C(``'AL
M+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"+0`4``8`"````"$`+_N>"HL"
M```Q!@``&0````````````````"E-P``>&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;%!+`0(M`!0`!@`(````(0`"AW/MY@0``/$2```8````````````````
M`&<Z``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"+0`4``8`"````"$`
M#".*#-\"``#C"```&`````````````````"#/P``>&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L!`BT`%``&``@````A`-JNYUC^*@``AID``!0`````````
M````````F$(``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`%``&``@````A
M`)YN(-&0#0```(@```T`````````````````R&T``'AL+W-T>6QE<RYX;6Q0
M2P$"+0`4``8`"````"$`^V*E;90&``"G&P``$P````````````````"#>P``
M>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0!;G]R&M@(``.,&
M```9`````````````````$B"``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L!`BT`%``&``@````A`/;F%.7Z`@``1P@``!D`````````````````-84`
M`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`'5R@
MC?("``!`"```&0````````````````!FB```>&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+`0(M`!0`!@`(````(0#-<<KAS`(``+P'```9````````````
M`````(^+``!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`BT`%``&``@`
M```A`.%Z]AM!`P``5`H``!D`````````````````DHX``'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"+0`4``8`"````"$``2X\W`,)``"U*```&```
M```````````````*D@``>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`BT`
M%``&``@````A`.^8KFA,!```&@\``!@`````````````````0YL``'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+`0(M`!0`!@`(````(0".%O9L]00``%X3
M```8`````````````````,6?``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"+0`4``8`"````"$`YK^F7#\'```''P``&`````````````````#PI```
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@````A`!R1,?#Q
M!```?!,``!@`````````````````9:P``'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+`0(M`!0`!@`(````(0`8UQ!ZK1```#=4```9````````````````
M`(RQ``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`BT`%``&``@````A
M`*9Q*X\X$P``6&4``!D`````````````````<,(``'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"+0`4``8`"````"$`_MC6_)$"``!H!@``&0``````
M``````````#?U0``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`
M!@`(````(0#;O.4L?P(``/`%```9`````````````````*?8``!X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L!`BT`%``&``@````A`!5G0T^"`@``^P4`
M`!D`````````````````7=L``'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"+0`4``8`"````"$`097W@GD"```@!@``&0`````````````````6W@``
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0#GA`CS
M,`@```XC```9`````````````````,;@``!X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L!`BT`%``&``@````A`$6^&0&/#@``<$4``!D`````````````
M````+>D``'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"+0`4``8`"```
M`"$`==B'B<@-```D0```&0````````````````#S]P``>&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+`0(M`!0`!@`(````(0`<A!K^E0```*D````0````
M`````````````/(%`0!X;"]C86QC0VAA:6XN>&UL4$L!`BT`%``&``@````A
M`*_Z+\^]`@``[P@``!``````````````````M08!`&1O8U!R;W!S+V%P<"YX
M;6Q02P$"+0`4``8`"````"$`#>WMC3(!``!``@``$0````````````````"H
J"@$`9&]C4')O<',O8V]R92YX;6Q02P4&`````"D`*0`("P``$0T!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001144204-15-029365-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-15-029365-xbrl.zip
M4$L#!!0````(`#"(JT84]TX82'$``$6?"``0`!P`<WEN+3(P,34P,S,Q+GAM
M;%54"0`#K!A15:P8455U>`L``00E#@``!#D!``#L77ESX[:2__]5Y3M@E<U+
M4B79I`[+QXQ?^9RXXNO9RDNR6ULNF(0D[%"D`I"VM5O[W;<;)"52HFS)(YF4
MA*G)1"2N/G[H;H`X/OWCI>>0)R8D]]S/)7/+*!'F6I[-W<[GTF^M\\INB?SC
M\+N_??JW2H5\82X3U&<V>1R04^K3EJ#65QF7)^:6N;5+\(=9N:*#2M4P&^0_
MC>I^H[9?;_P7^=_;J_\C9_<M4B'/S\];-M3@JQJV+*]'*I6XG6,JH0VHYX_C
MNTM2W3*CM)='X?!]_)<`V:[<EP,@NNO[_?WM;:P1GOTN\[GUR#W'ZW!+U;R-
M=!BUFEF*BCG<_9HJAU5N>:(#.8W:-B8_`@EQ=DRU^;!`,O/.=I@XS#I1]7--
MY37W]O:V5>HPJ^19&:%2<_N/J\M[J\MZM,)=Z5/72M'"7Z%]/#^77KUJ-E\K
M$>:("]BL+YB%2IY:9F^;"DMX#MMN4\NOL)>^0UWJ>V)P#L]Q1987N+X8I,4F
MF;75\9ZVHT343*UBF)61;JQ`"$#@M')1*A:LIPO:C&>7@82,[.S%ZF;GQY2,
M`MQ]8M+/+A*F97#C4L!@=AF5A$7,=!')K>P"D)"5W>^+*?DA):-`("L=2OO#
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ML`L72.CP1X<=2<G\*]9[9"*0&+K>"@]H\0>W,![QCUS[[*^`]Z%A_WC0@MCR
MZ(7+#U;!N$MD'21GV%Z48`,A,(CB%H_8(78LK\^E*"S?GXFY./-,0ONTG=GX
M2!K;6507VW--X@9$==-N<XL-!:8ADV0.QE;[;\EJ#9$R\N3:PJR7A?F@.*>N
M+<RJ6YB/BH@?SGI]QQLP=N][UM>;/@9`28B$;RY<F[TPN^5=2!DP(5%"_AI@
M9#;NXMQ3194+0I8W,LB>,]-(62FDK-[<H0;8Z@*L@'.HVG*M*+`^+`K2IF?U
M$;*\D?C02=4249".EU<+*2DG57N/DZI]>!3TPH3%);L5,!0UZTEPW5&WL^((
M2K"`8^],9G4,,S,\FHU-PD?,K0;(K`"I5JL;!)`AMQH@LP*D5C,V""!#;C5`
M9@;(1KF8FG8Q<\<@NYMD08;<:H!D3:/HL<MZ38*\JM^-\@PY##YRU[`>/:R[
MAG7XO_8:WB@KG4/\GKN&=0"^1AJN&O#7:#ZH;R:X=`V?4FOVX-TU[:VXAM-<
MH)(S&,Y#PT83-5PUEM^'DPR;FZ9A<YW[<):&=1]><PV;QH9IV%Q?/VR:#T85
M-6QH#>>E8:."IT-4EZ#A>%+;,$<+>^#%%7WAO:"7&4IK9_TJ#+XQQH]?I320
MS_RZFER?=WX=2BQ[C9#13&"U.3M6US#L>#]PUB#(26&U^1ZL-I>_GBUUALUP
MP:0\<NT3SY6!@X9<IK#+'#S5Z1;H'[0$=255&['E\2"9LN*PG8-'->GQFMAR
M^OA8U+-]LK>1:(3-AC#]/?M-&Q:>+NA`5SRR>]SETA?4YT_L[*4/6E!]](Y)
M1H75A9^G[(DYGMI!&F5(0O'"M;P>N_>!8LQQZ5D4U;3:V'N5*03;8B2H[=XK
M=D^#=*-!6E1+F@;IK6!/1X_BTK&T>W[=/8]+2L,J8P)6PZGX<,IM8OYW*L3X
M4/.<<O$OZ@3L>'#)Z2-W@(T3ATJYVFAX@ZWAO$5:)&N(`=-X,(TP:-<8*"P&
MZA6<WU_61_;$SG^-@2)CX&//K]%8*!865O"$&@VA`D.H8",5"$-&5DA')2L!
M(167O,,*)8.9Y0UVKSR7#:ZH^,K\(TM=4Y("T`F5."V%_\,3.9ZH`W)8<?2\
MQA-"9ZI(UG%H,PIE-!(*CH3E!;?SNI7A='=X2@\>=@J26GDXO,&6=BL+F"?1
MT"G`&'F9\R0`@`9BH/H0\:JU'V=+"207W5=1]]7&,EU(5;D0C8%B82#E.JKO
M<1UCT,EQ7F0S`92["RGRO,BL7^HT=/*./C[@;-7T,KLI9ZH>`?DV=P)<BG//
MK$!PGS-Y]F(Y@<WL<^'UPBL<U&J>F_89%2YW._*6B?LN%>QXD%W!:N-HJ4(9
M@;48)[<6=0%>&KX9`92&;E[0+4+P5E389@1OVNH6![I%L;H%"QRGP%=;W0)!
MMPA6MV"PC6?:JN']`5?<G6GKIMYMOK1MQDD-Y#*PJJGYF67L;1\'VXS[A#78
MUFQ/^[+`%K@\1)I$GS".CAZC,A#L,.)"98FKB].236!M4^K_[?YT2N5<>O6J
MV=R''.^O^P$8?E!^;:P5FS\!(,?%B46O@QX3U/?$.!IG)BTI\/$:,QH\9:[7
MX^[K3;XEZO$V)RN-4Q.<SR##?C`ANC1)F&$F_>`=W&>.FA(;OX';9GS_U+,"
M3,/K94B$R3O6GAH/EA1YY[@;PGXP2X<`_G]^VAZO*>8*WQ_!2QL3SAW:F;N)
M:NFP31W)PC92=24;B1N_51WM+`POYFZL5DK%*E,KSFKYG$N+.G\R*L[AC9R[
M[7K8=KK5L4JGMQN2][Z6&Z7#?YI9[28J3;9\I@SE'>NH#7RNCUY@[D9W2H?W
M`]?O,I];Y)A[CM?AEBR3"]?:"FG):F:2C!.@5E!'W9GT*QO,34<S[3.G5IQL
M^200(J6<]^)MMW18B5>RO%;Q)-OGW&'B!)(ZGIB?Z;W2X9%E,0?-([.)JBS)
M>ZKV9.,M06T8M=P/>H^>,[^Y,$#I?UZ'+:6JRM"KU^MYK@HIE!^1-X&/GA7+
MI!M6'SP:#\9N1H-FB:`A5!DCETIL9O$>F)3/I8OK\])ALV8V]VI&,Z7[5QJ/
M21W.)@3]?FA>J7-,(?JQV'V7,?\4E.AX:)=E"V@]=J"R^24&YN_OCG\`SH-(
M?^!`Y'=U=/?EXGJ?&'T?_GLY(.<WUZU]8N)S"V(F2:[9,[GS>M0MAR_*8/<%
M;Y/2WSO^`1FK[N3R[.AN_]'SNV%-E?.CJXO+/_?'JCI0:?<7_W$6-G40DE%I
MW=PJ4F8GXX!$18]O6JV;*U5Z1!ET=<_MX&-]"Y^W1R_&TN\!OA:B-Q(Z45('
M^]'V1$\-LL?*JT?@?)%2:)W]T:I<7)^>(>^U^I:)DGBWADJ$.KP#`>]_!Q)"
M]D$I)INK'[37/_C>W#%"3OBR>%H6^?"C#?"/R4N21'X<J_C'\H\2J_PQ(GU$
MW@@JVU@;/MT*UJ?<)BS:1DZ@HQ)@&P815FA0"<6+Z27YB;O$[WJ!A!SRY_WE
MRC&%C6ISJ[$&V%`\'5U>?+G>OV1MJ#?%I,'=`_+[Q6GK%\QN_##2E4\?'39A
MP1+9]XP?#LCQS=WIV5WEY.;R\NCV'MJT/,>A?<D.R,V_SN[.+V]^WR=/7'*H
MK$3`?SFR3RVPR9]+1OC<I[8=/T?R<H#.!"$BIN*7LXLOOZ#HJ_V71+H=IR=8
MA:K!;(L8BZT_+X$V%\V,DQ8?\97\7)"?4/(CQT<GOWZYN_GM^G2??-]6?R8@
M?4"`N=;%R=%EW!XHQO=Z4<;?(T+K!C#US&V_^[FT8_Z0LN89&$AJ?MNW5XW#
M13`8X2EV--\;Z@\Q^R]$>@ZW(_@65@2U'TK8!0#D@./JA#RN\*",D5!J9GGT
M@)&$AL%&P."466J::SH2ZIN-A&U??*/]=Y2O^T91P("++<_Z7\!HE;UX+NE'
MT9"(3M)1T9`].DMG&":]`Q0?*X<>MVV'+=DXY*_FR#RID52&;9J'^W]_!]."
M=[I3N+X].CV]N/Y2N0L;;\3Q:N$D49T4A5DV=HS"8T!#7$/\FR#>+#P&E@CQ
M@CCVY0[KXMD-[LI`X$177AJ?F<W5-&I%B%0_VGPMD.<L^U3/S0%KK&JLSH75
M:G6W\,I<?T^ZW"'R^'>"30Z=WCL[5C`U?[P`"C26F,O`U9KOF074>-=X7TV\
M5QNU3<9[01SZ<H?&+<^GSB:';6]VZAIT:ML+'K']_)6;PS3@G'(IT/!EL3.%
MC?S<O^XHNJ,44EC9':6N)P*&OW'5UNAQF>OCC*T&K@9;\/*XZ3P7;IUDJ\L(
M=7UN\;Y:DSW\GO_F=WS2]@3QH;B+V]3\9^8\,=+S7+\K"16,6'@:+&X`LPF%
M-^DUD5L$&\:=J=0=D!X=$)\)M8&%J3K5?M-.N'N$PE_(A"!6Q`AF,0YM0954
M=N&Q'>#"R[8J*%B/<MSA2AZC];E0:R!5#;2GSH\DWC/0Y'M#7K>6H*:H(ZP0
M$I"HI:^8]?I,^`.E1O97P$-$35\>.Q3?DB6YX#6S'Z#[I:V(W=4K8N<9'S;T
MBEB]%%*OB-4PZ.@5L:LR.[BX&>`LZQ\>M\)$N!VHW>80@PYCG4V>&RX">WIE
MX%*G,4RS\`C0`-<`?S?`]_3'O?S=]W(';_=>VW^F0B]WS6O50A$"U>*M6ECR
MDMG<_+:&NX:[AOLFNO'ECL)7*&37(Y)Y1R0%W2J0[]B[6BT\%#32-=(7@'1C
MHY>4%\1]+W<4?LFD)-2R@E[@J'4I-NL+9O'1`6L;&KSIL<KBQRJ%&9?\5&_^
MK,&MP;V>X*[M;32X"^*WESOLSG5K3!&BLWQ7_*_"9\+"K/C/=1#3?,^B,-U+
M="_9J%ZRL]&]9&4WQ824Z;T/3F+OPY%EB8`E3@O7AX+K+1!Z"\1*<*C7ONLM
M$!H&>@N$G@6:S?K'L0ZT&[2IY0<BO#U)^OKPLX+H4Z\/7\JLSD9_F2X">QK?
MR\1WM:X/_L[?>2]WZ!8[[R?FVIX@?3K`C8NY.>XB?+HK`GOZ2.69CU3.;=)8
M8U5C=2ZLFLV=PBMS_?WI!PV&N<.D[[DL=Y=:A%"J".RMD9E:[J'&9AD&#857
MIT:K1BO^KC4V&JL%<:H?,TBU'.YRBSIXP[T,'!_GF2433]S*[YZ-(D16>B7U
MIFUI+M?RFYO3B->(_W#$-S9[GJ<@;EYO)]`+I?5"Z?P_S)5WZKE-)>J.HCM*
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M;59J9X7TA>=VU$@@O,!C]&(L_=X'@5:4G$E2%6.E)KK`HO==5&K-K7K&Q@OU
M_SAM5N$4>Y--AA;PB0_502Y<7-6+][C<0L=2U(]VBGR@4FKU+;/PMWTL=J=.
M,:DZ#5<)5PW#+*NK?*+;@4+)[E;-YH$DQQX5ZJZ?4RZ8Y7M"JF/6)4*JZSG@
M1>"%[?7QR!BL`VLC68`C/V%R7'<5EZ8/<RI`QBGFP<_A944^CD6)&^#R=J1`
MHO&6ZI<J]<Q]O(Q(]H$NO%WHN<NM;I0&!(&]2=!*:']TGDT8:TEU#=(C(QU!
M73^\H0AO+<(OQJS7=[P!8_$M1_'%29X@E,C@47*;4S$@=BC#J%AEP*@@?9"X
M9Y/`!>&,RT1)`AAQ@#$/KW:"`,5>J/LGU88Q_'H8AP%;Y`A:I,^@2TGZ@9`!
M<(S\3B=O=#U4T/=<E3%^A1*,Y!**CJ4@$\I.732$-U:A;`2CTG.!BI`"[EI.
M8+-82V74HB^XA4H(M5R>KK4R"KB-L2!>-A6!`O6,EU-5'I73B3@=AUS8_"32
MQB6`H0#E`!^+"?RA+NRJV-P)%!U]X>$^-,07#R7#GI!;D`F-Z)9]A_LQ$]#S
MN<WP<@+`,6070&J?([BIC1T2157&.[MLUN8ND!_5V@=:L@E4%-C1E6`4T=GC
MOC^":]AK0;]*/['844CPSF:A(L.+O]@+$Q:7T!HH@)7)$Z@"(8UYRKAYDHM0
M^C9B`:M`=(1L8)Y(]IYK\[#+122$;98C7:M.`M&XPT0*/W%K*#HW+).\?@P0
MHRI4FYU(#>P4AF'*6@E&GO&?A?:=G=UJN5[?2X?0L2WA4N(7,'7+1.!+'WX@
MZ5/[^=@M9]I??2-5-VZ$@ZJ!.#":\WFM/G::D9=JSNREFE.\U/`^/@2&,D;0
M8-#'+K98@UYN&),F/>$.+>C^T*5"8P.M)UU:5WA!IXN],.(RY1_+X(7<OP(0
MMKHV<"SM%1,\-&EXT<H3==#\Q6E)8XXU3+Z!/L/]T'"$AD2]3=MNX".\RT5`
ME6&NV"FK]I/12/0MFJJ[!M,.&Y.QK:'/YDRB3>52F5?R3!/0>!RD`QM@^!H2
M5`!2#3$7VN.TT1R%)+&I2-F$)'X`*R/[JQK$3%9BC*2TF6',DV`N*[:BZ(6A
M_I2X!*B=45^U3$,7TJ9<0$;QE?D$U!2,!S2I7I/"4>3S[?B"R)`UI#_"UOH%
M:<T0$GF$9S>1*!X9*&&(+S57`P`4H#L@-Y`1V>#WA=<;Z0?X5^()<=%A+GA9
MQQF$WAOC-I<@TR#IMA^Q&P8&6/IU'TL7[6+KU=WR3J/Y?A?;U"Y64_4NJL)R
M.,O=+3"W-^-.QS3*4_S`6T-QTY@2Y*0"G&&NO`*<&AI$'>`L,L`!$-U`<86A
M$$2U$$1IM,2!CQK61=`!?%`8D=IJ`!]-$61%"PHX(V`E8APH!.K`,7\8.F1%
M!S/%('@EMD#Z$(A#$(Z\@6I-N<*/P..B8;^3V<S\`6:J_ZY5@+DY45&C7*]F
M0&Z.N"B%@LD+UF<)DJ8_%,Y)7HS/N[E#XYE"7&+*,C5;`.,2B/&MT$1Y>,.]
MUW'Y_XSUE.CHL,@/4G_8ANJD`ATC^!><MF-"X.+H9&&L4]CP5LV?<G`('+K1
M"&$X-29]1NWRJ".E>E#29T0[F+#!(:TV$12_H0["SA`646>WQ[-J8;^8!,.B
M/^DLZ7RS%0KG6PEH=<,I!0<#CH16J65Y@:OTHF9M`7_*'9*TAJ/H0&)`HZ(:
M90)"KY#&"*-@F2*K"15".86M.#("J"`,>@H126,;VT422#71BQ[`H0"U>PL"
M`W3/_6B:F^/7?M+S;.9L+=;>I<Q<:X(""O:N%[LZ.9H1AV@/W!;X$+\+W+G8
MN](&6IE(//1(F6B*$^2.XSW+_0D(I0ZE&UNJ8XS6ND0IEV?GK=3[Q$%W&<M+
MD@MH)BN+EO$,$V9:7$%&JRM>6343']R4>0Y?=J\9'Q6]=S'+PK\39W^[+[11
M6=H)B3OZA,2WEC8W$ZNUJCOK>$)B,]=M"X4007))7JV:/!IO9W(M.SJ+D5"N
ME-<8/9^A^T@D3YZGN-$P^?;M#H43AK8*ZV,5WKU$N?'Z>9HK=G1J46Z^VT3^
M-[ZCK.S)LD7QD`7;$)CE'\]>\,L]W@<8?1`I_B$Z'WYN1SY;58IB^A=S%=K'
M[5&J3_)?_.-+WH/I']:2*]U3=4\MLM(7WU,+$F<L;N+FU3CCR7.HSQWN#_)2
M=;'.%EG+LS26:9\6J+X,`V36S,(K;J6"!=W;=&^;WMNJQ3^N=VT=_G(G%NZX
M_$K:^#F?XXP0DSXN9V%K&=_E;X:*<!!&H08E<YFAZI91*[SF5LKKZ^ZFN]MT
MK[_5*/ZM-VOK]C]HG._PMEJ*&"XV7,LH+W\[I$<?WV2'C'"#0.&UM^;@7'/V
M=-_+Z'L-W?4*$@]\T/J"MB?:C/MXQ-]:QG[Y&R0]*/D6@[2)7QY7E2O=UW1?
MRYNM;QG]YW-,\,(W<&W>09_);:#A_E^9VL:;VB`<OAJ>KIC8NXO;02?.&!3A
M.<:$=@131R3+<%/H<+/OJ$1T;H=DB<RD2Y_8<,=\='+?*_LC5WX[7VI/76J[
MYBO[Z&8G9O8MFS$-XS;$]_I9`7R\XV\!=C^J*L/"OF9)[@>]1\])B'=WSS#3
M]F*^]O>,20)XK\=LCMN1(_R^OMTJ>RSTAD3?+;^/E=9X:UWJM(>]>B@G)SSJ
M);0$/<K5T0_1QO__9^];FQM%DD6_;\3^!Z[OSNGN"$DC0.C1WID(M>WN\3U^
MA>V=/G._=&`HR;6#0%N`NS6__E05H+<`(1`)JHB=;=E&5+XJ7Y69Q4Y1>;@L
MB!BM]A]?)U3)+88C"!IMK*;;ML\GH@@2[5J-S0OT7C$QI0V%Q;=CL!6#GU:(
M^=T1I-P@I<15VR8EPR&1$2GG0X$9)6TVJ#B8^"!HN4S+4,/M(N?"4,Q)*79X
M;J14U5`FSYD:$,0,'^$TV6)0MLRC*F>H2%/NM;J[;@3IMUOJ03>"5"A2A0E5
M>"5%JE$_J_.\HJE'<?*^_U2V+;-ZYS/9/&<QKY$%UX$3$,Q4_,''+JW-:_I'
MGK#UY=XF:&L9A113G18BNT1Z5Y^@:$`RMODXI6,0N]]C@\Y3$'M](N;1B2^W
M.JM@3K!E;4GII&'`BJ:HD`+)E?<;-J>0+.=0<OW)A$T$7YNG*;$;O=ZPA_GH
ML6UC'YG(1=-P^?SP0"-=(B,8U!L^2?<)KGE:+2\$A@5,R4I,[XDQ6:LW`&])
MS%5R#,C13L\$@D='4,BH0!`Z@D)&*X_@EJN+OR)6*X'BTSM5P:_V#*P]@D+)
MU'U8I?#-!8*50E#(J$`0.H)"1BN/X!;??/B&B#[.,BX"'GJUYU_M$10Z1KCF
M@MT"04`("AFM/()R_`1VD9ZL$H);?-C'J*:P%@C6GH,)VW$X'A,TSC;"#AZR
MPM\3_IY`L$(("AFM/())!B9,>2UNL`LO":\%\K7G[A8'\,*Q/:(;GJ];M4"Q
M]CQ,V*'7E)W8=K%1"V2%"RA<P#K>B)=Y>]\'S2B"VR?![0>"#>%:U8376YRO
M&SP2[*T)>Q.V\N^L"_"T>2U\LI-B-RP$H5R`6#G\A817!$$AX4+"!8?3NMZ5
M)(#@L,!?Z+!3O\-@6]#Q2;=TVT!2<V,>2#UOC1/CU7>C%S->_6%X>7E]]Z7Y
M&$"A15-:CL_2+3*L-@;M04/KPQ^]?G26PM^0_S@A095;O3YX)D)2.^5P;HO7
MK[6T0;FW.L'BWXZDNTI=3M/Q7]CZ]51#>R)>54W5ZVOS$8TG*NQ`W/]BSQR^
M!-,PR^(SA#`/`GJ0;.Z!>BE'EFZ15Z6A]I7YJ%7!TDIM2%BN?L&"VE*[X)D(
M2>V4P[F\$_PUYU\Y.F9;<GO9X:Z[^&;'/^_L?FW$&XAS7VQN/^JQ*<V]%YG\
M2MO98E,,[[L-K:]^$,RKWM:#Y<@7*Z;MEB9R]O`5#$A''B[_X.N8>HDG2$<<
M@G@"<<2+S;)_=L@(89%GS]2Q4YN8,RL!P"7-MCGS:KO34`=R:>Y\E1D,?XL?
M>#J^OV"#SNW+K4%IQ9&PY!RTF@(9$L#E'WPM5"_Q!!D20!!/("%!L;GY\ED-
M-WHO)[B%TD)44NX"3`=1;5(;$-"#UA\GA+O6P@TN[PHR!H#+OYH[%N#$4Z@7
MV#%`L<<"NWMO.^#COVH&!1#"VWK5.6N-05]NR&U1[%S!#0FKCJ?H@ORV#)Z)
MD-0.F*2]UNJWR^V]A<6_,GIO0:@A,+VWQ6JJ;KF]MQ"$'8C[7^P10,F]MW##
M]-I$L?6JA-:T]JG/!("`7O4=_:*'[&BEI4_@RBBXU*?(S`-&KZ:=MT?$7V3V
M8;OVQ6;V2^^\%7E\>'86=-*A*5A9O8T(RZT7`@I'UX!)WE=H!PH%4W/Q!.F3
M0Q!/(#YYL>GVTIMP827<2VA1A!!^PNM5+#8;6IK;5&5FP]_N56O(%4)>R=A`
MY/LK'1O`\CA`BR?(V`"">`*)#8K-UY?/:KAA?#E1;KT:%O?F;KT:%B'D.""@
M5\]N7"'<0(4;7`(69`P`EW\U=RS`B:=0+[!C@&/=A'NK$^,U:L75Z"\<WW,]
MW3:Q/08?"I9Y>`#C^C^(35A5S:QV&YI::GMOI;D.?^=7KO6NZ-Z!04](.OAD
M[=8FX9ZXH%=HJI/15$JCJ_1/O1T/2%PBSB;$V42%NZ)RR=]6N"L*0H8%`GHU
M;?H3X@U5O,$E@,7Y!&#TA'H2ZJG><41IYQLH:%?6J?R`#R?%^0;$_%%5TRB=
MAMSM-]J=TNYSJC37X>]\D35<.]_H#X2D5_%\H],:],7YAM!4)Z.I&@-U(,XW
M0,0EQ9YO\#&HDJE[2!KIF$AONN4CR1E)SM3#CNU*XV!.ZD;@`CYB%<<A(B$C
M$C+5L_.EIB0KYP>4NU_Z<N_4AZ6#4H;B<*62Z(G#%6'+ZQW$B.N<*QV50`C'
M*Y(]K+9X5M/0BLGJ8K(Z3/$&IYY`Q@%P^5=SYP"<>`KU`MN/+_8PXBMB\HA,
M27]#1!^CX/!AXW1"'$7`0J^B5E7,KA!'":=4,E"LO,NM3FG%3;`D';2F`NG_
MP^4??#54+_$4AA2V_W^$.YG3%2-=(@--7A")@@#XEXY6,PB`$/N*W$5=^%>)
MNN&3KB>*J'5Q?W/_.`>DK*.%3F/0ZYQZ'7)%U!_(R`(N_VKN?(`33V&=84<6
MQ9XLE,]JN$F`VL3((L=1%_Y5XK"@U"*B_`(&F"02FZ3:2@YD-`"7?S5W,<")
MIU`OL*.!8L\94M<9B5,&8.A5U+"*/$;=HP=QR@"46MNFM[?:8@X3?$T',H2`
MR[^:^QG@Q%,8XA0AQ,\>'VLZ_W'Y.R.'^MPA(590?/?,<;RC.#XR'-\UWKF(
MX-&[#;PXB/S%[&71#X6\.")$].*+FZOAXT<J)J^K#%I;XGR=$YSEUW>75W>4
MX$JOI3'NW`X?OUQ3KM`'Z'^A+0V^(*V]L!'\HB$],<C/)-W"8_N7LW_[KH='
ML[,$/N6`0+ZP/GF.\6?S17=I-&8XDRFR79W5>DGH!_N,)&P;EF_2OV);&B.;
MQFN6I-LT=#,GV,:N1^CC;RAZW.5_(\A%O$.$_6"B-V0YTPFB0C%_BB"+?L\>
M2YY#Z4%!F)>88=?UZ6KT]V@RM9P9"M]IT#_ZED?C1%<:.43R7A']CR`D3:B$
MO+H2LAF4:]-]V3=9W"A]1P1)_\A3.OM*=UX9,1=2MEZNJZA=96.5!B/P%!F,
M\-:L"!D3FV0%UJ'+BB!71:M!1=2C>\&W"3*<L8W_0F8@RG&[B<M](-ZK8O]=
M=_,5G$YK330GV++H4@WI^RNF>&"7`V6$T+S,M[#)MI7CCU^ES^B%^#J9,7Q[
MK4V;$YDE9E*9F:%&FYB(_')&K5B(`3=F'^5V^Z=SB3_3M/29XWL?1_@',L_/
M)`-9ECO5#:H+^/?8SU/=-,.?Y^\G\T_FW#0L?R2+CY'%^^?/OML<Z_KTXR5V
M#<MQ?8+N1Q=+;'D,N''AN)[[]*H3](EQ[D&?,67E/J,?WB>+,NG7O__M[W^3
MI']&K^,Z\]6Q**[NU7]\[,WN'`\M%IE_D2DMC_[PB$:_G#VTY6_T?TQVGIVV
M^DT-/I])V*2<UNEN-K_)G;-?UW9`9DF6SO+?4$$`R!V:M&!$>F,>]3(!C389
M\[GF/'YA'T(Y>YG#_C*W4B'%`\715^3>N1107WI_B4;8P-Z'Q7>+4RK%T:!"
M&O'2)]QZIS'"#?X8VW>Z/8OL>YZJ3E)DI=$/IYC/]9W+-C17W%034_!"A4MU
MW0-!;]+PTZ-T<W-!U2'VJ*.R5O">KPW7VILV?)7;RTM]O;Z\__I$OQ]F@YX?
MAW=/G^\?;UE$8D<YHL@Z<UY>7C\]W`PI9-BVL(VD_X,G4X<P9VG.9Y:MV80[
MXK0;B.G7WZZ?KYI/#\.+Y?#GYG[X'*U]<_7\?/7('[F^^[)X**Q7)>.7]Q39
M1OL#?=G]X^7B00YG\SMZ^1-[3:84F]1W=/Y$S<!$L+\'S/1>=8^9PUPCB=6M
MM1RLK`88RPLN!X>A[%.D]F?.5J(62<=SB:'!?H\\XS5Z=T!=YJP0MD=U-]%-
M;ZP2:TY#&@DP;QQ3;1QX-\P?UXU7C-XBI3#"Q/4D[[O#W`Y$=Y[-W'B7RIG'
MGJ8[CKZ$/3ATV:\>?`H&M;W2<$R5"8?!Y'[2G?,6'``I?:Y,E)9T;4L61C[;
MI109A/F:3+,8NOLJ30/CG1*DQHHNB&X"8<$.C3("UXPIC&`=Q%\S_W*TE,M0
M62B;)5VW9*G<%274DI[I4[;/,:/?V:&J0E7I3^EO`EP"TM#G$/UY"13F/09>
M)W^8P1`=K84@.92C`:&H9TK=%/9Y2K#!EQ6Z:*<NVLK,-4,3./(!V?D9YA;N
MA/SC^X[%;GB$@Y@Z;A-4V>=.[22O>]<7=!L/;9/]P[Y'33+;9$/O0B=D1D'\
MG=OH%<]ZZ-[;NSQJ^J-OX^#!?SU=GE%%9V`J)NXO9TWU[%=9:7<&U#@O`$^U
M?DY`RTH(=&<5Z&X"T#U-T0X'FNJ^J8[-JT#;TZ_?4V$D7!C="Y\0IFM2T[F7
M`++6ZZQ`G&+Q7.#=1>)^$KR=_J'P9J3D(`$RM:NH*Z`=`L0.\BCM!"`&[=X>
M0#P0:G^(-WNPJ!F@M&,RREV-.Y2>,(H<#U-/6V/8[C4/@V\7S91X^+K[P^?.
M[(^7:$K--=W,*R)WY]C&GH*EJ`D\#00^S9J'P;>+?IT$^NT-WJILIB=4DLU0
M>W)WB_"G7787_DE:?R!W.FF6-0S'I]K_09\QL[RO_E$2-;FV:C"WKY<5JEW$
M2=#7@T$W&U"$NM@W6'_!%O8PVEM;*PG:6NEV-@#;ON0!L.V@F9JDQ)5!/QML
M!Q!,3=#BLJ9VY!6H\@%G%XT2E/9`Z_>S0Y.>*DFZ.8XJ>P&PBPX)RC>.#AO.
M,`UBL<=C8^:34@BH!XIL8R^";.C@'R[^:&/KES./RNB9]/-!J^ZBPH8*3EJ5
MNH4C1,7`Y/'.?K&)FJ!I5[W/]64R0;(+[P3MNA\D%SR)D84@"<ITS>5<7V=_
M.':0HY.@.'O*7G`,:6C-4DFZ]4`CB&O[0I]B3[>6OI::0ITD[2G+O?8J=,FK
MYP'O+DHFJ%=9;FM*]T!X'Y&G8QN95SIA.2Z7FC%_XO.CO?!@*#U]$_1P4Y;5
M#B]_7`"<O'P>`.\B<(+>;LIMN=U1#@1X,YF3GJ()SG13[J[E,C87RP+.+GHE
M.-D#3>ON"<TMMAU"?W]-(2#(W4/8TNO_]37VAV$7/=)K_B08-BEUS6N'J(@]
M.(1MZ:'G$?SB\VSAL\/B-0HE<2R+/K(_]1*,11K!R@+@L=#>P3`MP3:E$.`\
ML%YR_ZBW=8!^T)(LVD:PG;3TX:#N(GV2,=L(T/<%]<EX1:9OH?L1SVN$`480
MYC]S]F0N+=%4J*4E*T=(:J<E%U!L!KZ@@@&%V8<PS[Q:4.DP:9"BA)H>Y)7>
M\],CQW?I$^Z'CQQ'7!2VQZ@(C$BP=EI?+$[!`?\-+_Y>/<S$-C_N?_Z-/;Y<
M;1X<O*UOHJ7'!^SH+6R9N;B_N1D^/-$U#:I1]:F+SJ7[WZ\>/]_<?_THO6$7
MTY<EGLEM%`L=T"!J(*;3`74#=_/N50"'88%==?+TA^0Z%C97>\?@D4#]Z8QM
M`2KD5(Z5#7KPFK$%451YJ4(JXR4#\&@@Q"!)#**.[]V2D*4''!X9Q("`..U/
MHPZ"?CBV-`V]H<2.DE-N^(*`7ERC\))N*J*KND(MTZDHL:7O5FZTNV(&JQ#Q
MFHMX#[P,U'_R3[%A793=P+;K$]TV4%D<AS#K"0)ZD.8(P+E?:9M^ZI1F@(6L
M"EG=2U85I0^>F?6WI,6&R.OG!*?L.F7-C@%C\_$)`"B6V$O!J3WXDR"%O`MY
MS\V@:^HIRSL0@UYL:/S,QLF<LMM6@^L'"DX#@ID?>CQB;<T4:N69?[%1Q$8!
M2:SM&Z4C$@'SS[LG859HJD+J`M'4+<X'E)1"G596O9K/@#>\N@%%C(DI\)R+
MOU3LT+"<JSX#T(J'N(B:SKZHZ=SKV@]1TRF*^41-IQ"#L:CIK$I^*\=+G[;0
M@LU1\RG'@H:6T0@;:.'KG')V$P)ZHK:MT$!<EL%+@!!P(>"9!7P@CJ?*-]_%
M!F]/SLC[KA-1L%G6N3L$1Q7>N7O!19^EV6TA[D+<A;B?HADO-@JOD,LN(I)]
M(Q*@Q>[EQMZ*`EX4A*0+2<]!TMLG710-Q'P7&X7?()?=)3*?URB9:$J0@?D]
M/*?LO(E8)?]8!4Q<\K[3^R"$6PAW/85;'9RT<`.QV\6&W:4V=T#PSLJM6:_"
M,2&8FO52@YA>EJ(PL4O$+CFI7=(]Z5U2O[:.Y.:,Y1O7PFN:PJL(#QX,K@'M
MXECM/FBW-%:-?VCSP;J,P&T*";F\&`0NYGV+WA#1&U()#$53@.@-$6(@>D-$
M>BR=]H]\';JN/Z)NJ4^H':1BXWIBKAD0?HK"^4+272=]9`\!/2'?1<JWTA$S
MO<LWWL6&;I'Q?D.VZ1!IJL_X)<RG?*8)`3TQ+3GUM.32LNE"5H6L[B6K<J\+
MGIGUMZ='"H:QA5S/L5'I)A6"*P4!O1JIJ6+G%<L-&C2`9Z>05B&M[+.JG;2L
M`C&JQPE2#0O;V-`M5B;A^I;'\LPN(F_8*.\*#0B>E2@Q/[5>[X9:7FY.2+R0
M^*-+O';:>1X@9E[T68@*<E%!7O[!7*/;*2V5*#:*V"@@B;753U8&I5VB`6&C
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MCH3N9@J!&8L%46ZYU5C\?,7,Q]*?-]M83EI,#L\R@2.&T`KUT0J9(T,MOHVI
M8AUK4"8QGB+^)[]1*MO0!\5"`CN'V68?HTR'1'_&)@VYX=<N'KU<JIP,(135
MG\]HON.EACN;^,.O&LLBTS_5$BNQ4\5.A<ST_'<J$#\CO\1-K)_QYEBZARWL
MS<IB-:R2KEJ6,!6IGW)DWQ8%)*OPK]:IE+,@=IO8;;MWFP*_2[*V!K_8Q,(C
M=O^41NPX'[.,$'(]B>A>:;=2BIBETFHH1_9M44-*JPW_7MQ*67VQW<1VVVWU
M6QK\84.U-?M'BO,M/$*2,Y*<:25NO*JF'A+1QT%ZJ"W-D$[@MQ/77#AKCI[8
M>UOVGB:V'A!_X$CU!2.'C!#V?%+>^`81E%1:(14;E)SBR6-5L1)[3>RULM$Z
M)/JO?G<FF*;+J!,TNJ#KR7A%IF^A^]%V$)\\^J4(",/#;]B;'=K&V3N--LX-
M404)X8AR+X)J13.\6WO?N\8[E[WIW88Z6&#+7L9^&$JN/YGH9,8R6BX3H3"O
M)>F!#&'>U,K^NMJOVN`-J]3WY>VM+.0)VUJCZU2B)SL-";NQ#:VB_[+`_LM`
MEXH&S+3F3VOG[+:`P[`N'30GC*"048$@=`2%C%8>P2VSB+XB%H4CLQ;XU9Z!
MM4=0*)FZCT$0OKE`L%(("AD5"$)'4,AHY1'<XIL/WQ#1QUD:$>"A5WO^U1Y!
MH6.$:R[8+1`$A*"0T<HC*,?/]A+IR2HAN,6'?403'=O8'M<"P=IS,&$[#L=C
M@L;9FJ/A(2O\/>'O"00KA*"0T<HCF&1@PI378C9Z4$Y[X@:G*@AN<0`O'-LC
MNN'YF2[1@X=B[7F8L$.O*3NQ[6*C%L@*%U"X@'6<M9YY>X<-)X+;)\'M!X(-
MX5K5A-=;G*\;/!+LK0E[$[;R[[KEGSBOA4]V4NR&A2"4T?J5PU](>$40%!(N
M)%QP.*WK74D""`X+_(4.._7I>-N"CD^ZI=L&DIH;\T#J.8]<#.[:C5[,X*Z'
MX>7E]=V7YF,`A19-:3D^2[?(L-H8M`<-K0]_J-?160I_0_[CA`15;O7ZX)D(
M2>V4P[DM7K_6T@;ES@N&Q;\=27>5NIRFX[^P]>NIAO9$O*J:JM?7&A2O4Q9V
M(.Y_L6<.7]@`S$QM&,"0`^DXI48/DLT]4"_ER-(M\JHTU+[2T,K33'!9"G]#
MPG+U"Q;4E@K_8DE(:J<<SN6=X*\Y_\K1,=N2V\L.=]W%-SO^>6?W:R/>0)S[
M8G/[48]-:>Z]R.17VLX6FV)XWVUH??6#8%[UMAXL1[Y8,6VW-)&SAZ]@0#KR
M</D'7\?42SQ!.N(0Q!.((UYLEOUS</.DR+-GZ=BI3<R9E0#@DF;;G'FUW6FH
M`[DT=[[*#(:_Q0\\'=]?L$'G]N76H+3B2%AR#EI-@0P)X/(/OA:JEWB"#`D@
MB">0D*#8W'SYK(8;O9<3W$)I(2HI=P&F@Z@VJ0T(Z$'KCQ/"76OA!I=W!1D#
MP.5?S1T+<.(IU`OL&*#88X'=O;<=\/%?-8,"".%MO>J<M<:@+S?DMBAVKN"&
MA%7'4W1!?EL&ST1(:@=,TEYK]=OE]M["XE\9O;<@U!"8WMMB-56WW-Y;",(.
MQ/TO]@B@Y-Y;N&%Z;:+8>E5":UK[U&<"0$"O^HY^T4-VM-+2)W!E%%SJ4V3F
M`:-7T\[;(^(O,ONP7?MB,_NE=]Z*/#X\.PLZZ=`4K*S>1H3EU@L!A:-KP"3O
M*[0#A8*IN7B"],DAB"<0G[S8='OI3;BP$NXEM"A""#_A]2H6FPTMS6VJ,K/A
M;_>J->0*(:]D;"#R_96.#6!Y'*#%$V1L`$$\@<0&Q>;KRV<UW#"^G"BW7@V+
M>W.W7@V+$'(<$-"K9S>N$&Z@P@TN`0LR!H#+OYH[%N#$4Z@7V#'`L6["O=6)
M\1JUXFKT%X[ON9YNF]@>@P\%RSP\@'']'\0FK*IF5KL-32VUO;?27(>_\RO7
M>E=T[\"@)R0=?+)V:Y-P3US0*S35R6@JI=%5^J?>C@<D+A%G$^)LHL)=4;GD
M;RO<%04APP(!O9HV_0GQABK>X!+`XGP",'I"/0GU5.\XHK3S#12T*^M4?L"'
MD^)\`V+^J*IIE$Y#[O8;[4YI]SE5FNOP=[[(&JZ=;_0'0M*K>+[1:0WZXGQ#
M:*J3T52-@3H0YQL@XI)BSS?X&%3)U#TDC71,I#?=\I'DC"1GZF''=J5Q,"=U
M(W`!'[&*XQ"1D!$)F>K9^5)3DI7S`\K=+WVY=^K#TD$I0W&X4DGTQ.&*L.7U
M#F+$=<Z5CDH@A.,5R1Y66SRK:6C%9'4Q61VF>(-33R#C`+C\J[ES`$X\A7J!
M[<<7>QCQ%3%Y1*:DOR&BCU%P^+!Q.B&.(F"A5U&K*F97B*.$4RH9*%;>Y5:G
MM.(F6)(.6E.!]/_A\@^^&JJ7>`I#"MO_/\*=S.F*D2Z1@28OB$1!`/Q+1ZL9
M!$"(?47NHB[\JT3=\$G7$T74NKB_N7^<`U+6T4*G,>AU3KT.N2+J#V1D`9=_
M-7<^P(FGL,ZP(XMB3Q;*9S7<)$!M8F21XZ@+_RIQ6%!J$5%^`0-,$HE-4FTE
M!S(:@,N_FKL8X,13J!?8T4"QYPRIZXS$*0,P]"IJ6$4>H^[1@SAE`$JM;=/;
M6VTQAPF^I@,90L#E7\W]#'#B*0QQBA#B9X^/-9W_N/*=Z+6,).PQ2G1B(O++
M&84B)!`'YJ/<;O]T+O%GFI8^<WSOXPC_0.;YF60@RW*GNH'M,?\>^WFJFV;X
M\_S]9/[)C#[]O/R1+#Y&$/_S9]]MCG5]^O')>$6F;Z'[T=.K3M`GW47FA3.9
M(MO566'2D^<8?]X'-4I#P\-OV)L]L]<\HQ_>)XO^\=>__^WO?Y.D?T9O?"!H
MA`A!)O_J@T[NR9-'PP_S=Q9Y/"#"%Y(,Q_;H*Q[1Z)>SAZ%[;[?5;ZK\C34]
MG$G8_.7LLTZ7,[]I_3/)MW'PX+^>+K]-$?G&7W$FF<C`5(S<7\[4LU_;K79;
M7B"6#HR\@)>5$/C.*O"#\H#GC[A#WWMU"/Z+1H1I*=YM+P'M\K<L0WM]]_GL
M5SEP5-J[0%Y?_%!0=]"W*Y<#ZK7K^OM05$D&,P&^8,5#8-M%0O6(L-TO[KM,
M3[S.P0`N+7LPE+O(J!4))=7(DU`7'ZQ0N]UL.BD%#+F`O8O`O3+`SJY$^^DU
M4WLKM$EZ:2\H=Q%U<'0H]U2=O13&J*?T%&W0[\4`N%U%I09N!_EZ*<P/`ZW3
M5;J'`Y=%>?926)Z>TF_W.MU!#(3I5%-V[=E+880H(655[G3V`].=V4S93G5L
M7OU@7BUR'Y&+6)/MT#8OT1NRG.D$V5YZDG96%=$RH$V5[9=NL%M2+YT#K+OH
MJB7"VLL&ZY(A8U^ZMEV?\%L@4I.QFP!:9\-I6UEH?T!VT:@7#XA"MT<&0$(R
M7OC4RN\C7?UX:-1>9QLTJZME!&D7@08)!-+4_4&Z]UX1&;HN\MQ]2=1O)TB.
MMD:CS;6R0+.#.GTY"9I.?T]H'HA#G1MO]F#IMD>WW]5_?,PWWQ?BN&X<G;ZQ
MT-WWJ%_CC+SO5"5>VU0?CC&-U_F*M_S(SW?9,CM7^31[GDW1\`=V5Q%5$A"5
MUZ0@#HD"4*;?NA^-L('FWST(6S4)VW+0704RR10IRA&!7&R00L4PR:0=DR];
M4,Y9#!.LY&!=]1X'VU48$PRHW%XW6?L`.30,?^);+&B[1%-"W\SSDO2SA=@'
M^H+AQ"$>_HO_?N?+TV^J!`O<Z:U@DQ=\Q\-[%QL3S+PZ*!1OYH'2=Q(:"=WJ
MMC^B0/F$.O(7CNNEUXB#!-\@]`QB%\L(T0ZR#A+\`Z73RP32[\@V'?*@SQ@1
M]R!0@A57%&T=G-65,H"RBS)))K;730?*_"QCZPG&D%`W?8P");MX)'S)D)HG
M\[.."<\(4>OD3X+##N:^&DRX\1LVZ;*/K()J!;6V_*T=H/7LS*F]AN*R@9[Z
MJ[FJ]DI&L'#@H5!+6Z+6FFQJ)T:MWQVJ/[&%O5DVZ>K&T$NA&ZBUG'8Z`@9P
MB!8C9+TDHJER?8CVB-T_/Q/$''!$D.MED[-^#,DZ/.-.8^Z"B+8-`R@DBY&R
M02+)E+9:-LE>DA=\V4>PGQ&9R'N+%PW8SGY]T/Y8HT8AP)5.AMTB([=E2@:Y
M?50Z,-\JL^S=K[[XLT-&"%.O%3&!N[8?$,&.F4$<E$0WH'BP2R=0G*"H@`AT
ML`8+5ULZN[GS>6/"[CA"_78UF5K.#*&E\J3E-$OPFVO;1#^HP#O\@(VX+.;T
MMN=9Y':**@,:`0^T?AY>Z"Z<\R8JGSKE)F_%I3Q6_I1-41FAJ'T6=^9'V57$
M2R'KR@8N@*S=9+)JVNH96L%49:@%9]F7/'41/!8<S2[7$5X%M\*O'[0?32![
MR93K:OUE[VQOS`JC3=%2E:)LI9TK80X4R85Q<EE6\<<4$_Z&LI5>BL(:M=U1
M!WG$FFE)`87V!<NPG*)D*$>E>'2R[^,I%2#:<HJB)VW0IVS((_ET+$\I!5$+
ME=D4=5I=3:T844.MS]H%2B%JBJJRCMSM4SV<'U$W<"Y04J-F[V'0ZQT9V0>"
M8^N?"@B?Y+5*A.W5N3R]VNL7(L%QM-B;!>Y>CG!Z-AS+_9"UE.Q06NH^"B4_
MNL!C2=%>2:JR>[Y#M$X]6!*]'?)&2=55H+"$O;:/WLJ5-"`94_1V2=7VM^>A
M<+E<.32.`+A[4K4W<ITVR-'%.HA256!;P7M+:1>PMZK$L\-=Z`(VDR*G]MG:
M.6:-BG*ABV)!H1M#2:_/\JAW*)<%2Y$J(!:HJ5G0'Q02M>_-@BP'](F<?T03
M'=N\_M/V""L&U2UV<J_L,!GJDJ4O(+Y7.KQ$HW>K7.90GI`=>[@,*-C54C3.
M@,&MW!<<*,=KZD8<Z-2+`[MUWRX04A4W%<"!'N5`YP]9OE74'%F0`?\"O:%K
MNA*V76SP^JWC9G&5F-87&@[T^EJNY00[L89`WB)T>$R'#25O]P3(6Z1Z4&-Z
M?RAYE>Y:(_=QZ9N/@EI=2#XR@6-:F2B!Y<%:BUAQ>.=9G;F:(.<_7>H>FI?0
MEN/OJ3%]6I36G<%2)UO1%`!`[8(]"S6F%8U2NR_WCD[L8FKVUAP<,-*>]OB8
MS;<MJIXQD38P65/TUDA[E,QN2:\^:P)27-NN1WQ^9,3'=3R_ZG8(V)UCOR&7
MPI)<I;Y&R!0%NW)75;1<LKO[XG$\`NY?D[Y&QQ3EN[VV,NBW\R@TV1,=8&2,
M:2)1]ZST/3(!#S.U:TMLG.MFD+H4!;V*JG3EP:%N0A+LI5(H1J`ZZ<INCT.<
MXL4V/-!$9G:9ZJ2HI.UHG?X@CYK/_1&"1\LXZ=MOQ&XMR9C>-5D7Q#3C%VG$
MV1OL4YE6/=<DD8`[I2]%]^!)$7#/8";.;^ZD#T`&>00@.2)9EC>82Y2_QH7T
MY:L][?AN8^U8$6?J4M6LYE2^510?BG4#B]@`J0I2@SQ(KV@WM^)DCA/N5"6E
M>0PYR(W&1_,I6?%D`9*MI2H'#4JNCI)2V0?=2C$A1NZU5-6?QU+J,#F0BW>Y
M+ORI2CYE+ORGZEP>0O>=\IZJSK,*=/^";/JDQ>:=FA-L8[H$A>H-A?//]Y]_
MI"5-=5X?ZYP`03X`Q^FNI)',/5D]!.#M-Q%DIV_"3&6E)Z^.^(U=/P]@XVB;
M,%RYVQETL@-[3W<=I;P]CBY]R$#-I`L+^FM5(1MK9@4JCFH)LXS[2KN7$:AK
MVW`FZ&9C0'8:6G43IA,W=Q-KL6QVR&((UDV84MS<3;'=D%USE<K$+W@FFD>8
M@7!)=P^L@+9KW0/ABR-?TBCC3/!1F^2L4CFSSNLFV905`'<N?"B$<21,,"+-
M#O61LT'Y0)P1]C)NV01CP;;L^OTPT6I[PQ%'G@0[T)0554L+R!WR%KMVZ'D$
MO_C\;M!GAQ*5P48<RPKJ&K/NV`2SL,S'?:$I"ITX\B<8E,+0V9_RO11&9E50
M5A;,`DT,X7I)AF53;F/!N=()*\AWH[O[J*>/#>;K8,OWXB;*[217VIZ_9KO5
M7FKZ2P`D'[CC")NV48["+6>'>RT<"@Z4PLN"EPJ@#V=#BA,TK:\J':6[)"K9
MH"L4QSB6I9B$V5.Z/76@#?+"D>5(O^J$)^DSM)XO?T/N+%<2/K*0>[-<</U:
MMYAD8C=,X6X%KPCX>UH:!-).!`D.NHZ)@*(H:1!(>U"AM!3EN`BH:CL-`FFG
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MKQE?4GJ@;-:;++AR-*ZDTV)]?D7IK=P3;#F.<4GGZ`ZX<5%NY6ZE^/*2#-S+
MWL`-QV."QORFTN6984LPY^L"*^WXN7-ROY?/5+0<,*\H%]+H)OJU6#:H@[8J
M^'`0'U)Y5$H[?G*=X,`!'$CE.RDK]T,+#N3+@72Z**;<6G#@0&N0QB52VC'E
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M.0:#>/MZ>W25?TL8W<'$-'8"Q3*!@R[/)X]"QIZX83`R]#<I&M/\S(+Y[NH\
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M98`CCC8)$T_ZJ>&@-H(@2K1+%/Q+'0*"ICJFIF6$"$%FJ,VIL>'9Z:'K(F__
MT1**DC0,1=%6QQ=E`ZQ0].(8DC!C9<V"'H8<<_\VWT"Y[+C8<P_F5,+X%67N
M@J:%(4>XXUB0,&=%S@[X;K8-#</QJ1]-'6Q6/+P_M>-N'N1#VM3U`5`)(.0%
M<PREXR[S8S!K7;4`F`FUF#=8?\$6]G"&<7-*W+UX:X-XT@"0(]!QM$X:#Z9V
M^LG$3@#]#GD7NOOZ0)PW;"+ST^Q?+O-.YG/:AA26MZQ43S"93;736W61TD.3
M.QYQC$@:,J9U-H<19<0C#-=I^#`TJ+]($'T'_98W8PE<C^HHYD7RJ"\#/Q(,
M\>I(R/20Y(Y#'"\2K*W<SPF)'2P,IO`=NC$2[&RSDT::MH"2.Q)QG$@PNDTY
MU9Z(P8+9:_JX@9#I?B;.A(5.NFV@^Q%U\R>.S8/*SPY9BJ(I1]=GBF3@3R?!
M,B\N4<T!O.-@&\/(3H)-SQ_5!)'X3.-AVSAPCW423'ZJ+;8%DMQQB.-,@@>0
M"P+\:SP;L^X_9"#ZWA9_]^H'PQE'V&2+WNL>`"<[=J'_,./RIEO,``TI>PB9
M44[L=Y&1LGZ%SH;!ZW05;0/41`!R@GJG("29:5G6<H`Z&H;Y0./G#-*:?MKH
M\D(9@(@3Q?0S0N.!8`G_9_T'<K,18_T^C_@0:7FM;*#$D&3]5HOLH-R3L6[C
MO\+\N^TZ%C;UT#H]4%)2$>,_WH]"1:E;\S,3=Y&%?:;@?[*H:<N`BW+VZW]9
MWKF)WR37FUGHE[/;X>.7Z[N/4GOJT?]^G$N?[^^>/THR^_D93ZBAN$/?I4=G
MHMN-X!<-Z8FJGI%T]E]C[UQ:>]W%S=7P\>.+X[T&;VI^'MY>W_SQ<>U5Y_QO
M3]?__RI8ZCP`H_E\_\!!20_&N11^]=/]\_/]+?_VF:1;>&S_<O9OGSISHQF'
ME`'ZPC[(+?;QYY<Y^/S3,G,DW3:E.YW='2(Y(RD,E-BI#OO#)]W%+OO],L\6
MK^2?*$7RI,[SU?\\-Z_O+J\839IJK]5A)%IC'?\W^EM:\H5,U"?3\_\K=]N%
M0)]9Q.+YR#Y@]N$2N0;!W,]C;(G.,C@J>,Z2XS!'[;3D+;PY%.?M_'F:V=XK
M\K`A?<*.Y8RQ0=]"E5!+>D]_'W*UKRCM<W82H=NS^6_D<\DARP]L>=72PQ\D
M*O&Z-,$&<5XPU7'-D6/XU*=K+"`S+&QC0[>:KJ>/F7'F*U)ER4^&67D\RV?J
M4^3355S)<Z0I<3QD>.SW2Z^6OK]B"TF>3L:(16+25/=>G3&RF^Z4*MX1!=&D
M[COU==R6]$R_&N+&0%Q:3*>R0'1+>@G165]P['O+B[X?ZZY''$P5*HO_Z!??
M?[G^$#PQLNB;/D@C&FI(F+4$OB';\5WI_?7O'^@Z'J:OX#B-*$W9NZ>$PF%'
M\CB7TXL6A7Q$$:#X+823OG*$C+G:B>!VF5ZQ)8]Z=7S,/H.?(-,W$%\"4YPI
M)O3U$^2]ZC9;U*%_9:@[7)6Y$ZJD;`D3@OGH;NG%^8[H>V>V23B9L??*+`A%
M=QIHO??7GYZ:%Q]:5(0DW30Q^V6#K[:#Q!(-MAQJE1BY.!T<<\88'QTAS@FR
MP(*I340\WV4Z%+,3)\O27YQ`OP8PL1X#](/^=.&0:?27]W=_/-$-]S_W=Q\:
M`9VDAU?F;2L!N2C7J#ML22;QQ]N7)<C2IU0SC)L$3;#'16OB6Q1[2AMJ6Q%Q
M&$SO;Y\^\`7XJ3BK>)#,F3OR[8!%%.3;IU8QJF.[6B]&=;`?`K$(4?AZ??G\
M&UNE_=.Y].G^\?+JL7EQ?W,S?&!TYVR:NF@?8`QD62Z54DIH=@+-?YXRN0I^
M7H!!(AA^OWI\OKX8WC2'-]=?*`4H03UGLO2D&3T9`AC9_!=+I^X05;P2=ZK.
M)4[8\"T&8I[JN11BJ'1_2O)<@H]L^==5D\/T3:3"%H0=4C&+,3$_>^86#&(@
ME/<'<#>3MZ]>%OT>N)+R%O!>L)IQZ@6CTR%@YP`"LGC`=U/2ZF>/I-ADGC/=
MML,V$2B<IF+)JB^Y*G&[()D',C)WE1^&EY?7=U^:-U>?F67AOXL5TO1[)IW;
MM7#7#E`]2;:K(-9F(-3A_L62##W]<==LMSLIXZI<EWX?.'[V7[,)^G`2G-LF
MXB.'NK?AHS?7=U?-WZZNO_S&-Y+VTZHW*KU;H_&[QCN74?==^-S",PT@N68.
M,"LYC'QM70KY+471'O6Q,?U_DY=12C*#R/6G$4`,N";__-%VR$2W^'M=CU.%
M/L=7^8^O$\H(B:6KSJ.57E@\XXR:]'\L2#$0E9`=:U.G'?V@H2&#DP9).`0Z
M@DE)!9-M+L.TQ,SYIU?=&G$8^8/L+<(`BR6!+0G)`%_OG7DX"26>O_F5V^69
M7Y;F<WS;/`W>;8@X1<!>M3I15FK52+DKUFC99F\SO%DLUHI1VF*^(BOKC$)#
M>[&9>;M`ID[<YA.V=2S=(I/#?\&Y).R<6!+0DI#LW#R??1(JL(#H42O%?&V>
M76#DGJ89>V`M!^RD@[7G1':+A-V=T@CSL1XN_<W4(2S*TCWIZN+B]OJ2'8<,
MIP1;H4UY0NA/9N5LQVZ:[!)']M*1'TS'HE:2&BOVBH5Q-!=]H\PRA?*P9IS<
MM7,A=CK##O[^9=/7$PKZC'WW&?W070;:D)U^Q*=RA,$22YZNP7K<<A)Z^W02
MFB]7$_),V`.>7E[T%9YZGZ;56H^D\LY^,A-C(=VD5A';!IZR5&/0'C#6/8<P
M8\G*OY@]#(LEZ!,;X9_C>ZPH4#)U3V_0%QB6SZWAQ"'TE\C3L47?0%_E6UY0
ML#&9$N<M*/H+*B2B.@1F]TQV.0CKGII)$Z2S<D!N\UBUP_#B^?'Z]JEY%?PK
M_3]6S4+#N*"*AK[I"4T]WFC.K'6'JA<:$=K4@+[B*7NOP9Q89FT=>^SPPAL4
M&&X&>E#]LFIQ+ZA8CAQB8XK8C>-*0WN,+`K/^W]=W`P_G$NWC]?!=PEZPY3J
MU`]`Y+L^DUYF$GMD-685]EHL"6=)2/;Z8G<ETDDH?F&TJ\N[C5"31G0LV$,V
MH2$>C_OF9H%*]/;L:>J=^C,_;T@`*7N%7KNE8?N0`KT`,J#%UG,HYI5%O%!B
M=[E[K6NK2V?'-EB92ZH;86EU.'$\;".A3N0HZAJ1W'G;B/2J4[OQ@A`O<YGJ
MA#XW]0EKF.0EQ<QQ)#[SVIAW2=#8M\*<"TO'(,,G0;<@^^O5#^.5#75CY<`3
MS)U%Z?UR#?G5Q4K-."O#90755.,NP8;M$3O$8(NT)#9_@3`GTYKQ2N.99#J2
M[7BAHTRQM2P&"2]Y7GR1@T,?0RPIQ3NI3>Y4MIY:4CBXS)JQES./UY3"*0^,
M8`^!+\_=U"70OPR'#QNP,SI;R$-;"1O4GN_)C&6L=)-QEO^^P9<BV*7?H\@&
MASP4,TI]?FBT]JCM8JHQZ;,V,I#KZH1[U%2"]&#@'N/K2,>$DH"O36,0LH@P
M1I(S[V=I+(')YXY$M#5T]U4:6<[W$$\GFA4P?T]48QTQ>,K;$:F@T+"&,3""
M#5M,L;.C).[!\$+LX`W>*PU<)BP<0(L"#O9:5FGNL&:!M9>SEH5HV9%/23A#
M.N'P!5V7"<1W7QW?,MEJA$5U/+2R_QVY4SS%R-Z<_**%\#$@$3_]XWSE+V7$
M'MJV3[_SR!.F+*C[3%E*-WWSO^<(,-BI%61?NJ2D8F'90A.I<H/':"LRRG\Q
M?]&*M.J4'SR.G&-!]V+`N8B$ZWSS7@E"K(#?>W5#.&YYNC=<6VOLP<I-KA1N
M#`ZVQ76P!2EDE:"%X@]$GFE1%L%S60E4)M5^#=9W0]D?ZE,NVY+O<C:SG`=5
MO`R>?_OF>+$+=-?U)^'`0[Z=]=$H:K#1)WRR#ON^'DQ28M^PEF;0A'F+X%@A
M3#0$68ZU[_/Z3#_X$PKG3S)D>*]-J'?FV9B6])49/`O3+P5`>:&B#DW`'!L)
M!9,434XE?3HE#E7"RS`$\LV^]*);;,1`0%#6:>W8S-4\EUZ=[W0ATI!,"F!H
M4+'-]`)W;0U$/)WN01Q`/-'_7`4AN%YLOI$,KJ)8N2K5?CSEPM[G$#SF/4E+
MC`CXM&8=_K>]:_UM&TGRWQ?8_X'GVP4R@,R0E*B'YP$X3C+(71+GG.P.]E-`
MBRV;&XK4\&%;^]=?5S6;#XF69(D4FU0O9F=DB8^NKJKN>G3]*AD`Y5HZ7OK2
M68R5C,E,K:LF_P.-_>3`3D!W&*S:2&3^T;&C^PM6'8+7G+O6TH^CBYGS1.R?
M=ZKVR'QIYE:D1F/^8Y!]Y+9\5F!;=05M'NTBP8=X%B1I$X:GN0T<29MHXQ2F
M8_U-+QU'6IZ_6C:]!?%@.#*'.PPCQ5=E@$T<</0-M:QF3A1>4;-D#2YGX_1L
M`3@PC"(XR^;W'CK*9R=O"[:!V3]DE"F<YF6JKM<SCDFR1X'\%DB#W#@WOKF*
M86XJ.-\":C#0S2*TYXL&NPXQQIF10*4>!--F;H,4&H_-+8AGSP^G!E(VL&&X
M!4[A',']#B0%UI1$)SY18S2,?(^40OMM6BJ&6]`6=(Z&O.%M>PWHN55AN`V;
MUMQG/%=)?"N!PZ>;9(+F_()-9[@=D6^T.K3GWWO@()^=OBT[DIG`Q;QHC`6D
M76RHMKWU$%]#\E#+Z6+S9LGE>7GE4FMU'5UYN+*%?:?6U'=\?YXB@^YEJK[:
M^@I'^)*QZ]IW76-8]96,?;CCV'5U9!X\]E00JAG[:.>Q#X:[C#W;8#+?Y5T2
M?7CK`%R59]^`#_#L?E$UA?DM<A$7"=.>V<DWC[UBFHOP[970/!&49JIV&9^K
MU<*1UBC-__0AL`OC.ZITC_0-5.N4:G6R&]W%\5=.>?4R/C*$IKQ.2>]OH-Q`
MRLVZ2+]QPA_O`T(X.MEQA7VP@?`!$$Z%:PO7RPBHF/`:9-W<3K@Q;(KP.D5]
MN)WP?DT<YTKRC03SXXGXZ.RW+X-_33[I@[>[Z3`,KR)R:A#<,9(S_*2/CT9.
MG>(XH>28_]J?$H9@^-$/$5B7>F#4_8JI!Y9!X'TA`9P(F$+3)SCAGS1?>GEX
M9:SM:-F?4R4:K8(L[C'$NFG=$'\9Z[O3JE=)*S9HR[H=O?>#?'""Y0Q>SKGM
M_0MV>._A0]PTX5MB(^?YL,T+!IKE$#ZEZ78`;S\`DW,\.`U,SN+Q(J,4A#.;
M5)[>UD<_APK,\!'/&1DCU93GC#CFW[V%YU8@JX'HA-9T&L]C#`)3I0)8'2S=
M^MOJ<?Q#SM[K>E\=%(Z'*W/'=>&<1G0?^/'=_<IA!57Y@Y]\($]PZB?!7H0O
M>.4S.^3P/[%'E+Z&MVE%=,,"I1ZY8\<<TJ,P+!^;'9Y10GHQ41R@V,*Z.'C8
M;8(^6L2FA$>'"RK7O32)/67IVBE;U#%W#%?8/26,;Z&7=@2I?)X%9ZE[C^0.
MJSAP.@ET!8_WTVOXJQ7LU4CNEOEZ`\R54SWRX``80V$K5-^1V<P/\'Q1L7"]
MEQP,2XH!DQJ$J?]`@B6_J?[3'H<?_1/ZZ.7S9_WP=``3`I!GJ*4,"T+[2/6"
M"BO#OF'"20`2APK1O_$HA@\GPY;*C#[+#^@;0ZA&H8]BQSW`G+DE2S\Y\+""
M$XNK+TAHX+O\H%7RH/0L&Y[[\5VJ(%3,+CH@"<+!8KZYO/K?WV^N__'Y+;SZ
M^N8">!>1+;4%V;'MA(8]8`=?>D"<(QSN!7#XW.;Q=3F_]=W<@,8335\!O'CY
M4?I$U5)4QHGVXD$SJ%__+H`UEYV&2Q;)M+W%/F5-^[*[+N:VA97[L,^+L1X.
M=C6ZIRU(@8W(6VLNF2@X$_,ZF$<PP(/,94@#4C_;R%KXN\1B1:Y3^QL.QJ!=
M_'B?')O,&]]8.(5'8!%'/6_-Y@6#OHP=%I2"(;9@3/T03A2'H3]E")7(^EPA
M]BK^%JX-S.V9<LQIR67!N<Q+W=&)H:IK@1N<G.M\5HE=9TJ\$$]&0S#]+E>U
M09\#M9^WKD-]>H]:Z,^O!'A6O>Q!4F9:(S/6]!ZK`.8\I!NR8E/)V59REJWY
MCO?@NP^LFH6NZ"&9QA%K^&+379Z:!-.D:0P>_G8M9\YT/ZLH<UW"XBJ+I/VJ
M$CAW]Y3_<)V4@1;(`*[ESAR;W<QXU:H?+%D1SP/=[TNJ7)JI&3\\F<"&UK+(
M9=[VOK6@L!4BU+Q^"4HBUVK'H!04H6]@Z;XERF/@>W?%,#I<DL8Z;]$<R)E\
M+#@:^G2A#Q2L/5;NH`,0./A)&!U:)4'$/C$BW"5B_P&X3P3MI+[XL&I@"9T?
M!W#0&6*NO&MI&O),XNO.%)L*(0GWSH+.R2*FIL5407`@YP$(#2V7I-Y+670U
MA'1M"+?8Y#;*K53)".J/K<MTUZJ(A83\8/8#%+ZRU,D:9Z'^#E"8K.`'%#<^
MWA-,T3!I9'6",^O!#S":G!0'NE2BSR,\$6(MG`@+_[#<,E=2S@=B^Y0**+_%
M"G[X9@IE]Q$X.Z72B96.3@@+(V%9&RKH3I@5(<(84;16=`9NQC0"53KKP7)<
M'#(2!,H&1>F>`J-.%#6]%NOK\6*H@8YZ,#U0!.JZJO*A(/)*8&$[:*:BMS#%
MKLN*%].A<$V8(:'TE2'DY>&9B4)D:`1TGA\H30Z\&CWZ_!TLJ><_<F@K)SE7
MQ;60/#G8XIM=?>^[U"(,4Z)L=HIBC0"',8-3FZP^V>SGIJL'$Y\4ML<>OV,*
MK6,!#JR0)L2<G*I<0GL]5@1:S$G"8U``(#U(!1?ZWUFX<+ET_XMP5?6+_2GS
MJ<!\@7\JG#RCMXX'H#SR$GE8I<%Q=N'UP9Q.R/J&*GS9Z$XG-IX]S)7=&1YR
MO,,\Q>,=_=+C'3"U"NO=3,4N+=%5/GAT1XUQ#<QNJWW?DW`RL-T`4(CR@#S)
MU<C#^0/;"NP0CWAXQ<O"7'U^LB-DR!I3XCPP`PV6>#PP`M7_N'-"_V6H4*<N
M=P@%[E8*!X#@3]CZDBX@=,W!2RQVV.&61(^`7\-V6A;K!8L-=\Q+R'1/[WOY
M`6*72MBO'#CLP*S/>%%N<JX],J$%D`_0P72F23?1E(QTS*KR/GMI@L:8H2X$
M&):$MS*LC7.Z<P7*/?T7!)R6B-F!:?.P_J3YN=Y7C>=:!@]T=5QIRV#A$N@'
MY<E?Y'IO3H2_V-O6Q_V]G.UG<MKP^2,$.16="O<BCL(+Y?]B/\(C05C7^8K:
M*UAX3>R?,J(1R,D&SPC3:@S-(Z<)";@%IM4(MXAWCZ;5C=I6P(FAXT3!A__"
M#U+J3T?JC53J/^!_>XEG@5&!/PN*D$=TXBK#$&Z@)_QM2(('Y#=Q\`DV]>&F
M8)5CV('_];*`8LUJL+X'Y%5!-:0RG)8R]%-E^(>7$VCV)2)ZL1."B'$&-A5=
MZ",7P(BH(\PM)X9J74".6L%T@EV#96.2]!IS61\+UI@PT5KI$WS@8(LH!G'(
M;/G$NLU;V3,`,:1+!P.KPL0K,#@-=N8N38U>%MO(;&"\`V0K9Z3#%=0JAH`-
M^YD^#T?#UE\XVIK%03CBUJS4$&_#N>2VR\L5'(]/(2-A":!L*(!=SGV/\#@I
M]S'#C,2J:P?&:K%#9UHY`(.LMDJAKPZ?>15J0;%$`=_/H1[YMP,`<@NA&(!:
MS@P#-;$Q$C$&3Q26T:+9WL9@W$[QM=5@'$C7NTRF+J,KB*+2\;`HTB;4ET\@
M=I]0ZA+\UT)5)3SYTK-77[!64CG>A`IFGOV&&%!YZ*3-0SZ4P%PY;U4$;D(2
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M@BGT%W))@L.M6'=W`11"5B\KHYYF3'IC;;S+2'L\"<['2&H3I)&Y+DB,R8QY
MKC,C+._^P$"\P^(T*B!5$#>:SXD-1Y/QC`F6?()S7.5@5]::26'@M?@^=2V<
M[5SN"VQW$#_@653YYY<7N(5S$B'>TR8!>!K*@38+B5_@%(\D/$)@!HXTPP$'
M=@["2A>[7`:M!_X(R^/9'#8[K71@&U1*1IK)XRN3G<%0LZ,2?!TG<R>>KW=P
MR/8Z`C\D5='I\Z%%9R[KQ]"YJ>_.3X;9>5<^B0;`U`*8=88/SOI0X,I=>B,_
MS)&.P0JQ)RGZJ`Z":D`<*\$2YW-2>CR+PT>O')2@`R>P*T"M-G5ZX0*&KTUG
M)%I#TE\)423;!=\'LNEXI..L=CW3U$FI,9`%[;(V=ND,\7FI>G4=J$:Y9;)S
M4P)5^8`(!)2K*!&LZB..[OW`B5B]?BZ+?1<[>%E!QG&2D0\V%S`[V>#N\'<\
M0^.M<S9,7'&XXXUK37^<?YU2E2#L::POR=RWB:M6NU,6I@RKPG-I;`S0W2X+
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MU`P?DZ4$,STEZ\A+J/_;'D1CJ6HYU;S]]`U[N<G=+N%FPEB?"FB;T1H1Z*B$
M2P66"KRW`D/_E=:(0$<E7"JP5.`#%'BT3RBF,PHLB%\QP__5Y5=P['_%3MH(
MA4VQ?&<ZV[FH5<?&JLFK;_FJD.:2]4GK)"O_+CQ54O^D_DG]D_HG$-.D_G6&
ME9OU3Q";O-Y8?VJ3/Z3=#H7WP]JY*(G@9@H?4WC1HC1I;%6JE9>-6052`:4"
M2@64"M@X>5(!=U7`;@;-6V&7UQLKA[[,R@P*$E($T6"_@U8R8"`#!L</&.BJ
MT5A&7L;LI`I*%:0J:#9VJDVJH%1!J8)4!?NGJ(*"6.A'BIQS4(:DQ%=XCZR=
MBU,7@@=#H8('`]4T&8B(Y*G4R"YQK[T:.9I(C12!/*F14B/AL]P@-P%@%^ZI
M"G(&'YR"]"3CK1:,?J@.5V$B,\"8Y$=X@LB0,4<DID+F*@7N?EM'!LJP@UBC
MGW)HKN<@K.#I#CSY%>(.^7%H>7;X$[X4OS]"MYLN"!=;58Z!1S06'(](L&5\
M6!*(>&.Y"$=F1>L(W\)O7-+0ZEI9X(OLJV%O9(I?N5NCD`H2*JTN6%RV0ETA
M8B9@`18W\;4-7/A8^5&6JY?A!0G&_^-/0%N30X.>;AJG+/&"K'U'L\Z*:+*G
MO.MM5?4^577;CV_A_<TSO`',AQ?.BT#V7Z6P$%IODH#TGZBFR.B;D`&2XQ%S
M6=+-JZ=`^[MB%"Q4`C*W$&7?CR-LH0WM0SHP`VUJ2)=KPF.8R"RCV)@`@U*(
MBXX-$ZY8GY&5_DF7O#\"@YCG716LZ93>ZF"##]X_!IN00PMQ)@Y.N-I<@;\X
M:1&12DMM_5^&?;,W-G?J`<,;*"Y<:\KHM>YPX-#(EHYQ`6W4HPA;*$#?Q=5N
M)T?KRS+4BN0(VXTE$;IB/R)5^>J`"4JG.LQWVX`.'MAU@/6HX%($$_IG#.%T
M[!A5%",J+TH4$(S(T^_GK*?&:E>1J1]&;"XHUV,WXFM5KB\(/LFC.D#OF6([
M(O92->T>EE_'RIL:(@65"F]?'_9,H]@H0C;RK'_=K,V$N4P22LM\O`E[Q8.`
M\]8?7+IW;@6">LRO!M5/KEH+P$/+6"M,LEQA_>FG_D@="-\"+V>I?T1#?7.&
M:4M*:>7RFM))X%$TU]RBIK#42)R.%P*'(R6!C1)8TD2^8Q1VGD!]<UN!/PB$
MKXB=47WY0`+J"W2"^`;CX\)-AMQP1&H8TI"Z?X[!1,YFQ9]EGPNMHZ4H=%T4
MWB61FVQ>ONS9;D0\TF5>=-.JO^'46E_XA,^)5#]4F/<4M/SW>-G-$B]&[PW[
M1L_4]-8(1$?E7?9VJ%7,U8GXW96Z?\RI7B?N=Y9':HK/(IAM(I!W](6Z%8<O
M2Q:E44\S)KUQ<X>+Q&6I^`HIUN9:KZ`VV1E)!!D59/>LUQGF89#&]D_I^8JW
M?S;#OI(EZ)5!W=2A/OE)LJ]]RB?67EFOH.KJ8"0\$[N_5];K:;[W@QEQI*_9
M@F)!`:LEJ]EOZS7Y7PW,06\\&3:VW[:9P>*K^($E8&VN@BW=L\<G'8,19,]N
M+-DK/D3)B;B\,ME;:Q9LU)N,!KW11'QY/Q$G6B9[ZTGVCL5O"M;][5PF>]N[
M<XM@E78KAW8N6=D^111K4Y4"VO4M4V9XV[QIBF#["6_HMV--$I>5XBNB6)NF
M%-"N;YHRU2M3O:)F`J4S<$+,%E_=9=I7"KE8F_?1<KXM`SYN<C,7`_A8A)SP
M"2(@R[1QJ[5&PH7+Y+,P=D4WP,(/1T9E0ZL3SK)R`%.E,*\%!%/$_<[#XB*<
M,*86$!LS!?<MQ<N56*02BY0O0\+A)1G:9J@H"1,G"12*P''G*90$MIU`*:.M
M)["$A1(O5Q(H,H%RU3DE3.=MAGN*\7K2C&\+@9,M4.T2G[E%!$IF=HB9);OJ
M#;;\<[R[3A#8>0YN4<?+N[N`W%G1B>^4^YE(+0?*WV9$25C\[O!ZVSIPG25X
M),=/@N/OLA2>Y'@W.%YBK5WY7A18TRBVW&PZ/CHSR?..\'R+EG^@['>\T)EF
M$_-/RXU/G/UM/0PK\4,.GHE)V1&NH?A'N$ZD1%8B0E4GZB7F0+[7N,CB<'1I
MKQ83^^KZX_5-RBTI_E5,T2FKP]&KSBNR]1I=ZPS5'"E+8@7[Y!HZSE]IOG9G
M3]?'HQZ]7W@IZ'YQ8ZVNK5@27VT$8]TC:T$#HG9Z9#N3UR'0HGI#K-C636U#
M6S<IL5)B4XF5C0C;$>0NX=]`-?O->C;B,E#\%;6SAEQ9@*4WT?I->B<B"*H@
MWHD$`:S(.S'4%H0,VVGKB1!,:+&PEJS`IC[J&:;X+0JEO$IY;9.\MM4SJ9=[
MNCH<RIR+".1)(VZSI$HDY^8]$NEF5^21]-6^^!YV.RT\$0((+1;6DI5WJ/<,
MK3$#3XJK%-<NBFM;_9%ZF:>I>L/^B+@,%'\Y[:P))Y(_(H*`'J/\NCONMRC=
M&NK-LO0;/`,FH]9'W),Z*,YE<6VM%8=T!:RYE2(O1;[U'&]=)D=3QV.9R6G'
MFB6-S=9Z7R((>:7>5ZUM<5[L@I]R6YSC359I!4]S;7%DB+_Y?;'+XEY:4=%P
MRS2Q9%[HO4$$K`6I->W2FK;ZB'77(1FZS*ZU9-F3)G'#JUV_9XP;C8B)H"P;
MVD7:U75%++Z^[`^<:FRG=^L'-@FPU5WR=B3R@O72PVO.76OIQ]'%S'DB]L];
M6^:ESP_23W8ZLOS'(/O(9^*7U^'2N_@:^=,?7^)@>F^%A"/F?R-/T1N7_O#;
M7__RU[\HRB]Q>'YG68N+]Y83(*CC91B2*+ST[(^.=>NX3N20\!.QPC@@]K5W
M0Z9Q$-`QT@L^^U[`_WQCA4X(]UN1XWO?R/3><_Z,2?@-QI2^5)GZ=$=ZBF[(
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M,V&4`9[HD]:(0$<E7"JP5."]%5A7!\/6B$!')5PJL%3@`Q3XM(MA!/$KJDNG
ME_D5[YX69!H16Z%_.S;Q;)E6%YV-)UDD7[(^B9_3WH>5?Q>>*JE_4O^D_DG]
M$XAI4O\ZP\K-^B>(35YOK#^UR1]\UXK@3-52>#^LG8N2"&ZF\#&%%RU*$_%K
MKUME%4@%E`HH%5`J8./D207<50&[&31OA5U>;ZS\Q@E_*+.`$,6!<U(DC)1@
MOX-6,F`@`P;'#QCHJM%81E[&[*0*2A6D*F@V=JI-JJ!40:F"5`7[IZB"@ECH
M1XJ<N\Z,*/Y,>61US,)[9.U<G+H0/!@*%3P8J*;9$@1,>72VS>1)C=Q9(T<3
MJ9$BD"<U4FHD?)8;Y"9$HY8A#QT53XB#&"'<T?2>V+%+KF?O0LIPBWH-Z1BN
M9PG^$1_#\E!<HHDF*BY1`=CF?*@.093+87N2'W<=9SEPSZJ(MH^$;^O821FZ
M4HC02H2+E#*C,J4\@%"!.PJ_)2XI=5$3V<)I<.#)KQ"9R8]#R[/#GW"J\/M:
MH)F.S?@N(3:-!4=L$FRC&Y:$:MY8+J!6*%:DY&%6]L56D:9H2WH[=.&(Q[`W
M,L6O;1:N>X/`X?2R%>KJWO+NX*S'RB:^MH$+GTWH:K,:L9)CHG2MJ3=]-NCI
MIG'*$B_(VG<TZRR%:=P7F[$SNUZSH.MM0,40!G2]6>`,K3?1QJ>L*=V)3QX:
M*BP/.2;W7$XCYZ&*Z*+>BNAB?Z#JJT&F"J#`:P@G53O"RR0\N,Q[#U;">V7F
M!P6P=OYW=`\GS>=4%NY#A7@VL5>V8L7R[/1J2(DD5ZV%4Q0G5*PPB5F&]0<3
M^R-U<!B?V=".%3'\B,ONYGCAE@#ARN4U!0=A?V@.S+TF)V,D#L*[P,ZE)+!1
M`K7.4]AY`O7-,-I_$'!&B)U1??E``NONN#C:PG'W\&B'<),A-QR1`/(;4O?/
M,9C(V:SXL^PS;WXE1>$D1.'=$PFF3DBR>?FR)[R^>*3+*/>F57_#&82^\.&[
M$SGMVV3'Y*[%JDN\&+TW[!L]4]-;(Q`=E7>)95ZKF*L3\;N)=#]I7:\3]SM8
M[=2#;XC/(IAM(I!W](6Z%4=I2A:E44\S)KUQ<ZEB<5DJOD**M;G6*ZA-=@(1
M048%V3WK=89Y&*2Q_5-ZON+MG\VPKV0)>F50-W6H3WZ2[&N?\HFU5]8KJ+HZ
M&`G/Q.[OE?5ZFN_]8$8<Z6NVH/1#P-J7:O;;>DW^5P-ST!M/AHWMMVUFL/@J
M?N"!_C;7-)7NV>.3CL$(LF<WENP5O^#\1%Q>F>RM-0LVZDU&@]YH(KZ\GX@3
M+9.]]21[Q^(WP>G^=BZ3O>W=N46P2KN50SN7K&R?(HJUJ4H![?J6*3.\;=XT
M1;#]A#?TV[$FB<M*\151K$U3"FC7-TV9ZI6I7E$S@=(9."%FBZ_N,NTKA5RL
MS?MH.=^6P5@VN9F+`6,I0D[X!/$L9=JXU5HCP5]E\ED8NZ)+T*\;(5LWHKQ>
MQU$869[-NE8E07B\_5#85^-$8%_+)>CP<:ZCLUJNJ_@9OQ!BE60<X^BMB*=*
M+U\!9)4XJQ)GE2^QPF%!&=IF&"P)@2<)%(K`<><IE`2VG4`IHZTGL(2%$@M8
M$B@R@7+5.26\ZFV&>XI?>]*,;PN!DRTP]!)[ND4$2F9VB)DEN^H-F5N.YWAW
MG2"P\QS<HHZ7=W<!N;.B$]\I]S.16MX$8)L1)2'_N\/K;>M`+B$G.7X2',\E
M727'N\'Q$FOMRO>BP)I&L>5FT_'1F4F>=X3G6[3\`V6_XX7.-)L8[-%[VNQO
MZT%?B8UR\$Q,RHZG#<4_GG8BY;\2[:HZ42\Q!_KZL&<:AO#B<'1IKQ;O^^KZ
MX_5-RBTI_E5,T2FKP]$KZBNR]1I=ZPS5'"E+8@7[Y!HZSE]IOG9G3]?'HQZ]
M7W@IZ'[A9JVNK5@27VT$8]TC:T%SI79Z9#N3UR%`IGI#K-BR3FU#RSHIL5)B
M4XF531;;$>0NX=]`-?O->C;B,E#\%;6SAEQ9@*4WT?I->B<B"*H@WHD$.*S(
M.S'4%H0,VVGKB1!,:+&PEJS`IC[J&:;X[1>EO$IY;9.\MM4SJ9=[NCH<RIR+
M".1)(VZSI$J4ZN8]$NEF5^21]-6^^!YV.RT\$0((+1;6DI5WJ/<,K3$#3XJK
M%-<NBFM;_9%ZF:>I>L/^B+@,%'\Y[:P))Y(_(H*`'J/\NCONMRB=*.K-LO0;
M/`,FH]9'W),Z*,YE<6VM%8=T!:RYE2(O1;[U'&]=)D=3QV.9R6G'FB6-S=9Z
M7R((>:7>5ZTM?U[L@I]RRY_C359I!4]S+7]DB+_Y?;'+XEY:4=%P.SBQ9%[H
MO4$$K`6I->W2FK;ZB'77(1FZS*ZU9-F3)G'#JUV_9XP;C8B)H"P;6F':U?0N
M7']]V1\XU>UIL;ECOTS><S,.S^\L:W'Q)?"GA-CA>RH.'\(PAL;?U[,K?S[W
MO:_16H--74L:;`Z^^?0S_0<^?\<K.6[_)S*_)4$<PO._1E9$YG2G>O=G[$1+
M^MR%[]$_P\LG)USIR]D_4V+/82_ZQ]>W9XI-I@Z5X/#7LW/S[#=]HJ-V_?)Z
MY[&O$OO5@@G#GS[',$CZQ[T5D!#N)O8'[QLE((3Q^-[QZ![DZ`YQ.'G2/WQ^
M3VD?:.9DJ`\SVE]"RH9I0`#O+R3`>XLD7X;77M6DFD46?U^0X#N^.D^Q0>E5
M!Z-26@OCS?>/S?C/Q_C-_Q('TWLKW"3/=1`YW,Y/3369&N\\[.IH-4R@U?B>
MW+LOE:/M5`[[YM@\A%#D\AMZA0U#(52>09POX?X['.>;97;)%VL)7UT^6H'-
MWY%;!IF6U,_]\?9Y&6GT,FV<+.25TYB?P9*+-JA\NLH9N,I5)"F3G95^J+$Y
MV3;J"BBL?!WO@_&S(YTC\V5T\H7PO>4$B,U\:?\[#B,85Z9/NW3"KH90?<M&
MK4U6-NJ-XRYAYD?'NG5<)W)(N*ZP55-C;*9F8"3$E(^OL"Y[#X11ES%VX02H
MT&_I@/3ZM:VO]<]^HX\9G>O:N<'7WFWCJH*(&A1J@*1,@!1=>R$I7/2N7"L,
M,R,YN`'/,6<K;Y*OE>&8VU?VOCXT#2,3_&UO7QWM.RN`ODDA7P#V;W/?UX:B
MMKEGPV`>,SJ7NPZ#]VQ/PP3<H<.1W<*GL8K.TFWQV\\D4C[Z8:C0)5G!B<VN
M6O/_*J"PT*S=&*GF8?WF>8-U6#N=V3+U'F]+O.K::*IV^,`1EW,$E4EQ8*V?
M+^*(V,KM4J%#=E!!/7XI_3*Z)\ICTF96L5AW6<5CEIT_@_NI&<F>%RI^IF>J
M\M9Q\<E'?*GB>%,WQD_P"#*;D6FT>H="Z#KX0!T<NI2IRJ7K\E^S[_FC'PF]
MG"XCSKD-Q#@/]*](^611(UKIZST%%E[ZNPT?S)YBA4H8TY_HNQFAGJ^$9&'1
MQ9(D1..RJ<S\0+%+IT=5OMWG2?47<$.(+WGD9@?<#O0M$FL^3R'L`CWZ*QTG
MCIX\P8S0]\RHRXYWY082PIU>7C`*$\7?$]T'A"CT^^@^5(@'3RO,@<E>->R9
M]`M=&^)HTSQ"3Z%3N:",H-/G+GOXXZY/'K`G#WJ#B4;_/\*;)\-^3Q^.B\]5
M6QA5VKH'K6Y6EU04N21^)=,X0(/H7<)B",I<9<R]GJT^]W+NQU2XRS>V06YC
M2ZR):Q2^O"UQX`#>+,L?4&*)[.#L#JA04)G(YK&2Z6ENSDO,T./-]PY.--4[
MJG8MGNX2QZQ)$9_L$,^A*RI=4#LSYTV*N*[M$">B>Q;=LFJ>[USL[<I:.)'E
MLD#R#0E)\$`?ZP?OXR@."`_AE4<5#9C3_O=/CN?,XWE^3F\@D@4SP(3\BVMY
M]%(M?PE\]]F:DY)YTG?PNK25>,.+2:IY3JRG:N?$V$%7JYF37_[K_/R][T>?
M?6HT?B4L,T+?>W[.I\QUO!\7,WJ)1R_Y2/]0GO"KP`>3YCZ*%A>O7S\^/JI/
MMX&K^L'=:T/3^J_AY]=PX5ER?;1<T.OI%*+A=?8;/OSUVM/I][^\AD<Y%_!O
M',7_`U!+`P04````"``PB*M&\QF81F4(``!-;@``%``<`'-Y;BTR,#$U,#,S
M,5]C86PN>&UL550)``.L&%%5K!A1575X"P`!!"4.```$.0$``.U=;6_;-A#^
M/F#_07,_*XZ3=FN#=H7K)(.!I#&2M!LP#`4MG6.N,NF25!)OV'\?*4N)]492
MCA-3V3XE57GD/??<\8XO4MZ^OYU%WC4PCBEYU^GM['8\(`$-,;EZU_ET>>R_
M[GCO?_[^N[<_^+[W"Q!@2$#HC1?>(1+HDJ'@*\_DO=Y.;^>UIW[I^:=HX>_M
M]EYYO^_N';S:/WCYZ@_O[]'I/][1Q:7G>S<W-SNA[$$D/>P$=.;YOAHGPN3K
M&''PI&*$O^M,A9@?=+NJ_>V813N4777W=G?WNUG#SK+EP2W'N=8W^UG;7O>W
MTY.+8`HSY&/"!2+!O93JIDJN]^;-FV[RO[(IQP<\D3^A`1*)J8QZ>;4MU+_\
MK)FO'OF]/7^_MW/+PXZT@>>]932"<YAXB0('8C&'=QV.9_-(*9X\FS*8R&<+
MDEAY=W\I_N("(@@D0Q]0I&!>3`'$D$PHFR5Z=SS5\Z?S80Z`[$5,0>!@C&E$
MKW"0$-)53;O&#KM2XX?I/*"$TPB'J#`,;ZZMIJN'ZVDPQ2$(A*,UE+;M]ZD0
M]!X+0N_I,.P]%H:]37O\A9P$809$\+/)V5S-KW*P![I^79^/I_D`\>EQ1&\V
MJ/A*EW=Z!R@*XBB!<R*US.D/MP)("&&&0'6^@8DCF9#ET!$-<L-%*A50EK=7
M.EHRWT\0'R>3?LS]*X3F<O+OO>Q")'CV1)GVI;_;2^?^%^GC+WW.DREKV7.$
MQA`EXWTI-LCLL@WU!C%CDBBCEG?M5I1=H;'/\GHC%F1=RE]+'.8S:=JBR^/9
M,DA]+-TGDY\P.JNV6SH@U>H;<SDTG:MN4=3Q*`N!R1))5D@W@*^F0OZ^+094
M:/1)J'X<?8OQ-8I4R/3%`#&VD*7;9Q3%H&'&4MX9Q@J^5B3.$H[#A(X8S!$.
MCV[G0#A(+&=RIF*V@68EW18RK<!44[GG!I549ERQ&,DD(J3ZRB/G*J5]!#V'
M.C%GR*MG3:?^H]!5JDWD@R^',*<<R^#/^<U'2H+:*+(3<Y8!._6K&=@O,R#Q
M=0M5UG^K^#K!:(PC+#`H<UX(&GR=TDB:BRN?%@M-#)M%MS,EK>AEI[T3[FY+
M1'$JRN%P..>OZ&E.\56-W>+(@HXVE-;](*"QK!Y':('&$5BL<FH$W&+'4'35
M@7";*!9#V"B*-#)MHZL.Q].56K_*U94L]O3)I:YA*\Q=I[QU,;6UJ#B:S2.Z
M`/@`!";8:K/&(-@*PFS!5!/XT@4"!W0VPR+9`E5;&I0(3*Z`!/K:32OE%G6-
M:CDM+H<W`<H(AR2(8G6L.J(L,;\0#(]CH=+M)55+-0E.VE2J<C4D`AAP7;AN
M:H`6^\:F3.#P;-YH]6E8;VZ+WLV&@MD)G"Y:1[(OD$EHZ>:F;?K*UDY2JMG,
M+2-PF!^5;RBQ(J?<M%7,E-5W.)WVPQ`O]1HA'`[)`,VQ0-$*!EUE:R'<*NIL
M`#F<U,[510HBJW/$B)SAN2S6XYFR.(2'LDP/L*[NL1%N%9DV@!Q>KIQB0EF2
MTXTE:[FIDT1MLCHI0[:>9+=Q#F-Y$6T+AS*-CL,-I]_K[WCECZ;Y.7"0_J:N
M'AS"-40T.?"LV02SE'4@).IMO;HO9HG'X5HO13`D/&;IE6!-(5YHV@J>ZM5W
MN-;+.U;3RR\N[5<V)JB(P>E#>]LKOUO(%H]]!<<%*+\PRG4[PB9!!^+#AB;K
M>T8I+(?S3:ZRGS,(<!HH\P@2VY.P/U,UYU_)\UJD^D.<#0W14O?8G`',&=)W
MY,94S67_+<R['U4&D#K"B7YN*K3;VLPZP<*@Z6HC!T*BTL`54^2=S@Y/AZFK
MJD6TA<M4MG:`D;(7%>FHU+P-O&1+.QM6[MLZP(G&LVK)N0=@IL;?&C?+%W`C
ME<7"&2:8"Z7]-:3::Y@R2KK$6]'SBJP9P3@<7M4;)68"#7)MHL\`Q>&]B8^4
MT/SD8B9.(^,`:>;\I='?8::.$6;)N68__#/FR0VBLTEZET^7T0QR#C!F],$B
M@09(+N>[(;F&I<9+I!:G3/4B;>2N'HW#L9=;I3SPGML:?;G`L\TZ;0UH_V]*
M-/?&[&!]!.QBBAA\0!P'JO3`42SND5;XGE%R6Y-BYC3'TO&6=V)CJ>>]F:7"
M!5T3_;6SYMI].A!NEA27)]>U05LO,%R*P_L/:FPA#-7@TIR8AM+L#!"'0UC^
MU-VQTPAM+;<E2C%ZC24_'Q:?.$CE[M8^_4`N1$UO6C;IQ('P,E-7D=JL`3J\
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MO`?N#%9VX@#_&]L9K`3H\!%GMGJ_I/W@6XP9K'-;NTDG#I#=W,%+.XL-`+M\
M+:'&$L>8(!(\,-0K.W&`_8V%>B7`1WE=O>8=3AH`A,F1G]J54^\NG4U6WIT_
MIBSY>39/7QC(MG2.;H$%N/I"[,9Z=H#IYMZ=?R]T`U9P^GC5]N]$;.,/!SS:
M-Q'7#[BT_U-$X@D*1,RD"PTHK]W)T+1W(#B,%EZ-!0V41SE8T]G_LW1XR@RG
M,35M6VKW(HRG.PO+B%\Y[*G9TM&V;JG=RT">+KVG*@QD.QRH;^(0'D>J.KT`
M=HV#VN1M(==2-G20K,^HJO/LV[L_=I:8YE]02P,$%`````@`,(BK1F6P^":R
M*0``$KD"`!0`'`!S>6XM,C`Q-3`S,S%?9&5F+GAM;%54"0`#K!A15:P8455U
M>`L``00E#@``!#D!``#M75MSX[:2?M^J_0_>.<\>VY(=2:ED3VGL<=:UXTO9
MGF1/;6VQ:!*R>4*1"DEY[&SM?]\&=1=Q)0&BI<Q+XK$!L+_^<&UT-W[Z^]LX
M/G@E61ZER<\?3CX>?S@@29"&4?+\\X>OCY>'_0\'?__W?_V7G_[M\/#@%Y*0
MS"](>/#T?G#A%_YCY@>_YXOZ!R<?3S[V#^@/)X?7_OMAY_CD[."_CSL_GG5_
M/#W[GX/_O;O^OX//#X\'AP??OGW[&$(+1=G"QR`='QP>TN_$4?+[DY^3`Q`L
MR7_^\%(4DQ^/CFCYMZ<L_IAFST>=X^/NT:+@AUG)']_R:*/TM^ZB[,G1?UU_
M>0A>R-@_C)*\\)-@58LVPZIW,A@,CLJ_0M$\^C$OZW])`[\H5265ZX!;@O[K
M<%'LD/[J\*1SV#WY^):'2[F@3%@L/[/>P-G1[(\?0%T'!S]E:4SNR>B@E/7'
MXGU"?OZ01^-)3#&6OWO)R`A^]YZ4A!QW9U_ZVT4:3,<D*89)^#DIHN+]*AFE
MV;C$]^&`-OOU_FH#*#11O)`B"IZB-$Z?HZ`D[H@6/1*W=@2R-I/V/$WR-(Y"
MVOT^^3'E\.&%D"+7%U70E$4Y[_R,S&7R8X-";[7;',$#B4FP]94U,B](X4=Q
M#;6KMML6@A-;$$[:P]"QA:%C!$.1!N4D%YZGXPE)\H8=2-R<97GK=!=)>X8D
MOIMFP0M\Y3<_R_RDR!OT#7%S9F?'!UC]"5TR\MO1[81N+$`Y#:=S7IMV-=TU
MJ^FN];[\2-Z*:9U52*U50]*_I'$(.\O/?TQA.W%!1E$0%48`J#3<',.UG_C/
ML\YX!U-M4\DES367]]*/LE_]>$IN1Y=1`FM#Y,=7L%W.RGU=WE1^S>;MCMAF
M_4?6:'/9;TCQ)<WS.Y(]O,#^KJG4DN;LS>OG?OYR&:??#$[K:TW:[2-F.X=M
M:>MN3_C-+>7ULV`A\OS']:\LCZ914AR%T?AH7N;(C^,/4HR<0_+BC$M/QV<E
M]K*UIB+!S[!FP8IU&)*1/XT+@P(RVC8H;CKVH\2.M/.F&PM;MG,X)N,GDIF4
M=+/=IF*^@$19,'TBATL5&!26V7I3D9.T&!H=2XL&EX)!CXV2B&[EOD!S&Q^"
M-8(D(0D7GZ(2F3$*E>8K^'B<!AM?C*F-+<V8V$I<.0D^/J>O1R&)`-_)*?V!
M3I2GA\<G<S/:W^!7WN+K:Q\%>.0*EI)\T7KL/Y&X_*8GJ^*=KC36LMB/_M.*
M;+G(97&ONR'NBN)AMBDX=+-%T_,>IS6WC[)TK*[`^8=3-?FG.<B23NCOZ#XE
MS6#;_O,'6)MF/?K'($T*Z*"?XW)S`*."/-,?5G^/4SBJ_/P!-IFD&7DC/W\J
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MI.-QFI0;B-(ZG-]."^HD0R45KQ&"BM[)V:Z1HPB*<R8];M<X\`C-2@P"M(BW
M<RQL2\]1]TD[ZAZ"*"$5YS+V>8-AHXSWPZXIO"(^1^,-S^*Z'?R.9%$:BC='
MS+)>;]<8X,+@,-'PQ*W+Q&S#-A/N$GXGLYU6RGM6;2$V&6%"X;#2LG5XM8U6
MYV19VK-I1&R!D0T@'#[F*Q_`.]J\WK!]Z<%W+ZU]XV'`^BRZ^>`7]GH-%UH#
MDO,N/]@%O1]L]FWFO8=$?1)[^$KJO;KM>`A(XL.\J7K3L5[>^\'FBJ%TR2&@
M2<)G!0BRJXV%?%^3?$*":!214&H]Y];Q>E8MM/KW'!7M<]@2`D)VT6&:,:2W
M'@:HLWSM49_"89[#!F#X1"\%@D+`VV9!K^?0REMK66/(;^7FHRD5<V.T,B-;
MY;V>0Z.O0-<B4E@0K%R%-+C2]?.781+2_U'G[%<_ICZ?P^+<S[+W*'DN_8=%
MM[PJ];V>0[NQG!(VA>K(K-RDU*?T+B,3/PH_O]%H`0(0;N'@E&W`%Q"J4-OK
M.;1QUJ53%9>5&QE#<Z?JG.GU'-I$ZQ)416#EIJ;)N$KA&%.\TUB0TK\29H4)
M7:5OB'A`\:MY/8>F4^U%38K$W$5-Q1$??N%=D$F:1R#JQN"]29.`.SQ4JGEV
M/<<,D:",Q,[U3=,93#IU>7V'GD<U]W>ES'8N;^KK^TOD/T4Q:([0?E*-OE/8
M@*LVX?4=^BC5.BQI(;-S&62$6?7#%+^2UT=PU-4B1,HI"Z&=RZ,&\V$0I%,:
M4NJ_4P.GPM:.6<'K(S@/2U3/F3OY>,072TZXRJ8DK,(4T\6NX_41G(+K,B:`
MQ"&MADF#N>N;ATFN?9RSSZL6]/H_(%B@M%0N`L)1M#-#P[Q;?!Y/XO2=D$\D
M`?4J'5:%%0$LKH5)>Z`(@7%8=&9AT)K<6%,``F-0+;(X6#C\.#,[B"<^1BGH
M9J@8,;"O*R%Q;G4;NH$V,)VGXW%4E#D2J)TX38HH>29)("9*4,OK([`&&2!.
M!I%#I$._EQIG9)%F'/IZ&:11@I##HC.[QQVT16`:GX&5W5LQ2GM]!'9`B=*Y
M=QM,,!R*W,6/KCS]I?>*6T6]`0+S8"URF$@XS+@S2H1A-!/FSH_"J^3<GT2%
M'Z_)+MK.2RM[`P3GL%KL*6+C\.G,<'%/<PHE<!+QLP06WQP.)M/Q-*8.LO/L
M:P(^Y96]`8(36BT^%;%Q^'3FIE'%JK4U\08(C(6U^.)@X?#CS!1R'25I5F;;
M*4A&<M'HVB[J#1"8!6MQPT3"8<:9>:.*["H)XBD-+KQ+LU+-19%%3]."&J,?
M4WJ;"B<64!Z(\JS`IYD/>`,$9A1#([0V?D[?P6!Z81ZB&ERA>H.],]+P<7*\
MNX_1Q0MM9G;?P>"ASK&S(T3=Z"%H#E'X4*E`WD17E?M[`-$B?*!S;/-(T"2"
MJ"1*0FD5RE['$'6.K9X'&@81E?KG$":&M-=A1(!P%^*(ZK*'-I)HT[H*6X3;
MK$0>EN:\189O95LSKP'0`8HC@,Z2J(,,65#2INBSQ#/#:?$")]H_5]M**9O;
M%0$K@HU]$Q;9B)"%+;%$OLKSJ39SLTJ`$<'5:W/6UM'@BTJJB"M.>Z58$]`B
MN&]MSET%$K)(I+4KCQIKH$)M0(WB`E:'2&58R&*9*CG7E)8^02VOXS)S;&/R
MV'#L))XSR)ITR>/4`'@H+F0;L;4.!5O0DV:&1Y5J`!3%I6LCSBIXQ-%3[9N&
M%9_,U#(-,]W:RP"^A;-J&4TF,OE*:GB=;HVNSI2+OMH;3F-R.ZI^CV?95:KG
M=3JMYXE24MMFU]7`\MWXN[3Y=)RGC]+@3<L6W-GW?%*=+N:$4J7^M:V)W7U/
M*04(=\(67),]"[9@YF*WF10DOR<Y`>PT[<L%>25Q.AGSTPHHU04P#C=M-9<_
M#63XC+J3TDTSGV9T^R:V*FT4!3P.?>1J,"4&@L]>N]:E=+,0+<*S.EV'KG+-
M*6*A06:EU4H5Q<B@U.DZO/UHP!`/BM`&B_5T>N+"<XF;'$ATK%6O['5.W3E?
M+X\57#FE/D^*34"OLWF2$GI#J9+`V\_I(-R'HS,7YZ=W^I2&Y""M4!O4;?-H
MIN=3I44O;QE4A(SLO,U'#%^6'N(4:@-JJ^9XY3.X,D.:!&]#178V;X5@7.?U
M=IA&Z].UE/=Z8R_)8'>K)*!"<`NC/-#8[#$Q&3O*,RTMY^EX,BU@CYV$MZ-1
M%!`Y`RK50'0$D6TUZ5`'B.PTOQ#Z(1T5W_R,7"6%GSQ'L/R71RCIF%*J#\@1
M!,8U'&D:2(U9`ICC[XO_E&:T[+O:P..6!V$1N*DV&'$29,B\KKA`?\G2O-;Y
MHJP(6!$X/#8[<:H@1.9VM1%M/LE($,WM-I.8E+I/PN&8!DW^6?Z>BU#`NZE/
M@/X0N%4VZR%F=8'-&\Q&/O+.*0(73$O3PA*?V%D,JU6W8\#I:)&?<'ZS)S+-
MBHI[G3-3YX*576GK8VJ^1JQ*()W-(QK7T4BLK>I&1`7%/MA)EZX!Y[&?Y[>C
MTAU0U<UHNPZHQ>:!KX:K$9\\CJ%<#`V9[7-=2*DEK%H8,%D]Q.E[%[&USCF]
M<?`@,U\:X`B7<=(@66UY$LUG@6L_F8[\H)AF4?)\GN;,AR^$Y4%HQU?HNNN8
M!(I=N^+\X[_"[BO-[OSW,NNH6.>;94%(AR?A!OIFP3!F)Q3V\2@F>9$F9)[`
M7]+#MTI[?9=O'C7IWTP@=JUV\T^?0SF:D8;FK8&Y#,;7`\E>HX";"E]:#X1W
M>+IOP((,$C+SG=D')#IG#D_GNJ0IPA%:Z!R<Q>GVX<F'0Q,UW0/*^F$_ADY/
M-&[JT[9`0_I"Q#.97=BNBLQ7@^$W/PM%AWMSC7N#OC,#V.H,)L61\X"H.VXU
M_(;7L?JJA3C/E2&:.0=:LRK:!Y/'/04L,7$LRP!LYR8-2URR.\P6<F06CU(Z
MZ17V6BE`@</&L:57@?+7!4=FS*BE?ESFBSH\H/64N@8=CJ=C*2,;Y0`1`B>!
M2E=G,\&0'%E8T[7_IL;!>CE`@B`3E2H'5<F1^3Q=^E%6YG7Y]+XXRKR7)D?)
M,B^L!TAM&D/P+?T*VD`6$;64>.T`>TW\?)J1\#:Y)_3IY2AY!E5$^=<D?<I)
M]DJU<)5,I@7\.4T"J%5J<!NSU%9O_=NPK<?A>*[0+R0=RJZ*D)F5]KY3XMK0
MX>Z=LJUC#6\WMJL&-8W-WR;-A<ZCC)(@*`*_^99FBZKUFJL1;$YEM4U%2]4.
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M\\7+B@HYAE2J@[+V\0JJQXT/5%<*,L<4F>!2R[U:`X#=JFNP\IV0.E'UB%Z'
MB\P)ID6J<=VTM,<Y6H>;S^-)G+X34FXA9WCD28IX=0`I`HNWSDAD\RH!B,Q?
MI^F)9^V5C)NIA'KCWX(MVGZ8ZT1;33M*0^:RU!3E+^5MI<`V8N=#H,O]L,)9
M[(`LC2%SG"JGZMD;31=E3.A,UMD[0&OS>/[Y#4X(42Y\QTJ_,=#)?EC51+VH
MIE:0>3,U'0PKPV!.\[V\3:*L;*&-J4OZ;=`X@C1VN&<S124B2^;5W*Y=#DIJ
MK["^RZM\"S2*P#L<=[?D*&UO7+:JF]G?2/3\4I!P^$HR_YDLEHV[+!*^I=*2
M!*!^!$D+<?=9+57NG!,7U^K+W!;;ZLWFI``:$"19=-RC3:MSYYR[9`I88'3>
ML;4$`3(0F!Z1]^T:&D7I`V9S\^]H4])(+J\SV`]O79>G/KF"S3F;X1@+:R<.
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M#IXK:>;,&V95M`_!<\.DB,(HGA;1*WF@J9W*=$^?WX)X"A/3)1`T>YVUU,_M
MZ+.?T2-\#C/G3#WO[`8D,7<6OPK4V#32.`K5Z_*?]+&N2V01?FQQ;_RQ/.!+
M5A7P6C63*$?U6>=4IRMMZP=9&*#E_H`K]`]QQT`;*UA[3S&+O;M*<EB@RSGZ
M%C;CV>.+G\S/$3=I\DIR.#K8<TW6E0&8V`_W3]$VKEUE[DO<I!2]_5`V31%`
M__MA%';2F5FZM/OV77V[S);H%8\_X[9AV0=!7?MA%69TO38TARW.TMHHFSOH
MD=#IO%F1PNO^L!]F8"=3)T>=^Q(2JKX/<G+Q85`\X&T_7##=;H<5];POL:>:
M6RN<@T3[DLOJ`WM[/E)J*=M<C&S+N_$Z'=ZQ1*#Q_?#=;'T_KZC:G0N3;;HY
MI"$Y.&=^'0&!O/WP#'5Y3M#0M#CNMGTO$OI$?!I'(4@:/A3PWQG.T>V$S`/-
MG+B2+"11<@VI%/:Z/6?7DTMII/X:&P6A=]BT-XF=+C@*Y(PFAMS[X`FQQ/40
MD,2'E4_BP\`L#XJS:7;1\SY@$"6AM`H%V>7_0L"O23XA032*2"B]Y>76`80X
M'G84Z)_GR"2$A.R&WCAIN.[DS;*']AI]OB-(GNE3$PD<$(9/>1G')6"16P>0
M8K`V:"U\$C#(KHE_(0F(&P^3<!B.0;545.J^,1=>0)JD)J!%<)*6D,%F4`D9
MLORT]R0GH)L7$/J"O)(XG=`.*V=16`^0(CCUU>)0`1>RN\<*3)T)$Q`A2$%8
MBRD.%F27:$LIKQ(X%),O::[$SZHTH,+@<55O*=N&@>P&YR9-TDU1YWU)8>\A
MK0N(,7@7:1&G"`I;]LW5LWCA/Z=Y0>'>CA8Q2P(.A?6\/H8;*T5&V'0JX,-F
M5[\JKX2II#.TB_<W!2SRJH!F$/A8-2)0#`U;DD4NU#K3J-?%\`1&(_8DV+`E
M$;S+TE%42'8HJT(``L%!36]]VY8>6^ZZ&U*LMDS#HLBBIVE!S:N/*70F:N8&
MW<2S%"*R:5&[+5`)@E.;YH:E'DALF=XV8*AR"E`0G-T:\#4#@"T/V4J^6;Q3
M`M/W%'K0ZLKRCF2?_#P*J(V`1BV1V6L?PBU*S3:]07?G#A$-P6++U%4)<MN4
M7,"ZI*;719&?5HM;)4C8<EE)A%8X["NV`!/:SMEJM*"92P%EAMDMKYA96-T\
M''XMX9KZD*W7('1[!&<5/=Z;(!5G8\*5JZ;[/5=-U9OM]-A=5,ENY:JQFI+5
M=JZ:DF:>DX!1%>V#A]8>YJJQFI;55:Z:@68>"8.Z1.:N9C4WR<"J<0%'KAK*
MJ4Y7VM8/,D\XR_T!EU\<XHZ!ULENOC>6OF6_40X0(3C5J@U(SEFG"@>9.]T]
M7?PD.X5E&4!@TRB(;UW?0H[-A8Y*)QU2:Z4`A=6+:>6U=4NO`N6O"X[,_ZV6
M^G$M975XD*TQ-0[XS##?C7>23KAZYA6%,R@"(W>E#V^J6"R\,:<U!?V>:BCX
M="DD@AP4VAK>D-YRJ/KFEWMG&DI>%`8Y$9AXM;6\*;XY9R^YFCN=8W4U+PN#
MG`B<[G35O"6^.;\L%35W=-3<6<J)P'='7\T;XIOSGY*KN=O5Z,W+PB`G`H\:
M735OB6_.1TI!S3IS<W=M<D/@"*.MYDWQS;DD*2R!@X'&$K@H#'(BL`-H+X&;
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M!N!M&A\=^;R4C+*[314\,N?3A8!2U\+-@H#%:D2CLO-+5<%B(M;%1^;WV8`*
M7(XP]3FQX'+)M@Z5H4;P^<[QL=@;AE$2!$5@=69U:(;=A">^,<])J7Y[ROKM
M+03L(+"SZNMW0WS+;ZBM/GLBOIUBE`0!$=@*M?6[*;XQ]T6^?A<&0KE^-TMZ
M@QWKORSQD27@NR<Q33Y_YV?%^R,(F_M!>1#_]+[^%YGKM7(CT,=LV@WQ[5-U
M58,L!>"ZD-+M4[4P8+)J#%-WY=:D04[F.D!L"?\,L(9KXVN3/MG6V)S_YW@2
MI^^$Y&6^@(P$4$V\!@IJ@.087!0Y`X+A#2.#8MLK=.W[]-45(%RZ!1'6`:DQ
M."_6(H`#QK;'Z%P")9TOY<+@[*6MY'7I+3N(KK@4ZG6[&,B&P5M16;-L^;$E
MJGN8/N7DCRE-B?Y*GWZ![\G>L6'7`'A[&,,HV"<+]8`M!QY#6/F3*KPZ`!%'
MN*.0`F76UD%ARU5GG#=<NV33!$IWQLZL%K,<BJN,7O1+5-_BN590RSOMXGDY
MK(WY5JH+;+GL.`)+QZ^P'D#%\0:9E`XM%M?!87.WM,8CKKG8%J&R.;F.+R#S
M7"%YK8D>(X6/`0E/(V8:!WT@<$)5&(/5XXQ)!8A]X;`G:SGMVK00XUMXMY!S
MR'/F*Z&?+N2T:]4062-;2ZE8@?;7!>?HWUD*JEKZQ[7TU2%"NJPY,^E<^V_1
M>#J64K)1#B!A,`YO=W8V%0S).20X,[A<@_*42%@O!U`P&(\52:A*SB&AH?4D
M)\''Y_3U*"313/_PP[;:X5?>%_+LQY^3(N+>_C-*@>!_#3=4+G8.:0TM):JD
MS:3AGJ6VBX#(;IU-N6JL:KLJ-T?5#2T4%E6-8YENH'/9*MTUE9'J/!RET^Q3
ME.9!1)*`Y'#($E]O<2N`W`Z=2MD]EW&])9&?HV]CK@F3J$@GDIO9]3+>Z:E#
M5SQ5K3)$YBC2V6%Y:3>8A<;1!2I-Z)(DNS<4U0.H-LV:>)9A#6UPB'=VT-Z2
M5&K_9)8':%8M8.IWAW("V,P)8'$8<W8T-\88CGV`/>JDVP1GA_EZ";Y/3Q%$
M=`L&"IL>!@8.'6:#)[;>&2HCNF?3.V=)4ZT*&&Q:&O&L:GH*X9!J-&)#(`AW
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MI7'ZX>X]:#"'^4MYKKA*[D@6I>$O69I;R5'*_QJH%8%S)^Z^R%4;IS<Z?YV`
M*?>E'V5E_F'>TFGG:Z`I!(ZK=CJ8=;5Q\N\YBW<;QF7C)&2CGL?SB*P$2@T`
M>`3Y'.Q.2CJ:X'0#9YGR%YE!YO8K-H*;M+1<DMD>-7],"S]>__MYFA<W:?$/
M4MR3('U.HC])N+XY%3FCM/%]4+U#*W,[G;!%17+ZL#-?Q34C_+D_B0!3B3ZG
MD8K9*PFIO79:3#-RE>=3/V$^.5:[+6_0V_L)KJ92./VDZ_0QA)<T!C'RF=O2
M!7PIB(HF[R'P32`;7_HB>+=`4L/K]TS=_E6_PGLI0%#:.^W9/&<P<_XKJ8AC
M(>$AV(>4_#1/2A1&?O;^X)?W(J4-2)[:B5D'U&)S?Z]TU2-EC7,N%&-"EH-_
M349JY;L=K>6.E)O+I94!L]4E22MSDX`5#I6*^)`E\V^!4UP7&A;)M?`J@*$D
M,7>W4A_M91E`@N'4H3B<V'QM@3'VB("A!S2RZ!7.W7>Q'Y1KM)0;=@7`AN!]
MAV9$B9`9>YH`=6A9W[F;2MV]BQR7L<</4$4<]7%X@"CHGV-RX<-"]IJ",<*0
M;4&,,R?;>3A+,U@S0JR/P"5",$S8[#`P8'[)H)7G2?K.LY'57-UT09I[[`#)
MFQ5])&G(-'F0L[D.T-PK"6A8P[74V:1/FD_9U$L+]/%D\I8F0K^_S4(@'P*G
M%EZWKUJ<6=);?FGA+B.OPZ?L2RQ.1;-=#&1#X,VAKEFV_.9>6F"'SY#0S_(\
M2OSHFH11X,?GL(4AF3A.1E@)Y$9P8:BN=Q4TYAY"8+)PDXU_C:+_@'U'E#SG
M5[*>SBL.LB(PR*EK7HP#VR,&M5Z'[MLTO-G<UE9A8'N+H/;KP@.K&;1J/O1,
M-2QF8EU\;(\$-.`"US:T/BG23+JFPMEG`_AV-"(93)O4JIXO(S?%B>2D%0$'
MPH=T!Q4SEPX:<^GZS0R5F:?951*2-Q(^IM2C:#4KRV-75:H#<)MF,9O+CCH\
M;-GW99)+IT:U!@`\CI==U9FJQ_0Z7&S)^EOD&M?RV![ITN7473K"A2/RRF]8
M>FO!K>/U>PAN,'3&(N?"20P0V^,"I9@ES/!B2O</LY"6F=?O#?E6_DE\5Z_2
M`&C,H7&OAD]I'7C8WBR8P9P)?Y5\FN8`.,_/T_%3E)1>X\O`I8LHISZNTTSD
M,%^G.>_LV&'4;`/>ZX,5/YK0OB_\M9_X\X!T>IXP[@&_U?X7B?L[K[C7JY,"
M6T4BD>,[JZC7L_KR+=?K7:R9ZKF/+_L^^+NW?>_>L_H&KO))D4^J_)Y/!2$R
M__BFM[<]JX^F6KES+VE0OK3M\5]"=?="6W/2<!WF;+)GP<.=?7_I)P7-5E?\
M^4S?=0R'27B>BB\O^35`<`3F3]YP8-Q<RJ`@<V>_IYNPA(2?_2RA-W[#()B.
MIR7:>:"B<$3)*GL#NX\RR'?=.GL975Q")_?V]]?+@\#M:)DKDB8#S::SG),-
M]MN&O?!%6W-^8:#,7::>A32\/3R[((C<>MRJ3($\\T)5[GW8O9_[.7TVF/Z/
MGJ1?_5@A[(-?"13C/%Y51!F;7!D>='MQF+2B`*9;MN#LW\I?BFW0+.@)1WRK
MC$K>BM84.KJ=/\HN@NLTX::OM'7.N$X3\G[M9[^3`C9HZ53$K[`\;.90>$<V
M':(,PYP8,K*SR'8_+<[]+'N'#3@O[YQ:1<"*P`53;S>F@@C9Z8.9\GX/SAP]
M9QY\M<\<5N^OM<\</:Z=BB7W/IPY[$2;]WK.X_%$Q$DHYD-"=O@P$[?<Z^$(
MP5/0O^C:F0D+V5'`&&&X-N_FF4.;XJ9>H'G/:DJX1H'FY3!AL\/`8&P;SL^_
MM]B/R5\_V"SI#3"DTE56LA`%LI0T5PELG<EJPT2_1-4JWB((:H%"T)HF^1L$
M*2!D>6@X\DI7'6$]0(K#NBAE0XO$=7#(LM-8HQ'7)L(6GQ9RUC`7KU](0J_1
MATDX#,>@PKS(0))7,L]O3I^@H0F!03/4-G9!7DF<3LI-TZR`<+TSTSBH`X%Y
M26$$5I=*DPK`EBWG+DL#0L+\$E2U2!%].UK+*BT8Y-*ZL*%`P+F>L441%+9<
M..LI"LN7?.8/,>8+C^@U-RF1:46C&5`$AMR,>J8T;7S8TN>L(;C+HH#<D:Q$
MH$;J1A5O\(-59TS+!#*PV$Z2LYP/%@>GQW1ARI=-FEKU`0T"=SXU9FH`LYQU
MI_:+"POA/[_!$2[*Z9F,^VZ=G0^!?A`$U:D3;TL#EG,',;XNFTQ5JH'L5B.<
M3;.GAL=<!B$S*^#2?W,8_G.:%Q3I:MX1+(/">@`5PVN16FNA`B!SF8A$X^A+
MY#]%,2B+&7C*+@CR(;!+:X^5"@)SN84X>?GHJU!4PM5@G439[-0*LI_PMAJR
M>B`]@AQS&EL,-4#8T@N=QWZ>+T?E;58^_+OV[*K(74=2%0`CN'30F[+4,(G3
M$+7OLW-#BB]IGB^6Q=WWUAG4>;;*L;>.U02!NMXZ`U$"@JK<>^6M,Q_#2N]9
M\>J`6IQ'[XH(DU#+AH/,0V==2.F%3;6PUT.2;5"B=>%"4\&#S"G'`$>X;M(,
MDH76#V>8%%$8Q5-Z!_1`@FE6'@<^OP7Q%'88].*`&D.F1;DWO1TMPB,7VX=/
M[^P&)'.IQ:^"MFV:&RW-QM85@LSOGRVN4NY26578SU@U.RK/]=8YU>E*V_I!
MYAEEN3_@6E<0=PS9.N7,!TLGS5\U^]W`JA^]HG5!;6#R=NM,2,@\K.HY]0[L
M^LW;)X<!!]FS7@UGG.&8QA':V\_-V@?-X;S"%QA(#`(7>U.U;R@\3Y,\C:.0
MID!9*@5.-C1.\3).O^6[:"SL#1RN8#6-A0.;TZ-V:-^`^S8L2^Z],A8^!"3Q
MLRA5-12NEP=UV+PB;'0L'7`C5P10D!D(%P)^3?()":)11$+Y<^B\.H#0ZGVB
MOKFPJG\.86)(R"R&QDG#=<XSRQY:$^(-*>B>X"Y+7R/8;'QZ_YI3[]-;F)%@
MVY,\#P/8'<U.J$_4W3P0[23U&P/=('7,YB^5=5$BL^*!_*.HO$X6,+HJ!!@0
M.%G7U3V;R6UTV.QJ2V^J_#&])[#="J*8@`IFP2-4[L?4W.BU\3FO?XS@6&BV
MU]C3$S:S'=.G5K2\,RL`-@0^Y/98XVP'!+HP9OGC!Y#/PD@NT^P:4.9%FI"Y
MTS//,5)2RQMT$4S_;9&HK!!DID(['LE]#.Y];8]?!95@"Z&\(),,3AZR67J]
M&&@`@?-SV]Q6-8`MBA*`9P06CPLR^_\:U'-_$A5^K+"A4V_$ZY\@6*+-;M-T
MT6.+KZS*?Y>1B1_1E.8DRT@X#^H>)N%M\4*R89X3X21?KT%0#H+K5UTR5;N$
MN@9L1W161(-)*LVC(I?RJU,=L""XKVW&ICY><V&>MH;V(MLK["XE%TS2N@`9
MP9)N:\`RP9H+TK3(;P8'"7%\FDYU`(X@:LHBRTR\V")`JY(O'O&<OT!3EW!^
M,W#T0&`QMT6\#+>Y,-*VKT^,7)N`,A$<Q<WNTW71FXMSM=H%9F&BAF[0!(V!
M4A#,!T9NT*0HL<74+FR!C^DP^&,:90000;<MWNG+507L1&DBS,G<)X9[Q:;<
M""@!@0VV+GF<*SA-].*(7,RCW\BH]_H=O/=I-;N`+GI.%W!FJ^/(/W_2S<P"
M(&@,E(+`=F=D`9"BY%!?PT;'-,)(4^Y=IMF:,S_,3EN):[AI1PRT#!I`D)&I
M+G-5$XXQE7`ZA3/'.'45&9D'0`D([#UF^D5=])PNX,S`5PI/LB@-MX^X`LKY
ME0`D`F./WA0O0\.AS.EC5HRWU[3>M)+6!^@(SN_Z1"H"XW#JS#SW,)U,9L$)
M?KR(?+E*1FDVGF4'E&_'%%L`^`A.9IH1'SK0.,PZS.I?D`R.!W=^%`KH6R_F
M];L(CDY:6N=93;=!<=AQG*S_T7\CN92@C9(`!\-9Q@1'#%P<FMREA)MCNTF3
M`'Y<';B3D+'3NHAR&M`US8C"O-FT:6^`X;$@_86R.69.E(^S2%+1,Y$N@DA7
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M==5,QZ58]$4"$A0DO(CH_5D2WON%ZBE,U`3@1W!]@>5L)=<4LGAND?"_IC'H
M@TYU#?K*9B.@`P2>B5A["TM7R#)"LL2_C_+?+S-"%I<0-7H+JPG`C^`"#5M?
MX6L*;=QYM:,_DFQ<<SZA5;V^W>S_N]DSJAK"EH%2=&]P\OWBP'#O&:#8?N[-
MQ<'`ILG,\<7!@/N*O'V=?K\XX%J8K":*171Q,*@83S04]/WBH$T[E]6DM\8N
M#O@)<%M2T?>+@W8UOE,7!XY[9UL7!TW>W^T/_A)&Q>J^2Z0/9)<&EA++84@I
MBV/'S56/\+:!>:S_Z8A^ZPF.W:5F_Q]02P,$%`````@`,(BK1O</F$2&0```
M\*D#`!0`'`!S>6XM,C`Q-3`S,S%?;&%B+GAM;%54"0`#K!A15:P8455U>`L`
M`00E#@``!#D!``#E??]OW#BRY^\'W/_`FSDL$J"=Q$EF,YG=?0^.D\P9Y\1&
M[)F]A\'#0BVQ;;Y12[V2VDG/X?[WXQ=)38GB-[5$LKW`?G%L%E55_%3Q6['J
MK__^;9V"!UB4*,_^]MWILQ??`9C%>8*RN[]]]\OMQY,?OP/__F___;_]]7^<
MG("?80:+J(()6.[`^ZB*;HLH_KULZ,'IL]-G/P+RP^G)IVAW\O+%Z0_@MQ<O
M?_KAU4^O?_A/\'^O/_T_\.'F%IR`KU^_/DMP#Q7MX5F<K\')"?E.BK+?EU$)
M`68L*__VW7U5;7YZ_IRT_[8LTF=Y<??\Y8L7KYXW#;]C+7_Z5J).ZZ^OFK:G
MS__/I\N;^!ZNHQ.4E564Q7LJTLT0W>G;MV^?T[_BIB7ZJ:3TEWD<55156KZ`
MM`7YUTG3[(3\ZN3TY<FKTV??RN0[K`,`_EKD*?P"5X`R\%.UV\"_?5>B]28E
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MA.<[3$BF=9B=_'+SW;\U9`#3`48(.$KP6T/[GW]EG^_)=%9TU1\5<<,@_E$C
M5-WB>9SCR7A3G73D6Q7YVE;C-2>YK5KXD3+!4RT1E::$\;.[_.%Y`A&6ZO0U
M^8&`[?7)B]-Z/O\>_ZKEA&/@-EKN+9.#F+JY,UAIN)9"J8,?VMHC>$Q4WP#&
M7.^V(%E%Y9*ROBU/[J)HPY`"TZIL?M.'3/WK?^"9OX*$H?,T*LNKU4V5Q[^?
M?4/E`&X,:)R!QX3_/H)H$Y"O`&V$?0]NYA$ZQD/0X,=2_W-Y&N;HOL`[1/Q;
M5GV.UC(O,]S4J8>1<-O'1CTW[=L!TM"O7U$IFO<I>BW/"X5S#,4B2B_P0NO;
M_X8[)1:$MA[`(/(K04/=$-"6`#<-`0\2;8N`4*IZ+D2<;XL"?_<C*N,H_0\8
M%7A;_!Z[*PDHY,V=XD+!M3")L*:`M06D,5[8)N2HRK.[T*F>1XB9WN=U&Q]1
M"HMS_-&[O%`[C5Y+#RZCSZO$8=!FH&D7@K<85++H*Q0:G@L$MT5$3H!O=NME
M+BB_EJ'7QNG`]_GK#WG]=\`:^!WK05WRHZQ0Y,QK@WR]SC.Z0KVYC_`876TK
M<CI.N%$O%)2$/E8-:DED2PA*Q78<"\`(`4<9@H\P&:.!Y87Q`,U]Y'&+N]4<
M<[`F7HXV:NZDQQGD[V&<7_!Z'#JS$)4XU\B>X<\EY),?TTCF)GIMG(YMG[_^
MX+9_!Z2!W]$=U"4_O`I%SFVY[<V98HL@:>O%EOO\2HV:-0QD8Z#4]I"A*U0]
M-R+8CH0Q\!'_;N@<4M/>"S*&^):BH]X[UB"AS<-`B%3[0RC1J-X-4LC>U1PG
M7&N/*.%YUF&$GB\$AQ!!ZW)\2%3N[H;CJKB+,O0'O6HYS[,R3U'"[N>RY!H/
M-.:4_O-J]1%E41:C*&T/V$O%1>W$_3N_.9E*+WT$\_TN0*=G@'<'@.^;7,:T
MO8-]]T'<"\\"H/Y=S@SH<7AYN-UL4LI*E+Z+4A+S=G,/8?4>6WZ:EUO,_RW\
M5KW#+/RNND^TZL;]%:.=E'U[X,E!30]H!X#K`?Q&^@"T$PGF#Q;T`1;+O(WJ
M"5Y>IW>P(Y`L7,N.AK$[B]WS<K4ZS]<;F)74O7R!*8GZ.L_+JJ2G.21L-+F.
M=J:SX*$=.[?J@S4AK-S:#LFLQG<)ZCX![;0^!3RA_8*FXZ!FO&E0TK>/*2$2
MH,6\X[DVF?8.[CE<FY'J8FJC"6;2/$+5!.E1U%8TVJ68F)#+H#O\\?L\36!1
M?OCG%E6[SWD%#699':&'\#N-),+JD"/XT_>OWOX%,#)`Z(*:!,T&28S-,Q\A
MWX#;6X_1+LV\CT!@."R?"I$=,'(..)QY9BI)1=NS$M>_(2K`:V:36N1Z",+F
M3GFN\Q)IGHK8D?L+S59+):*T)@-7_.%@0QG8'&$^<-(H;N-1\P!(V1,264-_
M(),]&]G#R?M;$;5VI?@(XWW(30RSJ$"YZ=N0;GM_N.CQ+<"C_G-XKT&&%"[%
MB%S;#J%2\_!+5FY@C%8()N_S=80R%5SD-.XAH^!?!IL%X%J#WUC[$%"D&PL!
M268#X<'Q7*(,7N`?C;P.U]B?R^$Y5DQ'I!F@[4(`C%3=4I\CT;4[B)R5)32Z
MG.@W=`X-@5,A8)`VT*YM7>TR#?GU#]MA"/0AJQI_UW"M7]X8HU9H[PF\(M_#
MF%B`YH74[&"NN!P5!W/?<!T6LB5H&0:X$BKN<'X>E?=G64+^CYRV/$0IO<>K
MSJ.BV*'L[M<HW:KVE(;TSNW`5"X!69B`1C[1'SC2!8@JT%`#2KX`-+&-7^]_
ML*`Q^0'N27W:OXM1FTF^C9";:28I*["$=RC+B$#Y"K#OSBK4/EG6;")!/'8:
M85SZ<RNOV/?O(URB.W]_7<!-A)(/W\CU*\1L7E7WL.A,20IO;T3MW->;R=2'
M7DT%:C+J/B@AZ*V-?#K$PT2#C*RDLN54MKA>.46!K)PL\-BW,VLP>MH]F.X:
M?.\6]+N$N2R!2P\XFE6Z%`-!;PR,-@3^)H8<S[[5[AIKE69(PU/7AIP<?8;J
M&4%%YF$J4$HA.DK6?`$H`?63+<D"8"*_B_N1XE`YX%Z.;#8YC$S74@K%ILKM
MS*0W"'%*,K6&\9DJX8;<.Y?=^>XSEDDZVYB1N<U0J9=""+&L282%&MB3^;'6
M*01BJS/5JNQ@*9+ZJ1\-NIQ.C'9W_4#V-607%ZWS+8EJ)?G-RA7$A`FH<E#=
MHR(!&[Q!1GA)NLH+4$+<+8EIVFP+_%W\V^H>;P:C`M*E:UPQPB4$!:RV18;_
MB:FBS29%]"]?HR(I<8\T4A1$*[RD!GD&P8Z\P\0MEW"78]UB00"Q2RPX9C/>
MQ2E<`+0":9[=$:7C)E%:Y@!E<;I-R'+Y[JZ@F75!W`C'9%K@$2(2DAZ7]6N9
MDKZ627#K!?E3UNJJ'DW\FPI+BN7&3=(=2%@H$Q8`94,=81UBF=>X<8&BE&@'
M.ZP2)91__-,S#N_-)P8UAHG_8!HC'>"A3_HJ>H+_1CC(2';+5*&CI\\\9WPU
M='J=;*]6'L_UWD"[*?"V&["\0'*Y^I<N^\-:[JO7^;YP=XFB)<+^!#M?;!)B
MF*7!)9=Y%\ZQ:R%='T(<*9T+AF*,0[GKG4G,3H#QD_=PA6)4/?5O3[:8[5O<
M.,!ZL4GSJV85D4^[TU_;<HT=WCS;FY;Y!31']%-0YF)X%VV*)8?+HSBFNX?K
M:$=":0W.4"4$[I=/,LZ%Y53=$-0MYSY?-8TCLN9_PUKZ![X:-,(ZS``Q3@%?
M;&$B6J(:\S(:'["7\C^`'-(6#$T$WL%O+45SO>9U8V3!=R`'JUK`#]BK"=I'
M'ZG^/2I()GZN?\DAZE!#I\>F@YSVA[EN!-)]*W_GHH%Q;!"E8\SUNS8,ITX@
MXRL(QYCC#S3?[\SLFAPS&W%[48$";EA:K7)_NOQ5!(OGTTFY_^#/(W7.P\NN
MTVR;Z7=?J=M(SAF$:30'JWEE)Y27.M?F:9]HL#'T%IJ<K]>H8GF%LN0\S\C5
M!,QB-6R55.[#D)4R"*<*^]8LFI5O[SG,>&Y!G(9WZI$E!'6:PLIGGI!126F"
M2DACF(RF.:H^JZH"+;<5V<;C>0!<1T$=*8Z6;_@\/H`31OLC^/`.W:]Q7S0H
M@;*F>^`RV-I'B/,`SP-QOW6X15W"I'ZF<E&6>/_L.Y3-3H*22?`_7SQ[\>*4
M1(VP'<!?P.F+Q8L7]+^@9!5:HFUUGQ<DV&%!PB\@0%1>%E<30O46`^0-!#>K
M8>=V'5;7CM&^!A.:>EEQ];@=6IWLR_P$9"/FO"NL0VD>;UXNWKS\8?'VQS>\
MD>#?_OCBS>+UG]_R]M+\Z8>WKQ=_?OGG'L$/IZ\6IZ]?AV5@,J@.K>;D.'5X
M]I\D-(50E%Y'*+G(SJ,-PKM%CCW5)8`!L?O;`!.)A`/UE@@0*G"1@9INT:G)
MY?F*X$#1R&.5$Y2!F-'YMQ9S]`DG\I;0<V=17V`5H0PF'Z*"',V69W&\76]I
M@M%Z&:VP*!-BYQ9E)%$?=@T1:*C`$XX.J"-\7!G4*,EX,1+6RN<#O7EE<.D-
MS"VG[PULS<;G$8G5T4@01R(V1P7#YR$^S\:-Y&%'Y#>[K+J'%8K!.Y2G^1V*
M2[PLS^)G+%QQNRQ1@J*"Q"^&%ZDH1YK^0,27=7Q"64Z>7UQDV-7!4C4SBDV=
M6\8`M]9'A%5.'T_D684_F9(]3M.;SSG$0#+,]0G/-E*R[1+X,A#U8:]&D,\I
MX8(^^\%:O<X+FL^50\QMWL6+@:E,]8$`IIZ1FC$P2^K86=^@[MS44A?`5>#%
MR`EN(JW5D^+(*/V#A;?(9S.;"CS'U?B5S^_JY1"GJ%_Q'.X1PWDW919"(R$-
M[IV4.MA&]CXJD.@;4XF$D)R!!U$_OCQ]\Q>E>"$]A#((XS%`H,OTT_<PV:;P
M:D7?YC9O3^@#29I"W:C(B44G'A)46T@H9JQFQ*2J`DMUT$UL4Z?'!^%4.IE$
MVOQ`:=TF[;9%L)C%>QQ\`\@)9&*=)L3AY`=2X5.9)2@X4_0H8A#I>;1V9PO,
MT>]*ZG<K=8(Z_;QF0./TM8F.?]F[J(;`G6F8O#FPE08WV*91T>1KJ4L[1KVW
M7YZ?'AA!C'^%8(&OT;C?%W'DRSR>D></=[08P;N=4.?QC.3RN=K0##?8)NO'
M$N6O>.,'$V*D=7:;VYS\ZFH?=$+_!HL8E504$QL+B#^G]AR0W.(:D'P8T"]W
MRZ=R[(%W.\"WJUD$E$=0,TFGKH9-P/ADTUF3'^DVI[\&5[U0)X[=8";UHQBV
MNIJM=-B6NZ&JM[;#5H4T;"833LCC-C"Y%;0,;TGT3`,'`1NMF!_5J#NJ?+LV
M"QL=U9P;U:_-J#[L1Y5/5D9^+<0=PKTPGJ?8D(91F,X#8L[W0=*P*NB15R-L
M7*$'5.U&'#"-[]SCP=,!&E$=2#%?+D[5"W:"VGCT!6AZ#V8V=:.B?`5DT^+A
M*O)SQ'6H;<F/OJ8QK-%;E?H&[H:DWF3!4C0"*4H53^D,Z9PN[4WDD-P^`DH$
M.E3SOZ`S64!-+)3?980QTOCIW1)FOM[08=:N"EIJ,*'/*:YA0>U:>3ILUH'G
MEW8*R;2/[S`MN"H`HV;/C`"F9Y.#[S/B@X6L7R"U3X_`$Y2!)$_QKJ(D=7S8
MYB"`R$P[J*K?X9GAU)<94E;*L_:YE['YB82>S6Y`$JVY,1JP)PK)Q*P$JDU+
M>+X7FBW)\*:V(378_-H.>P1J:3<-41`VTTI@:B\AO'L=*4C73I!"$-\VTL65
MB7T,@<JO;7`'098&TJ$,PDJZLIB:RI7NJ;-/>S$5J6LT0;W>-D2=B?E((><E
M;<*(_9$1M<_D"A:;AFZ^A8"W10>)=]"&Z&`)S<KK3C1\N=WP><H`8;O5LS8Y
M+[[$8I.GI/+I.PQV0UW0!;:W&R5*N+LZ`W0I;"64_9S`DG8S)Z7P;QO2W<^0
M7027O,A,AHY!+(+9OVEPI+4$OSLW@1VS;9N:S+\]J'<WPT81S'9MG#0!;]1,
M0*:UDX.V:,-QI[H'%;)X4#V=VSA-`SE&OACR&%5@-4*=&">[X1D-'['W2Y3!
MBPJN9?4@E!1.(:/FO0^688`0"D!)/*/$8"!X?!B/PFAD7!>0)&]K@N:_P!)B
M<>[/LN0]?(!I3E^/2#!B2.L4+:;R#)PB$KK]`X^&DH9L<K0^#CD.$>PBJPKX
M#4^ZFUK"@A<LV=/.7?/')"QFK)`WVW53N[BIT$QE11F(D@<:-4.*,FM%]QR/
M:V6,O)\888E.;UPV-)5BN2W(4*BO6'I-?=RI]+F5^8JVC?<K$U..D9ICQS<B
M@Z@8N`)10,(YBFL3T]>QD[3WA6>!;\T$&$CM.EONU7.8!WP/XT4"<A58W"&=
M*RFOA_E08^<8'^1X>&?`6LV-;J/L+D9<!U+84(Z)/I1U@/#Q?D;^+%YR=&+?
MA<>W,%KIQF1$".J-AMGXR5]BV`Q>`"E(WNUN\;?/OB%5,3`CZG"2D'1DL@+D
M`A!*\!NA#0"5%J-FG)U#-F0!8)$P]CY?1TC8LALE+.&HP\%B1Z916&34(:-1
M'#?S7#&207.'QI:53W"]A(4">4)+YR@3>15*T^ZG5M;&\Q-1/<>?HFR[BN)J
M6Y`WZ]"0?Y>XER"DCW$E/$:?F9/GG-L*KW*SY&JU0C'4X]6,S.E)N8$4`]>W
ME(0Z148$0D'W%"+E3*20`&^#-_Y$V`YL3H,X*%\W^:KZ&A7P(JOP<""\#*=[
M1JW#-Z3W$=9A))<4?PTA21_>D++3BD"FC;$2-NT#,*91(!R(]K!%X.B9!H])
M7I"V.[,I1M'>Z=RBXEO(P=RV-9Y+7#E>K?IYCVNH^P#V=)>*V`\;XG!V=)>*
MB!#-:==E"*$A]D-FO)N3C%<`,/RYR,M1$*P)PX%?(XGE60(E\WV_YDRD(.RH
M@SEC&QH`G,-"JGS)N4T!8T0C:/#/*:09T;+D;$UJ3?Q!?R\50F%ITWW"?5'6
MZ;2C*F7(][T`;>\4_GS_V"RZ!K+H6LC4UOZ6:2F#=X1-G;7/J*Q+6)8D@S!7
M_''_`?\.86HC$JK&SF)!$X2+#R5%EFP>=$2>`L4E$JBBQ"79NH.)$%<-RG!X
MN'Y$'![AI%%97JWH>P?MU=!08_>',T,<"R<QI!'-<$CS&(9SQR/7MW`TH5'V
M5.G^51M(=7.?2?Y5FT318P2Q+S31O2(%_@%[/Q4,.M=#YWE9:7`PU-X'$`;Y
MEB%AW;D#BTEK7Z'_8;-O4:#"2(+;>SC$/4!9O*5I7E!&`_TW19YL8[H*QT[[
M+L^3D@;YEY'WO-I:.QFP69V1'&JTO\(LR8LZ3[;&8/MM?1BKP*\,Z:QADWK?
MTWG*&,8?&..;>1FW,$\MY^=14>R(1;(L,%'9/+I9UJEI2YJ:-L';(/*7?)FB
MNVB?+1]+2M:M-&5,A1<GI">:)+^CAS!L=]A<!NQ692L'3[0(:ZO*,WC--*>9
M9H767B99D6>9`;1-0=W6N^U:,+]NF0_'@`W8)[-KW#5CKO23*%1CM-38LP%#
M#\-<998R--$JS22<\@Y<I8M25NK"/'[]X&\$5^S!1C]C"AKP=7Y*=:$?[\=+
MLV'*MKK!2$"YL[HOA#U-:#W7QCGJ>?[ZJ*5_"R807M!D'RL2-3H>:VU$6:>5
MG_&6QL;4(Q[,4>2`1@='W6_@RR>\M5AOU]J1[[5S/O9]/H4P;/;W`(*AE)KM
M(T"A5H<8B+Z98:#;SCT&>GR*H?C?0L/`D&8%#,C5Z@X#'R-4T!RG[W:7*%JB
M%%4[>D6BF?\U=,XQHI-#N(MO&@%VIQ7*BL%H//I(LA@,AWNWL;4)6VG.RG*[
M9E7`FJ*$[]$#2F"6?,&[:M6>;OYON]_K.=#G<'U7P[*\)P-E>1>`?+W.$\U]
M?[$O[-JP``@/G@L#>E!QJX>D;A=`:*`STQ6VSF[M]LB=X:]YBKLASMZ'.^Q_
M_7$X1$&G/ESBGHG'ZA2U:FYU\="V?*1^<=B*G7A&E0D?J6_\@LK?/Q:0O#B#
MV"@JEYYQ^-O'[1<E^G3H%0D'@+``&A[F=(I&A51\:)BJ8474@!HU%(]K;IA#
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ML&#?:6Y:'92$++5F.#J"6ZM+@\QR4W1^//=.EXJD`R8O3S0/3RY#R%(P/6PF
MNP608.8(3*G>87"E9#]O-?/1#-\Z'D-3Z&N&L_RKYO">^]X"L"_.-(&RLX&;
M*BJJV:XN+938:N`=O$,9/59XQQZ'SBK_ATR;Y<RI]!]HNYE%3^`*98A\\><M
M2H9J*'JQH`-FKC$6=!13F<YM3S:SF?GLXYGH?B8W7Z7B/F2N#QW=%"=H:L[Y
MC7UL?\^!3116),?>Q]D/_^<-5S)59E<34'+1<TR^:=C2IG9,*C-SZ)7(EIH>
M-27OZ84+8X=R7G+[[?+#-UC$"(NB\CPC.G/O7<9(/*<':;Y3SG=9:I<%=Q(-
M">)YN@&>5"A"']77C'&^7N,!9W>$)*\:K`GII2=W<UB")RBKKT&?!N`=1UN\
MX`$/-/?C67MQ<SE)1OQM@PJ6MLO!<LS@VT>W0C/1YYPNE_L^2S^^YR`8)^Q!
MQ7W]/(;%G+'I3KV^L[3;XW&&M3<G28IF/W$=^-;1.;LA?3E83Y+OS7SB.O=#
M$0L%#DE_S-MN<]!,<\AH#)IC\OU23S6UK]>XJ>/Q[=QIZ=\ANKO'2X`S;.71
M'6S6\-<%$D_7YSD85G-P=/.`N6Z=W<<U?(":D7:S#B@KC^JBSE+G&M4\[FN]
MJ77EY!+0T6KD4#.>X5)PE!D?TT1N.2W->(=H/B<%-.E+,\T.7D7,-?%/R45X
MD_^D.AZS`"C'WUCZ609,Y:]GU;QV:CN>6\_IO8"UGYW+!1R1KVUO^WR[6TM&
MCL_CVFIZ5J<[<,GKR^].<WXUM_;U>PKUO?)1N=Y13F%R[WN`1PC(`1]Z+>/I
MW.M`OL)SSS./@_?KX>-VWXY'1^O-_Y5NG'T<84SH7H['UW/7,IZ\NC$'1^>_
MS77K[*[[N(\Q9M.WZ4I:?F5^3-[7TN9GO`D.UJ,N]>(MK4_"O\`U2YYSOL^N
M0]*+O=1Y5]?<'$\:QH-T[N\.N>4*<&S-F;O1_O6?]]$P5-HE6I&;YKJF*/?I
M`.8R[SIT=YUJB^BCR$1YN$>?+$7E5.[\>.91^3)!)NHL68L/X>;HYM%Q.G<6
M=.E_'G7D_:<9!ZL9-+P=CA_?,;7'/MAQ',]9$C<Y76")4%:BF*95=A,+V__F
MT9T7J?3G;*_2?IFEF7]4\:U:K9[=W17T[5E?#8\[EO40O9C$K1[3X9C6B<T8
M.:GR8$>Y<.\*Y&A]+GSTF)?AH@:=W16XF0G<KZCU*E6YNT>Z3)98ZHRK8:69
M>BNQT0VOI/]ZCX'05@@9<&%N/GM4938,M#A?H8U^\#;[!2`,</63CK?8Q@CE
M,@TD1`,KHH$'6D&*E(6H=7:G"M$^_/;!00F.$5KYV%$%RT?S)"]`7MW#`A!Q
MR>\AS2[^M%$17W1CN-1&E.UJHOIL*^;A3&ID-%^XQS_B_\`FEW:=$N=K!HOR
M'FU8VR<?;JZNGQYY60U3MSIE80T[GWH\QRS*%P!&,Y8W3H[N2,9>UW,>AM<S
M&U+$5P8TUX4S!JV6HEI+=T/S83!7[V'H2HFH8WK4-8\[G3?7I:4O=3=YG645
M2E"ZK=`#O($Q7@M5".)M79QN$YA\Q*-#Q-^RI=[5ZD-4D#/3$DO%I-\-=Z`I
M)S7K5YU/2O/J4#C,X!J#?6O0?`^0#P+NBR0S;_--,M&PJ6E!-E^ROD*I?.4`
MG7V[=P9-WS;^.5KK*VSI20.QMHXTAB:S`(0JH&):I@-EAEG9*!W!SHA5`+O(
MRJJ@!PWE%=E@W^+]=3V[?LZS!UCB"76^='SV/!S/;FB$?F?8!S$N`,<&N-H?
MI+2[I):7)DN;Z\O;>:^U)QB+SVWEV;]'!5UW/J;[[9D4]&@NNL<ZR\EV/(=Y
MRL<P'<U?J,2:A4<T&1D6-W$Q%_5/[([T).YPE0]YU.,_0AIIZ.X\Z:$55":^
M8^]Q)V33F/QV7?_!([E7-]#<##?JU*/=<AXMG$HLSM4YN";T6[C%#Z0.O,P:
MF"7WH)I[HIPW$N$@5)74#+_6V&I+Y0P$'!QM+("I^Y\F"L#.]S^&;46;(<;K
MSF*`BT>TN1C2L;_]1<O-?)[344V>210_-$<_AK1)XRW?W59#8_:/P;^VYU)>
M@JXF9>\1>62K40GB6L(TQN9?\]IBDJBEQUN*PK,B_P6O0=S'A,WFZA_#+!Q`
M_//T/#ZB^3B(F.F1]S.//*+:P=@]HFH0KCV4KVNA&>80Q_=&8R8![QP]DING
MT0[>P=54T-X\O&$YM*#$D5_/3/*TB'M?&Y7D))+<VW#OC=H7I?6Z):)P)B\]
M2_Y9:/T:=9NAZFG]2K=N1"RBN1PB"Y='?B=D/7MZ9^>Q[;>XO/AA;K;L&'Q$
M.RW+D?%^3448_5??81TX9O\254)F<4G.;\)&^"-WT\5%%N=K>(-76E36LV5)
M4U`J_+>4PKE#E?/>MQ;6$K1-P6]-XP!>;VF&H(]7(_V[`]`57G=BB\GN/GPC
MQ@-+`P@I:)R#2,5_'T9M6]`TU@+)U40U3HSSO*S:NEV4["?_]J!%5-\B#.'D
MSB9^AAGF*#W+DK-DC3)$N"%O+&O^%):AI71N'WI9A"13C(+"JDO3H,ROJ1PF
M4=2A\6\MAECKVXP5T-Q9SA=80JR`>\S7>_@`TWQ#YCB]W6CHG%N-3HX^PIKV
M%&(<11@6<Y`TR9["O[48X:MO*Q;@\KCNLEEOA;#.,EI?S548-*^BU'I)-<#Q
M+>D(J!94_C$O18IV'>4=VVRO<YF71NCF6_O#=X=G.<+K+>D3TO!I$#!7,DY^
M#0BV&K#G64C0%H$B!;<,)>[@_3G/\BXWM<$9;)T-:)U#WT0>(4*?HVEMH29[
M&LRN>HQD[-R[+U(`^VICV/5-QQ)S[@RI/3T]2_YK6U9D57:U:EY\*(Q(0^?<
M@'1R#"8LI@1@3\&_=O'[]L=6G/-[<M1.[K"[2:GK-Y`@1=$2I:C:^74&<XF%
M0E@D&IE2WS%8V)'+&PT2$4UX8;[J(JL@1H7Z2D-&XN%.0\J]>*G1-*UG&UJJ
M@[;V:RA6,K`_82LA+?W;@0X]XFV,"73<H?^ZR%>HTNR8^$;.$=[A4%@6PJJ[
M,R*8)BDTR3+Q.B]86$)5%6BYK4CU$%#EY$553$KGY6G*5I-L"!:`[LY][JVT
MLI(_^356+8OI?"SB<9J`0;D.73H.T?#ZKD)F=0XWGK#:[WYY*[K-NS9D,&>.
MZ,O]QG2$O%J/%(;[,=W`3J0!>OPS(/C)D.3^C7$TT(6M[V$H]V3:IF;KVR3M
MS>TV!]=1(;U*<C.KF\@P:#`WNZRZAQ6*P3N4I_D=BDNZOGE&;PQNMLL2)2@J
MI!M"+U[#>EG@S="-C-AOH!WA@.6"SRJ4;;'CV!^G7\/B752BF%PSDJ3<,*%Q
MA\I]Z^@^/07KC9-?$LY7.X@5JUO0=,A=4"QHV0+:*;M89]VR0&;?>^3IU-'Z
MF[9(`SCI2TVB;YZ@#"1XNHJ*DKP689G&9KM[,EG;3ZD%#@%Y2VXEL_N@SP/<
MP7!8Z,&^P)U#%"I@='E3N#TMI7/GII>EC];!PBI]1^5SD6,OTH`;&K\`<NNL
M#)WV.)V0E=)>!.R:E^TX)V-<LTLW96BD?6=D9:'!N!R#ZW?C'D)S08H+:R-7
M%,R5_'@YQ:VE>KT4O/7I[NU'@=6=-=87A9^@IA)/KYUSR^KS*3S%J^]S?V,M
M`GA1-*C9/CH4:AV=V:-YA$C?()Y*1U;>U&DN#`FW@G_LO*P$IYJ!GML1'L#Y
ML]/7`:!4!Q3^`;\>)1-A];4%6%\'@-;7QH.N&W+W>#7G_=F?7\S-O?*<8E[>
M_1C;:U-K&X3Y1.;VY@<+>]LW]FAP',?:D7_S0W`V-RG[?H#;QXP<N<.`F0:Z
M+U^^,(<NU]@?='F.-6./FX:&7!ONGVG9]X)<`3)2Y$KP,A5R7]H@]V4(R'UI
M//88N^%!UYS]9UKV/4'WI3%T!P$S#71?O;)PNEQC?]#E.=:,_2OP*CBO:\/^
M,RW[7J`K8$8*70E@)H*NS5+W50A+W5?F:\57(+REK@W[@2YU!<S(H3OG4O?T
M[5N+7=J^L<==&L>Q;IOS]FUHR+7A_IF6?3^;M#YDY)NT8;R,1F[S[*CS$0EP
M)6V=XE;&K^1VH>PE^/,'65/&G?!KDBC8FN$--;$Z96]3B-%S8ETEO'DC,\#V
M$22C_9S7213%)(O;JJPB6GRF6Y:>LW&WGS^>1+)V6ITA32QY,<`X&,@8NP`<
M%[@MY<-=Q::Y,\(>IOQV&N`:^[]H=FG?D^5M'6W<[@M>R%GMN7D28"=UA^Y9
M.(Z2%N.T.WT-"\P'D'I%T%\`TEA*QLT1UJN81N=#.CG&4A33:.,6+U/[E2:6
M;*X$Y3V$=<6)J`)?[U%\SZI00%B".,I`%.-/8V`2(AIU6@+\7U@\8)BN\@*@
MLMS2GC`Z6:DYL&'OL.FW\KKH2KYWG32(+MX6Y)E6NFMJ5%#8;K.$YH2'_2KG
MI*3%L9:N.,!)3U*KXF`/?03[`6VN=6[J[N5:_P+7$2+K1_(F@L0[;J/T%A9K
MU2O)P/@\GAW&3./DKV)%9TLB%%UH>08<TX!R[?-95>C#9ZC'2[0*(`@[-&5.
MNQF:WV$YGEV6>B4LK95P=G=7T-QG%UA2E)4HIFFO.-WH)A-O;/F9._R-@K^I
MHF4/M/PU!=RUAS8.YX5PAF9(80_RFD_.G;YG5S+HXX/P(P[3F6'`?([6\.P;
M4B8TZS1SG]*LRV4?Y^3/@/P=_$9:!/!`:$BM0KHJJ4[=#__[G"PU#`#0-/0&
M@993!0A8FX!@T%6O#`A#NAU_)$[JFI*>,=_JAV*#+=T>,`_R*BPT:*56.LRD
M70#!)69\4V8YYL.(*E'@HW-HI@/')`!]8PS0-]X!^L80H&\"`ZB<;\ILT`!]
M8P;007!,`=!3=73T8$M?`#V5!Q9W`'H:0DRT&=^4V9`!VL>'!*##X'!9_"LE
MZ>6OHZ+:W>)=31G%='OR;L?_1;,5L.G$0UDP"PG%JEJT":!M@ME*V`^:6%YK
MW(CY`:9V*S+4V"O0I%N2'J""V9;(U:V"SJ3;DP_K39KO("QINI0"QIBL5`?#
MJRC<1L0K>1>B7IO6X(SFOJG;!S*)&8Q#)\+<=!`F`<8Y=E+;M"(W[,;0&*#Q
M!HXA_M7PX"@"!(AT/&00T0S&P2`Q0H57&&C'/;!AUH_KI`.Y!XAR*,5F3@=S
M@,N!Y*AUDT`&5*99?DC5:G5XK[Q=EO"?6U+S]0'_SRW^GF83(J5P?QLKY5W8
M?;<M`6T*2-M@MAF:,1#NRDP&P"N"M/L(!4T(*)+N*B0X"F9WH1T+`RR-W6M,
MF4K^IL);'W*=>TF^1&Z"U3Y)2>4I';Q,!DG"][8Y:-H'XY\,QF0X8[?!@'A'
MEM97:>A"09?49RGP%8S?,AH;0XQ->E;R,\Q@$:5X/W66K%&&2%99DC^WJ2*.
M__`%EA"+>T^VY?`!IOF&<%,W4"ZMI^K<Z8)\,HWT<5IW3%]8=+MNZ\W3OS6]
MLWS&^_Z;5H%L`J9%#K]UF`,VMFZXA/&SN_SA>0(1\\#XA[[CQ;_ZQR6\B](/
M686D=QN#K9PA>IA'H4`\:0%8$^^SLD*M#4JT.IUKN-GWI%.JV,3I0/>X$XZ%
MZO'U/BO*-,D/KUR-XP^$DA56]SN4ES&"F,$23[#JHR$%@=M#(A7GPG$1;0RX
MUB1S?B"SAGX,.H=(A@,P_K!W@ZI\HSGK[;9Q>]3;XT\P:?;W0`9W4)N=<UZY
M*AV>YS0+:A9:3>*Q\XQ$5NO.!=5T[L]U-'((6&$O(?;MO,_T5B,BG.R8#X?#
M(C5=7K1[;TE[]P5H)'SK,!3`8L)(]4)U%;W>#XSMPR-T'Y6P><5-7VE0N,K<
MC#FIA^@_K322<,":;I\'@Z/T[GYL!TN,O+,9J=GP)'4R-L1!84I^/6&"*N\>
MR7[0;)`U[98H7Z_SK//)L^9+?T?5_0W*[E)XD9'D(;H@JI%].;YM'R>O>"5/
M^@$]/+9=`=(78)V!MK=`5ND'C7GWBO_@`9_&*7:^>HNI('DOB:HM.2Z/4C/X
M'M2C/_=I+;O&I_8P3'L$G2Z#`_0$6)`ZX$.`,)M7'H'NP[H,RD=;XMO(58<-
M\"GP8..XG4"<AH?A&:+]\L>\^(BR*(M1E)XE#ZC,B]T-+!Y0#'78'M67CS`_
M:WDEL8`DV\X>PK@GT'8%FKY`TUDP*#Y@R`=""P\9;W<G0C2)@T'48:^=\Q.@
M/I]"O@^:[3*HL,)!U?9/>A1Z#2AU7BE+\;1G/TN,$RK,\[GP$MF-TYKD3),!
MW/_I@0O,6&<@.Q@PAVWTFE0W64+_>;;9%!"[>O+++R2M67D3F>SNK+IQOZ6S
MDW)X'U?W06.'V&_X;@#K!Y".`ED5C!U?8<<V>G`#F@9D5E;+]C,]"[S(KF&!
M\N3G(B]GR8.J^EIXD\`HG0TGFC/,`WXRD`=\L4\EQ[Z(-Y&`?9/\!G]UKA37
M<(4R1#[]\Q8E)-FS?V7RGJC6!TR.M/+#"!@=E*^P#R/D!D;SIJ8]#B4&M;H;
M/Q5,EE[6=!YP7UICD+./$2IHZD/9$G"NKQU'P0RMSJ:OC=$L1OLS(B"?9>E5
MC[`*QCA%SN;09M?EK$4TK)5)Q64%,_(5*.E2XTE>@)PE]27G4_CWD.[IG];5
M,A*0;`MR9$J*5VP8!".\1R+%,K9I10BB;%<3U0,0\P-%*EPT7R!I@_%_8//&
MGK&0?\WP#'J/-JSMDP\W5]=/C[4HAIE[G:3^A8UO=7AHF]+.83(L5_W.1'6:
M:]B!^V->4\F$\]^&$$C=64WL?W%E-WS"B?&(L7,885K[G?IV8YC'SWG&ROU0
M&RMO\RI*^;^?YV7U.:_^`U9?8)S?9>@/F/"'**J(53??=Q\!ZTBOTEPM]8>E
MYD4+,-9%G-CG%UWSPQ\&.UB!_:<7H+,5]V^83L$KQ/RZ1^YAI][W>9K@106[
MG[@E!:!4A]M#K=V?80_R/'A`5+=L"C3\1AN'<!@M5[MPYJS3N=LD)2A!4;&[
MB5)XM6)GX/I$-Q(:+TE*9/P/)2EA;;&#PZW)^ITYNE!NIK6C,92FQ&`H'.)I
MSP:YTKM:<<D]]??/!L3N$68BD0`U'EX+5@(`_Y,C#>G&V'C,!/A9#IC#I";7
M5])[W8$V[I.5</P)B4FNKP*X9)5J4D@W,JQ&AP5#"O2`]UW7:133,P/MP,L(
MW!<0D7$N%!)A#4';,B"`J-4O%!8QT/WHY2\I902_Y9DRI*/?R.EB5^!0S$K$
M&@0PP'*-\@M:E3I'#^1U`1_.EL5EJDZT(#9S.I@#7(J&"Q\`;@-PHT"&5*9;
M?E#5BAT?O0V3J"A+E$7H$TQ0C/?(V`7`0AVFK2%R&X^MDT`(O*8$)S>$`M0D
M@-$$@@>S0>D$4EN,R&BL?"[6OR+TO_!.&65WY87.%<B;.\6'@NL^,CY_^01^
MO;@`36-PL0"7E^>!H$*G?AX/9KH?GVR%'I-<K5:07,:1/4?9!O"K,[`8$+I-
MRV(BB23.N*&B1Q<E]XHC#+R8#U(GL8OE"+G,]H(WM1=EN87)>WH)S*X8Z>EO
M^1E^I7]2IWTQZ\!#_A=#R8;C\Q@E8*1M-`&C7@!,SUK,%7!F&K<W5DCR!Q(-
M28YK8O8$L&2'.!FD-_ZH:1#G956")P@WH+T^];\5LP.MF!G''K&N4^0P]BZR
M=UN\_(!E>9ZOEW@=0@Z<VMO_]ZB,T[S<%JJ;]G'=>4JP8RVU9`ZI;1=#MND)
M<%WQ,4%@WYU_6!\R],,9?`X9]]'KF'V'GZ(L8O$MY.W+V9)D*HTKR2I&3^9T
M#6,@11]]>Q*PIZG+YC5DGI<OIF/#+U[L!F8T;/:=EZ1WU87N<%.G\)!PVX?$
MOMF?OG_U]B]EC880+G-5^N:'7Z_L\><D45:1E\G5'W<DHW%"RQ:I#TE4%&Y/
M2)2\"\<CM#78-Z]+3@6RJS$8B,[!B.DH3.4,+O'L=5'!M2PQG+RY3Z?`<VWH
M&`@)H#1A>0=A`!0>0J)]=TOH@:5-J5A\F)$Y7Q)KI!@,_.ZO:<L@%AXVX])?
MQYH/BCM\G4<ER:Q/_H\LLQ^B5)&WTH3(.;:4$HAS5\F*+=`?N/;!Q!/I!Z0/
M*]/1<%F'%X,:Q15,AGD;_JTV!N"P;CW4]CU("Q;0#28L:8J!%VL'3S7J$Z=E
M51\!:&@"2,(JGW]EN5=#F("-QT.?:-7SU/LA*C)R^78-"WI>:["LDY.X/^64
M<R^<9-9-R<U#_80T!"29CH-P'&DT"!Z*'%RMB!/\F.9?3;8(:C)_)0Z&I1!=
M5%,"[FK%9D1*$12P3`9&6NI`.RKN`/895H27ZR)_0`E,WNU^*<E!_-4&DF)=
MV=U97*$'5"&CG>F8SIR#<93$0K`(K!@RFV[("_HGI"=PD3T%;6=@WYL6OJ[N
M8B=1`&>6'[%Q#$K\DW\S'0_OOO$>BFV'KYZ3_]J6%3WFNLW)\[8L1BG$_+-"
ME)=YB7\_G='/\SGW+ZKGT9KP_GK_&7";@_9#@'B4N@3J$_*QI^3/P;D8H_Q"
M'E19Y:!H54DB0U+\$?);\G-,M+@MV4U[WNHM"LE1S6FTPLOXV2W6=RX^U=)8
M0A!(1KRAY;`DJ5V(F=AD!PX#V5C\VYP:.V;YMZ8\A6)1,!_SXA,VQ[+*,UBG
M6%'6F5)1N3^)4LHP?!:%6!34*B_`NB$"FYIJ:I"_97)D\(ZD!I&!_&C$L<GM
M9"W/[3WLIVAJ$C$-2R?F9_*=.LG,K(3C1%.;<C?/O8?[/+B*V:W;S/F<UN-2
M"#SC_NQW]CJ849?SU-#8]V<G^<`[?.2=Q07$$^1[R/Z?6S">1QM41:G!=M*F
M$_?/Q&TD%)^2,B+PI"%_2G(I[C=R=1?!'!0=).WY/<D95_:V7&4)*Y;5/$71
M$J6A;+_LH2L\NQ^)6Y_F>5W`3822]W`%BP(F=4JTLRRY(CD2S^A@69FJ68<!
MF*VAY(8F7/?69,ZC^*8=`=:3GT7LY-(W8D+6GMDQ2Z<9;W%'654;>(CV;(-U
MO6W;`_V`)`K]C^.Y/B]156H-U8[<<>(%8ZFD1MC0$A-LJ`.QO0-%[$C#+$QE
M64[VCP>(0S:2$2E]2W3&CF3IZH#?+V*#R@NZ2*@S^^*%PQIOO'8EN$,/,".9
M?DN(_0RJ=@L0YVF*^RJB=`'(5C0J[G#[I&;H&3A+RQSW$*?;A#R#Y#Z)F@S`
MPJHDRROVIZ\(8XH69&!'QH2]*OJ69_EZYWE#:^L,NIE!QG@"G^N3LSC.MR1:
M.]I)7ME8T`:PZA#E,5Q@-(2@I@QM7Z`7K)5@HY+`[Q)!`C?]:D")-<\&5&SQ
M++7?:]G:D$`>AAF)4IE;$J$%''&`QJ07KY$CU<GAW:0D`#2R*B7Z0@R2FB0X
M*NB@J&F"H>8*3R!YGG46-XVLM7@6TH49]W1XO%-@5LD*74\4NJCL+!0K54ML
M::UM9T<4NFBG@'[HXI#$`1Q)CX>WH2D;8]MAZMCZEO4V/XO_N44%Q#QCAU/M
MR'O="F]3R2N@#6FB,&6;3MRGF+614#B`;>[9;W-0DX.&?D%?9E<+>F34=N+W
MY/DP8>LG/26)/MC4A%0ZJ);.:;)=:\`*"7A'HC7$>7:2^37H>76:^33`U:^E
MK,WJUURZ,*?.PZ?,P*SR(\JB+)YH]:OL+!0K54ML::UM9T>T^K530'_U.R1Q
MN*M?`W@;FK(QM@](FI['$"8E47.3QO)J=4Z36-(HPX]YP=6<PE-]\WKYPS=8
MQ*@<G%`GZ]EQ:O8I="$&)+!>ZWU<DPF4O!IEJ4)91"[NNU-!C>:T:A^^MQ_P
M5\-V9NT0Z]KG2>TE4J6AO'7Q4Z8=.+-"3"Z;Y]$(N8>FCX%0ML(>D"F&W.Y&
M28)(/U&*_\Z"\+"?J@JTW%*55#EMAIDF:3L%C9%-R=<&3ZWZ/%\53^A^NJ4(
M)O8];O,AL1RZ_<L&Q=)(1>0E'Y)4@L&9OJ[4+<3,^-R"6$E!%FQ)$^B#,FJ_
M_I<G>B@-97(RP9'+6H.;34KS$41IDX_@(L/.;<VJ/ANDF3#MP4,=0E/9Q*J$
M>\I]\@G`$0>S'YA(R(1+PT<6!T1F.CVB?5\![`@LX2J69AR!59>Q&Q7$`U!=
M1RA1QFCPS3S$8G2X'"B61?\,R-]]AU4H.:6&38.9R6(.U8W]@WP(!F*DA`P#
M3D.-\C6\C;[!4HO87DL?`40]7@=BA4C>!=HD".SJ&.["MR(M0\#N("8&`GWD
M@'"'X*OB+LK0'W4U\*S,4Y1$]8[E&@]NLT&]6M4G15':YF\J]TE>;^&WZAUF
M\W>%"4S_*><V-(.V^ICF/[$`G8_0#3;_&7+$TWX([+_$I10&OY&/`?HUS^NT
MT)273Z$\EYYE+EOMNZ9Y#=5A!B@6.?EAO4GS'83O8`97J"K/V2,MA:?2$;K/
MRJ231!87VU"`A@1;!2/RZPM&"P0;@98UB7^S-(.9D'W(`F/N3(:+,M:;R5!C
MYZ8QR'$?/5RCU@`6X):<TOD\`33BG7+9,*T/V'>)?#E:^FC70<5AP$">M4_>
MV!J\?K6JB@N0T[B__E?P+QP:<VW;K'IU<TE=0#?`MQ&"X9^]9363P>D%O0Y.
MPCV\&99\/I=JYJ0O,*7AC2.?3:FZ">#YE%)*DV=4*-LOK^I.0GY/925OP,NM
M,7C5O[(R!6N(D6V31+0%'<DV301;@/&F!\AJ+F&8`6N'!ZI-F73R/D\36)2L
M#NNEIGZ=DL)]LDDI[X.9&>O6H"Z^&TX-.X-Q$#(4F@S":&#4D^`Y;H?B*"5'
M8=N4K-MN8/&`8FE<H@&=4Y"8R"%;`#1$8$\%&C)_D8*'2!0W$L5[B<IY)3()
M]1LC$@OD*XH=D:%-41H9"-KDGR#I9/(,+*.4!D66]Y#$&>$5D.>H/6/3XSV"
MI=UYJ'#),LN<9?SZ\A->@&X+F%QE7TA>'Y()"#?`V\2B^>>[J$0EH:?XN87Q
M?8;^N86EK.:RF\_ZJ[`YCQ85%3KKSNG]Q@*T'Z!72OPG%J#M'^P_X+]^M$L<
M2BN"S@Y"#_:L%H7R_DN6+XG7)?Q>9)MMU50:8$EJW^V:/G;G:526K,ZAB5'/
M]VU_ECVC/A7FO=RUYS8[0*D"JC?I#&M2PW4#M*.?C56;1G>??BRSLFH;.^',
M',3FUS4P'4W14V_'Z8:_>44CK:0L;>G^7$;@=;A2QK[V+&L8PC',L)J%XQ>5
MCAT7/[HN4*S:#/&-_!0Y:C@<+&P$Z%\#J&4DX_(\S4MZ@D`QNY%SZ[QT46?D
M!\L5#0R[G^7&=DU?`Y;DRI>4^WZ/R!EWEGR)*M.-O+H+K]._1CK%-,X1+T!#
M#AIZ0#KP:QH'B-F*D]3M`KBEL<6D:L5@#L@P;.[7/,4+%;(7.<#J^IT$97>"
MA-:6M^\A<-O3BMJ*]-"V#-O\AN%I8X`J;/HUP2^H_/UC`6'S=&N$`0YW$83Y
M2:0S-3Y"#@@]:-\/AFE[AG)2>59$GN9=(2BD\OBV/A4R36Q/#\LP)K];6*Q'
M3GF,-`A+ZTEC/;T1NO#L2B-5RWV*5O2>MTZU$J9!#0'.9A(3T>;.@/X.T=T]
MYN$,#V9T!S]OR>'&U8IN):^V55E%65*?>\5G&5[PIEO<6F%68SMT;FRC)>^#
MM>D(U#T!UA5YL$@[*P'7W0+0#NFA;=VES[KMTRLAJI70))RB!SXG8-E*G9`^
MT`,$3U#]YW*N^'Q#!S6?$C*&!%)+ER$AWW<G5L[%:NJ!PTA-+MW?8>ZB[Q2G
M\!6CC]CWCS<_11G^.KE7(0EX5<^[#>F<'K^;R"$4&]L_^]T3T6S2+MY0FX2(
MC9'JML[7AJ7:)[@!1?U<H<HY6?_T_:NW?RFIQ)ZCOXQAR%](6&+0PWI\SV%I
MDB]!0^=O)2Z10[$,YR@">U-O-#C2A:M^9$:[XD^DZ-^GJ/@=5DU=+>6=IZ*]
M4]>KXKN/$-H6L,;[XFYA7(-J]<_['D/EN\WQ2(+B'Z*4A$:<5>=UF#"%K<+I
MZ`B]Y'I42C*8%(BC6("(O)ZIHZ0IE7^W8S8^0\D330?GL#"+INI$<\&O6P#J
MB-P'7Z@D&([#:"BX@(PPUGW6\F@7?1*!/2_[S)`G!*$8PN[H`PQIR+/5PG'>
M[S^64$-!KW._!`!AKH!=H-7EZX"I5^0W\3U,MBF\6GTH*[0FOK1E_VI5>Y\V
MT%EKK8=WZ792/4QZ8<JMNR,GPFV'@+,T_'LRC=4=<P'ZIC;D9FJ>5BNXP3:-
M"G[6SE<`MOI9$?VT#_W(*6E]"=06P/5=F7T*(^G,\)-9R`1V7W^N?H%N:^(:
M:D_6K)-)9;B-<3;$[FS3X(WP!"+F/D6T<S^V,@Y[FL:;1'4WP3@3(\L;]AL6
M9C>=B^!N:DCM0E;R@WYYE,\P[LZO$S&7VL2K<+VQ:I[[_L)V-!.H(0],#:.<
MT7@]#'@G=GI1DM.+QDOE/<W`_1="<UR6_D#IR48Y@]&NK2E71-]0G/[X0GD)
M(6OLU"U).18CJEA#T+347#VX<"8CF0>GS[3LNP*_&C$\M$W@XK#JMJZDE^+(
MS8#6?8UM`WG4Q?+:4H)YMY2@W]"DP^62%0'T?QAGC$&A?K8=`!T^SHS(U$59
MZ,0RE81+DMCM%L]I)=EPB`L+_J6?53?N'WC:22FL^R*VYJ,=+)I@R;P-EF2]
MD(RC7#_^T3IF;(4'FJ,'U@N&Z51U#0O*HQE>>R0^L=GG7H-#MK3`[1D.@P+<
MX$`HP*48A=%KX[VC;>\>\^8V4K=RL*1WNH*VD4O(E,R5'VXOTF_S_67S50AK
MB<FDS#DI*TY*-RLFDVWY(6*VHB$V`6$)-XV$_,+)\W;;V@[Y3<A((QQ_5D@<
MT#O<>8+[)IG?66D=\FD6M/INMV]R'>W(K\Z^1D6_@##9[+,94W:*.,.'W)XO
MSJ&IX>P;M`O`?P9PWR'IEOEV];<`_9A00IT>R;'O>3R4=*:[DZ5:=\M:=W6[
MCNX6K?(6[K1G=);I0GWD?GO_&H8[O:Q?"+6UU*O[J`+K:`>6Q.UF>/CI@YJR
MN00.+GWK?#ZN<S(ZLX,;[>('^M?M&\S(G+I?`RFDZP7>F(UV$4ZL^A")>/.D
MV8_(`S5FJ)Z-S11MO.G806W\!@G[JK(BP[+_X`85=(S>8S=U*ML8Z>G<;H@,
MY!!+QC0T_`JAH0*4S./F9QZ)?.YS1DC$<4]F32X$H@3W,$U\[VM,S:>SG[&S
M'8=O4DCJU_TM9O&%/'3E+C,5IVEZ4O?O4O32B"GT2&IA[FH_+P`E6_"7_/Y/
MV4P'2GB>8C5*[H#W(2HR_/FRF=Q,8N@5-,ZAIN)?\&AUV_UZ*[`'E]K!Z*/*
M<"0<EA7.*M0D;+@AD>@T6/W#MSC=)C`A%W!D.[)M:B3W^3];D_>!"NA-U+_[
M(L43Z44HW,+U"_8=@Z9G=J?+]4U<K&@'"\"^X-\$)@604%=X>O0XO&@CYZQ7
M-!.0-,Y(T=;]U=H`OX)'9G6V6*L`0G2TNA8NT=2*=ONH^6.:?_V,!<0_LH4N
MBX(;J`ZW?YM_MBRK(HI5/O?PKKT\C#Y0&X-/ITF?"U#W"MIN:83E4,U!+KD#
M^*WIW%,$W8RZN=EN-BD]58Q2/BYUA1?Q69Z=4&TADN[^)_^V/96E##U`G\Y,
M''J._2W>>;1!>`A9C,D72*J6X&DQ+SYN*\QH<QFH<A7V?;GW#2/D%9P!=WV]
M`'4W34!2TQ&%/^NJC18,`/YCAUO`^V%C;0OP$L;/[O*'YPE$#-OXASZD\:_^
M\;X^#KO(L/K7="5WJ:@^HR=Q!E`#[H6\7'5SP+4/I'"+Z5@TL#(;""P!DPC_
M_G?\;_PO_`.Y/:4B_G]02P,$%`````@`,(BK1JD2HA6T+@``V"X#`!0`'`!S
M>6XM,C`Q-3`S,S%?<')E+GAM;%54"0`#K!A15:P8455U>`L``00E#@``!#D!
M``#M?5MSV\B2YOM$['_0>IYM2Z)LBAVG=X*Z]2C&EAB2NGLG-C80$%"2:AH$
MV``HBV=B__MF@3>0J"M08"5AO73;=%6AOORR;IE96?_XM[=Q=/!*THPF\:\?
MCCX=?C@@<9"$-'[^]</O#U<?3S\<_-O_^A__\H__^?'CP6\D)JF?D_#@<79P
MX>?^0^H'?V7+^@='GXX^G1ZP/QQ]_.[//AX?'GTY^#^'Q[]\Z?UR\N7_'OSW
MZ/O_.[B\?SCX>/#CQX]/(;20%RU\"I+QP<>/[#L1C?]Z]#-R`!V+LU\_O.3Y
MY)?/GUGYM\<T^I2DSY^/#P][GY<%/\Q+_O*6T8W2/WK+LD>?__?W;_?!"QG[
M'VF<Y7X<K&NQ9GCUC@:#P>?B7Z%H1G_)BOK?DL#/"U$I^W4@+,'^]G%9["/[
MZ>/1\<?>T:>W+/P`,C@X^$>:1.2./!T4'?@EGTW(KQ\R.IY$K./%;R\I>8+?
M9G$AY</>O/J_7B3!=$SB?!B'EW%.\]EU_)2DXZ+3'PY8L[_?76_T'IK(7TA.
M@T>:1,DS#0HV/K.BG^6M?8:^-NOM=S_VGPG[PBCRX\R\@Y4&FO?IRJ?I'WXT
M);=/5S0&7:%^=`U:DQ:2J-%'98/-^WQ/(A+`N#SS(Z;<]R^$Y(V(5S9HH<]Y
M$A0C(#Q/QA,29W6[*FC'4@]'TS1X@=;_]-/4K\6_H!E+_7M)HA"FW\N_IS`\
M+\@3#6A>LX_\IIKW\X;DWY(L&Y'T_L5/B7GO*@VT/F(>_,>(U.%:K]FV1D_M
M;DM;:VDD->JLJ+'F?3U/XBR):.AOT5BCIY*F;*Z=&5O[+DCNTRA[(&_YU(^:
MK*3<YEI?5YOVW[#YUF>0Q0>M3R&K=G>%X*@M"$>[PW#<%H;C]N;R^@HD;Z[E
M_M91%T5[+?>X]I2CUVI+JV<S]1"VUN+Z.8*MVZ);=:2MVVZ[\JZKWN+FVNUO
MG9E/WER[_>W9[6^O[?XVFSQ4C;9X1K32?YV&K9\?F_9<T9S=&?`^A_\6.]#;
MI]L)LY["$M'P*"%JL[V>G_O9RU64_+#8\5*3S?M]FS[[,?UG(8AA'-[X^30E
M9>'`CV=^1N&[HY1DT(.:QJ;:'UIAG)1^_@:0-L""#I(X).$2+ONF'6-M85:&
MST=)L/'%B!FTDU0A7_C!DS4_?,R8(3]?-A/YCR0J&O=TJWJEI46WGPO!%-;U
MC`2?GI/7SR&AGZ'O)^P/#,3)Q\.CA6W]7^&G55^VK3*<KLN*>[V-[I99'::;
M7??38-DX_+%"Z:9O8%'B\Z38U'P,7FBTTH:G-!F;"W71E40/TS2#WB43]AN;
M#),4YO=?/\`V!1`^D30EX;>Y@(0(BNX74FQ&Z).?/1:M3K./S[X_F;-*HCQ;
M_K)-[^)G;S7-G$=^!B.Q6*J&;S3C<*RLXPWZIRZI5A&V2:\F'#[+QWO%<AG9
M13+V:2RAMUH8!#%PR:LF4WQZ17#XO/8<\-I@.H95D5R#3'C#557%.]F?L:J#
MA4_H"6)"YVO1'7FF;`F*\QM_+%I;>46]HT.$#&YP4F51"(1/WQ?T])T#_)39
MST/R]A]D)N5OJZQW=+2O!/*0\!G\BIC!\VG*!'1%L\"/_I/XZ64<7L`:(R!1
M5-P[.MX_'J5@^%3V$5,Y5\LK&I'T'%`\)ZE\*&Z4](Z<'E&:#,0J#CYWIXBY
M>TA]%D1W/QL_)I&`M8TRWA'&O8N"KRH"/E,#Q$PM)O]D/$[B8D==F`6SVVG.
M0@49//GZ)ZGH'7W9/TXU80DL!8>(F5[*X@&:51PN6!%O#\G;[K^`)1<&'5V6
MAM#_D&&XBGS1T-LHXWW=/YXJ``1$N;#)F`ZG$4EI$LJWF=RR7G__B!,"$1"X
M#\:7^7YYCN@*?E-97BKE/:>FM&9$<L$(R,1L>-G$PPX_^E2N2GL8;=U&1&Y`
M$=#8Q``#4OF\[<-KW[>W?<_!@CL/I!4EV30EFVVK7'F*:M[@Y-!<WXUZR#SU
M9]#,7X9=7-6#/CJU4>G+<5/9#<#9=^.YT7O5W1FC<6#'[[3JTIJ*3#)H=*H!
M9SU7;C1>OV0C3*L>`')JS-`7.M^_I@&N*R-,==/+P0@K!]FLPX?F$3?EJ)K2
MG+".+-(8BE;:]XX'KH;L_70RB8K>^%&9-L,1;-*,UW/JEK//G"!LPE0DEF:!
M5Y(^)AGYYGPRX-^E=#`'K"5^^U3NRQV)6"3A>9+E66&7+'H[\F>Z@[]9PUZO
M89C:#B1R5NZXSD30L&6OY]319)%8_J1@0SQ=G"<J5YJ;'TJY[2I.I-(ZL%>K
ML4SK]TUU%I57\@9?G"ZKFN*KGD)U8'5F@RR\&N]@6:QVYB;)B<:R)Z_H];XX
MV\QR.[:><[5VLKIM>#VGKB(#,@3[4R.@'5MTMK-`.!A^EWX:T_AYU0>-@2>J
MX@V^GKH:<]M]TAECPCH`!$4@M5S0_/&D`-69)4PK*\F[I4=@+S@Z/'&V.@8O
M))Q&[(H9L)LNXAN'6486*4^TED?M1@"JTYB7%G@3+*2&(FEM*=V]2HW29$+2
M?,:\1L7E,=A'3(J0(0U54E<&>:'88[6N0KJBL'37JIGJ<$^TPR!(IR2\?&,F
M#:*>3Y1U`+#3B)[6N=>4@/UK6)C,P>ZV"UB-PD>'UHQ,*SMBN1M#9F"9^_K/
M9A53X_"'GX:WA;:QZ^=+<\P?)(.NLXD)-)7M_AX2]E,IC+?X-Y(&-"MT6&?X
MH^F?=^3VHIA-S>'8UW")N4.[G_7&CR_C8LI;2C'(Z2O-9S4VVG4;!WD[#4UJ
M3ZUMRZBU;14BCTJ=E797?I4O1\XCEN;'-9B^OE'_D48TIR3[3GRFM>$MJ&H`
MI[KY_':3Q.GRKT5Z%E9_OIDAP4M,_YYJ;']W^GT0L-/[EYH:H`B?:E]";O.5
M\`?;:H:[S'(Z9O-E*8QQ(<>E0-2+2],F04[.<]48:Y(=T&[3G"B48P%`>Y-A
M4!O0.PV_M$"Y!CZWR4[TV&UXVJK9',C'J1G7'O]&@.TG2W&S%Q2G#7<2<;`P
MC)6,9:,DHX4JZ<0=J*M[7_ONH@\6W1/E@.,7]+XZO2=E+%Q1-$$%4Z?2O]T'
M)/93FNBF?BN7]W`XM3D4*;BL@.A"KK<EJ-_C;$("^D1)J$SY)JSC]5%8#L6,
MB0PG,CQX,K]9&+C?)!G@Q(6]/@K3F?F0W42`)^5;?287YW[U]F"SH-=W:O-0
M$,-GD8/`4M8W#.;R.;IE>(0NGUOEO3Z*"P(<IF24\D!8R@:7D]0QKRS[-ARH
MV/]8W,*K'Q7V^_P<CETS.&P51A8)SUKUO3Z*2Z!B.OGTZV.SE%$.PT`?I63B
MTV54`\`OXJ(V1"<-"U+6]OHH(LM,E4$7F:4$=>YG!EW*MT2`(N;+E-PJ!DO9
MZ_(D]R.<47XW1#Z0Q=6\/HK@+NUE7(G%5@:[%D+S+LB$V7&RS0GG)HD#X<#4
MJ>;AR'FNI%`;BZWT=AB6X#E`Y93KG:(P7QCNIHM>V\IQYWYZ+?FS03^KU[(T
MCDJZ37BGN,P:.H=B(VRV$N=A&,,EX/J'9G$E[Q2%0<2(3J5&\##:RK>'00>&
M09!,V3.Z_HQ9`#6VTMP*WBD*JXF".,&<+T9D*R4?$J;958"JB.1D\^MXIRBL
M)77YEH`24&YL-FMAG[T5140);__%+^B=?D6Q,!L1)H,BH&DOS5G+2SKC293,
M"#DC,7FB6F8-:440%+8%V7B02J$)=,#8CH5!!XRF9=[4A<)@68MJ`1H!NWMH
MWI)/V)Q2H-[(V+2PDRY`">([C*U8[DEE3T[0?'Z3)`[/DSBG\3.)`SG)DEK>
M*0J+I07252`%2K"7=K!:UA295%'$ZEE0`@5&@0[L^*:Y-7?DO,<%9I4WFE/:
M.T5AZ590)O0Y<N$("-Y+0UGI>2%EK,%646^`P@!>BUHN%@&O^VG\"D,Z!S+R
M:7@=G_L3"ON*$F[9X4M9V1N@.'/7XEX3G4`;]M)`=D=RG\9PYESDV8(CZ'0\
M+:X0+Y,HBK5!7=D;H#B-U](&370";=BQ[:RMC9W1ALX;H#"(UV);@$;`KK')
MS?W9[3N-DQ1@7<<Y`5YDXWJ[J#=`8?BNQ2L7BX#5/0P&J\KD.@ZB*;N.-TK2
M@J`\3^GC-"^NXR4L.@/.IM![Z,JSAB[8^8`W0&&JLS0SU):`0._VV[S'/2PW
M"*OP!ATT!(J1"NX%-;8.NGX&+6-1?1=L#Q45B<>G@`[OHVC]XQHW7+D]W)*`
MZ-JJJ"CTQ*DU3%]:5;^E&$\7;JTN,BN-_#2?/:1^G($D6`ZDLUGY7Q176?4;
M`<$Y-9#)"14=F<S0=>'F:QF9\LIKM;#7Q_%PDREU:@4HXT.8">3<CZ'@%<W_
M^4Q2/PH+K\UW,GXDJ6"ZEM0`E"C,7B+Y5^=J)1BWMUQUEM9ODDO(LN*`SWGF
M+MV958W#TEU6QW-HRU;($VR$;Y%8WP)Y(E2!QI=>W9P@%`_*-CE16,YN:/%Y
MV7[/W0,&-1/L]'LH3#IJL8JL.E4T73BE".Y&RT\EXDH@&!36&!Y=`@>N`DLW
MSAR@X)3EBN:CY?\JW-S::!:$BR*42T6_:*5MBASA">=[$I/9=S_]B^3+ZQ[2
M\XVP/.PR4'#;G"7.YEH.N@NY?AIG;>JAB,_37P)$&+IP5&J4$$:2+65P@HOD
M+>K$:[T*DZ7#4>3Z7*1X(FYQ+GI_(T[XIKPU#X_R:3+!^JJL!WU$,0@M"KRZ
MX&I*H0MG,3MY3H_=^X$T.5.LQE5473B+V<U\>HS#&R3A3$"R'!'"TU%5DU7^
M!$D-0.G4_U-[D&KA0N@*VLSZEL')D("DV.GO@KR2*"G22`EXU*H+R)W[#)3$
M5+DTP&;I-.0^!G*!^3K.IBG;&DLFWNVB(`GG3Z\8LBR'8NFT@R$8?5.535-<
M+F]5'_><QBXW)YB'IT-I38VRF')2>QZ[]4\TX%<$QE:B4A3QH'I6BZ-WLX7P
M%+UE?-WIR6:YH12_I*WR&6LV`3!1W`:VR)GHG&0BD"X8080XSV8/\&V%242C
MMG=\@N/,;$2M:,W7A-L%RXE83/!EI0U%HS:("D54IC:KADJQC;0+3\RLP"FC
M%;9*@@A0W#769HM/-A>5)0-,"^GYV,/0TQSVL7%X^_1$`Z+F3Z<:P$9QE;@F
MF?H0._02S1+P??*4_P#I7@-=\3.%%:\XY"C'LU9]D!J*N\@-1[D!5A06'>[8
MA[:2E)6=Z0UZ87D`BB*6M,%H5V"S9+#!N5V3^4WT*X.@<$2:MKF-WT)KR=2#
M4RU^2Y.LEDH4%4%`*&(.=:DT5(021DLOVF#8`FQ<4('N!W1AY9M$9&%%&8Y9
MSH2YA44H'8G6V/H$R!Y%K$TS_;(KC<;/[0SFJAB39]8CQ]XC^\\K'9^@,%*V
M-"6M$-IZLF>?/!#'[QX(H37[RY&E`\-Z:[7,=+X(4]"+FN15@MZAL/I8%'7U
M<*$C@BZX"E82.8_\++M]*C+FZ,9,;M<!L3@/[=`A3N`GDL/J@OF_C$QI[:\6
M!D&@L`0IF!+8?P1P$,9);FFN[+`O*P[XG-IXZ@U'-2*$L9&+#G_WX^D3K"K3
ME,;/YTG&?;E06AX0.@^ND4M?R)8(#(*@1QEG?\`^-TE'_JS8%\CYVBP+\)S:
M2QIPQ0."U^J]5#`:D2Q/8K)X04TQMK9*>Z=NG^IM,K*X4%!$),KX.H=R-&#)
MO.-L&K''.>Y)^DH#X7MBRGH`W'FFOIH<JD!9LDLC,4E:?`'P^(OSNU@FE&L"
M:NE-=4?V'K:G?O0ST/)DS&3D^GKL.C'-[5.Y2XM<;<7FY/X%>"\ZO5P&-<P[
MS1KVCK_6L.O8CBPM^G>VS=:0O7^XR)9U-EN766`8_O#34#_TM.$W0%`H3$PV
MZ!88&^R*J@NFJ#L&6)7+=5D&8*.(5K+,(U]9ME!WP1)50%)G1UJ7`N@H;$];
M7$@(*_>["V&BWV$#.YZ.E:1ME`/X*.*,*HSPB>/TO0OIB+[[;WK4E<L!?!31
M0;K45?O>A>1#JV2+9[/E66)6F+(5*Z6T'H@'1:3/3E9/#4G83UCD4%%*1\[O
MQ&>;U_`6=JP!'#]I_`SRH]GO<?*8D?25B>XZGDQS^.<D#J!6(?9M02E=1:U_
MVQN<HKA6HJ%+"B5L5T)N@U[Y$0C,./"GST:R(ADBIR2@0G$0W!%]G#@$D4RZ
M$,>JG/1%<[[,(VJO<1`TLEN.+:Z2ML1ER;"YGWJYFB:&638=%T+(F-68!<-=
MT%<:DCB\\W.I#:WM;X,2H`BIM*5PEM793(R-PW<1N6U:$=D?203-L,7.A=YO
M?MT[[N.8S_=/\WF"M!6SW#G=OZ/97U<I(<MW*'>I^;QO`UTH#D][I/=B,0JT
MWMCZ[CZ'V]IQ)1?8H\E$\4#2\9%*V5OY*-"#XJBX`RUO47X"]3;V5%B/UJLM
MUMM-K%=)^D1H#@=W-J:OXQ%):1**+!*M?A0DCL.'V8K&[DI^`HVUD*D#83"-
MDZQM:*-I^E_>HVFTS#Y]%(X\&W2W'DW3%_H-]RN:9CZ#7L,T]`8+?'(-J_[J
M$72-)'`ZU4%87?,B]H5W>/4%TH7P'!5:I4=0KP$0&(J,`/KDUE..,MHNA`)=
MCB=1,B.DV*O,P:MSQXGJ@%A0&*1-2.2K@0(BBI1R/X?G[KASGCOQRF1+7%V(
MEFIZX+R=YEGNQR&-GV^FB@G-^K>`AJ[8:8];L-/*Q68IA&M26!;N<S_-]W."
M74CIMR)@1&+>:N=#P$57C+`MJC!/9I8BMQ"X%=CFI]@\A1?%5?`YRD(@66EG
ME%V^D32@&9%JIW%C(,VN&%5E&EA3+DVCQA!E&VLZ"-<VY8REY'J;T+1H81>3
MIO+;P!:*VRZXYU%-,38-2>N0TKO>WZ*X"X1;J05BLQ5I-M_@7L;[K<>+98T=
MC5O7X\JW@!`4_A3<>BP0VWO4&'>H_TGH\PNL+D/`Y3^3Y;9ME%+IXXH[Z@%0
MA\/3@UKCC81I*XYL;PP60@,G]U#<UGBPUPN@$87ORO&8L"U06P%H>[$^J(2W
ME(_S86'4$2`2A4,/^<BH(5-;L6X(K(1M'_T=;:@:]<L['N!P6Z+>9ED0L6`<
M[>%#[#_1$63P[ARU*TS!**CI,^V02<G12-#L`9#W[F.U*TS!2-AQ+EW'U[J4
M4\@=80%P17+ON`C)GOH1NSITK!H3N^T-4/HS>(!="58P5HPSCX3D";["FOEM
M2D/V3M"^CACQ5",292LW).OW!HC]6;S-+@0K&#%[^=R@Q0WJ-<B*QAD-BFNI
MNSEA;'X3Z'EW2#<5G^"Z2TW']!XX,O9,P]\==TW%)]!P8Y<UHG.RG65P4U@[
MVM1L?10H^EG<<"W*3Z#BQM[H%AZ3L1ML7?SMPL_)*A]&2ZD?5)\%N7?82;8[
M"0HTMYO^XB:^=BW-=]03KW?X[OAJ1ZB"\='-]"@/T#2<O=^3I*RS9IP<O2=)
MT;IA>W*$(JC7!MV"Z<>NJ+J0)&44^?&-/U8E0RD7`_`X3M1VV>2K3!5X%Y*;
M+%$IDYAL%@0!H#AI5DF1DU?N/<+'KHL%G?45FC]2OP^P61)0H3A%\63-.1&)
M`*#(#*)DIZ_-3G\)[AC%MMZ<G0T`EA)CM,O.T:$N.\N2``Y%1)4Q.YL`\#Y;
MW?#ED[T;.SP`;A^DL?16X7SK/?+3?/8`"#/8:+/S^-FL_"^JERNU&P&UQA'?
MM8L=IJE8NO#L31F9<@]:+0R"0!'?9$J=6@'*^-R^(\.=SY?IW5C8^05-20#5
MY/.ZI`:@1!%S(Y)_=8Y7@K%U1;TMSLY!.:=1KER-I74`*HJ8D7J\">#8NI3=
M!G-:5*W`H+#AF7-3[K^MF\$VR5CKC92.[6(`"(6Q3)\0/@);EU+=YD:</F;D
M[RF(Z_(5_J.1!%I0`V2"PA"VDPVJ5`:V[F-BTPOEKE18!^2"PB`GI4V;Z3(F
M6W<&G7)]'0?)F-P#'<6P^,:^Q(B1SP.26MY)#X698B=S@5(.MF[48=01Y9P@
MK0?R06%L5%)HQ'P9FZT[9#:W;;^1F*1^!!O_83BF,65.XIR^$O:N3IP5)X([
MH`%$^,(.=>251,F$`5P4D&[V[#0.PD-A[=)@N+I;M"D"6_>JW)JVV"2KLH0N
MRP!N%(:LW1@Z-U';NA/DGFWEPP^E4H`=A]%KDPP)8^5^V[KIXI2S[_X;'4_'
M2M8VR@%^'$:O;4KXS''Z;NL.AUON8(G1XJY<#O#C,(II<E?MNZW+"1:XRTCP
MZ3EY_1P2.J<-_K#-%OSD?2//?G09YU3H%^24`K0HK&6MKH="W+8"^7?(\AR"
M\&"T701P.K6;"45?9:C:;5MQY%:MTN%3,DW/:)(%E,0!RZ06R.W3P@H`TJG=
MBB]TCGU:@4!`TZZL5'Q/SH3FR43AR"F7\4Y.G!J5=,G@=%H@__VR`*U.P?/'
MS]C<G\1%F+G"7R"K!_)!80':C==`+0F!INQ7:-06/*6-D%L>Y('"!*1!&I]M
M"2H!R_MEU5D$]BG/'1OE`#\*ZXZ$'#Z;'!0"%IU&(\T#8J=I\`*STS+T<OC\
MG)+YW"68JW6K`G`4III6IVLS80@N3SB-;U+U7C@CZU<&\$Z-/V8DF1-<1BF@
MV&D@%&C[.(DW4`R7G?^3YB_W-'YF:1U>2:8,2*S5%HC&J07)E$3.J:D^;(%&
M.(W&$@-Y@%J`(X.SRW3>93V]:-`BB,FIU:JY=C0&+]`1I]?J5"I?0TF:-`F"
M<FK[:G\.4:,7J(E;$]H\WA'FOQ68JR2]HK$?!]2/AN$KS9)T=D_25QH0E7[4
M:`M$X]3P9D,Q:L,6:,1^Q93-M]CJ:-*-<M[)EY\G;HR#7,#\GMD):XML+9$X
MU+Z.W\;G@`T45DF.B@@LBZT)0:"23@/8RD\90[>+OPXGT!^868NL*"P'4G;O
MZVQO#9H!@>"P2+9&MF`7;"PC@=+LEWVS>=JO)K.6.J?8R1<4EM3=>$XLB4N@
MF/L58&<QL:V#YYY/ON"P(%O2*,OZ*A>;(".,L:T9V2L+%M.!)EDKLZ[X:T`,
MBB!(W/HL%)Q`HW?\\/,.4@SO-K/P.MWGR1<4<9[MJ&?K@A.HYXXS8%NRR$1%
MXR3D2VQQ^41FJM%J``2'(UZUU0G11!8")=JO>^++G`0+@R4?]DU26+C)_*"9
M/22Y'Y7_G>4IO4GR_R3Y'0F2YYC^DX3E$Z8L1F@7WP>^<-QA;U5W=RA*@>KO
MUU7XDH_GW)]0$$0ALHQ=XDM?2<CL^E/V\NQUEDWGFVFA&ANWY0WZ/\%T6E,L
M`O5JXBEQF+]\V]>T2%_N(F_Y:ANT3CRMDY5<5LT[/3UT-8)7_1IF&<F9(?,;
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M7M!7&I(XO/-SW6.HK`F0'0I3DTM-,I.5I7<,L.O9'TD$LF0;E`::MMD(R`^%
MI1VKKO&D9>F5`ZS:=D>SOZZ*FS4Y`67(:^@:KPF0'8K<L]@T32PK2X\L8-6S
MY1![(.FXYES&JGJG`Q1W%;#I555&MEZ`P/+8++O:DT0T9.[_,S]B[JC[%P*R
M'Q6$%=5,GYOE6DK*C6^T+7'%:-7SC@^=^6)6^324C[AN%(0N._5W&,A5<$;A
MP.F"BV*%ZSX@L9_21#<=4+D\B`.%2X)'DH+.*HPN.`^6J'Z/,YC.Z1.%XX_R
M)I:H#H@%A;%>PIF`9#DBM\9UR\-7QTA:+0R"0&'6K#%PMS!TP7X^6G9U'D_B
MI[=I`3<L-FDCDA:&,@G!>@V`P%`X8414\HDWP8;B<=<V=&(>5C6<YB])RD+V
MM'5ANR+("879N8D.\#%UR'C,@\LBZ(QYGU<"^:`P$#?GO(RG0T9<'M3253)#
MTDLU05(HS+7-F:^`ZI!5M9R,QGSMUZ@-$D-A2S53`VU@'3)\EC`;+/F26M[Q
M$0IS9VWJ^8#:LTTBX%RYU`MJ@&A0Q!8WY+H,QM9;MBAYUEOB9=5`2+CL;_48
MKR"R]6HN%M>#[)[(46<NB@R.,?@+.W-19(#"^*JF7.UC;$<V7?#"M'119(#"
MN-N^"BA43RR<+OAZ.GY19(#"5JVA2PHE;%="7?!E=?KZP`"%N=WY5-RJ?-WZ
M`+DQ0(M-?@FM(.BG6A`PH3#7[X:[3;V12<22<V]2)`R"$VN:(XEQ#/]KFN7L
M]'S[M#P;:DU9G'H@*1267A>Z8R`@%+Y"Z_/&X!"%J1?1O%%(Q)*C<#YO7,8A
M:FO2L0MKTMHT</M43C-S1R+FLF$YA[+"TO=8RC*C8V]JUK#7^^+,(F4MO:XT
M<,]6"M\>CIS$-NCFKPF61=4%T],PSFE(HVE.7\D]FWR+*?/R+8BF,#%=`3E,
M0-.Y$MP^7?II#+-SMG2]GLWX#:C>C6COJT`-"K.795WC*W3K<NR"A8R/4>MY
M"E55$!(*^U3K>F"B?MOBZ8)Q"OMS`CTDB8)W,>G9$E<78L9KRV+^A"Y[X"R=
M%G3<PD$C?7CQXT4*T%4*T?9>&3#M`]"&PB1F2P$MJW<]<7;,GM:>]#93C3L9
M#YM=`/YPA/7NZ7#@21.O2;!^IOPMV)=O)`UH1F2JW.X'0=0HS-/M*.XN9-?4
MF#F8JVE,GIE%I:,3]E62/A$*^)S.V95>>+VO*`ST^SIM"P3:]";(3S$D4&[J
MO^((5]_3X<`5IZ6[,#QG5R>'PY^$O81)PB%LW/QG4NP,+V`>D+W[A*E[P#J.
M&P#[/H@T)6WKXM'/=FK&.<X,^P@J@,)/NJ^#K9:X<5P!V_')O,YP<=PC8`N'
M^W4/S_::PFWO6ER7%I[%,9%=5,*YZIAT$(A'X6?>UR7'7-:"06;LM>[V(.O2
M`0J'`WU/!YBII`7#R]CYOA_AN+WW<-Q2?.;6C>;W<%Q1"`R.^[LVZ&X]'%=\
MF_<]'-=Q."Z.&[R6=<U!.*[XGN][..XJWA3'/=O6]:!N.*[XFNQ^A>,N]E?"
M]P>YY0`^BO!!/9KX%',`=2&,]8[-O8I%:E4&8..(>]O%DK*%N@M/Y!60E$.W
M5`J@HX@7V^)"0EBYWY9""FVF)5A:GHM']XZDK[CRBGHG.*X85T1=-=:+NX\B
M<;`&.R<&])RL`**(!C#F9Z/_*%+[:A#4_V+`T+(P0$01]61,T28`%#EWU1P=
M'Q_J<[0J#!!1^/E-.=H"@"-)K@Y)QR8D':\PHK"2F9.T`0!Q>,-&MWL]@Y&T
M*@P841B!3$G:`H##\:Y!DLF2U"O-Z"B,)\8D;0+`X;C5V#<,!@;[AF5AP(C"
MAF&\;]@$8,O]USI)IP;3W:JP-\!Q&]N8I$T``I+V\ATE[/?W3Y"\T+(+DY8M
M<0GTTZEE9>GXWQA7@LF#6Q:@H;!UV2*I.N5(8`L8W<O7G&H+\"99!-54@V[6
M#R2T=W_+X//>"9)795K1U=U+4J#^&$Q>+0AA:QY@JX90JW?=!>`#A7FNO5EX
M]](4:/=>/M#57B!E:6K8"J6\(\PY#+^?)W$16C7UHP>2MK,S;:.?H`8HW!)(
MEXOV1"Z(&C*V`.<DQ3#N'M7"?306[O#Y.2VN_E^#!&F<T:"(5M9[G,MEMX!B
M%%Z*'8PJIQ(6#")C"_WV(,(7K?X`+<,$8A:SSM\U\KXBB3!7UO'Z_2-G<\_&
M(_6RV6#S-?M^W^FJIRE3P;#C0.E"F/4*UWQZ8'-*$A=AZ_(8-&D]$`^.F9A#
MFH)>,9PN1!QOH5.&&7/+@SA0.)HU...3+4'U\X8$]_LH'-,2;OAD<E`@?/ZH
M6'>6ZXW4D<8IZ0UP9'O5YD:*HPN!N]<Q[!_)^I5?]B7&A7S-E-0"*:)PE.JO
MF$HP;J-]6^59N6Y*ZX%X4`QG)8-&Q)>Q68HHMCD!_T9BDOK1,`Z'X9C&E.WX
MV;63RS=VAB89_,,=L``2?($_7I!7$B638G,Q+R"=L^TT#K)#X?K6(+@ZW=L4
M@:5X9QSG*JVPB>IS\?T^#N>W^0EJ"X.EP&BG9([2)"`DS-A]Q>LLF_IQ,+\"
M/D[B8I\CX599%W9%*(:]B$`^W9JP;(5<NQW+?A$'Q%#-W7B+H*",`6?9=Q]@
MDYOY`4,I&^4&S8#T<(U_+:4P1V@KVAN+?A0A/,O;RWJZL%'%&R!)B5V7=PX:
M6\'B-K>#ZREK>41]2)9F8=7,;E0?1(`C?D*+T!K0;$696[6VU/7`[2P21QPA
M,D"2OUA;7]J2@:W(^!:#6EF753.^3C4`C,M?HB1=#Y&MN'FGJWL[[Y(/D"2'
M-5KG-2`A#D6O]X8XDG2CIB.S@L%61+G575B1*I'!6L\G$YK.S4T`^$BT^U+5
M`\BXS.GJ79<>)%N!T4YGU//(S[+5Q'&;WK$0/KWX,E55D!(*V[K9O*J'RE;8
M<(E[AR%7+TD$_<_F/L4+\D0#FC<)N[)EMMWNVDV2$XU4H/**WLE6R$1#3_+&
MAT116)+2T!\DRYI::@+7L@A4)X*RIH\9#:F?SDJ6%55`EJ@.B,7I6JAD3&!3
MDN/I0C16V5SJC^&/)?.HTL6LK@R"PK$6RIE4FY)E\+H0L'4]NE4&:ZW*`&P<
M[B)-@@1!!)MPNI"Y<9325]CTC2(_*'9^2DKY%4`@.#P_C?B58>M"`%@[8=,G
MITZ=/W57:C6F+L2"V8F=/CG%Y0X2<\8G6X+*;=27R]CIDU,4/AL)-WPR.2BZ
M$'NU>(]AY*<P>ZU7K>QL5OX759)E[49`<$Z]-S6G;5.`70CD*B-33N#5PB`(
M%%X;4^K4"E#&YSAF2^`IR%/REL32,-S-0@`&A8U+)&:>#Z#:?\<!4EPR1BEY
M'3ZFWZ)`2L=V,0"$PBFC3P@?`<9XIG,2^FF6T=BGWTE(`S\Z!TF05$J0O!*`
M16$^TJ=+!P_&<*6;=/P'I?\.JS=[^^1:-:Y$Q0$@"LN0/F%R)(X#@"Q9A2(_
M9O83Q6ZS7`S0.[4`U=Q/5B%T(OQG"4NY7=PLZ)T,4`3R5EF1LU?N/<98GKDR
MWC[!YV'.8$;*;/B<$KG%5:\B@$9AF^%149T[=?$XCONQ,PCG&6JNXY"\D?`A
M*:X3K"8F^+AB=M6I#M+"D9W$;-;5A]:)T"$57.4LK=<`2`Q%0*X^N_6THXRV
MA?`B!T;Z\21*9H04(VF.7FG+%=;Q3MTF+*K#HL!J+X=H*RV>]8P9&W/A-\E-
M6D4-@.ET:3><W+70V$K#YMB/"BCGMP,OIFPC,RJ>,9_?&KPA/XI_DCM4=1J`
ML>'4%JA%J,B[J@]0H!+[%16UR%.XN#%Z-LU`2EEVGHP?:5SPM;J%L'Z/6^F&
M-6O.^^+V*:4&ZE(?KD!YFEC&W(07WY#\6Y*MWA!V'U2\_:JQ1CBQJ(K7WS+*
MNHAY,4W[B,,L*1>I:/*M(NE$@/$2U^+F@5:`L:@.B`5'Q!J'+`6M?"A=B"TN
M(U,>BJN%O3X.\Z6"*3Z](CA=B!7F/YE^^19$4U@O6386%O\SG1-U^[0]Z9W-
M^`THQGZ+7P5J4%A=]6>/UH71A6AH/D8M1XJJJC?`899I70],U&];/-T(LM8W
MXE4M6P,<.:CUZ)*<_:N@NA!-72_0=H`C\W033CF`NA`XW33?X<"M@;;!&6(+
M0Q<"J!NN;,-Q,HUEU@TK[8.X<1U1MA2AE<UC&;K]@&PW]KKS),Z2B(8L:&PE
M3#B_W4[(//]%YL)HMY4%5\-F)ZCA];Z>.I^5#4UVO:\H+#I2B6I9[`H@G;+8
MW0<D]E.:Z%KKRN6]'K(ILT22@LXJC"Y8Z9:H?H^S"0GH$R6A^N*_J`Z(!=<>
MJLJ9@&0YHBZ8[9INCWLX3!XU!NX6AB[8MA8;D_AYE=Q>O3D0U@&QH+!3B`CC
MTZN`8\GZA.&!6\7#!A+*%35!4BB,&0HJ^?QK8;-DI\*@!=*W*R0Z(*T'4D)Q
M0[&6!F@@LV37PL!_140F4SU(`\7%QUH\"]!8,G/E2>Y'.)B='S99Y)`.M^O2
M(`\4]R1K+N#;0"Q9E=P3>Y/$R2;(A09K[-:4=4%6*(*:S$C7A&4K`0"&B;N=
M[-VG./*U:_+)5P8-A(V3#PSFBA`7SXJ'3A5AG6!Y+JEK=C,<?I$:=/E50*HH
MS*.-Z)>#LY7C`,,4(!13G07`Z^%(X-6(>P4Z6SD2W.\!1FGR1'/%GFY="."C
M.)*;K>K;_;>5-\$]?3<D7V]/AWF>TL=ISBR/#PFH<)#$.70T*I18.9D;MP7"
M1'$Z-]SBU8-I*U4#BOF^+`)=C0`QH#BC-V![#L%6T@;WHW^-;!X6$<-R-07-
M7<<%C$AZYF<T8#8H%E-!0M6[>[7;]`:]/3SP-81K*W<$AEFA$GZ[B5JB,XJ:
M7@_950DMS=`"92MEA/NY1`&WQHT\00LP">^A-=`(G*U$$1AFA3\)>VH'$$)G
M_&>R\6IMZ0$>_<FB7H,PW%"<*LVTI@E66RDGJDJ$*XCQW,]>KJ+DAY,8QE5'
M2OW0>LM(7,WK;V7&V8-HQOX`UZE>*%9%*$T)S7M(XS*NK.\VLX>,)`6=51CO
M(8W;`8#]`:Y3>94S`<ER1.\AC4QZN#;*^@-W"T,70AIO2,[6I%&:O%+8`IW-
M?L]8_IA5E,`PR.GK_'JJAO?<N#$0)%;K2D&QT/I6"V>'HB--'2S]`0[/:4WF
ME`Z8`I^EN,><I([974<&9`_)'0F2.*`1V3`Z/R3VYHTV/N>='J*PSMG5N/8D
M92EFT[WN+NU8)&07*DF<%8S+MBC<"B`5%):9]A@7;'8DTK`4^]EL_1(G#9TG
MO[M*TN\@H2Q/8C+R9X7D..QKU/(&/12+UJY40%LD34-%$46'M14FB.*(L^NY
M0T,H70HQO2#0YX"JUI=R,9`>"JO5KC6C*@-;[UMA4`006DI@R;P@\_^7Q'3N
M3VCN1WI9!#0;\4Z/4&Q-[&YM3?%W*5*UBGV4DHE/PXL%DF6,9QS>YB\D'689
MD2Y/]1H$P:((;S=5!5V%TI=!XTA8*UL<P8N(V[!@<DTRFF=*[3"I#G)`X3QK
MI@OFB!L'T2+:W%:1#X.`Y1'*8#^O<*4JZX*X4&QEVIHLN'"[%"[+A9S"P>\;
M]1]I5"S<I@JR51V$AL*-UZ*.<!';BL7%J2;+1V46[SW651=Q,W!41.$5:DMM
M5,B[%'ZK?TBPXE@$(E"87NR>C4SQ=R=^5X!\?HG1DG]:TAB($\5,9,4_K<39
MI0#?I<7Z(1D&?T]I2D`:,%SR&7ME,X>=/WLPITA=(G-@:S<"`D3A*ZA+O<#!
M;8B_<7`OHL.3OB2MS#C>Z3%F?W5-!3+%;^MM.[0+UQ6-_3BPM'!)&@-QHK`1
M6UFXE#AMO7_7@F<:L`2$A,4]/.97!2#D]ND\&8^3N'"V7B5I*=T_S*E+A]GE
M&TD#RD\Y9:EED!Z*]))U>:\:^ZP)Q=:K>!CV0OKBM3('@0!16`;M:%5=_`(%
MVL-L#`7LXO'1;5.&1%W$E4`\*(R"9DN3"H^`;F/+,`ZZ85YD_V/;^U<_8D>`
M(6A_FLY`T8L(#P7SROH@-!1V&G,ET(0FT`=C$_!D_NIO[J?Y3Z$5>VAN,8`F
MT`ICR^Y<*RYCMT?D^^ED$A5R\J/ES<;K^"E)QW/"-&Z<ZK4`PD-A73'3"R-P
M`LW8<7"M+9?1/,70R*>R*_/E8MYI#X7YPX@SD;]G&Y:`V[VTJ\X#!!_\-Y(I
MZ=TH":+`89&PP3`'F>!JYUY&MB[EPC*'P1_7YKHXY)QWU@_*:\SX39OV!CAR
MIYMO$9JC%JB8A9A9-[DS;M-G/Z;_]!>6F!L_!\CE][_@1Y9$)+M]&I4ZX2*C
M1KFKZY0?\WZ7^W;[M.#3C];90'2>";'1OG=Z<NAJRF@$8*WP#Z!09]#-O]J2
M%>=3(#84*Y-%'>#/0NT(SE)*$NU)Z1^?&;A'/R,%8_\?4$L#!!0````(`#"(
MJT:O7GK5Q`P``.^-```0`!P`<WEN+3(P,34P,S,Q+GAS9%54"0`#K!A15:P8
M455U>`L``00E#@``!#D!``#M76UOXS82_EZ@_T&7`PZ]#XXC>]/=Y'9;Y&73
M!L@;-NEN@<.AH"7:)E8679+*QCW<?[\A)=FR)%*4[<UR6WU)))$S?(8/.1I2
M)/WZQZ=9Y#UBQ@F-W^SY^P=['HX#&I)X\F;OEX>+WJL][\<?OOWF]=]Z/>\G
M'&.&!`Z]T<([1P(],!1\Y+F\Y^_[^Z\\>>'WKM&B-SCP#[U_'PR.#X?'+P[_
MX_WW[OI_WMO[!Z_G??KT:3\$#4)IV`_HS.OU9#D\F.(9\@1B$RQNT`SS.0KP
MF[VI$//C?E_*\44LIEB08$1H1"<D4/)]6=K!<.B#!1&>X5A<4#8[QV.41.+-
MWN\)BLB8X'#/`Y-C?@Q:VFE58FLBGX;[E$T@RX'?__7ZZEY!S_5')/ZXEOMI
MQ*(\_[`ODT>(XSR[3`W%4J"8^;"?)BZS1@:]OUZ!XJ)28LA,8BY0'*Q`5$!G
M)OI'1T=]E9IG37AO@M!\F7F,^$AES1)DQ;WH'?B]9=4=!S2)!5NLV\AQL#^A
MC_TL48H-2V()8]`F=7)9:DUY(2;U,I!0DQT_!=/Z_#*E1H#$CYB+>I$TK<::
M&$'+JI=125+$7Q?A)*@7@(2:[$"`6,PQKZ5&I=38PL6<:0J!E)I20CQG.)#.
M0-N^COJ(!8Q&&!`$HH>?YA&*D:!L<0'WRPJA<9S,ZI6$@O4EXCYDZD$NS$BP
ME&L6R@3`K7C>:Q3'%/P-^"EU+Y_,YR0>T^P6'LCV?2P!/X"X)R]^>7=IXR24
MD><T2*3;.8G#M[$@8G$)RME,%;GG$:@G8XXEC!Q(B,<D)@JP?^"#S\S%BY>@
MRDMU>05EK_ME#=]^4U:?<!S>QC^H:Z"2@S8E*_U')I]E,<NN"FDK&:`H2")M
MH9E8?XV5@LHMZ3JC,:<1"643/D61=(/W4XP%3[G2)YN)&@`[]U"3.&.JJ,?+
M%'FIIHZE+5BZ0^#V4S$4-5"VGM?,W]">/^^[-<7_[/ALQ^>RFOGM^'8N(TO`
M5-/]-/G,/+XP\;C2Z-&QM]+9,;@Y@V>(3R\B^JF!P%4V,W^']OQ)E9[2V?'7
MS-\MFZ"8_*&*A^CA!HF$X6+'@H>GB!/@ZJY0/2FKFPJ;N?Y>1C2$!Q'EH`YN
MBL5X"$*<M*#USJH25&'R>;&XKADT-X-K",4GJ@_=P3LMZ[3EAV;:7I9I6XE[
M2K[CH9F'"T38>Q0ET(LN2`S1!4'1)0S+F8KO,UZ:,IEY>E7F2:KSE#[9<Y8:
MO8+*CKIFZNYQA(-2K%D9\S5E,E-W5*8N5[<>BG9COY;,"1JHV;?PC,[F..9%
MPNK3C#SY!Q6>I);>J53C%?5T[%BR<Y>P8`K5]P$QAI:.L#[)S(U?RXV7:_%R
M-1TUEM1,:11BQM_^GA"Q.`=+`B(*]-0FFRDJ3YH4]?SC[\.C?WFI-N^[3%\W
MUK8@ZP:+*\KY'6;W4\1P2E'YH9F88;GO@+@GY3T(PSVEH6-BZTCA`8TBS*WB
MA2RKF;47[:,&[[M4<]>Q-@X?UE@TY3"3=V@;2G24;1M35!C39#`35IF]T,07
M'5\;34]P.95PC@4B$7_`3R+)I_O-6<R<&:8N5+S!U02&##>44B_3VE&W_8Q&
M'97M1,S4;C+;T1']&:*:K$JMPIH\KYG:#69#ELQVC.Z,4;\-I;Z9TT%UYL2>
M4\_O6-T9JX,VK`X:6*W.N;1@=="QNO$@9-WI&K.8&1S8#T,Z#[LCUGP+VIK\
M:67&II&WSHMNS]Q:-&N5T\QB=0:GD<4N<MUR-J#J.G4YS-S53^#4S0=TCG,W
ME/G-G#6Y3?M)G,YK[HJV03-M37%F91ZGD;8NN-R6MF$S;<,&VBIS-(VT#3O:
MMJ2M&J(T9#136)V+::*P"U!V\)U=2Z9%9B.AP_HE+,:/\!VW._@L7\>H.8N9
MQ\K42_63_5^:-_E'#L[>X;&G=C0>R\UB;_8XF<TCN1-2/9LR/(9GB[B7;P#]
M#6S>?YI%>0Y9@&%KI:*Z7$U9N;F*;'N<><,E**'`G""8]W/L>UY_=W8!'VWM
M6J?02:LB-&IK%8C@R%F#H/&W-:C47W9K5MK7BGLHX:ZXQU(]`JLH$UY<NY%;
MMQDYW0-^10.ERB`B[WJY7$\^ZOF#WM#??^+AJO+;@%C9V`Y$+K<!B/JMWI;%
MYP*RW$/;$HU[M34%JT)K!?LX$CQ_TENI:F6_8=^T"5"-6';=6ZG8"$C=?G0;
M)$6Y_&9K+'5[W*W`%`67=]MR5-D.;P-E*:2NMH50W2IO@V$EE5[V5@HV0E'>
M?V^#(9>1%UN77]Z:;P4@%U)7&T"H;O-7+YL83^3>/#O/%3&V)B7=UY%TF_[W
M6\.P=)X%"&(GQ9L/.["%5-3R=J5D`X3&(R]L6DHN(R\VZ+#F0QFL*J0LM2U/
M]>=)M$-"XYN-P9A/XMC\S:MTZ2G*SL-1@,RG4)R,N#R1!]IK&I6J`V2.X1F)
M)Y<"S^2(:L]#6:XW>X(E,F95N2!,)#1\4')APK(M-3&)(KGL,<_+$Q`F(I&I
M/S&:S/-""*A/1[\0]OYF!U)G(9Y33H3<C'H+PW!VPCD6_(;&Z1NP9-V,@@=`
M;%%GWQA%O-;`-.@45?O2K*-TE0-4!![)S1&V5C<"UUB<S;9=$30B$9'1^C/:
M&#`<MC"R#JO&K),@@`)#\(,XYCA=CBNG+$XC&GS,+4P/D#D6^?-6-F[=4!L@
M:@Q3TS"GY4_$)[)BTE6HIXM5ECNT4%WA$V+A[5QFE`TDGV!]#\$N#F4_`0AR
MB<T#E8]N$R'9DP=YJ33,`L(5.`<KT:'JT!!67`ZU=NJ',Q[3`J&N,<)[)TPB
MN8]?.IVSU->DOD=5S[/;%HKC*4BR(!GAR_66THQ58V4U_Q6)E7;^Q;DS8M/8
M<\?P')&EXWF'.8;8<0JM^QP_XHC.9RZ_Z2S1:VR77B(1\'Z$]^1X3`(LOTPH
MD6L\&V%6\FHAG2$2/RNCS0@UIEVA$64JY'?.)@.T1L]2]YITTJW4`[6+3]QQ
M*'I@9DNN49S(D6<B$9]1+AR.(PV0S4:^QW%(619&N&]@&6X#@R2"<`>L`(%J
M)W/0O"K@SQ0SYP'A!65C3.1Y0N^0P)?QG3)UZ5[!MTH7`<)?5PS<9-YGJM6?
M5-2=%Z/NSJ'<Y8ZN';0_?=5NUP`_O^D[KW,9)SY,4;SD7(UC,"^WXNS%(Y7P
MKZ49-]OV[-7Y`9/)5`XG'S%#$ZQOW9G74,7\6>K;PG@-(;FJ.P:!K^]*^%J/
MRLJ$%V[:\**5$2\/W;1BA<O&C,'@P$DS"KCLS!@X:L:@C1G#H9ML%'!9F>%H
MWQBVZQO^T9&39A1PF;]?\#6Q+_]RU<#:=1QR0[.7<+K`MG`P00F`-.$F*3*\
M<:"G'=1][KAC(V-U-:Z6L4/T+W^"PY6F7PO*PH"7+AKPTMX`WYE702THG0.=
MS2.ZP%A^0SHG#(;0E'%7##&"LS!('IJ=1+*?.VE2#;P&HURSH@'VRD!7@%<1
M::"GO_44`4LGX8S$1"(3Y!'G4\J04/_1)LO@BL&[LD/'<#BF"3LEE`<$QX$<
M/0>NF&["INMG<R+HW!GR2G",[Z#29K:3R83A]'2PDR?R_%]D0G$<$BA>_C#:
M9<W;J0GNAK:>*Y*^/'.V./4?>&<T7E-RDLM^(&)Z#_1%^%*M]';H?;TA;!NN
MU_0\3.%&1LX9)'E:FF-5L17X#5N%VS6R'7ISA"&7->6Z+BA;'G)W$CX23MGB
M'K-'&+HZ5!<;P39UE-52,'5[,I>_3T<4S'=R(IO?(W?:0GO$S_+Y[J_WU<[B
M8UUE=[5SBU=T"#467<:"X2<:N](9RGCT"]X>3T;L*G(FP*XBTGEI'$)7YN#>
MR#4T]@!%9Y"(F2N&-.'3F'7#9N\)^1E:'C1^?ND0,WIDNH&/ZC>WXS&6'?D>
M13`RS-],KAAE@U&W(V)Y(,#Z3SPYLWJY&:#&LM(IT*[YYGIX.C<!;R89!8D_
M)G+.(E139*ZT/B,X.W+<61^I!]9JW.U*[VE`9[+IDO-$+1HKKL/;U<+(SQ8#
M-B'71CY0$%31.4[_7\;U.ZX<-MW>!&T810.,0W[!Z$Q6H41Q.RX,3J%&"\.3
MPM::Y0JAYZR>MML*=F"<]4#`'7]FQ&9>,'P6D5A%?,LA>3[J=G[IL`FZB<2<
M<U=>K;6@6D9RCNWHLX"IBQF@G2VN$?N(!=`L#]!PAB<#M#9A@V-4-6%LW-OS
M%DJ9R5,<"C_C4=KDNW!RU^E6%C162Z;@)!#DT?D::`!K:^S7M>MX8_16B_%>
M.;,>1H=+%R4O`Z>E-Z"Y?U@+IK[X(K062'<]?_XG7)G7?OU=C81J8ZN?G,R:
MOBLK.&L0:H>*\@.<^C:W5#$G*1JY"\)?YSF4>ZV>U3(+@-*TU_WT6!EEY?\!
M4$L!`AX#%`````@`,(BK1A3W3AA(<0``19\(`!``&````````0```*2!````
M`'-Y;BTR,#$U,#,S,2YX;6Q55`4``ZP8455U>`L``00E#@``!#D!``!02P$"
M'@,4````"``PB*M&\QF81F4(``!-;@``%``8```````!````I(&2<0``<WEN
M+3(P,34P,S,Q7V-A;"YX;6Q55`4``ZP8455U>`L``00E#@``!#D!``!02P$"
M'@,4````"``PB*M&9;#X)K(I```2N0(`%``8```````!````I(%%>@``<WEN
M+3(P,34P,S,Q7V1E9BYX;6Q55`4``ZP8455U>`L``00E#@``!#D!``!02P$"
M'@,4````"``PB*M&]P^81(9```#PJ0,`%``8```````!````I(%%I```<WEN
M+3(P,34P,S,Q7VQA8BYX;6Q55`4``ZP8455U>`L``00E#@``!#D!``!02P$"
M'@,4````"``PB*M&J1*B%;0N``#8+@,`%``8```````!````I($9Y0``<WEN
M+3(P,34P,S,Q7W!R92YX;6Q55`4``ZP8455U>`L``00E#@``!#D!``!02P$"
M'@,4````"``PB*M&KUYZU<0,``#OC0``$``8```````!````I($;%`$`<WEN
M+3(P,34P,S,Q+GAS9%54!0`#K!A1575X"P`!!"4.```$.0$``%!+!08`````
..!@`&`!0"```I(0$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Details) (Stock Warrants [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 10, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price</a></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">$ 1.75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">$ 2.19</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">$ 1.46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedDividendRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedDividendRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedDividendRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedDividendRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedDividendRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedDividendRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">95.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">90.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsExpectedVolatilityRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">90.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">1.39%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">1.26%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAssumptionsRiskFreeInterestRate[us-gaap_FairValueByLiabilityClassAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">1.59%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_FairValueByLiabilityClassAxis<br>= syn_StockWarrantsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life of warrant</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">4 years 6 months 18 days<span></span></td>
        <td class="text">4 years 9 months 14 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Disclosures [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <strong>4.</strong> <strong>Selected Balance Sheet Information</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Prepaid expenses and other current assets (in thousands):</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Intrexon prepaid research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,060</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Prepaid insurance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>228</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>253</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,574</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The anticipated Intrexon research and development expenses for the next twelve months are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment (in thousands):</i>&#160; &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Computer and office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>122</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(47)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(39)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accrued expenses (in thousands):</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued manufacturing costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued vendor payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>225</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>176</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued milestone payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued clinical consulting services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,347</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>525</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,646</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,298</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P
M9#8V8C`R,C(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S
M-S8P9#8V8C`R,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C%C
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V%S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T
M:6]N7V%N9%].871U<F5?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^36%N86=E;65N=%]0;&%N<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?;V9?1FEN86YC
M:6%L7TEN<W1R=3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-E;&5C=&5D7T)A;&%N8V5?4VAE971?26YF;W)M83PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K0F%S961?0V]M<&5N
M<V%T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4W1O8VM?4'5R8VAA<V5?5V%R<F%N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7T1E9FEC:70\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.971?3&]S
M<U]P97)?4VAA<F4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y396QE8W1E9%]"86QA;F-E7U-H965T7TEN9F]R;6$Q/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP
M96YS871I;VY?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VM?4'5R8VAA<V5?5V%R<F%N='-?5&%B;&5S/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^36%N86=E;65N='-?
M4&QA;E]$971A:6QS7U1E>'1U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^1F%I<E]686QU95]O9E]&:6YA;F-I86Q?26YS=')U,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-E;&5C=&5D
M7T)A;&%N8V5?4VAE971?26YF;W)M83(\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y396QE8W1E9%]"86QA;F-E7U-H965T7TEN9F]R
M;6$S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4V5L
M96-T961?0F%L86YC95]3:&5E=%]);F9O<FUA-#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N
M7T1E=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N7T1E=&%I;#$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A
M=&EO;E]$971A:6PR/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4W1O8VM?4'5R8VAA<V5?5V%R<F%N='-?1&5T86EL/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM?4'5R8VAA<V5?
M5V%R<F%N='-?1&5T86EL,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-T;V-K7U!U<F-H87-E7U=A<G)A;G1S7T1E=&%I;#(\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]0=7)C
M:&%S95]787)R86YT<U]$971A:6PS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(X+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W1O8VM?4'5R8VAA<V5?5V%R<F%N='-?1&5T86EL
M-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K
M:&]L9&5R<U]%<75I='E?1&5F:6-I=%]$93PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DYE=%],;W-S7W!E<E]3:&%R95]$971A:6QS
M7U1E>#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE
M970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T
M:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C
M='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T
M5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7
M;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D
M>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC
M<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B
M-S1F7S,W-C!D-C9B,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H
M965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D-!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY$;V-U;65N="!!;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#`X+"`R,#$U/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O
M8W5M96YT($EN9F]R;6%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N
M="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3>6YT:&5T
M:6,@0FEO;&]G:6-S+"!);F,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#`X.30Q-3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U
M<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^06-C96QE<F%T960@1FEL
M97(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1R861I;F<@4WEM8F]L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#Y364X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N
M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,L,3<Y+#,P
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^,3`M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^43$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T
M7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO-C%C-65D8S=?.3=D-%\T,CDW7V(W-&9?,S<V,&0V-F(P,C(R
M+U=O<FMS:&5E=',O4VAE970P,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15`S044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S
M("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P
M96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT($%S<V5T<SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R
M+#`T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3<L-3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R
M96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU
M-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#4T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L($-U<G)E;G0@07-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,RPV,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PP-S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E
M<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5P;W-I=',@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@07-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPW,38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PQ-#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0W5R<F5N="!,:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C0V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#DP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8L-S4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5M<&QO>65E(&)E;F5F:71S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!#=7)R96YT($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-2PS-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY+#4X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PS-#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#4X.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET
M;65N=',@86YD($-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5F:6-I="DZ/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M)#`N,#`Q('!A<B!V86QU93L@,3`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE
M9"P@;F]N92!I<W-U960@86YD(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,#$@<&%R
M('9A;'5E.R`Q,#`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9"P@-S(L-S(U
M+#DX-R!I<W-U960@86YD(#<R+#@P-RPT-CD@;W5T<W1A;F1I;F<@86YD(#<R
M+#4Y-"PV,C8@:7-S=65D(&%N9"`W,BPU,3,L,30T(&]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L
M('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$Q+#<P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Q,"PU,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q,RPT,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`Q+#`T,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!3>6YT:&5T:6,@0FEO;&]G:6-S+"!);F,N(&%N9"!3=6)S:61I87)I
M97,@17%U:71Y("A$969I8VET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PV,C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PU-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUC;VYT<F]L;&EN9R!I;G1E<F5S=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!3=&]C
M:VAO;&1E<G,G($5Q=6ET>2`H1&5F:6-I="D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L-C(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDL-34V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@3&EA8FEL:71I97,@
M86YD(%-T;V-K:&]L9&5R<^*`F2!%<75I='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3,L-S$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.2PQ-#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B
M-S1F7S,W-C!D-C9B,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0TU!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@*%!A<F5N
M=&AE=&EC86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('!A<B!V
M86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K
M+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P
M87(@=F%L=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@
M<VAA<F5S+"!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<R+#<R-2PY.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW,BPU.30L-C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(L
M.#`W+#0V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<R+#4Q,RPQ-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B
M,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y
M-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#`T
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,DM!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG($-O<W1S(&%N9"!%>'!E;G-E
M<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2PW,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,3(R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V
M96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-#DT
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPW,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!/<&5R871I;F<@0V]S=',@86YD($5X<&5N<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#(P-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#,Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S
M<R!F<F]M($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@L,C`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,L.#,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!);F-O;64@*$5X<&5N
M<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT(&QI86)I;&ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PQ-3(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E
M<W0@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L($]T:&5R($EN8V]M92`H17AP96YS92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0L,34Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L,S4X*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L.#,X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@
M071T<FEB=71A8FQE('1O($YO;BUC;VYT<F]L;&EN9R!);G1E<F5S=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<R!!='1R
M:6)U=&%B;&4@=&\@4WEN=&AE=&EC($)I;VQO9VEC<RP@26YC+B!A;F0@4W5B
M<VED:6%R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$R
M+#,U."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#,L.#,X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T($QO<W,@4&5R(%-H87)E("T@0F%S:6,@86YD
M($1I;'5T:79E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@
M4&5R(%-H87)E($%T=')I8G5T86)L92!T;R!3>6YT:&5T:6,@0FEO;&]G:6-S
M+"!);F,N(&%N9"!3=6)S:61I87)I97,@*&EN(&1O;&QA<G,@<&5R('-H87)E
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C$W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F('-H87)E<R!O=71S=&%N
M9&EN9R!D=7)I;F<@=&AE('!E<FEO9"`M($)A<VEC(&%N9"!$:6QU=&EV92`H
M:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(L
M-C<S+#DU.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4X+#,R-"PR-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B
M,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y
M-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#`U
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%-C5!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M87-H($9L;W=S($9R;VT@3W!E<F%T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$R+#,U."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L.#,X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@
M=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!F;W(@;6EL97-T;VYE('!A>6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N
M9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT(&QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P;W-I=',@86YD
M(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS-#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5M<&QO
M>65E(&)E;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH.#@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!#87-H(%5S960@26X@3W!E<F%T:6YG($%C=&EV:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L-#4X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-#<P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@26YV97-T:6YG($%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!U<F-H87-E<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!#87-H(%5S960@
M26X@26YV97-T:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@1FQO=W,@1G)O;2!&:6YA
M;F-I;F<@06-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM
M;VX@<W1O8VL@9F]R('-T;V-K(&]P=&EO;B!E>&5R8VES97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($-A<V@@4')O=FED960@
M0GD@1FEN86YC:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&1E8W)E87-E(&EN(&-A<V@\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4L-#<V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-#<P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A="!B
M96=I;FYI;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-RPU,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PV,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@870@96YD(&]F('!E<FEO9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,#0Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,34U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!C87-H(&9L;W<@:6YF
M;W)M871I;VXZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@<&%I9"!F;W(@:6YT97)E<W0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R('1A>&5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y
M-U]B-S1F7S,W-C!D-C9B,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R
M:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!.871U<F4@;V8@3W!E<F%T
M:6]N<R!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N
M+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L
M(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<F=A;FEZ871I;VXL($-O;G-O;&ED871I
M;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<R!$
M:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&(^,2X\+V(^(#QB/D]R9V%N:7IA
M=&EO;B!A;F0@3F%T=7)E(&]F($]P97)A=&EO;G,@86YD($)A<VES(&]F(%!R
M97-E;G1A=&EO;CPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`M,S<N-'!T.R!-05)'24XZ(#!P="`P<'@@,'!T(#,W
M+C1P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/&(^/&D^1&5S8W)I<'1I;VX@
M;V8@0G5S:6YE<W,\+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z(#,T+C%P=#L@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG
M;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(%-Y;G1H971I8R!":6]L;V=I8W,L
M($EN8RX@*'1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3L@;W(@)B,X,C(P.U-Y
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M(&ER<FET86)L92!B;W=E;"!S>6YD<F]M92!W:71H(&-O;G-T:7!A=&EO;B`H
M24)3+4,I+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@:7,@9&5V96QO<&EN
M9R!A(&UO;F]C;&]N86P@86YT:6)O9'D@8V]M8FEN871I;VX@9F]R('1H92!T
M<F5A=&UE;G0@;V8@4&5R='5S<VES(&EN(&-O;&QA8F]R871I;VX@=VET:"!)
M;G1R97AO;B!#;W)P;W)A=&EO;B`H3EE313H@6$].*2P@86YD(&$@4&AA<V4@
M,B!O<F%L(&5S=')I;VP@9')U9R!F;W(@=&AE('1R96%T;65N="!O9B!R96QA
M<'-I;F<M<F5M:71T:6YG(&UU;'1I<&QE('-C;&5R;W-I<R`H35,I(&%N9"!C
M;V=N:71I=F4@9'ES9G5N8W1I;VX@:6X@35,N(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4E.1$5.5#H@,S<N-'!T.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L
M:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)U=)
M1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z(#(V
M)2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&(^
M(%1H97)A<&5U=&EC)B,Q-C`[07)E83PO8CX\+V1I=CX@/"]T9#X@/'1D('-T
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M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$Q
M<'0[(%!!1$1)3D<M3$5&5#H@,3%P=#L@5D525$E#04PM04Q)1TXZ('1O<"<^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&D^0RX@
M9&EF9FEC:6QE/"]I/B!I;F9E8W1I;VX@<')E=F5N=&EO;CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!T;W`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!A;&EG;CTS1&-E;G1E<CY364XM,#`T/"]D:78^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$8V5N
M=&5R/BAO<F%L(&5N>GEM92D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S
M='EL93TS1"=,24Y%+4A%24=(5#H@,3$U)3L@1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^($EN:71I
M871E9"!0:&%S92`R82!364XM,#`T(&-L:6YI8V%L('1R:6%L(&1U<FEN9R`Q
M/'-U<"!S='EL93TS1&9O;G0M<W1Y;&4Z;F]R;6%L/G-T/"]S=7`^('%U87)T
M97(@,C`Q-3L@4&AA<V4@,F(@<')O;V8M;V8M(&-O;F-E<'0@4UE.+3`P-"!C
M;&EN:6-A;"!T<FEA;"!I<R!E>'!E8W1E9"!T;R!I;FET:6%T92!D=7)I;F<@
M,CQS=7`@<W1Y;&4],T1F;VYT+7-T>6QE.FYO<FUA;#YN9#PO<W5P/B8C,38P
M.R8C,38P.VAA;&8@,C`Q-3PO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97(G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3%P=#L@4$%$1$E.1RU,
M1494.B`Q,7!T.R!615)424-!3"U!3$E'3CH@=&]P)SX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY)<G)I=&%B;&4@8F]W96P@<WEN
M9')O;64@=VET:"!C;VYS=&EP871I;VX@*$E"4RU#*3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!T;W`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!A;&EG;CTS1&-E;G1E<CY364XM,#$P/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$8V5N=&5R
M/BAO<F%L(&-O;7!O=6YD*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DEN=&5N9"!T
M;R!I;FET:6%T92!0:&%S92`R(&-L:6YI8V%L('1R:6%L<R!D=7)I;F<@,CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/'-U<"!S='EL93TS1&9O
M;G0M<W1Y;&4Z;F]R;6%L/FYD/"]S=7`^/"]F;VYT/B8C,38P.R8C,38P.W%U
M87)T97(@;V8@,C`Q-3L@0V]L;&%B;W)A=&EO;B!W:71H($-E9&%R<RU3:6YA
M:2!-961I8V%L($-E;G1E<CPO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97(G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97(G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,7!T.R!0041$24Y'+4Q%1E0Z(#$Q
M<'0[(%9%4E1)0T%,+4%,24=..B!T;W`G/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/E!E<G1U<W-I<SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H
M)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!T;W`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)R!A;&EG;CTS1&-E;G1E<CY364XM,#`U/"]D:78^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$8V5N=&5R/BAM
M;VYO8VQO;F%L(&%N=&EB;V1I97,I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O
M<"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^4&]S
M:71I=F4@<')E8VQI;FEC86P@<F5S96%R8V@@9FEN9&EN9W,@<F5P;W)T960@
M870@14-#34E$(&EN($%P<FEL(#(P,34[(%-E96MI;F<@;F]N+61I;'5T:79E
M(&9U;F1I;F<@=&\@<W5P<&]R="!C;&EN:6-A;"!D979E;&]P;65N="!O9B!3
M64XM,#`U.R!#;VQL86)O<F%T:6]N<R!W:71H($EN=')E>&]N(&%N9"!4:&4@
M56YI=F5R<VET>2!O9B!497AA<R!A="!!=7-T:6X\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97(G/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3%P=#L@4$%$
M1$E.1RU,1494.B`Q,7!T.R!615)424-!3"U!3$E'3CH@=&]P)SX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY296QA<'-I;F<M<F5M
M:71T:6YG($U3/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$8V5N=&5R
M/E1R:6UE<W1A/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G(&%L:6=N/3-$8V5N=&5R/BAO<F%L(&5S=')I;VPI/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^/&9O;G0@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$Q
M-24[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
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M(%-E<'1E;6)E<B`R,#$T.R!087)T;F5R<VAI<"!D:7-C=7-S:6]N<R!O;F=O
M:6YG('!E;F1I;F<@9&%T82!F<F]M(%5N:79E<G-I='D@;V8@0V%L:69O<FYI
M82P@3&]S($%N9V5L97,@*%5#3$$I.R!-4DD@9&%T82!R979I97<@=6YD97)W
M87D@8GD@54-,03PO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97(G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#
M3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3%P=#L@4$%$1$E.1RU,1494.B`Q
M,7!T.R!615)424-!3"U!3$E'3CH@=&]P)SX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SY#;V=N:71I=F4@9'ES9G5N8W1I;VX@:6X@
M35,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SY0871I96YT(&5N<F]L;&UE;G0@=6YD97)W87D@:6X@4&AA<V4@
M,B!C;&EN:6-A;"!T<FEA;#PO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^(#QB/CQI/D)A<VES(&]F(%!R97-E;G1A
M=&EO;CPO:3X\+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4E.1$5.5#H@,S0N,7!T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S
M=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!
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M97)A;&QY($%C8V5P=&5D($%C8V]U;G1I;F<@4')I;F-I<&QE<R`H)B,X,C(P
M.T=!05`F(S@R,C$[*2!F;W(@8V]M<&QE=&4@9FEN86YC:6%L('-T871E;65N
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M9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30@*"8C.#(R,#LR,#$T($9O<FT@
M,3`M2R8C.#(R,3LI(&%S(&9I;&5D('=I=&@@=&AE(%-%0RX@5&AE(&EN=&5R
M:6T@<F5S=6QT<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S
M,2P@,C`Q-2P@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F(')E
M<W5L=',@9F]R('1H92!F=6QL('EE87(N/"]D:78^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@
M86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
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M<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I
M>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D
M/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C%C-65D8S=?.3=D-%\T,CDW7V(W-&9?,S<V,&0V
M-F(P,C(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8Q8S5E9&,W
M7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,B]7;W)K<VAE971S+U-H965T
M,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY-
M86YA9V5M96YT(%!L86YS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!-86YA9V5M96YT(%!L86X@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$:7-C;&]S=7)E($UA;F%G96UE;G0@4&QA;B!;5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-
M05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<^(#QB/C(N/"]B/B`\
M8CY-86YA9V5M96YT)B,X,C$W.W,@4&QA;CPO8CX\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`R-RXU<'0[($U!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^
M5&AE($-O;7!A;GD@:&%S(&EN8W5R<F5D(&%N(&%C8W5M=6QA=&5D(&1E9FEC
M:70@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$Q,RXT/"]F;VYT
M/B!M:6QL:6]N('1H<F]U9V@@36%R8V@@,S$L(#(P,34N(%=I=&@@=&AE(&5X
M8V5P=&EO;B!O9B!T:&4@<75A<G1E<B!E;F1E9"!*=6YE(#,P+"`R,#$P+"!T
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M>2!E9F9O<G1S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#,T+C%P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/
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M+4E.1$5.5#H@,S0N,7!T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@
M/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#8E)SX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`T)2<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&9O;G0^)B,X.3`Q.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%=)
M1%1(.B`Y,"4G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/G1H92!P<F]G<F5S<R!O9B!R97-E87)C:"!A8W1I=FET:65S.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M=VAI=&4[(%9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\
M9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
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M(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
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M+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
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M=&]P)SX@/'1D/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&9O;G0^)B,X.3`Q.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/G1H92!C;W-T
M<R!A<W-O8VEA=&5D('=I=&@@861D:71I;VYA;"!C;&EN:6-A;"!T<FEA;',@
M;V8@<')O9'5C="!C86YD:61A=&5S.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!T;W`G/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N=#XF(S@Y,#$[/"]F;VYT
M/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
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M)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T-,14%2
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M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#
M3$5!4CH@8F]T:"<^/&9O;G0^)B,X.3`Q.SPO9F]N=#X\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/G1H92!C;W-T<R!I;G9O;'9E
M9"!I;B!P<F]S96-U=&EN9R!A;F0@96YF;W)C:6YG('!A=&5N="!C;&%I;7,@
M86YD(&]T:&5R(&EN=&5L;&5C='5A;"!P<F]P97)T>2!R:6=H=',[(&%N9#PO
M9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H
M)SX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
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M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
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M<B!S;W5R8V5S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#(W+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I
M9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
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M=VYE<G-H:7`@:6YT97)E<W0@;V8@=&AE(&5X:7-T:6YG('-T;V-K:&]L9&5R
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M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\
M+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B
M,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y
M-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#`X
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I
M<B!686QU92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E
M($1I<V-L;W-U<F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!$:7-C;&]S=7)E<R!;
M5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<^(#QB
M/C,N/"]B/B`\8CY&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT
M<SPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`S-"XQ<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C
M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`M,3,N,G!T.R!-05)'24XZ(#!P="`P<'@@,'!T(#0Q+CAP=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C
M,38P.SPO9&EV/B`\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#$P,"4[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D
M('-T>6QE/3-$)U=)1%1(.B`V)2<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=724142#H@-"4G/B`\9&EV/CQF;VYT/B8C,3@S.SPO
M9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Y,"4G/B`\
M9&EV/DQE=F5L(#$@:6YP=71S.B!1=6]T960@<')I8V5S("AU;F%D:G5S=&5D
M*28C,38P.V9O<B!I9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S(&EN
M(&%C=&EV92!M87)K971S.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2
M1TE..B`P:6X@,'!X(#!I;B`P:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE
M/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@-B4G/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#0E
M)SX@/&1I=CX\9F]N=#XF(S$X,SL\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=724142#H@.3`E)SX@/&1I=CY,979E;"`R(&EN<'5T<SH@26YP
M=71S+"!O=&AE<B!T:&%N('%U;W1E9"!P<FEC97,@:6YC;'5D960@:6X@3&5V
M96P@,2!T:&%T(&%R92!O8G-E<G9A8FQE(&5I=&AE<B!D:7)E8W1L>2!O<B!I
M;F1I<F5C=&QY.R!A;F0\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M,3,N,G!T.R!-
M05)'24XZ(#!I;B`P<'@@,&EN(#`N,FEN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QT86)L92!S
M='EL93TS1"=724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#8E
M)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(
M.B`T)2<^(#QD:78^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO9&EV/B`\+W1D/B`\
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M,3!P=#M415A4+4E.1$5.5#H@,S0N,7!T.R!-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N
M/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
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M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`S-"XQ<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J
M=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^0V%S:"!A;F0@8V%S:"!E
M<75I=F%L96YT<R!I;F-L=61E(&UO;F5Y(&UA<FME="!A8V-O=6YT<R8C,38P
M.V]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXX+C4\+V9O;G0^(&UI
M;&QI;VX@86YD("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ,RXV/"]F
M;VYT/B!M:6QL:6]N(&%S(&]F($UA<F-H(#,Q+"`R,#$U(&%N9"!$96-E;6)E
M<B`S,2P@,C`Q-"P@<F5S<&5C=&EV96QY+"!T:&%T(&%R92!M96%S=7)E9"!U
M<VEN9R!,979E;"`Q(&EN<'5T<RX\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E
M<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO
M=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C%C-65D8S=?.3=D-%\T,CDW7V(W-&9?,S<V,&0V-F(P
M,C(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8Q8S5E9&,W7SDW
M9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,B]7;W)K<VAE971S+U-H965T,#DN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY396QE
M8W1E9"!"86QA;F-E(%-H965T($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N
M+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L
M(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=7!P;&5M96YT86P@0F%L86YC92!3:&5E
M="!$:7-C;&]S=7)E<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XM5$]0.B`P<'0[($9/3E0Z
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M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\:3XF(S$V,#L\+VD^
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3X\:3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SX@/"]F;VYT/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@
M87-S971S("AI;B!T:&]U<V%N9',I.CPO:3X\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`R-RXU<'0[($U!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<@86QI9VX],T1J=7-T:69Y/CQI/B8C,38P.SPO:3X\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%
M3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.
M.B`P:6X[(%=)1%1(.B`Y,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($]615)&3$]7.B!V:7-I8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0V,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3,E(&-O;'-P86X],T0R/B`\9&EV/DUA<F-H)B,Q-C`[,S$L)B,Q-C`[,C`Q
M-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CY$96-E;6)E<B8C
M,38P.S,Q+"8C,38P.S(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#8Q)3X@/&1I=CY);G1R97AO;B!P<F5P86ED(')E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!E>'!E;G-E<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R
M)3X@/&1I=CXQ+#`V,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I
M=CXQ+#`V-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q)3X@/&1I
M=CY0<F5P86ED(&EN<W5R86YC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ-#`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
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M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-C$E/B`\9&EV/E!R97!A:60@97AP96YS97,\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXS-S0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR-3,\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3(E/B`\9&EV/C$L-3<T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ+#4T.#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
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M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J
M=7-T:69Y/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^
M4')O<&5R='D@86YD(&5Q=6EP;65N="`H:6X@=&AO=7-A;F1S*3H\+VD^)B,Q
M-C`[("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#(W+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%
M6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3CH@,&EN.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O
M;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CY-87)C:"8C,38P.S,Q+"8C
M,38P.S(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/CDS/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-3$E/B`\9&EV/E-O9G1W87)E/"]D:78^(#PO
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M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
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M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,C(\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,#0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^*#0W*3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXH,SDI/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$-3$E/B`\9&EV/E1O=&%L/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXW-3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,B4^(#QD:78^-C4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D
M:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L
M:6=N/3-$:G5S=&EF>3X\:3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@
M/"]F;VYT/D%C8W)U960@97AP96YS97,@*&EN('1H;W5S86YD<RDZ/"]I/CPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(W
M+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/&D^)B,Q-C`[
M/"]I/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'
M3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L
M92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#@P)3L@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78^36%R8V@F
M(S$V,#LS,2PF(S$V,#LR,#$U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M/B`\9&EV/D1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[,C`Q-#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3$E/B`\9&EV/D%C8W)U960@;6%N=69A
M8W1U<FEN9R!C;W-T<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I
M=CXW-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR-#<\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,24^(#QD:78^06-C<G5E9"!V
M96YD;W(@<&%Y;65N=',\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/C$W-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#4Q)3X@/&1I=CY!8V-R=65D(&UI;&5S=&]N92!P87EM96YT<SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$R)3X@/&1I=CXQ+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXS
M-3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
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M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
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M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXU,C4\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3(E/B`\9&EV/C(L-C0V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ+#(Y.#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#PO9&EV/CQT86)L92!B
M;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF
M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT
M9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D
M-C9B,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C
M-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E
M=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8VQO<W5R92!O9B!#;VUP
M96YS871I;VX@4F5L871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$:7-C;&]S=7)E(&]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O
M<W1S+"!3:&%R92UB87-E9"!087EM96YT<R!;5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XM5$]0
M.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3BU"3U143TTZ(#!P="<^(#QS=')O;F<^-2X\+W-T<F]N9SX@
M/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+W-T<F]N9SX\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M,S<N
M-'!T.R!-05)'24XZ(#!P="`P<'@@,'!T(#,W+C1P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N
M9SX\:3Y3=&]C:R!);F-E;G1I=F4@4&QA;CPO:3X\+W-T<F]N9SX\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`S-"XQ<'0[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S
M=&EF>3Y$=7)I;F<@,C`P,2P@=&AE($-O;7!A;GDF(S@R,3<[<R!";V%R9"!O
M9B!$:7)E8W1O<G,@86YD('-T;V-K:&]L9&5R<R!A9&]P=&5D('1H92`R,#`Q
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M>2!D=7)I;F<@86YY(&]N92UY96%R('!E<FEO9"!U;F1E<B!T:&4@,C`P,2!3
M=&]C:R!0;&%N('-H86QL(&YO="!E>&-E960@/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^(#(U,"PP,#`\+V9O;G0^+B!!;&P@87=A<F1S('!U<G-U86YT
M('1O('1H92`R,#`Q(%-T;V-K(%!L86X@<VAA;&P@=&5R;6EN871E('5P;VX@
M=&AE('1E<FUI;F%T:6]N(&]F('1H92!G<F%N=&5E)B,X,C$W.W,@96UP;&]Y
M;65N="!F;W(@86YY(')E87-O;BX@07=A<F1S(&EN8VQU9&4@;W!T:6]N<RP@
M<F5S=')I8W1E9"!S:&%R97,L('-T;V-K(&%P<')E8VEA=&EO;B!R:6=H=',L
M('!E<F9O<FUA;F-E('-H87)E<R!A;F0@8V%S:"UB87-E9"!A=V%R9',@*'1H
M92`F(S@R,C`[07=A<F1S)B,X,C(Q.RDN(%1H92`R,#`Q(%-T;V-K(%!L86X@
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M:"`S,2P@,C`Q-2P@=&AE<F4@=V5R92`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX@-C@R+#0T.3PO9F]N=#X@;W!T:6]N<R!I<W-U960@86YD(&]U='-T
M86YD:6YG('5N9&5R('1H92`R,#`Q(%-T;V-K(%!L86XN/"]D:78^("8C,38P
M.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!A;&EG;CTS1&IU<W1I9GD^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y/;B!-87)C:"`R,"P@,C`P
M-RP@=&AE($-O;7!A;GDF(S@R,3<[<R!";V%R9"!O9B!$:7)E8W1O<G,@87!P
M<F]V960@=&AE(#(P,#<@4W1O8VL@26YC96YT:79E(%!L86X@*'1H92`F(S@R
M,C`[,C`P-R!3=&]C:R!0;&%N)B,X,C(Q.RD@9F]R('1H92!I<W-U86YC92!O
M9B!U<"!T;R`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@,BPU,#`L,#`P
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M<G,@;VX@3F]V96UB97(@,BP@,C`P-RX@5&AE(&5X97)C:7-E('!R:6-E(&]F
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M87)Y(&1U<FEN9R!A;GD@;VYE+7EE87(@<&5R:6]D('5N9&5R('1H92`R,#`W
M('!L86X@<VAA;&P@;F]T(&5X8V5E9"`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX@,C4P+#`P,#PO9F]N=#XN($]P=&EO;G,@8F5C;VUE(&5X97)C:7-A
M8FQE(&]V97(@=F%R:6]U<R!P97)I;V1S(&9R;VT@=&AE(&1A=&4@;V8@9W)A
M;G0L(&%N9"!G96YE<F%L;'D@97AP:7)E('1E;B!Y96%R<R!A9G1E<B!T:&4@
M9W)A;G0@9&%T92X@07,@;V8@36%R8V@@,S$L(#(P,34L('1H97)E(&%R92`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@-#(X+#8U-SPO9F]N=#X@;W!T
M:6]N<R!I<W-U960@86YD(&]U='-T86YD:6YG('5N9&5R('1H92`R,#`W(%-T
M;V-K(%!L86XN/"]D:78^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S
M=&EF>3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@
M86QI9VX],T1J=7-T:69Y/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%
M05(Z(&)O=&@G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)R!A;&EG;CTS1&IU<W1I9GD^3VX@3F]V96UB97(@,BP@,C`Q,"P@=&AE
M($)O87)D(&]F($1I<F5C=&]R<R!A;F0@<W1O8VMH;VQD97)S(&%D;W!T960@
M=&AE(#(P,3`@4W1O8VL@26YC96YT:79E(%!L86X@*"8C.#(R,#LR,#$P(%-T
M;V-K(%!L86XF(S@R,C$[*2!F;W(@=&AE(&ES<W5A;F-E(&]F('5P('1O(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`S+#`P,"PP,#`\+V9O;G0^('-H
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M;B!/8W1O8F5R(#(R+"`R,#$S+"!T:&4@<W1O8VMH;VQD97)S(&%P<')O=F5D
M(&%N9"!A9&]P=&5D(&%N(&%M96YD;65N="!T;R!T:&4@0V]M<&%N>28C.#(Q
M-SMS(#(P,3`@26YC96YT:79E(%-T;V-K(%!L86X@=&\@:6YC<F5A<V4@=&AE
M(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM
M;VX@<W1O8VL@<F5S97)V960@9F]R(&ES<W5A;F-E('5N9&5R('1H92!0;&%N
M(&9R;VT@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#,L,#`P+#`P,#PO
M9F]N=#X@=&\@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#8L,#`P+#`P
M,#PO9F]N=#XN(%1H92!E>&5R8VES92!P<FEC92!O9B!S=&]C:R!O<'1I;VYS
M('5N9&5R('1H92`R,#$P(%-T;V-K(%!L86X@:7,@9&5T97)M:6YE9"!B>2!T
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M<F-H(#,Q+"`R,#$U+"!T:&5R92!A<F4@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^(#4L-#(P+#`P,#PO9F]N=#X@;W!T:6]N<R!I<W-U960@86YD(&]U
M='-T86YD:6YG('5N9&5R('1H92`R,#$P(%-T;V-K(%!L86XN/"]D:78^(#PO
M9&EV/B`F(S$V,#L\+V1I=CX@/"]D:78^(#PO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
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M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,C<N-7!T.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
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M:78^(#QT86)L92!S='EL93TS1"="3U)$15(M0D]45$]-.B`P<'@@<V]L:60[
M($)/4D1%4BU,1494.B`P<'@@<V]L:60[(%=)1%1(.B`Q,#`E.R!&3TY4+5-)
M6D4Z(#$P<'0[($)/4D1%4BU43U`Z(#!P>"!S;VQI9#L@0D]21$52+5))1TA4
M.B`P<'@@<V]L:60G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5TE$5$@Z
M(#$P,"4G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,W+C1P=#L@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A
M;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)
M1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN.R!72414
M2#H@-C`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@
M=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG
M;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,C8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,R)2!C;VQS<&%N
M/3-$-CX@/&1I=CY4:')E928C,38P.TUO;G1H<R8C,38P.T5N9&5D)B,Q-C`[
M36%R8V@F(S$V,#LS,2P\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,C8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^(#QD:78^,C`Q-3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-24@8V]L<W!A;CTS
M1#(^(#QD:78^,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,C8E/B`\9&EV/D5X<&5C=&5D(&1I=FED96YD<SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$T)3X@/&1I
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,30E/B`\9&EV/C`\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B4\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,C8E/B`\9&EV/D5X<&5C=&5D('9O;&%T:6QI='D\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,30E/B`\9&EV
M/C$S,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#(V)3X@/&1I=CY2:7-K(&9R964@:6YT97)E<W0@<F%T93PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M-"4^(#QD:78^,2XU-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\+W1R/B`\
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,30E/B`\9&EV/C$P('EE87)S/"]D:78^(#PO
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,30E/B`\9&EV/C4@>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,30E/B`\9&EV/C`\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,30E/B`\
M9&EV/C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B4\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@
M/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`S-"XQ<'0[($U!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
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M-'!T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I
M=CX@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS
M1"=724142#H@-B4G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#0E)SX@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#DP)2<^(#QD:78^:6UM
M961I871E('9E<W1I;F<L/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0^(#QD:78^/&9O;G0^)B,X.3`Q.SPO9F]N=#X\+V1I=CX@
M/"]T9#X@/'1D/B`\9&EV/FAA;&8@=F5S=&EN9R!I;6UE9&EA=&5L>2!A;F0@
M=&AE(')E;6%I;F1E<B!O=F5R('1H<F5E('EE87)S+#PO9&EV/B`\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9#X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/CQF;VYT/B8C.#DP
M,3L\+V9O;G0^/"]D:78^(#PO=&0^(#QT9#X@/&1I=CYQ=6%R=&5R;'D@;W9E
M<B!T:')E92!Y96%R<RP\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9#X@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\
M+W1D/B`\=&0^(#QD:78^86YN=6%L;'D@;W9E<B!T:')E92!Y96%R<RP\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T
M;W`G/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=CX\
M9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0^(#QD:78^;VYE
M+71H:7)D(&EM;65D:6%T92!V97-T:6YG(&%N9"!R96UA:6YI;F<@86YN=6%L
M;'D@;W9E<B!T=V\@>65A<G,L/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0^(#QD:78^/&9O;G0^)B,X.3`Q.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D/B`\9&EV/F]N92!H86QF(&EM;65D:6%T92!V97-T:6YG
M('=I=&@@<F5M86EN:6YG('9E<W1I;F<@;W9E<B!N:6YE(&UO;G1H<RP\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T
M;W`G/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=CX\
M9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0^(#QD:78^;VYE
M('%U87)T97(@:6UM961I871E('9E<W1I;F<@=VET:"!T:&4@<F5M86EN:6YG
M(&]V97(@=&AR964@>65A<G,L/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0^(#QD:78^/&9O;G0^)B,X.3`Q.SPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D/B`\9&EV/F]N92!Q=6%R=&5R(&EM;65D:6%T92!V97-T
M:6YG('=I=&@@=&AE(')E;6%I;FEN9R!O=F5R(#,S(&UO;G1H<SL@86YD/"]D
M:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M=&]P)SX@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^
M/&9O;G0^)B,X.3`Q.SPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/FUO
M;G1H;'D@;W9E<B!T:')E92!Y96%R<RX\+V1I=CX@/"]T9#X@/"]T<CX@/"]T
M86)L93X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M
M,3<N-G!T.R!-05)'24XZ(#!P="`P<'@@,'!T(#@P+C-P=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.R8C,38P
M.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!A;&EG;CTS1&IU<W1I9GD^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y$=7)I;F<@=&AE('1H<F5E
M(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2P@=&AE($-O;7!A;GD@9W)A
M;G1E9"`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@-34P+#`P,#PO9F]N
M=#X@;W!T:6]N<R!T;R!E;7!L;WEE97,@:&%V:6YG(&%N(&%P<')O>&EM871E
M(&9A:7(@=F%L=64@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C@Q
M-RPP,#`\+V9O;G0^(&)A<V5D('5P;VX@=&AE($)L86-K+5-C:&]L97,@;W!T
M:6]N('!R:6-I;F<@;6]D96PN)B,Q-C`[1'5R:6YG('1H92!S86UE('!E<FEO
M9"!I;B`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/B`U.#<L-3`P/"]F;VYT/B!O<'1I;VYS('1O(&5M<&QO
M>65E<R!A;F0@8V]N<W5L=&%N=',@:&%V:6YG(&%N(&%P<')O>&EM871E(&9A
M:7(@=F%L=64@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$N-#PO
M9F]N=#X@;6EL;&EO;B!B87-E9"!U<&]N('1H92!";&%C:RU38VAO;&5S(&]P
M=&EO;B!P<FEC:6YG(&UO9&5L+CPO9&EV/B`F(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T
M:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/D$@<W5M;6%R>2!O9B!S=&]C
M:R!O<'1I;VX@86-T:79I=&EE<R!A<R!O9B!-87)C:"`S,2P@,C`Q-2P@86YD
M(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P@:7,@87,@
M9F]L;&]W<SH\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`S-RXT<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y
M/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!
M3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT
M86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CY796EG:'1E9#PO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,B4^(#QD:78^079E<F%G93PO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N
M/3-$,CX@/&1I=CY796EG:'1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
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M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E
M/B`\9&EV/E)E;6%I;FEN9SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O
M;'-P86X],T0R/B`\9&EV/D%G9W)E9V%T93PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0U,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/D%V
M97)A9V4F(S$V,#M%>&5R8VES93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
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M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E
M/B`\9&EV/D-O;G1R86-T=6%L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,24@8V]L<W!A;CTS1#(^(#QD:78^3W!T:6]N<SPO9&EV/B`\+W1D/B`\=&0@
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)2!C
M;VQS<&%N/3-$,CX@/&1I=CY0<FEC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CY,
M:69E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/E9A;'5E/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0U,"4^(#QD:78^0F%L86YC92`M($1E8V5M8F5R(#,Q
M+"`R,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,L.3`Y+#4X,#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^,2XW.#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C4N
M-3D@>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXW.#4L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E
M/B`\9&EV/D=R86YT960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BPS.#(L-3`P
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
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M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D5X97)C:7-E9#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M*#8L-3@S*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,"XU.#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$-3`E/B`\9&EV/D9O<F9E:71E9#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXH,S`T+#,Y,2D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^,2XY,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0U,"4^(#QD:78^0F%L86YC92`M($1E8V5M8F5R(#,Q+"`R,#$T
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C4L.3@Q+#$P-CPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^,BXP,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C4N.#`@>65A
M<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV
M.#4L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV
M/D=R86YT960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-34P+#`P,#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^,2XU-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CY%>&5R8VES960\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D9O<F9E:71E9#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0U,"4^(#QD:78^0F%L86YC92`M($UA<F-H
M(#,Q+"`R,#$U("T@;W5T<W1A;F1I;F<\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
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M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C8L-3,Q+#$P-CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$N.3<\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BPV,C@L,#`P/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#4P)3X@/&1I=CY"86QA;F-E("T@36%R8V@@,S$L(#(P,34@+2!E>&5R
M8VES86)L93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
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M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^,2XX.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\
M9&EV/C0N.3@@>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXQ+#DS.2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0U,"4^(#QD:78^1W)A;G0@9&%T92!F86ER('9A;'5E(&]F(&]P=&EO
M;G,@9W)A;G1E9"`M($UA<F-H(#,Q+"`R,#$U/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C@Q-RPP,#`\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CY796EG:'1E9"!A
M=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92`M($UA<F-H(#,Q+"`R,#$U
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,"4^(#QD
M:78^1W)A;G0@9&%T92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"`M
M($1E8V5M8F5R(#,Q+"`R,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C0L.3<T+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/E=E:6=H=&5D(&%V97)A
M9V4@9W)A;G0@9&%T92!F86ER('9A;'5E("T@1&5C96UB97(@,S$L(#(P,30\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+C`Y/"]D:78^(#PO=&0^(#QT9"!S
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M,T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`R-RXU<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C
M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T('=E<F4@)#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/C@R-BPP,#`\+V9O;G0^(&%N9"`D/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^,S8R+#`P,#PO9F]N=#XL(')E<W!E8W1I=F5L
M>3PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#(W+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3Y!<R!O9B!-87)C:"`S,2P@,C`Q-2P@=&]T86P@
M=6YR96-O9VYI>F5D('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M(')E;&%T960@=&\@<W1O8VL@;W!T:6]N<R!W87,@)#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/C0N,#PO9F]N=#X@;6EL;&EO;BP@=VAI8V@@:7,@97AP
M96-T960@=&\@8F4@97AP96YS960@=&AR;W5G:"!&96)R=6%R>2`R,#$W+CPO
M9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ
M,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y
M-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-C%C-65D8S=?.3=D-%\T,CDW7V(W-&9?,S<V,&0V-F(P
M,C(R+U=O<FMS:&5E=',O4VAE970Q,2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K(%!U<F-H87-E(%=A<G)A;G1S/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W1O8VL@4'5R8VAA<V4@5V%R<F%N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!0=7)C:&%S
M92!787)R86YT<R!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<^(#QS=')O;F<^-BX\+W-T<F]N9SX@/'-T<F]N9SY3=&]C:R!0
M=7)C:&%S92!787)R86YT<SPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(W+C5P=#L@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'
M24XZ(#!P="`S+C-P="`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^3VX@3V-T;V)E
M<B`Q,"P@,C`Q-"P@=&AE($-O;7!A;GD@<F%I<V5D(&YE="!P<F]C965D<R!O
M9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,3DN,3PO9F]N=#X@;6EL
M;&EO;B!T:')O=6=H('1H92!S86QE(&]F(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/B`Q-"PP-3DL-C$V/"]F;VYT/B!U;FET<R!A="!A('!R:6-E(&]F
M("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ+C0W/"]F;VYT/B!P97(@
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M3E0M4TE:13H@,3!P="<^(#`N-3PO9F]N=#X@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:RX@5&AE('=A<G)A;G1S+"!E>&5R8VES86)L92!F;W(@86X@86=G<F5G
M871E(&]F(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`W+#`R.2PX,#@\
M+V9O;G0^('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL(&AA=F4@86X@97AE<F-I
M<V4@<')I8V4@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$N-S4\
M+V9O;G0^('!E<B!S:&%R92!A;F0@82!L:69E(&]F(&9I=F4@>65A<G,N(%1H
M92!W87)R86YT<R!V97-T960@:6UM961I871E;'D@86YD(&5X<&ER92`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SY/8W1O8F5R(#$P+"`R,#$Y/"]F;VYT
M/BX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T
M(#,N,W!T(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#,N,W!T(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3Y4:&4@=V%R<F%N=',@:7-S=65D(&EN(&-O;FIU
M;F-T:6]N('=I=&@@=&AE(')E9VES=&5R960@9&ER96-T(&]F9F5R:6YG(&EN
M($]C=&]B97(@,C`Q-"!I;F-L=61E(&$@<')O=FES:6]N+"!T:&%T(&EF('1H
M92!#;VUP86YY('=E<F4@=&\@96YT97(@:6YT;R!A(&-E<G1A:6X@=')A;G-A
M8W1I;VXL(&%S(&1E9FEN960@:6X@=&AE(&%G<F5E;65N="P@=&AE('=A<G)A
M;G1S('=O=6QD(&)E('!U<F-H87-E9"!F<F]M('1H92!H;VQD97(@870@82!P
M<F5M:75M+B!!8V-O<F1I;F=L>2P@=&AE($-O;7!A;GD@<F5C;W)D960@=&AE
M('=A<G)A;G1S(&%S(&$@;&EA8FEL:71Y(&%T('1H96ER(&5S=&EM871E9"!F
M86ER('9A;'5E(&]N('1H92!I<W-U86YC92!D871E(&%N9"!C:&%N9V5S(&EN
M(&5S=&EM871E9"!F86ER('9A;'5E('=I;&P@8F4@<F5C;W)D960@87,@;F]N
M+6-A<V@@:6YC;VUE(&]R(&5X<&5N<V4@:6X@=&AE($-O;7!A;GDF(S@R,3<[
M<R!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<R!A="!E86-H('-U8G-E<75E;G0@
M<&5R:6]D+B!!="!-87)C:"`S,2P@,C`Q-2P@=&AE(&9A:7(@=F%L=64@;V8@
M=&AE('=A<G)A;G0@;&EA8FEL:71Y('=A<R`D/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^,3`N.3PO9F]N=#X@;6EL;&EO;BP@=VAI8V@@<F5P<F5S96YT
M960@;F]N+6-A<V@@97AP96YS92!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^-"XR/"]F;VYT/B!M:6QL:6]N(&9O<B!T:&4@=&AR964@;6]N=&AS
M(&5N9&5D($UA<F-H(#,Q+"`R,#$U+B!);B!A8V-O<F1A;F-E('=I=&@@875T
M:&]R:71A=&EV92!A8V-O=6YT:6YG(&=U:61A;F-E+"!T:&4@=V%R<F%N="!W
M87,@=F%L=65D(&]N('1H92!D871E(&]F(&=R86YT(&%N9"!I;B!S=6)S97%U
M96YT('!E<FEO9',@=7-I;F<@=&AE($)L86-K+5-C:&]L97,@=F%L=6%T:6]N
M(&UO9&5L+B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/E1H
M92!A<W-U;7!T:6]N<R!U<V5D(&)Y('1H92!#;VUP86YY(&%R92!S=6UM87)I
M>F5D(&EN('1H92!F;VQL;W=I;F<@=&%B;&4Z/"]D:78^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`S+C-P="`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS
M1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4%,24=..F-E;G1E<CL@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z
M(#$P,"4G(&%L:6=N/3-$8V5N=&5R/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.
M.B`P<'@Z875T;SL@5TE$5$@Z(#DP)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$-#4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$S)2!C;VQS<&%N
M/3-$,CX@/&1I=CY-87)C:"`S,2P\8G(O/B`R,#$U/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$S
M)2!C;VQS<&%N/3-$,CX@/&1I=CY$96-E;6)E<B`S,2P\8G(O/B`R,#$T/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CY)<W-U86YC93QB<B\^
M($1A=&4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#0U)3X@/&1I=CY#;&]S:6YG('-T;V-K('!R:6-E
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C(N,3D\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,B4^(#QD:78^,2XW-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0U
M)3X@/&1I=CY%>'!E8W1E9"!D:79I9&5N9',\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD
M:78^,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXP/"]D:78^
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C`\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B4\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-#4E/B`\9&EV/D5X<&5C=&5D('9O;&%T:6QI='D\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,B4^(#QD:78^.3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B4\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^
M(#QD:78^.3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B4\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV/E)I<VL@9G)E92!I
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C$N,C8\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2XU.3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#0U)3X@/&1I=CY%>'!E8W1E9"!L:69E(&]F('=A<G)A;G0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`V<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,B4^(#QD:78^-"XU-2!Y96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-G!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3(E/B`\9&EV/C0N-SD@>65A<G,\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXU('EE87)S/"]D:78^(#PO=&0^(#QT
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M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`M-BXV<'0[($U!4D=)3CH@,'!T(#,N,W!T
M(#!P="`V+C9P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TV+C9P=#L@34%21TE.
M.B`P<'0@,RXS<'0@,'!T(#8N-G!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#Y4:&4@9F]L;&]W:6YG('1A8FQE
M('-U;6UA<FEZ97,@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F('1H92!W
M87)R86YT(&QI86)I;&ET>2`\:3XH:6X@=&AO=7-A;F1S*3PO:3XZ/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@+38N-G!T
M.R!-05)'24XZ(#!P="`S+C-P="`P<'0@-BXV<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF
M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)
M1TXZ8V5N=&5R.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<@86QI
M9VX],T1C96YT97(^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!P>#IA=71O
M.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D52
M1DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!A;&EG;CTS1&-E;G1E<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$-C4E/B`\9&EV/D)A;&%N8V4@870@1&5C96UB97(@,S$L
M(#(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3(E/B`\9&EV/C8L-S4V/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$-C4E/B`\9&EV/D-H86YG92!I;B!F86ER('9A;'5E(&]F
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M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,B4^(#QD:78^-"PQ-3(\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0V-24^(#QD:78^0F%L86YC92!A="!-87)C:"`S,2P@,C`Q-3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,B4^(#QD:78^,3`L.3`X/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`M-BXV<'0[($U!4D=)3CH@,'!T(#,N,W!T(#!P="`V+C9P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI
M9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z("TV+C9P=#L@34%21TE..B`P<'0@,RXS<'0@
M,'!T(#8N-G!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^07,@;V8@36%R8V@@,S$L(#(P,34L
M(&%L;"!O9B!T:&4@=V%R<F%N=',@<F5M86EN960@;W5T<W1A;F1I;F<N/"]D
M:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@+38N
M-G!T.R!-05)'24XZ(#!P="`S+C-P="`P<'0@-BXV<'0[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF
M>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)
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M9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,2XV,#PO9F]N=#X@86YD
M(&$@;&EF92!O9B!F:79E('EE87)S+B!4:&4@=V%R<F%N=',@=F5S=&5D(&EM
M;65D:6%T96QY(&%N9"!E>'!I<F4@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^3V-T;V)E<B`R-2P@,C`Q-SPO9F]N=#XN(%-I;F-E('1H97-E('=A<G)A
M;G1S('=E<F4@9W)A;G1E9"!A<R!P87)T(&]F(&%N(&5Q=6ET>2!R86ES92P@
M=&AE($-O;7!A;GD@:&%S('1R96%T960@=&AE;2!A<R!A(&1I<F5C="!O9F9E
M<FEN9R!C;W-T+B!4:&4@<F5S=6QT(&]F('1H92!T<F%N<V%C=&EO;B!H87,@
M;F\@869F96-T('1O(&5Q=6ET>2X@5V%R<F%N=',@;W5T<W1A;F1I;F<@87,@
M;V8@36%R8V@@,S$L(#(P,34@=V5R92`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX@,S$V+#4R,CPO9F]N=#XN/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4E.1$5.5#H@,S0N,7!T.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L
M:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#Y!('-U;6UA<GD@;V8@=V%R<F%N
M="!A8W1I=FET>2!F;W(@=&AE($-O;7!A;GD@9F]R('1H92!T:')E92!M;VYT
M:',@96YD960@36%R8V@@,S$L(#(P,34@86YD(&9O<B!T:&4@>65A<B!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q-"!I<R!A<R!F;VQL;W=S.CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,W+C1P=#L@34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(
M.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@
M,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I
M<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#<U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#<U
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD
M:78^3G5M8F5R)B,Q-C`[;V8F(S$V,#M787)R86YT<SPO9&EV/B`\+W1D/B`\
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M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q
M)2!C;VQS<&%N/3-$,CX@/&1I=CY%>&5R8VES928C,38P.U!R:6-E/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0W-24^(#QD:78^0F%L86YC92!A
M="!$96-E;6)E<B`S,2P@,C`Q,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C$L-C,R+#4P,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-S4E/B`\9&EV/D=R86YT960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-RPP,CDL
M.#`X/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXQ+C<U/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-S4E/B`\9&EV/D5X97)C:7-E9#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXQ+C0W/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-S4E/B`\9&EV/D9O<F9E:71E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH
M-#4T+#@Y-BD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^,2XX.#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#<U)3X@/&1I
M=CY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$T/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$N.#`\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0W-24^(#QD:78^1W)A;G1E9#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-S4E/B`\9&EV/D5X97)C:7-E9#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-S4E/B`\9&EV/D9O<F9E:71E9#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#<U)3X@/&1I=CY"86QA;F-E(&%T($UA<F-H(#,Q+"`R,#$U
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C<L.3<T+#<Y-#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2XX
M,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^
M(#PO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,S0N,7!T.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/D$@
M<W5M;6%R>2!O9B!A;&P@;W5T<W1A;F1I;F<@86YD(&5X97)C:7-A8FQE('=A
M<G)A;G1S(&%S(&]F($UA<F-H(#,Q+"`R,#$U(&ES(&%S(&9O;&QO=W,Z/"]D
M:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,S<N
M-'!T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I
M;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE..B`P:6X[
M(%=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D52
M1DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,C`E(&-O;'-P86X],T0R/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q."4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y)2!C
M;VQS<&%N/3-$,CX@/&1I=CY787)R86YT<SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3DE(&-O;'-P86X],T0R/B`\9&EV/E=A<G)A;G1S/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q.24@8V]L<W!A;CTS1#(^(#QD:78^3W5T<W1A;F1I;F<\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q.24@8V]L<W!A;CTS1#(^(#QD:78^17AE<F-I<V%B;&4\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3DE(&-O;'-P86X],T0R/B`\9&EV/DEN=')I;G-I8R8C,38P
M.U9A;'5E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y
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M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q."4^
M(#QD:78^,S$V+#4R,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/C,Q-BPU
M,C(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3@E/B`\9&EV/C(N-3<@>65A<G,\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q."4^(#QD:78^,3@W+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/C<L,#(Y+C@P.#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$X)3X@/&1I=CXW+#`R.2PX,#@\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q."4^(#QD:78^-"XU,R!Y96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q."4^(#QD:78^,RPY
M,#,L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3DE/B`\9&EV/C(N,C(\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q."4^(#QD:78^-3$W+#(U-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXU
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/C$N-C8@>65A
M<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3@E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q.24^(#QD
M:78^,RXS,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXV,2PR,#<\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q."4^(#QD:78^-C$L,C`W/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\
M9&EV/C`N,38@>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/BT\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y)3X@/&1I=CXS+C<U/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X
M)3X@/&1I=CXU,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$X)3X@/&1I=CXU,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q."4^
M(#QD:78^,"XX."!Y96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M<CX@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3DE/B`\9&EV/C$N.#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3@E/B`\9&EV/C<L.3<T+#<Y-#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
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M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXS+#(X
M,"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@
M/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@
M=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C%C-65D8S=?.3=D-%\T
M,CDW7V(W-&9?,S<V,&0V-F(P,C(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,B]7
M;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5F:6-I="D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2!.;W1E(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VMH;VQD
M97)S)R!%<75I='D@3F]T92!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3BU4
M3U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!A;&EG;CTS1&QE9G0^/&(^-RX\
M+V(^(#QB/E-T;V-K:&]L9&5R<R8C.#(Q-SL@17%U:71Y("A$969I8VET*3PO
M8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3BU43U`Z
M(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE.+4)/5%1/33H@,'!T)R!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]D
M:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L
M:6=N/3-$:G5S=&EF>3Y$=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-
M87)C:"`S,2P@,C`Q-2P@=&AE($-O;7!A;GD@:7-S=65D(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`R,3(L.#0S/"]F;VYT/B!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K('1O(%!R978@04)2($Q,0RP@=VET:"!A(&9A:7(@=F%L=64@
M;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C,U,"PP,#`\+V9O;G0^
M+"8C,38P.SQF;VYT('-T>6QE/3-$)U=)1$]74SH@,3L@5$585"U44D%.4T9/
M4DTZ(&YO;F4[(%1%6%0M24Y$14Y4.B`P<'@[($1)4U!,05DZ(&EN;&EN92`A
M:6UP;W)T86YT.R!&3TY4.B`Q,W!X("=4:6UE<R!.97<@4F]M86XG+"!4:6UE
M<RP@<V5R:68[(%=(251%+5-004-%.B!N;W)M86P[($9,3T%4.B!N;VYE.R!,
M151415(M4U!!0TE.1SH@;F]R;6%L.R!#3TQ/4CH@<F=B*#`L,"PP*3L@5T]2
M1"U34$%#24Y'.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>"<^('1H870@=V%S/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/CPO9F]N=#X@/&9O;G0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@5TE$3U=3.B`Q.R!415A4+51204Y31D]233H@;F]N93L@5$585"U)
M3D1%3E0Z(#!P>#L@5TA)5$4M4U!!0T4Z(&YO<FUA;#L@3$545$52+5-004-)
M3D<Z(&YO<FUA;#L@0T],3U(Z(')G8B@P+#`L,"D[(%=/4D0M4U!!0TE.1SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R
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M9V4@;V8@=&AE(&]P96YI;F<@86YD(&-L;W-I;F<@<')I8V5S(&]F)B,Q-C`[
M/&9O;G0@<W1Y;&4],T0G5TE$3U=3.B`Q.R!415A4+51204Y31D]233H@;F]N
M93L@5$585"U)3D1%3E0Z(#!P>#L@1$E34$Q!63H@:6YL:6YE("%I;7!O<G1A
M;G0[($9/3E0Z(#$S<'@@)U1I;65S($YE=R!2;VUA;B<L(%1I;65S+"!S97)I
M9CL@5TA)5$4M4U!!0T4Z(&YO<FUA;#L@1DQ/050Z(&YO;F4[($Q%5%1%4BU3
M4$%#24Y'.B!N;W)M86P[($-/3$]2.B!R9V(H,"PP+#`I.R!73U)$+5-004-)
M3D<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X)SX@=&AE
M($-O;7!A;GDF(S@R,3<[<SPO9F]N=#X@<W1O8VL@;VX@=&AE(&1A=&4@96%C
M:"!M:6QE<W1O;F4@=V%S(&%C:&EE=F5D(&%S('-P96-I9FEE9"!I;B!T:&4@
M07-S970@4'5R8VAA<V4@06=R965M96YT+CPO9&EV/B`\+V1I=CX\=&%B;&4@
M8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z
M9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\
M=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P
M9#8V8C`R,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C%C-65D
M8S=?.3=D-%\T,CDW7V(W-&9?,S<V,&0V-F(P,C(R+U=O<FMS:&5E=',O4VAE
M970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/DYE="!,;W-S('!E<B!3:&%R93QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5A<FYI;F=S(%!E<B!3:&%R92!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5A<FYI;F=S(%!E<B!3:&%R92!;5&5X="!";&]C:UT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XM5$]0.B`P
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU"3U143TTZ(#!P="<^(#QB/C@N/"]B/B`\8CY.970@3&]S<R!P
M97(@4VAA<F4\+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4E.1$5.5#H@,C<N-7!T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S
M=&EF>3X\8CXF(S$V,#L\+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
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M92!A="!-87)C:"`S,2P@,C`Q-"!A;F0@,C`Q-2P@87,@<W5C:"!T:&5R92!I
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M(#,Q+"`R,#$U('=E<F4@-BPU,S$L,3`V(&%N9"`W+#DW-"PW.30L(')E<W!E
M8W1I=F5L>2P@86YD(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H
M(#,Q+"`R,#$T('=E<F4@-"PT.3`L-#DW(&%N9"`Y-C,L,38X+"!R97-P96-T
M:79E;'DN/"]D:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$
M)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L
M93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8Q
M8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S
M-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M2T@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4V5L96-T960@0F%L86YC92!3
M:&5E="!);F9O<FUA=&EO;B`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0V]N
M<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA;"!3=&%T
M96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@3W1H97(@0W5R<F5N="!!<W-E
M=',@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,T+C%P=#L@34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/"]D:78^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\:3Y0
M<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&%S<V5T<R`H:6X@
M=&AO=7-A;F1S*3H\+VD^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4E.1$5.5#H@,C<N-7!T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$
M:G5S=&EF>3X\:3XF(S$V,#L\+VD^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)
M1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN.R!72414
M2#H@.3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@
M=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG
M;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$-C$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$S)2!C;VQS<&%N
M/3-$,CX@/&1I=CY-87)C:"8C,38P.S,Q+"8C,38P.S(P,34\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2PP
M-C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,2PP-C<\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3(E/B`\9&EV/C(R.#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8Q
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M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
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M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
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M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-C$E/B`\9&EV/E1O=&%L/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ
M+#4W-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,B4^(#QD:78^,2PU-#@\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O
M<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I
M>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D
M/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I
M<&UE;G0@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/&D^4')O
M<&5R='D@86YD(&5Q=6EP;65N="`H:6X@=&AO=7-A;F1S*3H\+VD^)B,Q-C`[
M("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#(W+C5P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M
M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3CH@,&EN.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CY-87)C:"8C,38P.S,Q+"8C,38P
M.S(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^,3$Q/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/CDS/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-3$E/B`\9&EV/E-O9G1W87)E/"]D:78^(#PO=&0^
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M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
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M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,C(\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ,#0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^*#0W*3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-3$E/B`\9&EV/E1O=&%L/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXW-3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,B4^(#QD:78^-C4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y
M;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\
M+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C<G5E9"!%>'!E;G-E<R!;5&%B;&4@5&5X="!";&]C:UT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4
M+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#PO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I
M9GD^/&D^06-C<G5E9"!E>'!E;G-E<R`H:6X@=&AO=7-A;F1S*3H\+VD^/"]D
M:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,C<N
M-7!T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\:3XF(S$V,#L\
M+VD^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,24=.
M.DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@.#`E.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX@/&1I=CY-87)C:"8C
M,38P.S,Q+"8C,38P.S(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^
M(#QD:78^1&5C96UB97(F(S$V,#LS,2PF(S$V,#LR,#$T/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
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M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C(T-SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CY!8V-R=65D('9E
M;F1O<B!P87EM96YT<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXR,C4\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
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M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-3$E/B`\9&EV/D%C8W)U960@;6EL97-T;VYE('!A>6UE;G1S/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/C$L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C,U
M,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CY!8V-R
M=65D(&-L:6YI8V%L(&-O;G-U;'1I;F<@<V5R=FEC97,\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ+#,T-SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C4R-3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CY4;W1A;#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,B4^(#QD:78^,BPV-#8\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C$L,CDX/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/"]D:78^(#PO9&EV
M/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE
M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B
M-S1F7S,W-C!D-C9B,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H
M965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D8^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&ES8VQO<W5R92!O9B!#;VUP96YS871I;VX@4F5L871E9"!#;W-T<RP@4VAA
M<F4M8F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS
M871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R
M9"!/<'1I;VYS(&%N9"!787)R86YT<R!697-T960@86YD($5X<&5C=&5D('1O
M(%9E<W0@3W5T<W1A;F1I;F<@86YD($5X97)C:7-A8FQE(%M486)L92!497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/E1H92!";&%C:RU3
M8VAO;&5S(&%S<W5M<'1I;VYS('5S960@:6X@=&AE('1H<F5E(&UO;G1H<R!E
M;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"!A<F4@87,@9F]L;&]W<SH\
M+V1I=CX@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(#!P>"!S;VQI
M9#L@0D]21$52+4Q%1E0Z(#!P>"!S;VQI9#L@5TE$5$@Z(#$P,"4[($9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+51/4#H@,'!X('-O;&ED.R!"3U)$15(M4DE'
M2%0Z(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!72414
M2#H@,3`P)2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,S<N-'!T.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@
M5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE..B`P:6X[(%=)
M1%1(.B`V,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7
M.B!V:7-I8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L
M:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0R-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S(E(&-O;'-P
M86X],T0V/B`\9&EV/E1H<F5E)B,Q-C`[36]N=&AS)B,Q-C`[16YD960F(S$V
M,#M-87)C:"8C,38P.S,Q+#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0R-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX@/&1I=CXR,#$U
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)2!C;VQS<&%N
M/3-$,CX@/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,30E/B`\
M9&EV/C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-"4^(#QD:78^,#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)3PO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0R-B4^(#QD:78^17AP96-T960@=F]L871I;&ET
M>3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-"4^(#QD
M:78^,3,Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXE/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$T)3X@/&1I=CXQ,C8\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B4\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,C8E/B`\9&EV/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$T)3X@/&1I=CXR+C`S/"]D
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M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(V)3X@
M/&1I=CY%>'!E8W1E9"!L:69E(&]F(&]P=&EO;CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M14E'2%0Z(#0P,"<@=VED=&@],T0Q-"4^(#QD:78^,3`@>65A<G,\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M,T0Q-"4^(#QD:78^-2!Y96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#(V)3X@/&1I=CY%>'!E8W1E9"!F;W)F96ET=7)E<SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-"4^(#QD:78^,#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M(#QD:78^,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE
M/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED
M=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3=&]C:R!/
M<'1I;VYS+"!!8W1I=FET>2!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
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M5#H@,S<N-'!T.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ
M3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@
M<W1Y;&4],T0G34%21TE..B`P:6X[(%=)1%1(.B`Q,#`E.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3(E/B`\9&EV/D%V97)A9V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I
M=CY296UA:6YI;F<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N
M/3-$,CX@/&1I=CY!9V=R96=A=&4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY!=F5R86=E
M)B,Q-C`[17AE<F-I<V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I
M=CY#;VYT<F%C='5A;#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
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M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O;'-P
M86X],T0R/B`\9&EV/DEN=')I;G-I8SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0U,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O
M;'-P86X],T0R/B`\9&EV/D]P=&EO;G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^3&EF93PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY686QU93PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,"4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-3`E/B`\9&EV/D)A;&%N8V4@+2!$96-E;6)E<B`S,2P@,C`Q
M,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS+#DP.2PU.#`\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/C$N-S@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXU+C4Y('EE
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M-S@U+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(L,S@R+#4P,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^,BXS-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CY%>&5R8VES960\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@V+#4X
M,RD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C`N-3@\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#4P)3X@/&1I=CY&;W)F96ET960\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^*#,P-"PS.3$I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C$N.3,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-3`E/B`\9&EV/D)A;&%N8V4@+2!$96-E;6)E<B`S,2P@,C`Q-#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXU+#DX,2PQ,#8\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(N
M,#$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXU+C@P('EE87)S/"]D
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M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-C@U+#`P
M,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CY'<F%N
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C4U,"PP,#`\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/C$N-30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#4P)3X@/&1I=CY&;W)F96ET960\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D)A;&%N8V4@+2!-87)C:"`S,2P@
M,C`Q-2`M(&]U='-T86YD:6YG/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXV+#4S,2PQ,#8\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+CDW/"]D:78^(#PO=&0^(#QT
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M=&@],T0Q,B4^(#QD:78^-2XW.2!Y96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(L-C(X+#`P,#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U
M,"4^(#QD:78^0F%L86YC92`M($UA<F-H(#,Q+"`R,#$U("T@97AE<F-I<V%B
M;&4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/C0L,38X+#`T,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C$N.#D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXT
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M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^,2PY,SDL,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-3`E/B`\9&EV/D=R86YT(&1A=&4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R
M86YT960@+2!-87)C:"`S,2P@,C`Q-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXX,3<L,#`P/"]D:78^(#PO=&0^(#QT9"!S
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M,T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M,"<@=VED=&@],T0Q,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0U,"4^(#QD:78^5V5I9VAT960@879E<F%G
M92!G<F%N="!D871E(&9A:7(@=F%L=64@+2!-87)C:"`S,2P@,C`Q-3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M,2XT.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D=R
M86YT(&1A=&4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960@+2!$96-E
M;6)E<B`S,2P@,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXT+#DW-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CY796EG:'1E9"!A=F5R86=E(&=R
M86YT(&1A=&4@9F%I<B!V86QU92`M($1E8V5M8F5R(#,Q+"`R,#$T/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^,BXP.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\
M+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B
M,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y
M-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#$V
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,4%!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=&]C:R!0=7)C:&%S92!787)R86YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K(%!U<F-H
M87-E(%=A<G)A;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!-96%S=7)E;65N=',L
M(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG+"!686QU871I;VX@5&5C:&YI
M<75E<R!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`S+C-P="`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A
M;&EG;CTS1&IU<W1I9GD^5&AE(&%S<W5M<'1I;VYS('5S960@8GD@=&AE($-O
M;7!A;GD@87)E('-U;6UA<FEZ960@:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#,N
M,W!T(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ8V5N=&5R.R!415A4+4E.
M1$5.5#H@,&EN.R!724142#H@,3`P)2<@86QI9VX],T1C96YT97(^(#QT86)L
M92!S='EL93TS1"=-05)'24XZ(#!P>#IA=71O.R!724142#H@.3`E.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0T-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3,E(&-O;'-P86X],T0R/B`\9&EV/DUA<F-H(#,Q+#QB<B\^(#(P
M,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/B`\9&EV/D1E8V5M8F5R
M(#,Q+#QB<B\^(#(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/B`\
M9&EV/DES<W5A;F-E/&)R+SX@1&%T93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV/D-L
M;W-I;F<@<W1O8VL@<')I8V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^
M(#QD:78^,BXQ.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3(E/B`\9&EV/C$N-#8\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ+C<U/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV/D5X<&5C=&5D(&1I=FED96YD<SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3(E/B`\9&EV/C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B4\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^
M,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T-24^(#QD:78^17AP96-T960@
M=F]L871I;&ET>3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXY,#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXY,#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$R)3X@/&1I=CXY-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^
M(#QD:78^,2XR-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXQ
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M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C$N,SD\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B4\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV/D5X<&5C=&5D(&QI9F4@
M;V8@=V%R<F%N=#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXT+C4U('EE87)S/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`V<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,B4^(#QD:78^-"XW.2!Y96%R
M<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-G!X
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C4@>65A
M<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE
M/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED
M=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@3V8@17-T:6UA=&5D($9A:7(@5F%L=64@3V8@5&AE(%=A<G)A
M;G0@3&EA8FEL:71Y(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@
M)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M-BXV
M<'0[($U!4D=)3CH@,'!T(#,N,W!T(#!P="`V+C9P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y
M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M("TV+C9P=#L@34%21TE..B`P<'0@,RXS<'0@,'!T(#8N-G!T.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!E<W1I
M;6%T960@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N="!L:6%B:6QI='D@/&D^
M*&EN('1H;W5S86YD<RD\+VD^.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z("TV+C9P=#L@34%21TE..B`P<'0@,RXS<'0@
M,'!T(#8N-G!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M415A4+4%,24=..F-E;G1E<CL@5$585"U)3D1%
M3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G(&%L:6=N/3-$8V5N=&5R/B`\=&%B;&4@
M<W1Y;&4],T0G34%21TE..B`P<'@Z875T;SL@5TE$5$@Z(#@P)3L@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8U)3X@/&1I
M=CY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$T/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'
M2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I
M=CXV+#<U-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8U)3X@/&1I
M=CY#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT(&QI86)I;&ET>3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C0L
M,34R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C4E/B`\9&EV/D)A
M;&%N8V4@870@36%R8V@@,S$L(#(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3(E/B`\9&EV/C$P+#DP.#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO
M9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ
M,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE
M9'5L92!/9B!787)R86YT($%C=&EV:71Y(%M486)L92!497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`S-"XQ<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y
M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!A;&EG;CTS1&IU<W1I9GD^02!S=6UM87)Y(&]F('=A<G)A;G0@86-T:79I
M='D@9F]R('1H92!#;VUP86YY(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H(#,Q+"`R,#$U(&%N9"!F;W(@=&AE('EE87(@96YD960@1&5C96UB
M97(@,S$L(#(P,30@:7,@87,@9F]L;&]W<SH\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`S-RXT<'0[($U!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^
M(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F=#X@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0W-24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/E=E:6=H=&5D)B,Q-C`[079E<F%G
M93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0W-24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/DYU;6)E
M<B8C,38P.V]F)B,Q-C`[5V%R<F%N=',\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,24@8V]L<W!A
M;CTS1#(^(#QD:78^17AE<F-I<V4F(S$V,#M0<FEC93PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-S4E/B`\9&EV/D)A;&%N8V4@870@1&5C96UB
M97(@,S$L(#(P,3,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXQ+#8S,BPU,#$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^,2XY.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#<U)3X@/&1I
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C<L,#(Y+#@P.#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^,2XW-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#<U)3X@/&1I=CY%>&5R8VES960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@R,S(L-C$Y*3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^,2XT-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#<U)3X@/&1I
M=CY&;W)F96ET960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$N.#@\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0W-24^(#QD:78^0F%L86YC
M92!A="!$96-E;6)E<B`S,2P@,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/C<L.3<T+#<Y-#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-S4E/B`\9&EV/D=R86YT960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#<U)3X@/&1I=CY%>&5R8VES960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#<U)3X@/&1I=CY&;W)F96ET960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0W-24^(#QD:78^0F%L86YC92!A="!-87)C:"`S,2P@,C`Q-3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXW+#DW-"PW.30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$N.#`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@
M/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@
M=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@
M3V8@5V%R<F%N="!/=71S=&%N9&EN9R!A;F0@17AE<F-I<V%B;&4@6U1A8FQE
M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#,T+C%P=#L@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P="<^02!S=6UM87)Y(&]F
M(&%L;"!O=71S=&%N9&EN9R!A;F0@97AE<F-I<V%B;&4@=V%R<F%N=',@87,@
M;V8@36%R8V@@,S$L(#(P,34@:7,@87,@9F]L;&]W<SH\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`S-RXT<'0[($U!4D=)
M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@
M,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P
M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I
M8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$
M;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0R,"4@8V]L<W!A;CTS1#(^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CY7
M96EG:'1E9"8C,38P.T%V97)A9V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q."4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#(P)2!C;VQS<&%N/3-$,CX@/&1I=CY%
M>&5R8VES93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3DE(&-O;'-P86X],T0R
M/B`\9&EV/E=A<G)A;G1S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$X)3X@/&1I=CY296UA:6YI;F<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y
M)2!C;VQS<&%N/3-$,CX@/&1I=CY!9V=R96=A=&4\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#(P)2!C;VQS<&%N/3-$,CX@/&1I=CY0<FEC93PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$Y)2!C;VQS<&%N/3-$,CX@/&1I=CY/=71S=&%N9&EN9SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$Y)2!C;VQS<&%N/3-$,CX@/&1I=CY%>&5R8VES86)L93PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$X)3X@/&1I=CY#;VYT<F%C='5A;"8C,38P.TQI9F4\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M.24@8V]L<W!A;CTS1#(^(#QD:78^26YT<FEN<VEC)B,Q-C`[5F%L=64\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3DE/B`\9&EV/C$N
M-C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXS,38L
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M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q."4^(#QD:78^,S$V+#4R,CPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M."4^(#QD:78^,BXU-R!Y96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X
M)3X@/&1I=CXQ.#<L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3DE/B`\9&EV/C$N
M-S4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q."4^(#QD:78^-RPP,CDN.#`X/"]D:78^(#PO=&0^
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3@E/B`\9&EV/C<L,#(Y+#@P.#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@
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M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXS+#DP,RPP,#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q.24^(#QD:78^,BXR,CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@
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M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/C4Q-RPR-3<\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q."4^(#QD:78^,2XV-B!Y96%R<SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M."4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$Y)3X@/&1I=CXS+C,P/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3@E/B`\9&EV/C8Q+#(P-SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I
M=CXV,2PR,#<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q."4^(#QD:78^,"XQ-B!Y
M96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q."4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3DE/B`\9&EV/C,N-S4\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/C4P
M+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\
M9&EV/C4P+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXP+C@X
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M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q.24^(#QD:78^,2XX,#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$X)3X@/&1I=CXW+#DW-"PW.30\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
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M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E
M/B`\9&EV/C0N,C$@>65A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3@E/B`\9&EV/C,L,C@P+#`P,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P="<^/"]D:78^(#PO9&EV/B`\+V1I=CX\=&%B
M;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO
M=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S
M-S8P9#8V8C`R,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C%C
M-65D8S=?.3=D-%\T,CDW7V(W-&9?,S<V,&0V-F(P,C(R+U=O<FMS:&5E=',O
M4VAE970Q-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P139'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/DUA;F%G96UE;G0G<R!0;&%N("A$971A:6QS(%1E>'1U86PI("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY-86YA9V5M96YT)W,@4&QA;B!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU
M;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q,3,L-#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,3`Q+#`T,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D
M-C9B,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C
M-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E
M=#$X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%0T1!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<R`H1&5T86EL
M<R!497AT=6%L*2`H36]N97D@36%R:V5T($%C8V]U;G1S(%M-96UB97)=+"!5
M4T0@)"D\8G(^26X@36EL;&EO;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-;VYE>2!-87)K970@06-C;W5N=',@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!%<75I=F%L96YT<RP@870@
M0V%R<GEI;F<@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@."XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,RXV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C%C-65D8S=?.3=D-%\T
M,CDW7V(W-&9?,S<V,&0V-F(P,C(R+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14%&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4V5L96-T
M960@0F%L86YC92!3:&5E="!);F9O<FUA=&EO;B`H1&5T86EL<RD@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D]T:&5R($-U<G)E;G0@07-S971S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1R
M97AO;B!P<F5P86ED(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`V,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PP
M-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R97!A:60@:6YS=7)A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3<T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4T.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C%C-65D8S=?.3=D-%\T
M,CDW7V(W-&9?,S<V,&0V-F(P,C(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,B]7
M;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$541D%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/E-E;&5C=&5D($)A;&%N8V4@4VAE970@26YF;W)M
M871I;VX@*$1E=&%I;',@,2D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0
M;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@
M86YD($5Q=6EP;65N="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@86-C=6UU;&%T960@9&5P<F5C:6%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M<'5T97(@86YD(&]F9FEC92!E<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA
M;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N
M9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V]F='=A<F4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD
M($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I
M<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-C%C-65D8S=?.3=D-%\T,CDW7V(W-&9?,S<V,&0V-F(P,C(R#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8Q8S5E9&,W7SDW9#1?-#(Y-U]B
M-S1F7S,W-C!D-C9B,#(R,B]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5!2$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/E-E;&5C=&5D($)A
M;&%N8V4@4VAE970@26YF;W)M871I;VX@*$1E=&%I;',@,BD@*%531"`D*3QB
M<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D%C8W)U960@17AP96YS97,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;6%N
M=69A8W1U<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-R=65D('9E;F1O<B!P87EM96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&UI;&5S
M=&]N92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@8VQI;FEC86P@8V]N<W5L=&EN9R!S97)V:6-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS-#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#8T-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PR.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,@T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y-V0T7S0R.3=?8C<T
M9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%24A!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX@*$1E=&%I;',I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS
M871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R
M9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AP96-T960@9&EV:61E;F1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S$N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(V
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(N,#,E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2XU-R4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&QI9F4@;V8@
M=V%R<F%N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>'!E8W1E9"!F;W)F96ET=7)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C%C-65D8S=?.3=D-%\T,CDW7V(W
M-&9?,S<V,&0V-F(P,C(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,B]7;W)K<VAE
M971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5/4$%'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL<R`Q
M*2`H4W1O8VL@3W!T:6]N(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K($]P=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PY.#$L,3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY,#DL-3@P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS+"!'
M<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPS.#(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<'1I;VYS+"!%>&5R8VES960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V+#4X,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,L($9O<F9E:71E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,P-"PS.3$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I
M;VYS+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPU,S$L,3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PY.#$L,3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY,#DL-3@P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS+"!%
M>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ
M-C@L,#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!"96=I
M;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E
M+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N
M-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(N,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4L($5X
M97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!&;W)F96ET
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XY,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@16YD:6YG($)A;&%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XY-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXP
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,2XW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@17AE
M<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF
M92P@0F%L86YC92!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^-2!Y96%R<R`Y(&UO;G1H<R`Q-"!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<R`Y(&UO
M;G1H<R`Q."!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^-2!Y96%R<R`W(&UO;G1H<R`R(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D
M($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4L($5X97)C:7-A
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S(#$Q
M(&UO;G1H<R`R,R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!"
M96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`V.#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`W.#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A
M;'5E+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPV,C@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C@U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<X-2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R
M:6YS:6,@5F%L=64L($5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#DS.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT(&1A=&4@9F%I<B!V86QU92!O
M9B!O<'1I;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.#$W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-"PY-S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&=R
M86YT(&1A=&4@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R+C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V
M8C`R,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C%C-65D8S=?
M.3=D-%\T,CDW7V(W-&9?,S<V,&0V-F(P,C(R+U=O<FMS:&5E=',O4VAE970R
M-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14E40TD^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS(%1E>'1U86PI("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,#$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`P-SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#(P+"`R,#`W/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DYO=BX@,#(L(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3V-T+B`R,BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I
M;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS
M871I;VXL($YO;G9E<W1E9"!!=V%R9',L($-O;7!E;G-A=&EO;B!.;W0@>65T
M(%)E8V]G;FEZ960L(%-T;V-K($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!!9&UI;FES
M=')A=&EV92!%>'!E;G-E<R!A;F0@4F5S96%R8V@@86YD($1E=F5L;W!M96YT
M($5X<&5N<V4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06QL;V-A=&5D(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,C8L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8R+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16UP;&]Y965S($%N9"!#;VYS=6QT86YT<R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O
M;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT
M($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N
M<RP@1W)A;G1S(&EN(%!E<FEO9"P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4X-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO
M;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/
M<'1I;VYS+"!'<F%N=',@:6X@4&5R:6]D+"!&86ER(%9A;'5E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D
M($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM
M96YT($%W87)D+"!/<'1I;VYS+"!'<F%N=',@:6X@4&5R:6]D+"!'<F]S<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($=R86YT<R!I;B!097)I;V0L($9A
M:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#$W
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^,C`P,2!3=&]C:R!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E
M;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!/
M=71S=&%N9&EN9RP@3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV.#(L-#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XR,#`Q(%-T;V-K(%!L86X@6TUE;6)E<ET@?"!-87AI
M;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E
M9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!'<F%N=',@:6X@4&5R:6]D+"!'
M<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M,C`P-R!3=&]C:R!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B
M>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!/=71S=&%N
M9&EN9RP@3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,C@L-C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#XR,#`W(%-T;V-K(%!L86X@6TUE;6)E<ET@?"!-
M87AI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB
M87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!'<F%N=',@:6X@4&5R:6]D
M+"!'<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^,C`Q,"!3=&]C:R!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N
M="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!/=71S
M=&%N9&EN9RP@3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#0R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3`@4W1O8VL@4&QA;B!;365M8F5R
M72!\($UA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N(%-T;V-K+"!#87!I=&%L(%-H87)E<R!297-E<G9E9"!F;W(@
M1G5T=7)E($ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/C(P,3`@4W1O8VL@4&QA;B!;365M8F5R72!\($UI;FEM
M=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@
M8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M(%-T;V-K+"!#87!I=&%L(%-H87)E<R!297-E<G9E9"!F;W(@1G5T=7)E($ES
M<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8Q
M8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,@T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S
M-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M5$A!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!0=7)C:&%S92!7
M87)R86YT<R`H1&5T86EL<RD@*%-T;V-K(%=A<G)A;G1S(%M-96UB97)=+"!5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y/8W0N(#$P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@5V%R<F%N=',@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY&86ER(%9A;'5E($UE87-U<F5M96YT<RP@4F5C=7)R:6YG(&%N9"!.;VYR
M96-U<G)I;F<L(%9A;'5A=&EO;B!496-H;FEQ=65S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&]S
M:6YG('-T;V-K('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$N-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(N,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$N-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&1I=FED96YD<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S="!R
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C,Y)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,C8E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2XU.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D(&QI9F4@;V8@=V%R<F%N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,@-B!M;VYT:',@,3@@
M9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C0@>65A<G,@.2!M;VYT:',@,30@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C%C-65D8S=?.3=D-%\T,CDW7V(W
M-&9?,S<V,&0V-F(P,C(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,B]7;W)K<VAE
M971S+U-H965T,C8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)1$%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-T;V-K(%!U<F-H87-E(%=A<G)A;G1S("A$971A:6QS(#$I
M("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P
M96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<RP@4F5C=7)R:6YG(&%N
M9"!.;VYR96-U<G)I;F<L(%9A;'5A=&EO;B!496-H;FEQ=65S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V+#<U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=V%R<F%N
M="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PQ-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q,"PY,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B
M,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y
M-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#(W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%2D-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=&]C:R!0=7)C:&%S92!787)R86YT<R`H1&5T86EL<R`R*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(%=A<G)A;G1S+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPY-S0L-SDT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,S(L-3`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@5V%R<F%N=',L($=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#`R.2PX,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!787)R86YT<RP@
M17AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C,R
M+#8Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!787)R86YT<RP@1F]R9F5I=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#4T+#@Y-BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!7
M87)R86YT<RP@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<L.3<T+#<Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<L.3<T+#<Y-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G
M92!%>&5R8VES92!0<FEC92P@0F5G:6YN:6YG($)A;&%N8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+CDY/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-S4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M17AE<F-I<V4@4')I8V4L($5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E+"!&;W)F96ET960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0
M<FEC92P@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B
M,#(R,@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y
M-V0T7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#(X
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%6$="1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=&]C:R!0=7)C:&%S92!787)R86YT<R`H1&5T86EL<R`S*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E
M(%!R:6-E(#$N-C`@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2XV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S$V+#4R,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@17AE<F-I<V%B
M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q-BPU,C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(@>65A<G,@-B!M;VYT:',@
M,C4@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!V86QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.#<L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC
M92`Q+C<U(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$N-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#`R.2XX,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`R.2PX,#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,@-B!M;VYT:',@
M,3$@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!V86QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY,#,L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC
M92`R+C(R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(N,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,3<L,C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$W+#(U-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,2!Y96%R(#<@;6]N=&AS(#(X(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E(#,N,S`@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C$L,C`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C$L,C`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I
M;FEN9R!#;VYT<F%C='5A;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XQ(&UO;G1H(#(X(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@
M=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E(%!R:6-E(#,N-S4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@
M07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RXW-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@17AE<F-I
M<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`@;6]N=&AS(#$W(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E(#$N.#`@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPY-S0L-SDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-RPY-S0L-SDT/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E
M(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XT('EE87)S(#(@;6]N=&AS(#$V(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E
M9V%T92!);G1R:6YS:6,@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPR.#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?8C<T9E\S-S8P9#8V
M8C`R,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C%C-65D8S=?
M.3=D-%\T,CDW7V(W-&9?,S<V,&0V-F(P,C(R+U=O<FMS:&5E=',O4VAE970R
M.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14PT04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W1O8VL@4'5R8VAA<V4@5V%R<F%N=',@*$1E=&%I;',@5&5X='5A;"D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D]C="X@,C4L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^3V-T+B`Q,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($%D:G5S=&UE
M;G0@;V8@5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-"PQ-3(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY,#@L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW-38L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;&%S<R!O9B!787)R86YT(&]R(%)I9VAT+"!/=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$V+#4R,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC
M92!/9B!787)R86YT<R!4;R!0=7)C:&%S92!/9B!#;VUM;VX@4W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S-2PX-34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M($5X97)C:7-A8FQE(%!R:6-E(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G0@5V%R<F%N=',@17AP
M:7)A=&EO;B!$871E,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M3V-T(#(U+`T*"0DR,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!787)R86YT<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M($ES
M<W5A;F-E(&]F($-O;6UO;B!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3DL,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!3=&]C:RP@3G5M8F5R(&]F
M(%-H87)E<R!)<W-U960@:6X@5')A;G-A8W1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T+#`U.2PV,38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@;V8@4W1O8VLL(%!R
M:6-E(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!/9B!787)R86YT<R!4;R!0=7)C:&%S92!/9B!#
M;VUM;VX@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H
M87)E($)A<V5D(%!A>6UE;G0@07=A<F0@5V%R<F%N=',@17AE<F-I<V%B;&4@
M3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`R.2PX
M,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE(%!R:6-E(%!E<B!3:&%R93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C<U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E
M($%D:G5S=&UE;G0@;V8@5V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PR,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E
M<W1M96YT(%=A<G)A;G1S($5X<&ER871I;VX@1&%T93$\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/D]C="`Q,"P-"@D),C`Q.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C%C-65D8S=?.3=D-%\T
M,CDW7V(W-&9?,S<V,&0V-F(P,C(R#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,B]7
M;W)K<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$1D%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("A$969I8VET
M*2`H1&5T86EL<R!497AT=6%L*2`H4')E=B!!8G(@3&QC(%M-96UB97)=+"!5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E=B!!8G(@3&QC(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S($5Q=6ET>2!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VL@27-S=65D($1U<FEN9R!097)I;V0L(%-H87)E<RP@3F5W($ES
M<W5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$R+#@T,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17%U:71Y($ES<W5E9"!I;B!"=7-I;F5S<R!#;VUB:6YA=&EO;BP@1F%I<B!6
M86QU92!$:7-C;&]S=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S8Q8S5E9&,W7SDW9#1?-#(Y-U]B-S1F7S,W-C!D-C9B,#(R,@T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,6,U961C-U\Y-V0T7S0R
M.3=?8C<T9E\S-S8P9#8V8C`R,C(O5V]R:W-H965T<R]3:&5E=#,Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%04M!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.970@3&]S
M<R!P97(@4VAA<F4@*$1E=&%I;',@5&5X='5A;"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='D@3W!T:6]N(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&ED:6QU
M=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@
M16%R;FEN9W,@4&5R(%-H87)E+"!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8L-3,Q+#$P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#DP+#0Y-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I9&EL
M=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F
M($5A<FYI;F=S(%!E<B!3:&%R92P@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#DW-"PW.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-C,L,38X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T7S0R.3=?
M8C<T9E\S-S8P9#8V8C`R,C(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
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M9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT
M;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\V,6,U961C-U\Y-V0T
;7S0R.3=?8C<T9E\S-S8P9#8V8C`R,C(M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EL4AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 25, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 10, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">$ 4,152,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantLiabilities', window );">Warrant liabilities</a></td>
        <td class="nump"><a title="syn_WarrantLiabilities" onclick="toggleNextSibling(this);">10,908,000</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantLiabilities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="syn_WarrantLiabilities" onclick="toggleNextSibling(this);">6,756,000</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightOutstanding" onclick="toggleNextSibling(this);">316,522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssuanceOfWarrantsToPurchaseOfCommonStock', window );">Issuance Of Warrants To Purchase Of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="syn_IssuanceOfWarrantsToPurchaseOfCommonStock[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">635,855</a><span style="display:none;white-space:normal;text-align:left;">syn_IssuanceOfWarrantsToPurchaseOfCommonStock<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisablePricePerShare', window );">Warrants Exercisable Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="syn_WarrantsExercisablePricePerShare[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 1.60</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantsExercisablePricePerShare<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_InvestmentWarrantsExpirationDate1', window );">Investment Warrants Expiration Date1</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 25,  2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember', window );">Stock Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">19,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_StatementEquityComponentsAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction[us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">14,059,616</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction<br>/ us-gaap_StatementEquityComponentsAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare[us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">$ 1.47</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare<br>/ us-gaap_StatementEquityComponentsAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssuanceOfWarrantsToPurchaseOfCommonStock', window );">Issuance Of Warrants To Purchase Of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="syn_IssuanceOfWarrantsToPurchaseOfCommonStock[us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">0.5</a><span style="display:none;white-space:normal;text-align:left;">syn_IssuanceOfWarrantsToPurchaseOfCommonStock<br>/ us-gaap_StatementEquityComponentsAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber[us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">7,029,808</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber<br>/ us-gaap_StatementEquityComponentsAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisablePricePerShare', window );">Warrants Exercisable Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="syn_WarrantsExercisablePricePerShare[us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">$ 1.75</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantsExercisablePricePerShare<br>/ us-gaap_StatementEquityComponentsAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants[us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">10,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants<br>/ us-gaap_StatementEquityComponentsAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantLiabilities', window );">Warrant liabilities</a></td>
        <td class="nump"><a title="syn_WarrantLiabilities[us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember]" onclick="toggleNextSibling(this);">$ 4,200,000</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantLiabilities<br>/ us-gaap_StatementEquityComponentsAxis<br>= syn_StockWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_InvestmentWarrantsExpirationDate1', window );">Investment Warrants Expiration Date1</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 10,  2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_InvestmentWarrantsExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration date of warrants held.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_InvestmentWarrantsExpirationDate1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssuanceOfWarrantsToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_IssuanceOfWarrantsToPurchaseOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of exercisable share warrants that may be converted as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents value of warrant liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_WarrantLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisablePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants exercisable price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_WarrantsExercisablePricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=syn_StockWarrantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXGBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=syn_ExercisePrice14Member', window );">Exercise Price 1.60 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump"><a title="syn_WarrantsExercisePrice[us-gaap_RangeAxis=syn_ExercisePrice14Member]" onclick="toggleNextSibling(this);">$ 1.60</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantsExercisePrice<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice14Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_RangeAxis=syn_ExercisePrice14Member]" onclick="toggleNextSibling(this);">316,522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice14Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber[us-gaap_RangeAxis=syn_ExercisePrice14Member]" onclick="toggleNextSibling(this);">316,522</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice14Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">2 years 6 months 25 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding[us-gaap_RangeAxis=syn_ExercisePrice14Member]" onclick="toggleNextSibling(this);">$ 187,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice14Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=syn_ExercisePrice175Member', window );">Exercise Price 1.75 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump"><a title="syn_WarrantsExercisePrice[us-gaap_RangeAxis=syn_ExercisePrice175Member]" onclick="toggleNextSibling(this);">$ 1.75</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantsExercisePrice<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice175Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_RangeAxis=syn_ExercisePrice175Member]" onclick="toggleNextSibling(this);">7,029.808</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice175Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber[us-gaap_RangeAxis=syn_ExercisePrice175Member]" onclick="toggleNextSibling(this);">7,029,808</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice175Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">4 years 6 months 11 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding[us-gaap_RangeAxis=syn_ExercisePrice175Member]" onclick="toggleNextSibling(this);">3,903,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice175Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=syn_ExercisePrice222Member', window );">Exercise Price 2.22 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump"><a title="syn_WarrantsExercisePrice[us-gaap_RangeAxis=syn_ExercisePrice222Member]" onclick="toggleNextSibling(this);">$ 2.22</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantsExercisePrice<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice222Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_RangeAxis=syn_ExercisePrice222Member]" onclick="toggleNextSibling(this);">517,257</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice222Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber[us-gaap_RangeAxis=syn_ExercisePrice222Member]" onclick="toggleNextSibling(this);">517,257</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice222Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">1 year 7 months 28 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding[us-gaap_RangeAxis=syn_ExercisePrice222Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice222Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=syn_ExercisePrice330Member', window );">Exercise Price 3.30 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump"><a title="syn_WarrantsExercisePrice[us-gaap_RangeAxis=syn_ExercisePrice330Member]" onclick="toggleNextSibling(this);">$ 3.30</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantsExercisePrice<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice330Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_RangeAxis=syn_ExercisePrice330Member]" onclick="toggleNextSibling(this);">61,207</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice330Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber[us-gaap_RangeAxis=syn_ExercisePrice330Member]" onclick="toggleNextSibling(this);">61,207</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice330Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">1 month 28 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding[us-gaap_RangeAxis=syn_ExercisePrice330Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice330Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=syn_ExercisePrice375Member', window );">Exercise Price 3.75 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump"><a title="syn_WarrantsExercisePrice[us-gaap_RangeAxis=syn_ExercisePrice375Member]" onclick="toggleNextSibling(this);">$ 3.75</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantsExercisePrice<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice375Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_RangeAxis=syn_ExercisePrice375Member]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice375Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber[us-gaap_RangeAxis=syn_ExercisePrice375Member]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice375Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">10 months 17 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding[us-gaap_RangeAxis=syn_ExercisePrice375Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice375Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=syn_ExercisePrice180Member', window );">Exercise Price 1.80 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump"><a title="syn_WarrantsExercisePrice[us-gaap_RangeAxis=syn_ExercisePrice180Member]" onclick="toggleNextSibling(this);">$ 1.80</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantsExercisePrice<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice180Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_RangeAxis=syn_ExercisePrice180Member]" onclick="toggleNextSibling(this);">7,974,794</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice180Member</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber[us-gaap_RangeAxis=syn_ExercisePrice180Member]" onclick="toggleNextSibling(this);">7,974,794</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice180Member</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">4 years 2 months 16 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding[us-gaap_RangeAxis=syn_ExercisePrice180Member]" onclick="toggleNextSibling(this);">$ 3,280,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding<br>/ us-gaap_RangeAxis<br>= syn_ExercisePrice180Member</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_WarrantsExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=syn_ExercisePrice14Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=syn_ExercisePrice14Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=syn_ExercisePrice175Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=syn_ExercisePrice175Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=syn_ExercisePrice180Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=syn_ExercisePrice180Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=syn_ExercisePrice222Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=syn_ExercisePrice222Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=syn_ExercisePrice330Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=syn_ExercisePrice330Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=syn_ExercisePrice375Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=syn_ExercisePrice375Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Details Textual) (Prev Abr Llc [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Prev Abr Llc [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_PrevAbrLlcMember]" onclick="toggleNextSibling(this);">212,843</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= syn_PrevAbrLlcMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure', window );">Equity Issued in Business Combination, Fair Value Disclosure</a></td>
        <td class="nump"><a title="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_PrevAbrLlcMember]" onclick="toggleNextSibling(this);">$ 350,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= syn_PrevAbrLlcMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockholdersEquityLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_StockholdersEquityLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of equity issued in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss per Share (Details Textual)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">6,531,106</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">4,490,497</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">7,974,794</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">963,168</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <b>3.</b> <b>Fair Value of Financial Instruments</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -13.2pt; MARGIN: 0pt 0px 0pt 41.8pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div>&#160;</div> </td> <td style="WIDTH: 4%"> <div><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td style="WIDTH: 90%"> <div>Level 1 inputs: Quoted prices (unadjusted)&#160;for identical assets or liabilities in active markets;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div>&#160;</div> </td> <td style="WIDTH: 4%"> <div><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td style="WIDTH: 90%"> <div>Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -13.2pt; MARGIN: 0in 0px 0in 0.2in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div>&#160;</div> </td> <td style="WIDTH: 4%"> <div><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td style="WIDTH: 90%"> <div>Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">If the inputs used to measure fair value fall in different levels of the fair value hierarchy, the hierarchy level is based upon the lowest level of input that is significant to the fair value measurement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cash and cash equivalents include money market accounts&#160;of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.5</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.6</font> million as of March 31, 2015 and December 31, 2014, respectively, that are measured using Level 1 inputs.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EP3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 12,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 17,525</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">1,574</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">1,548</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">13,623</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">19,073</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">65</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
        <td class="nump"><a title="syn_DepositsAndOtherAssetsNoncurrent" onclick="toggleNextSibling(this);">18</a><span style="display:none;white-space:normal;text-align:left;">syn_DepositsAndOtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="syn_DepositsAndOtherAssetsNoncurrent" onclick="toggleNextSibling(this);">6</a><span style="display:none;white-space:normal;text-align:left;">syn_DepositsAndOtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">13,716</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">19,144</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">1,559</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">996</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">2,646</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">1,298</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantLiabilities', window );">Warrant liabilities</a></td>
        <td class="nump"><a title="syn_WarrantLiabilities" onclick="toggleNextSibling(this);">10,908</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantLiabilities</span><span></span></td>
        <td class="nump"><a title="syn_WarrantLiabilities" onclick="toggleNextSibling(this);">6,756</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee benefits</a></td>
        <td class="nump"><a title="us-gaap_AccruedEmployeeBenefitsCurrent" onclick="toggleNextSibling(this);">228</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedEmployeeBenefitsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedEmployeeBenefitsCurrent" onclick="toggleNextSibling(this);">538</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedEmployeeBenefitsCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">15,341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">9,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">15,341</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">9,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity (Deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized, 72,725,987 issued and 72,807,469 outstanding and 72,594,626 issued and 72,513,144 outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">73</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">72</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">111,702</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">110,526</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(113,400)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(101,042)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(1,625)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">9,556</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
        <td class="nump"><a title="us-gaap_MinorityInterest" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_MinorityInterest" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterest</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders' Equity (Deficit)</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">(1,625)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">9,556</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#x2019; Equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 13,716</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 19,144</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DepositsAndOtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_DepositsAndOtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents value of warrant liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_WarrantLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 4I<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="justify"><b>1.</b> <b>Organization and Nature of Operations and Basis of Presentation</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -37.4pt; MARGIN: 0pt 0px 0pt 37.4pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Description of Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;) is a microbiome-focused,&#160;clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of <i>C. difficile</i> infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 26%"> <div style="CLEAR:both;CLEAR: both"><b> Therapeutic&#160;Area</b></div> </td> <td style="TEXT-ALIGN: center; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 26%"> <div style="CLEAR:both;CLEAR: both"><b> Product&#160;Candidate</b></div> </td> <td style="TEXT-ALIGN: center; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 46%"> <div style="CLEAR:both;CLEAR: both"><b>Status</b></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both"><i>C. difficile</i> infection prevention</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">SYN-004</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(oral enzyme)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Initiated Phase 2a SYN-004 clinical trial during 1<sup style="font-style:normal">st</sup> quarter 2015; Phase 2b proof-of- concept SYN-004 clinical trial is expected to initiate during 2<sup style="font-style:normal">nd</sup>&#160;&#160;half 2015</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Irritable bowel syndrome with constipation (IBS-C)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">SYN-010</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(oral compound)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Intend to initiate Phase 2 clinical trials during 2<font style="FONT-SIZE: 10pt"><sup style="font-style:normal">nd</sup></font>&#160;&#160;quarter of 2015; Collaboration with Cedars-Sinai Medical Center</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Pertussis</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">SYN-005</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(monoclonal antibodies)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Positive preclinical research findings reported at ECCMID in April 2015; Seeking non-dilutive funding to support clinical development of SYN-005; Collaborations with Intrexon and The University of Texas at Austin</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Relapsing-remitting MS</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">Trimesta</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(oral estriol)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The lead principal investigator presented additional Phase 2 clinical outcome data, including more detailed results on improvements in cognitive and disability measures at the ACTRIMS-ECTRIMS Joint Meeting in September 2014; Partnership discussions ongoing pending data from University of California, Los Angeles (UCLA); MRI data review underway by UCLA</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr> <td style="TEXT-INDENT: -11pt; PADDING-LEFT: 11pt; VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Cognitive dysfunction in MS</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">Trimesta</div> <div style="CLEAR:both;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">(oral estriol)</div> </td> <td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="VERTICAL-ALIGN: top"> <div style="CLEAR:both;CLEAR: both">Patient enrollment underway in Phase 2 clinical trial</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) for complete financial statements. The accompanying consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2014 (&#8220;2014 Form 10-K&#8221;) as filed with the SEC. The interim results for the three months ended March 31, 2015, are not necessarily indicative of results for the full year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">131.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">126.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">2.03%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">1.57%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of warrant</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod', window );">Expected forfeitures</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod</span><span></span></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were expected to be cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EITCI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2001</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007</div>
        </th>
        <th class="th">
          <div>Mar. 20, 2007</div>
        </th>
        <th class="th">
          <div>Nov. 02, 2010</div>
        </th>
        <th class="th">
          <div>Oct. 22, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" onclick="toggleNextSibling(this);">$ 4,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember', window );">General and Administrative Expenses and Research and Development Expense [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">826,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">362,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndConsultantsMember', window );">Employees And Consultants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndConsultantsMember]" onclick="toggleNextSibling(this);">587,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= syn_EmployeesAndConsultantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndConsultantsMember]" onclick="toggleNextSibling(this);">1,400,000</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= syn_EmployeesAndConsultantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeeMember', window );">Employee [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeeMember]" onclick="toggleNextSibling(this);">550,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= syn_EmployeeMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeeMember]" onclick="toggleNextSibling(this);">$ 817,000</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= syn_EmployeeMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2001Member', window );">2001 Stock Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=syn_StockPlan2001Member]" onclick="toggleNextSibling(this);">682,449</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2001Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2001Member', window );">2001 Stock Plan [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_PlanNameAxis=syn_StockPlan2001Member;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2001Member<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member', window );">2007 Stock Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=syn_StockPlan2007Member]" onclick="toggleNextSibling(this);">428,657</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2007Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=syn_StockPlan2007Member]" onclick="toggleNextSibling(this);">2,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2007Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member', window );">2007 Stock Plan [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_PlanNameAxis=syn_StockPlan2007Member;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2007Member<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member', window );">2010 Stock Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=syn_StockPlan2010Member]" onclick="toggleNextSibling(this);">5,420,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2010Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_PlanNameAxis=syn_StockPlan2010Member]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2010Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member', window );">2010 Stock Plan [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance[us-gaap_PlanNameAxis=syn_StockPlan2010Member;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2010Member<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member', window );">2010 Stock Plan [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance[us-gaap_PlanNameAxis=syn_StockPlan2010Member;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance<br>/ us-gaap_PlanNameAxis<br>= syn_StockPlan2010Member<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2001Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2001Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2007Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2010Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeeMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeeMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndConsultantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndConsultantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Management Plans<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisclosureManagementPlanAbstract', window );"><strong>Disclosure Management Plan [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisclosureManagementPlanTextBlock', window );">Disclosure Management Plan [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <b>2.</b> <b>Management&#8217;s Plan</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has incurred an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">113.4</font> million through March 31, 2015. With the exception of the quarter ended June 30, 2010, the Company has incurred negative cash flow from operations since it started the business. The Company has spent, and expects to continue to spend, substantial amounts in connection with implementing its business strategy, including the planned product development efforts, clinical trials, and research and discovery efforts.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company&#8217;s control. These factors include the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 4%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 90%"> <div style="CLEAR:both;CLEAR: both">the progress of research activities;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the number and scope of research programs;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the progress of preclinical and clinical development activities;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the progress of the development efforts of parties with whom the Company has entered into research and development agreements;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the costs associated with additional clinical trials of product candidates;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the ability to achieve milestones under licensing arrangements;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">the costs and timing of regulatory approvals.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has based its estimate on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales of the Company&#8217;s shares or debt and other sources.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company may seek to access the public or private equity markets when conditions are favorable due to long-term capital requirements. The Company does not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when needed on terms that will be acceptable to it, or at all. If the Company raises funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out the business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisclosureManagementPlanAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_DisclosureManagementPlanAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisclosureManagementPlanTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure related to Management's Plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_DisclosureManagementPlanTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">72,725,987</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">72,594,626</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">72,807,469</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">72,513,144</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6G">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Management's Plan (Details Textual) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ManagementsPlanLineItems', window );"><strong>Management's Plan [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (113,400)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (101,042)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ManagementsPlanLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ManagementsPlanLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2CAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>May 08, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Synthetic Biologics, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000894158<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">SYN<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">73,179,307</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_TradingSymbol</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details Textual) (Money Market Accounts [Member], USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Money Market Accounts [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents, at Carrying Value</a></td>
        <td class="nump"><a title="us-gaap_CashEquivalentsAtCarryingValue[us-gaap_CashAndCashEquivalentsAxis=syn_MoneyMarketAccountsMember]" onclick="toggleNextSibling(this);">$ 8.5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashEquivalentsAtCarryingValue<br>/ us-gaap_CashAndCashEquivalentsAxis<br>= syn_MoneyMarketAccountsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashEquivalentsAtCarryingValue[us-gaap_CashAndCashEquivalentsAxis=syn_MoneyMarketAccountsMember]" onclick="toggleNextSibling(this);">$ 13.6</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashEquivalentsAtCarryingValue<br>/ us-gaap_CashAndCashEquivalentsAxis<br>= syn_MoneyMarketAccountsMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2KAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">$ 1,713</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">$ 1,122</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">6,494</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">2,717</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Costs and Expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">8,207</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">3,839</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(8,207)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(3,839)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
        <td class="num"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">(4,152)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(4,151)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">(12,358)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">(3,838)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (12,358)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,838)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net Loss Per Share - Basic and Dilutive (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (0.17)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" onclick="toggleNextSibling(this);">$ (0.07)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.17)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.07)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">72,673,959</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">58,324,260</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"><b>7.</b> <b>Stockholders&#8217; Equity (Deficit)</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the three months ended March 31, 2015, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 212,843</font> shares of common stock to Prev ABR LLC, with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font>,&#160;<font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> that was<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font></font> <font style="TEXT-ALIGN: justify; WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal"> recorded as research and development expense,</font>&#160;in consideration for achieving the first two milestones as set forth in the Asset Purchase Agreement dated November 28, 2012. In lieu of receiving any cash payment for achieving the first two milestones, Prev ABR LLC exercised its option to receive the milestone payments in shares of the Company&#8217;s common stock. The number of shares of common stock issued upon achievement of each milestone was based upon the average of the opening and closing prices of&#160;<font style="WIDOWS: 1; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px 'Times New Roman', Times, serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> the Company&#8217;s</font> stock on the date each milestone was achieved as specified in the Asset Purchase Agreement.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsAbstract', window );"><strong>Stock Purchase Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsTextBlock', window );">Stock Purchase Warrants [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <strong>6.</strong> <strong>Stock Purchase Warrants</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 10, 2014, the Company raised net proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19.1</font> million through the sale of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,059,616</font> units at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.47</font> per unit to certain institutional investors in a registered direct offering. Each unit consisted of one share of the Company&#8217;s common stock and a warrant to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.5</font> shares of common stock. The warrants, exercisable for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,029,808</font> shares of common stock, have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.75</font> per share and a life of five years. The warrants vested immediately and expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">October 10, 2019</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The warrants issued in conjunction with the registered direct offering in October 2014 include a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date and changes in estimated fair value will be recorded as non-cash income or expense in the Company&#8217;s statement of operations at each subsequent period. At March 31, 2015, the fair value of the warrant liability was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.9</font> million, which represented non-cash expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.2</font> million for the three months ended March 31, 2015. In accordance with authoritative accounting guidance, the warrant was valued on the date of grant and in subsequent periods using the Black-Scholes valuation model. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The assumptions used by the Company are summarized in the following table:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>March 31,<br/> 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>December 31,<br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Issuance<br/> Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Closing stock price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected life of warrant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.55 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.79 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the estimated fair value of the warrant liability <i>(in thousands)</i>:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Balance at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,756</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4,152</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Balance at March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,908</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of March 31, 2015, all of the warrants remained outstanding.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 635,855</font> shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.60</font> and a life of five years. The warrants vested immediately and expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">October 25, 2017</font>. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. Warrants outstanding as of March 31, 2015 were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 316,522</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of&#160;Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,632,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,029,808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(232,619)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(454,896)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Contractual&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>316,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>316,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>2.57 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>187,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>7,029.808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>7,029,808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>4.53 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>3,903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>1.66 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>3.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>0.16 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>3.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>0.88 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>4.21 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>3,280,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_StockPurchaseWarrantsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure related to Stock Purchase Warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_StockPurchaseWarrantsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 1) (Stock Option [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Option [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Beginning Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">5,981,106</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">3,909,580</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">550,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,382,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(6,583)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options, Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(304,391)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">6,531,106</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">5,981,106</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">3,909,580</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">4,168,043</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.78</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.54</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.36</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.58</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.97</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.78</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.89</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Balance Outstanding</a></td>
        <td class="text">5 years 9 months 14 days<span></span></td>
        <td class="text">5 years 9 months 18 days<span></span></td>
        <td class="text">5 years 7 months 2 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable</a></td>
        <td class="text">4 years 11 months 23 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 685,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 785,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,628,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">685,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">785,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1,939,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value of options granted</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 817,000</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 4,974,000</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.49</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 2.09</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OtherCurrentAssetsLineItems', window );"><strong>Other Current Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidExpensesResearchAndDevelopment', window );">Intrexon prepaid research and development expenses</a></td>
        <td class="nump"><a title="syn_PrepaidExpensesResearchAndDevelopment" onclick="toggleNextSibling(this);">$ 1,060</a><span style="display:none;white-space:normal;text-align:left;">syn_PrepaidExpensesResearchAndDevelopment</span><span></span></td>
        <td class="nump"><a title="syn_PrepaidExpensesResearchAndDevelopment" onclick="toggleNextSibling(this);">$ 1,067</a><span style="display:none;white-space:normal;text-align:left;">syn_PrepaidExpensesResearchAndDevelopment</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
        <td class="nump"><a title="us-gaap_PrepaidInsurance" onclick="toggleNextSibling(this);">140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidInsurance</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidInsurance" onclick="toggleNextSibling(this);">228</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidInsurance</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">374</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">253</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 1,574</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 1,548</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_OtherCurrentAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_OtherCurrentAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidExpensesResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for research and development expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_PrepaidExpensesResearchAndDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5865-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: center; WIDTH: 100%"> <div style="CLEAR:both;CLEAR: both"></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%" colspan="6"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>126</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>2.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected life of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average&#160;Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,909,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.59 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>785,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,382,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(6,583)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(304,391)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,981,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.80 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>685,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - March 31, 2015 - outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,531,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.97</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.79 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,628,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - March 31, 2015 - exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,168,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.98 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,939,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Grant date fair value of options granted - March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>817,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Weighted average grant date fair value - March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Grant date fair value of options granted - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4,974,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Weighted average grant date fair value - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <b>8.</b> <b>Net Loss per Share</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive at March 31, 2014 and 2015, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2015 were 6,531,106 and 7,974,794, respectively, and for the three months ended March 31, 2014 were 4,490,497 and 963,168, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Prepaid expenses and other current assets (in thousands):</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Intrexon prepaid research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,060</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,067</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Prepaid insurance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>228</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>253</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,574</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,548</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Property and equipment (in thousands):</i>&#160; &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Computer and office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>122</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>104</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Less accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(47)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>(39)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedExpensesTableTextBlock', window );">Accrued Expenses [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Accrued expenses (in thousands):</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>&#160;</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>March&#160;31,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued manufacturing costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued vendor payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>225</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>176</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued milestone payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>350</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued clinical consulting services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,347</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>525</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,646</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,298</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedExpensesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_AccruedExpensesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amounts of other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsAbstract', window );"><strong>Stock Purchase Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The assumptions used by the Company are summarized in the following table:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 3.3pt 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>March 31,<br/> 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>December 31,<br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Issuance<br/> Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Closing stock price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Expected life of warrant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.55 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.79 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock', window );">Schedule Of Estimated Fair Value Of The Warrant Liability [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The following table summarizes the estimated fair value of the warrant liability <i>(in thousands)</i>:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -6.6pt; MARGIN: 0pt 3.3pt 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Balance at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,756</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Change in fair value of warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4,152</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Balance at March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>10,908</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule Of Warrant Activity [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">A summary of warrant activity for the Company for the three months ended March 31, 2015 and for the year ended December 31, 2014 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Number&#160;of&#160;Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,632,501</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,029,808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(232,619)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(454,896)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Balance at March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock', window );">Schedule Of Warrant Outstanding and Exercisable [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">A summary of all outstanding and exercisable warrants as of March 31, 2015 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="20%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>Contractual&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>1.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>316,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>316,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>2.57 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>187,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>1.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>7,029.808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>7,029,808</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>4.53 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>3,903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>2.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>517,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>1.66 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>3.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>61,207</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>0.16 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%"> <div>3.75</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>0.88 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>1.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>7,974,794</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>4.21 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>3,280,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of estimated fair value of the warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ScheduleOfEstimatedFairValueOfWarrantLiabilityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrant activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ScheduleOfWarrantActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure relates to warrant outstanding and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_StockPurchaseWarrantsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bbb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details 2) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedExpensesLineItems', window );"><strong>Accrued Expenses [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedManufacturingCosts', window );">Accrued manufacturing costs</a></td>
        <td class="nump"><a title="syn_AccruedManufacturingCosts" onclick="toggleNextSibling(this);">$ 74</a><span style="display:none;white-space:normal;text-align:left;">syn_AccruedManufacturingCosts</span><span></span></td>
        <td class="nump"><a title="syn_AccruedManufacturingCosts" onclick="toggleNextSibling(this);">$ 247</a><span style="display:none;white-space:normal;text-align:left;">syn_AccruedManufacturingCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedVendorPayments', window );">Accrued vendor payments</a></td>
        <td class="nump"><a title="syn_AccruedVendorPayments" onclick="toggleNextSibling(this);">225</a><span style="display:none;white-space:normal;text-align:left;">syn_AccruedVendorPayments</span><span></span></td>
        <td class="nump"><a title="syn_AccruedVendorPayments" onclick="toggleNextSibling(this);">176</a><span style="display:none;white-space:normal;text-align:left;">syn_AccruedVendorPayments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedMilestonePayable', window );">Accrued milestone payments</a></td>
        <td class="nump"><a title="syn_AccruedMilestonePayable" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">syn_AccruedMilestonePayable</span><span></span></td>
        <td class="nump"><a title="syn_AccruedMilestonePayable" onclick="toggleNextSibling(this);">350</a><span style="display:none;white-space:normal;text-align:left;">syn_AccruedMilestonePayable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedClinicalConsultingServices', window );">Accrued clinical consulting services</a></td>
        <td class="nump"><a title="syn_AccruedClinicalConsultingServices" onclick="toggleNextSibling(this);">1,347</a><span style="display:none;white-space:normal;text-align:left;">syn_AccruedClinicalConsultingServices</span><span></span></td>
        <td class="nump"><a title="syn_AccruedClinicalConsultingServices" onclick="toggleNextSibling(this);">525</a><span style="display:none;white-space:normal;text-align:left;">syn_AccruedClinicalConsultingServices</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 2,646</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 1,298</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedClinicalConsultingServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value of accrued clinical consulting services payable as on balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_AccruedClinicalConsultingServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedExpensesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_AccruedExpensesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedManufacturingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The manufacturing costs incurred in the production of goods for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_AccruedManufacturingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedMilestonePayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value of accrued milestone payments payable as on balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_AccruedMilestonePayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedVendorPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_AccruedVendorPayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantLiabilities', window );">Beginning Balance</a></td>
        <td class="nump"><a title="syn_WarrantLiabilities" onclick="toggleNextSibling(this);">$ 6,756</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantLiabilities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">4,152</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantLiabilities', window );">Ending Balance</a></td>
        <td class="nump"><a title="syn_WarrantLiabilities" onclick="toggleNextSibling(this);">$ 10,908</a><span style="display:none;white-space:normal;text-align:left;">syn_WarrantLiabilities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents value of warrant liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_WarrantLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E65AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">$ (12,358)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_ProfitLoss" onclick="toggleNextSibling(this);">$ (3,838)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProfitLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">827</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">362</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedForMilestonePayments', window );">Stock issued for milestone payments</a></td>
        <td class="nump"><a title="syn_StockIssuedForMilestonePayments" onclick="toggleNextSibling(this);">350</a><span style="display:none;white-space:normal;text-align:left;">syn_StockIssuedForMilestonePayments</span><span></span></td>
        <td class="nump"><a title="syn_StockIssuedForMilestonePayments" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">syn_StockIssuedForMilestonePayments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">4,152</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_FairValueAdjustmentOfWarrants" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAdjustmentOfWarrants</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(26)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">259</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
        <td class="num"><a title="syn_IncreaseDecreaseInDepositsAndOtherAssets" onclick="toggleNextSibling(this);">(12)</a><span style="display:none;white-space:normal;text-align:left;">syn_IncreaseDecreaseInDepositsAndOtherAssets</span><span></span></td>
        <td class="num"><a title="syn_IncreaseDecreaseInDepositsAndOtherAssets" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">syn_IncreaseDecreaseInDepositsAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">563</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">631</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">1,348</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued employee benefits</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(310)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(885)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(5,458)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(3,470)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(18)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(4)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(18)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(4)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises', window );">Proceeds from issuance of common stock for stock option exercises</a></td>
        <td class="nump"><a title="syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises</span><span></span></td>
        <td class="nump"><a title="syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises" onclick="toggleNextSibling(this);">4</a><span style="display:none;white-space:normal;text-align:left;">syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">4</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
        <td class="num"><a title="us-gaap_CashPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(5,476)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashPeriodIncreaseDecrease</span><span></span></td>
        <td class="num"><a title="us-gaap_CashPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(3,470)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">17,525</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">14,625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">12,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">11,155</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxesPaid" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxesPaid" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaid</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInDepositsAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_IncreaseDecreaseInDepositsAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity for stock option and warrants exercises.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedForMilestonePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of stock granted for milestone payments during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_StockIssuedForMilestonePayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <strong>5.</strong> <strong>Stock-Based Compensation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -37.4pt; MARGIN: 0pt 0px 0pt 37.4pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Stock Incentive Plan</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During 2001, the Company&#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font>. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant Awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the Awards, including acceleration of the vesting of an Award at any time. As of March 31, 2015, there were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 682,449</font> options issued and outstanding under the 2001 Stock Plan.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500,000</font> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font>. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 428,657</font> options issued and outstanding under the 2007 Stock Plan.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company&#8217;s 2010 Incentive Stock Plan to increase the number of shares of the Company&#8217;s common stock reserved for issuance under the Plan from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000,000</font>. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2015, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,420,000</font> options issued and outstanding under the 2010 Stock Plan.</div> </div> &#160;</div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Black-Scholes assumptions used in the three months ended March 31, 2015 and 2014 are as follows:</div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr> <td style="TEXT-ALIGN: center; WIDTH: 100%"> <div style="CLEAR:both;CLEAR: both"></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="32%" colspan="6"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="26%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>126</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>2.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>1.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected life of option</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="26%"> <div>Expected forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="14%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 34.1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6%"> <div>&#160;</div> </td> <td style="WIDTH: 4%"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td style="WIDTH: 90%"> <div>immediate vesting,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>half vesting immediately and the remainder over three years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>quarterly over three years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>annually over three years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>one-third immediate vesting and remaining annually over two years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>one half immediate vesting with remaining vesting over nine months,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>one quarter immediate vesting with the remaining over three years,</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>one quarter immediate vesting with the remaining over 33 months; and</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>monthly over three years.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -17.6pt; MARGIN: 0pt 0px 0pt 80.3pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During the three months ended March 31, 2015, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 550,000</font> options to employees having an approximate fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">817,000</font> based upon the Black-Scholes option pricing model.&#160;During the same period in 2014, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 587,500</font> options to employees and consultants having an approximate fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million based upon the Black-Scholes option pricing model.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activities as of March 31, 2015, and for the year ended December 31, 2014, is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Average&#160;Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,909,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.59 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>785,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,382,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(6,583)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(304,391)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,981,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.80 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>685,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>550,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - March 31, 2015 - outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,531,106</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.97</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.79 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,628,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Balance - March 31, 2015 - exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,168,043</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.98 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,939,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Grant date fair value of options granted - March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>817,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Weighted average grant date fair value - March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Grant date fair value of options granted - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4,974,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Weighted average grant date fair value - December 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2.09</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees and consultants for the three months ended March 31, 2015 and 2014 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">826,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">362,000</font>, respectively</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of March 31, 2015, total unrecognized stock-based compensation expense related to stock options was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.0</font> million, which is expected to be expensed through February 2017.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants (Details 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" onclick="toggleNextSibling(this);">7,974,794</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" onclick="toggleNextSibling(this);">1,632,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" onclick="toggleNextSibling(this);">7,029,808</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod', window );">Number of Warrants, Exercised</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod</span><span></span></td>
        <td class="num"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" onclick="toggleNextSibling(this);">(232,619)</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</span><span></span></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" onclick="toggleNextSibling(this);">(454,896)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" onclick="toggleNextSibling(this);">7,974,794</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" onclick="toggleNextSibling(this);">7,974,794</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.99</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Exercised</a></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.47</a><span style="display:none;white-space:normal;text-align:left;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.88</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 1.8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share warrants exercised during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>63</ContextCount>
  <ElementCount>152</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>24</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Disclosure - Organization and Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Organization and Nature of Operations and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Disclosure - Management Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ManagementPlans</Role>
      <ShortName>Management Plans</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - Stock Purchase Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrants</Role>
      <ShortName>Stock Purchase Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Statement - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - Selected Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables</Role>
      <ShortName>Selected Balance Sheet Information (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - Stock Purchase Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsTables</Role>
      <ShortName>Stock Purchase Warrants (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - Management's Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ManagementsPlanDetailsTextual</Role>
      <ShortName>Management's Plan (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - Fair Value of Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/FairValueOfFinancialInstrumentsDetailsTextual</Role>
      <ShortName>Fair Value of Financial Instruments (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - Selected Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails</Role>
      <ShortName>Selected Balance Sheet Information (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - Selected Balance Sheet Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1</Role>
      <ShortName>Selected Balance Sheet Information (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - Selected Balance Sheet Information (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2</Role>
      <ShortName>Selected Balance Sheet Information (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockbasedCompensationDetailsTextual</Role>
      <ShortName>Stock-Based Compensation (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - Stock Purchase Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails</Role>
      <ShortName>Stock Purchase Warrants (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - Stock Purchase Warrants (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails1</Role>
      <ShortName>Stock Purchase Warrants (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - Stock Purchase Warrants (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails2</Role>
      <ShortName>Stock Purchase Warrants (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - Stock Purchase Warrants (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetails3</Role>
      <ShortName>Stock Purchase Warrants (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - Stock Purchase Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockPurchaseWarrantsDetailsTextual</Role>
      <ShortName>Stock Purchase Warrants (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - Stockholders' Equity (Deficit) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockholdersEquityDeficitDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Deficit) (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - Net Loss per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/NetLossPerShareDetailsTextual</Role>
      <ShortName>Net Loss per Share (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element syn_WarrantLiabilities had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_FairValueAdjustmentOfWarrants had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_FairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 1 2.</Log>
    <Log type="Info">'Monetary' elements on report '124 - Disclosure - Stock-Based Compensation (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '129 - Disclosure - Stock Purchase Warrants (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 102 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Cash Flows</Log>
    <Log type="Info">Process Flow-Through: 112 - Statement - Stockholders' Equity (Deficit)</Log>
  </Logs>
  <InputFiles>
    <File>syn-20150331.xml</File>
    <File>syn-20150331.xsd</File>
    <File>syn-20150331_cal.xml</File>
    <File>syn-20150331_def.xml</File>
    <File>syn-20150331_lab.xml</File>
    <File>syn-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 122</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 104</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(47)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(39)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">65</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputerAndOfficeEquipmentMember]" onclick="toggleNextSibling(this);">111</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= syn_ComputerAndOfficeEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputerAndOfficeEquipmentMember]" onclick="toggleNextSibling(this);">93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= syn_ComputerAndOfficeEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember]" onclick="toggleNextSibling(this);">$ 11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerSoftwareIntangibleAssetMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember]" onclick="toggleNextSibling(this);">$ 11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerSoftwareIntangibleAssetMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputerAndOfficeEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputerAndOfficeEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
